Novel substituted octahydrocyclopenta[c]pyrrol-4-amines as calcium channel blockers

ABSTRACT

The present application relates to calcium channel inhibitors containing compounds of formula (I) 
     
       
         
         
             
             
         
       
     
     wherein L 1 , L 2 , R 1 , R 2 , and R 3  are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.

CROSS-REFERENCE SECTION TO RELATED APPLICATIONS

This application claims priority to provisional application Ser. No.61/117,995 filed Nov. 26, 2008, which is incorporated herein byreference.

TECHNICAL FIELD AND BACKGROUND

The present application relates to compounds that are calcium channelblockers, compositions comprising such compounds, and methods oftreating conditions and disorders using such compounds and compositions.

Voltage-gated calcium channels (VGCC) play an integral role in theregulation of membrane ion conductance, neurotransmitter release, andcellular excitability. VGCC are composed of the pore-forming α1 subunitand auxiliary α2δ and β subunits that modulate channel expression andfunctional properties (Dolphin, A. C. A short history of voltage-gatedcalcium channels. British Journal of Pharmacology 2006, 147 (Suppl. 1),S56-S62.). These channels can be classified into low-voltage activated(LVA; T-type or Ca_(v)3.x) and high-voltage activated (HVA; L-type orCa_(v)1.x and N-, P/Q- and R-types or Ca_(v)2.x) channels. N-, P/Q and Rchannels typically activate at more positive membrane potentials (˜−30mV) and are involved in “presynaptic” neurotransmission (McGivern J. G.Targeting N-type and T-type calcium channels for the treatment of pain.Drug Discovery Today 2006, 11, 245-253.). T-type channels are activatedat relatively negative membrane potentials (˜−60 mV) and are primarilyinvolved in “postsynaptic” excitability (Shin, H.-S.; et al. T-type Ca²⁺channels as therapeutic targets in the nervous system. Curr. Opin. inPharmacology 2008, 8, 33-41.).

N-type channel α_(δ) subunits are encoded by a single gene (α₁B orCa_(v)2.2) in contrast to pharmacologically defined L- and T-typecurrents that are encoded by multiple α₁-subunit genes. A diversity ofN-type channels arises due to extensive alternative splicing of the αsubunit gene that generates variants with different expression patternsand GPCR-modulated biophysical properties (Gray, A. C.; et al. Neuronalcalcium channels: splicing for optimal performance. Cell Calcium, 2007,42(4-5), 409-417.). The primary sequence for Ca_(v)2.2 is highlyconserved across species (rat and human share 91% identity at the aminoacid level).

N-type channels are widely expressed in the central nervous system (CNS)(cortex, hippocampus, striatum, thalamus, brain stem nuclei and spinalcord) and in the peripheral nervous system (PNS) (adult sympatheticnervous system and dorsal root ganglia) (Ino, M.; et al. Functionaldisorders of the sympathetic nervous system in mice lacking the α_(1B)subunit (Ca_(v)2.2) of N-type calcium channels. Proc. Natl. Acad. Sci.USA 2001, 98(9), 5323-5328). In pain pathways, N-type channels areexpressed in the rostral ventral medulla, an important site ofdescending pain modulation (Urban, M. O.; et al. Medullary N-type andP/Q-type calcium channels contribute to neuropathy-induced allodynia.Neuroreport 2005, 16(6), 563-566.) and are a major contributor to thesynaptic neurotransmission that occurs between C/Aδ nociceptors andspinal lamina I neurons (Bao, J.; et al. Differences in Ca²⁺ channelsgoverning generation of miniature and evoked excitatory synapticcurrents in spinal laminae I and II. J Neurosci. 1998, 18(21), 8740-50.Heinke, B.; et al. Pre- and postsynaptic contributions ofvoltage-dependent Ca²⁺ channels to nociceptive transmission in ratspinal lamina I neurons. Eur. J. Neurosci. 2004, 19(1), 103-111.). Incontrast, P/Q type channels are expressed almost exclusively in laminaeII-IV of the spinal cord and show little co-localization with SubstanceP and N-type channels (Westenbroek, R. E.; et al. Localization of Ca²⁺channel subtypes on rat spinal motor neurons, interneurons, and nerveterminals. J. Neurosci. 1998, 18(16), 6319-6330.).

Following nerve injury there is increased expression of Ca_(v)2.2(Westenbroek, R. E.; et al. Localization of Ca²⁺ channel subtypes on ratspinal motor neurons, interneurons, and nerve terminals. J. Neurosci.1998, 18(16), 6319-6330. Cizkova, D.; et al. Localization of N-type Ca²⁺channels in the rat spinal cord following chronic constrictive nerveinjury. Exp. Brain Res. 2002, 147, 456-463. Yokoyama, K.; et al. Plasticchange of N-type calcium channel expression after preconditioning isresponsible for prostaglandin E2-induced long-lasting allodynia.Anesthesiology 2003, 99(6), 1364-1370.) and α2δ1 subunits (Luo, Z. D.;et al. Upregulation of dorsal root ganglion α2δ calcium channel subunitand its correlation with allodynia in spinal nerve-injured rats. J.Neurosci. 2001, 21(6), 1868-1875. Newton, R. A.; et al. Dorsal rootganglion neurons show increased expression of the calcium channel α2δ-1subunit following partial sciatic nerve injury. Mol. Brain Res. 2001,95(1-2), 1-8.) in addition to increases in the superficial layers of thedorsal horn of the spinal cord supporting a role for N-type channels inneuropathic pain. Recently a nociceptor-specific Ca_(v)2.2 splicevariant has been identified in the dorsal root ganglion (Bell, T. J.; etal. Cell specific alternative splicing increases calcium channel densityin the pain pathway. Neuron 2004, 41(1), 127-138.). These channels havedistinct electrophysiological properties and current densities(Castiglioni, A. J.; et al. Alternative splicing in the C-terminus ofCa_(v)2.2 controls expression and gating of N-type calcium channels. J.Physiol. 2006, 576(Pt 1), 119-134.) compared to wildtype Ca_(v)2.2channels. While G-protein coupled receptor inhibition of wildtype N-typechannels is typically mediated by Gβγ and is voltage-dependent, thenociceptor specific splice variant is inhibited by GPCR activation (e.g.opioids) in a voltage-independent fashion (Raingo, J.; et al.Alternative splicing controls G protein-dependent inhibition of N-typecalcium channels in nociceptors. Nat. Neurosci. 2007, 10(3), 285-292.).This mechanism substantially increases the sensitivity of Ca_(v)2.2channels to opiates and gamma-aminobutyric acid (GABA) suggesting thatcell-specific alternative splicing of mRNA for Ca_(v)2.2 channels servesas a molecular switch that controls the sensitivity of N-type channelsto neurotransmitters and drugs that modulate nociception. Collectivelythese data provide further support for the role of Ca_(v)2.2 channels inpain states.

The relative contributions of various HVA Ca²⁺ channels in nociceptivesignaling have been evaluated using knockout mice studies. Ca_(v)2.2knockout mice are healthy, fertile, and do not display overtneurological deficits (Ino, M.; et al. Functional disorders of thesympathetic nervous system in mice lacking the alpha 1B subunit(Ca_(v)2.2) of N-type calcium channels. Proc. Natl. Acad. Sci. USA 2001,98(9), 5323-5328. Kim, C.; et al. Altered nociceptive response in micedeficient in the alpha_(1B) subunit of the voltage-dependent calciumchannel. Mol. Cell. Neurosci. 2001, 18(2), 235-245. Hatakeyama, S.; etal. Differential nociceptive responses in mice lacking the alpha_(1B)subunit of N-type Ca²⁺ channels. Neuroreport 2001, 12(11), 2423-2427.Liu; L.; et al. In vivo analysis of voltage-dependent calcium channels.J. Bioenerg. Biomembr. 2003, 35(6), 671-685.). This finding suggeststhat other types of Ca_(v) channels are able to compensate for the lackof Ca_(v)2.2 channels at most synapses in these mice (Pietrobon, D.Function and dysfunction of synaptic calcium channels: insights frommouse models. Curr. Opin. Neurobiol. 2005, 15(3), 257-265.). Ca_(v)2.2deficient mice are resistant to the development of inflammatory andneuropathic pain (Kim, C.; et al. Altered nociceptive response in micedeficient in the alpha_(1B) subunit of the voltage-dependent calciumchannel. Mol. Cell. Neurosci. 2001, 18(2), 235-245. Hatakeyama, S.; etal. Differential nociceptive responses in mice lacking the alpha_(1B)subunit of N-type Ca²⁺ channels. Neuroreport 2001, 12(11), 2423-2427.Saegusa, H.; et al. Suppression of inflammatory and neuropathic painsymptoms in mice lacking the N-type calcium channel. EMBO J. 2001,20(10), 2349-2356.), have decreased sympathetic nervous system function(Ino, M.; et al. Functional disorders of the sympathetic nervous systemin mice lacking the alpha 1B subunit (Ca_(v)2.2) of N-type calciumchannels. Proc. Natl. Acad. Sci. USA 2001, 98(9), 5323-5328.), andaltered responses to both ethanol and anesthetics (Newton, R. A.; et al.Dorsal root ganglion neurons show increased expression of the calciumchannel alpha2delta-1 subunit following partial sciatic nerve injury.Brain Res. Mol. Brain Res. 2001, 95(1-2), 1-8. Takei, R. et al.Increased sensitivity to halothane but decreased sensitivity to propofolin mice lacking the N-type Ca²⁺ channel. Neurosci. Lett. 2003, 350(1),41-45.). Additional behavioral studies indicate that Ca_(v)2.2 knockoutmice are less anxious, are hyperactive, and show enhanced vigilancecompared to wild-type littermates (Beuckmann, C. T.; et al. N-typecalcium channel alpha_(1B) subunit(Ca_(v)2.2) knock-out mice displayhyperactivity and vigilance state differences. J. Neurosci. 2003,23(17), 6793-6797.).

N- and P/Q-type channels are localized at neuronal synaptic junctionsand contribute significantly to neurotransmitter release (Olivera, B.M.; et al. Calcium channel diversity and neurotransmitter release: theomega-conotoxins and omega agatoxins. Annu Rev. Biochem. 1994, 63,823-867. Miljanich, G. P.; et al. Antagonists of neuronal calciumchannels: structure, function, and therapeutic implications. Annu Rev.Pharmacol. Toxicol. 1995, 35, 707-734.). N-type channels play a majorrole in the release of glutamate, acetylcholine, dopamine,norepinephrine, GABA and calcitonin gene-related protein (CGRP).P/Q-type channels may be involved in the release of glutamate,aspartate, 5HT, GABA and probably glycine (Pietrobon, D. Function anddysfunction of synaptic calcium channels: insights from mouse models.Curr. Opin. Neurobiol. 2005, 15(3), 257-265.).

L, P/Q and N-type channels are blocked by channel specific antagonistsi.e., dihydropyridines, ω-agatoxin IVA and ω-conotoxin MVIIA/ziconotide,respectively. Agatoxin IVa has been shown to block excitatory (Luebke,J. I.; et al. Multiple calcium channel types control glutamatergicsynaptic transmission in the hippocampus. Neuron 1993, 11(5), 895-902.)as well as inhibitory neurotransmission (Takahashi, T.; et al.

Different types of calcium channels mediate central synaptictransmission. Nature 1993, 366(6451), 156-158.). Intrathecal injectionof selective N-type channel blockers (e.g. conotoxin-derived peptidessuch as GVIA, MVIIA (ziconotide), and CVID) significantly attenuatespain responses in animal models of neuropathic pain, formalin-inducedpain, and post-operative pain (Chaplan, S. R.; et al. Role ofvoltage-dependent calcium channel subtypes in experimental tactileallodynia. J. Pharmacol. Exp. Ther. 1994,269(3), 1117-1123. Malmberg, A.B.; et al. Voltage-sensitive calcium channels in spinal nociceptiveprocessing: blockade of N-and P-type channels inhibits formalin-inducednociception. J. Neurosci. 1994, 14(8), 4882-4890. Bowersox, S. S.; etal. Selective N-type neuronal voltage-sensitive calcium channel blocker,SNX-111, produced spinal antinociception in rat models of acute,persistent and neuropathic pain. J. Pharmacol. Exp. Ther. 1996, 279(3),1243-1249. Wang, Y. X.; et al. Effects of intrathecal administration ofziconotide, a selective neuronal N-type calcium channel blocker, onmechanical allodynia and heat hyperalgesia in a rat model ofpostoperative pain. Pain 2000, 84(2-3), 151-158. Scott, D. A.; et al.Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphinein acute and neuropathic pain in the rat. Eur. J. Pharmacol. 2002,451(3), 279-286.). These peptide blockers bind to the pore region of thechannel, do not show voltage- or frequency-dependent activity, and showirreversible channel block (Feng, Z. P.; et al. Determinants ofinhibition of transiently expressed voltage-gated calcium channels byomega-conotoxins GVIA and MVIIA. J. Biol. Chem. 2003, 278(22),20171-20178.). Ziconotide potently blocks neurotransmitter release inthe spinal cord dorsal horn (Matthews, E. A.; et al. Effects of spinallydelivered N-and P-type voltage-dependent calcium channel antagonists ondorsal horn neuronal responses in a rat model of neuropathy. Pain 2001,92(1-2), 235-246. Smith, M. T.; et al. The novel N-type calcium channelblocker, AM336, produces potent dose-dependent antinociception afterintrathecal dosing in rats and inhibits substance P release in ratspinal cord slices. Pain 2002, 96(1-2), 119-127. Heinke, B.; et al. Pre-and postsynaptic contributions of voltage-dependent Ca²⁺ channels tonociceptive transmission in rat spinal lamina I neurons. Eur. J.Neurosci. 2004, 19(1), 103-111.) and in dorsal root ganglion (DRG)neurons (Evans, A. R.; et al. Differential regulation of evoked peptiderelease by voltage-sensitive calcium channels in rat sensory neurons.Brain Res. 1996, 712(2), 265-273. Smith, M. T.; et al. The novel N-typecalcium channel blocker, AM336, produces potent dose-dependentantinociception after intrathecal dosing in rats and inhibits substanceP release in rat spinal cord slices. Pain 2002, 96(1-2), 119-127.). Italso potently and fully blocks depolarization-induced release ofsubstance P from rat spinal cord slices. In contrast, intrathecaldelivery of the selective P/Q type blocker o)-agatoxin IVA had noeffects on mechanical allodynia in the spinal nerve ligation model(Chaplan, S. R.; et al. Role of voltage-dependent calcium channelsubtypes in experimental tactile allodynia. J. Pharmacol. Exp. Ther.1994, 269(3), 1117-1123.) or thermal hyperalgesia in the chronicconstriction injury model (Yamamoto, T.; et al. Differential effects ofintrathecally administered N- and P-type voltage-sensitive calciumchannel blockers upon two models of experimental mononeuropathy in therat. Brain Res. 1998, 794(2), 329-332.) of neuropathic pain.

Pain is the most common symptom of disease and the most frequentcomplaint with which patients present to physicians. Inadequate painmanagement across the spectrum of pain etiologies remains a major publichealth problem. Going forward, the development of novel therapeuticswith new mechanisms of action for the treatment of pain includingcalcium channel blockade will have a significant impact on the ongoingstruggle to balance efficacy and safety for those patients most in need.The compounds of the present invention are novel calcium channelblockers that have utility in treating pain, amongst other conditions.

SUMMARY OF THE INVENTION

The invention is directed to compounds of formula (I)

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or acombination thereof, wherein

L¹ is C(O), S(O)₂, SO₂N(R⁴), C(O)O or —(CR^(a)R^(b))_(m)—;

R¹ is alkyl, G¹, —CH(G¹)₂, —(CR^(a)R^(b))_(m)-G¹,—(CR^(a)R^(b))_(m)—CH(G¹)₂, —(CR^(e)R^(f))_(n)—N(R⁵)₂,—(CR^(e)R^(f))_(n)—N(R⁵)—C(O)O(alkyl),—(CR^(e)R^(f))_(n)—N(R⁵)—C(O)(alkyl), or —(CR^(e)R^(f))_(n)—N(R⁵)—SO₂R⁶;or

L¹-R¹ taken together are hydrogen, alkyl, hydroxyalkyl, G¹, or —CH(G¹)₂;

L² is —(CR^(e)R^(d))_(p)—, C(O), C(O)N(R⁴), S(O)₂, SO₂N(R⁵), or C(O)O;

R² is alkyl, G², —C(R^(c))(G²)(G³), —(CR^(c)R^(d))_(p)-G²,—(CR^(c)R^(d))_(p)—CH(G²)(G³), —(CR^(g)R^(h))_(q)—N(R⁵)—C(O)O(alkyl),—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)O-G², —(CR^(g)R^(h))_(q)—N(R⁵)—C(O)(alkyl),—(CR^(g)R^(h))_(q)—N(R⁵)—SO₂R⁶, —(CR^(g)R^(h))_(q)—N(R⁴)(R⁵),—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)N(R⁵)-(alkyl), or—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)N(R⁵)-G²; or

L²-R² taken together are alkyl, G², or —C(R^(c))(G²)(G³);

m and p, at each occurrence, are each independently 1, 2, 3, 4, 5, or 6;

n and q, at each occurrence, are each independently 1, 2, 3, 4, or 5;

R^(a), R^(b), R^(c), and R^(d), at each occurrence, are eachindependently hydrogen, alkyl, arylalkyl, halogen, haloalkyl or OR⁷; or

R^(a) and R^(b), or R^(c) and R^(d), together with the carbon atom towhich they are attached, optionally form a C₃₋₆ cycloalkyl ring;

R^(e), R^(f), R^(g), and R^(h), at each occurrence, are eachindependently hydrogen, alkyl, halogen, haloalkyl, OR⁷, cycloalkylalkyl,heteroaryl, arylalkyl, or heteroarylalkyl; wherein the aryl, cycloalkyland heteroaryl groups of aryl, cycloalkyl and heteroaryl are eachindependently unsubstituted or substituted with 1, 2, 3, 4, or 5substituents independently selected from the group consisting of alkyland haloalkyl;

G¹, G², and G³ at each occurrence, are each independently aryl,cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; wherein G¹, G²,and G³ at each occurrence are each independently unsubstituted orsubstituted with 1, 2, 3, 4, or 5 substituents selected form the groupconsisting of alkyl, alkenyl, alkynyl, cyano, haloalkyl, halogen, nitro,oxo, phenyl, N(R⁷)₂, N(R⁷)C(O)R⁷, OR⁷, C(O)R⁷, C(O)OR⁷, C(O)N(R⁷)₂,SO₂R⁸, and SO₂N(R⁷)₂; and wherein G¹ is other than quinoline,quinazolinedione, or pyridopyrimidinedione;

R³ is hydrogen, alkyl, haloalkyl, cycloalkyl, or cycloalkylalkyl;

R⁴, R⁵, and R⁷, at each occurrence, are each independently hydrogen,alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, or haloalkyl;wherein said aryl, the aryl of arylalkyl and cycloalkyl areindependently unsubstituted or substituted with 1, 2 3, 4, or 5substituents independently selected from the group consisting of alkyl,haloalkyl, and halogen;

R⁶ is alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle;wherein said aryl, heteroaryl, and heterocycle are independentlyunsubstituted or substituted with 1, 2 3, 4, or 5 substituentsindependently selected from the group consisting of alkyl, haloalkyl,and halogen;

R⁸ is alkyl or haloalkyl;

with the proviso that L¹-R¹ and L²-R² are not both alkyl at the sametime;

and with the proviso that when L¹-R¹ is alkyl, L²-R² is other thanC(O)N(R⁴), wherein R⁴ is alkyl;

and with the further proviso that the compound is other than:

N-(2-trityloctahydrocyclopenta[c]pyrrol-4-yl)acetamide;

N-(octahydrocyclopenta[c]pyrrol-4-yl)acetamide

N-methyl-N-(2-trityloctahydrocyclopenta[c]pyrrol-4-yl)acetamide;

N-methyl-N-(octahydrocyclopenta[c]pyrrol-4-yl)acetamide;

6-(2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)octahydrocyclopenta[c]pyrrol-4-ylamino)methyl-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one;

tert-butyl2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate;

tert-butyl 2-benzyl octahydrocyclopenta[c]pyrrol-4-ylcarbamate; or

tert-butyl octahydrocyclopenta[c]pyrrol-4-ylcarbamate.

Another aspect of the invention relates to pharmaceutical compositionscomprising therapeutically effective amount of compound(s) of theinvention or pharmaceutically acceptable salts thereof, in combinationwith one or more pharmaceutically acceptable carrier. Such compositionscan be administered in accordance with a method of the invention,typically as part of a therapeutic regimen for treatment or preventionof conditions and disorders related to calcium channels. Moreparticularly, the method is useful for treating conditions related to amethod of treating pain in a subject in need thereof. The methodcomprises administering to the subject a therapeutically suitable amountof a compound of formula (I), or a pharmaceutically acceptable saltthereof. Conditions related to pain include acute pain, chronic pain,neuropathic pain, inflammatory pain, visceral pain, cancer pain,allodynia, fibromyalgia, sciatica, back pain, and headache painincluding migraine, or combinations thereof.

Another aspect of the invention provides a method of treating disordersof the central nervous system in a subject in need thereof. The methodcomprising the step of:

administering a therapeutically suitable amount of a compound of formula(I), or a pharmaceutically acceptable salt thereof. The disorders of thecentral nervous system include stroke, epilepsy, manic depression,bipolar disorders, depression, anxiety, schizophrenia, migraine, andpsychoses; neural degenerative disorders including Alzheimer's disease,AIDS related dementia, Parkinson's disease, neuropathy caused by headinjury, and dementia caused by cerebrovascular disorders; disorders ofthe lower urinary tract including overactive bladder, prostatis,prostadynia, interstitial cystitis, and benign prostatic hyperplasia;disorders caused by psychogenic stress including bronchial asthma,unstable angina, and hypersensitive colon inflammation; cardiovasculardisorders including hypertension, atherosclerosis, heart failure, andcardiac arrhythmias; drug addiction withdrawal symptoms, includingethanol addiction withdrawal symptoms; skin disorders including pruritisand allergic dermatitis, inflammatory bowel disease; cancer; diabetes;and infertility and sexual dysfunction, or combinations thereof.

The compounds, compositions comprising the compounds, and methods fortreating or preventing conditions and disorders by administering thecompounds are further described herein.

These and other objects of the invention are described in the followingparagraphs. These objects should not be deemed to narrow the scope ofthe invention.

DETAILED DESCRIPTION

Compounds of formula (I) are disclosed in this invention

wherein L¹, L², R¹, R², and R³ are as defined above in the Summary ofthe Invention. Compositions comprising such compounds and methods fortreating conditions and disorders using such compounds and compositionsare also disclosed.

In various embodiments, the present invention provides at least onevariable that occurs more than one time in any substituent or in thecompound of the invention or any other formulae herein. Definition of avariable on each occurrence is independent of its definition at anotheroccurrence. Further, combinations of substituents are permissible onlyif such combinations result in stable compounds. Stable compounds arecompounds, which can be isolated from a reaction mixture.

a. Definitions

As used in the specification and the appended claims, unless specifiedto the contrary, the following terms have the meaning indicated:

The term “alkenyl” as used herein, means a straight or branchedhydrocarbon chain containing from 2 to 10 carbons and containing atleast one carbon-carbon double bond formed by the removal of twohydrogens. Representative examples of alkenyl include, but are notlimited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl,4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl.

The term “alkenylene” denotes a divalent group derived from a straightor branched chain hydrocarbon of 2 to 4 carbon atoms and contains atleast one carbon-carbon double. Representative examples of alkyleneinclude, but are not limited to, —CH═CH— and —CH₂CH═CH—.

The term “alkyl” as used herein, means a straight or branched, saturatedhydrocarbon chain containing from 1 to 10 carbon atoms. The term “loweralkyl” or “C₁₋₆ alkyl” means a straight or branched chain hydrocarboncontaining 1 to 6 carbon atoms. The term “C₁₋₃ alkyl” means a straightor branched chain hydrocarbon containing 1 to 3 carbon atoms.Representative examples of alkyl include, but are not limited to,methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl,tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl,2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, andn-decyl.

The term “alkylene” denotes a divalent group derived from a straight orbranched chain hydrocarbon 1 to 10 carbon atoms. Representative examplesof alkylene include, but are not limited to, —CH₂—, —CH₂CH₂—,—CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂—, and —CH₂CH(CH₃)CH₂—.

The term “alkynyl” as used herein, means a straight or branched chainhydrocarbon group containing from 2 to 10 carbon atoms and containing atleast one carbon-carbon triple bond. Representative examples of alkynylinclude, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl,3-butynyl, 2-pentynyl, and 1-butynyl.

The term “aryl” as used herein, means phenyl or a bicyclic aryl. Thebicyclic aryl is naphthyl, or a phenyl fused to a monocyclic cycloalkyl,or a phenyl fused to a monocyclic cycloalkenyl. Representative examplesof the aryl groups include, but are not limited to, dihydroindenyl,indenyl, naphthyl, dihydronaphthalenyl, and tetrahydronaphthalenyl. Thebicyclic aryl is attached to the parent molecular moiety through anycarbon atom contained within the bicyclic ring system. The aryl groupsof the present invention can be unsubstituted or substituted.

The term “arylalkyl” as used herein, means an aryl group, as definedherein, appended to the parent molecular moiety through an alkylenegroup, as defined herein. Representative examples of arylalkyl include,but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and2-naphth-2-ylethyl.

The term “cyano” as used herein, means a —CN group.

The term “cycloalkyl” or “cycloalkane” as used herein, means amonocyclic, a bicyclic, or a tricyclic cycloalkyl. The monocycliccycloalkyl is a carbocyclic ring system containing three to eight carbonatoms, zero heteroatoms and zero double bonds. Examples of monocyclicring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl, and cyclooctyl. The bicyclic cycloalkyl is a monocycliccycloalkyl fused to a monocyclic cycloalkyl ring, or a bridgedmonocyclic ring system in which two non-adjacent carbon atoms of themonocyclic ring are linked by an alkylene bridge containing one, two,three, or four carbon atoms. Representative examples of bicyclic ringsystems include, but are not limited to, bicyclo[3.1.1]heptane,bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane,bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane. Tricyclic cycloalkylsare exemplified by a bicyclic cycloalkyl fused to a monocycliccycloalkyl, or a bicyclic cycloalkyl in which two non-adjacent carbonatoms of the ring systems are linked by an alkylene bridge of 1, 2, 3,or 4 carbon atoms. Representative examples of tricyclic-ring systemsinclude, but are not limited to, tricyclo[3.3.1.0^(3,7)]nonane(octahydro-2,5-methanopentalene or noradamantane), andtricyclo[3.3.1.1^(3,7)]decane (adamantane). The monocyclic, bicyclic,and tricyclic cycloalkyls can be unsubstituted or substituted, and areattached to the parent molecular moiety through any substitutable atomcontained within the ring system.

The term “cycloalkylalkyl” as used herein, means a cycloalkyl groupappended to the parent molecular moiety through an alkyl group, asdefined herein.

The term “cycloalkenyl” or “cycloalkene” as used herein, means amonocyclic or a bicyclic hydrocarbon ring system. The monocycliccycloalkenyl has four-, five-, six-, seven- or eight carbon atoms andzero heteroatoms. The four-membered ring systems have one double bond,the five-or six-membered ring systems have one or two double bonds, andthe seven- or eight-membered ring systems have one, two or three doublebonds. Representative examples of monocyclic cycloalkenyl groupsinclude, but are not limited to, cyclobutenyl, cyclopentenyl,cyclohexenyl, cycloheptenyl and cyclooctenyl. The bicyclic cycloalkenylis a monocyclic cycloalkenyl fused to a monocyclic cycloalkyl group, ora monocyclic cycloalkenyl fused to a monocyclic cycloalkenyl group. Themonocyclic or bicyclic cycloalkenyl ring may contain one or two alkylenebridges, each consisting of one, two or three carbon atoms, each linkingtwo non-adjacent carbon atoms of the ring system. Representativeexamples of the bicyclic cycloalkenyl groups include, but are notlimited to, 4,5,6,7-tetrahydro-3aH-indene, octahydronaphthalenyl and1,6-dihydro-pentalene. The monocyclic and bicyclic cycloalkenyl can beattached to the parent molecular moiety through any substitutable atomcontained within the ring systems, and can be unsubstituted orsubstituted.

The term “halo” or “halogen” as used herein, means Cl, Br, I, or F.

The term “haloalkyl” as used herein, means an alkyl group, as definedherein, in which one, two, three, four, five or six hydrogen atoms arereplaced by halogen. Representative examples of haloalkyl include, butare not limited to, chloromethyl, 2-fluoroethyl, 2,2,2-trifluoroethyl,trifluoromethyl, difluoromethyl, pentafluoroethyl,2-chloro-3-fluoropentyl, and trifluoropropyl such as3,3,3-trifluoropropyl.

The term “heterocycle” or “heterocyclic” as used herein, means amonocyclic heterocycle, a bicyclic heterocycle, or a tricyclicheterocycle. The monocyclic heterocycle is a three-, four-, five-, six-,seven-, or eight-membered ring containing at least one heteroatomindependently selected from the group consisting of O, N, and S. Thethree- or four-membered ring contains zero or one double bond, and oneheteroatom selected from the group consisting of O, N, and S. Thefive-membered ring contains zero or one double bond and one, two orthree heteroatoms selected from the group consisting of O, N and S. Thesix-membered ring contains zero, one or two double bonds and one, two,or three heteroatoms selected from the group consisting of O, N, and S.The seven- and eight-membered rings contains zero, one, two, or threedouble bonds and one, two, or three heteroatoms selected from the groupconsisting of O, N, and S. Representative examples of monocyclicheterocycles include, but are not limited to, azetidinyl, azepanyl,aziridinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolanyl, 1,3-dithiolanyl,1,3-dithianyl, imidazolinyl, imidazolidinyl, isothiazolinyl,isothiazolidinyl, isoxazolinyl, isoxazolidinyl, morpholinyl,oxadiazolinyl, oxadiazolidinyl, oxazolinyl, oxazolidinyl, piperazinyl,piperidinyl, pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl,pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl,tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, 1,2-thiazinanyl,1,3-thiazinanyl, thiazolinyl, thiazolidinyl, thiomorpholinyl,1,1-dioxidothiomorpholinyl (thiomorpholine sulfone), thiopyranyl, andtrithianyl. The bicyclic heterocycle is a monocyclic heterocycle fusedto a phenyl group, or a monocyclic heterocycle fused to a monocycliccycloalkyl, or a monocyclic heterocycle fused to a monocycliccycloalkenyl, or a monocyclic heterocycle fused to a monocyclicheterocycle, or a bridged monocyclic heterocycle ring system in whichtwo non adjacent atoms of the ring are linked by an alkylene bridge of1, 2, 3, or 4 carbon atoms, or an alkenylene bridge of two, three, orfour carbon atoms. Representative examples of bicyclic heterocyclesinclude, but are not limited to, benzopyranyl, benzothiopyranyl,chromanyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl,2,3-dihydroisoquinoline, azabicyclo[2.2.1]heptyl (including2-azabicyclo[2.2.1]hept-2-yl), 2,3-dihydro-1H-indolyl, isoindolinyl,octahydrocyclopenta[c]pyrrolyl, octahydropyrrolopyridinyl, andtetrahydroisoquinolinyl. Tricyclic heterocycles are exemplified by abicyclic heterocycle fused to a phenyl group, or a bicyclic heterocyclefused to a monocyclic cycloalkyl, or a bicyclic heterocycle fused to amonocyclic cycloalkenyl, or a bicyclic heterocycle fused to a monocyclicheterocycle, or a bicyclic heterocycle in which two non adjacent atomsof the bicyclic ring are linked by an alkylene bridge of 1, 2, 3, or 4carbon atoms, or an alkenylene bridge of two, three, or four carbonatoms. Examples of tricyclic heterocycles include, but not limited to,octahydro-2,5-epoxypentalene,hexahydro-2H-2,5-methanocyclopenta[b]furan,hexahydro-1H-1,4-methanocyclopenta[c]furan, aza-adamantane(1-azatricyclo[3.3.1.1^(3,7)]decane), and oxa-adamantane(2-oxatricyclo[3.3.1.1^(3,7)]decane). The monocyclic, bicyclic, andtricyclic heterocycles are connected to the parent molecular moietythrough any carbon atom or any nitrogen atom contained within the rings,and can be unsubstituted or substituted.

The term “heteroaryl” as used herein, means a monocyclic heteroaryl or abicyclic heteroaryl. The monocyclic heteroaryl is a five- orsix-membered ring. The five-membered ring contains two double bonds. Thefive-membered ring may contain one heteroatom selected from O or S; orone, two, three, or four nitrogen atoms and optionally one oxygen orsulfur atom. The six-membered ring contains three double bonds and one,two, three or four nitrogen atoms. Representative examples of monocyclicheteroaryl include, but are not limited to, furanyl, imidazolyl,isoxazolyl, isothiazolyl, oxadiazolyl, 1,3-oxazolyl, pyridinyl,pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl,thiadiazolyl, 1,3-thiazolyl, thienyl, triazolyl, and triazinyl. Thebicyclic heteroaryl consists of a monocyclic heteroaryl fused to aphenyl, or a monocyclic heteroaryl fused to a monocyclic cycloalkyl, ora monocyclic heteroaryl fused to a monocyclic cycloalkenyl, or amonocyclic heteroaryl fused to a monocyclic heteroaryl, or a monocyclicheteroaryl fused to a monocyclic heterocycle. Representative examples ofbicyclic heteroaryl groups include, but are not limited to,benzofuranyl, benzothienyl, benzoxazolyl, benzimidazolyl,benzoxadiazolyl, 6,7-dihydro-1,3-benzothiazolyl,imidazo[1,2-a]pyridinyl, indazolyl, indolyl, isoindolyl, isoquinolinyl,naphthyridinyl, pyridoimidazolyl, quinolinyl,thiazolo[5,4-b]pyridin-2-yl, thiazolo[5,4-d]pyrimidin-2-yl, and5,6,7,8-tetrahydroquinolin-5-yl. The monocyclic and bicyclic heteroarylgroups of the present invention can be substituted or unsubstituted andare connected to the parent molecular moiety through any carbon atom orany nitrogen atom contained within the ring systems.

The term “heteroarylalkyl,” as used herein, means a heteroaryl groupappended to the parent molecular moiety through an alkyl group, asdefined herein.

The term “heteroatom” as used herein, means a nitrogen, oxygen, orsulfur atom.

The term “hydroxyl” or “hydroxy” as used herein, means an —OH group.

The term “hydroxyalkyl” as used herein, means at least one hydroxygroup, as defined herein, is appended to the parent molecular moietythrough an alkylene group, as defined herein. Representative examples ofhydroxyalkyl include, but are not limited to, hydroxymethyl,2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and2-ethyl-4-hydroxyheptyl.

The term “nitro” as used herein, means a —NO₂ group.

The term “oxo” as used herein, means a ═O group.

b. Compounds

Compounds of the invention have the formula (I) as described above.

Particular values of variable groups in compounds of formula (I) are asfollows. Such values may be used where appropriate with any of the othervalues, definitions, claims or embodiments defined hereinbefore orhereinafter.

More particularly, compound of formula (I) can include, but are notlimited to compounds wherein L¹-R¹ taken together are hydrogen, alkyl,hydroxyalkyl, G¹, or CH(G¹)₂.

In another embodiment, compound of formula (I) can include, but are notlimited to compounds wherein L¹ is C(O), S(O)₂, SO₂N(R⁴), C(O)O or—(CR^(a)R^(b))_(m)—; wherein m is 1,2,3, 4, 5, or 6.

In a further embodiment, compound of formula (I) can include, but arenot limited to compounds wherein L¹ is C(O), S(O)₂, or—(CR^(a)R^(b))_(m)—.

In another embodiment, compound of formula (I) can include, but are notlimited to compounds wherein R¹ is alkyl, G¹, CH(G¹)₂,—(CR^(a)R^(b))_(m-G) ¹, —(CR^(a)R^(b))_(m)—CH(G¹)₂,—(CR^(e)R^(f))_(n)—N(R⁵)₂, —(CR^(e)R^(f))_(n)—N(R⁵)—C(O)O(alkyl),—(CR^(e)R^(f))_(n)—N(R⁵)—C(O)(alkyl), or —(CR^(e)R^(f))_(n)—N(R⁵)—SO₂R⁶;wherein m is 1, 2, 3, 4, 5, or 6; and wherein n is 1, 2, 3, 4, or 5.

In a further embodiment, compound of formula (I) can include, but arenot limited to compounds wherein R¹ is G¹, CH(G¹)₂,—(CR^(a)R^(b))_(m)-G¹, —(CR^(a)R^(b))_(m)—CH(G¹)₂,

In one embodiment, compound of formula (I) can include, but are notlimited to compounds wherein L²-R² taken together are alkyl, G², orC(R^(c))(G²)(G³).

In a further embodiment, compound of formula (I) can include, but arenot limited to compounds wherein L²-R² together are alkyl, aryl,cycloalkyl, heteroaryl or —C(R^(c))(G²)(G³), wherein R^(c) is hydrogenand G² and G³ are each aryl or heteroaryl.

In another embodiment, compound of formula (I) can include, but are notlimited to compounds wherein L² is —(CR^(c)R^(d))_(p)—, C(O), C(O)N(R⁴),S(O)₂, SO₂N(R⁵), or C(O)O; wherein p is 1, 2, 3, 4, 5, or 6.

In a further embodiment, compound of formula (I) can include, but arenot limited to compounds wherein L² is —(CR^(c)R^(d))_(p)—, C(O),C(O)N(R⁴), or S(O)₂, wherein p is 1.

In another embodiment, compound of formula (I) can include, but are notlimited to compounds wherein R² is alkyl, G², —C(R^(c))(G²)(G³),—(CR^(c)R^(d))_(p)-G², —(CR^(c)R^(d))_(p)—CH(G²)(G³),—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)O(alkyl),—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)O-G², —(CR^(g)R^(h))_(q)—N(R⁵)—C(O)(alkyl),—(CR^(g)R^(h))_(q)—N(R⁵)—SO₂R⁶, —(CR^(g)R^(h))_(q)—N(R⁴)(R⁵),—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)N(R⁵)-(alkyl), or—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)N(R⁵)-G²; wherein q is 1, 2, 3, 4, or 5;and wherein p is 1, 2, 3, 4, 5, or 6.

In another embodiment, compound of formula (I) can include, but are notlimited to compounds wherein R^(a) and R^(b), at each occurrence, areeach independently hydrogen, alkyl, arylalkyl, halogen, or haloalkyl orOR⁷.

In a further embodiment, compound of formula (I) can include, but arenot limited to compounds wherein R^(a) and R^(b), at each occurrence,are each independently hydrogen, alkyl, or arylalkyl.

In yet another embodiment, compound of formula (I) can include, but arenot limited to compounds wherein R^(a) and R^(b), together with thecarbon atom to which they are attached, optionally form a C₃₋₆cycloalkyl ring.

In another embodiment, compound of formula (I) can include, but are notlimited to compounds wherein R^(c) and R^(d), at each occurrence, areeach independently hydrogen, alkyl, arylalkyl, halogen, or haloalkyl orOR⁷.

In a further embodiment, compound of formula (I) can include, but arenot limited to compounds wherein R^(c) and R^(d), at each occurrence,are each independently hydrogen, alkyl, arylalkyl, or OR⁷, wherein R⁷ ishydrogen.

In yet another embodiment, compound of formula (I) can include, but arenot limited to compounds wherein R^(c) and R^(d), together with thecarbon atom to which they are attached, optionally form a C₃₋₆cycloalkyl ring.

In one embodiment, compound of formula (I) can include, but are notlimited to compounds wherein R^(e) and R^(f), at each occurrence, areeach independently hydrogen, alkyl, halogen, haloalkyl, OR⁷,cycloalkylalkyl, heteroaryl, arylalkyl, or heteroarylalkyl; wherein thearyl, cycloalkyl and heteroaryl groups of aryl, cycloalkyl andheteroaryl are each independently unsubstituted or substituted with 1,2, 3, 4, or 5 substituents independently selected from the groupconsisting of alkyl and haloalkyl.

In another embodiment, compound of formula (I) can include, but are notlimited to compounds wherein R^(g), and R^(h), at each occurrence, areeach independently hydrogen, alkyl, halogen, haloalkyl, OR⁷,cycloalkylalkyl, heteroaryl, arylalkyl, or heteroarylalkyl; wherein thearyl, cycloalkyl and heteroaryl groups of aryl, cycloalkyl andheteroaryl are each independently unsubstituted or substituted with 1,2, 3, 4, or 5 substituents independently selected from the groupconsisting of alkyl and haloalkyl.

In a further embodiment, compound of formula (I) can include, but arenot limited to compounds wherein R^(g), and R^(h), at each occurrence,are each independently hydrogen, alkyl, arylalkyl or cycloalkyl.

In one embodiment, compound of formula (I) can include, but are notlimited to compounds wherein G¹ at each occurrence, is independentlyaryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; wherein G¹at each occurrence is independently unsubstituted or substituted with 1,2, 3, 4, or 5 substituents selected form the group consisting of alkyl,alkenyl, alkynyl, cyano, haloalkyl, halogen, nitro, oxo, phenyl, N(R⁷)₂,N(R⁷)C(O)R⁷, OR⁷, C(O)R⁷, C(O)OR⁷, C(O)N(R⁷)₂, SO₂R⁸, and SO₂N(R⁷)₂.

In another embodiment, compound of formula (I) can include, but are notlimited to compounds wherein G¹ at each occurrence, is independentlyaryl, cycloalkyl, or heteroaryl; wherein G¹ at each occurrence isindependently unsubstituted or substituted with 1, 2, or 3 substituentsselected form the group consisting of alkyl, cyano, haloalkyl, halogen,or OR⁷.

In one embodiment, compound of formula (I) can include, but are notlimited to compounds wherein G² at each occurrence, is independentlyaryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; wherein G²at each occurrence is independently unsubstituted or substituted with 1,2, 3, 4, or 5 substituents selected form the group consisting of alkyl,alkenyl, alkynyl, cyano, haloalkyl, halogen, nitro, oxo, phenyl, N(R⁷)₂,N(R⁷)C(O)R⁷, OR⁷, C(O)R⁷, C(O)0R⁷, C(O)N(R⁷)₂, SO₂R⁸, and SO₂N(R⁷)₂.

In a further embodiment, compound of formula (I) can include, but arenot limited to compounds wherein G² at each occurrence, is independentlyaryl, cycloalkyl, heteroaryl or heterocycle; wherein G² at eachoccurrence is independently unsubstituted or substituted with 1, 2, or 3substituents selected form the group consisting of alkyl, cyano,haloalkyl, halogen, nitro, oxo, OR⁷, C(O)R⁷, C(O)OR⁷ or SO₂R⁸,

In one embodiment, compound of formula (I) can include, but are notlimited to compounds wherein G³ at each occurrence, is independentlyaryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; wherein G²at each occurrence is independently unsubstituted or substituted with 1,2, 3, 4, or 5 substituents selected form the group consisting of alkyl,alkenyl, alkynyl, cyano, haloalkyl, halogen, nitro, oxo, phenyl, N(R⁷)₂,N(R⁷)C(O)R⁷, OR⁷, C(O)R⁷, C(O)OR⁷, C(O)N(R⁷)₂, SO₂R⁸, and SO₂N(R⁷)₂.

In a further embodiment, compound of formula (I) can include, but arenot limited to compounds wherein G³ at each occurrence, is independentlyaryl, cycloalkyl, heteroaryl or heterocycle; wherein G² at eachoccurrence is independently unsubstituted or substituted with 1, 2, or 3substituents selected form the group consisting of alkyl, cyano,haloalkyl, halogen, nitro, oxo, OR⁷, C(O)R⁷, C(O)OR⁷ or SO₂R⁸,

In one embodiment, compound of formula (I) can include, but are notlimited to compounds wherein R³ is hydrogen, alkyl, haloalkyl,cycloalkyl, or cycloalkylalkyl.

In a further embodiment, compound of formula (I) can include, but arenot limited to compounds wherein R³ is hydrogen, alkyl, or cycloalkyl.

In one embodiment, compound of formula (I) can include, but are notlimited to compounds wherein R⁴ and R⁵, at each occurrence, are eachindependently hydrogen, alkyl, aryl, arylalkyl, cycloalkyl,cycloalkylalkyl, or haloalkyl; wherein said aryl, the aryl of arylalkyland cycloalkyl are independently unsubstituted or substituted with 1, 23, 4, or 5 substituents independently selected from the group consistingof alkyl, haloalkyl, and halogen.

In a further embodiment, compound of formula (I) can include, but arenot limited to compounds wherein R⁴ and R⁵, at each occurrence, are eachindependently hydrogen, alkyl, arylalkyl, cycloalkyl or cycloalkylalkyl.

In one embodiment; compound of formula (I) can include, but are notlimited to compounds wherein R⁶ is alkyl, aryl, cycloalkyl,cycloalkenyl, heteroaryl, or heterocycle; wherein said aryl, heteroaryl,and heterocycle are independently unsubstituted or substituted with 1, 23, 4, or 5 substituents independently selected from the group consistingof alkyl, haloalkyl, and halogen.

In another embodiment, compound of formula (I) can include, but are notlimited to compounds wherein R⁶ is alkyl or cycloalkyl.

In one embodiment, compound of formula (I) can include, but are notlimited to compounds wherein R⁷, at each occurrence, is independentlyhydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, orhaloalkyl; wherein said aryl, the aryl of arylalkyl and cycloalkyl areindependently unsubstituted or substituted with 1, 2 3, 4, or 5substituents independently selected from the group consisting of alkyl,haloalkyl, and halogen.

In a further embodiment, compound of formula (I) can include, but arenot limited to compounds wherein R⁷, at each occurrence, isindependently hydrogen or alkyl.

In one embodiment, compound of formula (I) can include, but are notlimited to compounds wherein R⁸ is alkyl or haloalkyl.

In a further embodiment, compound of formula (I) can include, but arenot limited to compounds wherein R⁸ is alkyl.

In one embodiment, in a compound of formula (I), L¹ is—(CR^(a)R^(b))_(m)—; R^(a) and R^(b) are each hydrogen; m is 1; R¹ isG¹, wherein G¹ is aryl; L² is C(O); R² is —(CR^(c)R^(d))_(p)-G², whereinG² is aryl and p is 1; R^(c) and R^(d), together with the carbon atom towhich they are attached form a C₃₋₆ cycloalkyl ring; and R³ is hydrogen.

In another embodiment, in a compound of formula (I), L¹-R¹ together arealkyl; or L¹ is —(CR^(a)R^(b))_(m)—]or C(O); and R¹ is G¹; wherein G¹ isaryl, cycloalkyl, or heteroaryl; L² is C(O); R² is—(CR^(c)R^(d))_(p)-G²; wherein G² is aryl and p is 1 or 2; R^(a), R^(b),R^(c), and R^(d), at each occurrence are independently hydrogen, alkylor arylalkyl; and R³ is hydrogen or alkyl.

In one embodiment, in a compound of formula (I), L¹ is—(CR^(a)R^(b))_(m)—; m is 1 or 2; R^(a) and R^(b) are each hydrogen; R¹is G¹, wherein G¹ is aryl; L² is C(O)N(R⁴), wherein R⁴ is alkyl R² isG², wherein G² is aryl; and R³ is hydrogen.

In another embodiment, in a compound of formula (I), L¹ is—(CR^(a)R^(b))_(m)—, C(O), or S(O)₂; R^(a) and R^(b) at each occurrenceare each hydrogen; m is 1; R¹ is alkyl or G¹, wherein G¹ is aryl orcycloalkyl; L² is C(O); and R² is —(CR^(c)R^(d))_(p)-G²; wherein Rc andRd at each occurrence are independently hydrogen, alkyl or OR⁷; p is 1;G² is cycloalkyl or heterocycle; wherein said cycloalkyl or heterocycleis unsubstituted or substituted with 1, 2, 3, 4, or 5 substituentsindependently selected from the group consisting of alkyl, haloalkyl,halogen, oxo C(O)OR⁷; R⁷ is hydrogen; and R³ is hydrogen.

In one embodiment, in a compound of formula (I), L¹ is—(CR^(a)R^(b))_(m)—; R^(a) and R^(b) are each hydrogen; m is 1; R ¹ isG¹; wherein G¹ is aryl; L²-R² together are cycloalkyl; and R³ ishydrogen or cycloalkyl.

In another embodiment, in a compound of formula (I), L¹ is—(CR^(a)R^(b))_(m)—; R^(a) and R^(b) are each hydrogen; m is 1; R¹ isG¹; wherein G¹ is aryl; L² is C(O); R² is —C(R^(c))(G²)(G³) or—(CR^(c)R^(d))_(p)—CH(G²)(G³); wherein G² is aryl and G³ is aryl orcycloalkyl; R^(c) and R^(d), at each occurrence, are each independentlyhydrogen; p is 1, 2, 3, 4, or 5; and R³ is hydrogen.

In a further embodiment, in a compound of formula (I), L¹-R¹ togetherare hydrogen or —CH(G¹)₂; wherein each G¹ is aryl or heteroaryl; or L¹is —(CR^(a)R^(b))_(m)—, C(O), or S(O)₂; and R¹ is G¹, —CH(G¹)₂,—(CR^(a)R^(b))_(m)—G¹, —(CR^(a)R^(b))_(m)—CH(G¹)₂,—(CR^(e)R^(f))_(n)—N(R⁵)₂, wherein each G¹ is aryl or heteroaryl; R^(a)and R^(b) at each occurrence, are each independently hydrogen; R^(e) andR^(f) at each occurrence, are each independently hydrogen or alkyl; m is1, 2, 3, 4, or 5; n is 1 or 2; R⁵ is hydrogen or alkyl; L² is C(O); R²is —C(R^(c))(G²)(G³); wherein G² and G³ are each cycloalkyl; R^(c) ishydrogen or OR⁷, R⁷ is hydrogen; and R³ is hydrogen.

In one embodiment, in a compound of formula (I), L¹ is—(CR^(a)R^(b))_(m)—; R^(a) and R^(b) are each hydrogen; m is 1; R¹ isG¹, wherein G¹ is aryl; L² is C(O); R² is alkyl or G²; wherein G² iscycloalkyl or heterocycle; R³ is hydrogen.

In another embodiment, in a compound of formula (I), L¹ is—(CR^(a)R^(b))_(m)—, C(O) or S(O)₂, wherein R^(a) and R^(b) are eachhydrogen and m is 1 or 2; R¹ is G¹, —CH(G¹)₂ or —(CR^(a)R^(b))_(m)-G¹,wherein G¹ at each occurrence is aryl or heteroaryl; L² is C(O); R² is—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)O(alkyl),—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)O-G², —(CR^(g)R^(h))_(q)—N(R⁵)—C(O)(alkyl),—(CR^(g)R^(h))_(q)—N(R⁵)—SO₂R⁶, —(CR^(g)R^(h))_(q)—N(R⁴)(R⁵),—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)N(R⁵)-(alkyl), or—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)N(R⁵)-G²; q is 1 or 2; R^(g) and R^(h), ateach occurrence, are each independently hydrogen, alkyl, arylalkyl orcycloalkylalkyl; R⁴ and R⁵ at each occurrence, are each independentlyhydrogen, alkyl, arylalkyl, or cycloalkyl; R⁶ is alkyl, aryl, orcycloalkyl; G² is aryl or cycloalkyl; and R³ is hydrogen, alkyl,cycloalkyl or cycloalkylalkyl.

In one embodiment, in a compound of formula (I), L¹-R¹ together arehydrogen or hydroxyalkyl; or L¹ is —(CR^(a)R^(b))_(m)—, C(O) or S(O)₂;and R¹ is G¹ or —CH(G¹)², wherein G¹ is aryl or heteroaryl, and whereinR^(a) and R^(b), at each occurrence, are each independently hydrogen oralkyl; m is 1, 2, 3, 4, or 5; L² is S(O)₂; R² is G², wherein G² is arylor heteroaryl; and R³ is hydrogen, alkyl or cycloalkyl.

In a further embodiment, in a compound of formula (I), L¹ is—(CR^(a)R^(b))_(m)—; R^(a) and R^(b), at each occurrence, are eachindependently hydrogen; m is 1, 2, 3, 4, or 5; L² is C(O); R² is—(CR^(c)R^(d))_(p)-G²; wherein G² is aryl; p is 1; R^(c) and R^(d), ateach occurrence, are each independently hydrogen or alkyl; and R³ ishydrogen.

In another embodiment, in a compound of formula (I), L¹ is C(O), S(O)₂or —(CR^(a)R^(b))_(m)—; R^(a) and R^(b), at each occurrence, areindependently hydrogen or alkyl; m is 1; R¹ is G¹ or—(CR^(a)R^(b))_(m)-G¹, wherein G¹ is aryl or heteroaryl; L² is—(CR^(c)R^(d))_(p)—; R^(c) and R^(d) are each hydrogen; p is 1; R² isG², wherein G² is aryl, cycloalkyl or heteroaryl; or L²-R² takentogether are alkyl, G², or —C(R^(c))(G²)(G³), wherein G² and G³ are eacharyl or heteroaryl and R^(c) is hydrogen; and R³ is hydrogen or alkyl.

In a further embodiment, in a compound of formula (I), L¹ is C(O); R¹ is—(CR^(e)R^(f))_(n)—N(R⁵)₂; n is 1 or 2; R^(e) and R^(f) at eachoccurrence are each independently hydrogen or alkyl; R⁵ at eachoccurrence is independently hydrogen or alkyl; L² is C(O) or S(O)₂; R²is G² or —C(R^(c))(G²)(G³), wherein G² and G³ are each aryl orheteroaryl and R^(e) is hydrogen; and R³ is hydrogen, alkyl, orcycloalkyl. In an additional embodiment, in a compound of formula (I),L¹ is C(O); R¹ is —(CR^(e)R^(f))_(n)—N(R⁵)₂ or—(CR^(e)R^(f))_(n)—N(R⁵)C(O)O(alkyl); n is 1 or 2; R³ and R^(f) at eachoccurrence are each independently hydrogen, alkyl, or arylalkyl; R⁵ ateach occurrence is independently hydrogen, alkyl or cycloalkyl; L² isC(O); R² is —(CR^(g)R^(h))_(q)N(R⁴)(R⁵) or—(CR^(g)R^(h))_(q)—N(R⁵)C(O)O(alkyl); q is 1 or 2; R⁴ is hydrogen oralkyl; R^(g) and R^(h) at each occurrence are each independentlyhydrogen or alkyl; and R³ is hydrogen.

In another embodiment, in a compound of formula (I), L¹-R¹ takentogether are hydrogen, G¹ or CH(G¹)₂, wherein G¹ is aryl or heteroaryl;L² is C(O); R² is —(CR^(g)R^(h))_(q)N(R⁴)(R⁵) or—(CR^(g)R^(h))_(q)—N(R⁵)C(O)P(alkyl); q is 1 or 2; R⁴ is hydrogen,alkyl, or cycloalkylalkyl; R⁵ is hydrogen or alkyl; R^(g) and R^(h) ateach occurrence are each independently hydrogen or alkyl; and R³ ishydrogen. In a further embodiment, in a compound of formula (I), L¹-R¹taken together are G¹, wherein G¹ is aryl or heteroaryl; L² is C(O); R²is G², wherein G² is aryl or heteroaryl; and R³ is hydrogen or alkyl.

Specific embodiments of compounds contemplated as part of the inventioninclude, but are not limited to:

N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclopentanecarboxamide;

N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclopentanecarboxamide;

N-[(3aR*,4R*,6aS*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclohexyl-2-phenylacetamide;

N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclohexyl-2-phenylacetamide;

N-[(3aR*,4R*,6aS*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3aR*,4S*,6aS*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-phenylacetamide;

N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide;

N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;

N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;

N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

(2S)-2-(3-benzoylphenyl)-N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]propanamide;

(2S)-2-(3-benzoylphenyl)-N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]propanamide;

N-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylpropanamide;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-propylpentanamide;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]cycloheptanecarboxamide;

(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(4-isobutylphenyl)propanamide;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,3-diphenylpropanamide;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-methyl-3-phenylpropanamide;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-methyl-2-phenylpropanamide;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclopropanecarboxamide;

2-benzyl-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethylbutanamide;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;

(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;

(2R)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;

(2S)—N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

(2R)—N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide;

(2R)—N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylpropanamide;

(2S)—N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylpropanamide;

(2S)—N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(4-isobutylphenyl)propanamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopropyl-2-phenylacetamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclobutyl-2-phenylacetamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(4-chlorophenyl)-methylbutanamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-ethyl-2-phenylpentanamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(4-hydroxyphenyl)-3-methylbutanamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-methyl-2-phenylpropanamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclopropanecarboxamide;

2-benzyl-N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethylbutanamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,3-diphenylpropanamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-methyl-3-phenylpropanamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;

2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(2-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

N-{(3aS,4S,6aR)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[2-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(3-methylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(4-methylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-(trifluoromethoxy)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(3-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

N-{(3aS,4S,6aR)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

N-{(3aS,4S,6aR)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

N-{(3aS,4S,6aR)-2-[3-(3-chlorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-(3-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(3-phenylpropyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{3-[4-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide;

2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(pyridin-4-ylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(pyridin-3-ylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

2,2-dicyclohexyl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-N-{(3aS,4R,6aR)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

N-{(3aS,4R,6aR)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

N-{(3aS,4R,6aR)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

2,2-dicyclohexyl-N-[(3aS,4R,6aR)-2-(3,3-diphenylpropyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

N-{(3aS,4R,6aR)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

N-{(3aS,4R,6aR)-2-[4,4-bis(4-fluorophenyl)butyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;

3-methyl-2-phenyl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

N-[(3aR,4S,6aS)-2-(cyclohexylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

3-methyl-N-[(3aR,4S,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide;

N-[(3aR,4S,6aS)-2-(2-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3aR,4S,6aS)-2-(3-chlorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3aR,4S,6aS)-2-(3-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

3-methyl-2-phenyl-N-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

N-[(3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3aR,4S,6aS)-2-(3-methoxybenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

3-methyl-N-[(3aR,4S,6aS)-2-(3-methylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide;

3-methyl-N-[(3aR,4S,6aS)-2-(2-methylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide;

N-[(3aR,4S,6aS)-2-(2,6-dimethylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3aR,4S,6aS)-2-(2-methoxybenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutamide;

N-[(3aR,4S,6aS)-2-(4-tert-butylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3aR,4S,6aS)-2-(4-methoxybenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-[(3aR,4S,6aS)-2-(3-cyanobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

3-methyl-2-phenyl-N-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

3-methyl-2-phenyl-N-{(3aR,4S,6aS)-2-[2-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

N-{(3aR,4S,6aS)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-{(3aR,4S,6aS)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

3-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(thien-2-ylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide;

3-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(pyridin-4-ylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide;

3-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(2-phenylethyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide;

3-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(3-phenylpropyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide;

N-{(3aR,4S,6aS)-2-[3-(4-tert-butylphenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-{(3aR,4S,6aS)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

3-methyl-N-{(3aR,4S,6aS)-2-[3-(2-methylphenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2-phenylbutanamide;

N-{(3aR,4S,6aS)-2-[3-(3-chlorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

3-methyl-N-{(3aR,4S,6aS)-2-[3-(3-methylphenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2-phenylbutanamide;

3-methyl-2-phenyl-N-((3aR,4S,6aS)-2-{3-[3-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[c]pyrrol-4-yl)butanamide;

N-{(3aR,4S,6aS)-2-[3-(3-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

3-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(4-phenylbutyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide;

N-{(3aR,4S,6aS)-2-[3-(3-chloro-5-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

3-methyl-2-phenyl-N-((3aR,4S,6aS)-2-{3-[4-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[c]pyrrol-4-yl)butanamide;

N-[(3aR,4S,6aS)-2-(3,3-diphenylpropyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N-{(3aR,4S,6aS)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-{(3aR,4S,6aS)-2-[4,4-bis(4-fluorophenyl)butyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-{(3aR,4S,6aS)-2-[5,5-bis(4-fluorophenyl)pentyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;

N-[(3aS,4S,6aR)-2-benzhydryloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

N-[(3aS,4R,6aR)-2-benzhydryloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide;

3-methyl-2-phenyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

3,3-dimethyl-2-phenyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

2,2-dicyclohexyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

2-ethyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

2-propyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide;

N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}cyclohexanecarboxamide;

N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}cycloheptanecarboxamide;

N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}cyclopentanecarboxamide;

6,6-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}hexanamide;

3,3-diphenyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}propanamide;

5,5-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide;

3,3-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}propanamide;

4,4-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

2,2-diphenyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

2,2-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

N²-(tert-butyloxycarbonyl)-N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-(tert-butyloxycarbonyl)-N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;

N²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;

6,6-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}hexanamide;

3,3-diphenyl-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}propanamide;

5,5-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide;

3,3-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}propanamide;

4,4-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

2,2-diphenyl-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

2,2-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

3,3-dimethyl-2-phenyl-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

N²-(tert-butyloxycarbonyl)-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-(tert-butyloxycarbonyl)-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;

N²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamide;

2,2-dicyclohexyl-2-hydroxy-N-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

N²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

2,2-dicyclohexyl-2-hydroxy-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

N²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

2,2-dicyclohexyl-N-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-N-{(3aR,4R,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;

N²-methyl-N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;

N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;

N²-methyl-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;

N²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;

N²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-methyl-N²-(methylsulfonyl)-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-N²-(methylsulfonyl)-L-leucinamide;

N²-methyl-N²-(methylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-(methylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-(methylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;

N²-(cyclopropylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-(isobutylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-(cyclopropylsulfonyl)-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-acetyl-N²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-(2,2-dimethylpropanoyl)-N²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-(2,2-dimethylpropanoyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

isobutyl(S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;

cyclopentyl(S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;

N²-[(tert-butylamino)carbonyl]-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-[(cyclopentylamino)carbonyl]-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-methyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N¹(3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

3-(trifluoromethyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide;

3-(trifluoromethyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide;

3-(trifluoromethyl)-N-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide;

3-(trifluoromethyl)-N-{(3aR,4R,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide;

3-(trifluoromethyl)-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

N-{(3aS,4R,6aR)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;

N-{(3aS,4R,6aR)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;

N-{(3aS,4R,6aR)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;

N-{(3aS,4R,6aR)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;

N-[(3aS,4S,6aR)-2-(4-hydroxybutyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

(3aS*,4S*,6aR*)-N,N-dicyclopropyl-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-amine;

(3aS*,4R*,6aR*)-2-benzyl-N-cyclopropyloctahydrocyclopenta[c]pyrrol-4-amine;

(3aS*,4S*,6aR*)-2-benzyl-N-cyclopropyloctahydrocyclopenta[c]pyrrol-4-amine;

N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-cyclopropyl-N-[(3aS*,4S*,6aR*)-octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

N-{(3aS*,4S*,6aR*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-N-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-{(3aS*,4S*,6aR*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-N-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-cyclopropyl-3-(trifluoromethyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide;

2,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide;

2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[(2-phenylethyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

2,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{[2-(1-naphthyl)ethyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide;

2,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{[3-(trifluoromethyl)benzyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide;

2,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{[2-(4-fluorophenyl)ethyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide;

(2S)-2-phenyl-N-{(3aR,4R,6aS)-2-[(1S)-1-phenylethyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

(2S)-2-phenyl-N-{(3aR,4S,6aS)-2-[(1S)-1-phenylethyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

(2S)-2-phenyl-N-{(3aS,4S,6aR)-2-[(1S)-1-phenylethyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

(2S)-2-phenyl-N-{(3aS,4R,6aR)-2-[(1S)-1-phenylethyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N,3-dimethyl-2-phenylbutanamide;

N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N,3-dimethyl-2-phenylbutanamide;

(3aR*,4S*,6aS*)-N-benzyl-2-(3-methyl-2-phenylbutanoyl)octahydrocyclopenta[c]pyrrol-4-amine;

2,2-dicyclohexyl-N-[(3aS,4R,6aR)-2-(N,N-dimethyl-D-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

N-[(3aR,4S,6aS)-2-benzoyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;

N′-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-isopropyl-N-phenylurea;

(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide;

tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-ylcarbamate;

tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(ethyl)carbamate;

tert-butyl(2S,3S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate;

tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamate;

tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxohexan-2-yl(methyl)carbamate;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-bis(4-fluorophenyl)acetamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methylbutanamide;

tert-butyl(2S)-2-({[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylate;

tert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamate;

tert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide;

N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methylbutanamide;

2-cyclohexyl-2-hydroxy-N-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;

tert-butyl(S)-1-((3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl(S)-1-((3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl(S)-1-((3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl(S)-1-((3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

S-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(methylsulfonyl)-L-leucinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(methylsulfonyl)-L-leucinamide;

N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-neopentyl-L-leucinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-neopentyl-L-leucinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-neopentyl-L-norvalinamide;

tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;

(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-morpholin-4-ylpentanamide;

(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide;

(2S)—N-(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-piperidin-1-ylpentanamide;

N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-neopentyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-neopentyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N-(tert-butoxycarbonyl)-N-methyl-N-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide;

tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

N²-neopentyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-neopentyl-L-leucinamide;

tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;

isopropyl(S)-1-oxo-1-((3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;

tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(6-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;

tert-butyl(S)-4,4-dimethyl-1-((3aR,4S,6aS)-2-(2-(methylsulfonyl)pyrimidin-5-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-ylcarbamate;

(S)-tert-butyl2-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate;

tert-butyl(1R)-1-isopropyl-3-oxo-3-[((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]propylcarbamate;

tert-butyl(2S)-2-{[((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate;

N-(tert-butoxycarbonyl)-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide;

N-(tert-butoxycarbonyl)-N-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide;

(S)-tert-butyl2-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate;

tert-butyl(1R)-1-isopropyl-3-oxo-3-[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]propylcarbamate;

tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamate;

tert-butyl(2S)-2-{[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate;

tert-butyl(3S)-3-{[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate;

tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;

tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)hexan-2-yl)carbamate;

tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

isopropyl(S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;

isopropyl(S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;

(3aS,4R,6aR)—N-neopentyl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)—N-neopentyl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)—N-isopropyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N-isopropyloctahydrocyclopenta[c]pyrrol-4-amine;

(3aS,4R,6aR)—N-(4-fluorobenzyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)—N-(4-fluorobenzyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)—N-(4-fluorobenzyl)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)—N-ethyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)—N,N-diethyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)—N-propyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)—N,N-dipropyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)—N-(cyclopropylmethyl)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N-ethyloctahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N,N-diethyloctahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-amine;

tert-butyl(S)-1-(ethyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl(S)-4,4-dimethyl-1-oxo-1-(propyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)pentan-2-yl(methyl)carbamate;

tert-butyl(S)-1-((cyclopropylmethyl)((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;

2-nitro-N-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)benzenesulfonamide;

N-methyl-2-nitro-N-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)benzenesulfonamide;

(3aR,4S,6aS)—N-methyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;

tert-butyl(S)-4,4-dimethyl-1-(methyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-1-oxopentan-2-yl(methyl)carbamate;

(2S)-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methyl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide;

2-isopropyl-3-methyl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

2-isopropyl-3-methyl-N-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;

tert-butyl(S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;

tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butylethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl(S)-1-((3aS,4R,6aR)-2-(3-fluoro-4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluoro-3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamate;

tert-butylmethyl((S)-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

(2S)-4-methyl-2-morpholin-4-yl-N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;

(2S)-4-methyl-2-pyrrolidin-1-yl-N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;

(2S)-4-methyl-2-piperidin-1-yl-N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;

tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butylethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluoro-3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;

tert-butylmethyl((S)-1-oxo-1-((3aR,4R,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4R,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butylmethyl((S)-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylmethyl)carbamate;

tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;

tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;

tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;

tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamate;

tert-butyl(S)-3,3-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-ylcarbamate;

tert-butyl(S)-3,3-dimethyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-ylcarbamate;

tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)hexan-2-yl)carbamate;

tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;

(2S)-4-methyl-2-pyrrolidin-1-yl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzoyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide;

(2S)-4-methyl-N-[(3aS,4R,6aR)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-2-pyrrolidin-1-ylpentanamide;

(2S)—N-[(3aS,4R,6aR)-2-(cyclopropylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide;

N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;

tert-butylmethyl((S)-4-methyl-1-((3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl)carbamate;

(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]piperidine-2-carboxamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-valinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;

N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-isoleucinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-isoleucinamide;

N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²,4-dimethyl-L-leucinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-L-valinamide;

N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-L-valinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²,4-dimethyl-L-leucinamide;

N¹-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;

N¹-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;

N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-L-leucinamide;

N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norleucinamide;

N¹-[(3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;

N¹-[(3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;

N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;

N²-ethyl-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-methyl-N¹-{(3aS,4R,6aR)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-valinamide;

(2S)—N-[(3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]piperidine-2-carboxamide;

N¹-[(3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-valinamide;

(2S)—N-{(3aS,4R,6aR)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}piperidine-2-carboxamide;

N²-methyl-N¹-{(3aS,4R,6aR)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;

N¹-[(3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;

N²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-valinamide;

N¹-{(3aS,4R,6aR)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;

N¹-{(3aS,4R,6aR)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;

N²-methyl-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;

N²-methyl-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;

N¹-[(3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;

N²-methyl-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-methyl-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N¹-[(3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;

N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;

N²-ethyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide;

N-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide;

N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-prolinamide;

(3R)-3-amino-4-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;

N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide;

(2S)—N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)piperidine-2-carboxamide;

(3S)—N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;

4-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norleucinamide;

N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-prolinamide;

(3R)-3-amino-4-methyl-N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;

(2S)—N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)piperidine-2-carboxamide;

(2S)—N-{(3aS,4R,6aR)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}piperidine-2-carboxamide;

N¹-{(3aS,4R,6aR)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-valinamide;

(2S)—N-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)piperidine-2-carboxamide;

N²-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide;

N¹-{(3aS,4R,6aR)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;

N²-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-methyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide;

N¹-((3aS,4R,6aR)-2-{[4-fluoro-3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-leucinamide;

3-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide;

3-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide;

N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-isoleucinamide;

N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-isoleucinamide;

N²-methyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-isoleucinamide;

N²-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-isoleucinamide;

N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²,4-dimethyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²,4-dimethyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norleucinamide;

4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-methyl-N¹-((3aR,4R,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-methyl-N¹-((3aR,4R,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N¹(3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N¹-(3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N¹-(3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

3-cyclohexyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-alaninamide;

3-cyclohexyl-N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-alaninamide;

N¹-((3aR,4S,6aS)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-L-leucinamide;

N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-L-leucinamide;

N-methyl-N-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide;

N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²,4-dimethyl-L-leucinamide;

N-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N-methyl-L-phenylalaninamide;

N¹-cyclopropyl-N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N¹-ethyl-N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²,4-dimethyl-N¹-propyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N¹-(cyclopropylmethyl)-N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N¹,N²,4-trimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N¹,N²-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N¹,N²,4-trimethyl-L-leucinamide;

4-methyl-N¹-{(3aR,4S,6aS)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

4-methyl-N¹-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

4-methyl-N¹-{(3aR,4S,6aS)-2-[2-(methylsulfonyl)pyrimidin-5-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N¹-{(3aS,4R,6aR)-2-[(3-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;

N¹-{(3aS,4R,6aR)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;

N¹-{(3aS,4R,6aR)-2-[(3,4-difluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;

N¹-{(3aS,4R,6aR)-2-[(3,5-difluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;

N¹-{(3aS,4R,6aR)-2-[(4-chlorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;

N²-methyl-N¹-[(3aS,4R,6aR)-2-(phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-leucinamide;

N²-methyl-N¹-{(3aS,4R,6aR)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N¹-[(3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;

N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide;

N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-valinamide;

N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-4-methyl-L-leucinamide;

N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norleucinamide;

N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;

N²-methyl-N¹-((3aS,4S,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-methyl-N¹-((3aS,4S,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N¹-{(3aR,4S,6aS)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;

2,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-2-(N-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

2,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-2-(N-methyl-L-norvalyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

N-[(3aR,4S,6aS)-2-(N,4-dimethyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-2,2-bis(4-fluorophenyl)acetamide;

2,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-2-(4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

tert-butyl(S)-1-((3aR,4S,6aS)-4-((S)-2-(tert-butoxycarbonylamino)-4,4-dimethylpentanamido)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4,4-dimethyl-1-oxopentan-2-ylcarbamate;

4-methyl-N¹-[(3aR,4S,6aS)-2-(4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-leucinamide;

4-methyl-N¹-[(3aR,4S,6aS)-2-L-phenylalanyloctahydrocyclopenta[c]pyrrol-4-yl]-L-leucinamide;

(3aR,4S,6aS)—N-benzhydryl-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-amine;

(3aS,4R,6aR)—N-benzhydryl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;

(3aR,4S,6aS)—N-benzhydryl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;

N¹-[(3aS,4R,6aR)-2-benzhydryloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;

4-methyl-N²-propyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-(cyclopropylmethyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-(cyclobutylmethyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-isobutyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-(cyclopentylmethyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-(cyclohexylmethyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-butyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-ethyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-(cyclopropylmethyl)-4-methyl-N¹-{(3aR,4S,6aS)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-(cyclopropylmethyl)-4-methyl-N¹-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-isopropyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-isopropyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-isopropyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-isopropyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-isopropyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

3-cyclohexyl-N²-isopropyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-alaninamide;

N¹-((3aR,4S,6aS)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-isopropyl-4-methyl-L-leucinamide;

N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-isopropyl-4-methyl-L-leucinamide;

N²-isopropyl-N¹-[(3aR,4S,6aS)-2-(N-isopropyl-4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-L-leucinamide;

N²-isopropyl-N¹-[(3aR,4S,6aS)-2-(N-isopropyl-L-phenylalanyl)octahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-L-leucinamide;

N²-isopropyl-4-methyl-N¹-{(3aR,4S,6aS)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-isopropyl-4-methyl-N¹-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

2,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-2-(N-isopropyl-4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;

N²-isopropyl-4-methyl-N¹-{(3aR,4S,6aS)-2-[2-(methylsulfonyl)pyrimidin-5-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-isopropyl-L-norvalinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-isopropyl-L-norvalinamide;

N²-isopropyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²,N²-dimethyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

(3R)-3-(dimethylamino)-4-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;

N²-cyclopropyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²,N²-dicyclopropyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-cyclopentyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-cyclohexyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-(1-ethylpropyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-cyclobutyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

4-methyl-N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N²-cyclopentyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-cyclohexyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-cyclopentyl-N¹-[(3aR,4S,6aS)-2-(N-cyclopentyl-4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-L-leucinamide;

N²,N²-dimethyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-N²-neopentyl-L-leucinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(3,3-dimethylbutyl)-N²-methyl-L-leucinamide;

N²,N²-dimethyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;

N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(4-fluorobenzyl)-N²-methyl-L-leucinamide;

(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-(methylsulfonyl)piperidine-2-carboxamide;

(3R)-4-methyl-3-[(methylsulfonyl)amino]-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;

N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;

N²-ethyl-N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

4-methyl-N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

3-methyl-N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-valinamide;

N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;

N²-(isopropylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-(phenylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

N²-(cyclopentylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;

isopropyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;

isopropyl(S)-3,3-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-ylcarbamate;

cyclopentyl(S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;

N²-(2,2-dimethylpropanoyl)-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;

tert-butyl(S)-1-((3aR,4S,6aS)-2-(3-chloro-4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;

tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(pyridin-3-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(thiophen-2-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;

N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethoxy)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-methyl-N¹-[(3aR,4S,6aS)-2-(thien-2-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-norvalinamide;

N¹-{(3aR,4S,6aS)-2-[(3-chloro-4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;

N²-methyl-N¹-[(3aR,4S,6aS)-2-(pyridin-3-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-norvalinamide;

N¹-{(3aR,4S,6aS)-2-[(4-cyanophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;

N¹-{(3aR,4S,6aS)-2-[(4-methoxyphenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;

N¹-(3aR,4S,6aS)-2-{[3,5-bis(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-norvalinamide;

N¹-{(3aR,4S,6aS)-2-[(2-chloro-4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;

N²-methyl-N¹-[(3aR,4S,6aS)-2-(1-naphthylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-norvalinamide;

N¹-((3aR,4S,6aS)-2-{[4-bromo-3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-norvalinamide;

N¹-{(3aR,4S,6aS)-2-[(3,4-dichlorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;

N¹-{(3aR,4S,6aS)-2-[(4-tert-butylphenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;

N¹-[(3aR,4S,6aS)-2-(1,1′-biphenyl-4-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;

N¹-{(3aR,4S,6aS)-2-[(3,4-dimethoxyphenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;

N¹-{(3aR,4S,6aS)-2-[(3-cyanophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;

N¹-[(3aR,4S,6aS)-2-(2-furylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;

N¹-{(3aR,4S,6aS)-2-[(2,3-dichlorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;

N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)benzyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N²-methyl-N¹-((3aR,4S,6aS)-2-{[2-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;

N¹-{(3aR,4S,6aS)-2-[(3-bromophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;

N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-norvalinamide;

N¹-((3aR,4S,6aS)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-norvalinamide;

N²-methyl-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzoyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-isopropyl-3-(trifluoromethyl)benzenesulfonamide;

N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

N-isopropyl-N-[(3aR,4S,6aS)-2-(N-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

N-[(3aR,4S,6aS)-2-(N-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;

N-cyclopropyl-N-[(3aS*,4S*,6aR*)-[2-(N-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;and

4-fluoro-N-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}benzamide.

Compounds of the present application may exist as stereoisomers wherein,asymmetric or chiral centers are present. These stereoisomers are “R” or“S” depending on the configuration of substituents around the chiralcarbon atom. The terms “R” and “S” used herein are configurations asdefined in IUPAC 1974 Recommendations for Section E, FundamentalStereochemistry, Pure Appl. Chem., 1976, 45: 13-30.

On occasion, the relative stereochemistry of an enantiomeric pair isknown, however, the absolute configuration is not known. In thatcircumstance, the relative stereochemistry descriptor terms “R*” and“S*” are used. The terms “R*” and “S*” used herein are defined in Eliel,E. L.; Wilen, S. H. Stereochemistry of Organic Compounds; John Wiley &Sons, Inc.: New York, 1994; pp 119-120 and 1206. In a particularenantiomeric pair, the relative descriptors are reversed to indicatethat this pair of enantiomers is of unknown absolute stereochemistry.

The present application contemplates various stereoisomers and mixturesthereof and these are specifically included within the scope of thisapplication. Stereoisomers include enantiomers and diastereomers, andmixtures of enantiomers or diastereomers. Individual stereoisomers ofcompounds of the present application may be prepared synthetically fromcommercially available starting materials which contain asymmetric orchiral centers or by preparation of racemic mixtures followed byresolution which is well known to those of ordinary skill in the art.These methods of resolution are exemplified by (1) attachment of amixture of enantiomers to a chiral auxiliary, separation of theresulting mixture of diastereomers by recrystallization orchromatography and liberation of the optically pure product from theauxiliary or (2) direct separation of the mixture of optical enantiomerson chiral chromatographic columns.

Geometric isomers may exist in the present compounds. The inventioncontemplates the various geometric isomers and mixtures thereofresulting from the disposition of substituents around a carbon-carbondouble bond, a carbon-nitrogen double bond, a cycloalkyl group, or aheterocycle group. Substituents around a carbon-carbon double bond or acarbon-nitrogen bond are designated as being of Z or E configuration andsubstituents around a cycloalkyl or a heterocycle are designated asbeing of cis or trans configuration.

Within the present invention it is to be understood that compoundsdisclosed herein may exhibit the phenomenon of tautomerism.

Thus, the formulae drawings within this specification can represent onlyone of the possible tautomeric or stereoisomeric forms. It is to beunderstood that the invention encompasses any tautomeric orstereoisomeric form, and mixtures thereof, and is not to be limitedmerely to any one tautomeric or stereoisomeric form utilized within thenaming of the compounds or formulae drawings.

Compounds of this invention can exist in an isotopic form containing oneor more atoms having an atomic mass or mass number different from theatomic mass or mass number most abundantly found in nature. Isotopes ofatoms such as hydrogen, carbon, phosphorous, sulfur fluorine, chlorine,and iodine include, but are not limited to ²H, ³H, ¹¹C, ¹⁴C, ³²P, ³⁵S,¹⁸F, ³⁶Cl, and ¹²⁵I, respectively. Compounds that contain other isotopesof these and/or other atoms are within the scope of this invention.Compounds containing tritium (³H) and ¹⁴C radioisotopes are preferred ingeneral for their ease in preparation and detectability for radiolabeledcompounds. Isotopically labeled compounds of this invention can beprepared by the general methods well known to persons having ordinaryskill in the art. Such Isotopically labeled compounds can beconveniently prepared by carrying out the procedures disclosed in theExamples and Schemes below by substituting a readily availableisotopically labeled reagent for a non-isotopically labeled reagent.

c. Biological Data

Abbreviations which have been used in the descriptions of BiologicalData that follow are: EDTA for ethylenediaminetetraacetic acid; FBS forfetal bovine serum; FLIPR for fluorometric imaging plate reader; HBSSfor Hank's balanced salt solution; HEPES for4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; i.p. forintraperitoneal; MEM for minimum essential medium; MEM NEAA for minimumessential medium non-essential amino acid; p.o. for per orem (by mouth).

(i) In Vitro Methods—Assessment of Calcium Channel Activity Using FLIPR:

IMR32 cells endogenously expressing human Ca_(v)2.2 were assayed forCa²⁺ influx using a no-wash calcium indicator dye (Calcium 4 dye:Molecular Probes) and FLIPR technology (Lubin, M. L.; Reitz, T. L.;Todd, M. J.; Flores, C. M.; Qin, N.; Xin, H. A nonadherent cell-basedHTS assay for N-type calcium channel using calcium 3 dye. Assay and DrugDevelopment Technologies 2006, 4(6), 689-694.). The IMR32 cells weremaintained in MEM media containing 10% (v/v) FBS, 1% (v/v)antibiotic/antimitotic, 1% (v/v) sodium pyruvate and 1% (v/v) MEM NEAA.Following dissociation in 0.05% (v/v) trypsin/EDTA, cells were seededinto black 1×96-well plates (Corning Cellbind) at a density of 1-1.2×10⁵cells/well and incubated in the maintenance media above for 48 hours at37° C. Immediately prior to performing the assay the media was removedand cells were loaded for 1.5 hours with 1× Calcium 4 dye prepared inHBSS (137 mM NaCl, 5.4 mM KCl, 0.25 mM Na₂HPO₄, 0.44 mM KH₂PO₄, 1.3 mMCaCl₂, 1 mM MgSO₄, 4.2 mM NaHCO₃) containing HEPES pH 7.4 at roomtemperature. After dye loading and a subsequent 3 minute or 60 minutepre-incubation with compounds (full log dilutions from 10 μM to 0.1 nM)in the presence of 1.3 mM CaCl₂ and 2 μM nifedipine to block endogenousL-type channels, the external Ca²⁺ concentration was increased to 5 mMCaCl₂ and the cells concomitantly depolarized with 80 mM KCl to assaychannel activity. To determine the IC₅₀ values, the percent inhibitionof the compound at each concentration was determined relative to theactivity in the absence of inhibitor, and data was fitted usingnon-linear regression sigmoidal dose response curve analysis withGraphPad Prism®.

IC₅₀ (μM) or percent inhibition (* indicates 3 minute incubation,otherwise 60 Example minute) 1 3.5* 2 4.2* 3 91% @ 10 μM 4 3.5* 5 3.8* 62.2* 7 1.8* 8 1.1  9 1.8* 10 1.3* 11 4   13 23    14 3.8  15 15.7  169.8  17 1.6  18 2.7  19 25% @ 10 μM* 20 1.8  21 10.1*  22 14.7*  23 2.5 24 2.9* 25 3.7* 26 17.3*  27 9.7* 28 13.9*  29 5.6* 30 1.8  31 1.6  321.4  33 7.4  34 1.5  35 3.3  36 44% @ 10 μM* 37 15% @ 10 μM* 38 27% @ 10μM* 39 92% @ 10 μM* 40 3.6* 41 56% @ 10 μM* 43 1.5  44 1.7* 46 3.1* 4715.6*  48 10.5*  49 4.6* 50 5.0* 51 15.2*  52 3.4  53 8.6  54 0.5  550.8  56 1   57 0.3  58 1.4  59 0.5  60 1.5  61 1.5  62 1.6  63 0.6  641.3  65 4.5  66 0.9  67 1.3  68 1.7  69 1.7  70 1.9  71 1.2  72 3.2  733.3  74 11.2*  75 0.5  76 5.7  77 9.4  78 0.4  79 0.9  80 1.7  81 1.1 82 1.5  83 2.6* 84 5.8% @ 10 μM*  85 3.6  86 1.6  87 3.1  88 1.2  89 2  90 83% @ 10 μM* 91 1.8  92 2   93 3.3  94 2.3  95 1   96 2.4* 97 5.3* 984.9* 99 4.8* 100 4.2* 101 4.7* 102 2.8  103 31*t  104 79% @ 10 μM* 1051.5  106 5.8* 107 1.1  108 11.3*  109 9.0* 110 2.0* 111 2.2* 112 2.8*113 3.1* 114 2.8* 115 1.2  116 1.2  117 0.9  118 1   119 1.1  120 3.4 121 14.3  122 0.6  123 0.6  124 0.7  125 2.8  126 1   127 1.5  128 1  129 2.9  130 0.8  131 0.7  132 1.1  133 0.7  134 1.2  135 0.9  136 1.1 137 0.6  138 0.8  139 1   140 0.6  141 0.6  142 0.9  143 0.6  144 1  145 1.2  146 0.8  147 0.5  148 0.8  149 0.6  150 0.5  151 0.7  152 0.8 153 0.4  154 1.3  155 0.7  156 0.8  157 2.1  158 3.5  159 5.6  160 3.8 161 3.9  162 3.9  163 4.6  164 1.6  165 33.3  166 2.7  167 1.2  16812.9  169 0.9  170 4.6  171 6.2  172 2   173 1.8  174 1   175 1.5  1760.9  177 2.63 178 1   179 0.9  180 1.8  181 0.9  182 1.5  183 1.4  1841.5  185 0.9  186 0.6  187 1.2  188 0.8  189 1   190 1.3  191 0.5  1922.3  193 0.6  194 1.4  195 22.1  196 3.2  197 69.7  198 40.4  199 2.2 200 1   201 5.2  202 0.8  203 1.6  204 1.3  205 3.4  206 >100    207 >100     208 >100     209 >100     210 76% @ 10 μM* 211 3.8  2124.1  213 60% @ 10 μM* 215 2   216 85% @ 10 μM* 217 1.3  218 56% @ 10 μM*219 63% @ 10 μM* 220 >9    221 3.93 222 2.05 223 2.06 224 4.64 225 9.38226 4.06 227 3.17 228 2.09 229 13.10  231 6.14 232 3.60 233 2.81 2347.40 235 14.23  237 1.88 238 5.73 239 3.31 240 2.67 241 2.09 242 7.92243 8.59 244 9.10 245 8.08 246 8.39 247 3.62 248 1.67 252 0.64 253 0.36254 0.72 255 0.55 256 1.38 257 0.70 258 0.85 259 1.14 260 1.11 261 1.26262 1.80 264 0.28 265 2.62 266 0.87 267 14.06  268 0.73 269 1.90 2700.77 271 3.41 272 5.14 273 0.18 274 1.38 275 0.92 276 0.38 277 0.72 2780.34 280 5.04 281 4.18 282 5.24 283 8.69 284 3.71 285 0.48 286 0.38 2873.09 288 10.36  289 9.74 290 7.80 291 4.40 292 3.91 293 4.82 294 7.81295 2.97 296 2.14 297 7.88 298 9.00 299 3.68 300 1.54 302 1.14 303 3.11304 3.78 305 3.51 306 0.50 307 1.54 308 1.93 309 1.74 310 0.68 311 2.05312 1.59 313 2.10 314 2.15 315 5.36 316 2.02 317 0.90 318 1.07 319 1.21320 0.70 321 0.44 322 0.70 323 0.20 324 0.69 325 0.25 326 1.46 327 1.83328 1.38 329 2.60 330 1.11 331 0.75 332 0.48 333 0.57 334 0.69 335 0.83336 0.48 337 0.78 338 0.23 339 1.11 340 1.03 341 2.01 342 2.17 343 1.01344 0.99 345 4.32 349 17.65  358 9.00 361 24.74  364 8.12 366 5.28 3677.00 368 12.42  370 6.02 371 8.89 373 7.58 374 5.36 375 8.22 376 10.63 377 13.37 379 8.59 380 9.73 382 14.42  383 0.80 384 1.14 385 1.85 3861.62 387 5.88 388 4.53 389 1.48 390 2.46 391 1.46 392 0.95 393 1.08 3940.98 395 2.12 396 3.55 397 1.45 398 3.25 399 15.29  400 6.86 401 2.96402 2.06 403 8.66 404 1.02 405 3.84 406 3.69 407 5.43 408 5.11 409 5.02410 1.80 411 4.22 412 4.72 413 0.78 414 0.90 415 2.97 416 1.33 417 1.16418 0.82 419 0.80 420 5.70 421 2.56 422 7.83 423 6.46 424 3.11 425 3.21426 1.79 427 6.45 428 2.31 429 0.96 430 1.75 431 0.58 432 1.67 433 1.26434 2.70 435 2.32 436 1.77 437 2.43 438 5.70 439 1.43 440 3.19 441 0.37442 7.18 443 7.68 444 2.11 445 7.96 446 4.96 447 2.71 448 12.35  4494.06 450 9.25 451 0.80 452 9.12 453 4.23 454 2.03 455 3.03 456 5.33 4573.07 458 3.08 459 1.62 460 2.69 461 1.88 462 2.96 463 2.03 466 2.33 4673.49 468 2.25 469 2.24 470 1.03 471 0.65 472 1.27 473 2.66 474 1.74 4751.84 476 1.31 477 1.88 478 0.75 479 0.25 480 1.31 481 2.28 482 1.97 4830.49 484 0.97 485 1.50 486 1.21 487 0.56 488 7.43 489 9.76 490 3.12 4910.26 492 2.00 493 5.08 496 0.53 497 0.57 498 1.58 499 2.70 500 1.70 5010.82 502 0.97 503 0.89 504 0.91 505 2.24 506 1.72 507 0.87 508 8.60 5094.56 510 1.68 511 2.12 512 0.47 513 2.15 515 3.17 516 2.99 517 4.45 5180.81 519 5.14 520 12.82  521 9.60 522 2.90 523 4.43 524 2.07 525 1.39526 2.77 527 2.29 528 7.23 529 0.96 530 7.63 531 3.49 532 3.16 533 9.69534 6.38 536 8.38 537 11.32  538 3.76 539 4.39 540 1.67 541 2.57 5422.36 543 3.21 544 2.15 546 6.32 548 1.05 549 2.74 550 2.57 551 2.49 5520.78 553 1.94 554 10.32  555 2.51 556 2.58 557 1.14 558 4.88 559 1.68560 1.45

(ii) In Vivo Data—Capsaicin Induced Secondary Mechanical HyperalgesiaModel:

Sprague Dawley rats were briefly restrained, and capsaicin wasadministered at 10 μg in 10 μL of vehicle by intraplantar injection intothe center of the right hind paw. Secondary mechanical hyperalgesia(SMH) was measured at the heel away from the site of injection 180minutes following capsaicin exposure. Compounds and gabapentin (positivecontrol), were administered p.o. 60 minutes before testing (2 hoursafter capsaicin) or i.p. 30 minutes before testing (2.5 hours aftercapsaicin). SMH was measured using calibrated von Frey filaments(Stoelting, Woodale, Ill.). Following the 1 hour habituation in thetesting room, rats were moved to individual plexiglass chambers that siton top of a wire mesh to allow for access for stimulation of the plantarsurface of the hind paws. Rats were allowed to acclimate to the newchambers for 15 minutes before the onset of testing. The paw withdrawalthreshold was determined by increasing and decreasing stimulus intensity(force: g) and calculated using Dixon's up-down method (Chaplan, S. R.;Bach, F. W.; Pogrel, J. W.; Chung, J. M.; Yaksh, T. L.; Quantitativeassessment of tactile allodynia in the rat paw. J. Neuroscience Methods1994, 53(1), 55-63.). The filaments (maximum force of 15.0 g) were heldin place for 8 seconds or until there was a withdrawal response from themechanical stimulation.

% inhibition @ Example 30 mg/kg p.o. 54 38 75 85 156 67 157 57 165 92170 57 172 85 183 78 220 76 280 38 405 32 415 52 461 43 478 57 479 40480 64 488 55 489 47 560 42

d. Methods of Using the Compounds

One embodiment of the present invention provides a method of treatingpain in a subject in need thereof. The method comprises administering tothe subject, including a mammal, such as a human, a therapeuticallysuitable amount of a compound of formula (I), or a pharmaceuticallyacceptable salt thereof. Conditions related to pain include acute pain,chronic pain, neuropathic pain, inflammatory pain, visceral pain, cancerpain, allodynia, fibromyalgia, sciatica, back pain, and headache painincluding migraine, or combinations thereof. Preferably, the methodcomprises administering to the mammal a therapeutically effective amountof any of the compounds as described herein, or a pharmaceuticallyacceptable salt thereof. In certain embodiments, the method comprisesadministering to the mammal a therapeutically effective amount of any ofthe compounds as described herein, or a pharmaceutically acceptable saltthereof, in combination with one or more of the following: nonsteroidalanti-inflammatory drug (NSAID), opioid analgesic, barbiturate,benzodiazapine, histamine antagonist, sedative, skeletal musclerelaxant, transient receptor potential ion channel antagonist,α-adrenergic, tricyclic antidepressant, anticonvulsant, tachykininantagonist, muscarinic antagonist, cyclooxygenase-2 selective inhibitor,neuroleptic, vanilloid receptor agonist, vanilloid receptor antagonist,β-adrenergic, local anesthetic, corticosteroid, 5-HT receptor agonist,5-HT receptor antagonist, 5-HT_(2A) receptor antagonist, cholinergicanalgesic, α₂δ ligand such as gabapentin or pregabalin, cannabinoidreceptor ligand, metabotropic glutamate subtype 1 receptor antagonist,serotonin reuptake inhibitor, norepinephrine reuptake inhibitor, dualserotonin-noradrenaline reuptake inhibitor, Rho kinase inhibitor,inducible nitric oxide synthase inhibitor, acetylcholinesteraseinhibitor, prostaglandin E₂ subtype 4 antagonist, leukotriene B4antagonist, 5-lipoxygenase inhibitor, sodium channel blocker, 5-HT3antagonist, N-methyl-D-aspartic acid receptor antagonist, andphosphodiesterase V inhibitor.

Yet another embodiment of the present invention relates to a method forproviding a method for treating disorders of the central nervous systemincluding stroke, epilepsy, manic depression, bipolar disorders,depression, anxiety, schizophrenia, migraine, and psychoses; neuraldegenerative disorders including Alzheimer's disease, AIDS relateddementia, Parkinson's disease, neuropathy caused by head injury, anddementia caused by cerebrovascular disorders; disorders of the lowerurinary tract including overactive bladder, prostatis, prostadynia,interstitial cystitis, and benign prostatic hyperplasia; disorderscaused by psychogenic stress including bronchial asthma, unstableangina, and hypersensitive colon inflammation; cardiovascular disordersincluding hypertension, atherosclerosis, heart failure, and cardiacarrhythmias; drug addiction withdrawal symptoms, including ethanoladdiction withdrawal symptoms; skin disorders including pruritis andallergic dermatitis, inflammatory bowel disease; cancer; diabetes; andinfertility and sexual dysfunction in a mammal in need of suchtreatment. This method comprises administering to the mammal (includinghuman) a therapeutically effective amount of a compound of the inventionor a pharmaceutically acceptable salt thereof.

Calcium channel blockers have been associated with a slightly greaterdecreased risk of stroke compared to other types of antihypertensiveagents (Angeli, F.; et al. Calcium channel blockade to prevent stroke inhypertension. American Journal of Hypertension 2004, 17(9), 817-822).The enhanced effect did not correlate with differences in systolic bloodpressure and the mechanism of action remains unknown. However, calciumchannel blockers have been associated with blockade of central neuronalcalcium influx and subsequent ischemic injury in two rodent models(Barone, F. C.; et al. SB 201823-A antagonizes calcium currents incentral neurons and reduces the effects of focal ischemia in rats andmice. Stroke 1995, 26, 1683-1690.). In another model of global ischemia,a calcium channel blocker offered neuroprotection although notpermanently (Colbourne, F.; et al. Continuing postischemic neuronaldeath in CA1: Influence of ischemia duration and cytoprotective doses ofNBQX and SNX-111 in rats. Stroke 1999, 30(3), 662-668.). Additionally,diminished progression of carotid atherosclerosis has been observed withcalcium channel blocker use (Zanchetti, A.; et al. Calcium antagonistlacidipine slows down progression of asymptomatic carotidatherosclerosis. Principal results of the European lacidipine study onatherosclerosis (ELSA), a randomized, double-blind, long-term trial.Circulation 2002, 106, r47-r52.).

An increase in intracellular calcium concentration has been correlatedwith seizure activity (Heinemann, U.; et al. Extracellular free calciumand potassium during paroxysmal activity in the cerebral cortex of thecat. Exp. Brain Res. 1977, 27, 237-243.). Several studies have indicatedthat calcium channel blockers produce anticonvulsant activity (Vezzani,A.; et al. Effects of various calcium channel blockers on threedifferent models of limbic seizures in rats. Neuropharmacology 1988,27(5), 451-458. Otoom, S.; et al. Nifedipine inhibits picrotoxin-inducedseizure activity: further evidence on the involvement of L-type calciumchannel blockers in epilepsy. Fundamental & Clinical Pharmacology 2006,20, 115-119.).

Calcium channel blockers have been evaluated in the treatment of bipolardisorders and manic depression for decades. There are suggestions thatthe calcium channel subtype has influence on efficacy of these disorders(Gitlin, M. Treatment-resistant bipolar disorder. Molecular Psychiatry2006, 11, 227-240. Levy, N. A.; Janicak, P. G. Bipolar Disorders 2000,2, 108-119.).

Calcium channel blockers have also been associated with the treatment ofanxiety and depression (Saade, S.; et al. The L-type calcium channelblocker nimodipine mitigates “learned helplessness” in rats.Pharmacology, Biochemistry and Behavior 2003, 74, 269-278.).

Antischizophrenic drugs have been found to be calcium channelantagonists (Gould, R. J.; et al. Antischizophrenic drugs of thediphenylbutylpiperidine type act as calcium channel antagonists. Proc.Natl. Acad. Sci. USA 1983, 80, 5122-5125.). Other calcium channelblockers have been suggested for the treatment of schizophrenia (Tort,A. B. L.; et al. Atypical antipsychotic profile of flunarizine in animalmodels. Psychopharmacology 2005, 177, 344-348.).

Migraines are treated with calcium channel blockers (Arulmoshi, D. K.;et al.

Migraine: Current concepts and emerging therapies. Vascular Pharmacology2005, 43, 176-187. Gladstone, J. P.; et al. Current and emergingtreatment options for migraine and other primary headache disorders.Expert Rev. Neurotherapeutics 2003, 3(6), 845-872.).

Disorders of the lower urinary tract including overactive bladder,prostatis, prostadynia, interstitial cystitis, and benign prostatichyperplasia can be treated with calcium channel blockers (Fraser, M. O.;et al. US20050148587, 2005).

Ethanol withdrawal syndrome is decreased with calcium channel blockers(Little, H. J.; et al. Calcium channel antagonists decrease the ethanolwithdrawal syndrome. Life Sciences 1986, 39, 2059-2065.).

Several cardiac disorders are treated with calcium channel blockers.Atherosclerosis may be reduced by a decrease in free radical-mediateddamage as a result of influence on the biophysical properties ofmembranes (Mason, R. P.; et al. Antioxidant and cytoprotectiveactivities of the calcium channel blocker mibefradil. BiochemicalPharmacology 1998, 55, 1843-1852.). Hypertension and angina are bothsuccessfully treated with calcium channel blockers (Croom, K. F.; et al.Modified-release nifedipine: A review of the use of modified-releaseformulations in the treatment of hypertension and angina pectoris. Drugs2006, 66(4), 497-528.).

There is data suggesting that calcium channel blockers inhibit theproliferation of cancer cells (Gray, L. S.; et al. InternationalPublication No. WO200059882, 2000.).

Calcium channels have been suggested as a target for the treatment ofdiabetes (Bhattacharjee, A.; et al. T-Type calcium channels facilitateinsulin secretion by enhancing general excitability in theinsulin-secreting β-cell line, INS-1. Endocrinology 1997, 138(9),3735-3740.).

Ion channels including calcium channels play an important role in spermphysiology and fertilization (Darszon, A.; et al. Ion channels in spermphysiology. Physiological Reviews 1999, 79(2), 481-510).

Calcium channel blockers modulate inflammation (Bilici, D.; et al.Protective effect of T-type calcium channel blocker in histamine-inducedpaw inflammation in rat. Pharmacological Research 2001, 44(6),527-531.).

Increased calcium levels in neurones has been implicated in Alzheimer'sdisease. Two suggested mechanisms of increased calcium influx are thatβ-amyloid may form calcium permeable channels (Bhatia, R.; et al. Freshand globular amyloid beta protein (1-42) induces rapid cellulardegeneration: evidence for AβP channel-mediated cellular toxicity. FASEBJ. 2000, 14(9), 1233-1243.) or a G-protein-coupled receptor may beactivated by β-amyloid (Lorton, D. β-Amyloid induced IL-1 β release froman activated human monocyte cell line is calcium- andG-protein-dependent. Mech. Ageing Dev. 1997, 94(1-3), 199-211.).

Neurodegenerative diseases, including Parkinson's and Alzheimer'sdiseases can be modulated by calcium channel blockers (Rodnitzky, R. L.Can calcium antagonists provide a neuroprotective effect in Parkinson'sdisease. Drugs 1999, 57(6), 845-849. Vagnucci, A. H., Jr.; et al.Alzheimer's disease and angiogenesis. The Lancet 2003, 361(9357),605-608. Veng, L. M.; et al. Age-related working memory impairment iscorrelated with increases in the L-type calcium channel protein α_(1D)(Ca_(v)1.3) in area CA1 of the hippocampus and both are ameliorated bychronic nimodipine treatment. Molecular Brain Research 2203, 110,193-202. Geldenhuys, W. J.; et al. Structure-activity relationships ofpentacycloundecylamines at the N-methyl-D-aspartate receptor. Bioorganicand Medicinal Chemistry 2007, 15, 1525-1532. Cavalli, A.; et al.Multi-target-directed ligands to combat neurodegenerative diseases. J.Med. Chem. 2008, 51(3), 347-372.)

Actual dosage levels of active ingredients in the pharmaceuticalcompositions of this invention can be varied so as to obtain an amountof the active compound(s) that is effective to achieve the desiredtherapeutic response for a particular patient, compositions and mode ofadministration. The selected dosage level will depend upon the activityof the particular compound, the route of administration, the severity ofthe condition being treated and the condition and prior medical historyof the patient being treated. However, it is within the skill of the artto start doses of the compound at levels lower than required to achievethe desired therapeutic effect and to gradually increase the dosageuntil the desired effect is achieved.

Compounds of the invention can also be administered as a pharmaceuticalcomposition comprising the compounds of interest in combination with oneor more pharmaceutically acceptable carriers. The phrase“therapeutically effective amount” of the compound of the inventionmeans a sufficient amount of the compound to treat disorders, at areasonable benefit/risk ratio applicable to any medical treatment. Itwill be understood, however, that the total daily usage of the compoundsand compositions of the invention will be decided by the attendingphysician within the scope of sound medical judgment. The specifictherapeutically effective dose level for any particular patient willdepend upon a variety of factors including the disorder being treatedand the severity of the disorder; activity of the specific compoundemployed; the specific composition employed; the age, body weight,general health, sex and diet of the patient; the time of administration,route of administration, and rate of excretion of the specific compoundemployed; the duration of the treatment; drugs used in combination orcoincidental with the specific compound employed; and like factorswell-known in the medical arts. For example, it is well within the skillof the art to start doses of the compound at levels lower than requiredto achieve the desired therapeutic effect and to gradually increase thedosage until the desired effect is achieved.

The total daily dose of the compounds of this invention administered toa human or other animal range from about 0.01 mg/kg body weight to about100 mg/kg body weight. More preferable doses can be in the range of fromabout 0.01 mg/kg body weight to about 30 mg/kg body weight. If desired,the effective daily dose can be divided into multiple doses for purposesof administration. Consequently, single dose compositions may containsuch amounts or submultiples thereof to make up the daily dose.

e. Pharmaceutical Compositions

The present invention further provides pharmaceutical compositions thatcomprise compounds of the present invention or a pharmaceuticallyacceptable salt or solvate thereof. The pharmaceutical compositionscomprise compounds of the present invention that may be formulatedtogether with one or more non-toxic pharmaceutically acceptablecarriers.

Another aspect of the present invention is a pharmaceutical compositioncomprising compounds of the invention, or a pharmaceutically acceptablesalt thereof, and one or more pharmaceutically acceptable carriers,alone or in combination with one or more nonsteroidal anti-inflammatorydrugs (NSAID), opioid analgesics, barbiturates, benzodiazepines,histamine antagonists, sedatives, skeletal muscle relaxants, transientreceptor potential ion channel antagonists, α-adrenergics, tricyclicantidepressants, anticonvulsants, tachykinin antagonists, muscarinicantagonists, cyclooxygenase-2 selective inhibitors, neuroleptics,vanilloid receptor agonists, vanilloid receptor antagonists,β-adrenergics, local anesthetics, corticosteroids, 5-HT receptoragonists, 5-HT receptor antagonists, 5-HT_(2A) receptor antagonists,cholinergic analgesics, α₂δ ligands such as gabapentin or pregabalin,cannabinoid receptor ligands, metabotropic glutamate subtype 1 receptorantagonists, serotonin reuptake inhibitors, norepinephrine reuptakeinhibitors, dual serotonin-noradrenaline reuptake inhibitors, Rho kinaseinhibitors, inducible nitric oxide synthase inhibitors,acetylcholinesterase inhibitors, prostaglandin E₂ subtype 4 antagonists,leukotriene B4 antagonists, 5-lipoxygenase inhibitors, sodium channelblockers, 5-HT3 antagonists, N-methyl-D-aspartic acid receptorantagonists, and phosphodiesterase V inhibitors.

The pharmaceutical compositions of this invention can be administered tohumans and other mammals orally, rectally, parenterally,intracisternally, intravaginally, intraperitoneally, topically (as bypowders, ointments or drops), bucally or as an oral or nasal spray. Theterm “parenterally” as used herein, refers to modes of administrationwhich include intravenous, intramuscular, intraperitoneal, intrasternal,subcutaneous and intraarticular injection and infusion.

The term “pharmaceutically acceptable carrier” as used herein, means anon-toxic, inert solid, semi-solid or liquid filler, diluent,encapsulating material or formulation auxiliary of any type. Someexamples of materials which can serve as pharmaceutically acceptablecarriers are sugars such as, but not limited to, lactose, glucose andsucrose; starches such as, but not limited to, corn starch and potatostarch; cellulose and its derivatives such as, but not limited to,sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate;powdered tragacanth; malt; gelatin; talc; excipients such as, but notlimited to, cocoa butter and suppository waxes; oils such as, but notlimited to, peanut oil, cottonseed oil, safflower oil, sesame oil, oliveoil, corn oil and soybean oil; glycols; such a propylene glycol; esterssuch as, but not limited to, ethyl oleate and ethyl laurate; agar;buffering agents such as, but not limited to, magnesium hydroxide andaluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline;Ringer's solution; ethyl alcohol, and phosphate buffer solutions, aswell as other non-toxic compatible lubricants such as, but not limitedto, sodium lauryl sulfate and magnesium stearate, as well as coloringagents, releasing agents, coating agents, sweetening, flavoring andperfuming agents, preservatives and antioxidants can also be present inthe composition, according to the judgment of the formulator.

Pharmaceutical compositions of this invention for parenteral injectioncomprise pharmaceutically acceptable sterile aqueous or nonaqueoussolutions, dispersions, suspensions or emulsions as well as sterilepowders for reconstitution into sterile injectable solutions ordispersions just prior to use. Examples of suitable aqueous andnonaqueous carriers, diluents, solvents or vehicles include water,ethanol, polyols (such as glycerol, propylene glycol, polyethyleneglycol and the like), vegetable oils (such as olive oil), injectableorganic esters (such as ethyl oleate) and suitable mixtures thereof.Proper fluidity can be maintained, for example, by the use of coatingmaterials such as lecithin, by the maintenance of the required particlesize in the case of dispersions and by the use of surfactants.

These compositions may also contain adjuvants such as preservatives,wetting agents, emulsifying agents and dispersing agents. Prevention ofthe action of microorganisms can be ensured by the inclusion of variousantibacterial and antifungal agents, for example, paraben,chlorobutanol, phenol sorbic acid and the like. It may also be desirableto include isotonic agents such as sugars, sodium chloride and the like.Prolonged absorption of the injectable pharmaceutical form can bebrought about by the inclusion of agents which delay absorption such asaluminum monostearate and gelatin.

In some cases, in order to prolong the effect of the drug, it isdesirable to slow the absorption of the drug from subcutaneous orintramuscular injection. This can be accomplished by the use of a liquidsuspension of crystalline or amorphous material with poor watersolubility. The rate of absorption of the drug then depends upon itsrate of dissolution which, in turn, may depend upon crystal size andcrystalline form. Alternatively, delayed absorption of a parenterallyadministered drug form is accomplished by dissolving or suspending thedrug in an oil vehicle.

Injectable depot forms are made by forming microencapsule matrices ofthe drug in biodegradable polymers such as polylactide-polyglycolide.Depending upon the ratio of drug to polymer and the nature of theparticular polymer employed, the rate of drug release can be controlled.Examples of other biodegradable polymers include poly(orthoesters) andpoly(anhydrides). Depot injectable formulations are also prepared byentrapping the drug in liposomes or microemulsions which are compatiblewith body tissues.

The injectable formulations can be sterilized, for example, byfiltration through a bacterial-retaining filter or by incorporatingsterilizing agents in the form of sterile solid compositions which canbe dissolved or dispersed in sterile water or other sterile injectablemedium just prior to use.

Solid dosage forms for oral administration include capsules, tablets,pills, powders and granules. In such solid dosage forms, the activecompound may be mixed with at least one inert, pharmaceuticallyacceptable excipient or carrier, such as sodium citrate or dicalciumphosphate and/or a) fillers or extenders such as starches, lactose,sucrose, glucose, mannitol and silicic acid; b) binders such ascarboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone,sucrose and acacia; c) humectants such as glycerol; d) disintegratingagents such as agar-agar, calcium carbonate, potato or tapioca starch,alginic acid, certain silicates and sodium carbonate; e) solutionretarding agents such as paraffin; f) absorption accelerators such asquaternary ammonium compounds; g) wetting agents such as cetyl alcoholand glycerol monostearate; h) absorbents such as kaolin and bentoniteclay and i) lubricants such as talc, calcium stearate, magnesiumstearate, solid polyethylene glycols, sodium lauryl sulfate and mixturesthereof. In the case of capsules, tablets and pills, the dosage form mayalso comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers insoft and hard-filled gelatin capsules using such carriers as lactose ormilk sugar as well as high molecular weight polyethylene glycols and thelike.

The solid dosage forms of tablets, dragees, capsules, pills and granulescan be prepared with coatings and shells such as enteric coatings andother coatings well-known in the pharmaceutical formulating art. Theymay optionally contain opacifying agents and may also be of acomposition such that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of embedding compositions which can beused include polymeric substances and waxes.

The active compounds can also be in micro-encapsulated form, ifappropriate, with one or more of the above-mentioned carriers.

Liquid dosage forms for oral administration include pharmaceuticallyacceptable emulsions, solutions, suspensions, syrups and elixirs. Inaddition to the active compounds, the liquid dosage forms may containinert diluents commonly used in the art such as, for example, water orother solvents, solubilizing agents and emulsifiers such as ethylalcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzylalcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol,dimethyl formamide, oils (in particular, cottonseed, groundnut, corn,germ, olive, castor and sesame oils), glycerol, tetrahydrofurfurylalcohol, polyethylene glycols and fatty acid esters of sorbitan andmixtures thereof.

Besides inert diluents, the oral compositions may also include adjuvantssuch as wetting agents, emulsifying and suspending agents, sweetening,flavoring and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspendingagents as, for example, ethoxylated isostearyl alcohols, polyoxyethylenesorbitol and sorbitan esters, microcrystalline cellulose, aluminummetahydroxide, bentonite, agar-agar, tragacanth and mixtures thereof.

Compositions for rectal or vaginal administration are preferablysuppositories which can be prepared by mixing the compounds of thisinvention with suitable non-irritating carriers or carriers such ascocoa butter, polyethylene glycol or a suppository wax which are solidat room temperature but liquid at body temperature and therefore melt inthe rectum or vaginal cavity and release the active compound.

Compounds of the present invention can also be administered in the formof liposomes. As is known in the art, liposomes are generally derivedfrom phospholipids or other lipid substances. Liposomes are formed bymono- or multi-lamellar hydrated liquid crystals which are dispersed inan aqueous medium. Any non-toxic, physiologically acceptable andmetabolizable lipid capable of forming liposomes can be used. Thepresent compositions in liposome form can contain, in addition to acompound of the present invention, stabilizers, preservatives,excipients and the like. The preferred lipids are natural and syntheticphospholipids and phosphatidyl cholines (lecithins) used separately ortogether.

Methods to form liposomes are known in the art. See, for example,Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, NewYork, N.Y. (1976), p. 33 et seq.

Dosage forms for topical administration of a compound of this inventioninclude powders, sprays, ointments and inhalants. The active compoundmay be mixed under sterile conditions with a pharmaceutically acceptablecarrier and any needed preservatives, buffers or propellants which maybe required. Ophthalmic formulations, eye ointments, powders andsolutions are also contemplated as being within the scope of thisinvention.

The compounds of the present invention can be used in the form ofpharmaceutically acceptable salts derived from inorganic or organicacids. The phrase “pharmaceutically acceptable salt” means those saltswhich are, within the scope of sound medical judgment, suitable for usein contact with the tissues of humans and lower animals without unduetoxicity, irritation, allergic response and the like and arecommensurate with a reasonable benefit/risk ratio.

Pharmaceutically acceptable salts are well known in the art. Forexample, S. M. Berge et al. describe pharmaceutically acceptable saltsin detail in (J. Pharmaceutical Sciences, 1977, 66: 1 et seq). The saltscan be prepared in situ during the final isolation and purification ofthe compounds of the invention or separately by reacting a free basefunction with a suitable organic acid. Representative acid additionsalts include, but are not limited to acetate, adipate, alginate,citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate,camphorate, camphorsulfonate, digluconate, glycerophosphate,hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride,hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isothionate),lactate, malate, maleate, methanesulfonate, nicotinate,2-naphthalenesulfonate, oxalate, palmitoate, pectinate, persulfate,3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate,thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate andundecanoate. Also, the basic nitrogen-containing groups can bequaternized with such agents as lower alkyl halides such as, but notlimited to, methyl, ethyl, propyl, and butyl chlorides, bromides andiodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamylsulfates; long chain halides such as, but not limited to, decyl, lauryl,myristyl and stearyl chlorides, bromides and iodides; arylalkyl halideslike benzyl and phenethyl bromides and others. Water or oil-soluble ordispersible products are thereby obtained. Examples of acids which canbe employed to form pharmaceutically acceptable acid addition saltsinclude such inorganic acids as hydrochloric acid, hydrobromic acid,sulfuric acid, and phosphoric acid and such organic acids as aceticacid, fumaric acid, maleic acid, 4-methylbenzenesulfonic acid, succinicacid and citric acid.

Basic addition salts can be prepared in situ during the final isolationand purification of compounds of this invention by reacting a carboxylicacid-containing moiety with a suitable base such as, but not limited to,the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptablemetal cation or with ammonia or an organic primary, secondary ortertiary amine. Pharmaceutically acceptable salts include, but are notlimited to, cations based on alkali metals or alkaline earth metals suchas, but not limited to, lithium, sodium, potassium, calcium, magnesiumand aluminum salts and the like and nontoxic quaternary ammonia andamine cations including ammonium, tetramethylammonium,tetraethylammonium, methylamine, dimethylamine, trimethylamine,triethylamine, diethylamine, ethylamine and the like. Otherrepresentative organic amines useful for the formation of base additionsalts include ethylenediamine, ethanolamine, diethanolamine, piperidine,piperazine and the like.

The term “pharmaceutically acceptable prodrug” or “prodrug” as usedherein, represents those prodrugs of the compounds of the presentinvention which are, within the scope of sound medical judgment,suitable for use in contact with the tissues of humans and lower animalswithout undue toxicity, irritation, allergic response, and the like,commensurate with a reasonable benefit/risk ratio, and effective fortheir intended use.

The present invention contemplates compounds of the invention formed bysynthetic means or formed by in vivo biotransformation of a prodrug.

The compounds of the invention can exist in unsolvated as well assolvated forms, including hydrated forms, such as hemi-hydrates. Ingeneral, the solvated forms, with pharmaceutically acceptable solventssuch as water and ethanol among others are equivalent to the unsolvatedforms for the purposes of the invention.

f. General Synthesis

This invention is intended to encompass compounds of the invention whenprepared by synthetic processes or by metabolic processes. Preparationof the compounds by metabolic processes includes those occurring in thehuman or animal body (in vivo) or processes occurring in vitro.

The compounds of the invention may be prepared by a variety of processeswell known for the preparation of compounds of this class. For example,the compounds of the invention wherein the groups L¹, L², R¹, R², R³,R⁴, R⁵, R⁶, R^(e), R^(f), R^(g), R^(h), n, q, and G¹, have the meaningsas set forth in the Summary of the Invention section unless otherwisenoted, can be synthesized as shown in Schemes 1-20.

Abbreviations which have been used in the descriptions of the Schemesand the Examples that follow are: Ac for acetyl; AlMe₃ fortrimethylaluminum; Boc for t-butoxy carbonyl; Boc₂O for di-tert-butyldicarbonate; Bu for butyl; Et for ethyl, EtOH for ethanol; DMF orN,N-dimethylformamide; DMSO for dimethyl sulfoxide; 1 cms for liquidchromatography/mass spec; MeOH for methanol; MsCl for methanesulfonylchloride; NEt₃ for triethylamine; OAc for acetate; Ph for phenyl; PPh₃for triphenylphosphine; PS-cyanoborohydride for polymer-supportedcyanoborohydride; psi for pounds per square inch; tBu for tert-butyl;THF for tetrahydrofuran, and tic for thin layer chromatography.

Compounds of formula (1-3) and (1-4), wherein L¹ and R¹ are as definedin the Summary of the Invention, may be prepared as illustrated inScheme 1. Compounds of formula (1-1) can be treated with hydroxylaminehydrochloride in the presence of a base such as sodium carbonate, sodiumbicarbonate, or sodium acetate in a solvent such as water or aqueousmethanol and optionally heated to furnish oximes of formula (1-2).Oximes of formula (1-2) can then be reduced in the presence of hydrogen(30 psi) in the presence of Raney®-nickel in a solvent such as 20%ammonia in methanol at ambient temperature over 1 to 24 hours to providea diastereomeric mixture of amines, compounds of formulas (1-3) and(1-4). The diastereomeric amines can be separated by techniques know toone skilled in the art such as chromatography.

Compounds of formula (2-2) which are representative of compounds offormula (I), wherein L¹, R¹, R² and R³ are as described in the Summaryof the Invention, are prepared by reacting compounds of formula (2-1)with carboxylic acids of formula R²CO₂H under amide bond couplingconditions. Examples of conditions known to generate amides from amixture of a carboxylic acid and an amine include but are not limited toadding a coupling reagent such as but not limited toN-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC or EDCI),1,3-dicyclohexylcarbodiimide (DCC), bis(2-oxo-3-oxazolidinyl)phosphinicchloride (BOPCl), O-(7-azabenzotriazol-1-yl)-N,N,N,N′-tetramethyluroniumhexafluorophosphate (HATU),O-benzotriazol-1-yl-N,N,N,N′-tetramethyluronium tetrafluoroborate(TBTU),and2-(1H-benzo[d][1,2,3]triazol-1-yl)-1,1,3,3-tetramethylisouroniumhexafluorophosphate(V) (HBTU). The coupling reagents may be added as asolid, a solution or as the reagent bound to a solid support resin. Inaddition to the coupling reagents, auxiliary-coupling reagents mayfacilitate the coupling reaction. Auxiliary coupling reagents that areoften used in the coupling reactions include but are not limited to(dimethylamino)pyridine (DMAP), 1-hydroxy-7-azabenzotriazole (HOAT) and1-hydroxybenzotriazole (HOBT). The reaction may be carried outoptionally in the presence of a base such as triethylamine ordiisopropylethylamine. The coupling reaction may be carried out insolvents such as but not limited to tetrahydrofuran,N,N-dimethylformamide, dichloromethane, and ethyl acetate. The reactionmay be conducted at ambient or elevated temperatures.

Alternatively, compounds of formula (2-2) may be prepared from compoundsof formula (2-1) by reacting with an acid chloride of formula R²C(O)Cl.Compounds of formula (2-1), may be treated R₂C(O)Cl in a solvent such asdichloromethane in the presence of an amine such as triethylamine ordiisopropylethylamine at room temperature over 1 to 24 hours to affordcompounds of formula (2-2).

As illustrated in Scheme 3, compounds of formulas (3-3), (3-4), and(3-5) which are representative of compounds of formula (I), and whereinR¹, R² and R³ are as defined in the Summary of the Invention, can beobtained from compounds of formula (3-1). Compounds of formula (3-1) canbe converted to compounds of formula (3-2) by treatment with hydrogen(15-60 psi) in the presence of a catalyst such as palladium hydroxide oncarbon or palladium on carbon in a solvent such as methanol or ethanolat ambient temperature over 3-36 hours. Compounds of formula (3-2) canthen be reductively aminated with aldehydes of formula R¹CHO in thepresence of a reducing agent such as PS-cyanoborohydride, sodiumcyanoborohydride, or sodium triacetoxyborohydride and acetic acid in asolvent such as methanol or dichloromethane at room temperature over4-24 hours to supply compounds of formula (3-3). Alternatively,compounds of formula (3-2) can be reacted with a sulfonyl chloride offormula R¹SO₂Cl in the presence of a base such as triethylamine ordiisopropylamine optionally in the presence of (dimethylamino)pyridinein a solvent such as dichloromethane at ambient temperature over 4-24hours to supply compounds of formula (3-4). Compounds of formula (3-5)can also be prepared from compounds of formula (3-2). Compounds offormula (3-2) can be treated with a carboxylic acid of formula R¹CO₂H orand acid chloride of formula R¹C(O)Cl under the amide bond formingconditions described in Scheme 2 to give compounds of formula (3-5).

As illustrated in Scheme 4, compounds of formulas (4-2), (4-3), (4-4)and (4-5) which are representative of compounds of formula (I), whereinR¹, R² and R³ are as defined in the Summary of the Invention, can beobtained from compounds of formula (4-1). Accordingly, compounds offormula (4-1) can be treated with sulfonyl chlorides of formula R₂SO₂Clusing the conditions described in Scheme 3 to give compounds of formula(4-2). The benzyl group can be reductively cleaved with hydrogen and apalladium catalyst as described in Scheme 3 to deliver compounds offormula (4-3). Compounds of formula (4-3) can be reductively alkylatedwith aldehydes of formula R¹CHO under the reaction conditions describedin Scheme 3 to give compounds of formula (4-4). The secondary amine ofcompounds of formula (4-3) can be coupled with a carboxylic acid or acidchloride with the conditions described in Scheme 2 to give amides offormula (4-5).

Compounds of formula (5-4) and (5-5), wherein G¹ is aryl or heteroaryland unsubstituted or substituted as described in the Summary of theInvention, can be prepared from compounds of formula (5-1) as describedin Scheme 5. Compounds of formula (5-1) can be combined withchloromethyltrimethylsilane and triethylamine and refluxed for 8-24hours. The intermediate can then be reacted with formaldehyde in thepresence of potassium carbonate and in methanol to give compounds offormula (5-2). Compounds of formula (5-2) can be reacted withcyclopent-2-enone at room temperature in the presence of trifluoroaceticacid in a solvent such as dichloromethane to give compounds of formula(5-3). Compounds of formula (5-3) can be transformed to compounds offormulas (5-4) and (5-5) upon treatment first with hydroxylaminehydrochloride and subsequently with hydrogen in the presence ofRaney®-nickel as described in Scheme 1.

Chiral compounds of formulas (6-3) and (6-4), wherein L¹ and R¹ are asdefined in the Summary of the Invention, can be synthesized as describedin Scheme 6. To this end, compounds of formula (1-1) can be treated witha chiral sulfinamide such as (S)-2-methylpropane-2-sulfinamide in thepresence of titanium tetraethoxide in a solvent such as tetrahydrofuranand heated to 30-65° C. for 4 to 24 hours to give the diastereomericcompounds (6-1) and (6-2). The chiral diastereomers can bechromatographically separated and then treated individually in thefollowing sequence. Chiral compounds of formula (6-1) can be reducedwith sodium borohydride in methanol at −78° C. with gradual warming toroom temperature over 8 to 20 hours. Subsequent hydrolysis withhydrochloric acid in methanol delivers chiral compounds of formula(6-3). In similar fashion, chiral compounds of formula (6-2) can beconverted to chiral compounds of formula (6-4).

As illustrated in Scheme 7, chiral compounds of formulas (7-2), whereinL¹ and R¹ are as defined in the Summary of the Invention, can beobtained from chiral compounds of formula (6-2). Chiral compounds offormula (6-2) can be hydrolyzed with hydrochloric acid intetrahydrofuran at room temperature over 1-8 hours. Subsequent reductionwith sodium borohydride in methanol at −40° C. to room temperature over8-24 hours supplies chiral alcohols (7-1). Alcohols (7-1) can betransformed to chiral amines (7-2) in a three-step process. Compounds offormula (7-1) can be treated with methanesulfonyl chloride in thepresence of triethylamine in dichloromethane at ambient temperature for10 minutes to 2 hours. The sulfonates can then be displaced withinversion with sodium azide in heated N,N-dimethylacetamide over 8-24hours. The derived azides can finally be reduced with triphenylphosphinein a heated mixture of water and tetrahydrofuran to give chiralcompounds of formula (7-2).

As described in Scheme 8, compounds of formula (8-1) can be converted tocompounds of formula (8-2) wherein R³ is alkyl, haloalkyl, cycloalkyl,or cycloalkylalkyl. Compounds of formula (8-1) can be treated withamines of formula R³NH₂ in the presence of PS-cyanoborohydride, sodiumcyanoborohydride, or triacetoxy borohydride and acetic acid indichloromethane at ambient temperature for 1-6 hours to give compoundsof formula (8-2). Compounds of formula (8-2) can be used in Scheme 4 inplace of compounds of formula (4-1).

As illustrated in Scheme 9, compounds of formula (9-1), wherein R² andR³ are as defined in the Summary of the Invention, can be obtained fromcompounds of formula (3-2). Compounds of formula (3-2) can be reactedwith (bromomethylene)dibenzene in the presence of potassium iodide, andsodium carbonate in methyl ethyl ketone heated to 90° C. for 6 to 24hours to give compounds of formula (9-1) which are representative ofcompounds of formula (I).

As illustrated in Scheme 10, compounds of formula (10-2) which arerepresentative of compounds of formula (I) and wherein L¹, R¹, R³, R⁵,R^(g), R^(h), and q are as defined in the Summary of the Invention canbe obtained from compounds of formula (10-1). Compounds of formula(10-1) can be treated with an acid such as hydrochloric acid ortrifluoroacetic acid at room temperature in a solvent such as ether,dioxane, or dichloromethane for 2-24 hours to supply compounds offormula (10-2).

As illustrated in Scheme 11, compounds of formula (11-1), (11-2),(11-3), (11-4), and (11-5) which are representative of compounds offormula (I) and wherein L¹, R′, R³, R⁵, R^(g), R^(h), q, and G² are asdefined in the Summary of the Invention can be obtained from compoundsof formula (10-2). Compounds of formula (10-2) can be treated with asulfonyl chloride of formula R⁶SO₂Cl in dichloromethane in the presenceof diisopropylethylamine at room temperature for 2-24 hours to providecompounds of formula (11-1). Similarly, compounds of formula (11-2) canbe obtained upon treatment of compounds of formula (10-2) with ananhydride or acid chloride in dichloromethane at ambient temperature inthe presence of diisopropylethylamine over 2-24 hours. Compounds offormula (11-3) are obtained from compounds of formula (10-2) upontreatment with a carbonochloridate in the presence ofdiisopropylethylamine in dichloromethane at room temperature over 2-24hours. In like manner, compounds of formula (11-4) are made fromcompounds of formula (10-2) by reacting with an isocyanate indichloromethane at room temperature over 2-24 hours. Compounds offormula (11-5), wherein R^(B) is alkyl, arylalkyl, cycloalkyl,cycloalkylalkyl, or heteroarylalkyl can be prepared either by alkylationor reductive amination of compounds of formula (10-2) using methodologyknown to one skilled in the art.

As illustrated in Scheme 12, compounds of formula (12-5) which arerepresentative of compounds of formula (I) and wherein R¹ and R² are asdefined in the Summary of the Invention can be obtained from compound offormula (12-1). Compound (12-1) can reacted with di-tert-butyldicarbonate in the presence of (dimethylamino)pyridine in a solvent suchas dichloromethane or dioxane at room temperature for 20 minutes to 4hours to provide compound of formula (12-2). The benzyl group ofcompound of formula (12-2) can be removed with hydrogen in the presenceof a palladium catalyst as described and then coupled with a carboxylicacid or acid chloride as described in the methods of Scheme 3 to providecompounds of formula (12-3). Removal of the tert-butoxy carbonyl groupfrom compounds of formula (12-3) with the acid conditions described inScheme 10 supplies compounds of formula (12-4). Compounds of formula(12-4) can be reductively aminated with aldehydes of formula R²—CHOusing the conditions described in Scheme 3 to give compounds of formula(12-5).

As illustrated in Scheme 13, compounds of formula (13-2) which arerepresentative of compounds of formula (I), wherein R² and R⁴ are asdefined in the Summary of the Invention, and compound of formula (13-1)can be obtained from compound of formula (12-2). Compound or formula(12-2) can be treated with lithium aluminum hydride in tetrahydrofuraninitially at room temperature and then heated to reflux to affordedcompound of formula (13-1). Compound of formula (13-1) can be used inthe methods described in Schemes 2 and 4. Compound of formula (12-2) canbe treated with an amine in the presence of trimethylaluminum in tolueneinitially at 0° C. and then at 90° C. for 6 to 24 hours to provide ureacompounds of formula (13-2).

As shown in Scheme 14, compounds of formulas (14-2), (14-3), (14-4), and(14-5), wherein R⁴, R⁶, R^(g), R^(h), and q are as defined in theSummary of the Invention can be obtained from compounds of formula(14-1). Compounds of formula (14-1) can be treated with a sulfonylchloride of formula R⁶SO₂Cl in the presence of a base such astriethylamine or diisopropylethylamine in a solvent such asdichloromethane. Subsequent removal of the t-butyl group under acidicconditions deliver compounds of formula (14-2). Compounds of formula(14-1) can also be reductively aminated with an aldehyde of formulaR⁴CHO and a reductant such as sodium cyanoborohydride, polymer supportedcyanoborohydride resin, or sodium triacetoxyborohydride optionally inthe presence of an acid such as acetic acid in solvents such asdichloromethane or methanol. Acidic removal of the t-butyl groupsupplies compounds of formula (14-3). Compounds of formula (14-1) canalso be dialkylated with dibromo compounds. Accordingly, alkylation of(14-1) with 1-bromo-2-(2-bromoethoxy)ethane in heated acetonitrile inthe presence of a base followed by acid catalyzed t-butyl removaldelivers compounds of formula (14-4). Alkylation with 1,4-dibromobutaneor 1,5-dibromopentane under similar conditions followed by acidcatalyzed t-butyl removal delivers compounds of formula (14-5).Compounds of formulas (14-2), (14-3), (14-4), and (14-5) can be used inSchemes 2, 3, 4 and 12.

As illustrated in Scheme 15, compounds of formula (15-3) which arerepresentative of compounds of formula (I) and wherein R¹ and R² are asdefined in the Summary of the Invention can be obtained from compound offormula (12-2). The benzyl group of compound of formula (12-2) can beremoved with hydrogen in the presence of a palladium catalyst asdescribed in Scheme 3 and then coupled with a sulfonyl chloride offormula R¹SO₂Cl as described in the methods of Scheme 3 to providecompounds of formula (15-1). Removal of the tert-butoxy carbonyl groupfrom compounds of formula (15-1) with the acid conditions described inScheme 10 supplies compounds of formula (15-2). Compounds of formula(15-2) can be coupled with carboxylic acids of formula R²—CO₂H or acidchlorides of formula R²—C(O)Cl under the reaction conditions describedin Scheme 2 to give compounds of formula (15-3).

As illustrated in Scheme 17, compounds of formulas (16-3) which arerepresentative of compounds of formula (I), wherein L², R¹, R² and R³are as defined in the Summary of the Invention, can be obtained fromcompounds of formula (12-2). Compounds of formula (12-2) can beconverted to compounds of formula (16-1) by treatment with hydrogen(15-60 psi) in the presence of a catalyst such as palladium hydroxide oncarbon or palladium on carbon in a solvent such as methanol or ethanolat ambient temperature over 3-36 hours. Compounds of formula (16-1) canthen be reacted with an aryl halide or heteroaryl halide suitable for anucleophilic aromatic substitution reaction to furnish compounds offormula (16-2). For example, a compound of formula (16-1) can be heatedin a solvent such as ethanol in the presence of a base and heteroarylbromide to supply compounds of formula (16-2). Compounds of formula(16-2) can then be deprotected under acidic conditions and furtherfunctionalized as described in but not limited to Schemes 2, 4, 10, 11,12, 13 or 17 to give compounds of formula (16-3).

As illustrated in Scheme 17, compounds of formula (17-1) can betransformed into compounds of formulas (17-2), (17-3), (17-4), (17-5),and (17-6) which are represensentative of compounds of formula (I),wherein L¹, R¹, and R² are as defined in the Summary of the Invention.Compounds of formula (17-1) can be converted to compounds of formula(17-2) through either a nucleophilic aromatic substitution reactionunder conditions described in Scheme 16 or under cross-coupling reactionconditions known to one skilled in the art. Compounds of formula (17-1)can also be reductively aminated with an aldehyde to give compounds offormula (17-3) or a ketone to give compounds of formula (17-4), whereinR^(A) is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl,heteroaryl, or heteroarylalkyl. Alternatively, in compounds of formula(17-4), R^(A) and R² together with the atom to which they are attachedmay be joined to form a cyclic group. Reductive amination conditions aredescribed in but not limited to those in Schemes 3, 4, 8, 12, and 14.Compounds of formula (17-1) can be mono-alkylated to give compounds offormula (17-5) or di-alkylated to give compounds of formula (17-6).Compounds of formula (17-1) can be treated with an alkyl-, arylalkyl-,cycloalkyl-, cycloalkylalkyl-, or heteroarylalkyl-halide or sulfonateoptionally in the presence of a base in an optionally heated solventsuch as tetrahydrofuran or N,N-dimethylformamide to give compounds offormula (17-5), wherein R^(B) is alkyl, arylalkyl, cycloalkyl,cycloalkylalkyl, or heteroarylalkyl. Excess alkylating agent leads tocompounds of formula (17-6).

As illustrated in Scheme 18, compounds of formula (17-1) can beconverted to compounds of formulas (18-1), (18-2), and (18-3) which arerepresentative of compounds of formula (I), wherein, L¹, L², R¹, and R²are as defined in the Summary of the Invention and R^(B) is alkyl,arylalkyl, cycloalkyl, cycloalkylalkyl, or heteroarylalkyl. Compounds offormula (17-1) can be reacted with 2-nitrobenzene-1-sulfonyl chloride inthe presence of a base. The resultant sulfonamide can then be alkylatedunder conditions known to one skilled in the art to give compounds offormula (18-1). Treatment with 2-mercaptoethanol in the presence of abase in a solvent such as N,N-dimethylformamide gives compounds offormula (18-2). Compounds of formula (18-2) can be reacted as describedin Schemes 2, 4, 10, 11, 12, 13, or 17 to give compounds of formula(18-3).

As illustrated in Scheme 19, compounds of formula (19-2) which arerepresentative of compounds of formula (I), wherein L¹, L², R¹ and R²are as defined in the Summary of the Invention, can be obtained fromcompound of formula (17-1). Compound or formula (17-1) can be treatedwith lithium aluminum hydride in tetrahydrofuran initially at roomtemperature and then heated to reflux to afforded compound of formula(19-1). Compound of formula (19-1) can be used in the methods describedin Schemes 2, 4, 10, 11, 12, 13, 17 or 18 to give compounds of formula(19-2).

As illustrated in Scheme 20, compounds of formula (20-3), (20-4),(20-5), (20-6) and (20-7) which are representative of compounds offormula (I) and wherein L², R², R³, R⁴, R⁵, R⁶, R^(e), R^(f), and n areas defined in the Summary of the Invention can be obtained fromcompounds of formula (20-2). Compounds of formula (20-2) are obtainedfrom compounds of formula (20-1) upon treatment with an acid such astrifluoroacetic acid in dichloromethane or hydrochloric acid in dioxane.Compounds of formula (20-2) can be treated with a sulfonyl chloride offormula R⁶SO₂Cl in dichloromethane in the presence ofdiisopropylethylamine at room temperature for 2-24 hours to providecompounds of formula (20-3). Similarly, compounds of formula (20-4) canbe obtained upon treatment of compounds of formula (20-2) with ananhydride or acid chloride in dichloromethane at ambient temperature inthe presence of diisopropylethylamine over 2-24 hours. Compounds offormula (20-5) are obtained from compounds of formula (20-2) upontreatment with a carbonochloridate in the presence ofdiisopropylethylamine in dichloromethane at room temperature over 2-24hours. In like manner, compounds of formula (20-6) are made fromcompounds of formula (20-2) by reacting with an isocyanate indichloromethane at room temperature over 2-24 hours. Compounds offormula (20-7), wherein R^(B) is alkyl, arylalkyl, cycloalkyl,cycloalkylalkyl, or heteroarylalkyl can be prepared either by alkylationor reductive amination of compounds of formula (20-2) using methodologyknown to one skilled in the art.

It will be appreciated that the synthetic schemes and specific examplesas illustrated in the Examples section are illustrative and are not tobe read as limiting the scope of the invention as it is defined in theappended claims. All alternatives, modifications, and equivalents of thesynthetic methods and specific examples are included within the scope ofthe claims.

Optimum reaction conditions and reaction times for each individual stepmay vary depending on the particular reactants employed and substituentspresent in the reactants used. Unless otherwise specified, solvents,temperatures and other reaction conditions may be readily selected byone of ordinary skill in the art. Specific procedures are provided inthe Examples section. Reactions may be worked up in the conventionalmanner, e.g. by eliminating the solvent from the residue and furtherpurified according to methodologies generally known in the art such as,but not limited to, crystallization, distillation, extraction,trituration and chromatography. Unless otherwise described, the startingmaterials and reagents are either commercially available or may beprepared by one skilled in the art from commercially available materialsusing methods described in the chemical literature.

Routine experimentations, including appropriate manipulation of thereaction conditions, reagents and sequence of the synthetic route,protection of any chemical functionality that may not be compatible withthe reaction conditions, and deprotection at a suitable point in thereaction sequence of the method are included in the scope of theinvention. Suitable protecting groups and the methods for protecting anddeprotecting different substituents using such suitable protectinggroups are well known to those skilled in the art; examples of which maybe found in T. Greene and P. Wuts, Protecting Groups in ChemicalSynthesis (3^(rd) ed.), John Wiley & Sons, NY (1999), which isincorporated herein by reference in its entirety. Synthesis of thecompounds of the invention may be accomplished by methods analogous tothose described in the synthetic schemes described hereinabove and inspecific examples.

Starting materials, if not commercially available, may be prepared byprocedures selected from standard organic chemical techniques,techniques that are analogous to the synthesis of known, structurallysimilar compounds, or techniques that are analogous to the abovedescribed schemes or the procedures described in the synthetic examplessection.

When an optically active form of a compound of the invention isrequired, it may be obtained by carrying out one of the proceduresdescribed herein using an optically active starting material (prepared,for example, by asymmetric induction of a suitable reaction step), or byresolution of a mixture of the stereoisomers of the compound orintermediates using a standard procedure (such as chromatographicseparation, recrystallization or enzymatic resolution).

Similarly, when a pure geometric isomer of a compound of the inventionis required, it may be obtained by carrying out one of the aboveprocedures using a pure geometric isomer as a starting material, or byresolution of a mixture of the geometric isomers of the compound orintermediates using a standard procedure such as chromatographicseparation.

g. Examples Example 1 and Example 2N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclopentanecarboxamide(Example 1) andN-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclopentanecarboxamide(Example 2)

1-Hydroxybenzotriazole (33 mg, 0.24 mmol) andN-(3-dimethylaminopropyl)-N-ethylcarbodiimide (43 μL, 0.24 mmol) wereadded to a solution of 1-phenylcyclopentanecarboxylic acid (46 mg, 0.24mmol) in dichloromethane (2 mL). The reaction was stirred at roomtemperature for 10 minutes, then(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine (52 mg, 0.24mmol) was added and the reaction stirred at room temperature overnight.The reaction was quenched with water, and extracted withdichloromethane, then purified by silica gel chromatography using 1-10%methanol (2 N ammonia)/chloroform as eluent to give the title compounds.

Example 1

¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.52-7.28 (m, 9H), 7.25 (d, J=7.7,1H), 4.43-4.34 (m, 1H), 3.56 (d, J=12.9, 1H), 3.17 (d, J=12.9, 1H),2.83-2.67 (m, 2H), 2.59-2.50 (m, 1H), 2.50-2.44 (m, 1H), 2.35-2.29 (m,2H), 2.04-1.87 (m, 4H), 1.84-1.54 (m, 6H), 1.43-1.26 (m, 1H), 1.04-0.94(m, 1H); MS (ESI+) m/z 389 (M+H)⁺.

Example 2

¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.52-7.47 (m, 2H), 7.41 (d, J=7.4,2H), 7.38-7.29 (m, 4H), 7.25 (q, J=7.3, 2H), 4.36 (m, 1H), 3.57 (d,J=13.2, 1H), 3.40 (d, J=13.2, 1H), 2.78 (m, 3H), 2.33 (m, 3H), 2.27 (d,J=8.7, 1H), 2.21-2.13 (m, 1H), 1.99 (dt, J=5.8, 11.7, 3H), 1.87-1.75 (m,2H), 1.71-1.60 (m, 3H), 1.44 (ddd, J=7.7, 12.1, 14.5, 1H), 1.31 (m, 1H);MS (ESI+) m/z 389 (M+H)⁺.

Example 3 and Example 4N-[(3aR*,4R*,6aS*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclohexyl-2-phenylacetamide(Example 3) andN-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclohexyl-2-phenylacetamide(Example 4)

The title compounds were prepared by substituting2-cyclohexyl-2-phenylacetic acid for 1-phenylcyclopentanecarboxylic acidin the procedure that describes the preparation of Examples 1 and 2.

Example 3

¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.10 (s, 1H), 7.67 (d, J=7.2, 1H),7.44 (dd, J=5.7, 12.3, 3H), 7.40-7.35 (m, 3H), 7.33 (t, J=7.4, 1H), 7.27(dd, J=7.6, 16.2, 1H), 4.43-4.37 (m, 0.5H), 4.36-4.29 (m, 0.5H), 3.56(d, J=12.6, 0.5H), 3.42 (t, J=11.7, 1H), 3.26 (dd, J=6.6, 11.7, 1H),3.14 (d, J=10.5, 0.5H), 2.80 (d, J=8.3, 1H), 2.63 (d, J=6.9, 0.5H),2.24-2.13 (m, 1.5H), 2.02 (d, J=12.5, 0.5H), 1.91 (d, J=7.0, 1H),1.74-1.59 (m, 2.5H), 1.58-1.34 (m, 4H), 1.33-1.19 (m, 1.5H), 1.18-0.99(m, 3H), 0.87 (d, J=14.3, 0.5H), 0.81-0.68 (m, 1H); MS (ESI+) m/z 417(M+H)⁺.

Example 4

¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.65-8.56 (m, 1H), 7.66 (dd, J=3.1,7.3, 2H), 7.43 (d, J=7.4, 1H), 7.39-7.30 (m, 5H), 7.27 (dd, J=5.0, 7.6,2H), 4.35 (s, 1,H), 3.59 (d, J=13.1, 0.5H), 3.52 (d, J=13.2, 0.5H), 3.44(d, J=13.1, 0.5H), 3.33 (dd, J=8.2, 11.7, 1.5H), 2.89 (dd, J=3.1, 9.1,0.5H), 2.63-2.54 (m, 1H), 2.53-2.45 (m, 1H), 2.36 (m, 2H), 2.28 (t,J=8.0, 1H), 2.22 (t, J=7.0, 2H), 2.16 (dd, J=6.0, 12.2, 1H), 1.92 (dd,J=6.1, 12.2, 0.5H), 1.84 (dd, J=7.5, 12.6, 0.5H), 1.71 (dd, J=6.2, 12.8,2H), 1.44 (dd, J=20.6, 55.0, 4H), 1.29 (m, 1.5H), 1.18 (m, 1H), 1.06 (m,2H), 0.70 (m, 1H); MS (ESI+) m/z 389 (M+H)⁺.

Example 5 and Example 6N-[(3aR*,4R*,6aS*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide(Example 5) andN-[(3aR*,4S*,6aS*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide(Example 6)

The title compounds were prepared by substituting3-methyl-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylic acidin the procedure that describes the preparation of Examples 1 and 2.

Example 5

¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.13-8.03 (m, 1H), 7.65 (d, J=7.2,1H), 7.55 (d, J=7.3, 1H), 7.44 (d, J=4.3, 2H), 7.41 (d, J=7.0, 1H), 7.36(t, J=6.9, 3H), 7.28 (ddd, J=7.3, 14.7, 17.5, 2H), 4.40 (dd, J=6.7,13.3, 0.5H), 4.35-4.27 (m, 0.5H), 3.55 (d, J=12.7, 0.5H), 3.40 (dd,J=4.5, 12.8, 1H), 3.26 (d, J=12.9, 0.5H), 3.16 (d, J=10.5, 0.5H), 3.05(d, J=10.5, 0.5H), 2.78 (dd, J=8.1, 15.8, 1H), 2.69-2.54 (m, 1.5H),2.43-2.26 (m, 3H), 2.23-2.13 (m, 1H), 1.94-1.82 (m, 1H), 1.73-1.57 (m,1.5H), 1.50 (dt, J=7.1, 15.0, 0.5H), 1.38 (td, J=6.4, 12.2, 0.5H), 1.27(m, 0.5H), 1.19 (d, J=6.4, 1.5H), 1.11 (dd, J=5.7, 12.0, 0.5H), 1.03 (d,J=6.5, 1.5H), 0.73 (dd, J=6.7, 10.7, 3H); MS (ESI+) m/z 377 (M+H)⁺.

Example 6

¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.56 (d, J=12.9, 1H), 7.67-7.61 (m,2H), 7.43 (d, J=7.1, 1H), 7.39-7.31 (m, 5H), 7.29-7.24 (m, 2H),4.40-4.28 (m, 1H), 3.60 (d, J=13.1, 0.5H), 3.52 (d, J=13.1, 0.5H), 3.44(d, J=13.2, 0.5H), 3.33 (d, J=13.2, 0.5H), 3.22 (d, J=10.4, 1H), 2.89(dd, J=3.0, 9.1, 0.5H), 2.64 (m, 1H), 2.55 (m 1H), 2.51-2.44 (m, 1H),2.36 (s, 1H), 2.28 (t, J=8.3, 1H), 2.24-2.10 (m, 2H), 1.95-1.87 (m,0.5H), 1.81 (d, J=8.1, 0.5H), 1.77-1.62 (m, 1H), 1.36 (m, 1.5H), 1.20(dt, J=5.3, 10.6, 3H), 0.70 (dd, J=1.6, 6.7, 3H); MS (ESI+) m/z 377(M+H)⁺.

Example 7 and Example 8N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide(Example 7) andN-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide(Example 8)

The title compounds were prepared by substituting2-cyclopentyl-2-phenylacetic acid for 1-phenylcyclopentanecarboxylicacid in the procedure that describes the preparation of Examples 1 and2.

Example 7

¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.06 (dd, J=6.8, 23.5, 1H), 7.67 (d,J=7.2, 1H), 7.46-7.39 (m, 3H), 7.40-7.29 (m, 4H), 7.29-7.22 (m, 1H),4.45-4.37 (m, 0.5H), 4.35-4.27 (m, 0.5H), 3.54 (d, J=12.7, 0.5H), 3.42(dd, J=4.0, 12.8, 1H), 3.34-3.19 (m, 1.5H), 2.97-2.77 (m, 2.5H), 2.63(d, J=7.2, 0.5H), 2.46-2.27 (m, 3H), 2.26-2.05 (m, 1.5H), 2.03-1.84 (m,1.5H), 1.71 (dt, J=7.0, 14.1, 0.5H), 1.65-1.36 (m, 8H), 1.33-1.22 (m,0.5H), 1.20-0.98 (m, 2H); MS (ESI+) m/z 403 (M+H)⁺.

Example 8

¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.60-8.49 (m, 1H), 7.67 (dd, J=2.3,7.6, 2H), 7.44 (d, J=7.2, 1H), 7.36 (dt, J=5.0, 7.6, 5H), 7.26 (t,J=6.9, 2H), 4.36 (m, 1H), 3.61 (d, J=13.1, 0.5H), 3.52 (d, J=13.1,0.5H), 3.45 (d, J=13.2, 0.5H), 3.36 (dd, J=12.0, 16.0, 1.5H), 2.95-2.83(m, 1.5H), 2.63-2.55 (m, 1H), 2.53-2.46 (m, 1H), 2.38 (s, 1H), 2.29 (dd,J=7.0, 12.8, 1.5H), 2.22 (dd, J=6.1, 12.3, 1H), 2.18-2.504 (m, 1.5H),1.94 (dd, J=6.1, 12.2, 0.5H), 1.84 (dd, J=7.5, 12.7, 0.5H), 1.79-1.66(m, 1H), 1.65-1.24 (m, 8.5H), 1.09-0.92 (m, 1H); MS (ESI+) m/z 403(M+H)⁺.

Example 9 and Example 10N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide(Example 9) andN-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide(Example 10)

The title compounds were prepared by substituting1-phenylcyclohexanecarboxylic acid for 1-phenylcyclopentanecarboxylicacid in the procedure that describes the preparation of Examples 1 and2.

Example 9

¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.57-7.54 (m, 2H), 7.45 (t, J=7.3,2H), 7.37 (dd, J=7.6, 15.3, 5H), 7.29 (d, J=6.9, 1H), 7.25 (t, J=7.3,1H), 4.41 (m, 1H), 3.59 (d, J=12.9, 1H), 3.18 (d, J=12.9, 1H), 2.52 (dd,J=8.9, 17.6, 4H), 2.34 (dd, J=8.5, 15.2, 2H), 2.01-1.92 (m, 2H),1.91-1.80 (m, 2H), 1.79-1.68 (m, 3H), 1.61 (d, J=25.2, 4H), 1.43-1.33(m, 1H), 1.27 (d, J=8.7, 1H), 1.04-0.93 (m, 1H); MS (ESI+) m/z 403(M+H)⁺.

Example 10

¹H NMR (400 MHz, pyridine-d₅) δ ppm 7.60 (s, 1H), 7.42 (d, J=7.2, 2H),7.36 (t, J=6.7, 4H), 7.27 (d, J=7.5, 2H), 4.42 (m, 1H), 3.58 (d, J=13.2,1H), 3.40 (d, J=13.1, 1H), 2.81 (d, J=8.1, 1H), 2.68 (m, 2H), 1.41-2.24(m, 4H), 2.18 (m, 1H), 2.00 (m, 1H), 1.80 (m, 4H), 1.73-1.54 (m, 4H),1.52-1.39 (m, 1H), 1.36-1.18 (m, 2H); MS (ESI+) m/z 403 (M+H)⁺.

Example 11N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide

(3aS*,6aR*)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-amine (500 mg, 2.311mmol), 2,2-dicyclohexylacetic acid (570 mg, 2.54 mmol), and1-hydroxybenzotriazole (389 mg, 2.54 mmol) were combined indichloromethane (20 mL). The reaction was stirred at room temperaturefor 10 minutes, then N-(3-dimethylaminopropyl)-N-ethylcarbodiimide(0.449 mL, 2.54 mmol) was added dropwise. The reaction was stirred atroom temperature for 20 hours, and then the reaction was quenched with10 mL of water. The reaction was extracted with 2×20 mL ofdichloromethane, the solvent was removed in vacuo, and the crudematerial was chromatographed over a silica gel cartridge (Analogix®,Burlington, Wis., RS-40) eluting with 30-50% ethyl acetate/hexanes togive the title compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.60 (d,J=5.1, 1H), 7.45-7.38 (m, 4H), 7.35 (m, 1H), 4.49-4.41 (m, 1H), 3.57 (d,J=12.6, 1H), 3.37 (d, J=12.5, 1H), 2.76 (d, J=9.6, 1H), 2.69 (dd, J=7.9,15.7, 1H), 2.50 (d, J=9.1, 1H), 2.48-2.41 (m, 1H), 2.28 (t, J=8.2, 1H),2.15-2.08 (m, 1H), 1.99-1.06 (m, 26H), 1.04-0.92 (m, 1H); MS (ESI+) m/z423 (M+H)⁺.

Example 12 and Example 13(2S)-2-(3-benzoylphenyl)-N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]propanamide(Example 12) and(2S)-2-(3-benzoylphenyl)-N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]propanamide(Example 13)

The title compounds were prepared by substituting(S)-2-(3-benzoylphenyl)propanoic acid for 1-phenylcyclopentanecarboxylicacid in the procedure that describes the preparation of Examples 1 and2.

Example 12

¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.28 (d, J=6.9, 0.5H), 8.21 (d,J=7.1, 0.5H), 8.13 (d, J=15.9, 1H), 7.92-7.82 (m, 2H), 7.75 (t, J=9.1,2H), 7.56-7.52 (m, 1H), 7.50-7.25 (m, 8H), 4.49-4.32 (m, 1H), 3.90 (q,J=7.1, 0.5H), 3.81 (t, J=7.0, 0.5H), 3.45 (q, J=12.8, 1.5H), 3.25 (d,J=13.0, 0.5H), 2.75 (d, J=9.2, 1.5H), 2.49 (dd, J=2.9, 9.5, 0.5H),2.44-2.31 (m, 1.5H), 2.24 (dt, J=7.7, 16.5, 1.5H), 2.14 (d, J=9.6,0.5H), 2.09-2.01 (m, 0.5H), 1.90-1.71 (m, 1H), 1.66-1.44 (m, 5H), 1.20(dd, J=5.4, 28.1, 1H); MS (ESI+) m/z 453 (M+H)⁺.

Example 13

¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.67 (d, J=7.1, 1H), 8.10 (s, 1H),7.91-7.86 (m, 2H), 7.83 (d, J=7.7, 1H), 7.74 (d, J=7.6, 1H), 7.56-7.51(m, 7.47-7.32 (m, 7H), 7.30-7.24 (m, 1H), 4.47-4.29 (m, 1H), 3.93 (q, J=6.9, 1H), 3.56 (t, J=12.3, 1H), 3.44 (d, J=13.1, 0.5H), 3.37 (d,J=13.1, 0.5H), 2.81 (dd, J=3.0, 9.1, 0.5H), 2.72 (d, J=7.0, 0.5H), 2.53(m, 0.5H), 2.49-2.39 (m, 2H), 2.37-2.32 (m, 0.5H), 2.31-2.18 (m, 2H),2.12 (dd, J=6.0, 12.1, 0.5H), 2.03 (dd, J=6.0, 12.2, 0.5H), 1.86-1.71(m, 1H), 1.63 (t, J=9.9, 3H), 1.57-1.47 (m, 1H), 1.40-1.27 (m, 1H); MS(ESI+) m/z 453 (M+H)⁺.

Example 14N-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

Step A: 2-Benzylhexahydrocyclopenta[c]pyrrol-4(5H)-one (16.28 g, 76mmol), titanium tetraethoxide (28.5 mL, 137 mmol), and(S)-2-methylpropane-2-sulfinamide (10.452 g, 86 mmol) were combined intetrahydrofuran (200 mL). The reaction was heated at 60° C. overnight.The reaction was then reduced in volume to about half and poured into150 mL of saturated aqueous ammonium chloride. The precipitate wascollected by filtration and washed with ethyl acetate. The filtrate waspoured into a separatory funnel and the organic layer was removed. Theaqueous layer was extracted with ethyl acetate (3×100 mL). The organicwashes were combined and washed with brine, dried (Na₂SO₄) andconcentrated. The crude material was chromatographed using silica gelcartridge (Analogix®, Burlington, Wis., RS65-400) eluting with 5-100%ethyl acetate/hexanes to give(S,E)-N-((3aR,6aS)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)-2-methylpropane-2-sulfinamideand(S,E)-N-((3aS,6aR)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)-2-methylpropane-2-sulfinamide.

Step B: A mixture of(S,E)-N-((3aS,6aR)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)-2-methylpropane-2-sulfinamide(0.940 g, 2.95 mmol) from Step A in methanol (20 mL) was cooled to −78°C. in a dry ice/acetone bath. Sodium borohydride (0.335 g, 8.85 mmol)was added, and the reaction was allowed to warm to room temperatureovernight. The reaction was quenched with saturated aqueous ammoniumchloride, diluted with water, and extracted with 3×100 mL of ethylacetate. The extracts were dried (Na₂SO₄) and filtered. The solvent wasremoved in vacuo, and the crude material was chromatographed using asilica gel cartridge (Analogix®, Burlington, Wis., RS-40) with 5-50%acetone/hexanes to give(S)—N-((3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-2-methylpropane-2-sulfinamide:¹H NMR (300 MHz, CDCl₃) δ ppm 7.37-7.11 (m, 5H), 4.85 (d, J=7.0, 1H),3.90-3.71 (m, 2H), 3.28 (d, J=13.0, 1H), 3.09 (d, J=9.8, 1H), 2.72-2.50(m, 2H), 2.46 (d, J=9.6, 1H), 2.32-2.12 (m, 2H), 1.82 (td, J =5.5, 12.7,1H), 1.68-1.60 (m, J =10.6, 2H), 1.35-1.24 (m, 1H), 1.20 (s, J=5.5, 9H).

Step C:(S)—N-((3aS,4S,6aR)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-yl)-2-methylpropane-2-sulfinamide(855 mg, 2.67 mmol) from Step B and 2 N HCl (10 mL, 40.0 mmol) werecombined in methanol (10 mL). After 30 minutes, the solvent was removedand the crude material was purified on a silica gel cartridge(Analogix®, Burlington, Wis., RS-25) loading with 10% methanol(2 Nammonia)/dichloromethane solution and eluting with 2-10% methanol (2 Nammonia)/dichloromethane to give(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine: ¹H NMR (500MHz, pyridine-d₅) δ ppm 7.44 (d, J=7.4, 2H), 7.36 (t, J=7.5, 2H), 7.28(t, J=7.3, 1H), 3.52 (q, J=13.0, 2H), 3.29 (q, J=7.3, 1H), 2.84 (dd,J=3.7, 9.3, 1H), 2.55-2.43 (m, 3H), 2.37-2.30 (m, 1H), 2.24 (d, J=5.3,1H), 1.74-1.64 (m, 2H), 1.62-1.53 (m, 1H), 1.34 (dd, J=5.0, 10.1, 1H).

Step D: 3-Methyl-2-phenylbutanoic acid (1.049 mmol),1-hydroxybenzotriazole hydrate (1.049 mmol), andN-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (185 μL, 1.049 mmol) werecombined in dichloromethane (4 mL). The mixture was stirred at roomtemperature for 10 minutes, then(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine (1.049 mmol)from Step C was added in 2 mL of dichloromethane. The reaction wasstirred at room temperature for 3.5 hours, and then quenched with 0.5 mLof water. The organic layer was separated and chromatographed using asilica gel cartridge (Analogix®, Burlington, Wis., RS-12) eluting with1-10% methanol(ammonia)/dichloromethane to give the title compound: ¹HNMR (500 MHz, pyridine-d₅) δ ppm 8.08 (dd, J=7.2, 14.4, 1H), 7.64 (dd,J=7.5, 14.5, 1H), 7.56-7.52 (m, 1H), 7.43 (d, J=4.4, 2H), 7.42-7.40 (m,1H), 7.38-7.22 (m, 5H), 4.40 (dt, J=7.2, 14.3, 0.5H), 4.35-4.28 (m,0.5H), 3.55 (d, J=12.7, 0.5H), 3.40 (dd, J=4.5, 12.8, 1H), 3.26 (d,J=12.9, 0.5H), 3.15 (d, J=10.5, 0.5H), 3.05 (d, J=10.5, 0.5H), 2.83-2.74(m, 1H), 2.70-2.55 (m, 1.5H), 2.43-2.26 (m, 3H), 2.23-2.13 (m, 1H),1.94-1.83 (m, 1H), 1.74-1.57 (m, 1.5H), 1.50 (dt, J=7.1, 15.3, 0.5H),1.37 (td, J=6.5, 12.1, 0.5H), 1.31-1.23 (m, 0.5H), 1.18 (d, J=6.5,1.5H), 1.10 (dt, J=6.5, 11.5, 0.5H), 1.03 (d, J=6.5, 1.5H), 0.73 (dd,J=6.7, 10.7, 3H); MS (ESI+) m/z 377 (M+H)⁺.

Example 15N-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide

The title compound was prepared by substituting 2,2-dicyclohexylaceticacid for 3-methyl-2-phenylbutanoic acid in the procedure used to prepareExample 14: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.44-7.38 (m, 4H),7.37-7.32 (m, 1H), 4.49-4.38 (m, 1H), 3.57 (d, J=12.6, 1H), 3.37 (d,J=12.5, 1H), 2.77 (dd, J=1.7, 9.6, 1H), 2.68 (td, J=2.0, 9.3, 1H), 2.51(dd, J=1.9, 9.0, 1H), 2.45 (dd, J=7.1, 15.9, 1H), 2.30-2.25 (m, 1H),2.11 (dd, J=7.1, 9.6, 1H), 1.98-1.83 (m, 3H), 1.83-1.58 (m, 12H),1.57-1.51 (m, 1H), 1.48 (d, J=13.0, 1H), 1.44-1.37 (m, 1H), 1.36-1.09(m, 9H), 1.04-0.94 (m, 1H); MS (ESI+) m/z 423 (M+H)⁺.

Example 16(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide

Step A:(S,E)-N-((3aS,6aR)-2-Benzylhexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)-2-methylpropane-2-sulfinamide(2.67 g, 8.38 mmol) from Example 14 Step A and 2.0 N aqueous HCl (18.86mL, 37.7 mmol) were combined in tetrahydrofuran (25 mL). The reactionwas stirred at room temperature for 2 hours and the tetrahydrofuran wasremoved in vacuo and the remaining aqueous portion was made slightlybasic with aqueous sodium bicarbonate solution. The aqueous layer wasextracted with 3×200 mL of dichloromethane. The combined organic layerswere separated, and the solvent was removed in vacuo. The crude materialwas purified on a silica gel cartridge (Analogix®, Burlington, Wis.,RS25-25) eluting with ethyl acetate/hexanes to give(3aS,6aR)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-one: ¹H NMR (300MHz, CDCl₃) δ ppm 7.35-7.16 (m, 5H), 3.61 (d, J=13.1, 1H), 3.48 (d,J=13.1, 1H), 3.02 (dd, J=1.8, 9.1, 1H), 2.96-2.82 (m, 1H), 2.71-2.56 (m,2H), 2.43 (dt, J=8.2, 17.4, 3H), 2.34-2.21 (m, 1H), 2.12 (ddd, J=8.3,13.0, 16.9, 1H), 1.79 (dddd, J=4.2, 6.4, 9.2, 13.2, 1H).

Step B: A mixture of(3aS,6aR)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-one (1.462 g, 6.79mmol) from Step A in methanol (20mL) was cooled in an dry ice/acetonebath to −40° C. Sodium borohydride (0.514 g, 13.58 mmol) was added inportions over 5 minutes. The reaction allowed to warm to roomtemperature overnight, then it was quenched with saturated aqueousammonium chloride, diluted with water, and extracted with 3×150 mL ofethyl acetate. The combined extracts were dried (Na₂SO₄) and the solventwas removed in vacuo to give(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ol: ¹H NMR (300 MHz,CDCl₃) δ ppm 7.38-7.16 (m, 5H), 4.21-4.04 (m, 1H), 3.66 (d, J=12.8, 1H),3.51 (d, J=12.8, 1H), 3.07 (d, J=9.3, 1H), 2.65-2.53 (m, J=11.8, 2H),2.52-2.43 (m, 1H), 2.18-2.07 (m, J=7.5, 16.3, 2H), 2.05-1.94 (m, J=8.7,12.6, 1H), 1.84-1.74 (m, J=6.2, 1H), 1.49-1.34 (m, 3H).

Step C: (3aS,4S,6aR)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-ol (1.476 g,6.79 mmol) from Step B and triethylamine (1.420 mL, 10.19 mmol) werecombined in dichloromethane (30 mL). Methanesulfonyl chloride (0.635 mL,8.15 mmol) was added as a solution in 20mL of dichloromethane dropwisevia addition funnel. The reaction was stirred at room temperature for 30minutes and concentrated. The crude material was absorbed onto silicagel and chromatographed on a silica gel cartridge (Analogix®,Burlington, Wis., RS25-25) eluting with 20-100% ethyl acetate/hexanes togive(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylmethanesulfonate:¹H NMR (300 MHz, CDCl₃) δ ppm 7.35-7.27 (m, 4H), 7.27-7.20 (m, 1H), 4.96(ddd, J=6.1, 7.6, 9.1, 1H), 3.71-3.44 (m, 1H), 2.94 (s, J=13.5, 3H),2.85 (ddd, J=4.9, 8.1, 16.0, 1H), 2.75-2.68 (m, 2H), 2.67-2.55 (m, 1H),2.54-2.44 (m, 1H), 2.31 (dd, J =4.1, 8.7, 1H), 2.20-2.04 (m, 1H), 1.97(dtd, J=3.4, 6.2, 9.6, 1H), 1.79-1.63 (m, 1H), 1.61-1.49 (m, 2H).

Step D: (3aS,4S,6aR)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-ylmethanesulfonate (1.686 g, 5.71 mmol) from Step C and sodium azide(0.557 g, 8.56 mmol) were combined in N,N-dimethylacetamide (10 mL). Thereaction was heated at 90° C. for 15 hours. The reaction was cooled anddiluted with 200 mL of ethyl acetate and then quenched with 30 mL water.The organic layer was removed and washed with 2×20 mL of water, then 20mL of brine. The solvent was removed in vacuo to give(3aS,4R,6aR)-4-azido-2-benzyloctahydrocyclopenta[c]pyrrole: ¹H NMR (300MHz, CDCl₃) δ ppm 7.36-7.27 (m, 4H), 7.22 (dd, J=2.9, 5.8, 1H),3.72-3.61 (m, 1H), 3.54 (s, 2H), 2.76-2.60 (m, 1H), 2.55-2.40 (m, 4H),2.35 (dd, J=3.5, 9.1, 1H), 2.07-1.86 (m, 2H), 1.72-1.60 (m, 1H),1.49-1.38 (m, 1H).

Step E: Triphenylphosphine (4.49 g, 17.13 mmol) and water (1.234 mL,68.5 mmol) were added successively to a mixture of(3aS,4R,6aR)-4-azido-2-benzyloctahydrocyclopenta[c]pyrrole (1.384 g,5.71 mmol) in tetrahydrofuran (30 mL). The reaction was refluxed at 80°C. for 2 hours. The crude material was adsorbed onto silica gel andapplied to a silica gel cartridge (Analogix®, Burlington, Wis., RS-40)and eluted with 1-10% methanol (2 N ammonia)/chloroform to give(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine: ¹H NMR (500MHz, pyridine-d₅) δ ppm 7.45 (d, J=7.4, 2H), 7.38 (t, J=7.5, 2H), 7.29(t, J=7.3, 1H), 3.52 (s, 2H), 3.14 (dd, J=5.7, 10.7, 1H), 2.62-2.55 (m,1H), 2.52 (dd, J=3.2, 9.0, 1H), 2.38-2.29 (m, 3H), 2.20-2.13 (m, 1H),2.01-1.84 (m, 2H), 1.40-1.29 (m, 2H).

Step F: (S)-2-Phenylbutanoic acid (41.7 mg, 0.254 mmol),1-hydroxybenzotriazole (38.9 mg, 0.254 mmol), andN-(3-dimethylaminopropyl)-N-ethylcarbodiimide (0.045 mL, 0.254 mmol)were combined in dichloromethane (1 mL). The reaction was stirred atroom temperature for 10 minutes, and then(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine (50 mg, 0.231mmol) from Step E was added in 0.5 mL of dichloromethane. The reactionwas stirred at room temperature for 20 hours, and then quenched with 0.5mL of water. The organic layer was separated. The crude material waschromatographed using a silica gel cartridge (Analogix®, Burlington,Wis., RS-4) eluting with 1-10% methanol(ammonia)/dichloromethane to givethe title compound: ¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.47 (d, J=7.0,1H), 7.59 (m, 2H), 7.42 (d, J=7.1, 2H), 7.34 (dd, J=7.6, 16.5, 4H), 7.25(dt, J=5.0, 10.1, 2H), 4.45-4.29 (m, 1H), 3.62-3.51 (m, 2H), 3.44 (d,J=13.2, 1H), 2.85 (dd, J=2.7, 9.0, 1H), 2.58-2.50 (m, 1H), 2.50-2.42 (m,2H), 2.40-2.31 (m, 1H), 2.31-2.22 (m, 2H), 1.97 (dq, J=6.1, 12.1, 1H),1.85 (td, J=6.9, 13.6 1H), 1.74 (dt, J=6.4, 14.3, 1H), 1.46 (dt, J=7.1,19.2, 1H), 1.31 (dt, J=6.2, 20.5, 1H), 0.96 (dd, J=5.5, 9.1, 3H); MS(ESI+) m/z 363 (M+H)⁺.

Example 17N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide

The title compound was prepared by substituting2-cyclopentyl-2-phenylacetic acid for (S)-2-phenylbutanoic acid in StepF of the procedure used to prepare Example 16: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.61 (dd, J=7.4, 10.6, 1H), 7.69 (dd, J=1.5, 8.1,2H), 7.44 (d, J=7.3, 1H), 7.36 (dt, J=7.2, 15.3, 5H), 7.30-7.25 (m, 2H),4.42-4.29 (m, 1H), 3.61 (d, J=13.1, 0.5H), 3.52 (d, J=13.2, 0.5H), 3.43(dd, J=12.0, 18.8, 1.5H), 3.34 (d, J=13.2, 0.5H), 2.96-2.83 (m, 1.5H),2.55 (dt, J=15.9, 16.3, 2H), 2.41 (t, J=18.3, 1H), 2.31 (d, J=9.0,0.5H), 2.28 (d, J=6.3, 1H), 2.23 (d, J=5.0, 1H), 2.20-2.04 (m, 1.5H),1.94 (dt, J=7.1, 12.1, 0.5H), 1.89-1.81 (m, 0.5H), 1.80-1.67 (m, 1H),1.65-1.26 (m, 7H), 1.05-0.94 (m, 1H); MS (ESI+) m/z 403 (M+H)⁺.

Example 18N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting3-methyl-2-phenylbutanoic acid for (S)-2-phenylbutanoic acid in Step Fof the procedure used to prepare Example 16: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.64 (dd, J=7.3, 11.3, 1H), 7.66 (dd, J=2.4, 7.5,2H), 7.43 (d, J=7.5, 1H), 7.40-7.30 (m, 5H), 7.29-7.23 (m, 2H),4.40-4.28 (m, 1H), 3.60 (d, J=13.2, 0.5H), 3.52 (d, J=13.1, 0.5H), 3.44(d, J=13.1, 0.5H), 3.33 (d, J=13.1, 0.5H), 3.25 (d, J=10.5, 1H), 2.88(dd, J=3.1, 9.1, 0.5H), 2.66 (s, 1H), 2.60-2.56 (m, 0.5H), 2.55-2.46 (m,1.5H), 2.39 (t, J=18.7, 1H), 2.28 (t, J=8.0, 1.5H), 2.22 (d, J=5.1, 1H),2.18-2.09 (m, 0.5H), 1.91 (dd, J=6.0, 12.0, 0.5H), 1.84 (dd, J=7.1,13.4, 0.5H), 1.72 (ddd, J=6.5, 12.3, 25.1, 1H), 1.49-1.40 (m, 0.5H),1.33 (ddd, J=13.3, 19.9, 32.3, 1H), 1.20 (dd, J=5.0, 6.4, 3H), 0.70 (dd,J=1.7, 6.7, 3H); MS (ESI+) m/z 377 (M+H)⁺.

Example 19(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylpropanamide

The title compound was prepared by substituting (S)-2-phenylpropanoicacid for (S)-2-phenylbutanoic acid in Step F of the procedure used toprepare Example 16: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.41 (d, J=6.8,1H), 7.54 (d, J=7.0, 2H), 7.41 (t, J=9.7, 2H), 7.38-7.30 (m, 4H), 7.26(dd, J=5.3, 16.7, 2H), 4.43-4.32 (m, 1H), 3.84 (q, J=7.0, 1H), 3.56 (t,J=12.3, 1H), 3.40 (dd, J=13.1, 33.2, 1H), 2.81 (dd, J=2.9, 9.0, 1H),2.51 (m, 1H), 2.48-2.36 (m, 2H), 2.33-2.17 (m, 2H), 2.14 (s, 3H, OAc),2.00 (dq, J=6.1, 12.1, 1H), 1.73 (dt, J=6.3, 14.2, 1H), 1.60 (d, J=7.0,3H), 1.47 (dt, J=7.1, 14.8, 1H), 1.39-1.24 (m, 1H); MS (ESI+) m/z 349(M+H)^(').

Example 20N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide

The title compound was prepared by substituting 2,2-dicyclohexylaceticacid for (S)-2-phenylbutanoic acid in Step F of the procedure used toprepare Example 16: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.12 (d, J=7.2,1H), 7.45 (d, J=7.4, 2H), 7.36 (t, J=7.5, 2H), 7.27 (t, J=7.3, 1H),4.52-4.43 (m, 1H), 3.63 (d, J=13.1, 1H), 3.48 (d, J=13.1, 1H), 2.89 (dd,J=2.7, 8.9, 1H), 2.65-2.50 (m, 3H), 2.35 (d, J=4.5, 2H), 2.18-2.10 (m,1H), 2.03 (t, J=7.4, 1H), 1.96 (d, J=13.0, 2H), 1.87 (dt, J=7.4, 13.9,3H), 1.80 (d, J=12.6, 2H), 1.76-1.64 (m, 5H), 1.60 (d, J=10.7, 2H),1.51-1.38 (m, 3H), 1.30-1.05 (m, 8H); MS (ESI+) m/z 423 (M+H)⁺.

Example 21N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-propylpentanamide

The title compound was prepared by substituting 2-propylpentanoic acidfor (S)-2-phenylbutanoic acid in Step F of the procedure used to prepareExample 16: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.36 (d, J=7.2, 1H),7.43 (d, J=7.4, 2H), 7.36 (t, J=7.5, 2H), 7.27 (t, J=7.3, 1H), 4.56-4.38(m, 1H), 3.60 (d, J=11.8, 1H), 3.45 (d, J=13.1, 1H), 2.85 (dd, J=2.8,9.0, 1H), 2.61-2.50 (m, 2H), 2.50-2.45 (m, 1H), 2.39-2.25 (m, 3H),2.20-2.09 (m, 1H), 1.93-1.79 (m, 3H), 1.66 (dd, J=7.7, 12.2, 1H),1.53-1.29 (m, 7H), 0.87 (td, J=3.1, 7.2, 6H); MS (ESI+) m/z 343 (M+H)⁺.

Example 22N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]cycloheptanecarboxamide

The title compound was prepared by substituting cycloheptanecarboxylicacid for (S)-2-phenylbutanoic acid in Step F of the procedure used toprepare Example 16: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.08 (d, J=7.2,1H), 7.44 (d, J=7.4, 2H), 7.36 (t, J=7.6, 2H), 7.27 (t, J=7.3, 1H),4.50-4.34 (m, 1H), 3.60 (d, J=13.7, 1H), 3.44 (d, J=13.1, 1H), 2.83 (d,J=9.0, 1H), 2.54 (s, 2H), 2.49-2.41 (m, 2H), 2.33 (d, J=6.8, 1H),2.30-2.25 (m, 1H), 2.19-2.10 (m, 1H), 2.01-1.81 (m, 5H), 1.74-1.58 (m,3H), 1.47-1.37 (m, 5H), 1.31 (s, 2H); MS (ESI+) m/z 341 (M+H)⁺.

Example 23(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(4-isobutylphenyl)propanamide

The title compound was prepared by substituting(S)-2-(3-isobutylphenyl)propanoic acid for (S)-2-phenylbutanoic acid inStep F of the procedure used to prepare Example 16: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.37 (d, J=7.2, 1H), 7.49 (d, J=8.0, 2H), 7.42 (d,J=7.5, 2H), 7.36 (t, J=7.5, 2H), 7.27 (t, J=7.3, 1H), 7.14 (d, J=8.0,2H), 4.43-4.31 (m, 1H), 3.84 (q, J=7.0, 1H), 3.58 (d, J=13.1, 1H), 3.44(d, J=13.1, 1H), 2.82 (dd, J=2.8, 9.1, 1H), 2.55-2.48 (m, 1H), 2.48-2.42(m, 2H), 2.39 (d, J=7.2, 2H), 2.31-2.21 (m, 2H), 2.00 (dt, J=6.0, 12.1,1H), 1.83-1.69 (m, 2H), 1.63 (d, J=7.0, 3H), 1.48 (dt, J=7.0, 19.1, 1H),1.36-1.25 (m, 1H), 0.86-0.77 (m, 6H); MS (ESI+) m/z 405 (M+H)⁺.

Example 24N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide

The title compound was prepared by substituting1-phenylcyclohexanecarboxylic acid for (S)-2-phenylbutanoic acid in StepF of the procedure used to prepare Example 16: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.73 (d, J=7.8, 1H), 7.63-7.59 (m, 1H), 7.41 (d,J=7.3, 2H), 7.39-7.31 (m, 4H), 7.29-7.23 (m, 3H), 4.45-4.35 (m, 1H),3.58 (d, J=13.2, 1H), 3.40 (d, J=13.2, 1H), 2.80 (d, J=7.7, 1H),2.69-2.59 (m, 2H), 2.41-2.31 (m, 3H), 2.28 (d, J=8.6, 1H), 2.20-2.13 (m,1H), 2.00 (td, J=5.7, 11.7, 1H), 1.87-1.75 (m, 4H), 1.74-1.54 (m, J=9.1,18.8, 38.4, 4H), 1.46 (dt, J=7.8, 14.8, 1H), 1.36-1.19 (m, 2H); MS(ESI+) m/z 403 (M+H)^(′).

Example 25N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,3-diphenylpropanamide

The title compound was prepared by substituting 2,3-diphenylpropanoicacid for (S)-2-phenylbutanoic acid in Step F of the procedure used toprepare Example 16: ¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.52 (dd, J=7.3,13.3, 1H), 7.65 (d, J=7.4, 2H), 7.44 (d, J=7.1, 1H), 7.41-7.29 (m, 8H),7.26 (dt, J=4.8, 10.9, 4H), 4.35-4.22 (m, 1H), 3.96 (dt, J=5.0, 10.0,1H), 3.77 (ddd, J=3.7, 10.1, 13.5, 1H), 3.52 (dt, J=13.2, 18.8, 1.5H),3.33 (d, J=13.1, 0.5H), 3.05 (dt, J=4.7, 13.0, 1H), 2.77 (d, J=8.9,0.5H), 2.56 (d, J=6.2, 0.5H), 2.38-2.23 (m, 3H), 2.23-2.17 (m, J=8.7,1H), 1.94 (ddd, J=5.7, 11.8, 23.8, 1H), 1.72-1.57 (m, J=6.0, 1H),1.51-1.19 (m, 3H); MS (ESI+) m/z 425 (M+H)⁺.

Example 26N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-methyl-3-phenylpropanamide

The title compound was prepared by substituting2-methyl-3-phenylpropanoic acid for (S)-2-phenylbutanoic acid in Step Fof the procedure used to prepare Example 16: ¹H NMR (400 MHz,pyridine-d₅) δ ppm 8.12 (dd, J=7.0, 21.5, 1H), 7.47-7.22 (m, 10H),4.43-4.29 (m, 1H), 3.58 (dd, J=6.6, 13.2, 1H), 3.45 (dd, J=13.2, 21.2,1H), 3.20 (ddd, J=4.6, 10.8, 15.0, 1H), 2.81-2.66 (m, 3H), 2.48-2.19 (m,5H), 2.04 (ddt, J=6.0, 12.1, 24.4, 1H), 1.82-1.63 (m, 1H), 1.47 (ddd,J=7.1, 15.9, 18.8, 1H), 1.39-1.30 (m, 1H), 1.28 (d, J=6.3, 3H); MS(ESI+) m/z 363 (M+H)⁺.

Example 27N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-methyl-2-phenylpropanamide

The title compound was prepared by substituting2-methyl-2-phenylpropanoic acid for (S)-2-phenylbutanoic acid in Step Fof the procedure used to prepare Example 16: ¹H NMR (400 MHz,pyridine-d₅) δ ppm 7.44 (dd, J=7.9, 16.1, 4H), 7.31 (ddd, J=7.7, 14.5,22.6, 6H), 7.12-7.03 (m, 1H), 4.46-4.36 (m, 1H), 3.58 (d, J=13.2, 1H),3.43 (d, J=13.2, 1H), 2.84 (d, J=6.5, 1H), 2.39-2.26 (m, J=6.9, 20.1,4H), 2.23-2.14 (m, J=6.7, 1H), 2.04 (dd, J=5.8, 11.8, 1H), 1.67 (s, 7H),1.54-1.40 (m, 1H), 1.38-1.24 (m, 1H); MS (ESI+) m/z 363 (M+H)⁺.

Example 28N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclopropanecarboxamide

The title compound was prepared by substituting1-phenylcyclopropanecarboxylic acid for (S)-2-phenylbutanoic acid inStep F of the procedure used to prepare Example 16: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.42 (dd, J=7.2, 16.3, 4H), 7.33 (dt, J=7.6, 17.1,4H), 7.25 (dd, J=5.8, 13.1, 2H), 6.27 (d, J=7.5, 1H), 4.41-4.24 (m,J=5.8, 1H), 3.56 (d, J=13.2, 1H), 3.40 (d, J=13.2, 1H), 2.87-2.74 (m,1H), 2.37-2.19 (m, 4H), 2.12 (t, J=8.0, 1H), 2.03-1.94 (m, 1H), 1.75(dd, J=3.5, 6.6, 2H), 1.68-1.58 (m, J=8.7, 16.8, 1H), 1.37-1.23 (m, 2H),1.01 (dd, J=3.5, 6.6, 2H); MS (ESI+) m/z 361 (M+H)⁺.

Example 292-benzyl-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethylbutanamide

The title compound was prepared by substituting2-benzyl-3,3-dimethylbutanoic acid for (S)-2-phenylbutanoic acid in StepF of the procedure used to prepare Example 16: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.08 (dd, J=7.4, 13.5, 1H), 7.46 (d, J=7.3, 1H),7.44-7.32 (m, 5H), 7.32-7.23 (m, 4H), 4.33 (s, 1H), 3.58 (dd, J=13.2,16.9, 1H), 3.50 (d, J=13.1, 0.5H), 3.40 (d, J=13.1, 0.5H), 3.25 (q,J=11.9, 1H), 2.80-2.66 (m, 2H), 2.45 (d, J=6.9, 1H), 2.41-2.23 (m,3.5H), 2.20 (t, J=8.3, 0.5H), 2.16-2.09 (m, 0.5H), 2.06 (dd, J=5.8,11.6, 0.5H), 1.89 (dd, J=5.8, 11.8, 0.5H), 1.75 (s, 0.5H), 1.61 (s,0.5H), 1.47 (s, 0.5H), 1.38-1.20 (m, 2H), 1.16 (s, 9H); MS (ESI+) m/z405 (M+H)⁺.

Example 30N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide

The title compound was prepared by substituting3,3-dimethyl-2-phenylbutanoic acid for (S)-2-phenylbutanoic acid in StepF of the procedure used to prepare Example 16: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.57-8.49 (m, 1H), 7.73 (dd, J=3.3, 5.3, 2H), 7.44(d, J=7.1, 1H), 7.41-7.24 (m, 7H), 4.41-4.29 (m, J =6.9, 13.0, 1H), 3.62(d, J=13.2, 0.5H), 3.53 (d, J=13.1, 0.5H), 3.43 (s, 0.5H), 3.35 (d,J=13.1, 0.5H), 2.90 (dd, J=3.1, 8.9, 1H), 2.63-2.46 (m, 2H), 2.44-2.37(m, 0.5H), 2.36-2.30 (m, J=8.3, 1H), 2.28 (d, J=5.3, 1H), 2.23 (d,J=5.5, 1H), 2.15 (dt, J=6.2, 12.5, 0.5H), 1.91 (dt, J=6.1, 12.2, 0.5H),1.88-1.79 (m, 0.5H), 1.77-1.66 (m, 1H), 1.46-1.35 (m, 1H), 1.34-1.23 (m,1H), 1.15 (s, 4.5H), 1.14 (s, 4.5H); MS (ESI+) m/z 391 (M+H)⁺.

Example 31 and Example 32(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide(Example 31) and(2R)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide(Example 32)

The material from example 30 was subjected to separation by chiralsupercritical fluid chromatography on a ChiralCel® OD-H column (21×250mm, 5 μm, Chiral Technologies, Inc.), 5-50% methanol:CO₂ (100 bar), at40 mL/minute over 10 minutes to give the title compounds.

Example 31

¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.50 (d, J=7.1, 1H), 7.74-7.70 (m,1H), 7.44 (d, J=7.2, 2H), 7.40-7.24 (m, J =8.0, 15.4, 18.2, 7H),4.43-4.31 (m, 1H), 3.63 (d, J=13.1, 1H), 3.49-3.41 (m, J=6.6, 2H), 2.91(dd, J=3.0, 8.9, 1H), 2.63-2.43 (m, 3H), 2.28 (d, J=5.3, 2H), 1.92 (dq,J=6.1, 12.1, 1H), 1.78-1.68 (m, 1H), 1.41 (dt, J=7.0, 18.9, 1H), 1.30(dt, J=6.4, 14.5, 1H), 1.14 (s, 9H); MS (ESI+) m/z 391 (M+H)⁺.

Example 32

¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.52 (d, J=7.0, 1H), 7.72 (d, J=7.0,2H), 7.41-7.24 (m, J=7.2, 21.5, 29.9, 8H), 4.41-4.25 (m, 1H), 3.53 (d,J=13.1, 1H), 3.45 (s, 1H), 3.35 (d, J=13.1, 1H), 2.57 (d, J=5.7, 1H),2.45-2.36 (m, 1H), 2.31 (dd, J=5.1, 10.5, 2H), 2.25-2.20 (m, 2H), 2.15(td, J=6.4, 12.4, 1H), 1.83 (td, J=6.8, 14.8, 1H), 1.69 (td, J=6.7,13.4, 1H), 1.38 (td, J=6.7, 12.4, 1H), 1.14 (s, 9H); MS (ESI+) m/z 391(M+H)⁺.

Example 33(2S)—N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide

Step A: (3aR,4S,6aS)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-amine wasprepared according to the procedure described in Example 16 Steps A-Esubstituting(S,E)-N-((3aR,6aS)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)-2-methylpropane-2-sulfinamidefrom Step A in Example 14 for(S,E)-N-((3aS,6aR)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)-2-methylpropane-2-sulfinamidein Step A of Example 16 to give(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine: ¹H NMR (300MHz, CDCl₃) δ ppm 7.34-7.28 (m, 4H), 7.25-7.18 (m, 1H), 3.54 (s, 2H),3.09 (dd, J=4.8, 10.9, 1H), 2.75-2.58 (m, 1H), 2.48 (dd, J=8.6, 16.5,2H), 2.40 (dd, J=3.9, 9.3, 1H), 2.30 (dd, J=3.9, 9.0, 1H), 2.21-2.09 (m,1H), 2.01-1.84 (m, J=6.9, 12.0, 2H), 1.47-1.25 (m, 4H).

Step B: The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step Afor (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in Step Fof the procedure used to prepare Example 16: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.55 (d, J=4.5, 1H), 7.59 (s, J=5.1, 1H), 7.39 (d,J=7.2, 2H), 7.34 (dd, J=7.7, 16.5, 4H), 7.25 (dd, J=7.6, 16.2, 3H),4.43-4.33 (m, 1H), 3.59-3.50 (m, 2H), 3.36 (d, J=13.1, 1H), 2.69-2.61(m, 1H), 2.43-2.28 (m, 4H), 2.28-2.23 (m, 1H), 2.22-2.18 (m, 1H), 2.13(dq, J=6.3, 12.3, 1H), 1.89-1.77 (m, 2H), 1.65 (td, J=7.0, 14.2, 1H),1.40-1.32 (m, 1H), 0.97 (t, J=7.3, 3H); MS (ESI+) m/z 363 (M+H)⁺.

Example 34N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand substituting 2-cyclopentyl-2-phenylacetic acid for(S)-2-phenylbutanoic acid in Step F of the procedure used to prepareExample 16: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.54 (d, J=14.7, 1H),7.66 (dd, J=2.5, 7.5, 2H), 7.43 (d, J=7.4, 1H), 7.40-7.31 (m, 5H), 7.26(t, J=6.9, 2H), 4.41-4.30 (m, 1H), 3.61 (d, J=13.1, 0.5H), 3.52 (d,J=13.1, 0.5H), 3.45 (d, J=13.2, 0.5H), 3.36 (app. t, J=12.7, 1.5H), 2.89(d, J=9.0, 1H), 2.61-2.55 (m, 1H), 2.53-2.46 (m, 1H), 2.44-2.33 (m, 1H),2.29 (dd, J=7.3, 12.8, 1.5H), 2.22 (t, J=4.9, 1H), 2.19-2.04 (m, 1.5H),1.98-1.89 (m, 0.5H), 1.88-1.80 (m, 0.5H), 1.79-1.65 (m, 1H), 1.65-1.25(m, 8H), 1.05-0.95 (m, 1H); MS (ESI+) m/z 403 (M+H)⁺.

Example 35N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand substituting 3-methyl-2-phenylbutanoic acid for (S)-2-phenylbutanoicacid in Step F of the procedure used to prepare Example 16: ¹H NMR (500MHz, pyridine-d₅) δ ppm 8.64-8.49 (m, J=20.1, 1H), 7.67-7.61 (m, 2H),7.43 (d, J=7.0, 1H), 7.39-7.30 (m, 5H), 7.29-7.24 (m, 2H), 4.41-4.27 (m,1H), 3.60 (d, J=13.1, 0.5H), 3.52 (d, J=13.1, 0.5H), 3.44 (d, J=13.2,0.5H), 3.33 (d, J=13.2, 0.5H), 3.23 (d, J=10.5, 1H), 2.89 (dd, J=3.0,9.1, 0.5H), 2.69-2.60 (m, J=10.0, 1H), 2.59-2.53 (m, J=3.0, 9.0, 1H),2.52-2.44 (m, 1H), 2.44-2.33 (m, 1H), 2.30-2.25 (m, J=6.4, 10.0, 1.5H),2.25-2.20 (m, 1H), 2.14 (dd, J=5.9, 12.3, 0.5H), 1.91 (dd, J=6.1, 12.1,0.5H), 1.86-1.79 (m, J=4.7, 0.5H), 1.78-1.64 (m, 1H), 1.47-1.24 (m,J=30.2, 37.0, 1.5H), 1.20 (dd, J=4.9, 6.4, 3H), 0.70 (dd, J=1.6, 6.7,3H); MS (ESI+) m/z 377 (M+H)⁺.

Example 36(2R)-N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand substituting (R)-2-phenylbutanoic acid for (S)-2-phenylbutanoic acidin Step F of the procedure used to prepare Example 16: ¹H NMR (500 MHz,CDCl₃) δ ppm 7.38-7.21 (m, 10H), 5.29 (d, J=6.9, 1H), 4.04-3.90 (m, 1H),3.65 (d, J=12.9, 1H), 3.52 (d, J=12.9, 1H), 3.15 (t, J=7.6, 1H), 2.68(t, J=8.6, 1H), 2.64-2.48 (m, J=8.5, 3H), 2.30-2.22 (m, J=3.7, 8.3,1.5H), 2.14 (ddd, J=7.4, 13.9, 19.9, 1.5H), 1.93 (dt, J=6.2, 12.5, 1H),1.84-1.62 (m, J=7.6, 14.5, 20.6, 2H), 1.45-1.27 (m, 2H), 0.95-0.80 (m,4H); MS (ESI+) m/z 363 (M+H)⁺.

Example 37(2R)-N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylpropanamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand substituting (R)-2-phenylpropanoic acid for (S)-2-phenylbutanoicacid in Step F of the procedure used to prepare Example 16: ¹H NMR (500MHz, CDCl₃) δ ppm 7.37-7.26 (m, J=5.5, 7.5, 8H), 7.25-7.18 (m, 2H), 5.19(d, J=5.9, 1H), 4.06-3.89 (m, 1H), 3.59 (d, J=13.0, 1H), 3.48 (ddd,J=7.6, 13.7, 21.0, 2H), 2.60-2.46 (m, 3H), 2.43-2.33 (m, J=7.0, 14.4,1H), 2.26 (dd, J=3.8, 9.0, 1H), 2.20-2.07 (m, J=34.2, 1H), 2.03-1.93 (m,1H), 1.49 (d, J=7.2, 3H), 1.44-1.22 (m, 3H); MS (ESI+) m/z 349 (M+H)⁺.

Example 38(2S)-N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylpropanamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand substituting (S)-2-phenylpropanoic acid for (S)-2-phenylbutanoicacid in Step F of the procedure used to prepare Example 16: ¹H NMR (500MHz, CDCl₃) δ ppm 7.38-7.26 (m, 8H), 7.25-7.20 (m, 2H), 5.20 (d, J=6.7,1H), 4.03-3.91 (m, 1H), 3.60 (d, J=13.0, 1H), 3.52-3.43 (m, 2H), 2.54(dd, J=5.7, 13.8, 2H), 2.43 (dd, J=7.1, 16.0, 1H), 2.29-2.23 (m, 1H),2.22-2.08 (m, 2H), 1.98 (ddd, J=5.8, 11.9, 15.7, 1H), 1.74-1.60 (m, 1H),1.50 (t, J=6.4, 3H), 1.44-1.30 (m, 2H); MS (ESI+) m/z 349 (M+H)⁺.

Example 39(2S)-N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(4-isobutylphenyl)propanamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand substituting (S)-2-(4-isobutylphenyl)propanoic acid for(S)-2-phenylbutanoic acid in Step F of the procedure used to prepareExample 16: ¹H NMR (400 MHz, CDCl₃) δ ppm 7.28 (d, J=4.4, 3H), 7.25-7.18(m, 1H), 7.15 (dd, J=2.3, 8.2, 2H), 7.09 (dd, J=1.8, 8.2, 2H), 5.17 (d,J=7.2, 1H), 4.03-3.89 (m, 1H), 3.58 (d, J=13.0, 1H), 3.51-3.41 (m, 2H),2.55-2.48 (m, 3H), 2.45 (d, J=7.2, 2H), 2.39 (dd, J=7.3, 9.0, 1H),2.27-2.20 (m, 1H), 2.19-2.06 (m, 1H), 2.05-1.91 (m, 1H), 1.85 (dt,J=6.8, 13.5, 1H), 1.72-1.61 (m, 2H), 1.48 (d, J=7.2, 3H), 1.44-1.28 (m,2H), 0.89 (d, J=6.6, 6H); MS (ESI+) m/z 405 (M+H)⁺.

Example 40N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand substituting 2,2-dicyclohexylacetic acid for (S)-2-phenylbutanoicacid in Step F of the procedure used to prepare Example 16: ¹H NMR (400MHz, CDCl₃) δ ppm 7.32-7.27 (m, J=6.3, 4H), 7.24-7.18 (m, 1H), 5.22 (d,J=6.9, 1H), 4.11-3.99 (m, 1H), 3.62 (d, J=13.0, 1H), 3.46 (d, J=13.0,1H), 2.67-2.58 (m, 2H), 2.54 (dd, J=4.2, 9.4, 1H), 2.51-2.43 (m, 1H),2.31 (dt, J=4.0, 7.6, 1H), 2.25 (dd, J=4.2, 9.0, 1H), 2.08-1.99 (m, 1H),1.87-1.76 (m, 1H), 1.67 (dd, J=15.7, 26.7, 10H), 1.55 (s, 3H), 1.50-1.38(m, 2H), 1.31-1.02 (m, 8H), 1.00-0.85 (m, 2H); MS (ESI+) m/z 423 (M+H)⁺.

Example 41N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopropyl-2-phenylacetamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand substituting 2-cyclopropyl-2-phenylacetic acid for(S)-2-phenylbutanoic acid in Step F of the procedure used to prepareExample 16: ¹H NMR (500 MHz, CDCl₃) δ ppm 7.36-7.26 (m, 8H), 7.25-7.18(m, 2H), 5.57-5.40 (m, 1H), 4.08-3.97 (m, 1H), 3.60 (dd, J=5.8, 13.0,1H), 3.46 (dd, J=3.0, 13.0, 1H), 2.65 (d, J=9.5, 1H), 2.62-2.50 (m, 2H),2.46-2.38 (m, 1H), 2.30-2.18 (m, 2H), 2.03 (ddd, J=6.0, 12.1, 18.9, 1H),1.80-1.69 (m, 1H), 1.49-1.30 (m, 4H), 0.71 (ddd, J=5.7, 9.1, 10.4, 1H),0.60-0.51 (m, 1H), 0.38 (td, J=4.7, 9.0, 1H), 0.19 (dq, J=4.7, 9.4, 1H);MS (ESI+) m/z 375 (M+H)⁺.

Example 42N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclobutyl-2-phenylacetamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand substituting 2-cyclobutyl-2-phenylacetic acid for(S)-2-phenylbutanoic acid in Step F of the procedure used to prepareExample 16: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.51 (t, J=6.2, 1H),7.61 (d, J=7.7, 2H), 7.43 (dd, J=7.3, 16.6, 2H), 7.38-7.30 (m, 4H),7.30-7.23 (m, 2H), 4.42-4.31 (m, 1H), 3.67 (d, J=10.7, 1H), 3.59 (dd,J=13.1, 28.6, 1H), 3.43 (dd, J=13.0, 35.2, 1H), 3.34-3.23 (m, 1H), 2.85(d, J=7.5, 0.5H), 2.67 (d, J=7.1, 0.5H), 2.61-2.47 (m, J=9.6, 29.9,1.5H), 2.46-2.33 (m, 1.5H), 2.28 (d, J=17.6, 3H), 2.12 (dt, J=4.5, 12.2,0.5H), 2.03-1.91 (m, 1.5H), 1.87-1.55 (m, J=7.8, 17.0, 28.7, 5H), 1.47(dt, J=7.8, 14.5, 0.5H), 1.42-1.26 (m, J=16.4, 37.6, 1.5H); MS (ESI+)m/z 389 (M+H)⁺.

Example 43N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(4-chlorophenyl)-3-methylbutanamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand substituting 2-(4-chlorophenyl)-3-methylbutanoic acid for(S)-2-phenylbutanoic acid in Step F of the procedure used to prepareExample 16: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.69 (s, 1H), 7.54 (dd,J=2.9, 8.4, 2H), 7.47 (d, J=7.5, 1H), 7.42 (d, J=7.3, 1H), 7.38-7.31 (m,4H), 7.28 (t, J=7.5, 1H), 4.36 (s, 1H), 3.66 (d, J=13.1, 0.5H), 3.58 (d,J=13.1, 0.5H), 3.51 (d, J=13.1, 0.5H), 3.42 (d, J=13.1, 0.5H), 3.19 (d,J=10.4, 1H), 2.94 (d, J=5.0, 0.5H), 2.66 (d, J=5.0, 0.5H), 2.62-2.49 (m,2.5H), 2.40 (m, 1.5H), 2.34 (m, 1H), 2.31-2.25 (m, 1H), 2.14 (dt, J=6.2,12.3, 0.5H), 2.01-1.91 (m, J=4.7, 13.4, 0.5H), 1.87-1.62 (m, 1.5H),1.52-1.43 (m, 0.5H), 1.42-1.33 (m, J=10.3, 30.3, 1H), 1.17 (t, J=5.9,3H), 0.67 (dd, J=2.2, 6.7, 3H); MS (ESI+) m/z 411 (M+H)⁺.

Example 44N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-ethyl-2-phenylpentanamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand substituting 3-ethyl-2-phenylpentanoic acid for (S)-2-phenylbutanoicacid in Step F of the procedure used to prepare Example 16: ¹H NMR (500MHz, pyridine-d₅) δ ppm 8.69-8.62 (m, 1H), 7.65 (s, 2H), 7.45 (s, 1H),7.41 (d, J=7.8, 1H), 7.38-7.31 (m, 4H), 7.27 (d, J=7.0, 2H), 4.34 (dd,J=5.5, 10.8, 1H), 3.68-3.62 (m, 0.5H), 3.60-3.47 (m, 2H), 3.45-3.32 (m,0.5H), 2.97-2.86 (m, 0.5H), 2.67-2.21 (m, 5H), 2.19-2.08 (m, 0.5H),1.94-1.55 (m, 4H), 1.48-1.38 (m, 2H), 1.12-1.00 (m, 1H), 0.97 (q, J=7.5,3H), 0.93-0.84 (m, 1.5H), 0.83-0.74 (m, 0.5H), 0.61 (t, J=6.6, 3H); MS(ESI+) m/z 405 (M+H)⁺.

Example 45N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(4-hydroxyphenyl)-3-methylbutanamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand 2-(4-hydroxyphenyl)-3-methylbutanoic acid for (S)-2-phenylbutanoicacid in Step F of the procedure used to prepare Example 16: ¹H NMR (500MHz, pyridine-d₅) δ ppm 8.53-8.46 (m, 1H), 7.56 (d, J=2.8, 1H), 7.43 (d,J=7.2, 1H), 7.36 (dt, J=7.5, 18.2, 4H), 7.26 (q, J=7.1, 1H), 7.16 (dd,J=3.0, 8.6, 2H), 4.44-4.32 (m, 1H), 3.60 (d, J=13.1, 0.5H), 3.53 (d,J=13.1, 0.5H), 3.44 (d, J=13.2, 0.5H), 3.33 (d, J=13.1, 0.5H), 3.18 (d,J=10.4, 1H), 2.90 (dd, J=3.0, 9.1, 0.5H), 2.66 (s, 1H), 2.58 (d, J=8.8,1H), 2.49 (t, J=10.5, 1H), 2.44-2.35 (m, J=10.0, 1H), 2.33-2.11 (m, 2H),1.99-1.89 (m, 0.5H), 1.88-1.63 (m, 1.5H), 1.53-1.42 (m, 0.5H), 1.41-1.24(m, 2H), 1.22 (dd, J=4.4, 6.3, 3H), 0.97-0.82 (m, J=21.9, 35.1, 1H),0.79 (d, J=6.7, 3H); MS (ESI+) m/z 393 (M+H)⁺.

Example 46N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand 1-phenylcyclohexanecarboxylic acid for (S)-2-phenylbutanoic acid inStep F of the procedure used to prepare Example 16: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.73 (d, J=8.2, 1H), 7.59 (s, 1H), 7.41 (d, J=7.4,2H), 7.36 (td, J=2.7, 7.6, 4H), 7.26 (dd, J=6.0, 8.7, 2H), 4.45-4.33 (m,1H), 3.58 (d, J=13.2, 1H), 3.40 (d, J=13.2, 1H), 2.81 (d, J=7.3, 1H),2.68-2.59 (m, J=10.2, 2H), 2.41-2.31 (m, J=6.2, 14.8, 3H), 2.28 (d,J=8.8, 1H), 2.20-2.13 (m, 1H), 1.99 (dt, J=7.4, 14.8, 1H), 1.88-1.75 (m,J=9.0, 4H), 1.74-1.53 (m, J=8.8, 36.2, 4H), 1.50-1.40 (m, 1H), 1.36-1.20(m, 2H); MS (ESI+) m/z 403 (M+H)⁺.

Example 47N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-methyl-2-phenylpropanamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand 2-methyl-2-phenylpropanoic acid for (S)-2-phenylbutanoic acid inStep F of the procedure used to prepare Example 16: ¹H NMR (400 MHz,pyridine-d₅) δ ppm 7.49-7.38 (m, 4H), 7.31 (ddd, J=7.3, 14.4, 22.5, 5H),7.08 (d, J=7.3, 1H), 4.46-4.35 (m, 1H), 3.58 (d, J=13.2, 1H), 3.43 (d,J=13.2, 1H), 2.84 (d, J=6.7, 1H), 2.36 (d, J=4.8, 3H), 2.31 (d, J=9.6,1H), 2.21-2.13 (m, 1H), 2.04 (td, J=5.9, 11.7, 1H), 1.70 (dd, J=6.7,12.3, 1H), 1.67 (s, 6H), 1.53-1.41 (m, 1H), 1.38-1.26 (m, 1H); MS (ESI+)m/z 363 (M+H)⁺.

Example 48N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclopropanecarboxamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand 1-phenylcyclopropanecarboxylic acid for (S)-2-phenylbutanoic acid inStep F of the procedure used to prepare Example 16: ¹H NMR (400 MHz,pyridine-d₅) δ ppm 7.46-7.37 (m, 4H), 7.33 (dt, J=7.5, 11.5, 4H),7.28-7.22 (m, 2H), 6.22 (d, J=7.3, 1H), 4.31 (dd, J=6.7, 12.7, 1H), 3.56(d, J=13.2, 1H), 3.40 (d, J=13.2, 1H), 2.81 (dd, J=2.1, 8.9, 1H),2.39-2.18 (m, J=7.3, 12.5, 18.1, 4H), 2.13 (dd, J=7.3, 8.9, 1H), 1.99(dt, J=5.6, 11.0, 1H), 1.75 (q, J=3.6, 2H), 1.67-1.58 (m, J=8.3, 16.6,1H), 1.38-1.22 (m, 2H), 1.01 (q, J=3.6, 2H); MS (ESI+) m/z 361 (M+H)⁺.

Example 492-benzyl-N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethylbutanamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand 2-benzyl-3,3-dimethylbutanoic acid for (S)-2-phenylbutanoic acid inStep F of the procedure used to prepare Example 16: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.08 (dd, J=7.4, 13.6, 1H), 7.46 (d, J=7.3, 1H),7.44-7.40 (m, 1H), 7.38 (dd, J=7.6, 15.7, 2H), 7.34 (d, J=4.3, 2H),7.31-7.23 (m, 4H), 4.36-4.29 (m, 1H), 3.59 (d, J=13.1, 0.5H), 3.53 (dd,J=13.2, 32.6, 1H), 3.40 (d, J=13.1, 0.5H), 3.25 (q, J=12.0, 1H),2.79-2.67 (m, 2H), 2.48-2.42 (m, J=7.0, 1H), 2.41-2.23 (m, 3.5H), 2.20(t, J=8.3, 0.5H), 2.12 (d, J=6.7, 0.5H), 2.06 (dd, J=5.9, 11.7, 0.5H),1.88 (dd, J=5.8, 11.7, 0.5H), 1.74 (dd, J=9.4, 16.4, 0.5H), 1.60 (dd,J=7.0, 13.2, 0.5H), 1.51-1.42 (m, 0.5H), 1.37-1.21 (m, 2H), 1.15 (s,9H); MS (ESI+) m/z 405 (M+H)⁺.

Example 50N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,3-diphenylpropanamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand 2,3-diphenylpropanoic acid for (S)-2-phenylbutanoic acid in Step Fof the procedure used to prepare Example 16: ¹H NMR (400 MHz,pyridine-d₅) δ ppm 8.53 (dd, J=7.3, 13.7, 1H), 7.66 (d, J=7.4, 2H), 7.44(d, J=7.1, 1H), 7.41-7.22 (m, 12H), 4.36-4.23 (m, J=7.5, 14.9, 1H), 3.97(dt, J=4.9, 9.9, 1H), 3.77 (ddd, J=3.7, 10.1, 13.5, 1H), 3.52 (dt,J=13.1, 18.6, 1H), 3.33 (d, J=13.1, 0.5H), 3.05 (dt, J=4.7, 13.0, 1H),2.77 (dd, J=2.6, 9.0, 0.5H), 2.55 (d, J=6.3, 0.5H), 2.38-2.24 (m, 3H),2.21 (d, J=9.2, 1.5H), 2.03-1.86 (m, 1.5H), 1.72-1.56 (m, 1H), 1.52-1.20(m, 2.5H); MS (ESI+) m/z 425 (M+H)⁺.

Example 51N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-methyl-3-phenylpropanamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand 2-methyl-3-phenylpropanoic acid for (S)-2-phenylbutanoic acid inStep F of the procedure used to prepare Example 16: ¹H NMR (400 MHz,pyridine-d₅) δ ppm 8.13 (dd, J=7.0, 21.3, 1H), 7.40 (ddd, J=7.5, 15.5,25.3, 4H), 7.31-7.22 (m, 6H), 4.42-4.27 (m, 1H), 3.58 (dd, J=6.6, 13.1,1H), 3.45 (dd, J=13.1, 21.0, 1H), 3.25-3.15 (m, 1H), 2.81-2.67 (m, 3H),2.49-2.19 (m, 5H), 2.04 (ddd, J=6.0, 12.1, 24.6, 1H), 1.82-1.64 (m, 1H),1.57-1.40 (m, 1H), 1.40-1.30 (m, 1H), 1.28 (d, J=6.4, 3H); MS (ESI+) m/z363 (M+H)⁺.

Example 52N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 for (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amineand 3,3-dimethyl-2-phenylbutanoic acid for (S)-2-phenylbutanoic acid inStep F of the procedure used to prepare Example 16: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.53 (dd, J=7.4, 10.9, 1H), 7.73 (dd, J=3.3, 5.3,2H), 7.44 (d, J=7.0, 1H), 7.41-7.24 (m, 7H), 4.41-4.30 (m, 1H), 3.62 (d,J=13.1, 0.5H), 3.53 (d, J=13.1, 0.5H), 3.45 (d, J=15.0, 0.5H), 3.35 (d,J=13.1, 0.5H), 2.90 (dd, J=3.1, 8.9, 0.5H), 2.63-2.45 (m, 2.5H),2.44-2.36 (m, 0.5H), 2.31 (d, J=6.5, 1H), 2.28 (d, J=5.3, 1H), 2.23 (d,J=5.8, 1H), 2.15 (dd, J=5.9, 12.3, 0.5H), 1.92 (dd, J=6.1, 12.2, 0.5H),1.84 (dd, J=8.1, 12.6, 0.5H), 1.72 (ddd, J=6.5, 12.5, 18.9, 1H),1.46-1.25 (m, 2H), 1.14 (d, J=1.8, 9H); MS (ESI+) m/z 391 (M+H)⁺.

Example 532,2-dicyclohexyl-N-[3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide

N-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide(2.65 g, 6.27 mmol) from Example 15 and methanol 60 mL were added to 20%palladium hydroxide on carbon, (wet, 0.530 g, 3.77 mmol) in a 250 mLpressure bottle. The reaction was stirred for 16 hours under hydrogen(30 psi) at room temperature. The mixture was filtered through a nylonmembrane and the solvent removed in vacuo. The crude material waschromatographed on a silica gel cartridge (Analogix®, Burlington, Wis.,RS25-25) eluting with 1-10% methanol (2 N ammonia)/dichloromethane togive the title compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.97 (d,J=7.1, 1H), 4.57 (dt, J=7.0, 13.8, 1H), 3.03 (dd, J=3.2, 10.1, 1H), 2.89(dd, J=7.8, 9.7, 1H), 2.78 (dd, J=7.4, 10.1, 1H), 2.71 (ddd, J=3.2, 7.5,16.7, 1H), 2.58 (dd, J=3.2, 9.8, 1H), 2.50-2.39 (m, J=8.3, 1H),1.98-1.89 (m, 3H), 1.89-1.80 (m, 3H), 1.79-1.67 (m, J=6.4, 14.9, 7H),1.66-1.56 (m, 3H), 1.49-1.36 (m, 2H), 1.36-1.28 (m, 1H), 1.28-1.02 (m,8H); MS (ESI+) m/z 333 (M+H)⁺.

Example 542,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

2,2-Dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide(154 mg, 0.463 mmol) from Example 53 and 3-(trifluoromethyl)benzaldehyde(0.062 mL, 0.463 mmol) were combined in dichloromethane (5 mL), and then2 mL of acetic acid was added. The reaction was stirred at roomtemperature for 20 minutes, and then PS-cyanoborohydride (396 mg, 0.926mmol) was added. The reaction was stirred at room temperature overnight,then filtered and the resin was washed with dichloromethane. The solventwas removed in vacuo, and the crude material was purified using a silicagel cartridge (Analogix®, Burlington, Wis., RS-25) eluting with 1-10%methanol (2 N ammonia)/dichloromethane to give the title compound: ¹HNMR (500 MHz, pyridine-d₅) δ ppm 7.73 (s, 1H), 7.66 (d, J=7.7, 1H), 7.56(s, 1H), 7.50 (t, J=7.7, 1H), 4.51-4.43 (m, 1H), 3.55 (d, J=12.9, 1H),3.46 (d, J=12.9, 1H), 2.75 (d, J=8.6, 2H), 2.52-2.41 (m, J=8.5, 19.1,2H), 2.34-2.29 (m, 1H), 2.20 (dd, J=7.7, 9.8, 1H), 2.14 (s, 3H, OAc),1.96-1.54 (m, 15H), 1.49-1.05 (m, 12H), 1.03-0.93 (m, J=11.7, 21.1, 1H);MS (ESI+) m/z 491 (M+H)⁺.

Example 552,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(2-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide

The title compound was prepared by substituting 2-fluorobenzaldehyde for3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.55 (s, 1H), 7.36 (dt, J=6.6, 24.8, 2H), 7.20-7.15(m, 2H), 4.44 (s, 1H), 3.68 (d, J=12.6, 1H), 3.44 (d, J=12.6, 1H), 2.77(d, J=9.6, 1H), 2.64 (dd, J=7.5, 15.0, 1H), 2.53 (d, J=9.0, 1H),2.49-2.40 (m, 1H), 2.29 (t, J=8.3, 1H), 2.16-2.09 (m, 1H), 1.98-1.64 (m,12H), 1.61 (d, J=11.4, 2H), 1.55-1.37 (m, J=13.8, 20.5, 31.3, 3H),1.34-1.08 (m, 9H), 1.00 (dd, J=13.4, 22.1, 1H); MS (ESI+) m/z 441(M+H)⁺.

Example 562,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide

The title compound was prepared by substituting 4-fluorobenzaldehyde for3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.54 (d, J=6.0, 1H), 7.40-7.29 (m, 2H), 7.18 (d,J=8.7, 2H), 4.53-4.38 (m, 1H), 3.55 (d, J=12.5, 1H), 3.29 (d, J=12.6,1H), 2.72 (dd, J=8.6, 17.7, 2H), 2.56-2.39 (m, 2H), 2.29 (t, J=8.3, 1H),2.10 (t, J=8.1, 1H), 1.98-1.07 (m, 26H), 0.99 (dd, J=10.2, 22.0, 1H); MS(ESI+) m/z 441 (M+H)⁺.

Example 572,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting4-fluoro-3-(trifluoromethyl)benzaldehyde for3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.69 (d, J=6.9, 1H), 7.56-7.54 (m, 1H), 7.36-7.28 (m,1H), 4.52-4.42 (m, 1H), 3.53 (d, J=12.9, 1H), 3.39 (d, J=12.9, 1H),2.85-2.68 (m, 2H), 2.53-2.41 (m, 2H), 2.34 (t, J=8.3, 1H), 2.24-2.16 (m,1H), 1.96-1.56 (m, 16H), 1.49 (d, J=12.4, 1H), 1.44-1.05 (m, 10H),1.05-0.94 (m, 1H); MS (ESI+) m/z 509 (M+H)⁺.

Example 582,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting3-fluoro-4-(trifluoromethyl)benzaldehyde for3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (400 MHz,pyridine-d₅) δ ppm 7.62 (d, J=7.5, 2H), 7.32 (d, J=11.8, 1H), 7.25 (d,J=8.0, 1H), 4.51-4.40 (m, 1H), 3.54 (d, J=13.5, 1H), 3.42 (d, J=13.5,1H), 2.84 (dd, J=7.5, 16.5, 1H), 2.76 (dd, J=2.6, 9.5, 1H), 2.56-2.47(m, 1H), 2.44 (dd, J=2.6, 8.8, 1H), 2.40-2.34 (m, 1H), 2.23 (dd, J=7.7,9.3, 1H), 1.97-1.52 (m, 16H), 1.45-0.97 (m, J=14.9, 40.1, 72.1, 11H); MS(ESI+) m/z 509 (M+H)⁺.

Example 59N-{(3aS,4S,6aR)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide

The title compound was prepared by substituting3,5-bis(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehydein Example 54: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.10 (s, 1H), 7.97(s, 2H), 4.53-4.44 (m, 1H), 3.64-3.55 (m, 2H), 2.85-2.75 (m, 2H),2.55-2.46 (m, 1H), 2.45-2.35 (m, 2H), 2.31 (t, J=8.3, 1H), 1.95-1.55 (m,15H), 1.48 (d, J=12.6, 1H), 1.44-0.92 (m, 12H); MS (ESI+) m/z 559(M+H)⁺.

Example 602,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[2-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting2-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde inExample 54: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.74 (d, J=7.8, 1H),7.64 (d, J=7.7, 1H), 7.55 (d, J=7.6, 1H), 7.43 (dd, J=7.0, 13.9, 2H),4.51-4.43 (m, 1H), 3.82 (d, J=13.7, 1H), 3.54 (d, J=13.7, 1H), 2.81-2.70(m, 2H), 2.53-2.43 (m, 2H), 2.35 (t, J=8.1, 1H), 2.23-2.17 (m, 1H),1.95-1.68 (m, 10H), 1.67-1.52 (m, 5H), 1.46-1.04 (m, 11H), 0.97-0.86 (m,1H); MS (ESI+) m/z 491 (M+H)⁺.

Example 612,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(3-methylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide

The title compound was prepared by substituting 3-methylbenzaldehyde for3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.53 (d, J=5.8, 1H), 7.32 (t, J=7.5, 1H), 7.24-7.22(m, 1H), 7.20-7.14 (m, 2H), 4.50-4.42 (m, 1H), 3.57 (d, J=12.4, 1H),3.34 (d, J=12.3, 1H), 2.78 (d, J=9.4, 1H), 2.66 (dd, J=7.5, 15.1, 1H),2.55 (d, J=8.8, 1H), 2.50-2.42 (m, 1H), 2.33 (s, 3H), 2.31-2.24 (m, 1H),2.14-2.07 (m, 1H), 1.98-1.57 (m, 13H), 1.53 (ddd, J=6.4, 11.9, 18.4,1H), 1.42 (t, J=10.0, 2H), 1.38-1.08 (m, 10H), 1.02-0.92 (m, 1H); MS(ESI+) m/z 437 (M+H)⁺.

Example 622,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(4-methylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide

The title compound was prepared by substituting 4-methylbenzaldehyde for3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.54 (d, J=7.8, 1H), 7.30 (d, J=7.7, 2H), 7.21-7.18(m, 2H), 4.49-4.42 (m, 1H), 3.58 (d, J=12.3, 1H), 3.31 (d, J=12.4, 1H),2.77 (d, J=9.5, 1H), 2.66 (dd, J=8.3, 15.9, 1H), 2.54 (d, J=8.8, 1H),2.50-2.41 (m, 1H), 2.32 (s, 3H), 2.30-2.23 (m, 2H), 2.11-2.03 (m, 1H),1.99-1.58 (m, 13H), 1.57-1.08 (m, 12H), 1.03-0.90 (m, 1H); MS (ESI+) m/z437 (M+H)⁺.

Example 632,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-(trifluoromethoxy)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting3-(trifluoromethoxy)benzaldehyde for 3-(trifluoromethyl)benzaldehyde inExample 54: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.60 (d, J=7.3, 1H),7.42 (t, J=7.9, 1H), 7.37 (s, 1H), 7.30 (dd, J=7.9, 16.8, 2H), 4.51-4.44(m, 1H), 3.50 (d, J=13.0, 1H), 3.45 (d, J=13.0, 1H), 2.80-2.72 (m,J=4.8, 16.2, 2H), 2.51-2.42 (m, J=8.7, 2H), 2.29 (t, J=8.3, 1H), 2.20(dd, J=7.2, 9.2, 1H), 1.96-1.89 (m, 2H), 1.89-1.78 (m, 4H), 1.77-1.65(m, 5H), 1.64-1.51 (m, 4H), 1.42 (dd, J=9.4, 23.0, 1H), 1.36-1.09 (m,10H), 1.08-0.98 (m, 1H); MS (ESI+) m/z 507 (M+H)⁺.

Example 642,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(3-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide

The title compound was prepared by substituting 3-fluorobenzaldehyde for3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.36 (dd, J=7.8, 13.9, 1H), 7.19-7.11 (m, 3H),4.49-4.42 (m, 1H), 3.55 (d, J=12.8, 1H), 3.34 (d, J=12.8, 1H), 2.78-2.69(m, J=8.0, 15.6, 2H), 2.51-2.43 (m, J=10.6, 2H), 2.29 (t, J=8.4, 1H),2.13 (dd, J=7.2, 9.5, 1H), 1.97-1.77 (m, 7H), 1.77-1.64 (m, 5H),1.63-1.47 (m, 4H), 1.42 (ddd, J=3.0, 12.2, 23.0, 1H), 1.33 (dd, J=9.7,23.2, 1H), 1.29-1.08 (m, 8H), 1.02 (dd, J=11.8, 22.6, 1H); MS (ESI+) m/z441 (M+H)⁺.

Example 65N-{(3aS,4S,6aR)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide

The title compound was prepared by substituting3,3-bis(4-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde inExample 54: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.77 (d, J=7.3, 1H),7.39-7.31 (m, 4H), 7.20-7.13 (m, 4H), 4.58-4.50 (m, 1H), 4.13 (d, J=7.5,1H), 2.85 (dd, J=2.2, 9.4, 1H), 2.74 (dd, J=7.2, 14.4, 1H), 2.47 (d,J=7.4, 2H), 2.38-2.26 (m, 4H), 2.22 (t, J=8.6, 1H), 2.12 (dd, J=7.4,9.3, 1H), 1.98-1.90 (m, 4H), 1.90-1.82 (m, 2H), 1.82-1.76 (m, J=8.6,2H), 1.76-1.66 (m, 5H), 1.65-1.57 (m, 3H), 1.47-1.33 (m, 3H), 1.30-1.18(m, 4H), 1.18-1.03 (m, 4H); MS (ESI+) m/z 563 (M+H)⁺.

Example 66N-{(3aS,4S,6aR)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide

The title compound was prepared by substituting6,6-bis(4-fluorophenyl)hexanal for 3-(trifluoromethyl)benzaldehyde inExample 54: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.80 (d, J=6.7, 1H),7.35 (ddd, J=2.1, 5.4, 7.9, 4H), 7.16 (td, J=3.1, 8.8, 4H), 4.56-4.47(m, 1H), 3.99 (t, J=7.8, 1H), 2.82 (d, J=9.3, 1H), 2.65 (d, J=7.7, 1H),2.49 (dd, J=8.5, 19.2, 2H), 2.30 (d, J=31.9, 2H), 2.16-2.01 (m, 4H),1.99-1.68 (m, 11H), 1.67-1.57 (m, 2H), 1.57-1.04 (m, 14H); MS (ESI+) m/z605 (M+H)⁺.

Example 67N-{(3aS,4S,6aR)-2-[3-(3-chlorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide

The title compound was prepared by substituting3-(3-chlorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde inExample 54: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.87 (s, 1H), 7.31 (d,J=13.4, 2H), 7.27 (t, J=7.6, 1H), 7.13 (d, J=7.3, 1H), 4.57-4.49 (m,1H), 2.86 (d, J=8.6, 1H), 2.74 (dd, J=7.3, 14.6, 1H), 2.62 (dd, J=7.0,15.3, 2H), 2.53-2.45 (m, J=6.7, 2H), 2.39-2.32 (m, J=6.1, 2H), 2.23 (t,J=8.0, 1H), 2.01-1.68 (m, 16H), 1.65-1.56 (m, 3H), 1.48-1.33 (m, 3H),1.32-1.18 (m, 4H), 1.17-1.04 (m, J=12.5, 25.1, 4H); MS (ESI+) m/z 485(M+H)⁺.

Example 682,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-(3-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting3-(3-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde inExample 54: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.81 (d, J=3.1, 1H),7.31 (dd, J=7.3, 14.5, 1H), 7.10-7.02 (m, J=11.5, 3H), 4.60-4.46 (m,1H), 2.85 (d, J=8.2, 1H), 2.76-2.59 (m, 3H), 2.55-2.43 (m, 2H),2.41-2.28 (m, 2H), 2.25-2.16 (m, 1H), 2.15-2.06 (m, 1H), 2.00-1.90 (m,4H), 1.89-1.67 (m, J=37.4, 11H), 1.67-1.54 (m, 3H), 1.49-1.33 (m, 3H),1.30-1.18 (m, J=10.6, 4H), 1.17-1.05 (m, 4H); MS (ESI+) m/z 469 (M+H)⁺.

Example 692,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(3-phenylpropyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide

The title compound was prepared by substituting 3-phenylpropanal for3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.83 (d, J=5.1, 1H), 7.38 (t, J=7.6, 2H), 7.28 (d,J=7.4, 3H), 4.57-4.48 (m, 1H), 2.85 (d, J=8.7, 1H), 2.75-2.61 (m, 3H),2.48 (dd, J=8.7, 19.0, 2H), 2.35 (dd, J=7.0, 17.3, 2H), 2.17 (t, J=7.8,1H), 2.12-2.07 (m, 1H), 1.93 (dd, J=8.6, 14.2, 4H), 1.89-1.75 (m, 7H),1.71 (d, J=10.9, 4H), 1.65-1.53 (m, J=6.0, 14.1, 3H), 1.49-1.32 (m, 3H),1.30-1.18 (m, 4H), 1.17-1.04 (m, J=9.5, 21.4, 4H); MS (ESI+) m/z 451(M+H)⁺.

Example 702,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{3-[4-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide

The title compound was prepared by substituting3-(4-(trifluoromethyl)phenyl)propanal for3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.82 (d, J=7.1, 1H), 7.67 (d, J=8.1, 2H), 7.36 (d,J=8.1, 2H), 4.57-4.50 (m, 1H), 2.85 (d, J=9.5, 1H), 2.70 (tt, J=7.0,14.1, 3H), 2.49 (d, J=7.5, 2H), 2.35 (t, J=6.4, 2H), 2.22 (t, J=8.5,1H), 2.16-2.09 (m, 1H), 1.98-1.89 (m, 4H), 1.89-1.74 (m, 7H), 1.70 (d,J=8.5, 4H), 1.60 (dd, J=4.9, 12.1, 3H), 1.41 (dt, J=9.0, 20.3, 3H),1.30-1.17 (m, 4H), 1.10 (dt, J=10.4, 12.0, 4H); MS (ESI+) m/z 519(M+H)⁺.

Example 712,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting3-(4-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde inExample 54: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.94-7.77 (m, 1H),7.25-7.20 (m, 2H), 7.14 (t, J=8.7, 2H), 4.61-4.47 (m, 1H), 2.93-2.80 (m,1H), 2.79-2.69 (m, 1H), 2.62 (dd, J=7.6, 15.5, 2H), 2.55-2.44 (m, 2H),2.43-2.29 (m, 2H), 2.27-2.08 (m, 2H), 2.02-1.90 (m, 4H), 1.89-1.75 (m,7H), 1.70 (d, J=11.2, 4H), 1.60 (d, J=6.9, 3H), 1.49-1.32 (m, 3H),1.30-1.17 (m, 4H), 1.12 (dd, J=12.0, 24.1, 4H); MS (ESI+) m/z 469(M+H)⁺.

Example 722,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(pyridin-4-ylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide

The title compound was prepared by substituting isonicotinaldehyde for3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.76 (d, J=5.7, 2H), 7.75-7.69 (m, 1H), 7.31 (d,J=5.5, 2H), 4.48 (dd, J=6.9, 13.1, 1H), 3.47 (d, J=13.5, 1H), 3.39 (d,J=13.5, 1H), 2.87-2.75 (m, J=9.2, 21.0, 2H), 2.53-2.45 (m, 1H), 2.43 (d,J=9.0, 1H), 2.34 (t, J=8.3, 1H), 2.26-2.20 (m, 1H), 1.97-1.87 (m, 4H),1.87-1.76 (m, 4H), 1.75-1.64 (m, J=6.5, 12.2, 17.6, 5H), 1.63-1.56 (m,J=13.2, 3H), 1.43 (dd, J=10.1, 22.9, 1H), 1.35 (dd, J=5.6, 12.1, 1H),1.30-1.18 (m, J=12.4, 24.4, 4H), 1.17-1.08 (m, J=10.1, 19.2, 4H),1.09-0.99 (m, 1H); MS (ESI+) m/z 424 (M+H)⁺.

Example 732,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(pyridin-3-ylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide

The title compound was prepared by substituting nicotinaldehyde for3-(trifluoromethyl)benzaldehyde in Example 54: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.80 (d, J=1.7, 1H), 7.64 (d, J=6.4, 2H), 7.30 (dd,J=4.8, 7.7, 1H), 4.49-4.41 (m, 1H), 3.54 (d, J=12.9, 1H), 3.35 (d,J=12.8, 1H), 2.80-2.71 (m, J=7.7, 2H), 2.51-2.42 (m, J=8.7, 2H), 2.31(t, J=8.3, 1H), 2.16 (t, J=8.8, 1H), 1.91 (dd, J=6.4, 11.9, 2H),1.86-1.64 (m, 10H), 1.57 (dd, J=11.4, 24.2, 4H), 1.42 (d, J=12.8, 1H),1.35-1.08 (m, 10H), 1.03 (d, J=14.0, 1H); MS (ESI+) m/z 424 (M+H)⁺.

Example 742,2-dicyclohexyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide

The title compound was prepared by substitutingN-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamidefrom Example 20 forN-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamidein Example 53: ¹H NMR (300 MHz, CDCl₃) δ ppm 5.31 (d, J=7.5, 1H),3.97-3.82 (m, 1H), 3.09-2.85 (m, 3H), 2.66 (dd, J=3.7, 12.5, 2H),2.40-2.26 (m, 1H), 2.10-1.80 (m, 6H), 1.79-1.53 (m, 11H), 1.52-1.30 (m,J=21.5, 31.0, 2H), 1.29-1.03 (m, 7H), 0.93 (dd, J=11.9, 23.1, 2H); MS(ESI+) m/z 333 (M+H)⁺.

Example 752,2-dicyclohexyl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting2,2-dicyclohexyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidefrom Example 74 for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.07 (d, J=7.2, 1H), 7.75 (s, 1H), 7.63-7.54 (m, 2H), 7.43 (t,J=7.8, 1H), 4.51-4.42 (m, 1H), 3.61 (d, J=13.6, 1H), 3.46 (d, J=13.5,1H), 2.87 (dd, J=2.4, 8.9, 1H), 2.64-2.52 (m, 2H), 2.52-2.46 (m, 1H),2.30 (s, 2H), 2.18-2.08 (m, 1H), 2.03 (t, J=7.3, 1H), 1.99-1.76 (m, 7H),1.75-1.55 (m, 7H), 1.51-1.35 (m, 3H), 1.31-1.03 (m, 8H); MS (ESI+) m/z491 (M+H)⁺.

Example 762,2-dicyclohexyl-N-{(3aS,4R,6aR)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting3-fluoro-4-(trifluoromethyl)benzaldehyde for3-(trifluoromethyl)benzaldehyde and2,2-dicyclohexyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidefrom Example 74 for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.16 (d, J=7.3, 1H), 7.59 (d, J=10.3, 1H), 7.33 (d, J=11.7, 1H),7.28 (d, J=8.0, 1H), 4.52-4.44 (m, 1H), 3.56 (d, J=14.2, 1H), 3.45 (d,J=14.2, 1H), 2.92 (dd, J=1.8, 8.9, 1H), 2.63-2.52 (m, J=11.3, 2H), 2.43(dd, J=6.9, 8.8, 1H), 2.34 (dd, J=2.0, 9.0, 1H), 2.29-2.23 (m, 1H), 2.13(dq, J=5.9, 11.8, 1H), 2.04 (t, J=7.4, 1H), 2.00-1.84 (m, 5H), 1.80 (d,J=12.4, 2H), 1.76-1.56 (m, 7H), 1.46 (dd, J=10.4, 23.5, 3H), 1.30-1.18(m, 4H), 1.17-1.05 (m, 4H); MS (ESI+) m/z 509 (M+H)⁺.

Example 77N-{(3aS,4R,6aR)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide

The title compound was prepared by substituting3,5-bis(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehydeand2,2-dicyclohexyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidefrom Example 74 for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.16 (d, J=7.1, 1H), 7.99 (s, 3H), 4.50-4.42 (m, 1H), 3.69 (d,J=13.9, 1H), 3.54 (d, J=13.9, 1H), 2.92 (dd, J=2.7, 9.0, 1H), 2.65-2.56(m, J=10.2, 15.6, 2H), 2.55-2.50 (m, 1H), 2.31 (d, J=4.2, 2H), 2.10 (dq,J=5.9, 11.8, 1H), 2.03 (t, J=7.4, 1H), 1.99-1.83 (m, 5H), 1.80 (d,J=12.4, 2H), 1.75-1.64 (m, J=12.4, 18.4, 5H), 1.63-1.56 (m, J=8.7, 2H),1.44 (td, J=7.6, 21.0, 3H), 1.31-1.16 (m, 4H), 1.16-1.04 (m, 4H); MS(ESI+) m/z 559 (M+H)⁺.

Example 78N-{(3aS,4R,6aR)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide

The title compound was prepared by substituting6,6-bis(4-fluorophenyl)hexanal for 3-(trifluoromethyl)benzaldehyde and2,2-dicyclohexyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidefrom Example 74 for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.14 (d, J=7.3, 1H), 7.33 (dd, J=5.6, 8.5, 4H), 7.14 (t, J=8.7,4H), 4.52-4.44 (m, 1H), 3.96 (t, J=7.8, 1H), 2.94 (d, J=8.8, 1H), 2.58(s, 2H), 2.42 (d, J=8.1, 2H), 2.31 (d, J=22.9, 3H), 2.17-2.09 (m, 1H),2.08-1.85 (m, 8H), 1.85-1.77 (m, 2H), 1.76-1.64 (m, 5H), 1.61 (d,J=12.0, 2H), 1.52-1.42 (m, 5H), 1.41-1.34 (m, 2H), 1.31-1.19 (m, 5H),1.18-1.07 (m, 5H); MS (ESI+) m/z 605 (M+H)⁺.

Example 792,2-dicyclohexyl-N-[(3aS,4R,6aR)-2-(3,3-diphenylpropyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide

The title compound was prepared by substituting 3,3-diphenylpropanal for3-(trifluoromethyl)benzaldehyde and2,2-dicyclohexyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidefrom Example 74 for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.10 (d, J=7.7, 1H), 7.45 (d, J=7.3, 2H), 7.42 (d, J=7.1, 3H),7.38-7.30 (m, 5H), 4.56-4.48 (m, 1H), 4.27 (t, J=7.5, 1H), 2.92-2.86 (m,1H), 2.59-2.48 (m, J=6.7, 14.0, 2H), 2.38-2.26 (m, 5H), 2.21-2.12 (m,2H), 2.05 (t, J=7.4, 1H), 1.97 (dd, J=8.3, 17.0, 2H), 1.94-1.85 (m, 4H),1.81 (d, J=11.8, 2H), 1.72 (d, J=13.2, 4H), 1.66 (dd, J=7.4, 11.8, 1H),1.61 (d, J=12.6, 2H), 1.48 (ddd, J=3.4, 12.8, 15.5, 3H), 1.30-1.19 (m,4H), 1.19-1.06 (m, 4H); MS (ESI+) m/z 527 (M+H)⁺.

Example 80N-{(3aS,4R,6aR)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide

The title compound was prepared by substituting3,3-bis(4-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde and2,2-dicyclohexyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidefrom Example 74 for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.13 (s, 1H), 7.41 (dd, J=5.5, 8.7, 2H), 7.35 (dd, J=5.1, 13.8,3H), 7.14 (dt, J=8.8, 14.7, 4H), 4.60-4.51 (m, J=21.3, 1H), 4.30 (t,J=7.7, 1H), 2.95 (d, J=8.9, 1H), 2.57-2.51 (m, 2H), 2.40 (d, J=8.7, 1H),2.30 (d, J=7.0, 3H), 2.26-2.12 (m, 4H), 2.05 (t, J=7.4, 1H), 2.02-1.94(m, J=12.5, 2H), 1.94-1.85 (m, J=6.7, 18.0, 2H), 1.82 (d, J=11.7, 2H),1.72 (d, J=11.8, 4H), 1.67-1.57 (m, J=10.6, 16.3, 3H), 1.48 (qd, J=3.3,12.7, 3H), 1.25 (dd, J=15.5, 28.8, 4H), 1.13 (t, J=18.3, 4H); MS (ESI+)m/z 563 (M+H)⁺.

Example 81N-{(3aS,4R,6aR)-2-[4,4-bis(4-fluorophenyl)butyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide

The title compound was prepared by substituting4,4-bis(4-fluorophenyl)butanal for 3-(trifluoromethyl)benzaldehyde and2,2-dicyclohexyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidefrom Example 74 for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.12 (d, J=7.5, 1H), 7.36 (ddd, J=5.5, 8.6, 16.2, 4H), 7.17 (t,J=8.8, 2H), 7.11 (t, J=8.8, 2H), 4.52-4.45 (m, 1H), 3.99 (t, J=7.9, 1H),2.91 (d, J=9.1, 1H), 2.59-2.50 (m, 2H), 2.36 (t, J=7.1, 3H), 2.24-2.16(m, J=6.6, 13.0, 2H), 2.14-2.02 (m, J=9.6, 17.5, 3H), 2.02-1.86 (m,J=9.2, 27.4, 5H), 1.81 (t, J=10.7, 2H), 1.73 (d, J=9.6, 4H), 1.68-1.57(m, J=13.6, 3H), 1.53-1.37 (m, 6H), 1.31-1.19 (m, J=11.2, 23.8, 4H),1.18-1.07 (m, J=10.5, 22.1, 4H); MS (ESI+) m/z 577 (M+H)⁺.

Example 823-methyl-2-phenyl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide

Step A:3-Methyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidewas prepared by substitutingN-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamidefrom Example 18 forN-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamidein the procedure described for Example 53: ¹H NMR (300 MHz, CDCl₃) δ ppm7.31 (dd, J=1.5, 6.6, 2H), 5.50-5.38 (m, J=3.8, 9.7, 1H), 3.84 (dd,J=4.1, 13.5, 1H), 2.92 (ddd, J=10.1, 15.8, 20.7, 3H), 2.76 (dt, J=3.7,11.5, 2H), 2.65-2.53 (m, J=7.9, 12.1, 3H), 2.47-2.25 (m, J=9.8, 17.7,31.5, 2H), 2.20-2.07 (m, J=9.3, 17.5, 1H), 2.05-1.80 (m, 2H), 1.53-1.39(m, 1H), 1.27 (s, 2H), 1.03 (dd, J=3.4, 6.5, 3H), 0.70 (d, J=6.7, 3H);MS (ESI+) m/z 287 (M+H)⁺.

Step B: The title compound was prepared by substituting3-methyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.60 (t, J=7.9, 1H), 7.73 (d, J=26.6, 1H), 7.63 (dd, J=2.0, 7.5,1H), 7.57-7.52 (m, 2H), 7.43 (dd, J=7.7, 17.9, 1H), 7.33 (td, J=4.1,7.5, 2H), 7.26 (dt, J=3.6, 7.2, 1H), 4.38-4.28 (m, 1H), 3.60 (d, J=13.6,0.5H), 3.52 (d, J=13.5, 0.5H), 3.46 (d, J=13.6, 0.5H), 3.35 (d, J=13.5,0.5H), 3.22 (dd, J=1.4, 10.4, 1H), 2.90 (dd, J=3.0, 9.1, 0.5H),2.70-2.60 (m, J=5.3, 11.8, 1H), 2.59-2.53 (m, 1H), 2.52-2.46 (m, 1H),2.44-2.32 (m, 1H), 2.28 (d, J=9.1, 0.5H), 2.25 (d, J=5.1, 1H), 2.20 (dd,J=2.4, 4.7, 1H), 2.13-2.07 (m, 1.5H), 1.92-1.80 (m, 1H), 1.75 (dt,J=6.3, 18.8, 0.5H), 1.71-1.64 (m, 0.5H), 1.47-1.39 (m, 0.5H), 1.39-1.32(m, 0.5H), 1.32-1.24 (m, J=4.2, 16.6, 0.5H), 1.20 (dd, J=4.3, 6.4, 3H),0.70 (d, J=6.7, 3H); MS (ESI+) m/z 445 (M+H)⁺.

Example 83N-[(3aR,4S,6aS)-2-(cyclohexylmethyl)octahydrocyclopenta[c]pyrrolo-4-yl]-3-methyl-2-phenylbutanamide

Step A:3-Methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidewas prepared by substitutingN-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamidefrom Example 35 forN-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamidein Example 53: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.61 (d, J=6.9, 1H),7.65 (dd, J=4.6, 6.9, 2H), 7.34 (t, J=7.5, 2H), 7.26 (t, J=7.3, 1H),4.24 (tt, J=6.2, 12.6, 1H), 3.23 (d, J=10.4, 1H), 3.19 (dd, J=2.7, 10.8,0.5H), 2.99 (dd, J=7.2, 10.9, 0.5H), 2.84-2.72 (m, 2H), 2.70-2.61 (m,1H), 2.58 (dd, J=2.8, 10.7, 0.5H), 2.53 (dd, J=3.3, 10.5, 1H), 2.49-2.44(m, 0.5H), 2.43-2.35 (m, J=10.5, 0.5H), 2.35-2.28 (m, J=12.5, 0.5H),2.06 (dq, J=6.1, 12.2, 0.5H), 1.91-1.72 (m, 1.5H), 1.66 (dt, J=7.2,19.4, 0.5H), 1.42 (dd, J=7.9, 19.3, 0.5H), 1.30-1.13 (m, 4H), 0.71 (d,J=6.7, 3H); MS (ESI+) m/z 287 (M+H)⁺.

Step B: The title compound was prepared by substitutingcyclohexanecarbaldehyde for 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.57 (dd, J=7.0, 10.9, 1H), 7.64 (dd, J=4.9, 7.0, 2H), 7.34 (t,J=7.6, 2H), 7.25 (t, J=7.4, 1H), 4.37-4.28 (m, 1H), 3.23 (d, J=10.4,1H), 2.85 (dd, J=2.8, 9.0, 0.5H), 2.70-2.60 (m, 1H), 2.59-2.53 (m,J=4.6, 11.8, 0.5H), 2.51 (dd, J=3.1, 9.1, 1H), 2.44-2.38 (m, 1H),2.37-2.32 (m, 0.5H), 2.31-2.28 (m, 0.5H), 2.27-2.08 (m, 3.5H), 2.08-1.99(m, 1H), 1.93-1.73 (m, 3.5H), 1.73-1.54 (m, 3.5H), 1.47-1.27 (m, 2.5H),1.22 (dd, J=6.5, 10.5, 3H), 1.19-1.06 (m, 3H), 0.90-0.75 (m, 2H), 0.71(dd, J=2.2, 6.7, 3H); MS (ESI+) m/z 383 (M+H)⁺.

Example 843-methyl-N-[(3aR,4S,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide

The title compound was prepared by substituting formaldehyde for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.55 (t, J=5.4, 1H), 7.65 (t, J=6.5, 2H), 7.34 (ddd, J=3.7, 7.6,10.9, 2H), 7.29-7.25 (m, 1H), 4.42-4.28 (m, 1H), 3.22 (d, J=10.5, 1H),2.91 (dd, J=2.2, 9.0, 0.5H), 2.65 (dt, J=6.7, 17.3, 1H), 2.53 (dd,J=2.5, 9.2, 1H), 2.46 (dd, J=4.4, 10.2, 0.5H), 2.42-2.35 (m, 0.5H), 2.30(d, J=8.8, 1.5H), 2.25 (dd, J=2.8, 9.0, 0.5H), 2.19 (s, 1.5H), 2.16-2.05(m, 3.5H), 1.85 (td, J=6.2, 12.0, 1H), 1.75 (dd, J=6.6, 13.8, 0.5H),1.63 (dt, J=7.0, 15.3, 0.5H), 1.39 (dt, J=8.1, 14.4, 1H), 1.31 (dt,J=2.9, 9.4, 0.5H), 1.22 (dd, J=6.5, 11.7, 3H), 0.71 (dd, J=2.9, 6.7,3H); MS (ESI+) m/z 301 (M+H)⁺.

Example 85N-[(3aR,4S,6aS)-2-(2-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 2-fluorobenzaldehyde for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.66-8.58 (m, 1H), 7.63 (dd, J=3.1, 7.4, 2H), 7.53 (t, J=7.4, 1H),7.33 (td, J=2.2, 7.6, 2H), 7.28-7.22 (m, J=7.4, 9.9, 2H), 7.17-7.06 (m,J=8.2, 14.8, 26.9, 2H), 4.34 (dd, J=6.0, 11.5, 1H), 3.75 (d, J=13.6,0.5H), 3.71-3.62 (m, 1H), 3.57 (d, J=13.6, 0.5H), 3.22 (dd, J=2.2, 10.4,1H), 3.00 (d, J=6.7, 0.5H), 2.69-2.48 (m, J=23.7, 34.8, 3H), 2.47-2.28(m, 3.5H), 2.17-2.07 (m, 0.5H), 1.93-1.78 (m, J=6.7, 12.4, 20.1, 1H),1.78-1.62 (m, 1H), 1.49-1.27 (m, J=10.3, 19.5, 26.3, 1.5H), 1.20 (dd,J=2.9, 6.4, 3H), 0.70 (dd, J=1.4, 6.6, 3H); MS (ESI+) m/z 395 (M+H)⁺.

Example 86N-[(3aR,4S,6aS)-2-(3-chlorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 3-chlorobenzaldehyde for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.62 (t, J=6.5, 1H), 7.64 (dd, J=4.3, 7.0, 2H), 7.51 (s, 0.5H),7.46 (s, 0.5H), 7.33 (td, J=2.5, 7.5, 3H), 7.30-7.28 (m, 1H), 7.28-7.23(m, 2H), 4.37-4.28 (m, 1H), 3.60 (d, J=13.4, 0.5H), 3.51 (d, J=13.4,0.5H), 3.45 (d, J=13.4, 0.5H), 3.33 (d, J=13.4, 0.5H), 3.22 (dd, J=2.2,10.4, 1H), 2.93 (d, J=6.3, 0.5H), 2.69-2.48 (m, 3H), 2.31 (dddd, J=8.9,13.2, 14.5, 20.2, 3H), 2.16-2.05 (m, 1H), 1.92-1.79 (m, 1H), 1.78-1.62(m, 1H), 1.49-1.40 (m, 0.5H), 1.37 (dd, J=5.8, 12.6, 0.5H), 1.30 (dd,J=7.2, 13.5, 0.5H), 1.20 (dd, J=3.0, 6.5, 3H), 0.70 (dd, J=1.5, 6.7,3H); MS (ESI+) m/z 411 (M+H)⁺.

Example 87N-[(3aR,4S,6aS)-2-(3-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 3-fluorobenzaldehyde for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.61 (t, J=8.0, 1H), 7.64 (dd, J=4.1, 7.0, 2H), 7.37-7.16 (m, 5H),7.13 (d, J=7.6, 1H), 7.04 (s, 1H), 4.33 (dd, J=5.7, 12.4, 1H), 3.57 (d,J=13.5, 0.5H), 3.48 (d, J=13.4, 0.5H), 3.42 (d, J=13.5, 0.5H), 3.30 (d,J=13.5, 0.5H), 3.23 (d, J=10.5, 1H), 2.90 (dd, J=2.9, 9.1, 0.5H),2.70-2.61 (m, 1H), 2.59-2.53 (m, 1H), 2.53-2.45 (m, 1H), 2.44-2.31 (m,J=18.5, 1H), 2.27 (t, J=7.7, 1H), 2.19 (dd, J=6.3, 13.0, 1H), 2.12 (dd,J=6.0, 12.3, 0.5H), 1.93-1.80 (m, J=6.9, 12.4, 20.6, 1H), 1.79-1.64 (m,1H), 1.47-1.24 (m, 2H), 1.20 (dd, J=3.1, 6.4, 3H), 0.70 (d, J=6.7, 3H);MS (ESI+) m/z 395 (M+H)⁺.

Example 883-methyl-2-phenyl-N-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide

The title compound was prepared by substituting3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.60 (t, J=7.6, 1H), 7.76 (s, 0.5H), 7.71 (s, 0.5H), 7.64 (d,J=7.8, 2H), 7.57-7.53 (m, J=7.1, 2H), 7.43 (dd, J=7.8, 17.8, 1H),7.36-7.30 (m, 2H), 7.28-7.23 (m, 1H), 4.33 (dd, J=5.8, 12.3, 1H), 3.61(d, J=13.6, 0.5H), 3.53 (d, J=13.5, 0.5H), 3.47 (d, J=13.5, 0.5H), 3.36(d, J=13.5, 0.5H), 3.22 (dd, J=1.5, 10.4, 1H), 2.91 (dd, J=3.0, 9.0,0.5H), 2.69-2.59 (m, 1H), 2.55 (dd, J=3.0, 9.0, 1H), 2.52-2.47 (m, 1H),2.44-2.32 (m, J=10.5, 32.1, 1H), 2.29 (d, J=8.9, 0.5H), 2.26 (d, J=5.2,1H), 2.22-2.18 (m, 1H), 2.16-2.06 (m, 0.5H), 1.92-1.79 (m, 1H),1.79-1.63 (m, 1H), 1.48-1.25 (m, 1.5H), 1.20 (dd, J=4.5, 6.4, 3H), 0.70(d, J=5.8, 3H); MS (ESI+) m/z 445 (M+H)⁺.

Example 89N-[(3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 4-fluorobenzaldehyde for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.61 (t, J=7.2, 1H), 7.64 (dd, J=2.4, 7.5, 2H), 7.39 (dd, J=5.8,8.2, 1H), 7.33 (dt, J=5.8, 11.6, 3H), 7.28-7.23 (m, 1H), 7.11 (dd,J=8.8, 19.1, 2H), 4.34 (dd, J=5.8, 12.6, 1H), 3.56 (d, J=13.3, 0.5H),3.45 (dd, J=13.3, 16.8, 1H), 3.31 (d, J=13.1, 0.5H), 3.22 (dd, J=2.3,10.5, 1H), 2.92 (d, J=6.5, 0.5H), 2.69-2.60 (m, 1H), 2.57 (d, J=6.6,1H), 2.51 (d, J=8.4, 1H), 2.46-2.33 (m, 1H), 2.29 (d, J=4.4, 1H), 2.22(d, J=6.5, 1H), 2.14 (dq, J=6.2, 12.2, 0.5H), 1.95-1.80 (m, J=7.1, 12.4,20.7, 1H), 1.79-1.72 (m, 0.5H), 1.71-1.64 (m, 1H), 1.48-1.23 (m, 1.5H),1.20 (t, J=6.1, 3H), 0.70 (dd, J=2.1, 6.7, 3H); MS (ESI+) m/z 395(M+H)⁺.

Example 90N-[(3aR,4S,6aS)-2-(3-methoxybenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 3-methoxybenzaldehydefor 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.61-8.54 (m, 1H), 7.63 (d, J=7.6, 2H), 7.36-7.24 (m, J=5.6, 12.0,20.6, 4H), 7.17 (s, 0.5H), 7.11 (s, 0.5H), 7.06 (d, J=7.8, 0.5H), 7.00(d, J=7.5, 0.5H), 6.95-6.88 (m, 1H), 4.42-4.29 (m, 1H), 3.72 (s, 1.5H),3.70 (s, 1.5H), 3.60 (d, J=13.3, 0.5H), 3.52 (d, J=13.2, 0.5H), 3.48 (d,J=13.3, 0.5H), 3.36 (d, J=13.2, 0.5H), 3.23-3.19 (m, 1H), 2.93 (dd,J=2.7, 9.0, 0.5H), 2.68-2.61 (m, 1H), 2.58 (dd, J=3.0, 8.9, 1H),2.52-2.46 (m, 1H), 2.45-2.20 (m, 3H), 2.18-2.11 (m, 1H), 1.91 (dd,J=6.0, 12.0, 0.5H), 1.87-1.80 (m, 0.5H), 1.78-1.64 (m, 1H), 1.48-1.26(m, J=28.4, 35.4, 1.5H), 1.20 (t, J=6.7, 3H), 0.70 (dd, J=2.8, 6.7, 3H);MS (ESI+) m/z 407 (M+H)⁺.

Example 913-methyl-N-[(3aR,4S,6aS)-2-(3-methylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide

The title compound was prepared by substituting 3-methylbenzaldehyde for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.62-8.50 (m, 1H), 7.64 (d, J=7.5, 2H), 7.33 (td, J=3.7, 7.5, 2H),7.29-7.23 (m, J=5.5, 11.0, 3H), 7.18 (s, 1H), 7.07 (d, J=7.0, 1H),4.42-4.29 (m, 1H), 3.60 (d, J=13.1, 0.5H), 3.51 (d, J=13.0, 0.5H), 3.45(d, J=13.1, 0.5H), 3.33 (d, J=13.0, 0.5H), 3.22 (d, J=10.4, 1H), 2.90(dd, J=2.9, 8.9, 0.5H), 2.64 (tt, J=6.8, 13.6, 1H), 2.59-2.46 (m, J=5.3,12.0, 23.8, 2H), 2.44-2.34 (m, 1H), 2.30 (d, J=5.3, 1H), 2.28-2.23 (m,J=8.0, 4H), 2.13 (dt, J=6.3, 12.4, 1H), 1.94-1.78 (m, 1H), 1.78-1.64 (m,1H), 1.48-1.25 (m, 1.5H), 1.20 (t, J=6.1, 3H), 0.70 (dd, J=1.9, 6.7,3H); MS (ESI+) m/z 391 (M+H)⁺.

Example 923-methyl-N-[(3aR,4S,6aS)-2-(2-methylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide

The title compound was prepared by substituting 2-methylbenzaldehyde for3- (trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.57-8.51 (m, 1H), 7.63 (dd, J=3.5, 7.1, 2H), 7.43-7.36 (m, 1H),7.36-7.30 (m, 3H), 7.25 (dd, J=6.9, 9.6, 2H), 7.20-7.13 (m, J=10.0, 2H),4.31 (dd, J=5.5, 11.3, 1H), 3.57 (d, J=13.1, 0.5H), 3.48 (d, J=13.0,0.5H), 3.39 (d, J=13.0, 0.5H), 3.29 (d, J=13.0, 0.5H), 3.21 (d, J=10.3,1H), 2.92 (dd, J=2.8, 9.0, 0.5H), 2.68-2.60 (m, 1H), 2.60-2.53 (m, 1H),2.51-2.45 (m, 1H), 2.35 (s, 1.5H), 2.30 (s, 1.5H), 2.28-2.17 (m, 2H),2.15-2.06 (m, 1H), 1.84 (ddd, J=6.8, 12.4, 20.0, 1H), 1.76-1.62 (m, 1H),1.42 (dt, J=7.2, 19.2, 0.5H), 1.33 (dt, J=7.0, 12.5, 0.5H), 1.29-1.22(m, 0.5H), 1.20 (d, J=6.5, 3H), 0.70 (d, J=6.7, 3H); MS (ESI+) m/z 391(M+H)⁺.

Example 93N-[(3aR,4S,6aS)-2-(2,6-dimethylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 2,6-dimethylbenzaldehydefor 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.54-8.50 (m, J=6.7, 1H), 7.65-7.60 (m, 2H), 7.32 (t, J=7.1, 2H),7.28-7.23 (m, 1H), 7.11 (dd, J=6.2, 14.3, 1H), 7.04 (t, J=8.3, 2H),4.27-4.19 (m, 1H), 3.57 (d, J=12.5, 0.5H), 3.44 (dd, J=12.5, 15.5, 1H),3.34 (d, J=12.5, 0.5H), 3.20 (d, J=10.4, 1H), 2.92 (d, J=5.9, 0.5H),2.68-2.58 (m, J=10.2, 18.3, 1H), 2.55-2.51 (m, J=4.5, 1H), 2.48-2.42 (m,0.5H), 2.39 (s, 3H), 2.34 (s, 3H), 2.32-2.18 (m, 3H), 2.07 (td, J=6.6,12.6, 0.5H), 1.87-1.73 (m, 1H), 1.72-1.62 (m, 1H), 1.33 (dd, J=19.1,78.6, 2.5H), 1.19 (dd, J=4.9, 6.3, 3H), 0.69 (d, J=6.6, 3H); MS (ESI+)m/z 405 (M+H)⁺.

Example 94N-[(3aR,4S,6aS)-2-(2-methoxybenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 2-methoxybenzaldehydefor 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.50 (t, J=7.3, 1H), 7.62 (d, J=7.3, 2H), 7.55 (d, J=7.8, 1H),7.32 (dq, J=3.8, 11.6, 2H), 7.25 (dd, J=3.6, 7.5, 2H), 7.04 (dt, J=7.4,11.4, 1H), 6.89 (t, J=8.3, 1H), 4.43-4.31 (m, 1H), 3.80-3.57 (m, 5H),3.21 (d, J=10.4, 1H), 2.99 (d, J=6.2, 0.5H), 2.61 (ddd, J=4.5, 12.6,15.9, 2.5H), 2.52-2.45 (m, 0.5H), 2.45-2.31 (m, 3.5H), 2.19-2.09 (m,0.5H), 2.00-1.80 (m, 1H), 1.72 (ddd, J=6.5, 12.3, 19.3, 1H), 1.47-1.25(m, 2.5H), 1.20 (dd, J=3.0, 6.4, 3H), 0.70 (d, J=6.7, 3H); MS (ESI+) m/z407 (M+H)⁺.

Example 95N-[(3aR,4S,6aS)-2-(4-tert-butylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 4-tert-butylbenzaldehydefor 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.57 (dd, J=6.7, 11.0, 1H), 7.63 (dd, J=3.4, 7.1, 2H), 7.44-7.30(m, 6H), 7.25 (t, J=7.4, 1H), 4.36 (tt, J=6.3, 12.6, 1H), 3.63 (d,J=13.1, 0.5H), 3.55 (d, J=13.0, 0.5H), 3.46 (d, J=13.0, 0.5H), 3.35 (d,J=13.0, 0.5H), 3.21 (d, J=10.4, 1H), 2.90 (dd, J=2.7, 8.7, 0.5H), 2.65(dt, J=6.6, 16.9, 1H), 2.58-2.44 (m, 2H), 2.44-2.34 (m, 1H), 2.32 (d,J=8.6, 0.5H), 2.30 (d, J=5.2, 1H), 2.24 (d, J=5.0, 1H), 2.19-2.12 (m,1H), 1.92 (dq, J=6.1, 12.1, 0.5H), 1.82 (td, J=7.3, 14.3, 0.5H), 1.70(dq, J=8.1, 14.7, 1H), 1.48-1.30 (m, J=22.3, 41.1, 1H), 1.27 (s, J=1.6,9H), 1.20 (dd, J=3.5, 6.4, 3H), 0.70 (d, J=6.4, 3H); MS (ESI+) m/z 433(M+H)⁺.

Example 96N-[(3aR,4S,6aS)-2-(4-methoxybenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 4-methoxybenzaldehydefor 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.57 (dd, J=8.3, 10.9, 1H), 7.63 (dd, J=2.8, 7.4, 2H), 7.39-7.28(m, 4H), 7.28-7.23 (m, 1H), 6.98 (dd, J=8.7, 10.2, 2H), 4.41-4.30 (m,1H), 3.68 (s, 3H), 3.57 (d, J=12.9, 0.5H), 3.48 (d, J=12.9, 0.5H), 3.42(d, J=12.9, 0.5H), 3.31 (d, J=12.8, 0.5H), 3.21 (d, J=10.4, 1H), 2.90(dd, J=2.8, 8.9, 0.5H), 2.69-2.59 (m, 1H), 2.56 (dd, J=2.9, 9.0, 1H),2.53-2.46 (m, 1H), 2.45-2.33 (m, 1H), 2.32-2.26 (m, J=10.0, 1H), 2.24(t, J=5.2, 1H), 2.15 (dt, J=6.3, 12.3, 0.5H), 1.96-1.88 (m, 0.5H),1.88-1.79 (m, 0.5H), 1.79-1.65 (m, 1H), 1.48-1.24 (m, J=19.9, 48.8, 3H),1.20 (dd, J=4.3, 6.4, 3H), 0.70 (dd, J=2.0, 6.7, 2H); MS (ESI+) m/z 407(M+H)⁺.

Example 97N-[(3aR,4S,6aS)-2-(3-cyanobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 3-formylbenzonitrile for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.60 (t, J=7.1, 1H), 7.63 (d, J=5.9, 2H), 7.56-7.50 (m, 2H),7.39-7.30 (m, 3H), 7.29-7.23 (m, J=8.9, 13.2, 2H), 4.32 (dd, J=5.7,11.2, 1H), 3.53 (d, J=13.6, 0.5H), 3.44 (d, J=13.5, 0.5H), 3.40 (d,J=13.6, 0.5H), 3.28 (d, J=13.6, 0.5H), 3.21 (dd, J=1.3, 10.4, 1H), 2.90(dd, J=2.8, 9.1, 0.5H), 2.64 (qd, J=6.6, 13.2, 1H), 2.59-2.47 (m, 1H),2.46-2.37 (m, 1H), 2.37-2.30 (m, 0.5H), 2.26-2.20 (m, 1H), 2.19-2.13 (m,1H), 2.10 (dt, J=6.2, 12.3, 0.5H), 1.89-1.79 (m, 1H), 1.75 (dt, J=6.1,20.0, 0.5H), 1.66 (dt, J=7.0, 19.3, 0.5H), 1.47-1.38 (m, 0.5H),1.38-1.23 (m, 2H), 1.20 (dd, J=3.6, 6.4, 3H), 0.70 (d, J=6.7, 3H); MS(ESI+) m/z 402 (M+H)⁺.

Example 983-methyl-2-phenyl-N-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide

The title compound was prepared by substituting4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.62 (t, J=7.8, 1H), 7.64 (dd, J=7.0, 11.8, 4H), 7.51 (d, J=8.0,1H), 7.46 (d, J=7.9, 1H), 7.33 (dd, J=7.4, 12.1, 2H), 7.29-7.24 (m, 1H),4.40-4.30 (m, 1H), 3.58 (d, J=13.7, 0.5H), 3.48 (t, J=13.8, 1H), 3.35(d, J=13.7, 0.5H), 3.23 (dd, J=1.4, 10.4, 1H), 2.92 (dd, J=2.7, 9.0,0.5H), 2.69-2.60 (m, 1H), 2.57 (dd, J=2.7, 9.1, 1H), 2.54-2.47 (m,0.5H), 2.47-2.39 (m, 1H), 2.39-2.32 (m, 0.5H), 2.31-2.20 (m, 2H),2.19-2.11 (m, 1H), 1.95-1.82 (m, J=6.4, 37.0, 1H), 1.77 (dt, J=6.4,13.8, 0.5H), 1.69 (dt, J=6.9, 19.1, 0.5H), 1.50-1.25 (m, J=34.6, 62.0,1.5H), 1.21 (t, J=6.4, 3H), 0.70 (d, J=5.1, 3H); MS (ESI+) m/z 445(M+H)⁺.

Example 993-methyl-2-phenyl-N-{(3aR,4S,6aS)-2-[2-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide

The title compound was prepared by substituting2-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.61 (d, J=6.0, 1H), 7.93 (d, J=7.6, 0.5H), 7.85 (d, J=7.8, 0.5H),7.63 (t, J=5.8, 3H), 7.53 (dd, J=7.9, 16.0, 1H), 7.38-7.23 (m, 5H), 4.36(dd, J=5.7, 13.2, 1H), 3.76 (q, J=14.5, 1H), 3.66 (q, J=15.0, 1H), 3.23(dd, J=2.2, 10.5, 1H), 3.03 (dd, J=2.2, 9.0, 0.5H), 2.69-2.60 (m, J=5.6,17.6, 1H), 2.59-2.47 (m, 1H), 2.47-2.40 (m, J=10.2, 17.4, 1H), 2.39-2.12(m, 3H), 1.96-1.82 (m, 1H), 1.78 (dt, J=6.2, 20.1, 0.5H), 1.68 (dt,J=7.2, 13.8, 0.5H), 1.48-1.24 (m, 1.5H), 1.20 (t, J=6.7, 3H), 0.70 (dd,J=1.7, 6.7, 3H); MS (ESI+) m/z 445 (M+H)⁺.

Example 100N-{(3aR,4S,6aS)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting4-fluoro-3-(trifluoromethyl)benzaldehyde for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.63 (t, J=7.0, 1H), 7.69 (d, J=6.3, 1H), 7.64 (d, J=7.6, 2H),7.55-7.49 (m, 1H), 7.33 (dd, J=7.2, 13.6, 2H), 7.25 (dd, J=7.6, 15.5,2H), 4.33 (dd, J=5.7, 11.4, 1H), 3.54 (d, J=13.5, 0.5H), 3.44 (t,J=14.0, 1H), 3.31 (d, J=13.4, 0.5H), 3.22 (d, J=10.4, 1H), 2.91 (dd,J=2.6, 9.0, 0.5H), 2.69-2.60 (m, J=7.5, 13.7, 1H), 2.55 (dd, J=3.1, 9.1,1H), 2.53-2.39 (m, 2H), 2.38-2.32 (m, J=8.0, 0.5H), 2.29-2.21 (m, 1H),2.19 (d, J=4.0, 1H), 2.12 (dd, J=6.1, 12.1, 0.5H), 1.91-1.81 (m, J=10.9,16.7, 1H), 1.77 (dt, J=6.3, 19.8, 0.5H), 1.68 (td, J=7.0, 14.0, 0.5H),1.44 (dt, J=7.6, 14.7, 0.5H), 1.40-1.25 (m, 1H), 1.20 (t, J=5.7, 3H),0.70 (d, J=6.4, 3H); MS (ESI+) m/z 463 (M+H)⁺.

Example 101N-{(3aR,4S,6aS)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting3-fluoro-4-(trifluoromethyl)benzaldehyde for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.63 (t, J=6.6, 1H), 7.64 (dd, J=3.0, 7.5, 2H), 7.37-7.30 (m, 3H),7.30-7.23 (m, 3H), 4.38-4.30 (m, 1H), 3.56 (d, J=14.1, 0.5H), 3.46 (t,J=13.4, 1H), 3.33 (d, J=14.1, 0.5H), 3.23 (d, J=10.4, 1H), 2.94 (dd,J=2.5, 9.0, 0.5H), 2.65 (dt, J=6.2, 10.9, 1H), 2.58 (dd, J=2.8, 9.2,1H), 2.54-2.48 (m, 0.5H), 2.47-2.39 (m, 1H), 2.39-2.32 (m, 0.5H), 2.28(dd, J=2.7, 8.9, 0.5H), 2.26-2.20 (m, 1H), 2.19-2.09 (m, 1H), 1.87 (ddd,J=6.4, 12.3, 18.7, 1H), 1.78 (dt, J=6.2, 19.6, 0.5H), 1.68 (dt, J=7.5,14.6, 0.5H), 1.49-1.24 (m, 2H), 1.21 (dd, J=4.3, 6.2, 3H), 0.70 (d,J=6.7, 3H); MS (ESI+) m/z 463 (M+H)⁺.

Example 1023-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(thien-2-ylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide

The title compound was prepared by substituting thiophene-2-carbaldehydefor 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.62-8.53 (m, 1H), 7.63 (dd, J=4.4, 7.0, 2H), 7.33 (t, J=7.6, 3H),7.28-7.23 (m, 1H), 6.98 (dd, J=4.8, 9.3, 1H), 6.94 (d, J=3.0, 1H), 4.33(dd, J=7.7, 13.5, 1H), 3.77 (d, J=13.7, 0.5H), 3.68 (dd, J=4.6, 13.7,1H), 3.57 (d, J=13.7, 0.5H), 3.21 (d, J=10.4, 1H), 2.94 (d, J=8.5,0.5H), 2.69-2.44 (m, 3H), 2.44-2.28 (m, 3H), 2.28-2.22 (m, 0.5H),2.18-2.09 (m, 0.5H), 1.90 (td, J=6.1, 12.1, 0.5H), 1.86-1.79 (m, 0.5H),1.78-1.63 (m, 1H), 1.47-1.35 (m, 1H), 1.32 (dd, J=7.1, 13.2, 0.5H), 1.20(dd, J=2.0, 6.4, 3H), 0.70 (d, J=6.7, 3H); MS (ESI+) m/z 383 (M+H)⁺.

Example 1033-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(pyridin-4-ylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide

The title compound was prepared by substituting isonicotinaldehyde for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.70 (d, J=5.9, 2H), 8.62 (s, 1H), 7.64 (dd, J=3.0, 7.5, 2H),7.36-7.30 (m, 2H), 7.25 (dd, J=7.0, 12.4, 3H), 4.39-4.30 (m, 1H), 3.51(d, J=14.2, 0.5H), 3.41 (dd, J=11.5, 14.2, 1H), 3.28 (d, J=14.3, 0.5H),3.23 (dd, J=1.8, 10.5, 1H), 2.94 (dd, J=2.6, 9.2, 0.5H), 2.69-2.60 (m,1H), 2.57 (dd, J=2.9, 9.2, 1H), 2.52-2.46 (m, 0.5H), 2.42 (dd, J=7.2,8.8, 1H), 2.38-2.31 (m, 0.5H), 2.28 (dd, J=2.7, 9.0, 0.5H), 2.24-2.18(m, 1H), 2.17-2.11 (m, 1H), 1.95-1.82 (m, 1H), 1.77 (dt, J=5.8, 12.3,0.5H), 1.73-1.64 (m, 0.5H), 1.49-1.25 (m, 2H), 1.23-1.17 (m, 3H), 0.70(d, J=6.5, 3H); MS (ESI+) m/z 378 (M+H)⁺.

Example 1043-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(2-phenylethyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide

The title compound was prepared by substituting 2-phenylacetaldehyde for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.57 (dd, J=5.2, 12.0, 1H), 7.65 (t, J=7.1, 2H), 7.38-7.23 (m,8H), 4.40-4.29 (m, 1H), 3.23 (d, J=10.5, 1H), 3.00 (dd, J=2.6, 9.0,0.5H), 2.80 (t, J=7.8, 1H), 2.75-2.70 (m, 1H), 2.70-2.61 (m, 1H),2.61-2.52 (m, 1H), 2.52-2.46 (m, 1H), 2.43 (dd, J=7.6, 8.7, 0.5H), 2.38(dd, J=2.7, 8.8, 1H), 2.34 (dd, J=2.7, 8.5, 1H), 2.26 (d, J=8.3, 0.5H),2.24-2.18 (m, 1H), 2.12 (td, J=6.4, 12.4, 0.5H), 1.91-1.82 (m, 1H), 1.76(dt, J=6.2, 18.7, 0.5H), 1.70-1.61 (m, 0.5H), 1.46-1.26 (m, 2H), 1.23(dd, J=6.5, 13.5, 3H), 0.97-0.83 (m, 1H), 0.71 (dd, J=2.7, 6.7, 3H); MS(ESI+) m/z 391 (M+H)⁺.

Example 1053-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(3-phenylpropyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide

The title compound was prepared by substituting 3-phenylpropanal for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.60 (t, J=6.8, 1H), 7.69-7.63 (m, 2H), 7.39-7.22 (m, 8H),4.41-4.31 (m, 1H), 3.25 (d, J=10.4, 1H), 2.95 (dd, J=2.5, 8.9, 0.5H),2.68 (td, J=2.7, 7.2, 2H), 2.65-2.60 (m, 1H), 2.58 (dd, J=2.8, 9.2,0.5H), 2.56-2.52 (m, 0.5H), 2.51-2.46 (m, 0.5H), 2.44-2.38 (m, 0.5H),2.37-2.26 (m, 3H), 2.23 (t, J=7.2, 1H), 2.18 (d, J=7.3, 0.5H), 2.13 (t,J=8.8, 1.5H), 1.88 (dd, J=6.1, 12.1, 1H), 1.79 (dd, J=7.2, 14.5, 1.5H),1.74-1.64 (m, 1.5H), 1.48-1.37 (m, 1H), 1.37-1.28 (m, 0.5H), 1.23 (dd,J=6.5, 12.2, 3H), 0.71 (dd, J=3.0, 6.7, 3H); MS (ESI+) m/z 405 (M+H)⁺.

Example 106N-{(3aR,4S,6aS)-2-[3-(4-tert-butylphenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting3-(4-tert-butylphenyl)propanal for 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.57 (t, J=8.5, 1H), 7.65 (t, J=6.6, 2H), 7.40 (dd, J=5.4, 8.0,2H), 7.34 (t, J=7.4, 2H), 7.30-7.23 (m, 3H), 4.37 (dt, J=6.1, 11.1, 1H),3.23 (d, J=10.4, 1H), 2.96 (dd, J=1.9, 8.9, 0.5H), 2.67 (ddd, J=6.7,11.6, 23.3, 2H), 2.59 (dd, J=2.6, 9.3, 0.5H), 2.57-2.51 (m, 0.5H),2.50-2.44 (m, 0.5H), 2.43-2.38 (m, 0.5H), 2.35 (t, J=8.1, 2H), 2.29 (dd,J=2.6, 8.8, 0.5H), 2.25 (t, J=7.1, 1H), 2.19 (d, J=7.2, 0.5H), 2.17-2.11(m, 1H), 1.92-1.85 (m, 1H), 1.81 (dt, J=7.7, 15.5, 1H), 1.74 (dt, J=7.9,15.9, 1H), 1.69-1.63 (m, 0.5H), 1.46-1.31 (m, 2H), 1.28 (s, 9H), 1.23(dd, J=6.5, 13.4, 3H), 0.94-0.84 (m, 2H), 0.71 (dd, J=3.2, 6.6, 3H); MS(ESI+) m/z 461 (M+H)⁺.

Example 107N-{(3aR,4S,6aS)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting6,6-bis(4-fluorophenyl)hexanal for 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.59 (t, J=6.4, 1H), 7.65 (dd, J=4.9, 6.9, 2H), 7.33 (dd, J=6.8,11.6, 6H), 7.25 (dd, J=6.5, 8.2, 1H), 7.14 (dd, J=1.4, 8.7, 4H),4.40-4.30 (m, 1H), 3.97 (q, J=7.7, 1H), 3.23 (d, J=10.4, 1H), 2.96 (d,J=6.8, 0.5H), 2.71-2.61 (m, 1H), 2.59 (dd, J=2.5, 9.0, 0.5H), 2.56-2.46(m, 1H), 2.40 (dd, J=8.4, 16.1, 1H), 2.37-2.33 (m, 1H), 2.30 (dd, J=4.4,8.1, 1H), 2.20 (t, J=6.2, 2H), 2.17-2.10 (m, 1H), 2.01 (ddd, J=7.8,11.6, 15.5, 2H), 1.88 (dq, J=6.0, 11.8, 1H), 1.78 (dt, J=6.3, 20.2,0.5H), 1.67 (td, J=7.1, 14.5, 0.5H), 1.49-1.30 (m, 6H), 1.29-1.25 (m,2H), 1.22 (dd, J=6.5, 11.0, 3H), 0.71 (dd, J=3.2, 6.7, 3H); MS (ESI+)m/z 559 (M+H)⁺.

Example 1083-methyl-N-{(3aR,4S,6aS)-2-[3-(2-methylphenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2-phenylbutanamide

The title compound was prepared by substituting 3-o-tolylpropanal for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.57 (dd, J=7.2, 14.2, 1H), 7.68-7.62 (m, 2H), 7.34 (t, J=7.5,2H), 7.29-7.23 (m, 2H), 7.23-7.22 (m, 1H), 7.17 (dd, J=2.6, 3.9, 2H),4.42-4.31 (m, 1H), 3.23 (d, J=10.4, 1H), 2.98 (dd, J=2.3, 8.8, 0.5H),2.69-2.64 (m, 2H), 2.64-2.59 (m, 2H), 2.58-2.51 (m, 0.5H), 2.51-2.45 (m,0.5H), 2.45-2.39 (m, 0.5H), 2.39-2.34 (m, 2H), 2.32 (dd, J=2.7, 8.9,1H), 2.28 (s, 1.5H), 2.25 (s, 1.5H), 2.19 (d, J=8.1, 0.5H), 2.17-2.11(m, 1.5H), 1.93-1.85 (m, 1H), 1.84-1.77 (m, 0.5H), 1.73 (dd, J=7.6,15.1, 1H), 1.66 (dt, J=7.4, 9.4, 1.5H), 1.43 (dt, J=7.5, 13.8, 1H),1.38-1.30 (m, 1H), 1.23 (dd, J=6.5, 12.1, 3H), 0.71 (dd, J=2.8, 6.7,3H); MS (ESI+) m/z 419 (M+H)⁺.

Example 109N-{(3aR,4S,6aS)-2-[3-(3-chlorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting3-(3-chlorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.60 (d, J=4.6, 1H), 7.66 (dd, J=4.3, 7.0, 2H), 7.35 (dd, J=10.9,18.3, 3H), 7.29-7.23 (m, 3H), 7.16 (d, J=6.8, 0.5H), 7.12 (d, J=7.0,0.5H), 4.41-4.31 (m, 1H), 3.24 (d, J=10.4, 1H), 2.98 (d, J=8.9, 0.5H),2.72-2.62 (m, 2H), 2.62-2.55 (m, 2H), 2.55-2.51 (m, 0.5H), 2.50-2.45 (m,0.5H), 2.43-2.37 (m, 0.5H), 2.31 (ddd, J=2.6, 7.2, 12.1, 3H), 2.23-2.16(m, 1H), 2.15-2.09 (m, 1H), 1.91-1.84 (m, 1H), 1.80 (td, J=6.3, 12.5,1H), 1.72 (dd, J=7.5, 14.5, 1H), 1.69-1.61 (m, 1H), 1.46-1.37 (m, 1H),1.37-1.28 (m, 1H), 1.23 (dd, J=6.5, 13.3, 3H), 0.71 (dd, J=3.9, 6.7,3H); MS (ESI+) m/z 439 (M+H)⁺.

Example 1103-methyl-N-{(3aR,4S,6aS)-2-[3-(3-methylphenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2-phenylbutanamide

The title compound was prepared by substituting 3-m-tolylpropanal for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.57 (dd, J=7.1, 13.5, 1H), 7.65 (dd, J=4.8, 7.0, 2H), 7.34 (t,J=7.5, 2H), 7.29-7.22 (m, 2H), 7.12 (d, J=5.9, 1H), 7.09 (d, J=7.1, 1H),7.06-7.02 (m, 1H), 4.42-4.31 (m, 1H), 3.24 (d, J=10.4, 1H), 2.97 (d,J=6.8, 0.5H), 2.71-2.58 (m, 4H), 2.56-2.44 (m, 1H), 2.43-2.38 (m, 0.5H),2.35 (t, J=6.6, 3H), 2.29 (s, 1.5H), 2.27 (s, 1.5H), 2.27-2.23 (m, 1H),2.17-2.11 (m, 1.5H), 1.89 (dt, J=6.1, 11.8, 1H), 1.79 (dd, J=7.4, 14.7,1.5H), 1.72 (dt, J=7.6, 15.1, 1H), 1.66 (dd, J=5.9, 13.1, 0.5H), 1.42(dt, J=7.5, 12.0, 1H), 1.37-1.30 (m, 0.5H), 1.23 (dd, J=6.5, 11.7, 3H),0.71 (dd, J=3.0, 6.6, 3H); MS (ESI+) m/z 419 (M+H)⁺.

Example 1113-methyl-2-phenyl-N-((3aR,4S,6aS)-2-{3-[3-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[c]pyrrol-4-yl)butanamide

The title compound was prepared by substituting3-(3-(trifluoromethyl)phenyl)propanal for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.61 (d, J=6.4, 1H), 7.69-7.62 (m, 3H), 7.53 (d, J=6.5, 1H), 7.46(t, J=7.8, 1H), 7.42 (d, J=5.5, 1H), 7.34 (t, J=7.5, 2H), 7.26 (t,J=7.3, 1H), 4.37 (tt, J=6.4, 12.7, 1H), 3.24 (d, J=10.5, 1H), 3.00 (dd,J=1.9, 8.9, 0.5H), 2.78-2.63 (m, 3H), 2.61 (dd, J=2.3, 9.1, 0.5H),2.57-2.45 (m, 1H), 2.40 (dd, J=7.1, 14.3, 0.5H), 2.37-2.26 (m, 3H),2.24-2.07 (m, 3H), 1.93-1.83 (m, 1H), 1.83-1.71 (m, 2H), 1.71-1.63 (m,1H), 1.48-1.37 (m, 1H), 1.37-1.30 (m, 0.5H), 1.23 (dd, J=6.5, 13.6, 3H),0.72 (dd, J=4.4, 6.6, 3H); MS (ESI+) m/z 473 (M+H)⁺.

Example 112N-{(3aR,4S,6aS)-2-[3-(3-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide

he title compound was prepared by substituting3-(3-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.52 (s, 1H), 7.69-7.61 (m, 2H), 7.33 (t, J=7.5, 2H), 7.27 (ddd,J=3.5, 7.6, 10.6, 2H), 7.14-6.95 (m, 3H), 4.43-4.29 (m, 1H), 3.23 (d,J=10.4, 1H), 2.97 (dd, J=2.2, 8.8, 0.5H), 2.72-2.58 (m, 3H), 2.57-2.44(m, 1H), 2.44-2.38 (m, 0.5H), 2.36-2.26 (m, 3H), 2.25-2.16 (m, 1H),2.16-2.09 (m, 1H), 1.93-1.83 (m, 1H), 1.77 (dt, J=7.2, 14.6, 1.5H),1.72-1.63 (m, 1.5H), 1.47-1.27 (m, 2H), 1.22 (dd, J=6.5, 10.4, 3H),0.94-0.83 (m, 1H), 0.71 (dd, J=2.7, 6.7, 3H); MS (ESI+) m/z 423 (M+H)⁺.

Example 1133-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(4-phenylbutyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide

The title compound was prepared by substituting 4-phenylbutanal for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.58 (dd, J=9.0, 16.5, 1H), 7.66 (t, J=6.4, 2H), 7.34 (t, J=5.6,4H), 7.29-7.22 (m, 4H), 4.39-4.29 (m, 1H), 3.24 (d, J=10.4, 1H), 2.91(dd, J=2.4, 9.0, 0.5H), 2.66 (ddd, J=6.5, 10.6, 13.1, 1H), 2.57 (ddd,J=5.3, 12.3, 17.7, 3H), 2.51-2.45 (m, 1H), 2.43-2.29 (m, 3H), 2.26 (dd,J=3.0, 8.8, 0.5H), 2.24-2.08 (m, 2H), 1.91-1.83 (m, 1H), 1.81-1.72 (m,1H), 1.71-1.58 (m, 2H), 1.49 (dt, J=7.8, 15.9, 1H), 1.41 (dt, J=6.9,17.2, 2H), 1.31 (ddd, J=6.7, 13.2, 20.5, 1H), 1.23 (dd, J=6.5, 13.0,3H), 0.71 (dd, J=2.6, 6.6, 3H); MS (ESI+) m/z 419 (M+H)⁺.

Example 114N-{(3aR,4S,6aS)-2-[3-(3-chloro-5-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting3-(3-chloro-5-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehydeand3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.61 (d, J=7.4, 1H), 7.66 (dd, J=3.2, 7.5, 2H), 7.35 (dd, J=7.5,15.0, 2H), 7.25 (dd, J=6.1, 13.7, 2H), 7.12 (d, J=7.5, 1H), 7.06-6.95(m, 1H), 4.43-4.31 (m, 1H), 3.24 (d, J=10.4, 1H), 3.01 (dd, J=1.3, 8.7,0.5H), 2.73-2.64 (m, 1H), 2.62 (dd, J=6.0, 9.0, 1H), 2.59-2.54 (m, 1H),2.53-2.45 (m, 1H), 2.43-2.38 (m, 0.5H), 2.37-2.25 (m, 3H), 2.24-2.06 (m,3H), 1.93-1.76 (m, 2H), 1.75-1.58 (m, 2H), 1.47-1.28 (m, 2H), 1.23 (dd,J=6.5, 14.4, 3H), 0.72 (dd, J=5.0, 6.2, 3H); MS (ESI+) m/z 457 (M+H)⁺.

Example 1153-methyl-2-phenyl-N-((3aR,4S,6aS)-2-{3-[4-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[c]pyrrol-4-yl)butanamide

The title compound was prepared by substituting3-(4-(trifluoromethyl)phenyl)propanal for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 7.69-7.62 (m, 4H), 7.39 (d, J=8.0, 1H), 7.37-7.32 (m, 3H), 7.26(t, J=7.3, 1H), 4.41-4.33 (m, 1H), 3.25 (d, J=10.5, 1H), 3.00 (dd,J=2.2, 9.0, 0.5H), 2.76-2.59 (m, 3H), 2.56-2.46 (m, 1H), 2.44-2.39 (m,0.5H), 2.37 (dd, J=2.1, 8.9, 0.5H), 2.31 (dt, J=5.8, 14.1, 2H),2.23-2.07 (m, 3H), 1.94-1.71 (m, 2.5H), 1.67 (ddd, J=5.6, 7.9, 11.8,1H), 1.47-1.28 (m, 2H), 1.23 (dd, J=6.5, 13.1, 3H), 0.89 (dt, J=7.2,24.8, 1H), 0.72 (dd, J=3.7, 6.7, 3H); MS (ESI+) m/z 473 (M+H)⁺.

Example 116N-[(3aR,4S,6aS)-2-(3,3-diphenylpropyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting 3,3-diphenylpropanal for3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.59 (dd, J=2.9, 7.0, 1H), 7.65 (d, J=8.1, 2H), 7.46 (d, J=7.2,1H), 7.44-7.37 (m, 4H), 7.33 (tt, J=3.7, 7.7, 6H), 7.28-7.24 (m, 1H),7.23-7.18 (m, 1H), 4.44-4.34 (m, 1H), 4.28 (d, J=7.2, 1H), 4.20 (dd,J=5.4, 9.1, 1H), 3.24 (d, J=10.4, 1H), 2.93 (dd, J=2.4, 9.0, 0.5H),2.71-2.61 (m, 1H), 2.56 (dd, J=2.7, 9.2, 0.5H), 2.54-2.50 (m, 0.5H),2.50-2.43 (m, 0.5H), 2.43-2.36 (m, 0.5H), 2.35-2.28 (m, 3H), 2.24 (tt,J=5.1, 10.0, 2H), 2.18-2.07 (m, 2H), 1.94-1.83 (m, 1H), 1.82-1.74 (m,0.5H), 1.68 (td, J=7.0, 14.3, 0.5H), 1.47-1.37 (m, 1H), 1.37-1.29 (m,0.5H), 1.22 (dd, J=4.6, 6.4, 3H), 0.71 (dd, J=1.7, 6.7, 3H); MS (ESI+)m/z 481 (M+H)⁺.

Example 117N-{(3aR,4S,6aS)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting3,3-bis(4-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.62 (d, J=5.3, 1H), 7.65 (d, J=7.3, 2H), 7.42 (dd, J=5.6, 8.6,1H), 7.39-7.29 (m, 5H), 7.26 (td, J=5.3, 7.2, 1H), 7.19-7.09 (m, 4H),4.47-4.37 (m, 1H), 4.29 (t, J=7.7, 0.5H), 4.21 (t, J=7.6, 0.5H), 3.24(d, J=10.4, 1H), 3.02 (dd, J=1.2, 8.9, 0.5H), 2.71-2.60 (m, 1H),2.57-2.46 (m, 1H), 2.44-2.30 (m, 3H), 2.27-2.20 (m, 2H), 2.19-2.09 (m,4H), 1.90 (dq, J=6.0, 17.7, 1H), 1.81 (dq, J=6.2, 18.7, 0.5H), 1.67(ddd, J=7.6, 12.3, 14.8, 0.5H), 1.48-1.38 (m, 1H), 1.38-1.30 (m, 0.5H),1.22 (dd, J=2.5, 6.5, 3H), 0.71 (dd, J=1.4, 6.7, 3H); MS (ESI+) m/z 517(M+H)⁺.

Example 118N-{(3aR,4S,6aS)-2-[4,4-bis(4-fluorophenyl)butyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting4,4-bis(4-fluorophenyl)butanal for 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.61 (d, J=7.0, 1H), 7.66 (dd, J=5.3, 7.0, 2H), 7.44-7.31 (m, 6H),7.26 (t, J=7.4, 1H), 7.19-7.08 (m, 4H), 4.41-4.30 (m, 1H), 4.03-3.92 (m,1H), 3.24 (d, J=10.4, 1H), 2.95 (dd, J=2.3, 8.9, 0.5H), 2.67 (ddd,J=6.6, 13.3, 17.1, 1H), 2.56 (dd, J=2.8, 9.1, 0.5H), 2.54-2.43 (m, 1H),2.42-2.30 (m, 2H), 2.29-2.20 (m, 2.5H), 2.19-2.02 (m, 4H), 1.90-1.72 (m,1.5H), 1.65 (dt, J=7.1, 19.2, 0.5H), 1.52-1.34 (m, 3H), 1.34-1.26 (m,0.5H), 1.23 (dd, J=6.5, 15.3, 3H), 0.71 (dd, J=5.0, 6.5, 3H); MS (ESI+)m/z 531 (M+H)⁺.

Example 119N-{(3aR,4S,6aS)-2-[5,5-bis(4-fluorophenyl)pentyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide

The title compound was prepared by substituting5,5-bis(4-fluorophenyl)pentanal for 3-(trifluoromethyl)benzaldehyde and3-methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.61 (s, 1H), 7.66 (dd, J=4.3, 7.3, 2H), 7.37-7.30 (m, 5H), 7.25(dd, J=5.6, 13.1, 2H), 7.19-7.11 (m, 4H), 4.38-4.29 (m, 1H), 3.96 (dd,J=7.9, 18.0, 1H), 3.25 (d, J=10.5, 1H), 2.96 (d, J=10.4, 0.5H),2.72-2.62 (m, 1H), 2.62-2.57 (m, .50H), 2.56-2.51 (m, 0.5H), 2.50-2.45(m, 0.5H), 2.43-2.36 (m, 1H), 2.36-2.31 (m, 1H), 2.30-2.26 (m, 1H),2.23-2.06 (m, 3H), 2.07-1.96 (m, 2H), 1.86 (dt, J=6.0, 12.2, 1H),1.81-1.72 (m, 1H), 1.66 (dt, J=7.0, 19.1, 1H), 1.56-1.49 (m, 1H),1.48-1.40 (m, 1H), 1.38-1.26 (m, 3H), 1.23 (dd, J=6.5, 9.7, 3H), 0.71(dd, J=2.5, 6.7, 3H); MS (ESI+) m/z 545 (M+H)⁺.

Example 120N-[(3aS,4S,6aR)-2-benzhydryloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide

Potassium iodide (12.48 mg, 0.075 mmol) and sodium carbonate (80 mg,0.752 mmol) were combined with methyl ethyl ketone (5mL) and then2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide(200 mg, 0.601 mmol) from Example 53 was added followed by the additionof (bromomethylene)dibenzene (124 mg, 0.501 mmol). The reaction washeated overnight at 90° C. The reaction mixture was concentrated with astream of nitrogen and then purified by silica gel chromatographyeluting with 2-10% methanol (2 N ammonia)/dichloromethane to give thetitle compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.74 (dd, J=6.7,15.4, 1H), 7.61 (t, J=6.7, 3H), 7.35 (t, J=7.6, 4H), 7.28-7.23 (m, 3H),4.42 (dt, J=7.4, 14.4, 1H), 4.16 (s, 1H), 2.96 (qd, J=4.2, 8.0, 1H),2.63 (dd, J=4.1, 9.8, 1H), 2.57-2.48 (m, 1H), 2.42 (dt, J=9.4, 14.6,2H), 2.33 (dd, J=3.7, 9.3, 1H), 2.09-1.90 (m, 3H), 1.90-1.80 (m, 3H),1.79-1.70 (m, 4H), 1.69-1.55 (m, 6H), 1.46 (d, J=14.7, 1H), 1.39 (s,1H), 1.33-1.00 (m, 8H), 1.00-0.89 (m, 1H); MS (ESI+) m/z 499 (M+H)⁺.

Example 121N-[(3aS,4R,6aR)-2-benzhydryloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide

The title compound was prepared by substituting2,2-dicyclohexyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidefrom Example 74 for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 120: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.11 (d, J=7.2, 1H), 7.64 (d, J=7.1, 2H), 7.32 (t,J=7.6, 4H), 7.20-7.15 (m, 4H), 4.55-4.48 (m, 1H), 4.21 (s, 1H), 2.81(dd, J=2.9, 9.4, 1H), 2.63-2.57 (m, 1H), 2.57-2.51 (m, 1H), 2.41 (dd,J=7.0, 9.2, 1H), 2.36-2.24 (m, 3H), 2.01 (t, J=7.4, 1H), 1.99-1.90 (m,3H), 1.86 (ddd, J=3.3, 8.1, 15.4, 2H), 1.82-1.76 (m, 2H), 1.70 (ddd,J=8.9, 13.9, 15.3, 5H), 1.63-1.55 (m, 2H), 1.51-1.37 (m, 3H), 1.28-1.01(m, 8H); MS (ESI+) m/z 499 (M+H)⁺.

Example 1223-methyl-2-phenyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide

Step A: (3-(Trifluoromethyl)phenyl)methanamine (25 g, 143 mmol),(chloromethyl)trimethylsilane (19.92 mL, 143 mmol), and triethylamine(23.87 mL, 171 mmol) were combined neat and the resultant mixture wasrefluxed overnight. The reaction was cooled to room temperature and 150mL of heptane was added. The HCl salts were removed by filtration andwashed with heptane. The solvent was removed by placing under housevacuum and then high vacuum.N-(3-(Trifluoromethyl)benzyl)-1-(trimethylsilyl)methanamine was isolatedby vacuum distillation (bp 70-90° C./3.2 torr): ¹H NMR (300 MHz, CDCl₃)δ ppm 7.59 (s, 1H), 7.53-7.38 (m, 3H), 3.86 (s, 2H), 2.04 (s, 2H), 1.34(s, 1H), 0.06 (s, 9H).

Step B: Formaldehyde (4.08 g, 50.2 mmol) and methanol (2.032 mL, 50.2mmol) were combined, and the mixture was cooled to 0° C. (ice bath).N-(3-(trifluoromethyl)benzyl)-1-(trimethylsilyl)methanamine (10.94 g,41.9 mmol) was added dropwise via addition funnel over 30 minutes.Potassium carbonate (4.63 g, 33.5 mmol) was added, and the reactionstirred at 0° C. for 2 additional hours. The reaction product wasdecanted from the potassium carbonate, treated with more potassiumcarbonate, and decanted again. The potassium carbonate solids werewashed several times with ether, and these washes were added to theproduct solution. The solvent was removed in vacuo to give1-methoxy-N-(3-(trifluoromethyl)benzyl)-N-((trimethylsilyl)methyl)methanaminewhich was used directly in the next step.

Step C: Cyclopent-2-enone (3.31 g, 40.4 mmol) and trifluoroacetic acid(0.031 mL, 0.404 mmol) were combined in dichloromethane (40 mL).1-Methoxy-N-(3-(trifluoromethyl)benzyl)-N-((trimethylsilyl)methyl)methanamine(12.33 g, 40.4 mmol) from Step B was added as a solution in 10 mL ofdichloromethane dropwise via addition funnel over 45 minutes at roomtemperature under nitrogen. The reaction was quenched with aqueoussodium bicarbonate and extracted with 2×100 mL of dichloromethane. Theorganic washes were combined and washed with brine. The solvent wasremoved in vacuo to give2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[c]pyrrol-4(5H)-one: ¹HNMR (300 MHz, CDCl₃) δ ppm 7.54-7.34 (m, 4H), 3.66 (d, J=13.4, 1H), 3.52(d, J=13.4, 1H), 3.04 (dd, J=1.8, 8.9, 1H), 2.91 (ddd, J=2.8, 7.4, 11.7,1H), 2.72-2.65 (m, 1H), 2.62 (d, J=8.9, 1H), 2.52-2.23 (m, 4H), 2.15(ddd, J=8.1, 12.9, 17.1, 1H), 1.85-1.70 (m, 1H).

Step D: Hydroxylamine hydrochloride (3.47 g, 50.0 mmol) and sodiumacetate (4.27 g, 52.0 mmol) were dissolved in 15 mL of water and addedto a solution of2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[c]pyrrol-4(5H)-one(11.33 g, 40 mmol) from Step C in ethanol (80 mL). The reaction wasbrought to reflux for 5 minutes and allowed to cool to 70° C. After 1hour, the reaction mixture was cooled, and the solvent was removed invacuo to give(E)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[c]pyrrol-4(5H)-oneoxime which was used without additional purification in the next step.

Step E:(E)-2-(3-(Trifluoromethyl)benzyl)hexahydrocyclopenta[c]pyrrol-4(5H)-oneoxime (11.9 g, 39.9 mmol) from Step D in 20% ammonia-methanol (115 mL)was added to methanol-washed Raney®-nickel, (water-wet, 38.52 g, 295mmol) in a 500 mL pressure bottle. The vessel was pressurized withhydrogen (30 psi), and the mixture was shaken for 16 hours at ambienttemperature. The mixture was filtered through a nylon membrane, thesolvent was removed in vacuo, and the crude material was adsorbed ontosilica gel. Silica gel chromatography using a cartridge (Analogix®,Burlington, Wis., SF65-400) eluting with 1-10% methanol (2 Nammonia)/dichloromethane gave the following diastereomers.(3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine:¹H NMR (300 MHz, pyridine-d₅) δ ppm 7.58 (s, 1H), 7.50 (t, J=6.7, 2H),7.45-7.37 (m, 1H), 3.59 (s, 2H), 3.26 (dt, J=6.3, 12.6, 1H), 2.67-2.50(m, 4H), 2.38 (dd, J=6.6, 8.4, 1H), 2.31-2.20 (m, 1H), 1.79-1.62 (m,2H), 1.60-1.33 (m, 4H); and

(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine:¹H NMR (300 MHz, pyridine-d₅) δ ppm 7.58 (s, 1H), 7.50 (t, J=7.2, 2H),7.45-7.37 (m, 1H), 3.59 (s, 2H), 3.09 (dd, J=4.9, 11.4, 1H), 2.77-2.57(m, J=3.9, 1H), 2.52-2.38 (m, 3H), 2.34 (dd, J=3.7, 9.0, 1H), 2.22-2.09(m, 1H), 2.03-1.85 (m, J=4.7, 7.0, 10.8, 2H), 1.42-1.21 (m, 4H).

Step F: The title compound was prepared by substituting3-methyl-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylic acidand(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step E for (3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.23 (d, J=6.9, 0.5H),8.13 (d, J=7.1, 0.5H), 7.73 (s, 0.5H), 7.67 (s, 0.5H), 7.63 (dd, J=6.7,8.0, 2H), 7.56-7.53 (m, 1H), 7.50 (t, J=8.5, 2H), 7.38-7.22 (m, 3H),4.45-4.38 (m, 0.5H), 4.33-4.26 (m, 0.5H), 3.50 (s, 1H), 3.44 (d, J=13.4,0.5H), 3.21 (d, J=13.4, 0.5H), 3.17 (d, J=10.5, 0.5H), 3.10 (d, J=10.5,0.5H), 2.91 (qd, J=3.4, 7.9, 0.5H), 2.79 (dd, J=3.4, 9.5, 0.5H),2.74-2.56 (m, 1.5H), 2.47-2.31 (m, 2.5H), 2.27 (dd, J=3.1, 8.9, 0.5H),2.21 (d, J=2.7, 0.5H), 1.98-1.93 (m, 0.5H), 1.89-1.79 (m, 0.5H),1.74-1.56 (m, 1.5H), 1.53-1.46 (m, 0.5H), 1.46-1.39 (m, 0.5H), 1.30-1.23(m, 1H), 1.19 (d, J=6.5, 1.5H), 1.17-1.11 (m, 0.5H), 1.08 (d, J=6.5,1.5H), 0.72 (dd, J=6.7, 9.6, 3H); MS (ESI+) m/z 445 (M+H)⁺.

Example 1233,3-dimethyl-2-phenyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide

The title compound was prepared by substituting3,3-dimethyl-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylicacid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.32 (d, J=6.7, 0.5H), 8.13 (d, J=7.1, 0.5H), 7.74-7.70 (m, 1H),7.69-7.66 (m, 1H), 7.61 (t, J=8.6, 3H), 7.48-7.43 (m, 1H), 7.37-7.24 (m,3H), 4.48-4.39 (m, 0.5H), 4.36-4.28 (m, 0.5H), 3.51 (q, J=13.1, 0.5H),3.41 (d, J=17.1, 1H), 3.35 (d, J=13.3, 0.5H), 3.13 (d, J=13.4, 0.5H),2.98 (qd, J=4.0, 8.2, 0.5H), 2.81 (dd, J=3.9, 9.5, 0.5H), 2.74 (ddd,J=3.4, 7.8, 16.6, 0.5H), 2.49-2.37 (m, 2H), 2.31 (dd, J=3.4, 9.6, 0.5H),2.24-2.15 (m, 2H), 2.01-1.94 (m, 0.5H), 1.84 (ddd, J=8.1, 11.7, 14.5,0.5H), 1.73-1.65 (m, 1H), 1.64-1.56 (m, 0.5H), 1.52-1.38 (m, 1H), 1.27(dt, J=5.6, 12.2, 1H), 1.16 (s, 4.5H), 1.11 (s, 4.5H); MS (ESI+) m/z 459(M+H)⁺.

Example 1242,2-dicyclohexyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting 2,2-dicyclohexylaceticacid for 1-phenylcyclopentanecarboxylic acid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (400 MHz, pyridine-d₅) δ ppm7.73 (s, 1H), 7.65 (d, J=7.6, 1H), 7.57-7.44 (m, 3H), 4.46 (dt, J=6.4,12.6, 1H), 3.55 (d, J=12.9, 1H), 3.47 (d, J=12.8, 1H), 2.75 (d, J=8.1,2H), 2.53-2.39 (m, 2H), 2.32 (t, J=8.2, 1H), 2.21 (t, J=8.3, 1H),1.97-1.53 (m, 15H), 1.50-1.04 (m, 11H), 0.98 (dd, J=11.3, 23.1, 1H); MS(ESI+) m/z 491 (M+H)⁺.

Example 1252-ethyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide

The title compound was prepared by substituting 2-ethylbutanoic acid for1-phenylcyclopentanecarboxylic acid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm7.90 (d, J=6.7, 1H), 7.71 (s, 1H), 7.61 (d, J=7.7, 1H), 7.54 (d, J=7.7,1H), 7.46 (t, J=7.7, 1H), 4.51-4.43 (m, 1H), 3.49 (s, 2H), 2.83 (ddd,J=2.9, 7.8, 16.8, 1H), 2.75 (dd, J=2.9, 9.5, 1H), 2.52-2.43 (m, 1H),2.37 (dd, J=2.9, 9.1, 1H), 2.35-2.30 (m, 1H), 2.25 (dd, J=7.6, 9.4, 1H),2.01 (tt, J=4.8, 9.5, 1H), 1.89 (dt, J=7.3, 11.6, 1H), 1.77 (ddt, J=7.5,9.3, 15.2, 2H), 1.70-1.60 (m, 2H), 1.51-1.37 (m, 2H), 1.34-1.26 (m, 1H),0.95 (t, J=7.4, 3H), 0.83 (t, J=7.4, 3H); MS (ESI+) m/z 383 (M+H)⁺.

Example 1262-propyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide

The title compound was prepared by substituting 2-propylpentanoic acidfor 1-phenylcyclopentanecarboxylic acid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm7.94 (d, J=6.9, 1H), 7.72 (s, 1H), 7.62 (d, J=7.7, 1H), 7.56 (d, J=7.7,1H), 7.47 (t, J=7.7, 1H), 4.48 (dt, J=7.3, 14.6, 1H), 3.52 (d, J=13.0,1H), 3.48 (d, J=13.0, 1H), 2.84 (ddd, J=3.0, 7.7, 16.7, 1H), 2.74 (dd,J=3.1, 9.5, 1H), 2.52-2.45 (m, 1H), 2.38-2.34 (m, 2H), 2.27 (dd, J=7.6,9.5, 1H), 2.22 (td, J=4.6, 9.5, 1H), 1.90 (dt, J=7.3, 11.5, 1H),1.84-1.75 (m, 2H), 1.73-1.61 (m, 2H), 1.48-1.27 (m, 6H), 1.20-1.08 (m,1H), 0.88 (t, J=7.0, 3H), 0.83 (t, J=7.1, 3H); MS (ESI+) m/z 411 (M+H)⁺.

Example 127N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}cyclohexanecarboxamide

The title compound was prepared by substituting cyclohexanecarboxylicacid for 1-phenylcyclopentanecarboxylic acid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm7.74 (d, J=6.1, 1H), 7.71 (s, 1H), 7.62 (d, J=7.7, 1H), 7.57 (d, J=9.2,1H), 7.47 (t, J=7.7, 1H), 4.48-4.41 (m, 1H), 3.53 (d, J=13.2, 1H), 3.47(d, J=13.2, 1H), 2.84 (ddd, J=2.8, 7.9, 10.3, 1H), 2.75 (dd, J=2.8, 9.5,1H), 2.51-2.43 (m, 1H), 2.37 (dd, J=2.8, 9.1, 1H), 2.34-2.29 (m, 1H),2.27-2.19 (m, 2H), 1.94-1.83 (m, 2H), 1.80 (d, J=12.9, 1H), 1.73-1.60(m, 6H), 1.57-1.51 (m, 1H), 1.35-1.27 (m, 1H), 1.22-1.10 (m, 3H); MS(ESI+) m/z 395 (M+H)⁺.

Example 128N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}cycloheptanecarboxamide

The title compound was prepared by substituting cycloheptanecarboxylicacid for 1-phenylcyclopentanecarboxylic acid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm7.79 (d, J=6.9, 1H), 7.71 (s, 1H), 7.62 (d, J=7.7, 1H), 7.56 (s, 1H),7.47 (t, J=7.7, 1H), 4.48-4.40 (m, 1H), 3.54 (d, J=13.2, 1H), 3.46 (d,J=13.2, 1H), 2.86 (ddd, J=3.0, 7.8, 16.6, 1H), 2.76 (dd, J=3.0, 9.5,1H), 2.51-2.39 (m, 2H), 2.37-2.30 (m, 2H), 2.26 (dd, J=7.5, 9.4, 1H),2.00-1.80 (m, 5H), 1.75-1.60 (m, 4H), 1.49-1.41 (m, 4H), 1.33 (ddt,J=7.2, 8.9, 12.1, 3H); MS (ESI+) m/z 409 (M+H)⁺.

Example 129N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}cyclopentanecarboxamide

The title compound was prepared by substituting cyclopentanecarboxylicacid for 1-phenylcyclopentanecarboxylic acid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm7.82 (d, J=6.9, 1H), 7.71 (s, 1H), 7.61 (d, J=7.7, 1H), 7.55 (d, J=7.7,1H), 7.46 (t, J=7.7, 1H), 4.48-4.41 (m, 1H), 4.07 (q, J=7.1, 1H), 2.82(ddd, J=2.9, 7.8, 16.7, 1H), 2.72 (dd, J=2.9, 9.5, 1H), 2.66 (p, J=7.9,1H), 2.50-2.42 (m, 1H), 2.37 (dd, J=2.9, 9.0, 1H), 2.34-2.29 (m, 1H),2.21 (dd, J=7.5, 9.4, 1H), 2.03 (dt, J=7.0, 15.3, 1H), 1.86 (dddd,J=7.4, 12.3, 20.5, 23.4, 3H), 1.75-1.60 (m, 5H), 1.53-1.41 (m, 2H), 1.30(td, J=4.7, 11.1, 1H), 1.11 (t, J=7.1, 1H); MS (ESI+) m/z 381 (M+H)⁺.

Example 1306,6-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}hexanamide

The title compound was prepared by substituting6,6-bis(4-fluorophenyl)hexanoic acid for 1-phenylcyclopentanecarboxylicacid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm7.99 (d, J=7.1, 1H), 7.69 (s, 1H), 7.58 (s, 1H), 7.54 (d, J=7.6, 1H),7.42 (dd, J=6.9, 14.5, 1H), 7.26 (dd, J=5.5, 8.6, 4H), 7.14-7.08 (m,4H), 4.51-4.41 (m, 1H), 3.91 (t, J=7.8, 1H), 3.47 (d, J=2.3, 2H), 2.84(qd, J=3.0, 8.0, 1H), 2.69 (dd, J=3.1, 9.5, 1H), 2.53-2.43 (m, 1H),2.38-2.20 (m, 5H), 1.99 (dd, J=7.8, 15.6, 2H), 1.89-1.78 (m, 3H),1.70-1.59 (m, 2H), 1.37-1.25 (m, 3H); MS (ESI+) m/z 571 (M+H)⁺.

Example 1313,3-diphenyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}propanamide

The title compound was prepared by substituting 3,3-diphenylpropanoicacid for 1-phenylcyclopentanecarboxylic acid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.10 (d, J=7.0, 1H), 7.72 (s, 1H), 7.62 (d, J=7.8, 1H), 7.48 (t, J=7.7,1H), 7.39 (dd, J=2.6, 7.5, 5H), 7.26 (dt, J=7.6, 15.1, 5H), 7.17 (dd,J=6.2, 13.5, 2H), 4.38-4.27 (m, 1H), 3.54 (d, J=13.4, 1H), 3.38 (d,J=13.4, 1H), 3.15-3.09 (m, 2H), 2.75 (qd, J=3.6, 7.9, 1H), 2.44-2.35 (m,2H), 2.32 (t, J=8.3, 1H), 2.20 (dd, J=3.3, 8.9, 1H), 2.08 (dd, J=7.8,9.5, 1H), 1.70 (t, J=7.9, 1H), 1.58-1.46 (m, 2H), 1.18-1.10 (m, 1H); MS(ESI+) m/z 493 (M+H)⁺.

Example 1325,5-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide

The title compound was prepared by substituting5,5-bis(4-fluorophenyl)pentanoic acid for 1-phenylcyclopentanecarboxylicacid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.06 (d, J=7.0, 1H), 7.70 (s, 1H), 7.60 (d, J=8.0, 1H), 7.54 (d, J=7.7,1H), 7.44 (t, J=7.7, 1H), 7.26 (dd, J=5.6, 8.4, 4H), 7.08 (td, J=1.2,8.8, 4H), 4.51-4.42 (m, 1H), 3.96 (t, J=7.8, 1H), 2.86 (qd, J=3.2, 7.9,1H), 2.69 (dd, J=3.2, 9.5, 1H), 2.52-2.43 (m, 1H), 2.43-2.29 (m, 5H),2.24 (dd, J=7.7, 9.4, 1H), 2.15-2.06 (m, 3H), 1.85 (dt, J=9.9, 17.8,1H), 1.76 (dt, J=7.3, 15.3, 2H), 1.70-1.59 (m, 2H), 1.33-1.26 (m, 1H);MS (ESI+) m/z 557 (M+H)⁺.

Example 1333,3-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}propanamide

The title compound was prepared by substituting3,3-bis(4-fluorophenyl)propanoic acid for 1-phenylcyclopentanecarboxylicacid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.13 (d, J=7.0, 1H), 7.71 (s, 1H), 7.61 (d, J=7.7, 1H), 7.56 (s, 1H),7.47 (t, J=7.7, 1H), 7.32 (ddd, J=3.7, 5.4, 8.8, 4H), 7.11-7.02 (m, 4H),4.94 (d, J=8.0, 1H), 4.39-4.25 (m, 1H), 3.52 (d, J=13.4, 1H), 3.41 (d,J=13.4, 1H), 3.06 (d, J=7.9, 2H), 2.76 (qd, J=3.4, 7.9, 1H), 2.43 (dd,J=3.3, 9.5, 2H), 2.31 (t,

J=8.3, 1H), 2.23 (dd, J=3.1, 9.0, 1H), 2.10 (dd, J=7.8, 9.4, 1H),1.76-1.67 (m, 1H), 1.59-1.49 (m, 2H), 1.22-1.11 (m, 1H); MS (ESI+) m/z529 (M+H)⁺.

Example 1344,4-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide

The title compound was prepared by substituting4,4-bis(4-fluorophenyl)butanoic acid for 1-phenylcyclopentanecarboxylicacid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.16 (d, J=6.9, 1H), 7.66 (s, 1H), 7.58 (s, 1H), 7.50 (d, J=7.7, 1H),7.38 (t, J=7.7, 1H), 7.28 (dd, J=5.5, 7.3, 4H), 7.10-7.02 (m, 4H), 4.49(dt, J=7.6, 14.7, 1H), 4.10 (t, J=7.9, 1H), 3.50 (d, J=13.4, 1H), 3.42(d, J=13.4, 1H), 2.92 (qd, J=3.6, 7.9, 1H), 2.67 (dd, J=3.5, 9.5, 1H),2.55 (dd, J=7.2, 15.0, 2H), 2.52-2.46 (m, 1H), 2.40 (t, J=8.3, 1H),2.36-2.24 (m, 4H), 1.91-1.82 (m, 1H), 1.71 (td, J=5.8, 11.3, 1H),1.67-1.60 (m, 1H), 1.35-1.27 (m, 1H); MS (ESI+) m/z 543 (M+H)⁺.

Example 1352,2-diphenyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting 2,2-diphenylacetic acidfor 1-phenylcyclopentanecarboxylic acid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.50 (s, 1H), 7.71 (d, J=7.5, 2H), 7.63 (d, J=7.2, 2H), 7.45 (d, J=7.4,2H), 7.39-7.28 (m, 5H), 7.25 (dd, J=5.8, 8.9, 3H), 4.51-4.42 (m, 1H),3.44 (d, J=13.3, 1H), 3.25 (d, J=13.3, 1H), 2.85 (qd, J=3.2, 7.9, 1H),2.59 (dd, J=3.4, 9.5, 1H), 2.47-2.37 (m, 1H), 2.26 (t, J=8.3, 1H),2.21-2.13 (m, 2H), 1.85-1.76 (m, 1H), 1.67-1.52 (m, 3H), 1.27-1.18 (m,1H); MS (ESI+) m/z 479 (M+H)⁺.

Example 1362,2-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting2,2-bis(4-fluorophenyl)acetic acid for 1-phenylcyclopentanecarboxylicacid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.68 (d, J=7.0, 1H), 7.64 (s, 1H), 7.60 (t, J=6.4, 1H), 7.57-7.54 (m,2H), 7.52-7.43 (m, 4H), 7.17-7.07 (m, 4H), 4.48-4.41 (m, 1H), 3.46 (d,J=13.3, 1H), 3.30 (d, J=13.3, 1H), 2.90 (qd, J=3.5, 8.0, 1H), 2.59 (dd,J=3.5, 9.5, 1H), 2.50-2.42 (m, 1H), 2.32 (t, J=8.3, 1H), 2.25-2.19 (m,3H), 1.87-1.77 (m, 1H), 1.66 (td, J=5.7, 11.4, 1H), 1.62-1.54 (m, 1H),1.29-1.20 (m, 1H); MS (ESI+) m/z 515 (M+H)⁺.

Example 137N²-(tert-butyloxycarbonyl)-N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-L-leucine for 1-phenylcyclopentanecarboxylicacid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in Example theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.50 (d, J=7.1, 0.5H), 8.46 (d, J=6.8, 0.5H), 8.03 (dd, J=8.2, 17.0,1H), 7.74 (s, 1H), 7.71 (d, J=7.7, 0.5H), 7.61 (d, J=6.5, 0.5H), 7.47(t, J=7.7, 1H), 4.67 (dd, J=8.2, 14.1, 0.5H), 4.61 (dd, J=8.1, 14.7,0.5H), 4.53-4.39 (m, 1H), 3.81 (d, J=13.1, 0.5H), 3.70 (d, J=13.3,0.5H), 3.44 (d, J=13.3, 0.5H), 3.29 (d, J=13.2, 0.5H), 2.93-2.86 (m,1H), 2.85-2.74 (m, 1H), 2.46 (d, J=4.1, 1H), 2.39-2.21 (m, 3H),1.96-1.76 (m, 5H), 1.73-1.55 (m, 2H), 1.50 (s, 4.5H), 1.50 (s, 4.5H),1.34-1.23 (m, 1H), 0.91-0.82 (m, 6H); MS (ESI+) m/z 498 (M+H)⁺.

Example 138N²-(tert-butyloxycarbonyl)-N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-D-leucine for 1-phenylcyclopentanecarboxylicacid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.50 (d, J=7.0, 0.5H), 8.46 (d, J=6.8, 0.5H), 8.03 (dd, J=8.1, 17.2,1H), 7.74 (s, 1H), 7.71 (d, J=7.7, 1H), 7.61 (d, J=5.8, 1H), 7.48 (t,J=7.7, 1H), 4.67 (dd, J=8.3, 14.3, 0.5H), 4.61 (dd, J=7.9, 14.5, 0.5H),4.47 (ddd, J=7.0, 13.9, 17.8, 1H), 3.81 (d, J=13.1, 0.5H), 3.70 (d,J=13.1, 0.5H), 3.44 (d, J=13.3, 0.5H), 3.29 (d, J=13.2, 0.5H), 2.89 (t,J=13.2, 1H), 2.85-2.75 (m, 1H), 2.51-2.42 (m, 1H), 2.39-2.30 (m, 1H),2.28 (dd, J=6.1, 15.3, 2H), 1.97-1.77 (m, 4H), 1.73-1.55 (m, 2H), 1.50(s, 4.5H), 1.50 (s, 4.5H), 1.34-1.22 (m, 1H), 0.91-0.81 (m, 6H); MS(ESI+) m/z 498 (M+H)⁺.

Example 139N²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-D-leucine for1-phenylcyclopentanecarboxylic acid and(3aS*,4S*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 1: ¹H NMR (300 MHz, pyridine-d₅) δ ppm7.76 (d, J=15.9, 2H), 7.57 (s, 3H), 7.54-7.43 (m, 1H), 7.42-7.36 (m,0.5H), 7.34-7.21 (m, 1H), 4.86 (t, J=9.6, 0.5H), 4.48-4.35 (m, 0.5H),3.71 (d, J=13.3, 0.5H), 3.52 (d, J=13.4, 0.5H), 3.40 (d, J=13.2, 0.5H),2.98 (s, 1.5H), 2.97 (s, 1.5H), 2.77 (ddd, J=2.0, 7.2, 9.8, 2H),2.57-2.46 (m, 1H), 2.43 (dd, J=2.9, 9.2, 0.5H), 2.36 (dd, J=2.3, 6.4,0.5H), 2.34-2.22 (m, 2H), 1.93 (dddd, J=2.0, 6.2, 8.1, 14.3, 1H),1.85-1.59 (m, 4H), 1.52 (s, 4.5H), 1.50 (s, 4.5H), 1.39-1.28 (m, 1H),0.96-0.89 (m, 6H); MS (ESI+) m/z 512 (M+H)⁺.

Example 1406,6-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}hexanamide

The title compound was prepared by substituting6,6-bis(4-fluorophenyl)hexanoic acid for 1-phenylcyclopentanecarboxylicacid and(3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 2: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.31 (d, J=7.3, 1H), 7.77 (s, 1H), 7.61 (t, J=7.4, 1H), 7.57 (d, J=7.2,1H), 7.45 (t, J=7.7, 1H), 7.25 (dd, J=5.6, 8.2, 4H), 7.10 (t, J=8.7,4H), 4.46-4.37 (m, 1H), 3.90 (t, J=7.8, 1H), 3.61 (d, J=13.5, 1H), 3.47(d, J=13.5, 1H), 2.85-2.79 (m, 1H), 2.49 (d, J=16.3, 2H), 2.47-2.41 (m,1H), 2.30 (ddd, J=8.1, 15.0, 20.0, 4H), 2.15-2.06 (m, 1H), 1.98 (dd,J=7.8, 15.5, 2H), 1.90-1.79 (m, 3H), 1.60 (dt, J=7.4, 19.3, 1H),1.44-1.36 (m, 1H), 1.32 (dq, J=7.8, 15.3, 2H); MS (ESI+) m/z 571 (M+H)⁺.

Example 1413,3-diphenyl-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}propanamide

The title compound was prepared by substituting 3,3-diphenylpropanoicacid for 1-phenylcyclopentanecarboxylic acid and(3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 2: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.28 (d, J=7.4, 1H), 7.74 (s, 1H), 7.45 (t, J=7.7, 1H), 7.38 (dd, J=1.8,7.4, 4H), 7.28 (dt, J=7.6, 9.4, 4H), 7.20-7.17 (m, 4H), 5.00 (t, J=7.8,1H), 4.34-4.26 (m, 1H), 3.56 (d, J=13.5, 1H), 3.43 (d, J=13.5, 1H), 3.14(d, J=7.9, 2H), 2.65 (dd, J=2.1, 8.3, 1H), 2.45-2.36 (m, 1H), 2.36-2.28(m, 2H), 2.26-2.19 (m, 2H), 1.98-1.89 (m, 1H), 1.72 (ddd, J=6.3, 12.5,14.5, 1H), 1.43 (dt, J=7.4, 14.1, 1H), 1.34-1.25 (m, 1H); MS (ESI+) m/z493 (M+H)⁺.

Example 1425,5-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide

The title compound was prepared by substituting5,5-bis(4-fluorophenyl)pentanoic acid for 1-phenylcyclopentanecarboxylicacid and(3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 2: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.36 (d, J=7.2, 1H), 7.75 (s, 1H), 7.62-7.54 (m, 2H), 7.44 (t, J=7.7,1H), 7.24 (dt, J=5.7, 11.3, 4H), 7.07 (t, J=8.7, 4H), 4.47-4.39 (m, 1H),3.96 (t, J=7.8, 1H), 3.59 (d, J=13.5, 1H), 3.46 (d, J=13.5, 1H), 2.84(d, J=9.0, 1H), 2.51 (s, 2H), 2.42 (dd, J=7.0, 14.2, 3H), 2.30 (d,J=7.1, 1H), 2.27-2.22 (m, 1H), 2.15-2.06 (m, 3H), 1.85 (dd, J=6.2, 13.9,1H), 1.78 (dt, J=7.4, 15.1, 2H), 1.60 (dt, J=7.6, 14.6, 1H), 1.43-1.34(m, 1H); MS (ESI+) m/z 557 (M+H)⁺.

Example 1433,3-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}propanamide

The title compound was prepared by substituting3,3-bis(4-fluorophenyl)propanoic acid for 1-phenylcyclopentanecarboxylicacid and(3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 2: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.36 (d, J=7.4, 1H), 7.74 (s, 1H), 7.62-7.56 (m, 2H), 7.45 (t, J=7.7,1H), 7.32 (ddd, J=2.0, 5.4, 7.8, 4H), 7.07 (dt, J=8.7, 11.2, 4H),4.36-4.26 (m, 1H), 3.56 (d, J=13.5, 1H), 3.45 (d, J=13.5, 1H), 3.09 (d,J=7.9, 2H), 2.70-2.63 (m, 1H), 2.47-2.37 (m, 1H), 2.33 (t, J=6.7, 3H),2.26 (dd, J=3.0, 9.0, 1H), 2.24-2.18 (m, 1H), 1.96 (tt, J=6.0, 11.8,1H), 1.79-1.70 (m, 1H), 1.44 (dt, J=7.6, 14.4, 1H), 1.35-1.26 (m, 1H);MS (ESI+) m/z 529 (M+H)⁺.

Example 1444,4-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide

The title compound was prepared by substituting4,4-bis(4-fluorophenyl)butanoic acid for 1-phenylcyclopentanecarboxylicacid and(3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 2: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.39 (d, J=7.2, 1H), 7.77 (s, 1H), 7.62 (d, J=7.9, 2H), 7.45 (t, J=7.7,1H), 7.25 (dd, J=5.5, 7.3, 4H), 7.05 (t, J=8.7, 4H), 4.50-4.40 (m, 1H),4.08 (t, J=7.9, 1H), 3.61 (d, J=13.5, 1H), 3.49 (d, J=13.5, 1H), 2.87(dd, J=1.4, 8.8, 1H), 2.56 (dd, J=7.7, 15.3, 4H), 2.48 (d, J=8.8, 1H),2.31 (dd, J=8.0, 15.4, 4H), 2.13 (dq, J=6.0, 12.0, 1H), 1.87 (td, J=6.3,12.5, 1H), 1.62 (dt, J=7.4, 14.3, 1H), 1.41 (dd, J=11.7, 20.8, 1H); MS(ESI+) m/z 543 (M+H)⁺.

Example 1452,2-diphenyl-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting 2,2-diphenylacetic acidfor 1-phenylcyclopentanecarboxylic acid and(3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 2: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.94 (d, J=6.8, 1H), 7.74 (s, 2H), 7.64 (d, J=7.8, 4H), 7.47-7.40 (m,1H), 7.38-7.29 (m, 5H), 7.28-7.23 (m, 3H), 4.45-4.37 (m, 1H), 3.57 (d,J=13.5, 1H), 3.42 (d, J=13.5, 1H), 2.76 (dd, J=3.0, 9.1, 1H), 2.54-2.47(m, 1H), 2.47-2.42 (m, 1H), 2.39 (dd, J=7.3, 9.0, 1H), 2.23 (d, J=3.0,2H), 2.06 (dq, J=6.2, 12.2, 1H), 1.83-1.74 (m, 1H), 1.59 (dt, J=6.9,14.5, 1H), 1.33 (dt, J=6.3, 19.6, 1H); MS (ESI+) m/z 479 (M+H)⁺.

Example 1462,2-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting2,2-bis(4-fluorophenyl)acetic acid for 1-phenylcyclopentanecarboxylicacid and(3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 2: ¹H NMR (500 MHz, pyridine-d₅) δ ppm9.07 (d, J=7.1, 1H), 7.74 (s, 1H), 7.59 (s, 1H), 7.56 (d, J=5.3, 5H),7.44 (t, J=7.7, 1H), 7.12 (q, J=8.6, 4H), 5.23 (s, 1H), 4.45-4.36 (m,1H), 3.57 (d, J=13.5, 1H), 3.44 (d, J=13.5, 1H), 2.78 (dd, J=2.9, 9.1,1H), 2.56-2.49 (m, 1H), 2.49-2.44 (m, 1H), 2.41 (dd, J=7.3, 8.9, 1H),2.27-2.22 (m, 2H), 2.07 (dq, J=6.1, 12.1, 1H), 1.86-1.76 (m, 1H), 1.60(td, J=7.2, 14.6, 1H), 1.35 (td, J=6.3, 12.6, 1H); MS (ESI+) m/z 515(M+H)⁺.

Example 1473,3-dimethyl-2-phenyl-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide

The title compound was prepared by substituting3,3-dimethyl-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylicacid and(3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 2: ¹H NMR (400 MHz,) δ ppm 8.47 (t,J=6.7, 1H), 7.77 (s, 0.5H), 7.71 (d, J=7.3, 2H), 7.60 (d, J=7.7, 0.5H),7.54 (s, 1H), 7.43 (dd, J=8.1, 16.6, 1H), 7.35-7.24 (m, 4H), 4.39-4.29(m, 1H), 3.62 (d, J=13.6, 0.5H), 3.53 (d, J=13.5, 0.5H), 3.47 (d,J=13.6, 0.5H), 3.44 (s, 1H), 3.38 (d, J=13.5, 0.5H), 2.92 (dd, J=2.9,9.0, 0.5H), 2.62-2.54 (m, 1H), 2.54-2.46 (m, 1H), 2.46-2.36 (m, 0.5H),2.32 (dd, J=9.1, 12.0, 1H), 2.27 (d, J=5.2, 1H), 2.21 (d, J=5.6, 1H),2.17-2.07 (m, 0.5H), 1.86 (ddd, J=6.4, 13.3, 21.3, 1H), 1.71 (tdd,J=6.4, 13.0, 19.3, 1H), 1.36 (ddt, J=8.2, 14.4, 20.6, 1.5H), 1.14 (d,J=1.3, 9H); MS (ESI+) m/z 459 (M+H)⁺.

Example 148N²-(tert-butyloxycarbonyl)-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-L-leucine for 1-phenylcyclopentanecarboxylicacid and(3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 2: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.66 (dd, J=7.6, 11.3, 1H), 7.98 (d, J=6.0, 1H), 7.74 (d, J=7.5, 1H),7.58 (d, J=21.6, 2H), 7.44 (t, J=7.8, 1H), 4.74-4.66 (m, 1H), 4.45-4.36(m, 1H), 3.58 (t, J=13.6, 1H), 3.43 (dd, J=13.6, 20.1, 1H), 2.81 (s,0.5H), 2.73 (s, 0.5H), 2.57 (s, 0.5H), 2.47 (d, J=9.1, 2H), 2.34 (s,0.5H), 2.26 (d, J=6.7, 1H), 2.24-2.20 (m, 0.5H), 2.11 (s, 1H), 2.07-1.99(m, 0.5H), 1.87 (s, 4H), 1.71-1.62 (m, 0.5H), 1.61-1.55 (m, 0.5H), 1.50(d, J=2.8, 9H), 1.40 (s, 1H), 0.87 (d, J=5.8, 3H), 0.84 (d, J=5.5, 3H);MS (ESI+) m/z 498 (M+H)⁺.

Example 149N²-(tert-butyloxycarbonyl)-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-D-leucine for 1-phenylcyclopentanecarboxylicacid and(3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 2: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.66 (dd, J=7.4, 11.1, 1H), 7.97 (d, J=6.0, 1H), 7.74 (d, J=7.6, 1H),7.57 (d, J=10.9, 2H), 7.44 (dd, J=5.9, 13.6, 1H), 4.74-4.66 (m, 1H),4.41 (dd, J=6.2, 11.5, 1H), 3.58 (t, J=13.4, 1H), 3.43 (dd, J=13.6,19.7, 1H), 2.82 (dd, J=2.4, 9.0, 0.5H), 2.74 (d, J=8.7, 0.5H), 2.62-2.54(m, 0.5H), 2.54-2.43 (m, 2H), 2.37-2.32 (m, 0.5H), 2.27 (d, J=6.7, 1H),2.24-2.19 (m, 0.5H), 2.16-2.08 (m, 0.5H), 2.06-1.99 (m, 0.5H), 1.94-1.78(m, 4.5H), 1.66 (dt, J=7.2, 19.6, 0.5H), 1.62-1.56 (m, 0.5H), 1.50 (d,J=2.9, 9H), 1.43-1.31 (m, 1H), 0.86 (dd, J=5.7, 13.5, 6H); MS (ESI+) m/z498 (M+H)⁺.

Example 150N²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-D-leucine for1-phenylcyclopentanecarboxylic acid and(3aS*,4R*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described for Example 2: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.31 (s, 1H), 7.75 (s, 1H), 7.57 (d, J=11.6, 2H), 7.44 (t, J=7.7, 1H),5.18-5.09 (m, 0.5H), 4.84-4.73 (m, 0.5H), 4.44-4.32 (m, 1H), 3.59 (d,J=13.5, 1H), 3.47 (d, J=13.6, 1H), 3.07 (d, J=25.1, 2.5H), 2.83 (d,J=8.5, 0.5H), 2.79-2.72 (m, 0.5H), 2.55-2.44 (m, 2H), 2.44-2.39 (m, 1H),2.37-2.33 (m, 0.5H), 2.29 (d, J=7.4, 1H), 2.23 (dd, J=7.9, 15.2, 1H),2.08 (dt, J=5.2, 11.8, 1H), 1.88-1.78 (m, 3H), 1.64-1.51 (m, 2H), 1.46(s, 9H), 1.41-1.33 (m, 1H), 0.88 (d, J=6.4, 3H), 0.84 (d, J=6.5, 3H); MS(ESI+) m/z 512 (M+H)⁺.

Example 151N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-leucine for1-phenylcyclopentanecarboxylic acid in the procedure described forExample 2: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.28 (d, J=6.6, 1H), 7.41(s, 2H), 7.38-7.34 (m, 2H), 7.27 (t, J=7.3, 1H), 5.16-5.11 (m, 0.5H),4.82-4.74 (m, 0.5H), 4.44-4.33 (m, 1H), 3.57 (s, 1H), 3.46-3.38 (m, 1H),3.07 (d, J=26.9, 3H), 2.89-2.82 (m, 0.5H), 2.80-2.73 (m, 1H), 2.50-2.43(m, 2H), 2.40-2.29 (m, 2H), 2.24-2.19 (m, 1H), 2.10 (dq, J=5.8, 11.6,1H), 1.92-1.87 (m, 0.5H), 1.83 (dd, J=5.2, 9.3, 2H), 1.64-1.51 (m, 2H),1.46 (s, 9H), 1.42-1.35 (m, 1H), 0.88 (d, J=6.3, 3H), 0.84 (d, J=6.6,3H); MS (ESI+) m/z 444 (M+H)⁺.

Example 1522,2-dicyclohexyl-2-hydroxy-N-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

Step A: (3aS,4S,6aR)-2-(3-(Trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminewas prepared according to the procedure described in Example 14 StepA-C. Substituting2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[c]pyrrol-4(5H)-one fromSteps A-C in Example 122 for2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-one in Step A of Example 14gave(S,E)-2-methyl-N-((3aR,6aS)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)propane-2-sulfinamideand(S,E)-2-methyl-N-((3aS,6aR)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)propane-2-sulfinamide.(S,E)-2-Methyl-N-((3aS,6aR)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)propane-2-sulfinamidewas used as described in Example 14 Steps B-C to give (3aS,4S,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine:¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.72 (s, 1H), 7.59 (d, J=12.2, 1H),7.54 (d, J=7.7, 1H), 7.39 (t, J=7.7, 1H), 3.71-3.66 (m, 1H), 3.64 (d,J=13.3, 1H), 3.49 (d, J=13.3, 1H), 3.22 (dd, J=3.7, 9.9, 1H), 2.77 (qd,J=3.8, 7.9, 1H), 2.49 (dd, J=8.9, 16.7, 2H), 2.39 (t, J=8.3, 1H), 2.29(dd, J=3.4, 9.0, 1H), 2.10 (ddd, J=6.1, 9.7, 15.6, 1H), 1.90 (td, J=5.9,12.0, 1H), 1.69-1.60 (m, 1H), 1.42 (dt, J=5.6, 12.2, 1H); MS (ESI+) m/z284 (M+H)⁺.

Step B: The title compound was prepared by substituting2,2-dicyclohexyl-2-hydroxyacetic acid for 3-methyl-2-phenylbutanoic acidand(3aS,4S,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A for(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Step D of Example 14: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.45 (br s, 1H), 7.85 (s, 1H), 7.75 (d, J=7.4, 1H),7.54 (d, J=7.6, 1H), 7.36 (dd, J=5.4, 13.2, 1H), 5.93 (br s, 1H),4.64-4.57 (m, 1H), 3.85 (d, J=13.2, 1H), 3.29 (d, J=13.2, 1H), 2.92 (d,J=9.5, 1H), 2.66 (dd, J=7.4, 15.2, 1H), 2.49-2.41 (m, 1H), 2.39 (d,J=9.1, 1H), 2.24-2.01 (m, 5H), 1.96-1.83 (m, 4H), 1.83-1.70 (m, 6H),1.63 (t, J=13.2, 2H), 1.58-1.49 (m, 1H), 1.45-1.08 (m, 10H); MS (ESI+)m/z 507 (M+H)⁺.

Example 153N²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-leucine for 3-methyl-2-phenylbutanoicacid and(3aS,4S,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom 152 Step A for(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Step D of Example 14: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.01 (s, 1H), 7.83 (s, 1H), 7.76 (s, 1H), 7.64 (d,J=7.7, 2H), 5.12-5.04 (m, 1H), 4.42 (s, 1H), 3.61 (s, 1H), 3.52 (s, 1H),3.12-2.97 (m, 3H), 2.78 (s, 1H), 2.72 (d, J=9.5, 1H), 2.50-2.41 (m, 1H),2.37 (d, J=7.3, 1H), 2.32-2.16 (m, 2H), 1.98-1.72 (m, 3H), 1.64 (dt,J=6.8, 14.9, 1H), 1.60-1.53 (m, 2H), 1.50 (s, 9H), 1.33-1.20 (m, 1H),0.89 (d, J=6.5, 6H); MS (ESI+) m/z 512 (M+H)⁺.

Example 1542,2-dicyclohexyl-2-hydroxy-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

Step A:(3aS,4R,6aR)-2-(3-(Trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminewas prepared according to the procedure described in Example 16 StepsA-E substituting(S,E)-2-methyl-N-((3aS,6aR)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)propane-2-sulfinamidefrom Step A in Example 152 for(S,E)-N-((3aS,6aR)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)-2-methylpropane-2-sulfinamidein Step A-E of Example 16 to give (3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine:¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.78 (s, 1H), 7.59 (d, J=6.0, 2H),7.45 (t, J=7.7, 1H), 4.94 (br s, 2H), 3.53 (s, 2H), 3.13 (dd, J=5.1,11.6, 1H), 2.63-2.54 (m, 1H), 2.49 (dd, J=3.3, 9.0, 1H), 2.35 (dd,J=7.5, 9.0, 1H), 2.32 (d, J=5.9, 2H), 2.21-2.13 (m, 1H), 1.96 (dt,J=6.0, 8.7, 1H), 1.88 (td, J=3.9, 9.7, 1H), 1.38-1.29 (m, 2H); MS (ESI+)m/z 284 (M+H)⁺.

Step B: The title compound was prepared by substituting(3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A for(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine and2,2-dicyclohexyl-2-hydroxyacetic acid for (S)-2-phenylbutanoic acid inthe procedure described in Step F of Example 16: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.75 (s, 1H), 7.70 (d, J=7.8, 1H), 7.63-7.54 (m, 1H),7.44 (t, J=7.7, 1H), 6.25-6.09 (m, 1H), 4.45-4.37 (m, 1H), 3.61 (d,J=13.5, 1H), 3.44 (d, J=13.5, 1H), 2.91 (dd, J=2.1, 9.0, 1H), 2.58-2.46(m, 1H), 2.40 (dd, J=7.1, 8.8, 1H), 2.33 (dd, J=2.3, 8.9, 1H), 2.22 (dd,J=7.0, 8.7, 1H), 2.19-2.04 (m, 5H), 1.94-1.82 (m, 4H), 1.82-1.71 (m,4H), 1.63 (s, 3H), 1.58-1.46 (m, 1H), 1.37 (s, 4H), 1.25 (s, 7H); MS(ESI+) m/z 507 (M+H)⁺.

Example 155N²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substituting(3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 154 Step A for(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine andN-(tert-butoxycarbonyl)-N-methyl-L-leucine for (S)-2-phenylbutanoic acidin the procedure described in Step F of Example 16: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.30 (s, 1H), 7.74 (s, 1H), 7.57 (d, J=9.4, 2H), 7.44(t, J=7.7, 1H), 5.21-5.04 (m, 1H), 4.37 (s, 1H), 3.58 (d, J=12.2, 1H),3.44 (d, J=13.8, 1H), 3.07 (d, J=25.6, 3H), 2.77 (d, J=8.6, 1H), 2.47(s, 2H), 2.41-2.32 (m, 1H), 2.29 (d, J=7.2, 1H), 2.25-2.18 (m, 1H), 2.08(dq, J=5.8, 11.7, 1H), 1.83 (dd, J=5.4, 9.0, 3H), 1.64-1.52 (m, 2H),1.46 (s, 9H), 1.41-1.32 (m, 1H), 0.88 (d, J=6.3, 3H), 0.84 (d, J=6.5,3H); MS (ESI+) m/z 512 (M+H)⁺.

Example 1562,2-dicyclohexyl-N-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

Step A:(3aR,4S,6aS)-2-(3-(Trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminewas prepared according to the procedure described in Example 16 Step A-Esubstituting(S,E)-2-methyl-N-((3aR,6a5)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)propane-2-sulfinamidefrom Example 152 Step A for(S,E)-N-((3aS,6aR)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)-2-methylpropane-2-sulfinamideprepared in Step A of Example 14 to give(3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine:¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.78 (s, 1H), 7.59 (d, J=11.1, 2H),7.45 (t, J=7.7, 1H), 4.94 (br s, 2H), 3.14 (dd, J=5.2, 11.5, 1H), 2.58(tt, J=5.1, 10.1, 1H), 2.49 (dd, J=3.3, 9.0, 1H), 2.35 (dd, J=7.5, 9.0,1H), 2.31 (d, J=5.8, 2H), 2.21-2.14 (m, 1H), 2.01-1.91 (m, 1H), 1.88(td, J=4.2, 9.9, 1H), 1.38-1.29 (m, 2H).

Step B: The title compound was prepared by substituting(3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A for(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine and2,2-dicyclohexylacetic acid for (S)-2-phenylbutanoic acid in theprocedure described for Example 16 Step F: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.13 (d, J=7.2, 1H), 7.76 (s, 1H), 7.63-7.53 (m, 2H), 7.44 (t,J=7.9, 1H), 4.51-4.43 (m, 1H), 3.61 (d, J=13.5, 1H), 3.46 (d, J=13.5,1H), 2.88 (dd, J=2.8, 9.0, 1H), 2.63-2.52 (m, 2H), 2.49 (dd, J=7.1, 8.9,1H), 2.32-2.27 (m, 2H), 2.13 (dq, J=6.1, 11.9, 1H), 2.03 (t, J=7.4, 1H),1.96 (d, J=13.0, 2H), 1.92-1.83 (m, 3H), 1.80 (d, J=12.2, 2H), 1.75-1.68(m, 4H), 1.67-1.63 (m, 1H), 1.63-1.57 (m, 2H), 1.50-1.37 (m, 3H),1.30-1.18 (m, 4H), 1.12 (dtd, J=2.7, 12.5, 24.6, 4H); MS (ESI+) m/z 491(M+H)⁺.

Example 1572,2-dicyclohexyl-N-{(3aR,4R,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

Step A:(3aR,4R,6aS)-2-(3-(Trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminewas prepared according to the procedure described in Example 14 StepsB-C substituting(S,E)-2-methyl-N-((3aR,6aS)-2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)propane-2-sulfinamidefrom Example 152 Step A for(S,E)-N-((3aS,6aR)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)-2-methylpropane-2-sulfinamideprepared in Step A of Example 14 to give(3aR,4R,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine:¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.78 (s, 1H), 7.59 (d, J=11.1, 2H),7.45 (t, J=7.7, 1H), 4.94 (br s, 2H), 3.14 (dd, J=5.2, 11.5, 1H), 2.58(tt, J=5.1, 10.1, 1H), 2.49 (dd, J=3.3, 9.0, 1H), 2.35 (dd, J=7.5, 9.0,1H), 2.31 (d, J=5.8, 2H), 2.21-2.14 (m, 1H), 2.00-1.92 (m, 1H), 1.88(td, J=4.2, 9.9, 1H), 1.39-1.29 (m, 2H); MS (ESI+) m/z 284 (M+H)⁺.

Step B: The title compound was prepared by substituting2,2-dicyclohexylacetic acid for 3-methyl-2-phenylbutanoic acid in and(3aR,4R,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A for(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Step D of Example 14: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.73 (s, 1H), 7.66 (d, J=7.7, 1H), 7.55 (d, J=7.3,2H), 7.50 (t, J=7.7, 1H), 4.50-4.43 (m, 1H), 3.54 (d, J=12.9, 1H), 3.46(d, J=12.9, 1H), 2.74 (td, J=2.6, 10.5, 2H), 2.51-2.42 (m, 2H), 2.31 (t,J=8.3, 1H), 2.20 (dd, J=7.8, 9.8, 1H), 1.94-1.54 (m, 15H), 1.46 (d,J=13.0, 1H), 1.40 (d, J=14.4, 1H), 1.35-1.07 (m, 9H), 0.98 (qd, J=3.0,12.3, 1H); MS (ESI+) m/z 491 (M+H)⁺.

Example 158N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

N²-(tert-butyloxycarbonyl)-N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide(140 mg, 0.281 mmol) from Example 137 and 2 NHCl (2.5 mL, 5.00 mmol)were combined in ether, and the reaction was stirred at room temperatureovernight. The solids were collected and dried to give the titlecompound as the hydrochloride salt: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.59 (s, 0.5H), 8.48 (s, 0.5H), 7.89 (s, 0.5H), 7.83 (s, 0.5H), 7.69 (t,J=6.8, 1H), 7.60 (d, J=7.8, 1H), 7.50-7.44 (m, 1H), 4.96 (br s, 2H),4.57-4.48 (m, 1H), 3.73 (d, J=13.2, 0.5H), 3.67 (s, 1H), 3.64 (d,J=13.2, 1H), 3.39 (d, J=13.1, 0.5H), 3.35 (d, J=13.2, 0.5H), 2.81-2.70(m, 2H), 2.45 (dd, J=7.5, 15.3, 1H), 2.39-2.31 (m, 1H), 2.27-2.14 (m,2H), 1.95-1.79 (m, 2.5H), 1.72-1.56 (m, 2H), 1.53-1.46 (m, 0.5H),1.33-1.23 (m, 1.5H), 0.90 (dt, J=6.2, 14.1, 6H); MS (ESI+) m/z 398(M+H)⁺.

Example 159N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide

The title compound was prepared by substitutingN²-(tert-butyloxycarbonyl)-N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamidefrom Example 138 forN²-(tert-butyloxycarbonyl)-N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described for Example 158: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.67 (d, J=7.4, 0.5H), 8.57 (d, J=7.6, 0.5H), 7.88(s, 0.5H), 7.81 (s, 0.5H), 7.68 (d, J=7.3, 1H), 7.61 (s, 1H), 7.48 (dd,J=7.3, 14.5, 1H), 4.56-4.47 (m, 1H), 3.79-3.70 (m, 1H), 3.65 (d, J=13.2,0.5H), 3.38 (t, J=13.5, 1H), 2.82-2.71 (m, 2H), 2.50-2.42 (m, 1H),2.38-2.31 (m, 1H), 2.27-2.16 (m, 2H), 2.08 (dt, J=6.8, 19.9, 0.5H),1.96-1.88 (m, 1.5H), 1.88-1.80 (m, 1H), 1.70-1.59 (m, 2H), 1.58-1.52 (m,0.5H), 1.42-1.20 (m, 4H), 0.90 (dt, J=6.1, 13.2, 6H); MS (ESI+) m/z 398(M+H)⁺.

Example 160N²-methyl-N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide

The title compound was prepared by substitutingN²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamidefrom Example 139 forN²-(tert-butyloxycarbonyl)-N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described for Example 158: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.52 (s, 0.5H), 8.29 (s, 0.5H), 7.92 (s, 0.5H), 7.79(s, 0.5H), 7.69 (dd, J=7.6, 18.7, 1H), 7.62 (d, J=7.6, 1H), 7.48 (dd,J=7.8, 18.2, 1H), 4.59-4.48 (m, 1H), 3.82 (d, J=13.2, 0.5H), 3.63 (d,J=13.1, 0.5H), 3.42 (d, J=13.1, 0.5H), 3.31-3.18 (m, 1H), 2.81 (dd,J=1.9, 9.4, 0.5H), 2.74 (dd, J=8.5, 18.2, 1H), 2.50-2.43 (m, 1H), 2.41(s, 1.5H), 2.40 (s, 1.5H), 2.33 (dd, J=1.9, 9.0, 0.5H), 2.25 (dd, J=7.3,9.4, 0.5H), 2.21-2.03 (m, 1.5H), 1.92-1.81 (m, 2H), 1.80-1.48 (m, 4H),1.42-1.21 (m, 3.5H), 0.94 (d, J=6.6, 1.5H), 0.93 (d, J=6.6, 1.5H), 0.90(d, J=6.6, 1.5H), 0.87 (d, J=6.6, 1.5H); MS (ESI+) m/z 412 (M+H)⁺.

Example 161N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingN²-(tert-butyloxycarbonyl)-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 148 forN²-(tert-butyloxycarbonyl)-N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described for Example 158: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 9.33 (s, 1H), 7.76 (s, 1H), 7.63-7.58 (m, 2H), 7.45(d, J=4.3, 1H), 4.40 (dd, J=6.5, 12.5, 1H), 3.63-3.53 (m, 1H), 3.46 (dd,J=6.1, 13.6, 1H), 2.82-2.73 (m, 1H), 2.69-2.51 (m, 2H), 2.48-2.38 (m,1H), 2.33 (dd, J=8.8, 16.3, 1H), 2.24 (dd, J=7.6, 16.5, 1H), 2.16-1.88(m, 5H), 1.85 (dt, J=7.8, 15.2, 0.5H), 1.76-1.62 (m, 1H), 1.39 (qd,J=6.6, 14.9, 1.5H), 1.31-1.20 (m, 2H), 0.95 (d, J=6.0, 3H), 0.91 (dd,J=3.2, 5.6, 3H); MS (ESI+) m/z 398 (M+H)⁺.

Example 162N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide

The title compound was prepared by substitutingN²-(tert-butyloxycarbonyl)-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamidefrom Example 149 forN²-(tert-butyloxycarbonyl)-N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described for Example 158: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.31 (s, 1H), 7.75 (s, 1H), 7.62-7.53 (m, 2H), 7.44(dd, J=7.4, 15.0, 1H), 4.44-4.35 (m, 1H), 3.60 (d, J=13.5, 2H), 3.46(dd, J=5.5, 13.5, 1H), 2.87-2.79 (m, 1H), 2.57-2.43 (m, 2H), 2.42-2.37(m, 1H), 2.32 (dt, J=3.0, 8.8, 1H), 2.27-2.20 (m, 1H), 2.08 (td, J=6.0,12.2, 1H), 1.96-1.80 (m, 3H), 1.61-1.50 (m, 2H), 1.44-1.35 (m, 1H),1.30-1.19 (m, 2H), 0.90 (d, J=6.2, 3H), 0.85 (d, J=6.2, 3H); MS (ESI+)m/z 398 (M+H)⁺.

Example 163N²-methyl-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide

The title compound was prepared by substitutingN²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamidefrom Example 150 forN²-(tert-butyloxycarbonyl)-N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described for Example 158: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.32 (d, J=6.0, 1H), 7.76 (s, 1H), 7.61 (d, J=7.6,1H), 7.55 (d, J=14.8, 1H), 7.45 (t, J=7.7, 1H), 4.47-4.40 (m, 1H), 3.61(d, J=13.5, 1H), 3.47 (dd, J=3.1, 13.6, 1H), 3.30 (t, J=6.7, 1H), 2.86(d, J=8.9, 1H), 2.59-2.51 (m, 1H), 2.46 (d, J=2.5, 3H), 2.42 (dd, J=8.5,15.4, 1H), 2.35-2.30(m, 1H), 2.28-2.23 (m, 1H), 2.14-2.05 (m, 1H),1.93-1.82 (m, 2H), 1.74 (ddd, J=4.0, 9.7, 13.7, 1H), 1.62 (dt, J=7.4,15.4, 1H), 1.40 (dt, J=14.2, 15.7, 1H), 1.3-1.22 (m, 3H), 0.91 (dt,J=3.0, 6.0, 3H), 0.85 (d, J=6.7, 3H); MS (ESI+) m/z 412 (M+H)⁺.

Example 164N²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingN²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 153 forN²-(tert-butyloxycarbonyl)-N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described for Example 158: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.56 (d, J=7.4, 1H), 7.91 (s, 1H), 7.67 (d, J=7.6,1H), 7.61 (d, J=7.8, 1H), 7.47 (t, J=7.7, 1H), 4.54 (dt, J=6.6, 13.2,1H), 3.81 (d, J=13.2, 1H), 3.32 (dd, J=6.0, 7.9, 1H), 3.28 (d, J=13.2,1H), 2.81 (d, J=9.5, 1H), 2.78-2.71 (m, 1H), 2.48-2.44 (m, 1H), 2.42 (s,3H), 2.33 (d, J=9.1, 1H), 2.26 (dd, J=7.4, 9.3, 1H), 2.16-2.11 (m, 1H),1.91-1.83 (m, 2H), 1.82-1.75 (m, 1H), 1.65 (ddq, J=6.3, 12.1, 18.8, 3H),1.26 (td, J=6.2, 12.7, 1H), 0.95 (d, J=6.5, 3H), 0.90 (d, J=6.6, 3H); MS(ESI+) m/z 412 (M+H)⁺.

Example 165N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide

The title compound was prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Example 151 forN²-(tert-butyloxycarbonyl)-N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described for Example 158: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.35 (d, J=6.9, 1H), 7.44 (d, J=7.4, 2H), 7.37 (t,J=7.6, 2H), 7.27 (t, J=7.3, 1H), 4.50-4.42 (m, 1H), 3.61 (d, J=13.1,1H), 3.45 (d, J=13.2, 1H), 3.33 (t, J=7.0, 1H), 2.87 (d, J=8.7, 1H),2.56-2.50 (m, 1H), 2.47 (s, 3H), 2.43 (dd, J=5.5, 14.6, 1H), 2.37 (d,J=8.7, 1H), 2.29-2.23 (m, 1H), 2.17-2.04 (m, 1H), 1.94-1.82 (m, 2H),1.79-1.73 (m, 1H), 1.68-1.57 (m, 1H), 1.41 (dd, J=7.2, 13.5, 1H), 1.27(s, 2H), 0.92 (d, J=6.6, 3H), 0.85 (d, J=6.6, 3H); MS (ESI+) m/z 344(M+H)⁺.

Example 166N²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingN²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 155 forN²-(tert-butyloxycarbonyl)-N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described for Example 158: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.09-7.97 (m, 1H), 7.76 (s, 1H), 7.63-7.61 (m, 1H),7.45 (d, J=7.6, 1H), 7.42 (d, J=7.6, 1H), 4.49-4.40 (m, 1H), 3.60 (d,J=12.4, 1H), 3.47 (d, J=13.6, 1H), 2.87 (d, J=7.6, 1H), 2.59 (d, J=9.4,4H), 2.43 (dt, J=7.2, 9.1, 1H), 2.34 (dd, J=1.7, 8.9, 1H), 2.28-2.23 (m,1H), 2.16-2.03 (m, 2H), 1.98-1.77 (m, 3H), 1.70-1.61 (m, 1H), 1.46-1.33(m, 1H), 1.32-1.21 (m, 2H), 0.93 (d, J=6.4, 3H), 0.86 (d, J=6.4, 3H); MS(ESI+) m/z 412 (M+H)⁺.

Example 167N²-methyl-N²-(methylsulfonyl)-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

ToN²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 164 (122 mg, 0.296 mmol) in dichloromethane (0.5 mL) wasadded N,N-diisopropylethylamine (78 μL, 0.445 mmol) followed bymethanesulfonyl chloride (25.4 μL, 0.326 mmol), and the reaction mixturewas stirred at room temperature overnight. The reaction was reduced involume and loaded onto a silica gel cartridge (Analogix®, Burlington,Wis., RS-12). The title compound was eluted with a gradient of 0% to 5%methanol (2 N ammonia)/dichloromethane over 20 minutes: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.59 (d, J=6.7, 1H), 7.73 (s, 1H), 7.66 (d, J=7.6,1H), 7.62 (d, J=7.8, 1H), 7.51 (t, J=7.7, 1H), 4.78 (dd, J=6.2, 9.5,1H), 4.41-4.33 (m, 1H), 3.67 (d, J=13.3, 1H), 3.16 (s, 3H), 3.15 (s,3H), 2.90 (qd, J=3.3, 7.9, 1H), 2.75 (dd, J=3.3, 9.6, 1H), 2.53-2.44 (m,1H), 2.38-2.29 (m, 3H), 1.89-1.70 (m, 4H), 1.70-1.58 (m, 3H), 1.36-1.26(m, 1H), 0.83 (d, J=6.6, 3H), 0.81 (d, J=6.5, 3H); MS (ESI+) m/z 490(M+H)⁺.

Example 168N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-N²-(methylsulfonyl)-L-leucinamide

The title compound was prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamidefrom Example 165 forN²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described in Example 167: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.97 (d, J=7.0, 1H), 7.43 (d, J=7.3, 2H), 7.37 (d, J=7.3, 2H),7.30-7.25 (m, 1H), 4.78 (dd, J=5.1, 10.2, 1H), 4.42-4.35 (m, 1H), 3.58(d, J=13.1, 1H), 3.46 (d, J=13.2, 1H), 3.21 (s, 3H), 3.12 (s, 3H), 2.83(d, J=8.7, 1H), 2.55-2.47 (m, 2H), 2.36 (dd, J=8.1, 14.7, 2H), 2.26-2.22(m, 1H), 2.13 (dt, J=5.9, 11.7, 1H), 1.93-1.82 (m, 2H), 1.70-1.61 (m,2H), 1.44-1.36 (m, 1H), 0.82 (d, J=6.2, 3H), 0.73 (d, J=5.9, 3H); MS(ESI+) m/z 422 (M+H)⁺.

Example 169N²-methyl-N²-(methylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingN²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 166 forN²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described in Example 167: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.98 (d, J=7.4, 1H), 7.77 (s, 1H), 7.62-7.58 (m, 2H), 7.45 (t,J=7.7, 1H), 4.78 (dd, J=5.0, 10.2, 1H), 4.41-4.33 (m, 1H), 3.59 (d,J=13.5, 1H), 3.48 (d, J=13.6, 1H), 3.21 (s, 3H), 3.12 (s, 3H), 2.84 (d,J=7.4, 1H), 2.51 (t, J=5.4, 2H), 2.37 (dd, J=6.9, 8.9, 1H), 2.32 (d,J=7.1, 1H), 2.23 (dd, J=6.8, 8.9, 1H), 2.11 (dd, J=5.8, 11.8, 1H),1.93-1.82 (m, 2H), 1.70-1.61 (m, 3H), 1.44-1.35 (m, 1H), 0.82 (d, J=6.2,3H), 0.73 (d, J=6.0, 3H); MS (ESI+) m/z 490 (M+H)⁺.

Example 170N²-(methylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

Step A: N-(tert-Butoxycarbonyl)-L-leucine (180 mg, 0.778 mmol),hydroxybenzotriazole (119 mg, 0.778 mmol), and(3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine(201 mg, 0.707 mmol) from Example 154 Step A were combined indichloromethane (1 mL). After 20 minutes,N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (0.138 mL, 0.778 mmol) wasadded and the reaction stirred at room temperature for 24 hours. Thereaction was quenched with water, and the layers were separated. Theaqueous layer extracted with 1 mL of dichloromethane. The combinedorganic layers were applied to a silica gel cartridge (Analogix®,Burlington, Wis., RS15-24) and eluted with 1-10% methanol (2 Nammonia)/dichloromethane to giveN²-(tert-butyloxycarbonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.66 (d, J=7.1, 1H), 7.97 (d, J=8.5,1H), 7.73 (s, 1H), 7.56 (s, 2H), 7.44 (t, J=7.7, 1H), 4.70 (dd, J=5.9,11.0, 1H), 4.40 (br s, 1H), 3.56 (d, J=13.5, 1H), 3.41 (d, J=13.5, 1H),2.74 (d, J=8.9, 1H), 2.48 (s, 2H), 2.37-2.31 (m, 1H), 2.27 (d, J=8.4,1H), 2.24-2.19 (m, 1H), 2.12 (dq, J=6.0, 12.0, 1H), 1.91-1.81 (m, 4H),1.66 (td, J=7.4, 14.7, 1H), 1.50 (s, 9H), 1.43-1.35 (m, 1H), 0.87 (d,J=5.9, 3H), 0.84 (d, J=5.6, 3H); MS (ESI+) m/z 498 (M+H)⁺.

Step B:N²-(tert-Butyloxycarbonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Step A (0.731 g, 1.469 mmol) in ethanol (5 mL) was treated with HCl(4 N in dioxane, 10.0 mL, 40.0 mmol). The reaction was stirred at roomtemperature for 2 hours and the solvent removed in vacuo. The reactionwas quenched with saturated aqueous sodium bicarbonate and extractedwith 3×50 mL of dichloromethane. The solvent was removed in vacuo togiveN¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.27 (d, J=7.6, 1H), 7.75 (s, 1H),7.63-7.54 (m, 2H), 7.44 (dd, J=6.9, 14.6, 1H), 4.44-4.33 (m, 1H),3.62-3.53 (m, 2H), 3.45 (d, J=13.5, 1H), 2.84 (dd, J=2.5, 8.9, 1H), 2.52(dd, J=7.2, 14.0, 1H), 2.50-2.43 (m, 1H), 2.42-2.37 (m, 1H), 2.32 (dd,J=2.8, 9.0, 1H), 2.23 (dd, J=7.2, 8.8, 1H), 2.09 (td, J=6.0, 12.0, 2H),1.94-1.81 (m, 4H), 1.61-1.50 (m, 2H), 1.39 (ddt, J=6.3, 8.7, 12.6, 1H),0.90 (d, J=6.4, 3H), 0.84 (d, J=6.3, 3H); MS (ESI+) m/z 398 (M+H)⁺.

Step C: The title compound was prepared by substitutingN¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Step B forN²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described in Example 167: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.41 (d, J=9.4, 1H), 9.22 (d, J=7.3, 1H), 7.76 (s, 1H), 7.59 (d,J=14.0, 2H), 7.43 (dd, J=6.2, 13.9, 1H), 4.47 (tt, J=6.3, 12.5, 2H),3.59 (d, J=13.5, 1H), 3.48 (d, J=13.6, 1H), 3.17 (s, 3H), 2.87 (dd,J=2.3, 9.1, 1H), 2.59-2.50 (m, 2H), 2.38 (dd, J=7.0, 9.0, 1H), 2.34 (dd,J=2.3, 9.0, 1H), 2.24 (dd, J=6.9, 8.8, 1H), 2.20-2.12 (m, 1H), 1.99 (dq,J=6.7, 20.2, 1H), 1.89 (ddd, J=6.0, 10.8, 15.0, 2H), 1.80-1.66 (m, 2H),1.43 (ddd, J=6.3, 10.7, 12.2, 1H), 0.82 (d, J=6.7, 3H), 0.79 (d, J=6.6,3H); MS (ESI+) m/z 476 (M+H)⁺.

Example 171N²-(methylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-D-leucine for N-(tert-butoxycarbonyl)-L-leucinein the procedure described in Step A and then following the proceduresdescribed in Steps B and C of Example 170: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.42 (d, J=9.3, 1H), 9.22 (d, J=7.3, 1H), 7.78 (s, 1H), 7.61 (d,J=7.7, 2H), 7.44 (dd, J=8.7, 16.4, 1H), 4.51-4.41 (m, 2H), 3.62 (d,J=13.5, 1H), 3.49 (d, J=13.6, 1H), 3.19 (s, 3H), 2.87 (dd, J=2.8, 9.1,1H), 2.66-2.60 (m, 1H), 2.55 (dd, J=9.0, 15.6, 1H), 2.49 (dd, J=7.3,9.0, 1H), 2.33 (dd, J=3.0, 9.0, 1H), 2.30-2.25 (m, 1H), 2.12 (dq, J=5.8,11.9, 1H), 1.98 (td, J=6.7, 13.5, 1H), 1.93-1.83 (m, 2H), 1.77 (ddd,J=5.6, 8.5, 13.8, 1H), 1.63 (dt, J=7.5, 19.4, 1H), 1.45-1.36 (m, 1H),0.82 (d, J=6.7, 3H), 0.78 (d, J=6.5, 3H); MS (ESI+) m/z 476 (M+H)⁺.

Example 172N²-(cyclopropylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substituting cyclopropanesulfonylchloride for methanesulfonyl chloride andN¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 170 Step B forN²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described in Example 167: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.34 (d, J=9.4, 1H), 9.03 (d, J=7.2, 1H), 7.76 (s, 1H), 7.60 (d,J=10.5, 2H), 7.44 (dd, J=6.1, 13.8, 1H), 4.45 (dd, J=6.4, 11.7, 2H),3.57 (d, J=13.5, 1H), 3.49 (d, J=13.5, 1H), 2.84 (dd, J=2.4, 9.1, 1H),2.80-2.73 (m, 1H), 2.61-2.50 (m, 2H), 2.38 (dd, J=7.0, 8.9, 1H), 2.34(dd, J=2.5, 9.0, 1H), 2.28-2.23 (m, 1H), 2.18 (td, J=5.8, 11.9, 1H),2.04 (dt, J=6.9, 20.3, 1H), 1.91 (ddd, J=4.1, 7.2, 14.3, 2H), 1.77 (ddd,J=5.3, 8.7, 13.8, 1H), 1.73-1.65 (m, 1H), 1.44 (ddd, J=6.1, 12.3, 18.6,1H), 1.33 (td, J=4.7, 11.0, 1H), 1.22-1.16 (m, 1H), 0.91 (ddd, J=4.5,8.5, 11.2, 1H), 0.88-0.85 (m, 1H), 0.84 (d, J=6.7, 3H), 0.82 (d, J=6.6,3H); MS (ESI+) m/z 502 (M+H)⁺.

Example 173N²-(isobutylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substituting2-methylpropane-1-sulfonyl chloride for methanesulfonyl chloride andN¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 170 Step B forN²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described in Example 167: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.34 (d, J=9.3, 1H), 9.20 (d, J=7.4, 1H), 7.77 (s, 1H), 7.62 (d,J=7.6, 1H), 7.60-7.55 (m, 1H), 7.45 (t, J=7.7, 1H), 4.52-4.43 (m, 2H),3.61 (d, J=13.5, 1H), 3.52 (d, J=13.6, 1H), 3.19-3.16 (m, 2H), 2.91 (dd,J=2.0, 9.0, 1H), 2.63-2.46 (m, 3H), 2.42 (dd, J=6.8, 8.9, 1H), 2.37 (dd,J=2.1, 9.0, 1H), 2.27 (dd, J=6.9, 8.8, 1H), 2.18 (td, J=5.8, 11.7, 1H),2.01 (tt, J=6.7, 13.4, 1H), 1.96-1.85 (m, 2H), 1.73 (tdd, J=6.3, 10.3,14.9, 2H), 1.45 (ddt, J=6.2, 9.0, 12.2, 1H), 1.08 (d, J=6.7, 3H), 1.04(d, J=6.7, 3H), 0.81 (app t, J=7.0, 6H); MS (ESI+) m/z 518 (M+H)⁺.

Example 174N²-(cyclopropylsulfonyl)-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

Step A:N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidewas prepared as described in the procedures in Example 170 Steps A-B bysubstituting(3aS,4S,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom 152 Step A for(3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.57-8.51 (m, 1H), 7.90 (bs, 1H),7.71-7.65 (m, 1H), 7.47 (t, J=7.7, 1H), 4.57-4.49 (m, 1H), 3.73 (d,J=13.1, 1H), 3.66-3.59 (m, 1H), 3.35 (d, J=13.1, 1H), 2.80 (dd, J=2.6,9.4, 1H), 2.78-2.69 (m, 1H), 2.49-2.40 (m, 1H), 2.35 (dd, J=2.5, 9.0,1H), 2.24-1.79 (m, 7H), 1.73-1.50 (m, 3H), 1.47-1.21 (m, 2H), 0.95-0.85(m, 6H).

Step B: ToN¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Step A (80 mg, 0.184 mmol) in dichloromethane (0.5 mL) was addedtriethylamine (0.064 mL, 0.461 mmol) followed by cyclopropanesulfonylchloride (38.9 mg, 0.277 mmol) in a solution of 300 μL dichloromethaneand the reaction mixture was stirred at room temperature overnight. Thereaction was reduced in volume and loaded onto a silica gel cartridge(Analogix®, Burlington, Wis., RS-12). The title compound was eluted witha gradient of 20% to 100% ethyl acetate/hexanes over 20 minutes to giveN²-(cyclopropylsulfonyl)-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide:¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.34 (d, J=9.0, 1H), 8.84 (d, J=6.8,1H), 7.73 (s, 1H), 7.64 (d, J=7.5, 1H), 7.59 (d, J=12.3, 1H), 7.43 (dd,J=6.6, 14.3, 1H), 4.53-4.42 (m, 2H), 3.76 (d, J=13.2, 1H), 3.41 (d,J=13.2, 1H), 2.99 (qd, J=4.2, 8.0, 1H), 2.90 (dd, J=3.6, 9.5, 1H),2.82-2.74 (m, 1H), 2.57-2.48 (m, 1H), 2.40 (dd, J=8.5, 19.8, 2H), 2.30(dd, J=3.4, 9.2, 1H), 2.02 (td, J=6.5, 13.7, 1H), 1.94-1.85 (m, 2H),1.85-1.78 (m, 1H), 1.71 (td, J=6.2, 11.6, 1H), 1.67-1.58 (m, 1H),1.40-1.28 (m, 2H), 1.22 (dt, J=4.7, 10.8, 1H), 0.93 (ddd, J=6.6, 12.3,14.0, 2H), 0.87 (d, J=6.5, 3H), 0.84 (d, J=6.7, 3H); MS (ESI+) m/z 502(M+H)⁺.

Example 175N²-acetyl-N²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

ToN²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide(123 mg, 0.299 mmol) from Example 164 in dichloromethane (0.5 mL) wasadded N,N-diisopropylethylamine (78 μL, 0.448 mmol) followed by aceticanhydride (33.9 μL, 0.359 mmol), and the reaction mixture was stirred atroom temperature overnight. The reaction was reduced in volume andloaded onto a silica gel cartridge (Analogix®, Burlington, Wis., RS-12),and the product was eluted with a gradient of 0% to 5% methanol (2 Nammonia)/dichloromethane over 20 minutes. The solvent was removed invacuo to supply the title compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.10 (d, J=7.1, 1H), 7.81 (d, J=7.5, 1H), 7.76 (s, 1H), 7.63 (d, J=7.8,1H), 7.56 (d, J=7.7, 1H), 5.54 (dd, J=6.5, 9.2, 1H), 4.41 (dt, J=7.3,14.5, 1H), 3.62 (d, J=13.2, 1H), 3.49 (d, J=13.2, 1H), 3.01 (s, 3H),2.84-2.77 (m, 1H), 2.73 (dd, J=2.8, 9.5, 1H), 2.48-2.41 (m, 1H), 2.34(dd, J=2.8, 9.0, 1H), 2.25 (dt, J=7.7, 17.0, 2H), 2.09 (s, 3H), 1.85(ddd, J=5.6, 9.9, 13.2, 1H), 1.81-1.70 (m, 2H), 1.66-1.46 (m, 3H),1.30-1.23 (m, 1H), 0.87 (d, J=2.7, 3H), 0.85 (d, J=2.6, 3H); MS (ESI+)m/z 454 (M+H)⁺.

Example 176N²-(2,2-dimethylpropanoyl)-N²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

ToN²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide(38.9 mg, 0.095 mmol) from Example 166 in dichloromethane (0.5 mL) wasadded N,N-diisopropylethylamine (24.77 μL, 0.142 mmol) followed bypivaloyl chloride (12.79 μL, 0.104 mmol), and the resultant reactionmixture was stirred at room temperature overnight. The reaction wasreduced in volume and loaded onto a silica gel cartridge (Analogix®,Burlington, Wis., RS-4). The title compound was eluted with a gradientof 0% to 100% ethyl acetate/hexanes over 15 minutes: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.81 (d, J=7.4, 1H), 7.74 (s, 1H), 7.60-7.55 (m, 2H),7.43 (dd, J=6.6, 14.3, 1H), 5.45 (dd, J=7.0, 8.7, 1H), 4.35-4.29 (m,1H), 3.57 (d, J=13.5, 1H), 3.44 (d, J=13.5, 1H), 3.13 (s, 3H), 2.73 (dd,J=2.6, 8.9, 1H), 2.53-2.45 (m, 1H), 2.41 (ddd, J=2.7, 8.3, 12.0, 1H),2.37-2.32 (m, 1H), 2.29 (dd, J=3.0, 9.0, 1H), 2.26-2.21 (m, 1H), 2.05(dq, J=6.0, 12.0, 1H), 1.86-1.80 (m, 3H), 1.55 (ddd, J=6.9, 12.8, 19.6,2H), 1.41-1.31 (m, 1H), 1.30 (s, 9H), 0.88 (d, J=6.7, 3H), 0.82 (d,J=6.6, 3H); MS (ESI+) m/z 496 (M+H)⁺.

Example 177N²-(2,2-dimethylpropanoyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared as described in Example 176 substitutingN¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 170 Step B forN²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.77 (d, J=7.3, 1H), 7.86 (d, J=8.4,1H), 7.73 (s, 1H), 7.60-7.55 (m, J=10.6, 2H), 7.45 (t, J=7.7, 1H),4.42-4.35 (m, 1H), 3.55 (d, J=13.5, 1H), 3.41 (d, J=13.5, 1H), 2.71 (d,J=9.0, 1H), 2.50 (s, 2H), 2.34 (dd, J=6.9, 8.9, 1H), 2.29-2.20 (m, 2H),2.12 (dq, J=6.1, 12.3, 1H), 1.94-1.74 (m, 5H), 1.66 (dt, J=7.1, 19.3,1H), 1.39 (d, J=6.9, 1H), 1.33 (s, 9H), 0.84 (d, J=6.1, 3H), 0.82 (d,J=6.1, 3H); MS (ESI+) m/z 482 (M+H)⁺.

Example 178isobutyl(S)-4-methyl-1-oxo-1-(3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate

The title compound was prepared by substituting isobutylcarbonochloridate for methanesulfonyl chloride andN¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 170 Step B forN²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described in Example 167: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.83 (d, J=6.8, 1H), 8.42 (d, J=8.5, 1H), 7.73 (s, 1H), 7.65-7.53(m, 2H), 7.46-7.40 (m, 1H), 4.77 (dd, J=7.5, 15.2, 1H), 4.48-4.39 (m,1H), 4.01 (dd, J=6.7, 10.3, 1H), 3.92 (dd, J=6.7, 10.4, 1H), 3.56 (d,J=13.4, 1H), 3.40 (d, J=13.5, 1H), 2.77 (d, J=7.0, 1H), 2.57-2.45 (m,2H), 2.38-2.32 (m, 1H), 2.30-2.24 (m, 1H), 2.23-2.19 (m, 1H), 2.14 (td,J=5.9, 11.9, 1H), 1.95-1.79 (m, 5H), 1.73-1.63 (m, 1H), 1.45-1.34 (m,1H), 0.87 (d, J=5.9, 3H), 0.84 (d, J=5.8, 3H), 0.82 (d, J=4.3, 3H), 0.80(d, J=4.3, 3H); MS (ESI+) m/z 498 (M+H)⁺.

Example 179 cyclopentyl(S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate

The title compound was prepared by substituting cyclopentylcarbonochloridate for methanesulfonyl chloride andN¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 170 Step B forN²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure describe in Example 167: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.82 (d, J=7.0, 1H), 8.26 (d, J=8.6, 1H), 7.73 (s, 1H), 7.62-7.53(m, 2H), 7.43 (t, J=7.8, 1H), 5.32-5.24 (m, 1H), 4.77 (dd, J=7.0, 15.0,1H), 4.47-4.36 (m, 1H), 3.56 (d, J=13.4, 1H), 3.40 (d, J=13.6, 1H), 2.76(d, J=9.0, 1H), 2.55-2.46 (m, 2H), 2.38-2.31 (m, 1H), 2.27 (d, J=7.2,1H), 2.21 (t, J=7.9, 1H), 2.13 (dq, J=6.2, 12.5, 1H), 1.94-1.83 (m, 4H),1.77 (dd, J=6.9, 12.4, 2H), 1.73-1.64 (m, 3H), 1.58 (dt, J=8.0, 14.7,2H), 1.39 (td, J=9.0, 14.1, 3H), 0.87 (d, J=5.9, 3H), 0.84 (d, J=5.3,3H); MS (ESI+) m/z 510 (M+H)⁺.

Example 180N²-[(tert-butylamino)carbonyl]-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

ToN¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide(113 mg, 0.284 mmol) from Example 170 Step B in dichloromethane (0.5 mL)was added 2-isocyanato-2-methylpropane (35.1 μL, 0.313 mmol) and thereaction mixture was stirred at room temperature overnight. The reactionwas reduced in volume and loaded onto a silica gel cartridge (Analogix®,Burlington, Wis., RS-12). The title compound was eluted with a gradientof 0% to 10% methanol (2 N ammonia)/dichloromethane over 20 minutes: ¹HNMR (500 MHz, pyridine-d₅) δ ppm 8.74 (d, J=8.3, 1H), 7.73 (s, 1H), 7.57(d, J=9.5, 2H), 7.44 (t, J=7.7, 1H), 6.56 (d, J=8.6, 1H), 6.33 (s, 1H),4.88 (td, J=5.6, 8.9, 1H), 4.41-4.33 (m, 1H), 3.56 (d, J=13.5, 1H), 3.41(d, J=13.6, 1H), 2.71 (dd, J=1.7, 9.2, 1H), 2.55-2.45 (m, 2H), 2.35 (dd,J=6.9, 8.9, 1H), 2.29-2.20 (m, 2H), 2.11 (dq, J=6.1, 12.1, 1H),1.92-1.77 (m, 3H), 1.73-1.64 (m, 2H), 1.44 (s, 9H), 1.43-1.35 (m, 1H),0.85 (d, J=3.3, 3H), 0.84 (d, J=3.2, 3H); MS (ESI+) m/z 497 (M+H)⁺.

Example 181N²-[(cyclopentylamino)carbonyl]-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substituting isocyanatocyclopentanefor 2-isocyanato-2-methylpropane as described in the procedure inExample 180: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.84 (d, J=7.2, 1H),7.73 (s, 1H), 7.64-7.53 (m, 2H), 7.44 (t, J=9.1, 2H), 6.60 (d, J=7.4,1H), 6.57 (d, J=8.8, 1H), 4.42-4.36 (m, 2H), 3.56 (d, J=13.7, 1H), 3.40(d, J=13.6, 1H), 2.73 (dd, J=1.9, 9.3, 1H), 2.53-2.49 (m, 2H), 2.34 (dd,J=7.0, 9.0, 1H), 2.26 (dd, J=1.8, 8.9, 1H), 2.24-2.20 (m, 1H), 2.16-2.09(m, 1H), 1.90 (tdd, J=5.7, 12.5, 18.4, 4H), 1.80 (ddd, J=5.7, 7.9, 13.6,1H), 1.76-1.65 (m, 2H), 1.51 (dt, J=6.3, 14.9, 3H), 1.41 (tt, J=7.2,11.8, 4H), 0.85 (d, J=6.5, 6H); MS (ESI+) m/z 509 (M+H)⁺.

Example 182N²-methyl-N¹-(3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

Step A:N¹-[(3aS,4R,6aR)-Octahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidewas prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Example 151 forN-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamidein Example 53.

Step B: ToN¹-[(3aS,4R,6aR)-Octahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Step A (220 mg, 0.622 mmol) in dichloromethane (5.0 mL) was addedtriethylamine (0.130 mL, 0.934 mmol) followed by3-(trifluoromethyl)benzene-1-sulfonyl chloride (0.110 ml, 0.685 mmol)and the reaction mixture was stirred at room temperature overnight. Thereaction was reduced in volume and loaded onto a silica gel cartridge(Analogix®, Burlington, Wis., RS-24). The title compound was eluted witha gradient of 0% to 10% methanol (2 N ammonia)/dichloromethane over 20minutes to giveN²-(tert-butyloxycarbonyl)-N²-methyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.32 (bs, 1H), 8.18-8.13 (m, 1H),8.02-7.95 (m, 1H), 7.90-7.84 (m, 1H), 7.68 (t, J=7.9, 1H), 4.17-4.09 (m,1H), 3.77-3.69 (m, 1H), 3.20-3.11 (m, 2H), 3.05-2.97 (m, 4H), 2.53-2.47(m, 2H), 1.98-1.88 (m, 1H), 1.87-1.71 (m, 3H), 1.62-1.48 (m, 3H), 1.46(s, 9H), 1.32-1.22 (m, 1H), 0.87 (dd, J=6.6, 15.5, 6H).

Step C: The title compound was prepared by substitutingN²-(tert-butyloxycarbonyl)-N²-methyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamideforN²-(tert-butyloxycarbonyl)-N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidein the procedure described in Example 158: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.38 (s, 1H), 8.30 (d, J=6.8, 1H), 8.20 (d, J=7.8, 1H), 7.91 (d,J=8.0, 1H), 7.72 (t, J=7.8, 1H), 4.31-4.24 (m, 1H), 3.87 (dd, J=2.2,10.0, 1H), 3.21-3.17 (m, 2H), 3.15 (dd, J=7.4, 9.9, 1H), 2.95 (dd,J=7.2, 9.6, 1H), 2.60-2.49 (m, 2H), 2.38 (s, 3H), 2.00-1.92 (m, 2H),1.91-1.80 (m, 2H), 1.68 (ddd, J=5.8, 7.9, 13.6, 1H), 1.60-1.52 (m, 2H),1.29 (ddd, J=6.4, 12.8, 16.2, 1H), 0.89 (d, J=6.6, 3H), 0.84 (d, J=6.6,3H); MS (ESI+) m/z 462 (M+H)⁺.

Example 183N²-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared as described in Example 182 substituting4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in Step B: ¹H NMR (500MHz, pyridine-d₅) δ ppm 8.30 (d, J=7.1, 1H), 8.14 (d, J=8.2, 2H), 7.90(d, J=8.3, 2H), 4.30-4.23 (m, 1H), 3.86 (dd, J=2.6, 10.0, 1H), 3.22-3.13(m, 3H), 2.97 (dd, J=7.3, 9.6, 1H), 2.61-2.50 (m, 2H), 2.39 (s, 3H),2.00-1.92 (m, 2H), 1.91-1.80 (m, 2H), 1.68 (ddd, J=5.9, 7.9, 13.7, 1H),1.61-1.52 (m, 2H), 1.30 (ddt, J=6.7, 9.9, 13.4, 1H), 0.90 (d, J=6.6,3H), 0.84 (d, J=6.6, 3H); MS (ESI+) m/z 462 (M+H)⁺.

Example 184N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

Step A:N¹-[(3aS,4R,6aR)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-L-leucinamidewas prepared by substituting N-(tert-butoxycarbonyl)-L-leucine for(S)-2-phenylbutanoic acid in the procedure described in Example 16 StepF: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.64 (d, J=7.1, 1H), 7.97 (d,J=8.5, 1H), 7.41 (d, J=7.3, 2H), 7.36 (t, J=7.5, 2H), 7.27 (t, J=7.3,1H), 4.71 (s, 1H), 4.41 (s, 1H), 3.56 (d, J=13.1, 1H), 3.39 (d, J=13.1,1H), 2.74 (d, J=8.9, 1H), 2.48 (s, 2H), 2.39-2.19 (m, 3H), 2.14 (td,J=6.3, 12.4, 1H), 2.00-1.78 (m, 4H), 1.73-1.55 (m, 1H), 1.50 (s, 9H),1.39 (d, J=7.0, 1H), 0.86 (dd, J=5.8, 13.4, 6H).

Step B: The title compound was prepared as described with the proceduresin Example 182 Steps A-C substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-L-leucinamidefrom Step A forN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamide:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.37 (s, 1H), 8.33 (d, J=6.9, 1H),8.18 (d, J=7.9, 1H), 7.91 (d, J=7.8, 1H), 7.72 (t, J=7.9, 1H), 4.27-4.19(m, 1H), 3.84 (dd, J=2.5, 9.9, 1H), 3.55 (dd, J=4.4, 9.3, 1H), 3.17 (dd,J=2.7, 9.7, 1H), 3.07 (dd, J=7.6, 9.8, 1H), 2.91 (dd, J=7.3, 9.6, 1H),2.55-2.45 (m, 2H), 2.09 (s, 1H), 1.97-1.78 (m, 5H), 1.52 (ddd, J=4.5,9.5, 18.5, 2H), 1.27 (ddt, J=6.7, 9.6, 13.2, 1H), 0.89 (d, J=6.4, 3H),0.83 (d, J=6.3, 3H); MS (ESI+) m/z 448 (M+H)⁺.

Example 185 and Example 1863-(trifluoromethyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide(Example 185) and3-(trifluoromethyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide(Example 186)

To(3aS*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 122 Step E (200 mg, 0.703 mmol) in dichloromethane (2 mL)was added triethylamine (0.147 mL, 1.055 mmol) followed by3-(trifluoromethyl)benzene-1-sulfonyl chloride (0.124 mL, 0.774 mmol),and the reaction mixture was stirred at room temperature overnight. Thereaction was quenched with water and extracted with dichloromethane. Theorganics were reduced in volume and loaded onto a silica gel cartridge(Analogix®, Burlington, Wis., RS-24). The title compounds were elutedwith a gradient of 0% to 10% methanol (2 N ammonia)/dichloromethane over20 minutes.

Example 185: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.42 (s, 1H), 8.27 (d,J=7.9, 1H), 7.82 (d, J=7.8, 1H), 7.64 (s, 1H), 7.61 (d, J=7.8, 1H), 7.57(d, J=8.2, 2H), 7.50 (d, J=7.7, 1H), 7.40 (t, J=7.7, 1H), 3.91-3.84 (m,1H), 3.47 (d, J=13.4, 1H), 3.37 (d, J=13.4, 1H), 2.78 (dd, J=4.3, 9.6,1H), 2.69 (dd, J=4.4, 7.7, 1H), 2.47-2.39 (m, 2H), 2.22 (dt, J=8.0,12.6, 2H), 1.89 (qd, J=7.1, 11.0, 1H), 1.65 (dtd, J=2.9, 6.2, 8.9, 1H),1.57-1.47 (m, 1H), 1.34-1.26 (m, 1H); MS (ESI+) m/z 493 (M+H)⁺.

Example 186: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.51 (d, J=7.3, 1H),8.43 (s, 1H), 8.30 (d, J=7.9, 1H), 7.81 (d, J=7.7, 1H), 7.72 (s, 1H),7.60 (dd, J=3.2, 7.9, 2H), 7.55 (d, J=7.7, 1H), 7.46 (t, J=7.7, 1H),3.82-3.74 (m, 1H), 3.54-3.44 (m, 2H), 2.61 (dd, J=1.9, 9.2, 1H),2.57-2.44 (m, 2H), 2.33 (dd, J=2.0, 9.0, 1H), 2.18 (ddd, J=6.8, 9.0,12.7, 2H), 1.96 (td, J=5.9, 11.8, 1H), 1.89-1.79 (m, 1H), 1.64-1.54 (m,1H), 1.29 (ddt, J=6.4, 10.0, 12.6, 1H); MS (ESI+) m/z 493 (M+H)⁺.

Example 1873-(trifluoromethyl)-N-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide

The title compound was prepared by substituting(3aS,4S,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 152 Step A for(3aS*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 185: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.26 (s, 1H), 8.41 (s, 1H), 8.27 (d, J=7.9, 1H), 7.82 (d, J=7.8,1H), 7.62 (d, J=7.9, 1H), 7.57 (d, J=9.8, 2H), 7.50 (d, J=7.7, 1H), 7.40(t, J=7.7, 1H), 3.87 (dd, J=7.1, 16.1, 1H), 3.48 (d, J=13.4, 1H), 3.38(d, J=13.4, 1H), 2.77 (dd, J=4.3, 9.6, 1H), 2.73-2.65 (m, 1H), 2.47-2.41(m, 2H), 2.26-2.19 (m, 2H), 1.89 (qd, J=7.1, 10.9, 1H), 1.65 (dtd,J=2.9, 6.2, 8.9, 1H), 1.52 (dq, J=8.3, 12.8, 1H), 1.34-1.26 (m, 1H); MS(ESI+) m/z 493 (M+H)⁺.

Example 1883-(trifluoromethyl)-N-{(3aR,4R,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide

The title compound was prepared by substituting(3aR,4R,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 157 Step A for(3aS*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 185: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.27 (s, 1H), 8.42 (s, 1H), 8.27 (d, J=7.9, 1H), 7.82 (d, J=7.8,1H), 7.64 (s, 1H), 7.62 (d, J=7.9, 1H), 7.57 (d, J=9.2, 1H), 7.50 (d,J=7.6, 1H), 7.40 (t, J=7.7, 1H), 3.87 (dd, J=7.1, 16.2, 1H), 3.47 (d,J=13.4, 1H), 3.37 (d, J=13.4, 1H), 2.77 (dd, J=4.3, 9.6, 1H), 2.73-2.66(m, 1H), 2.47-2.41 (m, 2H), 2.26-2.19 (m, 2H), 1.89 (qd, J=7.1, 11.0,1H), 1.65 (dtd, J=2.9, 6.2, 8.9, 1H), 1.52 (dq, J=8.4, 12.9, 1H),1.33-1.26 (m, 1H); MS (ESI+) m/z 493 (M+H)⁺.

Example 1893-(trifluoromethyl)-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide

The title compound was prepared by substituting(3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 154 Step A for(3aS*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 185: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.51 (d, J=6.7, 1H), 8.43 (s, 1H), 8.30 (d, J=7.8, 1H), 7.81 (d,J=7.9, 1H), 7.72 (s, 1H), 7.62-7.52 (m, 3H), 7.45 (t, J=7.6, 1H),3.82-3.74 (m, 1H), 3.54-3.44 (m, 2H), 2.61 (d, J=9.4, 1H), 2.57-2.44 (m,2H), 2.33 (dd, J=1.9, 9.0, 1H), 2.18 (ddd, J=6.9, 9.0, 13.4, 2H), 1.96(ddd, J=5.1, 11.0, 16.3, 1H), 1.84 (dt, J=7.5, 12.3, 1H), 1.58 (dt,J=9.3, 12.1, 1H), 1.35-1.25 (m, 1H); MS (ESI+) m/z 493 (M+H)⁺.

Example 190N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide

The title compound was prepared by substituting(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Example16 Step E for(3aS*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 185: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.49 (d, J=7.0, 1H), 8.43 (s, 1H), 8.29 (d, J=7.9, 1H), 7.81 (d,J=7.8, 1H), 7.60 (d, J=8.0, 1H), 7.38 (d, J=4.7, 4H), 7.33-7.27 (m, 1H),3.84-3.75 (m, 1H), 3.47 (q, J=13.1, 2H), 2.61 (dd, J=2.0, 9.2, 1H),2.56-2.43 (m, 2H), 2.35 (dd, J=2.0, 9.0, 1H), 2.21-2.12 (m, 2H), 1.99(td, J=5.9, 11.7, 1H), 1.87-1.77 (m, 1H), 1.64-1.53 (m, 1H), 1.29 (ddt,J=6.4, 10.0, 12.6, 1H); MS (ESI+) m/z 425 (M+H)⁺.

Example 191N-{(3aS,4R,6aR)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide

Step A:N-((3aS,4R,6aR)-Octahydrocyclopenta[c]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamidewas prepared by substitutingN-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamidefrom Example 190 forN-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamidein the procedure described in Example 53.

Step B: The title compound was prepared by substituting6,6-bis(4-fluorophenyl)hexanal for 3-(trifluoromethyl)benzaldehyde andN-((3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamidefrom Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.53 (d, J=6.8, 1H), 8.46 (s, 1H), 8.33 (d, J=7.9, 1H), 7.82 (d,J=7.8, 1H), 7.63 (t, J=7.8, 1H), 7.36-7.31 (m, 4H), 7.15 (t, J=8.7, 4H),3.97 (t, J=7.8, 1H), 3.83-3.74 (m, 1H), 2.66 (d, J=9.4, 1H), 2.56-2.43(m, 2H), 2.39 (d, J=8.5, 1H), 2.24 (dt, J=5.8, 12.0, 2H), 2.10-2.04 (m,2H), 2.04-1.99 (m, 2H), 1.99-1.91 (m, 1H), 1.87 (dt, J=6.8, 11.4, 1H),1.62-1.52 (m, 1H), 1.34 (ddd, J=6.9, 17.6, 29.2, 7H); MS (ESI+) m/z 607(M+H)⁺.

Example 192N-{(3aS,4R,6aR)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide

The title compound was prepared by substituting3,5-bis(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehydeandN-((3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamidefrom Example 191 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.53 (d, J=7.4, 1H), 8.42 (s, 1H), 8.30 (d, J=7.9, 1H), 8.03 (s,1H), 7.96 (s, 2H), 7.81 (d, J=7.8, 1H), 7.60 (t, J=7.9, 1H), 3.82-3.74(m, 1H), 3.59 (s, 2H), 2.68-2.64 (m, 1H), 2.59-2.49 (m, 2H), 2.38-2.33(m, 1H), 2.23 (dt, J=5.9, 8.9, 2H), 1.97-1.81 (m, 2H), 1.59 (ddd, J=8.2,11.8, 13.0, 1H), 1.35-1.24 (m, 1H); MS (ESI+) m/z 561 (M+H)⁺.

Example 193N-{(3aS,4R,6aR)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide

The title compound was prepared by substituting3,3-bis(4-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehyde andN-((3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamidefrom Example 191 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.56 (d, J=7.4, 1H), 8.46 (s, 1H), 8.35 (d, J=7.9, 1H), 7.80 (d,J=7.8, 1H), 7.61 (d, J=7.8, 1H), 7.37 (dd, J=5.6, 8.4, 2H), 7.34-7.30(m, 2H), 7.16 (dt, J=8.7, 12.8, 4H), 4.19 (t, J=7.7, 1H), 3.87-3.78 (m,1H), 2.69 (d, J=9.1, 1H), 2.55-2.44 (m, 2H), 2.39 (d, J=8.7, 1H),2.28-2.24 (m, 2H), 2.17 (dd, J=7.8, 15.3, 2H), 2.06 (dd, J=9.2, 16.3,2H), 1.98 (dt, J=5.7, 16.5, 1H), 1.89 (dd, J=12.0, 19.0, 1H), 1.64-1.53(m, 1H), 1.38-1.23 (m, 1H); MS (ESI+) m/z 565 (M+H)⁺.

Example 194N-{(3aS,4R,6aR)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide

The title compound was prepared by substituting3-fluoro-4-(trifluoromethyl)benzaldehyde for3-(trifluoromethyl)benzaldehyde andN-((3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamidefrom Example 191 Step A for2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamidein the procedure described for Example 54: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.56 (d, J=6.8, 1H), 8.44 (s, 1H), 8.33 (d, J=7.9, 1H), 7.82 (d,J=7.6, 1H), 7.65-7.59 (m, 2H), 7.29 (d, J=11.8, 1H), 7.21 (s, 1H),3.81-3.74 (m, 1H), 3.46 (s, 2H), 2.64 (d, J=9.3, 1H), 2.55 (ddd, J=8.5,13.8, 27.5, 2H), 2.35 (d, J=8.7, 1H), 2.17 (dd, J=7.9, 15.7, 2H), 1.99(dt, J=5.9, 16.5, 1H), 1.87 (dt, J=7.3, 12.1, 1H), 1.60 (dt, J=8.3,10.0, 1H), 1.35-1.26 (m, 1H); MS (ESI+) m/z 510 (M+H)⁺.

Example 195N-[(3aS,4S,6aR)-2-(4-hydroxybutyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide

Step A:N-((3aS,4S,6aR)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamidewas prepared by substituting(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Example14 Step C for(3aS*,6aR*)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 185.

Step B:N-((3aS,4S,6aR)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-yl)-3-(trifluoromethyl)benzenesulfonamide(0.4237 g, 0.998 mmol) from Step A in tetrahydrofuran (10 mL) was addedto 20% palladium hydroxide on carbon (wet, 0.085 g, 0.603 mmol) in a 50mL pressure bottle under nitrogen. The reaction mixture was then placedunder a hydrogen atmosphere (30 psi) and shaken at 50° C. for 18 hours.The mixture was filtered through a nylon membrane and the solvent wasremoved in vacuo. The crude material was purified by silica gelchromatography using 1-10% methanol (2 N ammonia)/dichloromethanesupplied the title compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.50(s, 1H), 8.38 (d, J=7.9, 1H), 7.85 (d, J=7.8, 1H), 7.68 (t, J=7.8, 1H),3.89 (dd, J=8.4, 14.2, 1H), 3.82 (t, J=6.2, 2H), 2.82 (dd, J=3.3, 9.7,1H), 2.62 (qd, J=3.4, 7.9, 1H), 2.42-2.36 (m, 1H), 2.32 (d, J=4.5, 2H),2.26 (dd, J=6.8, 11.7, 2H), 2.10 (t, J=8.7, 1H), 1.91-1.82 (m, 1H),1.74-1.67 (m, 2H), 1.64-1.49 (m, 5H), 1.32 (dd, J=6.1, 9.6, 1H); MS(ESI+) m/z 407 (M+H)⁺.

Example 196(3aS*,4S*,6aR*)-N,N-dicyclopropyl-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-amine

(3aS*,4S*,6aR*)-2-(3-(Trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine(228 mg, 0.802 mmol) from Example 122 Step E and(1-ethoxycyclopropoxy)trimethylsilane (140 mg, 0.802 mmol) were combinedin dichloromethane (1.5 mL) and 5 mL of acetic acid was added. Thereaction was stirred at room temperature for 20 minutes, and thenPS-cyanoborohydride (343 mg, 0.802 mmol) was added. The reaction washeated to 40° C. overnight. Silica gel chromatography eluting with 1-10%methanol (2 N ammonia)/dichloromethane to gave the title compound: ¹HNMR (300 MHz, CDCl₃) δ ppm 7.58 (s, 1H), 7.48 (d, J=7.6, 2H), 7.42 (d,J=7.6, 1H), 3.64 (d, J=13.6, 1H), 3.51 (d, J=13.6, 1H), 2.94-2.82 (m,3H), 2.80-2.71 (m, 2H), 2.55 (dd, J=5.4, 9.4, 3H), 2.41 (t, J=8.3, 1H),2.16 (dd, J=4.7, 8.7, 1H), 1.97-1.70 (m, 7H), 1.70-1.59 (m, 3H), 1.40(dd, J=6.7, 12.6, 1H); MS (ESI+) m/z 365 (M+H)⁺.

Example 197 and Example 198(3aS*,4R*,6aR*)-2-benzyl-N-cyclopropyloctahydrocyclopenta[c]pyrrol-4-amine(Example 197) and(3aS*,4S*,6aR*)-2-benzyl-N-cyclopropyloctahydrocyclopenta[c]pyrrol-4-amine(Example 198)

2-Benzylhexahydrocyclopenta[c]pyrrol-4(5H)-one (0.578 g, 2.68 mmol),cyclopropylamine (0.189 mL, 2.68 mmol), and acetic acid (10 mL) werecombined in dichloromethane (20 mL). PS-Cyanoborohydride (1.147 g, 2.68mmol) was added. The reaction was stirred at room temperature for 2hours, then filtered and the resin was washed with dichloromethane. Thesolvent was removed in vacuo, and the crude material was applied to asilica gel column and was eluted with 1-10% methanol(2 Nammonia)/dichloromethane to give the title compounds.

(3aS*,4R*,6aR*)-2-benzyl-N-cyclopropyloctahydrocyclopenta[c]pyrrol-4-amine(Example 197): ¹H NMR (300 MHz, CDCl₃) δ ppm 7.34-7.29 (m, 2H),7.28-7.20 (m, 2H), 3.56 (s, 2H), 3.14 (ddd, J=5.7, 7.3, 10.5, 1H), 2.84(t, J=8.4, 1H), 2.77-2.55 (m, 3H), 2.41 (dd, J=6.2, 9.4, 1H), 2.14-2.02(m, 2H), 1.83-1.72 (m, 2H), 1.63-1.47 (m, 3H), 1.46-1.35 (m, 1H), 0.40(tdd, J=1.3, 3.0, 4.7, 2H), 0.31 (ddd, J=2.8, 4.3, 6.2, 2H); MS (ESI+)m/z 256 (M+H)⁺.

(3aS*,4S*,6aR*)-2-benzyl-N-cyclopropyloctahydrocyclopenta[c]pyrrol-4-amine(Example 198): ¹H NMR (300 MHz, CDCl₃) δ ppm 7.34-7.29 (m, 4H),7.29-7.20 (m, 1H), 3.66-3.50 (m, 2H), 3.04-2.92 (m, 1H), 2.63 (s, 1H),2.54-2.50 (m, 2H), 2.48-2.40 (m, 1H), 2.34 (dd, J=3.8, 9.0, 1H), 2.26(dt, J=5.0, 16.3, 1H), 2.13-2.04 (m, 2H), 2.03-1.82 (m, 2H), 1.46-1.35(m, 2H), 0.46-0.38 (m, 2H), 0.36-0.30 (m, 2H); MS (ESI+) m/z 256 (M+H)⁺.

Example 199N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide

(3aS*,4S*,6aR*)-2-Benzyl-N-cyclopropyloctahydrocyclopenta[c]pyrrol-4-amine(382 mg, 1.490 mmol) from Example 198, triethylamine (312 μL, 2.235mmol), and 3-(trifluoromethyl)benzene-1-sulfonyl chloride (262 μL, 1.639mmol) were combined in tetrahydrofuran (7 mL). A catalytic amount of(dimethylamino)pyridine was added, and the reaction mixture was stirredat room temperature overnight. The solvent was reduced in volume, andthe crude material applied to silica gel and eluted with 20% to 100%ethyl acetate/hexanes to give the title compound: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.46 (s, 1H), 8.31 (d, J=7.9, 1H), 7.93 (d, J=7.8,1H), 7.74 (t, J=7.9, 1H), 7.41 (d, J=7.2, 2H), 7.36 (t, J=7.4, 2H), 7.29(t, J=7.2, 1H), 3.97 (ddd, J=6.1, 7.7, 13.5, 1H), 3.54-3.45 (m, 2H),3.17 (dt, J=5.9, 11.8, 1H), 2.82 (dd, J=3.6, 9.7, 1H), 2.55 (t, J=8.2,1H), 2.51-2.43 (m, 2H), 2.36-2.22 (m, 2H), 1.88-1.82 (m, 1H), 1.57 (dt,J=5.9, 11.6, 1H), 1.43-1.32 (m, 3H), 1.05-0.98 (m, 1H), 0.80 (ddd,J=6.9, 9.8, 12.4, 1H), 0.73-0.65 (m, 1H); MS (ESI+) m/z 465 (M+H)⁺.

Example 200N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide

The title compound was prepared by substituting(3aS*,4R*,6aR*)-2-benzyl-N-cyclopropyloctahydrocyclopenta[c]pyrrol-4-aminefrom Example 197 for(3aS*,4S*,6aR*)-2-benzyl-N-cyclopropyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 199: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.45 (s, 1H), 8.29 (d, J=7.8, 1H), 7.92 (d, J=7.8, 1H), 7.69 (t,J=7.9, 1H), 7.49 (d, J=7.4, 2H), 7.41 (t, J=7.6, 2H), 7.31 (t, J=7.3,1H), 4.41 (dd, J=7.7, 17.3, 1H), 3.63 (d, J=13.2, 1H), 3.53 (d, J=13.2,1H), 2.87 (d, J=8.9, 1H), 2.70 (dd, J=8.2, 15.9, 1H), 2.49 (d, J=8.9,1H), 2.46-2.37 (m, 1H), 2.16-2.07 (m, 2H), 1.99-1.94 (m, 1H), 1.84-1.77(m, 1H), 1.73-1.65 (m, 1H), 1.65-1.57 (m, 1H), 1.35-1.25 (m, 1H), 1.18(ddd, J=5.1, 6.9, 10.5, 1H), 0.99 (dq, J=4.7, 6.7, 1H), 0.81-0.74 (m,1H), 0.69 (ddd, J=6.9, 10.8, 11.8, 1H); MS (ESI+) m/z 465 (M+H)⁺.

Example 201N-cyclopropyl-N-[(3aS*,4S*,6aR*)-octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide

(3aS*,4S*,6aR*)-2-benzyl-N-cyclopropyloctahydrocyclopenta[c]pyrrol-4-amine(0.308 g, 0.663 mmol) from Example 199 and methanol (2 mL) were added to20% palladium hydroxide on carbon (wet, 4 mg) in a 50 mL pressurebottle. The reaction was stirred for 16 hours under hydrogen (30 psi) atroom temperature. The mixture was filtered through a nylon membrane andthe solvent removed in vacuo. The crude material was chromatographed ona silica gel cartridge (Analogix®, Burlington, Wis., RS15-24) elutingwith 1-10% methanol (2 N ammonia)/dichloromethane to give the titlecompound: ¹H NMR (300 MHz, CDCl₃) δ ppm 8.14 (s, 1H), 8.07 (d, J=7.9,1H), 7.87 (d, J=7.9, 1H), 7.70 (t, J=7.8, 1H), 3.80-3.69 (m, 1H), 3.25(dd, J=7.8, 10.7, 1H), 3.06-2.88 (m, 2H), 2.79-2.71 (m, 1H), 2.63-2.51(m, 1H), 2.46 (dd, J=5.9, 10.8, 1H), 2.05 (qd, J=7.0, 12.1, 1H), 1.79(ddd, J=3.9, 6.8, 10.7, 1H), 1.72-1.63 (m, 2H), 1.56 (dd, J=4.8, 6.1,1H), 1.48 (td, J=6.9, 12.8, 1H), 1.31 (ddd, J=2.7, 5.5, 8.8, 1H),0.92-0.70 (m, 3H); MS (ESI+) m/z 375 (M+H)⁺.

Example 202N-{(3aS*,4S*,6aR*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-N-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide

N-Cyclopropyl-N-[(3aS*,4S*,6aR*)-octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamidefrom Example 201 (140 mg, 0.374 mmol) and 6,6-bis(4-fluorophenyl)hexanal(108 mg, 0.374 mmol) were combined in dichloromethane (2 mL) and thenacetic acid (1 mL) was added. The reaction was stirred at roomtemperature for 20 minutes, then PS-cyanoborohydride (306 mg, 0.748mmol) was added. The reaction was stirred at room temperature overnight,then filtered and the resin washed with dichloromethane. The solvent wasremoved in vacuo and the crude material purified using a silica gelcartridge (Analogix®, Burlington, Wis., RS-12) eluting with 1-10%methanol (2 N ammonia)/dichloromethane to give the title compound: ¹HNMR (500 MHz, pyridine-d₅) δ ppm 8.50 (s, 1H), 8.36 (d, J=7.9, 1H), 7.95(d, J=7.9, 1H), 7.76 (dd, J=6.4, 14.2, 1H), 7.33 (dd, J=5.6, 8.3, 4H),7.18-7.11 (m, 4H), 3.96 (dd, J=8.0, 16.3, 2H), 3.18-3.10 (m, 1H), 2.82(dd, J=3.5, 9.5, 1H), 2.50-2.44 (m, 2H), 2.39 (t, J=8.0, 1H), 2.31-2.21(m, 4H), 2.03 (dd, J=7.8, 15.3, 2H), 1.91 (dt, J=3.5, 10.4, 1H), 1.59(dt, J=5.6, 11.5, 1H), 1.51 (dd, J=10.6, 16.2, 1H), 1.46-1.33 (m, 6H),1.28 (dd, J=7.4, 15.1, 2H), 1.08 (td, J=5.0, 10.5, 1H), 0.84 (dt, J=6.9,12.6, 1H), 0.75-0.66 (m, 1H); MS (ESI+) m/z 647 (M+H)⁺.

Example 203N-{(3aS*,4S*,6aR*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-N-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide

The title compound was prepared by substituting3,3-bis(4-fluorophenyl)propanal for 6,6-bis(4-fluorophenyl)hexanal inthe procedure described for Example 202: ¹H NMR (500 MHz, pyridine-d₅) δppm 8.49 (s, 1H), 8.35 (d, J=7.9, 1H), 7.94 (d, J=7.8, 1H), 7.77 (t,J=7.9, 1H), 7.34 (ddd, J=2.1, 5.5, 8.4, 4H), 7.14 (td, J=2.2, 8.8, 4H),4.16 (t, J=7.3, 1H), 3.97-3.90 (m, 1H), 3.24-3.15 (m, 1H), 2.77 (dd,J=4.1, 9.1, 1H), 2.54 (t, J=8.1, 1H), 2.47 (dd, J=7.1, 15.3, 2H),2.32-2.20 (m, 6H), 1.91 (dt, J=3.5, 10.5, 1H), 1.63 (dt, J=5.8, 11.6,1H), 1.52-1.36 (m, 3H), 1.03 (dt, J=4.5, 10.6, 1H), 0.83 (dt, J=6.8,12.6, 1H), 0.78-0.70 (m, 1H); MS (ESI+) m/z 605 (M+H)⁺.

Example 204N-cyclopropyl-3-(trifluoromethyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide

The title compound was prepared by substituting3-(trifluoromethyl)benzaldehyde for 6,6-bis(4-fluorophenyl)hexanal inthe procedure described for Example 202: ¹H NMR (500 MHz, pyridine-d₅) δppm 8.46 (s, 1H), 8.32 (d, J=7.9, 1H), 7.93 (d, J=7.8, 1H), 7.76-7.72(m, 2H), 7.52 (d, J=7.7, 1H), 7.44 (t, J=7.7, 1H), 4.00-3.93 (m, 1H),3.50 (d, J=13.2, 1H), 3.43 (d, J=13.2, 1H), 3.15 (qd, J=3.8, 7.8, 1H),2.78 (dd, J=3.8, 9.7, 1H), 2.52-2.43 (m, 2H), 2.39 (dd, J=8.0, 9.5, 1H),2.32-2.22 (m, 2H), 1.90-1.82 (m, 1H), 1.59 (dt, J=5.9, 11.5, 1H),1.48-1.32 (m, 4H), 0.99-0.93 (m, 1H), 0.81 (ddd, J=6.9, 9.8, 12.4, 1H),0.75-0.67 (m, 1H); MS (ESI+) m/z 533 (M+H)⁺.

Example 2052,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide

2,2-Dicyclohexyl-N-((3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl)acetamidefrom Example 53 (101 mg, 0.304 mmol), triethylamine (0.042 mL, 0.304mmol), and 3-(trifluoromethyl)benzene-1-sulfonyl chloride (0.049 mL,0.304 mmol) were combined in dichloromethane (2 mL). A catalytic amountof N,N-dimethylaminopyridine was added. The reaction was stirred at roomtemperature for 1 hour and 1 cms showed product, and tlc showed no morestarting material. The reaction was quenched with aqueous sodiumbicarbonate and the aqueous layer was separated. The organic layers wasconcentrated to give a precipitate. The precipitate was washed withwater and ether and dried under a stream of nitrogen to give the titlecompound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.49 (d, J=6.3, 1H), 8.34(s, 1H), 8.19 (d, J=7.9, 1H), 7.93 (d, J=7.8, 1H), 7.73 (t, J=7.8, 1H),4.46-4.38 (m, 1H), 3.73 (dd, J=3.4, 9.3, 1H), 3.17 (dd, J=2.8, 9.7, 1H),3.07 (ddd, J=6.4, 12.0, 23.6, 3H), 2.49 (dd, J=8.0, 15.9, 1H), 2.12 (t,J=7.2, 1H), 2.02-1.77 (m, 8H), 1.73 (dd, J=5.3, 9.0, 4H), 1.68-1.58 (m,3H), 1.52 (ddd, J=3.2, 12.5, 14.7, 1H), 1.43 (ddd, J=3.1, 12.6, 15.0,1H), 1.37-1.03 (m, 9H); MS (ESI+) m/z 541 (M+H)⁺.

Example 2062,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[(2-phenylethyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting 2-phenylethanesulfonylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in theprocedure described in Example 205: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.35 (d, J=7.0, 1H), 7.33-7.25 (m, 4H), 4.60-4.51 (m, 1H), 3.79 (dd,J=4.8, 10.2, 1H), 3.56-3.39 (m, 4H), 3.27 (t, J=8.3, 2H), 3.24-3.16 (m,2H), 2.66-2.57 (m, 1H), 2.09 (t, J=7.4, 1H), 2.00-1.76 (m, 9H), 1.72 (d,J=12.9, 4H), 1.67-1.64 (m, 1H), 1.59 (t, J=13.7, 2H), 1.54-1.36 (m, 3H),1.30-1.18 (m, 4H), 1.18-1.06 (m, 4H); MS (ESI+) m/z 501 (M+H)⁺.

Example 2072,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{[2-(1-naphthyl)ethyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide

The title compound was prepared by substituting2-(naphthalen-1-yl)ethanesulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 205: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.37 (d,J=6.8, 1H), 8.13 (d, J=9.0, 1H), 7.97-7.94 (m, 1H), 7.85 (d, J=8.2, 1H),7.53 (p, J=6.9, 2H), 7.46-7.40 (m, 1H), 7.36 (t, J=7.9, 1H), 4.60-4.49(m, 1H), 3.81 (dd, J=4.8, 10.2, 1H), 3.75 (t, J=8.3, 2H), 3.57-3.46 (m,4H), 3.27-3.16 (m, 2H), 2.67-2.59 (m, 1H), 2.09 (t, J=7.3, 1H), 1.95 (t,J=13.3, 2H), 1.89-1.76 (m, 5H), 1.72 (d, J=12.2, 4H), 1.66 (dd, J=5.1,7.2, 1H), 1.60 (t, J=10.5, 2H), 1.46 (dt, J=10.8, 20.4, 3H), 1.29-1.18(m, 4H), 1.18-1.03 (m, 5H); MS (ESI+) m/z 551 (M+H)⁺.

Example 2082,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{[3-(trifluoromethyl)benzyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide

The title compound was prepared by substituting(3-(trifluoromethyl)phenyl)methanesulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 205: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.32 (d,J=6.7, 1H), 7.96 (s, 1H), 7.81 (d, J=7.7, 1H), 7.64 (d, J=7.7, 1H), 7.46(t, J=7.7, 1H), 4.69 (q, J=13.5, 2H), 4.58-4.49 (m, 1H), 3.81 (dd,J=4.9, 10.4, 1H), 3.52 (dd, J=6.3, 13.7, 2H), 3.26 (dd, J=3.1, 9.9, 1H),3.23-3.15 (m, 1H), 2.65-2.58 (m, 1H), 2.06 (t, J=7.3, 1H), 1.93 (d,J=13.8, 2H), 1.82 (dt, J=9.9, 14.4, 6H), 1.71 (t, J=10.2, 4H), 1.67 (dd,J=7.0, 11.0, 1H), 1.60 (d, J=9.5, 2H), 1.51-1.35 (m, 3H), 1.29-1.02 (m,8H); MS (ESI+) m/z 555 (M+H)⁺.

Example 2092,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{[2-(4-fluorophenyl)ethyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide

The title compound was prepared by substituting2-(4-fluorophenyl)ethanesulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 205: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.37 (d,J=6.8, 1H), 7.18 (dd, J=5.6, 8.5, 2H), 7.09 (t, J=8.7, 2H), 4.60-4.49(m, 1H), 3.80 (dd, J=4.9, 10.3, 1H), 3.57-3.39 (m, 4H), 3.27-3.16 (m,4H), 2.67-2.59 (m, 1H), 2.09 (t, J=7.3, 1H), 1.99-1.77 (m, 8H), 1.72 (d,J=12.4, 4H), 1.66 (dd, J=3.0, 8.1, 1H), 1.59 (t, J=14.2, 2H), 1.46 (ddd,J=7.9, 16.4, 33.2, 3H), 1.24 (ddd, J=3.2, 12.7, 25.7, 4H), 1.18-1.03 (m,4H); MS (ESI+) m/z 519 (M+H)⁺.

Examples 210 and Example 211(2S)-2-phenyl-N-{(3aR,4R,6aS)-2-[(1S)-1-phenylethyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide(Example 210) and(2S)-2-phenyl-N-{(3aR,4S,6aS)-2-[(1S)-1-phenylethyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide(Example 211)

Step A:(3aR,6aS)-2-((S)-1-Phenylethyl)hexahydrocyclopenta[c]pyrrol-4(5H)-oneand(3aS,6aR)-2-((S)-1-phenylethyl)hexahydrocyclopenta[c]pyrrol-4(5H)-onewere prepared as described in the procedure described in Example 122Step C substitutingS(−)-N-methoxymethyl-N-(trifluorosilyl)methyl-1-phenylethyl amine for1-methoxy-N-(3-(trifluoromethyl)benzyl)-N-((trimethylsilyl)methyl)methanamine.

(3aR,6aS)-2-((S)-1-phenylethyl)hexahydrocyclopenta[c]pyrrol-4(5H)-one:¹H NMR (300 MHz, CDCl₃) δ ppm 7.34-7.16 (m, 5H), 3.23 (d, J=8.9, 1H),3.12 (q, J=6.6, 1H), 2.80 (dt, J=7.5, 14.9, 1H), 2.60 (t, J=8.6, 1H),2.48 (dd, J=2.0, 9.5, 1H), 2.44-2.20 (m, 5H), 2.08 (ddd, J=8.2, 13.0,17.0, 1H), 1.72 (ddd, J=6.7, 10.1, 17.4, 1H), 1.31 (d, J=6.6, 3H); MS(ESI+) m/z 230 (M+H)⁺.

(3aS,6aR)-2-((S)-1-phenylethyl)hexahydrocyclopenta[c]pyrrol-4(5H)-one:¹H NMR (300 MHz, CDCl₃) δ ppm 7.39-7.13 (m, 5H), 3.15 (dd, J=6.5, 13.1,1H), 2.88 (dd, J=7.1, 13.7, 1H), 2.76 (t, J=9.0, 3H), 2.54 (dd, J=9.9,18.1, 2H), 2.45-2.35 (m, 2H), 2.34-2.26 (m, 1H), 2.13 (ddd, J=6.5, 10.8,17.2, 1H), 1.91-1.77 (m, 1H), 1.33 (d, J=6.2, 3H); MS (ESI+) m/z 230(M+H)⁺.

Step B:(3aR,6aS)-2-((S)-1-Phenylethyl)octahydrocyclopenta[c]pyrrol-4-amine wasprepared as described in Example 122 Step D-E substituting(3aR,6aS)-2-((S)-1-phenylethyl)hexahydrocyclopenta[c]pyrrol-4(5H)-onefrom Step A for2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[c]pyrrol-4(5H)-one: ¹HNMR (300 MHz, CDCl₃) δ ppm 7.47-7.09 (m, 5H), 3.12 (dd, J=6.1, 12.5,1H), 2.75 (br s, 2H), 2.48 (d, J=6.5, 3H), 2.33-2.20 (m, 1H), 2.11-1.95(m, 1H), 1.94-1.73 (m, 2H), 1.73-1.54 (m, 2H), 1.43 (s, 3H), 1.35 (d,J=6.3, 3H); MS (ESI+) m/z 231 (M+H)⁺.

Step C: The title compounds were prepared by substituting(S)-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylic acid and(3aR,6aS)-2-((S)-1-phenylethyl)octahydrocyclopenta[c]pyrrol-4-amine for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Examples 1 and 2.

Example 210: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 11.04 (d, J=6.9, 1H),10.39 (d, J=7.2, 2H), 10.16 (q, J=8.0, 4H), 10.13-10.04 (m, 4H), 7.19(dt, J=7.1, 14.1, 1H), 6.36 (dd, J=6.3, 8.7, 1H), 5.82 (q, J=6.5, 1H),5.69 (dd, J=2.5, 9.4, 1H), 5.56 (qd, J=2.7, 7.7, 1H), 5.22-5.07 (m, 2H),4.99-4.92 (m, 2H), 4.90 (dd, J=2.7, 9.2, 1H), 4.65 (td, J=6.8, 13.6,1H), 4.55 (dt, J=7.1, 11.8, 1H), 4.32-4.20 (m, 2H), 4.11 (d, J=6.5, 3H),3.86-3.80 (m, 1H), 3.75 (t, J=7.3, 3H); MS (ESI+) m/z 377 (M+H)⁺.

Example 211: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 11.35 (d, J=7.1, 1H),10.40 (d, J=7.1, 2H), 10.13 (dt, J=7.6, 15.2, 6H), 10.04 (dt, J=4.6,14.8, 2H), 7.22-7.14 (m, 1H), 6.36 (dd, J=6.3, 8.8, 1H), 5.78 (q, J=6.5,1H), 5.55 (d, J=8.8, 1H), 5.22-5.09 (m, 3H), 5.04-4.98 (m, 1H), 4.92(dd, J=8.9, 15.9, 3H), 4.70-4.60 (m, 1H), 4.59-4.52 (m, 1H), 4.42 (dt,J=6.9, 19.0, 1H), 4.10 (dd, J=6.6, 18.3, 1H), 4.01 (d, J=6.5, 3H), 3.75(t, J=7.3, 3H); MS (ESI+) m/z 377 (M+H)⁺.

Example 212 and Example 213(2S)-2-phenyl-N-{(3aS,4S,6aR)-2-[(1S)-1-phenylethyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide(Example 212) and(2S)-2-phenyl-N-{(3aS,4R,6aR)-2-[(1S)-1-phenylethyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide(Example 213)

Step A:(3aS,6aR)-2-((S)-1-phenylethyl)octahydrocyclopenta[c]pyrrol-4-amine wasprepared as described in Example 122 Steps D-E substituting(3aS,6aR)-2-((S)-1-phenylethyl)hexahydrocyclopenta[c]pyrrol-4(5H)-onefrom Example 210 Step A for2-(3-(trifluoromethyl)benzyl)hexahydrocyclopenta[c]pyrrol-4(5H)-one: ¹HNMR (300 MHz, CDCl₃) δ ppm 7.47-7.09 (m, 5H), 3.12 (dd, J=6.1, 12.5,1H), 2.75 (br s, 2H), 2.48 (d, J=6.5, 3H), 2.33-2.20 (m, 1H), 2.11-1.95(m, 1H), 1.94-1.73 (m, 2H), 1.73-1.54 (m, 2H), 1.43 (br s, 2H), 1.35 (d,J=6.3, 3H); MS (ESI+) m/z 231 (M+H)⁺.

Step B: The title compounds were prepared by substituting(S)-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylic acid and(3aS,6aR)-2-((S)-1-phenylethyl)octahydrocyclopenta[c]pyrrol-4-amine for(3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Examples 1 and 2.

Example 212: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 10.86 (d, J=6.3, 1H),10.31 (d, J=7.3, 2H), 10.18-10.07 (m, 7H), 10.04 (t, J=7.3, 1H), 7.12(dt, J=7.2, 14.6, 1H), 6.31 (dd, J=6.4, 8.6, 1H), 5.77 (q, J=6.6, 1H),5.61-5.53 (m, 1H), 5.21-5.08 (m, 3H), 4.99 (dd, J=4.6, 9.8, 1H), 4.94(dd, J=8.3, 16.1, 2H), 4.70-4.60 (m, 2H), 4.46 (dt, J=5.8, 16.8, 1H),4.41-4.33 (m, 1H), 4.13-4.06 (m, 1H), 4.01 (d, J=6.6, 3H), 3.75 (t,J=7.3, 3H); MS (ESI+) m/z 377 (M+H)⁺.

Example 213: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.50 (d, J=7.1, 1H),7.56 (s, 1H), 7.45 (d, J=7.3, 2H), 7.34 (dt, J=7.6, 16.7, 4H), 7.25 (dd,J=7.3, 13.4, 3H), 4.37-4.30 (m, 1H), 3.52 (dd, J=6.2, 8.8, 1H), 3.11 (q,J=6.5, 1H), 2.60 (dd, J=2.3, 8.1, 1H), 2.56-2.44 (m, 3H), 2.37-2.27 (m,3H), 2.04-1.96 (m, 1H), 1.85-1.74 (m, 2H), 1.49 (dq, J=6.8, 13.3, 1H),1.38-1.32 (m, 1H), 1.29 (d, J=6.6, 3H), 0.92 (t, J=7.3, 3H); MS (ESI+)m/z 377 (M+H)⁺.

Example 214N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N,3-dimethyl-2-phenylbutanamide

Step A: Di-tert-butyl dicarbonate (0.429 mL, 1.849 mmol),(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine (200 mg, 0.925mmol) from Example 33 Step A, and (dimethylamino)pyridine (22.59 mg,0.185 mmol) were combined in dichloromethane (5 mL). The reactionmixture was stirred at room temperature for 30 minutes. The crudematerial was purified on a silica gel cartridge (Analogix®, Burlington,Wis., RS-4) eluting with ethyl acetate/hexanes to givetert-butyl(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylcarbamate:¹H NMR (400 MHz, CDCl₃) δ ppm 7.39-7.12 (m, 5H), 4.47 (s, 1H), 3.74 (s,1H), 3.61 (s, 1H), 3.52 (s, 1H), 2.55 (t, J=31.6, 4H), 2.31 (s, 2H),2.03 (d, J=6.1, 1H), 1.83 (d, J=8.0, 1H), 1.58 (s, 1H), 1.43 (s, 9H),0.98-0.79 (m, 1H); MS (ESI+) m/z 317 (M+H)⁺.

Step B:tert-Butyl(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylcarbamate(59 mg, 0.187 mmol) from Step A was treated with lithium aluminumhydride (0.374 mmol) in tetrahydrofuran (0.5 mL). The reaction wasstirred at room temperature for 1 hour and then heated to reflux for 2hours. The reaction was cooled to room temperature and quenched withdropwise addition of saturated aqueous sodium sulfate (50 μL) to give aprecipitate. The precipitate was washed with tetrahydrofuran, and thenthe solvent was removed to give(3aR,4S,6aS)-2-benzyl-N-methyloctahydrocyclopenta[c]pyrrol-4-amine: ¹HNMR (500 MHz, pyridine-d₅) δ ppm 7.34-7.28 (m, 4H), 7.25-7.19 (m, 1H),3.60-3.51 (m, 2H), 2.76 (q, J=5.6, 1H), 2.64 (d, J=15.7, 1H), 2.58-2.53(m, 1H), 2.51-2.46 (m, 1H), 2.40-2.35 (m, 4H), 2.31-2.22 (m, 2H),1.98-1.85 (m, 2H), 1.39 (dt, J=5.7, 10.6, 3H); MS (ESI+) m/z 231 (M+H)⁺.

Step C: The title compound was prepared by substituting3-methyl-2-phenylbutanoic acid for 1-phenylcyclopentanecarboxylic acidand (3aR,4S,6aS)-2-benzyl-N-methyloctahydrocyclopenta[c]pyrrol-4-aminefor (3aS*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 2: ¹H NMR (300 MHz, CDCl₃) δ ppm7.59-7.41 (m, 5H), 7.39-7.16 (m, 5H), 3.64 (d, J=13.2, 1H), 3.50 (d,J=9.5, 1H), 2.69-2.52 (m, 2H), 2.50-2.33 (m, 3H), 2.25-2.15 (m, 1H),2.05 (dd, J=6.3, 9.2, 1H), 1.88-1.67 (m, 2H), 1.34 (dd, J=13.4, 19.6,3H), 1.08 (d, J=6.4, 3H), 1.03-0.95 (m, 1H), 0.79-0.66 (m, 6H); MS(ESI+) m/z 391 (M+H)⁺.

Example 215N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N,3-dimethyl-2-phenylbutanamide

The title compound was prepared as described in Example 214 substituting(3aR*,4S*,6aS*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine(International Publication No. WO2006/012396) for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in Example 214Step A: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.61-7.41 (m, 5H), 7.26 (dd,J=15.4, 37.9, 5H), 3.65 (d, J=13.2, 1H), 3.54 (dd, J=7.6, 19.9, 2H),2.70-2.53 (m, 2H), 2.50-2.36 (m, 2H), 2.25-2.15 (m, 1H), 2.07 (s, 1H),1.87-1.66 (m, 2H), 1.43-1.26 (m, 3H), 1.19 (d, J=6.4, 2H), 1.08 (d,J=6.5, 2H), 1.01 (d, J=6.4, 1H), 0.79-0.63 (m, 5H); MS (ESI+) m/z 391(M+H)⁺.

Example 216(3aR*,4S*,6aS*)-N-benzyl-2-(3-methyl-2-phenylbutanoyl)octahydrocyclopenta[c]pyrrol-4-amine

Step A:tert-Butyl(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylcarbamatewas prepared as described in Example 214 Step A substituting(3aR*,4S*,6aS*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine(International Publication No. WO2006/012396) for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine: MS (ESI+) m/z317 (M+H)⁺.

Step B:tert-Butyl(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylcarbamate(100 mg, 0.316 mmol) from Step A and ammonium formate (100 mg, 1.580mmol) were combined in ethanol. The reaction was deoxygenated at lowtemperature, and palladium on carbon (3.36 mg, 0.032 mmol) was added.The reaction was heated to reflux under nitrogen. After 3 hours, tlc and1 cms showed mostly starting material. Degussa's catalyst and 5equivalents more ammonium formate were added and the reaction mixturewas refluxed under nitrogen overnight. More ammonium formate andDegussa's catalyst were added and the reaction heated to 90° C. After 2hours, tlc and 1 cms show no remaining starting material. The reactionwas filtered through diatomaceous earth containing carbonatefunctionalized silica gel (Silicycle, Quebec, Canada) with methanol.Solvent removal in vacuo gavetert-butyl(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-ylcarbamate: MS(ESI+) m/z 226 (M+H)⁺.

Step C: 3-Methyl-2-phenylbutanoic acid (63 mg, 0.353 mmol),1-hydroxybenzotriazole (54.1 mg, 0.353 mmol), andN-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (0.063 mL, 0.353 mmol)were combined in dichloromethane (5 mL). The reaction was stirred atroom temperature for 20 minutes, and thentert-butyl(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-ylcarbamate (80mg, 0.353 mmol) from Step B was added. After 30 minutes, the reactionwas quenched with water and extracted with dichloromethane. The combinedextracts were concentrated, and the crude material purified using10-100% ethyl acetate/hexanes to givetert-butyl(3aR,4S,6aS)-2-(3-methyl-2-phenylbutanoyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate:MS (ESI+) m/z 387 (M+H)⁺.

Step D:tert-Butyl(3aR,4S,6aS)-2-(3-methyl-2-phenylbutanoyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate(39 mg, 0.101 mmol) from Step C was combined with 4 M HCl in dioxane (5mL, 20.00 mmol) in ether (5 mL). After about 2 hours, the solvent wasremoved in vacuo to give1-((3aR,4S,6aS)-4-aminohexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-methyl-2-phenylbutan-1-onehydrochloric acid salt which was used in the next step withoutadditional purification: MS (ESI+) m/z 287 (M+H)⁺.

Step E:1-((3aR,4S,6aS)-4-aminohexahydrocyclopenta[c]pyrrol-2(1H)-yl)-3-methyl-2-phenylbutan-1-onehydrochloric acid salt (49 mg, 0.152 mmol) and benzaldehyde (0.023 mL,0.228 mmol) were combined in dichloromethane (1.5 mL). Acetic acid (1.5mL) was added. The reaction was stirred at room temperature for 30minutes, then PS-cyanoborohydride (64.9 mg, 0.152 mmol) was added. After72 hours, 1 cms of the reaction showed no more starting material. Thereaction mixture was filtered, and the solvent was removed under astream of nitrogen. The crude material was purified using a silica gelcartridge (Analogix®, Burlington, Wis., RS-4) eluting with 1-10%methanol (2 N ammonia)/dichloromethane to give the title compound: ¹HNMR (500 MHz, pyridine-d₅) δ ppm 7.69-7.60 (m, 2H), 7.54-7.44 (m, 2H),7.44-7.34 (m, 5H), 7.29 (tdd, J=4.8, 7.8, 13.0, 2H), 3.90-3.36 (m, 4H),3.29 (dd, J=3.8, 10.6, 0.5H), 2.99 (dd, J=5.7, 11.4, 0.5H), 2.93 (dd,J=6.0, 11.3, 0.5H), 2.75-2.63 (m, 1H), 2.59-2.48 (m, 1H), 2.46-2.31 (m,1H), 2.25 (dt, J=4.1, 8.7, 0.5H), 1.97 (dt, J=9.3, 11.6, 1H), 1.93-1.85(m, 0.5H), 1.84-1.74 (m, 1H), 1.65-1.55 (m, 0.5H), 1.51-1.35 (m, 1H),1.33-1.21 (m, 1H), 1.18-1.10 (m, 3H), 1.01 (td, J=7.7, 13.1, 0.5H), 0.87(dt, J=6.6, 12.9, 0.5H), 0.75 (t, J=7.2, 3H); MS (ESI+) m/z 377 (M+H)⁺.

Example 2172,2-dicyclohexyl-N-[(3aS,4R,6aR)-2-(N,N-dimethyl-D-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide

Step A: N-(tert-Butoxycarbonyl)-D-leucine (72.7 mg, 0.314 mmol),2,2-dicyclohexyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide(95 mg, 0.286 mmol) from Example 74, and hydroxybenzotriazole (48.1 mg,0.314 mmol) were combined in dichloromethane (10 mL). After 20 minutes,N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (0.056 mL, 0.314 mmol)was added, and the reaction mixture was stirred at room temperature for18 hours. The reaction was quenched with water. The separated organiclayer was reduced in volume, and the crude material was applied to asilica gel cartridge (Analogix®, Burlington, Wis., RS-12) and elutedfirst with 10% to 100% ethyl acetate/hexanes and then with 1-10%methanol (2 N ammonia)/dichloromethane to givetert-butyl(R)-1-((3aS,4R,6aR)-4-(2,2-dicyclohexylacetamido)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4-methyl-1-oxopentan-2-ylcarbamate:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.26 (dd, J=7.2, 24.0, 1H), 7.91 (d,J=8.6, 1H), 4.48-4.36 (m, 1H), 4.12-3.96 (m, 1H), 3.87 (dd, J=7.4, 10.3,1H), 3.70 (ddd, J=8.0, 14.4, 23.7, 1H), 3.40 (dd, J=5.7, 12.3, 1H), 2.77(s, 1H), 2.58 (d, J=6.1, 1H), 2.08 (s, 1H), 2.01 (dd, J=5.6, 10.4, 2H),1.96-1.55 (m, 17H), 1.54-1.50 (m, 9H), 1.49-1.37 (m, 2H), 1.19 (qdd,J=12.3, 22.3, 24.7, 11H), 1.00 (t, J=6.6, 3H), 0.88 (d, J=6.6, 1H).

Step B:tert-Butyl(R)-1-((3aS,4R,6aR)-4-(2,2-dicyclohexylacetamido)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4-methyl-1-oxopentan-2-ylcarbamate(185 mg, 0.339 mmol) from Step A, and 2 N HCl in ether (2.5 mL, 5.00mmol) were combined in ether (1 mL). The reaction mixture was stirred atroom temperature overnight. The solids were collected and dried to giveN-((3aS,4R,6aR)-2-((R)-2-amino-4-methylpentanoyl)octahydrocyclopenta[c]pyrrol-4-yl)-2,2-dicyclohexylacetamide:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.34-8.24 (m, 1H), 4.92 (br s, 2H),4.46-4.31 (m, 1H), 4.07 (d, J=9.2, 0.5H), 3.91-3.81 (m, 1.5H), 3.77 (dd,J=8.8, 12.1, 1H), 3.72-3.64 (m, 0.5H), 3.59-3.53 (m, 0.5H), 3.45 (dd,J=5.2, 12.2, 0.5H), 3.32 (d, J=6.5, 0.5H), 2.82-2.69 (m, 1H), 2.63 (dd,J=8.4, 14.5, 0.5H), 2.54 (dd, J=8.0, 16.4, 0.5H), 2.21-2.06 (m, 2H),2.02 (q, J=7.6, 1H), 1.99-1.55 (m, 15H), 1.50-1.38 (m, 3H), 1.37-1.12(m, 9H), 1.09 (d, J=6.5, 3H), 1.01 (d, J=6.6, 2H), 0.96 (d, J=6.4, 1H),0.91 (d, J=6.6, 1H). MS (ESI+) m/z 466 (M+H)⁺.

Step C: ToN-((3aS,4R,6aR)-2-((R)-2-amino-4-methylpentanoyl)octahydrocyclopenta[c]pyrrol-4-yl)-2,2-dicyclohexylacetamide(0.133 g, 0.298 mmol) from Step B was added formaldehyde (0.228 mL, 2.98mmol) in dichloromethane (0.5 mL). Acetic acid (0.5 mL) was added. Thereaction was stirred at room temperature for 30 minutes,PS-cyanoborohydride (0.255 g, 0.597 mmol) was then added, and thereaction mixture was stirred at room temperature overnight. The reactionwas filtered, and the solvent was removed in vacuo. The crude materialwas purified on silica gel chromatography on a silica gel cartridge(Analogix®, Burlington, Wis., RS-12) eluting with 1-10% methanol (2 Nammonia)/dichloromethane to give the title compound: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.29 (dd, J=7.1, 15.9, 1H), 4.46-4.35 (m, 1H),4.09-3.99 (m, 1H), 3.92-3.80 (m, 1H), 3.70 (dd, J=8.6, 12.4, 1H),3.66-3.58 (m, 2H), 3.45 (dd, J=4.8, 9.1, 0.5H), 2.78-2.64 (m, 1H),2.63-2.53 (m, 1H), 2.42 (s, 3H), 2.38 (s, 3H), 2.23-2.14 (m, 0.5H),2.13-1.99 (m, 2H), 1.99-1.82 (m, 5H), 1.82-1.63 (m, 8H), 1.60 (d,J=14.0, 1H), 1.57-1.51 (m, 1H), 1.45 (ddd, J=8.6, 18.8, 29.3, 3H),1.36-1.05 (m, 9H), 1.01 (d, J=6.6, 3H), 0.91 (dd, J=6.6, 19.9, 3H); MS(ESI+) m/z 474 (M+H)⁺.

Example 218N-[(3aR,4S,6aS)-2-benzoyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide

3-Methyl-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamidefrom Example 83 Step A (25 mg, 0.087 mmol), triethylamine (0.018 mL,0.131 mmol), and benzoyl chloride (10.12 μL, 0.087 mmol) were combinedin dichloromethane (5 mL). After 5 minutes, tlc shows no more startingmaterial. The crude reaction mixture was concentrated and applied to asilica gel cartridge (Analogix®, Burlington, Wis., RS-4) eluting with1-10% methanol(2 N ammonia)/dichloromethane to give the title compound:¹H NMR (300 MHz, CDCl₃) δ ppm 7.49-7.42 (m, 2H), 7.41-7.35 (m, 3H),7.33-7.27 (m, 3H), 5.43 (d, J=6.7, 1H), 3.97 (m, 1H), 3.74 (m, 2H), 3.56(m, 2H), 3.39 (m, 1H), 2.74 (m, 2H), 2.48 (m, 1H), 2.38 (m, 2H), 2.07(dd, J=4.6, 10.8, 1H), 1.94 (m, 1H), 1.52-1.31 (m, 2H), 1.01 (d, J=6.3,3H), 0.68 (d, J=6.6, 3H); MS (ESI+) m/z 391 (M+H)⁺.

Example 219N′-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-isopropyl-N-phenylurea

2 M Trimethylaluminum in toluene (0.198 mL, 0.395 mmol) was addeddropwise to N-isopropylaniline (0.068 mL, 0.474 mmol) in toluene (2 mL)at 0° C. The reaction was warmed to room temperature and stirred for 1hour. The aluminum amide solution was then added dropwise to a solutionoftert-butyl(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylcarbamatefrom Example 214 Step A (50 mg, 0.158 mmol) in 1 mL of toluene at 0° C.The reaction was heated at 90° C. overnight, and then the reaction wasquenched with 1 mL of 5% aqueous sodium hydroxide. The separated toluenelayer was applied directly to a silica gel cartridge (Analogix®,Burlington, Wis., RS-4) eluting with 1-10% methanol (2 Nammonia)/dichloromethane to give the title compound: ¹H NMR (300 MHz,CDCl₃) δ ppm 7.40 (ddd, J=1.8, 3.2, 5.7, 3H), 7.29 (d, J=4.4, 4H),7.24-7.18 (m, 1H), 7.14 (t, J=2.0, 1H), 7.13-7.10 (m, 1H), 4.87 (dt,J=6.8, 13.6, 1H), 3.94-3.84 (m, 1H), 3.74 (d, J=7.1, 1H), 3.60 (d,J=13.0, 1H), 3.44 (d, J=13.0, 1H), 2.53 (t, J=5.5, 2H), 2.48-2.40 (m,1H), 2.40-2.33 (m, 1H), 2.22 (dd, J=3.7, 8.8, 1H), 2.07 (ddd, J=5.1,9.2, 11.7, 1H), 1.95 (td, J=6.0, 12.0, 1H), 1.63-1.52 (m, 1H), 1.40-1.30(m, 1H), 1.29-1.17 (m, 1H), 1.05 (d, J=3.2, 3H), 1.02 (d, J=3.2, 3H); MS(ESI+) m/z 378 (M+H)⁺.

Example 220(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide

Step A: (S)-tert-Butyl 2-amino-4-methylpentanoate hydrochloride (0.516g, 2.306 mmol) were dissolved in dichloromethane (15 mL) andtriethylamine (1.061 mL, 7.61 mmol) was added.3-Chloropropane-1-sulfonyl chloride (0.337 mL, 2.77 mmol) was addeddropwise, and the reaction mixture was stirred at room temperatureovernight. The solvent was removed in vacuo, and the crude material wastaken up in ether, filtered, and concentrated to give (S)-tert-butyl2-(3-chloropropylsulfonamido)-4-methylpentanoate: ¹H NMR (300 MHz,CDCl₃) δ ppm 4.70 (d, J=9.7, 1H), 4.02-3.91 (m, 1H), 3.77-3.60 (m, 2H),3.25-2.96 (m, 3H), 2.31 (tdd, J=2.2, 6.6, 9.2, 2H), 1.83 (dq, J=6.5,13.0, 1H), 1.58-1.53 (m, 8H), 1.38 (t, J=7.3, 1H), 0.96 (dd, J=2.1, 6.6,6H); MS (ESI+) m/z 345 (M+NH₄)⁺.

Step B: (S)-tert-Butyl 2-(3-chloropropylsulfonamido)-4-methylpentanoate(0.756 g, 2.306 mmol) from Step A was dissolved in tetrahydrofuran andpotassium tert-butoxide (0.517 g, 4.61 mmol) was added. The reaction wasstirred at room temperature overnight. The solvent was removed in vacuo,and the crude material was partitioned between ether and water. Theether layer was separated, washed with brine, dried (Na₂SO₄), andconcentrated in vacuo to supplytert-butyl(2S)-2(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanoate: ¹HNMR (300 MHz, CDCl₃) δ ppm 4.17-4.05 (m, 1H), 3.68 (dd, J=7.9, 16.6,1H), 3.40-3.28 (m, 1H), 3.21-3.09 (m, 2H), 2.39 (td, J=5.3, 13.6, 2H),1.68 (m, 3H), 1.47 (s, 9H), 0.97 (dd, J=3.2, 6.2, 6H).

Step C:tert-Butyl(2S)-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanoate(0.656 g, 2.251 mmol) from Step B was combined with HCl (4 N in dioxane,5 mL, 20.00 mmol). The reaction mixture was stirred at room temperaturefor 24 hours, then the solvent removed in vacuo to furnish(2S)-2(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanoic acid: MS (DCI+)m/z 253 (M+NH₄)⁺.

Step D: (2S)-2-(1,1-Dioxidoisothiazolidin-2-yl)-4-methylpentanoic acid(359 mg, 1.526 mmol) was combined with triethylamine (0.387 mL, 2.77mmol) in dichloromethane (10 mL). 1-Hydroxybenzotriazole (234 mg, 1.526mmol) and N43-dimethylaminopropyl)-N′-ethylcarbodiimide (0.270 mL, 1.526mmol) were added, and the reaction mixture was stirred for 15 minutes.Then (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine (300 mg,1.387 mmol) from Example 16 Step E was added, and the reaction mixturewas stirred at room temperature for 24 hours. The reaction was quenchedwith 10 mL of aqueous sodium bicarbonate and extracted with 3×20 mL ofdichloromethane. The solvent was removed in vacuo. The crude materialwas applied to a silica gel cartridge (Analogix®, Burlington, Wis.,RS15-24) and eluted with 1-10% methanol (2 N ammonia)/dichloromethane togive the title compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.76 (d,J=6.9, 1H), 7.46-7.39 (m, 2H), 7.40-7.33 (m, 2H), 7.26 (dd, J=9.9, 17.2,1H), 4.52 (t, J=7.7, 1H), 4.44-4.34 (m, 1H), 3.93 (dt, J=7.0, 14.5, 1H),3.57 (dd, J=5.4, 13.1, 1H), 3.49-3.36 (m, 2H), 3.30-3.20 (m, 2H),2.83-2.74 (m, 1H), 2.62-2.45 (m, 2H), 2.44-2.37 (m, 1H), 2.33-2.17 (m,4H), 2.11 (qd, J=6.5, 12.5, 1H), 1.92-1.78 (m, 3H), 1.77-1.59 (m, 2H),1.45-1.32 (m, 1H), 0.88 (d, J=6.6, 3H), 0.83 (dd, J=2.5, 6.5, 3H); MS(ESI+) m/z 434 (M+H)⁺.

Example 221tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-ylcarbamate

N-(tert-Butoxycarbonyl)-L-leucine (0.374 g, 1.617 mmol),1-hydroxybenzotriazole hydrate (0.248 g, 1.617 mmol), and(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 33 (0.318 g, 1.470 mmol) were combined in dichloromethane (3.0mL). After 20 minutes,N¹-((ethylimino)methylene)-N³,N³-dimethylpropane-1,3-diamine (0.286 mL,1.617 mmol) was added, and the reaction was stirred at room temperatureovernight. The reaction was quenched with water and extracted with ofdichloromethane (2×2 mL), and the extracts were applied directly to a 25g silica gel cartridge and purified with a gradient of 5-40%acetone/hexanes over 30 minutes to give the title compound: ¹H NMR (500MHz, pyridine-d₅) δ ppm 8.61-8.64 (m, 1H), 7.96-7.99 (m, 1H), 7.42-7.44(m, 2H), 7.36 (t, J=7.4 Hz, 2H), 7.28 (d, J=7.3 Hz, 1H), 4.65-4.73 (m,1H), 4.37-4.45 (m, 1H), 3.59 (d, J=13.1 Hz, 1H), 3.43 (d, J=13.1 Hz,1H), 2.81-2.84 (m, 1H), 2.55-2.58 (m, 1H), 2.44-2.54 (m, 2H), 2.24-2.36(m, 2H), 2.02-2.13 (m, 1H), 1.78-1.94 (m, 4H), 1.53-1.66 (m, 1H), 1.50(s, 9H), 1.26-1.43 (m, 1H), 0.87 (d, J=5.5 Hz, 3H), 0.83-0.85 (m, 3H);MS (ES+) m/z 430 (M+H)⁺.

Example 222tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-leucine forN-(tert-butoxycarbonyl)-L-leucine in the procedure described in Example221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.23-8.32 (m, 1H), 7.42-7.44(m, 2H), 7.36 (t, J=7.5 Hz, 2H), 7.27 (t, J=7.4 Hz, 1H), 5.02 (m, 0.7H),4.69 (m, 0.3H), 4.37-4.43 (m, 1H), 3.58 (d, J=13.1 Hz, 1H), 3.45 (d,J=13.1 Hz, 1H), 3.04-3.11 (m, 3H), 2.82-2.91 (m, 1H), 2.40-2.52 (m, 3H),2.31-2.34 (m, 1H), 2.21-2.25 (m, 1H), 1.99-2.14 (m, 1H), 1.77-1.94 (m,3H), 1.51-1.62 (m, 2H), 1.47 (s, 9H), 1.34-1.37 (m, 1H), 0.88 (d, J=6.4Hz, 3H), 0.85 (d, J=6.4 Hz, 3H); MS (ESI+) m/z 444 (M+H)⁺.

Example 223tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(ethyl)carbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-ethyl-L-leucine forN-(tert-butoxycarbonyl)-L-leucine in the procedure described in Example221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.11-8.14 (m, 1H), 7.42-7.44(m, 2H), 7.36 (t, J=7.4 Hz, 2H), 7.27 (t, J=7.3 Hz, 1H), 4.36-4.41 (m,1H), 3.59 (d, J=13.1 Hz, 1H), 3.43-3.47 (m, 3H), 2.80-2.85 (m, 1H),2.47-2.51 (m, 2H), 2.39-2.43 (m, 1H), 2.33-2.35 (m, 1H), 2.22-2.25 (m,1H), 2.05-2.13 (m, 1H), 1.94-2.04 (m, 1H), 1.81-1.84 (m, 1H), 1.72-1.78(m, 1H), 1.52-1.61 (m, 1H), 1.46-1.49 (m, 9H), 1.34-1.41 (m, 2H),1.17-1.33 (m, 3H), 0.89-0.91 (m, 6H); MS (ESI+) m/z 458 (M+H)⁺.

Example 224tert-butyl(2S,3S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-isoleucine forN-(tert-butoxycarbonyl)-L-leucine in the procedure described in Example221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.43 (d, J=8.7 Hz, 1H), 7.43(s, 1H), 7.37 (t, J=7.4 Hz, 2H), 7.25-7.30 (m, 1H), 4.68-4.72 (m, 1H),4.34-4.44 (m, 1H), 3.61 (d, J=13.1 Hz, 1H), 3.46 (d, J=13.1 Hz, 1H),3.22-3.26 (m, 1H), 3.13-3.14 (m, 2H), 2.87-2.90 (m, 1H), 2.46-2.54 (m,3H), 2.25-2.35 (m, 3H), 2.00-2.12 (m, 1H), 1.82 (dq, J=12.7, 6.3 Hz,1H), 1.52-1.63 (m, 1H), 1.48-1.50 (m, 9H), 1.32-1.43 (m, 3H), 0.96-1.10(m, 4H), 0.78-0.86 (m, 3H); MS (ESI+) m/z 444 (M+H)⁺.

Example 225tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-tert-leucine forN-(tert-butoxycarbonyl)-L-leucine in the procedure described in Example221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.71 (m, 1H), 7.70 (d, J=9.6Hz, 1H), 7.43-7.45 (m, 2H), 7.37 (t, J=7.5 Hz, 2H), 7.26-7.30 (m, 1H),4.61 (d, J=9.7 Hz, 1H), 4.39-4.45 (m, 1H), 3.63 (d, J=13.1 Hz, 1H), 3.44(d, J=13.1 Hz, 1H), 2.86 (dd, J=9.0, 2.9 Hz, 1H), 2.57-2.63 (m, 1H),2.45-2.55 (m, 2H), 2.26-2.33 (m, 2H), 2.00 (dd, J=12.1, 6.1 Hz, 1H),1.77-1.84 (m, 1H), 1.48-1.56 (m, 1H), 1.48 (s, 9H), 1.25-1.38 (m, 1H),1.18 (s, 9H); MS (ESI+) m/z 430 (M+H)⁺.

Example 226tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-L-neopentylglycine forN-(tert-butoxycarbonyl)-L-leucine in the procedure described in Example221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.54-8.57 (m, 1H), 8.10-8.13(m, 1H), 7.41-7.45 (m, 2H), 7.36 (t, J=7.4 Hz, 2H), 7.25-7.29 (m, 1H),4.72-4.76 (m, 1H), 4.38-4.42 (m, 1H), 3.59 (d, J=13.1 Hz, 1H), 3.43 (d,J=13.1 Hz, 1H), 2.84 (dd, J=9.0, 2.9 Hz, 1H), 2.53-2.60 (m, 1H),2.46-2.53 (m, 1H), 2.42-2.46 (m, 1H), 2.29-2.32 (m, 1H), 2.22-2.27 (m,1H), 2.16 (dd, J=14.1, 4.8 Hz, 1H), 2.01-2.07 (m, 1H), 1.77-1.87 (m,2H), 1.54-1.62 (m, 1H), 1.50 (s, 9H), 1.31-1.41 (m, 1H), 0.98 (s, 9H);MS (ESI+) m/z 444 (M+H)⁺.

Example 227tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxohexan-2-yl(methyl)carbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-norleucine forN-(tert-butoxycarbonyl)-L-leucine in the procedure described in Example221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.21-8.24 (m, 1H), 7.42-7.44(m, 2H), 7.36 (t, J=7.4 Hz, 2H), 7.24-7.31 (m, 1H), 5.02 (m, 0.7H), 4.66(m, 0.3H), 4.34-4.47 (m, 1H), 3.59 (d, J=13.1 Hz, 1H), 3.45 (d, J=13.1Hz, 1H), 3.05-3.10 (m, 3H), 2.82-2.85 (m, 1H), 2.45-2.50 (m, 2H),2.37-2.45 (m, 1H), 2.31-2.37 (m, 1H), 2.24 (t, J=7.5 Hz, 1H), 2.05-2.12(m, 2H), 1.79-1.84 (m, 2H), 1.53-1.62 (m, 1H), 1.47 (s, 9H), 1.34-1.38(m, 1H), 1.21-1.29 (m, 4H), 0.75-0.81 (m, 3H); MS (ESI+) m/z 444 (M+H)⁺.

Example 228N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-bis(4-fluorophenyl)acetamide

The title compound was prepared by substituting2,2-bis(4-fluorophenyl)acetic acid for N-(tert-butoxycarbonyl)-L-leucinein the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.04 (d, J=7.0, 1H), 7.57-7.52 (m, 4H), 7.42 (d, J=7.1, 2H), 7.36(t, J=7.5, 2H), 7.27 (t, J=7.3, 1H), 7.12 (dt, J=15.8, 8.0, 4H), 5.23(s, 1H), 4.45-4.37 (m, 1H), 3.57 (d, J=13.1, 1H), 3.43 (d, J=13.1, 1H),2.78 (dd, J=9.1, 2.9, 1H), 2.54-2.47 (m, 1H), 2.47-2.43 (m, 1H), 2.40(dd, J=8.9, 7.3, 1H), 2.29 (dd, J=9.0, 3.0, 1H), 2.27-2.21 (m, 1H), 2.10(dq, J=12.2, 6.2, 1H), 1.84-1.75 (m, 1H), 1.60 (td, J=14.6, 7.3, 1H),1.41-1.31 (m, 1H); MS (ESI+) m/z 447 (M+H)⁺.

Example 229N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide

The title compound was prepared by substituting2-isopropyl-3-methylbutanoic acid for N-(tert-butoxycarbonyl)-L-leucinein the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.18 (d, J=7.5, 1H), 7.44 (d, J=7.5, 2H), 7.37 (t, J=7.6, 2H),7.27 (t, J=7.3, 1H), 4.52-4.37 (m, 1H), 3.62 (d, J=13.2, 1H), 3.44 (d,J=13.1, 1H), 2.83 (dd, J=9.0, 2.8, 1H), 2.62-2.51 (m, 2H), 2.48 (dd,J=8.8, 7.1, 1H), 2.34-2.26 (m, 2H), 2.17-2.05 (m, 3H), 1.92-1.81 (m,2H), 1.64 (dt, J=19.2, 7.1, 1H), 1.44-1.34 (m, 1H), 1.13 (dd, J=6.6,3.9, 6H), 0.98 (d, J=6.8, 6H); MS (ESI+) m/z 343 (M+H)⁺.

Example 230N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methylbutanamide

The title compound was prepared by substituting 3-methylbutanoic acidfor N-(tert-butoxycarbonyl)-L-leucine in the procedure described inExample 221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.36 (d, J=7.8, 1H),7.44 (d, J=7.6, 2H), 7.37 (t, J=7.5, 2H), 7.28 (t, J=7.2, 1H), 4.48-4.40(m, 1H), 3.60 (d, J=13.1, 1H), 3.45 (d, J=13.2, 1H), 2.82 (dd, J=9.0,2.2, 1H), 2.59-2.50 (m, 2H), 2.50-2.43 (m, 1H), 2.31 (tt, J=19.8, 7.9,3H), 2.23 (d, J=7.3, 2H), 2.17-2.08 (m, 1H), 1.87 (dd, J=13.1, 6.7, 1H),1.68-1.58 (m, 1H), 1.46-1.34 (m, 1H), 0.95 (d, J=6.6, 5H); MS (ESI+) m/z343 (M+H)⁺.

Example 231tert-butyl(2S)-2-({[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylate

The title compound was prepared by substituting(D)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid forN-(tert-butoxycarbonyl)-L-leucine and(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step E ofExample 16 for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅,temperature 90° C.) δ ppm 7.35-7.39 (m, 2H), 7.30 (t, J=7.5 Hz, 2H),7.21 (t, J=7.2 Hz, 2H), 4.86-4.88 (m, 1H), 4.25-4.30 (m, 1H), 4.08-4.12(m, 1H), 3.58 (d, J=13.2 Hz, 1H), 3.47 (d, J=13.1 Hz, 1H), 3.29 (td,J=12.8, 3.1 Hz, 1H), 2.80 (d, J=6.1 Hz, 1H), 2.49-2.56 (m, 1H),2.42-2.47 (m, 2H), 2.36 (dd, J=9.0, 3.2 Hz, 1H), 2.32 (d, J=7.7 Hz, 1H),2.22-2.26 (m, 1H), 2.03-2.11 (m, 1H), 1.79-1.93 (m, 1H), 1.49-1.68 (m,5H), 1.48 (s, 9H), 1.32-1.44 (m, 2H); MS (ESI+) m/z 428 (M+H)⁺.

Example 232tert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-valine forN-(tert-butoxycarbonyl)-L-leucine and(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step E ofExample 16 for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 221: ¹H NMR (501 MHz, pyridine-d₅,temperature 90° C.) δ ppm 7.35-7.39 (m, 3H), 7.29 (t, J=7.5 Hz, 2H),7.21 (t, J=7.3 Hz, 1H), 4.30-4.38 (m, 1H), 4.20-4.29 (m, 1H), 3.56 (d,J=13.0 Hz, 1H), 3.47 (d, J=13.2 Hz, 1H), 3.00-3.02 (m, 3H), 2.76 (d,J=6.5 Hz, 1H), 2.48-2.55 (m, 1H), 2.33-2.47 (m, 4H), 2.28-2.32 (m, 1H),2.04-2.12 (m, 1H), 1.81-1.88 (m, 1H), 1.49-1.59 (m, 1H), 1.46 (s, 9H),1.36-1.45 (m, 1H), 1.00 (d, J=6.5 Hz, 3H), 0.87 (d, J=6.7 Hz, 3H); MS(ESI+) m/z 430 (M+H)⁺.

Example 233tert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-norvaline forN-(tert-butoxycarbonyl)-L-leucine and(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step E ofExample 16 for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅,temperature 90° C.) δ ppm 7.36-7.38 (m, 2H), 7.28-7.31 (m, 3H), 7.21 (t,J=7.2 Hz, 1H), 4.70-4.79 (m, 1H), 4.23-4.29 (m, 1H), 3.57 (d, J=13.2 Hz,1H), 3.47 (d, J=13.2 Hz, 1H), 2.95 (s, 3H), 2.77-2.81 (m, 1H), 2.48-2.52(m, 1H), 2.39-2.46 (m, 2H), 2.36 (dd, J=9.0, 2.9 Hz, 1H), 2.30 (t, J=8.0Hz, 1H), 2.07 (dq, J=12.1, 6.1 Hz, 1H), 1.92-2.03 (m, 1H), 1.72-1.86 (m,2H), 1.50-1.59 (m, 1H), 1.47 (s, 9H), 1.36-1.44 (m, 1H), 1.25-1.35 (m,2H), 0.86 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 430 (M+H)⁺.

Example 234tert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-L-tert-leucine forN-(tert-butoxycarbonyl)-L-leucine and(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step E ofExample 16 for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.71 (m, 1H), 7.69 (d, J=9.6 Hz, 1H), 7.39-7.42 (m, 2H), 7.36 (t,J=7.5 Hz, 2H), 7.25-7.29 (m, 1H), 4.61 (d, J=9.7 Hz, 1H), 4.32-4.42 (m,1H), 3.53-3.56 (m, 1H), 3.37-3.40 (m, 1H), 2.63-2.66 (m, 1H), 2.41-2.51(m, 2H), 2.27-2.33 (m, 2H), 2.20-2.25 (m, 1H), 2.11-2.19 (m, 1H),1.80-1.91 (m, 1H), 1.61-1.73 (m, 1H), 1.48 (s, 9H), 1.35-1.44 (m, 1H),1.18 (s, 9H); MS (ESI+) m/z 430 (M+H)⁺.

Example 235N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide

The title compound was prepared by substituting2-isopropyl-3-methylbutanoic acid for N-(tert-butoxycarbonyl)-L-leucineand (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from StepE of Example 16 for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.18 (d, J=7.1, 1H), 7.44 (d, J=7.3, 2H), 7.36 (t, J=7.6, 2H), 7.27 (t,J=7.3, 1H), 4.51-4.37 (m, 1H), 3.61 (d, J=13.1, 1H), 3.44 (d, J=13.2,1H), 2.83 (dd, J=9.0, 2.8, 1H), 2.61-2.51 (m, 2H), 2.48 (dd, J=8.8, 7.2,1H), 2.35-2.24 (m, 2H), 2.16-2.06 (m, 3H), 1.93-1.81 (m, 2H), 1.64 (dt,J=14.6, 7.1, 1H), 1.44-1.35 (m, 1H), 1.13 (dd, J=6.6, 3.9, 6H), 0.98 (d,J=6.7, 6H); MS (ESI+) m/z 343 (M+H)⁺.

Example 236N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methylbutanamide

The title compound was prepared by substituting 3-methylbutanoic acidfor N-(tert-butoxycarbonyl)-L-leucine and(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step E ofExample 16 for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.30-8.17 (m, 1H), 7.43 (dd, J=11.2, 4.2, 2H), 7.37 (t, J=7.5,2H), 7.27 (t, J=7.3, 1H), 4.49-4.39 (m, 1H), 3.60 (d, J=13.1, 1H), 3.45(d, J=13.1, 1H), 2.89-2.78 (m, 1H), 2.55-2.49 (m, 2H), 2.45 (dd, J=10.4,5.3, 1H), 2.36-2.24 (m, 3H), 2.21 (d, J=7.1, 2H), 2.17-2.08 (m, 1H),1.90-1.79 (m, 1H), 1.62 (ddd, J=15.1, 12.3, 7.2, 1H), 1.40 (dtd, J=9.2,8.2, 6.1, 1H), 0.95 (d, J=6.6, 6H); MS (ESI+) m/z 301 (M+H)⁺.

Example 2372-cyclohexyl-2-hydroxy-N-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide

The title compound was prepared by substituting2-cyclohexyl-2-hydroxyacetic acid for N-(tert-butoxycarbonyl)-L-leucineand(3aS,4S,6aR)-2-(3-trifluoromethyl)benzyloctahydrocyclopenta[c]pyrrol-4-aminefrom Step A of Example 152 for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.59 (d, J=7.9, 0.5H), 8.40-8.33 (m, 0.5H), 7.97 (s, 0.5H), 7.77 (dd,J=42.9, 9.6, 1.5H), 7.48-7.39 (m, 1.5H), 7.29 (d, J=5.3, 0.5H),4.67-4.57 (m, 1H), 4.37 (t, J=3.8, 1H), 3.80 (dd, J=21.0, 13.1, 1H),3.27 (dd, J=64.7, 13.0, 1H), 2.86 (dd, J=13.0, 4.7, 1H), 2.73-2.61 (m,1H), 2.50-2.40 (m, 1H), 2.36 (d, J=9.1, 1H), 2.28-2.08 (m, 3H), 2.03(dd, J=14.3, 6.2, 0.5H), 2.00-1.93 (m, 0.5H), 1.92-1.88 (m, 0.5H),1.86-1.45 (m, 9.5H), 1.35-1.06 (m, 4H); MS (ESI+) m/z 425(M+H)⁺.

Example 238tert-butyl(S)-1-((3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-norvaline forN-(tert-butoxycarbonyl)-L-leucine and(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step C ofExample 14 for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 221: ¹H NMR (501 MHz, pyridine-d₅,temperature 90° C.) δ ppm 7.44-7.45 (bs, 2H), 7.35-7.40 (m, 2H),7.30-7.37 (m, 1H), 7.25-7.29 (m, 1H), 4.70-4.75 (bs, 1H), 4.37-4.43 (m,1H), 3.56 (d, J=12.9 Hz, 1H), 3.52 (d, J=12.8 Hz, 1H), 2.95 (s, 3H),2.71 (d, J=8.9 Hz, 1H), 2.62-2.68 (m, 1H), 2.44-2.48 (m, 2H), 2.25 (t,J=8.5 Hz, 1H), 2.14 (t, J=8.3 Hz, 1H), 1.91-1.99 (m, 1H), 1.66-1.80 (m,3H), 1.56-1.63 (m, 1H), 1.50 (s, 9H), 1.26-1.38 (m, 3H), 0.88 (t, J=7.4Hz, 3H); MS (ESI+) m/z 430 (M+H)⁺.

Example 239tert-butyl(S)-1-((3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-leucine forN-(tert-butoxycarbonyl)-L-leucine and(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step C ofExample 14 for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 221: ¹H NMR (501 MHz, pyridine-d₅,temperature 90° C.) δ ppm 7.44-7.49 (m, 2H), 7.36-7.40 (m, 2H),7.32-7.39 (m, 1H), 7.27 (t, J=7.4 Hz, 1H), 4.82-4.89 (m, 1H), 4.37-4.43(m, 1H), 3.63 (d, J=13.2 Hz, 1H), 3.50 (d, J=13.0 Hz, 1H), 2.94 (s, 3H),2.73 (dd, J=9.7, 1.8 Hz, 1H), 2.64-2.70 (m, 1H), 2.44-2.47 (m, 2H),2.22-2.28 (m, 1H), 2.15-2.19 (m, 1H), 1.88 (ddd, J=14.1, 8.2, 6.0 Hz,1H), 1.64-1.81 (m, 3H), 1.55-1.65 (m, 2H), 1.50 (s, 9H), 1.28-1.38 (m,1H), 0.90-0.93 (m, 6H); MS (ESI+) m/z 444 (M+H)⁺.

Example 240tert-butyl(S)-1-((3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate

Step A: (3aR,4R,6aS)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-amine wasprepared according to the procedure described in Example 14 Steps B-Csubstituting(S,E)-N-((3aR,6aS)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)-2-methylpropane-2-sulfinamidefrom Example 14 Step A for(S,E)-N-((3aS,6aR)-2-benzylhexahydrocyclopenta[c]pyrrol-4(5H)-ylidene)-2-methylpropane-2-sulfinamideprepared in Step A of Example 14 to give(3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine: ¹H NMR (500MHz, pyridine-d₅) δ ppm 7.44 (d, J=7.4, 2H), 7.36 (t, J=7.5, 2H), 7.28(t, J=7.3, 1H), 3.52 (q, J=13.0, 2H), 3.29 (q, J=7.3, 1H), 2.84 (dd,J=3.7, 9.3, 1H), 2.55-2.43 (m, 3H), 2.37-2.30 (m, 1H), 2.24 (d, J=5.3,1H), 1.74-1.64 (m, 2H), 1.62-1.53 (m, 1H), 1.34 (dd, J=5.0, 10.1, 1H).

Step B: The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-norvaline forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step Afor (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm7.40 (d, J=7.4, 2H), 7.34 (t, J=7.5, 2H), 7.25 (t, J=7.3, 1H), 4.79-4.68(m, 1H), 4.44-4.32 (m, 1H), 3.82 (d, J=13.2, 1H), 3.36 (d, J=13.0, 1H),2.94 (s, 3H), 2.80-2.65 (m, 2H), 2.46 (s, 1H), 2.35 (dd, J=9.2, 2.7,1H), 2.31-2.25 (m, 2H), 1.99 (dt, J=14.0, 7.0, 1H), 1.83-1.72 (m, 2H),1.70-1.56 (m, 2H), 1.49 (d, J=4.5, 1H), 1.48 (s, 9H), 1.41-1.23 (m, 3H),0.89 (t, J=7.4, 3H); MS (ESI+) m/z 430 (M+H)⁺.

Example 241tert-butyl(S)-1-((3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-leucine forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step A ofExample 240 for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅,temperature 90° C.) δ ppm 7.40-7.43 (m, 2H), 7.31-7.37 (m, 3H),7.23-7.30 (m, 1H), 4.82-4.89 (m, 1H), 4.35-4.42 (m, 1H), 3.35 (d, J=12.9Hz, 1H), 2.95 (s, 3H), 2.68-2.78 (m, 2H), 2.42-2.50 (m, 1H), 2.26-2.36(m, 3H), 1.89 (ddd, J=14.1, 8.2, 5.9 Hz, 1H), 1.71-1.82 (m, 2H),1.60-1.70 (m, 3H), 1.48-1.51 (m, 1H), 1.48 (s, 9H), 1.22-1.35 (m, 1H),0.88-0.98 (m, 6H); MS (ESI+) m/z 444 (M+H)⁺.

Example 242N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(methylsulfonyl)-L-leucinamide

Step A: (S)-tert-Butyl 2-amino-4-methylpentanoate hydrochloride (1.53 g,6.84 mmol) was dissolved in dichloromethane and triethylamine (3.15 mL,22.57 mmol). Methanesulfonyl chloride (0.638 mL, 8.21 mmol) was addeddropwise, and the reaction stirred at room temperature for 1 hour. Thereaction was quenched with saturated aqueous NaHCO₃ and extracted withdichloromethane (3×50 mL). The solvent was removed in vacuo to give(S)-tert-butyl 4-methyl-2-(methylsulfonamido)pentanoate: ¹H NMR (300MHz, CDCl₃) δ ppm 4.71 (d, J=9.7, 1H), 3.98 (td, J=9.5, 5.5, 1H), 2.92(s, 3H), 1.84 (dt, J=13.1, 6.6, 1H), 1.54 (s, 9H), 1.44-1.48 br s, 1H),0.96 (dd, J=6.6, 2.4, 6H); MS (ESI−) m/z 264(M−H)⁻. (S)-tert-Butyl4-methyl-2-(methylsulfonamido)pentanoate was dissolved in 10 mL of 4 NHCl in dioxane and stirred at room temperature overnight. The solventwas removed under a stream of nitrogen and under high vacuum to give(S)-4-methyl-2-(methylsulfonamido)pentanoic acid: ¹H NMR (300 MHz,CDCl₃) δ ppm 4.86 (d, J=9.6, 1H), 4.17 (td, J=9.6, 4.8, 1H), 3.18-3.07(m, 1H), 2.99 (s, 3H), 1.96-1.80 (m, 1H), 1.64 (dddd, J=23.4, 13.9, 9.1,5.0, 2H), 1.40 (t, J=7.3, 1H), 0.98 (dd, J=6.6, 3.3, 6H).

Step B: The title compound was prepared by substituting(S)-4-methyl-2-(methylsulfonamido)pentanoic acid from Step A forN-(tert-butoxycarbonyl)-L-leucine in the procedure described in Example221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.41 (d, J=9.4, 1H), 9.21 (d,J=7.3, 1H), 7.45 (d, J=7.2, 2H), 7.37 (t, J=7.5, 2H), 7.29 (t, J=7.3,1H), 4.53-4.42 (m, 2H), 3.62 (d, J=13.1, 1H), 3.47 (d, J=13.1, 1H), 3.19(s, 3H), 2.87 (dd, J=9.1, 2.9, 1H), 2.66-2.58 (m, 1H), 2.57-2.45 (m,2H), 2.35 (dd, J=9.0, 3.0, 1H), 2.31-2.25 (m, 1H), 2.14 (dq, J=12.0,6.0, 1H), 1.99 (dq, J=13.2, 6.5, 1H), 1.93-1.82 (m, 2H), 1.77 (ddd,J=13.8, 8.5, 5.6, 1H), 1.63 (dt, J=19.3, 7.2, 1H), 1.46-1.35 (m, 1H),0.82 (d, J=6.7, 3H), 0.79 (d, J=6.5, 3H); MS (ESI+) m/z 408 (M+H)⁺.

Example 243N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(methylsulfonyl)-L-leucinamide

The title compound was prepared by substituting(S)-4-methyl-2-(methylsulfonamido)pentanoic acid from Step A of Example242 for N-(tert-butoxycarbonyl)-L-leucine and(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step E ofExample 16 for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.40 (d, J=9.4, 1H), 9.21 (d, J=7.2, 1H), 7.43 (d, J=7.5, 2H),7.36 (t, J=7.6, 2H), 7.27 (t, J=7.3, 1H), 4.52-4.38 (m, 2H), 3.57 (d,J=13.1, 1H), 3.47 (d, J=13.1, 1H), 3.17 (s, 3H), 2.85 (dd, J=9.1, 2.2,1H), 2.59-2.48 (m, 2H), 2.37 (dd, J=9.0, 6.8, 2H), 2.25 (dd, J=8.7, 7.1,1H), 2.19 (dq, J=11.9, 5.9, 1H), 1.99 (dq, J=13.1, 6.5, 1H), 1.94-1.84(m, 2H), 1.80-1.66 (m, 2H), 1.44 (ddd, J=18.9, 12.5, 6.2, 1H), 0.82 (d,J=6.7, 3H), 0.79 (d, J=6.5, 3H); MS (ESI+) m/z 408 (M+H)⁺.

Example 244N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-neopentyl-L-leucinamide

Step A: (S)-tert-Butyl 2-amino-4-methylpentanoate hydrochloride (1.022g, 4.57 mmol) and pivalaldehyde (0.502 mL, 4.57 mmol) were combined indichloromethane (25 mL). Acetic acid (1.0 mL) was added. The reactionwas stirred at room temperature for 5 minutes, then PS-cyanoborohydride(3.90 g, 9.14 mmol) was added. The reaction was stirred at roomtemperature overnight, then filtered and the solvent was removed invacuo. The crude material was diluted with dichloromethane and basifiedusing saturated aqueous sodium bicarbonate to give (S)-tert-butyl4-methyl-2-(neopentylamino)pentanoate: ¹H NMR (300 MHz, CDCl₃) δ ppm3.04 (t, J=7.4, 1H), 2.40 (d, J=11.1, 1H), 2.09 (d, J=11.1, 1H),1.86-1.70 (m, 1H), 1.46 (s, 10H), 1.40 (t, J=7.2, 3H), 0.95-0.89 (m,6H), 0.89 (s, 9H), (S)-tert-butyl 4-methyl-2-(neopentylamino)pentanoatewas dissolved in 10 mL of 4 N HCl in dioxane and stirred at roomtemperature overnight. The solvent was removed under a stream ofnitrogen and under high vacuum to give(S)-4-methyl-2-(neopentylamino)pentanoic acid: ¹H NMR (300 MHz, DMSO-d₆)δ ppm 8.89-8.37 (m, 1H), 8.34-8.03 (m, 1H), 3.82 (t, J=6.5, 1H), 2.88(d, J=12.3, 1H), 2.62 (d, J=12.2, 1H), 1.83-1.67 (m, 2H), 1.67-1.56 (m,1H), 1.00 (s, 9H), 0.97-0.88 (m, 6H).

Step B: The title compound was prepared by substituting(S)-4-methyl-2-(neopentylamino)pentanoic acid from Step A forN-(tert-butoxycarbonyl)-L-leucine in the procedure described in Example221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.06-8.08 (m, 1H), 7.43-7.46(m, 2H), 7.37 (t, J=7.5 Hz, 2H), 7.28 (t, J=7.3 Hz, 1H), 4.39-4.46 (m,1H), 3.61 (d, J=13.1 Hz, 1H), 3.46 (d, J=13.1 Hz, 1H), 3.27 (dd, J=8.5,5.6 Hz, 1H), 2.84 (dd, J=8.7, 2.5 Hz, 1H), 2.49-2.61 (m, 2H), 2.43-2.49(m, 2H), 2.36 (dd, J=9.1, 2.9 Hz, 1H), 2.32-2.36 (m, 1H), 2.30 (dd,J=8.8, 7.0 Hz, 1H), 2.15 (dq, J=12.1, 6.1 Hz, 1H), 1.80-1.96 (m, 2H),1.55-1.76 (m, 4H), 1.39-1.46 (m, 1H), 0.94 (s, 9H), 0.93 (d, J=6.8 Hz,3H), 0.87 (d, J=6.5 Hz, 3H); MS (ESI+) m/z 400 (M+H)⁺.

Example 245N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-neopentyl-L-leucinamide

The title compound was prepared by substituting(S)-4-methyl-2-(neopentylamino)pentanoic acid from Step A of Example 244for N-(tert-butoxycarbonyl)-L-leucine and(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine of Step E fromExample 16 for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.07-8.09 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, J=7.5 Hz, 2H), 7.28(t, J=7.3 Hz, 1H), 4.43 (p, J=6.2 Hz, 1H), 3.60 (d, J=13.1 Hz, 1H), 3.45(d, J=13.1 Hz, 1H), 3.26 (dd, J=8.6, 5.6 Hz, 1H), 2.86 (dd, J=8.9, 2.6Hz, 1H), 2.47-2.60 (m, 2H), 2.42-2.47 (m, 2H), 2.36 (dd, J=9.1, 3.0 Hz,1H), 2.29-2.35 (m, 1H), 2.29 (dd, J=8.7, 7.3 Hz, 1H), 2.14 (dq, J=12.1,6.0 Hz, 1H), 1.81-1.95 (m, 2H), 1.52-1.76 (m, 4H), 1.44 (dq, J=13.2, 6.6Hz, 1H), 0.94 (s, 9H), 0.93 (d, J=6.6 Hz, 3H), 0.87 (d, J=6.5 Hz, 3H);MS (ESI+) m/z 400 (M+H)⁺.

Example 246N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-neopentyl-L-norvalinamide

Step A: (S)-2-(Neopentylamino)pentanoic acid hydrochloride was preparedby substituting (S)-tert-butyl 2-amino pentanoate for (S)-tert-butyl2-amino-4-methylpentanoate in the procedure described in Step A ofExample 244: ¹H NMR (300 MHz, DMSO-d₆) δ ppm 8.49 (ddd, J=34.9, 23.2,14.1, 2H), 3.84 (dd, J=8.0, 5.2, 1H), 2.86 (d, J=12.3, 1H), 2.66 (d,J=12.3, 1H), 1.99-1.73 (m, 2H), 1.58-1.42 (m, 1H), 1.41-1.26 (m, 1H),1.00 (s, 9H), 0.92 (t, J=7.3, 3H); MS (ESI+) m/z 188 (M+H)⁺.

Step B: The title compound was prepared by substituting(S)-2-(neopentylamino)pentanoic acid from Step A forN-(tert-butoxycarbonyl)-L-leucine and(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step E ofExample 16 for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.00-8.03 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, J=7.5 Hz, 2H), 7.28(t, J=7.3 Hz, 1H), 4.40-4.45 (m, 1H), 3.60 (d, J=13.1 Hz, 1H), 3.45 (d,J=13.1 Hz, 1H), 3.20 (t, J=6.5 Hz, 1H), 2.85 (dd, J=8.8, 2.6 Hz, 1H),2.52-2.60 (m, 1H), 2.46-2.52 (m, 1H), 2.38-2.46 (m, 2H), 2.31-2.38 (m,2H), 2.28 (dd, J=8.8, 7.3 Hz, 1H), 2.13 (dq, J=12.1, 6.0 Hz, 1H),1.79-1.92 (m, 2H), 1.71-1.80 (m, 1H), 1.65-1.73 (m, 1H), 1.57-1.65 (m,1H), 1.39-1.57 (m, 3H), 0.93 (s, 9H), 0.86 (t, J=7.3 Hz, 3H); MS (ESI−)m/z 384 (M−H)⁻.

Example 247tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate

Step A: (S)-2-(tert-Butoxycarbonylamino)-4,4-dimethylpentanoic acid (50mg, 0.204 mmol) and iodomethane (0.102 mL, 1.631 mmol) were dissolved intetrahydrofuran (2 mL) at 0° C. and sodium hydride (24.46 mg, 0.611mmol) was added. The reaction was stirred at 0° C. for a half hour andat room temperature overnight. The reaction was cooled to 0° C. andethyl acetate (1 mL) was added followed by dropwise quenching with water(2 mL). The solvent was removed in vacuo and the crude material waspartitioned between ether and water. The ether layer was separated. Theaqueous layer was acidified to pH-5 using 1 N citric acid and extractedwith ethyl acetate. The organic layer was washed with 1 N sodiumthiosulfate and brine, dried (Na₂SO₄) and concentrated in vacuo. Thecompound was purified using a 4 g silica gel cartridge with a gradientof 0-3% methanol/dichloromethane over 20 minutes to give(S)-2-(tert-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid: ¹HNMR (300 MHz, DMSO-d₆) δ ppm 12.63 (s, 1H), 4.57 (ddd, J=74.4, 9.5, 3.1,1H), 2.69 (s, 3H), 1.83-1.53 (m, 2H), 1.39 (s, 9H), 0.89 (s, 9H); MS(DSI+) m/z 260(M+H)⁺.

Step B: The title compound was prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid fromStep A for N-(tert-butoxycarbonyl)-L-leucine in the procedure describedin Example 221: ¹H NMR (400 MHz, pyridine-d₅, temperature 90° C.) δ ppm7.35-7.38 (m, 2H), 7.29 (t, J=7.5 Hz, 2H), 7.20 (t, J=7.3 Hz, 1H),6.98-7.02 (m, 1H), 4.85-4.90 (m, 1H), 4.20-4.26 (m, 1H), 3.56 (d, J=13.2Hz, 1H), 3.48 (d, J=13.2 Hz, 1H), 2.92 (s, 3H), 2.79 (d, J=6.5 Hz, 1H),2.51-2.55 (m, 1H), 2.39-2.47 (m, 2H), 2.37 (dd, J=9.0, 3.1 Hz, 1H), 2.32(dd, J=8.9, 7.2 Hz, 1H), 2.19 (dd, J=14.3, 5.6 Hz, 1H), 2.00-2.08 (m,1H), 1.77-1.86 (m, 1H), 1.62 (dd, J=14.3, 6.9 Hz, 1H), 1.50-1.56 (m,1H), 1.48 (s, 9H), 1.35-1.47 (m, 1H), 0.95 (s, 9H); MS (DSI+) m/z458(M+H)⁺.

Example 248tert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid fromStep A of Example 247 for N-(tert-butoxycarbonyl)-L-leucine and(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step E ofExample 16 for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 7.41-7.43 (m, 2H), 7.36 (t, J=7.5 Hz, 2H), 7.25-7.29 (m, 1H), 5.14(m, 0.7H), 4.79 (m, 0.2H), 4.35 (dd, J=5.6, 2.9 Hz, 1H), 3.56-3.60 (m,1H), 3.40-3.44 (m, 1H), 3.02-3.09 (m, 3H), 2.76-2.84 (m, 1H), 2.42-2.51(m, 2H), 2.31-2.40 (m, 2H), 2.17-2.24 (m, 2H), 2.06-2.15 (m, 1H),1.79-1.83 (m, 1H), 1.62-1.70 (m, 1H), 1.51-1.63 (m, 2H), 1.47 (s, 9H),1.32-1.42 (m, 1H), 0.94 (s, 9H); MS (ESI+) m/z 458 (M+H)⁺.

Example 249(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-morpholin-4-ylpentanamide

Step A: (S)-tert-Butyl 2-amino-4-methylpentanoate (1.0042 g, 5.36 mmol),potassium carbonate (2.446 g, 17.69 mmol), and1-bromo-2-(2-bromoethoxy)ethane (1.368 g, 5.90 mmol) were combined inacetonitrile (30 mL). The reaction was heated at 80° C. overnight. Thereaction was cooled and filtered and the solvent removed in vacuo. Thecrude material was purified by silica gel chromatography using 5-50%ethyl acetate/hexanes to give (S)-tert-butyl4-methyl-2-morpholinopentanoate: ¹H NMR (300 MHz, CDCl₃) δ ppm 3.76-3.58(m, 4H), 3.11 (dd, J=6.9, 8.1, 1H), 2.74-2.53 (m, 4H), 1.71-1.55 (m,2H), 1.51-1.34 (m, 10H), 0.92 (dd, J=6.6, 7.3, 6H). (S)-tert-Butyl4-methyl-2-morpholinopentanoate (0.637 g, 2.475 mmol) and 4 Nhydrochloric acid in dioxane (5 mL) were combined. The reaction mixturewas stirred at ambient temperature for 24 hours, then the solventremoved in vacuo to give (S)-4-methyl-2-morpholinopentanoic acidhydrochloride: MS (DCI+) m/z 202(M+H)⁺.

Step B: (S)-4-Methyl-2-morpholinopentanoic acid hydrochloride (363 mg,1.526 mmol) and triethylamine (0.387 mL, 2.77 mmol) were combined indichloromethane (10 mL). 1-Hydroxybenzotriazole hydrate (234 mg, 1.526mmol) and N¹-((ethylimino)methylene)-N³,N³-dimethylpropane-1,3-diamine(0.270 mL, 1.526 mmol) were added, and the reaction was stirred for 15minutes. Then (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine(300 mg, 1.387 mmol) from Example 16 Step E was added, and the reactionmixture was stirred at ambient temperature for 24 hours. The reactionwas quenched with aqueous sodium bicarbonate and extracted withdichloromethane. The solvent was removed in vacuo and the crude materialwas purified by silica gel chromatography using 1-10% methanol (2 Nammonia)/dichloromethane to give the title compound: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.27 (d, J=7.3, 1H), 7.44 (d, J=7.4, 2H), 7.37 (t,J=7.5, 2H), 7.27 (dd, J=9.8, 17.3, 1H), 4.51-4.39 (m, 1H), 3.74 (t,J=4.5, 4H), 3.62 (d, J=13.1, 1H), 3.45 (d, J=13.1, 1H), 3.29-3.21 (m,1H), 2.87 (dd, J=2.4, 9.0, 1H), 2.79 (dt, J=4.5, 9.3, 2H), 2.75-2.68 (m,2H), 2.55 (d, J=14.8, 2H), 2.49-2.43 (m, 1H), 2.35 (dd, J=2.6, 8.9, 1H),2.32-2.26 (m, 1H), 2.11 (dq, J=6.1, 12.1, 1H), 1.86 (dd, J=6.6, 12.2,3H), 1.67-1.55 (m, 2H), 1.41 (dt, J=6.2, 20.1, 1H), 0.94 (dd, J=6.2,11.1, 6H); MS (HI+) m/z 400(M+H)⁺.

Example 250(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide

The title compound was prepared by substituting 1,4-dibromobutane for1-bromo-2-(2-bromoethoxy)ethane in Step A of Example 249: ¹H NMR (500MHz, pyridine-d₅) δ ppm 7.98-7.93 (m, 1H), 7.47-7.41 (m, 2H), 7.36 (t,J=7.4, 2H), 7.31-7.24 (m, 1H), 4.45 (t, J=5.2, 1H), 3.61 (d, J=13.1,1H), 3.45 (d, J=13.1, 1H), 3.16 (dd, J=5.1, 9.3, 1H), 2.87 (d, J=7.9,1H), 2.73-2.65 (m, 2H), 2.66-2.52 (m, 4H), 2.44 (dd, J=6.2, 8.9, 1H),2.36 (dd, J=2.1, 9.0, 1H), 2.30-2.23 (m, 1H), 2.12 (dq, J=6.0, 11.9,1H), 1.95-1.78 (m, 3H), 1.66-1.54 (m, 6H), 1.47-1.36 (m, 1H), 1.00 (d,J=6.4, 3H), 0.91 (d, J=6.4, 3H); MS (ESI+) m/z 384(M+H)⁺.

Example 251(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-piperidin-1-ylpentanamide

The title compound was prepared by substituting 1,5-dibromopentane for1-bromo-2-(2-bromoethoxy)ethane in Step A of Example 249: ¹H NMR (500MHz, pyridine-d₅) δ ppm 8.09 (d, J=7.5, 1H), 7.44 (d, J=7.3, 2H), 7.36(d, J=7.7, 2H), 7.28 (t, J=7.3, 1H), 4.46-4.36 (m, 1H), 3.61 (d, J=13.1,1H), 3.45 (d, J=13.1, 1H), 3.21 (dd, J=8.1, 5.4, 1H), 2.85 (d, J=8.8,1H), 2.70-2.50 (m, 6H), 2.49-2.44 (m, 1H), 2.32 (dt, J=27.0, 7.9, 2H),2.11 (dq, J=12.1, 6.1, 1H), 1.95-1.79 (m, 3H), 1.63-1.47 (m, 6H),1.45-1.32 (m, 3H), 0.94 (d, J=5.8, 6H); MS (ESI+) m/z 398(M+H)⁺.

Example 252N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

Step A: (3aR,4S,6aS)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-amine (0.83g, 3.84 mmol) from Step A of Example 33 was dissolved in anhydrousdichloromethane (5 mL) under nitrogen and triethylamine (0.588 mL, 4.22mmol) was added followed by di-tert-butyl dicarbonate (1.010 mL, 4.22mmol). The reaction was stirred at 25° C. for 1 hour. Thin-layerchromatography (SiO₂, 5% methanol/dichloromethane) showed completereaction. The volatiles were removed in vacuo, and the crude materialwas purified using a 24 g silica gel cartridge eluting with a gradientof 1-5% methanol (2 N ammonia)/dichloromethane over 20 minutes to givetert-butyl(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylcarbamate:¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.54 (d, J=6.3, 1H), 7.43 (d, J=7.3,2H), 7.36 (t, J=7.4, 2H), 7.27 (t, J=7.2, 1H), 4.12 (q, J=12.1, 1H),3.59 (d, J=12.9, 1H), 3.43 (d, J=13.0, 1H), 2.78 (s, 1H), 2.59-2.49 (m,2H), 2.49-2.41 (m, 1H), 2.37-2.25 (m, 2H), 2.16-2.05 (m, 1H), 1.88 (td,J=13.1, 6.1, 1H), 1.65 (td, J=14.8, 7.3, 1H), 1.52 (s, 9H), 1.43-1.35(m, 1H); MS (ESI+) m/z 317(M+H)⁺.

Step B:tert-Butyl(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylcarbamate(1.06 g, 3.35 mmol) from Step A and ethanol (20 mL) were added to 20%Pd(OH)₂ on carbon, wet (212.0 mg, 1.51 mmol) in a 250 mL stainless steelpressure bottle. The reaction mixture was stirred for 16 hours under 30psi hydrogen at room temperature. The mixture was filtered through anylon membrane and the solvent was removed in vacuo to givetert-butyl(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-ylcarbamate: ¹HNMR (500 MHz, pyridine-d₅) δ ppm 4.02-3.99 (m, 1H), 3.03 (d, J=10.4,1H), 2.98-2.89 (m, 1H), 2.84 (dd, J=10.1, 6.4, 1H), 2.61-2.50 (m, 3H),2.06-1.98 (m, 1H), 1.91 (td, J=12.9, 6.7, 1H), 1.63 (dt, J=19.5, 7.6,1H), 1.53 (s, 9H), 1.29-1.23 (m, 1H); MS (ESI+) m/z 227(M+H)⁺.

Step C:tert-Butyl(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-ylcarbamate (0.71g, 3.14 mmol) from Step B, triethylamine (0.656 mL, 4.71 mmol), and3-(trifluoromethyl)benzene-1-sulfonyl chloride (0.552 mL, 3.45 mmol)were combined in dichloromethane (10.0 mL). The reaction was stirred atroom temperature for 16 hours and quenched with saturated aqueousNaHCO₃. The organic layer was separated and concentrated in vacuo. Theresultant crude material was applied to a SF-25-60 g cartridge(Analogix®, Burlington, Wis.) and purified with a gradient of 0-2%methanol/dichloromethane over 20 minutes to givetert-butyl(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.30 (s, 1H), 8.14 (d, J=7.8, 1H),7.84 (d, J=7.8, 1H), 7.65 (t, J=7.8, 1H), 6.83-6.71 (m, 1H), 3.88-3.76(m, 1H), 3.61 (dd, J=10.1, 3.3, 1H), 3.24 (dd, J=9.8, 8.1, 1H), 3.12 (d,J=5.6, 2H), 2.64-2.44 (m, 2H), 1.99-1.78 (m, 2H), 1.55 (tt, J=12.4, 7.7,1H), 1.48 (s, 9H), 1.38-1.20 (m, 1H); MS (ESI−) m/z 433(M−H)⁻.

Step D:tert-Butyl(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate(0.814 g, 1.874 mmol) from Step C and HCl (26.2 mL, 52.5 mmol, 2 M inether) in ethanol (3 mL) were combined. The reaction was stirred at roomtemperature overnight and then the volatiles were removed. The compoundwas purified using a 24 g silica gel cartridge with a gradient of 1-10%methanol (2 N ammonia)/dichloromethane over 20 minutes to give(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amine:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.37 (s, 1H), 8.21 (d, J=7.9, 1H),7.93 (d, J=7.9, 1H), 7.75 (t, J=7.9, 1H), 3.41 (dd, J=9.8, 2.8, 1H),3.13 (dd, J=9.7, 3.1, 1H), 3.03-2.98 (m, 1H), 2.97-2.89 (m, 2H),2.56-2.45 (m, 1H), 2.14 (tdd, J=8.7, 5.9, 2.9, 1H), 1.5-2.0 (m,2H)1.95-1.85 (m, 1H), 1.79-1.69 (m, 1H), 1.32-1.15 (m, 2H); MS (ESI+)m/z 335(M+H)⁻.

Step E: The title compound was prepared by substituting(S)-4-methyl-2-(neopentylamino)pentanoic acid from Step A of Example 244for N-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.38 (s, 1H), 8.19-8.22 (m, 2H), 7.90-7.93 (m, 1H), 7.72 (t, J=7.8 Hz,1H), 4.21-4.29 (m, 1H), 3.87 (dd, J=9.9, 2.6 Hz, 1H), 3.25 (dd, J=8.6,5.6 Hz, 1H), 3.15-3.21 (m, 2H), 2.97 (dd, J=9.6, 7.0 Hz, 1H), 2.43-2.60(m, 3H), 2.28-2.32 (m, 1H), 1.79-2.01 (m, 3H), 1.67-1.78 (m, 1H), 1.69(ddd, J=13.6, 7.9, 5.7 Hz, 1H), 1.51-1.60 (m, 2H), 1.32 (ddt, J=9.3,12.8, 6.4 Hz, 1H), 0.93 (d, J=6.6 Hz, 3H), 0.93 (s, 9H), 0.86 (d, J=6.5Hz, 3H); MS (ESI+) m/z 518 (M+H)⁺.

Example 253N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substituting(S)-2-(Neopentylamino)pentanoic acid from Step A of Example 246 forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D of Example 252 for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.38-8.39 (bs, 1H), 8.19-8.21 (m, 1H), 8.13-8.16 (m, 1H), 7.90-7.93 (m,1H), 7.72 (t, J=7.8 Hz, 1H), 4.21-4.28 (m, 1H), 3.87 (dd, J=9.9, 2.8 Hz,1H), 3.15-3.21 (m, 3H), 2.97 (dd, J=9.6, 7.3 Hz, 1H), 2.45-2.59 (m, 2H),2.40 (d, J=11.2 Hz, 1H), 2.31 (d, J=11.2 Hz, 1H), 1.93-2.00 (m, 1H),1.76-1.89 (m, 2H), 1.61-1.93 (m, 1H), 1.61-1.70 (m, 1H), 1.41-1.58 (m,3H), 1.31 (ddt, J=9.4, 13.0, 6.5 Hz, 1H), 0.92 (s, 9H), 0.86 (t, J=7.3Hz, 3H); MS (ESI+) m/z 504 (M+H)⁺.

Example 254N²-neopentyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

Step A:(3aS,4R,6aR)-2-(3-(Trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminewas prepared by substituting(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step E ofExample 16 for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein Step A of Example 252 and following steps B-D in Example 252: ¹H NMR(500 MHz, pyridine-d₅) δ ppm 8.37 (s, 1H), 8.20 (d, J=7.9, 1H), 7.93 (d,J=7.8, 1H), 7.74 (t, J=7.8, 1H), 3.40 (dd, J=9.8, 2.8, 1H), 3.13 (dd,J=9.7, 3.1, 1H), 3.00 (dd, J=12.9, 5.7, 1H), 2.93 (ddd, J=12.0, 9.7,7.9, 2H), 2.52 (qd, J=8.6, 4.3, 1H), 2.17-2.09 (m, 1H), 1.94-1.84 (m,1H), 1.78-1.69 (m, 1H), 1.67-1.33 (m, 2H), 1.30-1.15 (m, 2H); MS (ESI+)m/z 335(M+H)⁻.

Step B: The title compound was prepared by substituting(S)-4-methyl-2-(neopentylamino)pentanoic acid from Step A of Example 244for N-(tert-butoxycarbonyl)-L-leucine and(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.37-8.38 (bs, 1H), 8.15-8.19 (m, 2H), 7.90-7.92 (m, 1H), 7.71 (t, J=7.8Hz, 1H), 4.22-4.28 (m, 1H), 3.88 (dd, J=9.9, 2.8 Hz, 1H), 3.23 (dd,J=8.5, 5.7 Hz, 1H), 3.19 (dd, J=9.7, 2.8 Hz, 1H), 3.15 (dd, J=9.9, 7.6Hz, 1H), 2.96 (dd, J=9.6, 7.2 Hz, 1H), 2.50-2.59 (m, 2H), 2.41-2.44 (m,1H), 2.32 (d, J=11.2 Hz, 1H), 1.92-2.01 (m, 1H), 1.82-1.92 (m, 2H),1.60-1.78 (m, 1H), 1.69 (ddd, J=13.5, 7.8, 5.7 Hz, 1H), 1.50-1.59 (m,2H), 1.32 (ddt, J=9.4, 13.0, 6.5 Hz, 1H), 0.92 (s, 9H), 0.92 (d, J=6.6Hz, 3H), 0.86 (d, J=6.5 Hz, 3H); MS (ESI+) m/z 518 (M+H)⁺.

Example 255N²-neopentyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substituting(S)-2-(neopentylamino)pentanoic acid from Step A of Example 246 forN-(tert-butoxycarbonyl)-L-leucine and(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A of Example 254 for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.37-8.38 (bs, 1H), 8.18 (d, J=7.9 Hz, 1H), 8.09-8.11 (m, 1H), 7.90-7.92(m, 1H), 7.71 (t, J=7.8 Hz, 1H), 4.20-4.27 (m, 1H), 3.88 (dd, J=9.9, 2.8Hz, 1H), 3.20 (dd, J=6.6, 3.1 Hz, 1H), 3.16-3.20 (m, 1H), 3.14 (dd,J=9.9, 7.8 Hz, 1H), 2.96 (dd, J=9.6, 7.3 Hz, 1H), 2.46-2.61 (m, 2H),2.38 (d, J=11.3 Hz, 1H), 2.33 (d, J=11.3 Hz, 1H), 1.92-1.99 (m, 1H),1.83-1.90 (m, 1H), 1.76-1.83 (m, 1H), 1.66-1.87 (m, 1H), 1.61-1.70 (m,1H), 1.38-1.58 (m, 3H), 1.26-1.37 (m, 1H), 0.92 (s, 9H), 0.85 (t, J=7.3Hz, 3H); MS (ESI+) m/z 504 (M+H)⁺.

Example 256N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

Step A:(3aR,4S,6aS)-2-(4-(Trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminewas prepared by substituting 4-(trifluoromethyl)benzene-1-sulfonylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in Step C ofExample 252 and following the procedure of Step D in Example 252: ¹H NMR(500 MHz, pyridine-d₅) δ ppm 8.15 (d, J=8.2, 2H), 7.92 (d, J=8.3, 2H),3.40 (dd, J=9.8, 2.9, 1H), 3.13 (dd, J=9.7, 3.2, 1H), 3.06-2.93 (m, 3H),2.54 (s, 1H), 2.21-2.12 (m, 1H), 1.93-1.85 (m, 1H), 1.78-1.69 (m, 1H),1.67-1.33 (m, 2H), 1.33-1.15 (m, 2H); MS (ESI+) m/z 335(M+H)⁺.

Step B: The title compound was prepared by substituting(S)-4-methyl-2-(neopentylamino)pentanoic acid from Step A of Example 244for N-(tert-butoxycarbonyl)-1-leucine and(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.20-8.23 (m, 1H), 8.13-8.16 (m, 2H), 7.89-7.92 (m, 2H), 4.21-4.29 (m,1H), 3.86 (dd, J=9.9, 2.8 Hz, 1H), 3.22-3.28 (m, 1H), 3.15-3.22 (m, 2H),2.99 (dd, J=9.6, 7.0 Hz, 1H), 2.50-2.62 (m, 2H), 2.43-2.47 (m, 1H),2.28-2.32 (m, 1H), 1.92-2.02 (m, 1H), 1.80-1.92 (m, 2H), 1.64-1.76 (m,1H), 1.69 (ddd, J=13.5, 7.7, 5.8 Hz, 1H), 1.50-1.61 (m, 2H), 1.25-1.40(m, 1H), 0.93 (d, J=6.8 Hz, 3H), 0.93 (s, 9H), 0.86 (d, J=6.5 Hz, 3H);MS (ESI+) m/z 518 (M+H)⁺.

Example 257N²-neopentyl-N¹-(3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-1-norvalinamide

The title compound was prepared by substituting(S)-2-(neopentylamino)pentanoic acid from Step A of Example 246 forN-(tert-butoxycarbonyl)-1-leucine and(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A of Example 256 for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.37-8.38 (bs, 1H), 8.13-8.18 (m, 3H), 7.89-7.91 (m, 2H), 4.21-4.28 (m,1H), 3.86 (dd, J=9.9, 2.9 Hz, 1H), 3.16-3.22 (m, 3H), 2.98 (dd, J=9.6,7.3 Hz, 1H), 2.47-2.61 (m, 2H), 2.41 (d, J=11.2 Hz, 1H), 2.32 (d, J=11.2Hz, 1H), 1.93-2.00 (m, 1H), 1.78-1.88 (m, 2H), 1.63-1.70 (m, 1H),1.41-1.58 (m, 3H), 1.28-1.36 (m, 1H), 0.93 (s, 9H), 0.86 (t, J=7.3 Hz,3H); MS (ESI+) m/z 504 (M+H)⁺.

Example 258N-(tert-butoxycarbonyl)-N-methyl-N-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-1-phenylalaninamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-1-phenylalanine forN-(tert-butoxycarbonyl)-1-leucine and(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A of Example 256 for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.09-8.12 (m, 2H), 7.83-7.86 (m, 2H),7.52-7.59 (bs, 1H), 7.28-7.32 (m, 2H), 7.23-7.28 (m, 2H), 7.15-7.21 (m,1H), 4.95-5.12 (m, 1H), 4.09 (p, J=6.9 Hz, 1H), 3.62 (dd, J=10.4, 3.4Hz, 1H), 3.48 (dd, J=14.0, 7.0 Hz, 1H), 3.26 (dd, J=10.1, 7.9 Hz, 1H),3.10-3.18 (m, 1H), 3.04-3.13 (m, 1H), 2.97 (s, 3H), 2.46-2.57 (m, 1H),2.36-2.46 (m, 1H), 1.86-1.96 (m, 1H), 1.74-1.83 (m, 1H), 1.44-1.55 (m,1H), 1.42-1.46 (m, 1H), 1.38 (s, 9H), 1.21-1.32 (m, 1H); MS (ESI+) m/z596 (M+H).

Example 259 tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-1-norvaline forN-(tert-butoxycarbonyl)-1-leucine and(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A of Example 256 for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.06-8.09 (m, 2H), 7.79-7.82 (m, 2H), 7.40 (d,J=3.1 Hz, 1H), 4.66-4.76 (m, 1H), 4.07 (p, J=6.8 Hz, 1H), 3.65 (dd,J=10.2, 3.4 Hz, 1H), 3.28 (dd, J=10.2, 7.7 Hz, 1H), 3.06-3.17 (m, 2H),2.93 (s, 3H), 2.53-2.62 (m, 1H), 2.45-2.53 (m, 1H), 1.93-2.02 (m, 1H),1.86-1.95 (m, 1H), 1.70-1.85 (m, 2H), 1.47-1.57 (m, 1H), 1.45 (s, 9H),1.27-1.37 (m, 2H), 1.22-1.32 (m, 1H), 0.86 (t, J=7.4 Hz, 3H); MS (ESI+)m/z 548 (M+H)⁺.

Example 260N²-neopentyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-1-norvalinamide

Step A:(3aS,4R,6aR)-2-(4-(Trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminewas prepared by following the procedures described in Example 252 StepsA-D substituting(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Step E ofExample 16 for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein Step A of Example 252 and 4-(trifluoromethyl)benzene-1-sulfonylchloride for 3-(trifluoromethyl)benzene-1-sulfonyl chloride in theprocedure described in Step C of Example 252: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.15 (d, J=8.2, 2H), 7.92 (d, J=8.3, 2H), 3.40 (dd,J=9.8, 2.9, 1H), 3.13 (dd, J=9.7, 3.2, 1H), 3.06-2.93 (m, 3H), 2.54 (s,1H), 2.21-2.12 (m, 1H), 1.93-1.85 (m, 1H), 1.78-1.69 (m, 1H), 1.67-1.33(m, 2H),1.33-1.15 (m, 2H); MS (ESI+) m/z 335(M+H)⁺.

Step B: The title compound was prepared by substituting(S)-2-(neopentylamino)pentanoic acid from Step A of Example 246 forN-(tert-butoxycarbonyl)-1-leucine and(3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.09-8.14 (m, 3H), 7.88-7.91 (m, 2H), 4.20-4.26 (m, 1H), 3.88 (dd,J=9.9, 2.9 Hz, 1H), 3.13-3.21 (m, 3H), 2.98 (dd, J=9.6, 7.4 Hz, 1H),2.49-2.64 (m, 2H), 2.38 (d, J=11.2 Hz, 1H), 2.33 (d, J=11.2 Hz, 1H),1.91-1.99 (m, 1H), 1.76-1.90 (m, 2H), 1.66-1.95 (m, 1H), 1.62-1.71 (m,1H), 1.41-1.58 (m, 3H), 1.33 (ddt, J=9.5, 13.0, 6.5 Hz, 1H), 0.92 (s,9H), 0.86 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 504 (M+H)⁺.

Example 261N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-neopentyl-1-leucinamide

Step A:(3aR,4S,6aS)-2-(4-Fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminewas prepared by substituting 4-fluorobenzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in Step C of Example 252and following Step D in Example 252: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.05-7.96 (m, 2H), 7.38-7.31 (m, 2H), 3.34 (dd, J=9.8, 3.0, 1H), 3.08(dd, J=9.7, 3.3, 1H), 3.05-2.98 (m, 1H), 2.97-2.89 (m, 2H), 2.59-2.49(m, 1H), 2.20-2.10 (m, 1H), 1.95-1.85 (m, 1H), 1.79-1.69 (m, 1H),1.67-1.33 (m, 2H) 1.31-1.15 (m, 2H); MS (ESI+) m/z 285(M+H)⁺.

Step B: The title compound was prepared by substituting(S)-4-methyl-2-(neopentylamino)pentanoic acid from Step A of Example 244for N-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.21-8.23 (m, 1H), 7.99-8.02 (m, 2H), 7.32 (t, J=8.5 Hz, 2H), 4.23-4.29(m, 1H), 3.78 (dd, J=9.9, 2.9 Hz, 1H), 3.26 (dd, J=8.5, 5.7 Hz, 1H),3.12-3.18 (m, 2H), 2.96 (dd, J=9.6, 7.1 Hz, 1H), 2.51-2.60 (m, 2H),2.44-2.47 (m, 1H), 2.29-2.32 (m, 1H), 1.93-2.01 (m, 1H), 1.81-1.93 (m,2H), 1.67-1.79 (m, 1H), 1.70 (ddd, J=13.5, 7.8, 5.7 Hz, 1H), 1.53-1.60(m, 2H), 1.23-1.36 (m, 1H), 0.93 (d, J=6.7 Hz, 3H), 0.93 (s, 9H), 0.87(d, J=6.5 Hz, 3H); MS (ESI+) m/z 468 (M+H)⁺.

Example 262tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate

Step A:tert-butyl(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-ylcarbamate fromStep B of Example 252 (250 mg, 1.105 mmol),2-bromo-5-(trifluoromethyl)pyridine (250 mg, 1.105 mmol), andtriethylamine (0.462 mL, 3.31 mmol) were combined in ethanol (0.6 mL).The reaction was heated at 81° C. for 16 hours. To the reaction mixturewas added 50% water/ethanol (5 mL), and the precipitate was collected byfiltration. This crude material was purified using a 12 g silica gelcartridge with a gradient of 0-1.5% methanol (2 Nammonia)/dichloromethane over 20 minutes to givetert-butyl(3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.62 (s, 1H), 7.76 (d, J=6.4, 1H),7.68 (d, J=8.6, 1H), 6.38 (d, J=8.8, 1H), 4.10 (s, 1H), 3.73 (d, J=10.4,1H), 3.65 (s, 1H), 3.61-3.53 (m, 1H), 3.32 (d, J=10.1, 1H), 2.82-2.71(m, 2H), 2.15 (td, J=12.6, 6.8, 1H), 1.97 (dt, J=13.1, 6.4, 1H), 1.74(dq, J=15.6, 7.9, 1H), 1.54 (s, 9H), 1.45-1.34 (m, 1H); MS(DCI+) m/z372(M+H)⁺.

Step B:tert-butyl(3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate(282 mg, 0.759 mmol) from Step A was combined with 4 N HCl in1,4-dioxane (2.5 mL, 9.87 mmol). The reaction was stirred at roomtemperature overnight and then the volatiles were removed in vacuo. Thecompound was purified using a 12 g silica gel cartridge eluting with agradient of 0-7.5% methanol (2 N ammonia)/dichloromethane over 20minutes to give(3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-amine:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.64 (s, 1H), 7.69 (dd, J=8.9, 2.5,1H), 6.38 (d, J=8.9, 1H), 4.95 (s, 2H), 3.56 (dd, J=23.7, 14.1, 3H),3.25 (d, J=6.2, 1H), 3.11 (q, J=6.0, 1H), 2.83-2.68 (m, 1H), 2.35 (ddd,J=13.1, 7.9, 5.3, 1H), 2.02 (dtd, J=13.5, 8.3, 5.5, 1H), 1.92 (ddd,J=18.3, 7.4, 5.6, 1H), 1.46-1.30 (m, 2H); MS (ESI+) m/z 272(M+H)⁺.

Step C: The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-L-neopentylglycine forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step B for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.52 (s, 1H), 7.81 (d, J=5.8, 1H), 7.60 (dd, J=8.9, 2.5, 1H), 7.07 (d,J=7.0, 1H), 6.35 (d, J=8.9, 1H), 4.53 (td, J=8.3, 4.7, 1H), 4.30-4.18(m, 1H), 3.72 (dd, J=11.3, 3.5, 1H), 3.65 (dd, J=11.3, 7.6, 1H), 3.57(dd, J=11.1, 7.8, 1H), 3.31 (dd, J=11.2, 3.9, 1H), 2.80-2.67 (m, 2H),2.10 (ddd, J=19.9, 13.5, 5.8, 2H), 1.93 (td, J=13.1, 7.7, 1H), 1.74 (dd,J=14.3, 8.0, 1H), 1.64 (dq, J=12.9, 7.8, 1H), 1.50 (s, 9H), 1.44-1.33(m, 1H), 1.00 (s, 9H); MS (ESI+) m/z 499(M+H)⁺.

Example 263isopropyl(S)-1-oxo-1-((3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate

Step A: (S)-2-Aminopentanoic acid (1.874 g, 16 mmol) was dissolved indioxane (16 mL) and 16 mL of 1 N NaOH at 0° C. 1 M Isopropylcarbonochloridate in toluene (16.00 mL, 16.00 mmol) was addedsimultaneously with 16 mL of 1 N NaOH dropwise using addition funnels.The reaction was stirred at 0° C. for 3 hours and allowed to warm toroom temperature overnight to give a biphasic solution pH 8-9. Thesolvent was reduced in volume. The aqueous layer was washed with ether,acidified with 1 M KHSO₄, and extracted with ethyl acetate to give(S)-2-(isopropoxycarbonylamino)pentanoic acid: ¹H NMR (300 MHz, DMSO-d₆)δ ppm 12.43 (s, 1H), 7.25 (d, J=8.0, 1H), 4.73 (hept, J=6.3, 1H), 3.89(td, J=8.6, 5.2, 1H), 1.68-1.46 (m, 2H), 1.41-1.22 (m, 2H), 1.16 (d,J=6.2, 6H), 0.85 (t, J=7.3, 3H); MS (DCI+) m/z 204(M+H)⁺

Step B: The title compound was prepared by substituting(S)-2-(isopropoxycarbonylamino)pentanoic acid from Step A forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step B of Example 262 for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.52 (d, J=1.0, 1H), 7.94 (dd, J=4.3, 2.4, 1H), 7.60 (dd, J=8.9, 2.5,1H), 7.07 (d, J=7.0, 1H),6.35 (d, J=8.9, 1H), 5.03 (dt, J=12.5, 6.2,1H), 4.49 (dd, J=13.9, 8.0, 1H), 4.35-4.19 (m, 1H), 3.73 (dd, J=11.3,3.6, 1H), 3.66 (dd, J=11.3, 7.6, 1H), 3.57 (dd, J=11.0, 8.0, 1H), 3.32(dd, J=11.2, 3.9, 1H), 2.81-2.66 (m, 2H), 2.10 (dt, J=12.4, 7.0, 1H),2.04-1.88 (m, 2H), 1.86-1.75 (m, 1H), 1.72-1.60 (m, 1H), 1.57-1.46 (m,2H), 1.45-1.33 (m, 1H), 1.21 (d, J=6.2, 3H), 1.18 (d, J=6.2, 3H), 0.87(t, J=7.4, 3H); MS (ESI+) m/z 457(M+H)⁺.

Example 264tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(6-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate

Step A:(3aR,4S,6aS)-2-(6-(Trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-aminewas prepared as described for Example 262 Steps A-B substituting2-bromo-6-(trifluoromethyl)pyridine for2-bromo-5-(trifluoromethyl)pyridine in Step A of Example 262: ¹H NMR(500 MHz, pyridine-d₅) δ ppm 7.53 (t, J=7.9, 1H), 6.98 (d, J=7.2, 1H),6.51 (d, J=8.6, 1H), 3.49 (dd, J=20.2, 8.4, 3H), 3.19 (dd, J=10.7, 4.8,1H), 3.08 (q, J=6.0, 1H), 2.78-2.69 (m, 1H), 2.32 (td, J=12.2, 5.8, 1H),2.04-1.95 (m, 1H), 1.89 (dt, J=12.7, 5.7, 1H), 1.80-1.49 (m, 2H),1.44-1.36 (m, 1H), 1.35-1.27 (m, 1H); MS (ESI+) m/z 272(M+H)⁺.

Step B: The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-L-neopentylglycine forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(6-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm7.78 (s, 1H), 7.45 (s, 1H), 7.05 (s, 1H), 6.91 (d, J=7.3, 1H), 6.47 (d,J=8.6, 1H), 4.53 (td, J=8.3, 4.7, 1H), 4.28-4.19 (m, 1H), 3.67-3.56 (m,2H), 3.52 (dd, J=10.9, 7.9, 1H), 3.27 (dd, J=11.0, 3.7, 1H), 2.76-2.66(m, 2H), 2.13 (dd, J=14.3, 4.6, 1H), 2.06 (dt, J=12.8, 6.4, 1H), 1.91(td, J=13.3, 7.9, 1H), 1.73 (dd, J=14.3, 8.0, 1H), 1.62 (dq, J=15.1,7.7, 1H), 1.50 (s, 9H), 1.37 (qd, J=7.9, 4.9, 1H), 1.00 (s, 9H); MS(ESI+) m/z 499(M+H)⁺.

Example 265tert-butyl(S)-4,4-dimethyl-1-((3aR,4S,6aS)-2-(2-(methylsulfonyl)pyrimidin-5-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-ylcarbamate

Step A:(3aR,4S,6aS)-2-(2-(Methylsulfonyl)pyrimidin-5-yl)octahydrocyclopenta[c]pyrrol-4-aminewas prepared as described in Example 262 Steps A-B substituting5-bromo-2-(methylsulfonyl)pyrimidine for2-bromo-5-(trifluoromethyl)pyridine in Step A of Example 262: ¹H NMR(500 MHz, pyridine-d₅) δ ppm 8.48 (s, 2H), 4.96 (s, 3H), 3.71 (dd,J=11.6, 8.6, 1H), 3.66 (d, J=6.1, 2H), 3.41 (dd, J=11.7, 4.9, 1H), 3.11(q, J=6.0, 1H), 2.80-2.71 (m, 1H), 2.37-2.30 (m, 1H), 2.00 (ddd, J=21.4,10.5, 6.5, 1H), 1.90 (td, J=12.5, 5.6, 1H), 1.82-1.51 (m, 2H), 1.44-1.29(m, 2H); MS (ESI+) m/z 283(M+H)⁺.

Step B: The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-L-neopentylglycine forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(2-(methylsulfonyl)pyrimidin-5-yl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.34 (s, 2H), 7.79 (ddd, J=3.5, 1.7, 0.7, 1H), 7.10-6.93 (m, 1H), 4.52(td, J=8.2, 4.7, 1H), 4.27 (qd, J=7.1, 5.4, 1H), 3.90 (d, J=11.1, 3H),3.85 (dd, J=8.1, 3.9, 1H), 3.77 (dd, J=12.1, 7.6, 1H), 3.67 (dd, J=11.8,7.9, 1H), 3.42 (dd, J=11.8, 4.1, 1H), 2.79-2.63 (m, 2H), 2.16-2.02 (m,2H), 1.97-1.83 (m, 1H), 1.72 (dd, J=14.3, 8.0, 1H), 1.68-1.56 (m, 1H),1.49 (s, 9H), 1.44-1.30 (m, 1H), 0.99 (s, 9H); MS (ESI+) m/z 510(M+H)⁺.

Example 266 (S)-tert-butyl2-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate

(S)-1-(tert-Butoxycarbonyl)pyrrolidine-2-carboxylic acid (53.1 mg, 0.247mmol), and2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouroniumhexafluorophosphate(V) (94 mg, 0.247 mmol) were combined indichloromethane (2 mL). After 10 minutes,(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amine(75 mg, 0.224 mmol) from Step A of Example 254 was added. After stirringfor 10 more minutes, N-ethyl-N-isopropylpropan-2-amine (0.098 mL, 0.561mmol) was added and the reaction mixture was stirred at room temperatureovernight. The reaction was quenched with saturated NaHCO₃ solution,extracted with 2 mL of dichloromethane, washed with 0.1 N HCl, andconcentrated in vacuo. The crude material was purified using a 12 gsilica gel cartridge with a gradient of 1-5% methanol (2 Nammonia)/dichloromethane over 20 minutes to give the title compound: ¹HNMR (501 MHz, pyridine-d₅, temperature 90° C.) δ ppm 8.29-8.30 (bs, 1H),8.13 (d, J=7.9 Hz, 1H), 7.83 (d, J=7.8 Hz, 1H), 7.66-7.72 (m, 1H), 7.64(t, J=7.9 Hz, 1H), 4.29-4.32 (m, 1H), 4.06-4.10 (m, 1H), 3.68-3.71 (m,1H), 3.46-3.51 (m, 1H), 3.34-3.42 (m, 1H), 3.26 (dd, J=9.9, 7.4 Hz, 1H),3.06-3.17 (m, 2H), 2.55-2.57 (m, 2H), 2.09 (d, J=3.0 Hz, 1H), 1.88-1.98(m, 3H), 1.80-1.88 (m, 1H), 1.59-1.68 (m, 1H), 1.55 (dd, J=13.2, 8.7 Hz,1H), 1.50 (s, 9H), 1.25-1.37 (m, 1H); MS (ESI+) m/z 532 (M+H)⁺.

Example 267tert-butyl(1R)-1-isopropyl-3-oxo-[((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]propylcarbamate

The title compound was prepared by substituting(R)-3-(tert-butoxycarbonylamino)-4-methylpentanoic acid for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid in theprocedure described in Example 266: ¹H NMR (501 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.29-8.31 (bs, 1H), 8.14 (d, J=7.8 Hz, 1H),7.83 (d, J=7.8 Hz, 1H), 7.76-7.80 (bs, 1H), 7.65 (t, J=7.9 Hz, 1H),6.53-6.62 (m, 1H), 4.08-4.15 (m, 1H), 4.02-4.08 (m, 1H), 3.67 (dd,J=10.1, 3.2 Hz, 1H), 3.28 (dd, J=9.9, 7.9 Hz, 1H), 3.08-3.16 (m, 2H),2.46-2.59 (m, 4H), 1.87-1.98 (m, 2H), 1.79-1.87 (m, 1H), 1.50-1.62 (m,1H), 1.48 (s, 9H), 1.24-1.36 (m, 1H), 0.89-0.93 (m, 6H); MS (ESI+) m/z548 (M+H)⁺.

Example 268tert-butyl(2S)-2-{[((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate

The title compound was prepared by substituting(S)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid in theprocedure described in Example 266: ¹H NMR (501 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.29-8.30 (bs, 1H), 8.14 (d, J=7.8 Hz, 1H),7.83 (d, J=7.9 Hz, 1H), 7.64 (t, J=7.9 Hz, 1H), 7.39-7.43 (bs, 1H),4.82-4.84 (m, 1H), 4.04-4.12 (m, 2H), 3.68 (dd, J=10.1, 3.3 Hz, 1H),3.28-3.32 (m, 1H), 3.23-3.28 (m, 1H), 3.08-3.16 (m, 2H), 2.48-2.58 (m,2H), 2.16-2.21 (m, 1H), 1.89-1.96 (m, 1H), 1.78-1.85 (m, 1H), 1.49-1.63(m, 5H), 1.47 (s, 9H), 1.32-1.39 (m, 1H), 1.23-1.32 (m, 1H); MS (ESI+)m/z 544 (M+H)⁺.

Example 269N-(tert-butoxycarbonyl)-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-L-phenylalanine for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D of Example 252 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.28-8.32 (m, 1H), 8.11-8.17 (m, 1H),7.82-7.93 (m, 2H), 7.63-7.69 (m, 1H), 7.21-7.29 (m, 4H), 7.16-7.21 (m,1H), 7.07-7.15 (m, 1H), 4.65-4.70 (m, 1H), 4.0 (m, 1H), 3.52-3.62 (m,1H), 3.26-3.31 (m, 1H), 3.12-3.21 (m, 2H), 3.03-3.11 (m, 2H), 2.42-2.48(m, 1H), 2.31-2.36 (m, 1H), 1.81-1.88 (m, 1H), 1.69-1.77 (m, 1H),1.37-1.48 (m, 1H), 1.42 (s, 9H), 1.16-1.26 (m, 1H); MS (ESI+) m/z 599(M+H)⁻.

Example 270N-(tert-butoxycarbonyl)-N-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-phenylalanine for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D of Example 252 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.65-8.52 (m, 1H), 8.38 (s, 1H), 8.22 (d, J=7.8, 1H), 7.93 (d,J=7.8, 1H), 7.75 (t, J=7.8, 1H), 7.39-7.23 (m, 5H), 5.40-5.29 (m, 1H),4.30-4.14 (m, 1H), 3.84-3.72 (m, 1H), 3.65-3.45 (m, 1H), 3.13 (d, J=5.4,2H), 3.06 (s, 3H), 3.03 (dd, J=9.7, 7.6, 1H), 2.89 (dd, J=9.5, 7.5, 1H),2.41 (dd, J=13.4, 6.1, 1H), 2.39-2.30 (m, 1H), 1.95-1.80 (m, 1H), 1.74(s, 1H), 1.55-1.40 (m, 1H), 1.36 (s, 5H), 1.25 (s, 4H), 1.22-1.15 (m,1H); MS (ESI+) m/z 596 (M+H)⁺.

Example 271 (S)-tert-butyl2-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate

The title compound was prepared by substituting(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D of Example 252 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.42-8.59 (m, 1H), 8.36-8.38 (bs, 1H), 8.16-8.22 (m, 1H), 7.92 (d,J=7.3 Hz, 1H), 7.74 (t, J=7.5 Hz, 1H), 4.31-4.55 (m, 1H), 4.09-4.31 (m,1H), 3.73-3.90 (m, 1H), 3.48-3.68 (m, 1H), 3.27-3.48 (m, 1H), 3.06-3.25(m, 2H), 2.85-3.03 (m, 1H), 2.42-2.65 (m, 2H), 1.72-2.22 (m, 5H),1.60-1.72 (m, 1H), 1.53-1.57 (bs, 5H), 1.49-1.54 (bs, 4H), 1.4 (m, 1H),1.13-1.26 (m, 1H); MS (ESI+) m/z 532 (M+H)⁺,549 (M+NH₄)⁺.

Example 272tert-butyl(1R)-1-isopropyl-3-oxo-[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]propylcarbamate

The title compound was prepared by substituting(R)-3-(tert-butoxycarbonylamino)-4-methylpentanoic acid for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D of Example 252 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.30-8.31 (bs, 1H), 8.14 (d, J=7.8 Hz, 1H),7.84 (d, J=7.6 Hz, 1H), 7.76-7.85 (bs, 1H), 7.66 (t, J=7.8 Hz, 1H),6.50-6.69 (bs, 1H), 4.08-4.16 (m, 1H), 3.64-3.72 (m, 1H), 3.24-3.33 (m,1H), 3.12 (d, J=5.2 Hz, 2H), 2.42-2.63 (m, 4H), 1.89-2.00 (m, 2H),1.79-1.89 (m, 1H), 1.49-1.63 (m, 1H), 1.48 (s, 9H), 1.23-1.33 (m, 2H),0.88-0.95 (m, 6H); MS (ESI+) m/z 570 (M+Na)⁺.

Example 273 tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-valine for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D of Example 252 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.30-8.32 (bs, 1H), 8.14 (d, J=7.8 Hz, 1H),7.84 (d, J=7.8 Hz, 1H), 7.64 (t, J=7.8 Hz, 1H), 7.58-7.69 (bs, 1H), 4.32(d, J=9.5 Hz, 1H), 4.03-4.12 (m, 1H), 3.68 (dd, J=10.2, 3.3 Hz, 1H),3.27-3.31 (m, 1H), 3.08-3.16 (m, 2H), 3.00 (s, 3H), 2.53-2.61 (m, 1H),2.46-2.53 (m, 1H), 2.33-2.43 (m, 1H), 1.85-1.93 (m, 1H), 1.77-1.85 (m,1H), 1.47-1.54 (m, 1H), 1.45 (s, 9H), 1.21-1.30 (m, 1H), 0.97 (d, J=6.5Hz, 3H), 0.86 (d, J=6.7 Hz, 3H); MS (ESI+) m/z 570 (M+Na)⁺.

Example 274tert-butyl(2S)-2-{[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate

The title compound was prepared by substituting(S)-1-(tert-butoxycarbonyl)piperidine-2-carboxylic acid for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D of Example 252D for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.37-8.38 (bs, 1H), 8.32 (d, J=5.2 Hz, 1H), 8.19 (d, J=7.9 Hz,1H), 7.91 (d, J=7.9 Hz, 1H), 7.71 (t, J=7.8 Hz, 1H), 4.07-4.23 (m, 2H),3.84 (dd, J=9.9, 2.2 Hz, 1H), 3.46 (td, J=12.9, 2.8 Hz, 1H), 3.16 (d,J=9.2 Hz, 1H), 3.12 (dd, J=9.5, 7.6 Hz, 1H), 2.90-2.94 (m, 1H),2.41-2.57 (bs, 2H), 2.24-2.29 (m, 1H), 1.75-1.97 (m, 2H), 1.53-1.65 (m,3H), 1.49-1.55 (m, 2H), 1.48 (s, 9H), 1.42-1.51 (m, 1H), 1.29-1.39 (m,1H), 1.17-1.29 (m, 1H); MS (ESI+) m/z 563 (M+H)⁺.

Example 275tert-butyl(3S)-3-{[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate

The title compound was prepared by substituting(S)-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylicacid for (S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D of Example 252 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.26-8.27 (bs, 1H), 8.08-8.10 (m, 1H),7.81-7.84 (m, 1H), 7.62 (t, J=7.8 Hz, 1H), 7.29-7.36 (m, 1H), 7.12-7.14(m, 2H), 7.08-7.11 (m, 2H), 4.83-5.02 (m, 1H), 4.78 (d, J=15.6 Hz, 1H),4.67 (d, J=15.6 Hz, 1H), 3.90-3.97 (m, 1H), 3.52 (dd, J=10.1, 3.3 Hz,1H), 3.30 (dd, J=15.3, 4.8 Hz, 1H), 3.14 (dd, J=9.9, 7.8 Hz, 1H), 3.11(dd, J=15.4, 6.3 Hz, 1H), 3.04-3.08 (m, 2H), 2.45-2.53 (m, 1H),2.38-2.45 (m, 1H), 1.64-1.75 (m, 2H), 1.50 (s, 9H), 1.35-1.46 (m, 1H),1.15-1.25 (m, 1H); MS (ESI+) m/z 594 (M+H)⁺,611 (M+NH₄)⁺.

Example 276tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-L-neopentylglycine for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D of Example 252D for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.29-8.30 (bs, 1H), 8.14 (d, J=7.9 Hz, 1H),7.83 (d, J=7.9 Hz, 1H), 7.79-7.87 (bs, 1H), 7.64 (t, J=7.8 Hz, 1H),7.05-7.18 (bs, 1H), 4.46-4.51 (m, 1H), 4.06-4.14 (m, 1H), 3.67 (dd,J=10.2, 2.8 Hz, 1H), 3.27 (dd, J=10.1, 7.6 Hz, 1H), 3.07-3.15 (m, 2H),2.50-2.59 (m, 2H), 2.08 (dd, J=14.2, 4.6 Hz, 1H), 1.85-1.92 (m, 1H),1.77-1.85 (m, 1H), 1.70 (dd, J=14.2, 8.0 Hz, 1H), 1.48-1.54 (m, 1H),1.47 (s, 9H), 1.21-1.30 (m, 1H), 0.96 (s, 9H); MS (ESI+) m/z 562 (M+H)⁺.

Example 277 tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)hexan-2-yl)carbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-norleucine for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D of Example 252 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.44 (d, J=6.9 Hz, 1H), 8.36-8.38 (bs, 1H), 8.19 (d, J=7.9 Hz,1H), 7.91 (d, J=7.6 Hz, 1H), 7.72 (t, J=7.8 Hz, 1H), 5.0 (m, 0.7H), 4.6(m, 0.3H), 4.18-4.24 (m, 1H), 3.83-3.86 (m, 1H), 3.13-3.19 (m, 1H),3.08-3.13 (m, 1H), 2.97-3.10 (bs, 3H), 2.91 (dd, J=9.4, 7.4 Hz, 1H),2.44-2.59 (m, 2H), 1.98-2.19 (m, 1H), 1.84-1.98 (m, 1H), 1.72-1.85 (m,2H), 1.47-1.60 (m, 1H), 1.44-1.46 (m, 9H), 1.22-1.34 (m, 1H), 1.15-1.34(m, 4H), 0.76-0.81 (m, 3H); MS (ESI+) m/z 562 (M+H)⁺,579 (M+NH₄)⁺.

Example 278 tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-norvaline for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D of Example 252 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.30-8.31 (bs, 1H), 8.14 (d, J=7.9 Hz, 1H),7.84 (d, J=7.8 Hz, 1H), 7.64 (t, J=7.8 Hz, 1H), 7.49 (d, J=5.6 Hz, 1H),4.72-4.73 (m, 1H), 4.04-4.11 (m, 1H), 3.67 (dd, J=10.1, 3.3 Hz, 1H),3.26 (dd, J=10.1, 7.7 Hz, 1H), 3.10-3.13 (m, 2H), 2.93 (s, 3H),2.46-2.59 (m, 2H), 1.86-2.01 (m, 2H), 1.71-1.84 (m, 2H), 1.46-1.58 (m,1H), 1.45 (s, 9H), 1.29-1.36 (m, 2H), 1.22-1.30 (m, 1H), 0.86 (t, J=7.3Hz, 3H); MS (ESI+) m/z 548 (M+H)⁺.

Example 279isopropyl(S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate

The title compound was prepared by substituting(S)-2-(isopropoxycarbonylamino)pentanoic acid from Step A of Example 263for (S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A of Example 256 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (501 MHz, pyridine-d₅)δ ppm 8.08 (d, J=8.2, 2H), 7.96 (d, J=4.8, 1H), 7.82 (d, J=8.3, 2H),7.18 (d, J=4.5, 2H), 5.01 (hept, J=6.2, 1H), 4.45 (dd, J=14.0, 7.7, 1H),4.11 (dt, J=13.0, 6.7, 1H), 3.67 (dd, J=10.2, 3.0, 1H), 3.30 (dd,J=10.2, 7.6, 1H), 3.16-3.07 (m, 2H), 2.57 (h, J=9.3, 2H), 1.99-1.85 (m,2H), 1.86-1.72 (m, 2H), 1.58-1.50 (m, 1H), 1.45 (ddd, J=20.8, 11.7, 7.2,2H), 1.26 (ddd, J=13.1, 10.9, 6.6, 1H), 1.19 (d, J=6.2, 3H), 1.16 (d,J=6.2, 3H), 0.84 (t, J=7.4, 3H); MS (ESI+) m/z 520 (M+H)⁺.

Example 280isopropyl(S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate

The title compound was prepared by substitutingN¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamidefrom Example 382 for (S)-tert-butyl 2-amino-4-methylpentanoate andisopropyl carbonochloridate for methanesulfonyl chloride in theprocedure described in Example 242: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.22-8.15 (m, 1H), 7.65 (d, J=8.0, 2H), 7.51 (d, J=7.9, 2H), 7.39-7.34(m, 1H), 5.11-5.02 (m, 1H), 4.74-4.64 (m, 1H), 4.48-4.40 (m, 1H), 3.57(d, J=13.7, 1H), 3.46 (d, J=13.6, 1H), 2.90-2.82 (m, 1H), 2.62-2.49 (m,2H), 2.44-2.38 (m, 1H), 2.34-2.28 (m, 1H), 2.24 (dd, J=9.7, 6.3, 1H),2.10-2.00 (m, 2H), 1.92-1.81 (m, 2H), 1.65-1.57 (m, 1H), 1.55-1.45 (m,2H), 1.42-1.33 (m, 1H), 1.22 (d, J=6.2, 3H), 1.15 (d, J=6.2, 3H), 0.81(t, J=7.4, 3H); MS (ESI+) m/z 470 (M+H)⁺.

Example 281 (3aS,4R,6aR)-N-neopentyl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

(3aS,4R,6aR)-2-(3-(Trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amine(100 mg, 0.299 mmol) from Step A of Example 254 and pivalaldehyde (0.043mL, 0.389 mmol) were combined in dichloromethane (1 mL). Acetic acid(0.3 mL) was added. The reaction was stirred at room temperature for 20minutes, then PS-cyanoborohydride (147 mg, 0.359 mmol) was added. Thereaction was stirred at room temperature for 72 hours, then filtered.The reaction mixture was washed with 1 N NaHCO₃ and concentrate invacuo. The crude material was purified using a 12 g silica gel cartridgewith a gradient of 0-4% methanol (2 N ammonia)/dichloromethane to givethe title compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.40-8.41 (bs,1H), 8.22-8.25 (m, 1H), 7.92-7.95 (m, 1H), 7.75 (t, J=7.8 Hz, 1H), 3.42(dd, J=9.8, 3.1 Hz, 1H), 3.17 (dd, J=9.6, 3.1 Hz, 1H), 3.06-3.10 (m,1H), 2.96 (dd, J=9.6, 7.7 Hz, 1H), 2.74-2.77 (m, 1H), 2.48-2.53 (m, 1H),2.30 (d, J=11.3 Hz, 1H), 2.22-2.27 (m, 1H), 2.22 (d, J=7.9 Hz, 1H),1.78-1.92 (m, 2H), 1.18-1.31 (m, 3H), 0.90 (s, 9H); MS (ESI+) m/z 405(M+H)⁺.

Example 282(3aR,4S,6aS)-N-neopentyl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared by substituting(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D of Example 252 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 281: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.40-8.41 (bs, 1H), 8.22-8.25 (m, 1H), 7.92-7.95 (m, 1H), 7.75 (t,J=7.9 Hz, 1H), 3.42 (dd, J=9.8, 3.1 Hz, 1H), 3.17 (dd, J=9.6, 3.0 Hz,1H), 3.05-3.09 (m, 1H), 2.96 (dd, J=9.6, 7.7 Hz, 1H), 2.73-2.77 (m, 1H),2.48-2.53 (m, 1H), 2.30 (d, J=11.3 Hz, 1H), 2.22-2.27 (m, 1H), 2.21 (d,J=11.0 Hz, 1H), 1.78-1.93 (m, 2H), 1.18-1.32 (m, 3H), 0.90 (s, 9H); MS(ESI+) m/z 405 (M+H)⁺.

Example 283(3aR,4S,6aS)-N-isopropyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared by substituting(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A of Example 256 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.14-8.22 (m, 2H), 7.91-7.98 (m,2H), 3.40 (dd, J=9.7, 3.0 Hz, 1H), 3.16 (dd, J=9.6, 3.3 Hz, 1H), 3.06(dd, J=9.7, 7.8 Hz, 1H), 2.99 (dd, J=9.6, 7.7 Hz, 1H), 2.85-2.90 (m,1H), 2.74 (hept, J=6.2 Hz, 1H), 2.46-2.53 (m, 1H), 2.14-2.25 (m, 1H),1.80-1.91 (m, 2H), 1.07-1.43 (m, 3H), 1.00 (d, J=6.2 Hz, 3H), 0.96 (d,J=6.1 Hz, 3H); MS (ESI+) m/z 377 (M+H)⁺.

Example 284(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N-isopropyloctahydrocyclopenta[c]pyrrol-4-amine

Step A:tert-butyl(3aR,4S,6aS)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamatewas prepared by substituting2-chloro-4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in Step C of Example 252:¹H NMR (500 MHz, pyridine-d₅) δ 8.33 (d, J=8.0, 1H), 8.00 (s, 1H),7.77-7.68 (m, 2H), 4.04-3.96 (m, 1H), 3.83 (d, J=9.5, 1H), 3.48 (dd,J=10.2, 7.5, 1H), 3.41-3.29 (m, 2H), 2.72-2.59 (m, 2H), 2.02 (td,J=12.0, 6.4, 1H), 1.90 (qd, J=7.1, 4.5, 1H), 1.64 (ddd, J=16.1, 12.4,8.8, 1H), 1.50 (s, 9H), 1.41-1.32 (m, 1H); MS (ESI+) m/z 486(M+NH₄)⁺.

Step B:(3aR,4S,6aS)-2-{[2-Chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-aminewas prepared by substitutingtert-butyl(3aR,4S,6aS)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamatefrom Step A fortert-butyl(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamatein the procedure described in Step D of Example 252: ¹H NMR (500 MHz,pyridine-d₅) δ 8.34 (d, J=8.2, 1H), 8.01 (s, 1H), 7.75 (d, J=8.3, 1H),3.55 (dd, J=10.1, 3.1, 1H), 3.38-3.31 (m, 2H), 3.28 (dd, J=9.9, 3.7,1H), 3.10 (q, J=6.1, 1H), 2.70-2.60 (m, 1H), 2.31-2.22 (m, 1H), 1.93(ddd, J=11.1, 8.2, 5.7, 1H), 1.87-1.76 (m, 1H), 1.74-1.49 (m, 2H),1.37-1.24 (m, 2H); MS (ESI+) m/z 369(M+H)⁺.

Step C: The title compound was prepared by substituting(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-aminefrom Step A for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.37 (d, J=8.2 Hz, 1H), 8.03 (d,J=1.7 Hz, 1H), 7.77 (d, J=9.0 Hz, 1H), 3.56 (dd, J=10.0, 3.1 Hz, 1H),3.41 (dd, J=10.1, 7.8 Hz, 1H), 3.31-3.38 (m, 2H), 2.97 (q, J=6.3 Hz,1H), 2.78 (hept, J=6.2 Hz, 1H), 2.58-2.63 (m, 1H), 2.30-2.35 (m, 1H),1.87-1.96 (m, 2H), 1.05-1.67 (m, 1H), 1.21-1.37 (m, 2H), 1.01 (d, J=6.2Hz, 3H), 0.98 (d, J=6.1 Hz, 3H); MS (ESI+) m/z 411 (M+H)⁺.

Example 285(3aS,4R,6aR)-N-(4-fluorobenzyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared by substituting 4-fluorobenzaldehyde forpivalaldehyde in the procedure described in Example 281: ¹H NMR (500MHz, pyridine-d₅) δ ppm 8.39-8.40 (bs, 1H), 8.23 (d, J=7.9 Hz, 1H), 7.94(d, J=7.9 Hz, 1H), 7.76 (t, J=7.8 Hz, 1H), 7.41 (dd, J=8.3, 5.5 Hz, 2H),7.11-7.15 (m, 2H), 3.71 (d, J=13.2 Hz, 1H), 3.67 (d, J=13.2 Hz, 1H),3.39 (dd, J=9.8, 3.1 Hz, 1H), 3.16 (dd, J=9.6, 3.0 Hz, 1H), 3.06 (dd,J=9.8, 8.0 Hz, 1H), 2.96 (dd, J=9.6, 7.6 Hz, 1H), 2.83-2.88 (m, 1H),2.47-2.56 (m, 1H), 2.30-2.36 (m, 1H), 1.92-2.09 (m, 1H), 1.87-1.94 (m,1H), 1.80-1.88 (m, 1H), 1.29-1.37 (m, 1H), 1.20-1.29 (m, 1H); MS (ESI+)m/z 443 (M+H)⁺.

Example 286(3aR,4S,6aS)-N-(4-fluorobenzyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared by substituting(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step D of Example 252 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand 4-fluorobenzaldehyde for pivalaldehyde in the procedure described inExample 281: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.39-8.40 (bs, 1H),8.22-8.24 (m, 1H), 7.93-7.95 (m, 1H), 7.75 (t, J=7.8 Hz, 1H), 7.41 (dd,J=8.3, 5.5 Hz, 2H), 7.13 (t, J=8.7 Hz, 2H), 3.71 (d, J=13.3 Hz, 1H),3.67 (d, J=13.2 Hz, 1H), 3.39 (dd, J=9.8, 3.1 Hz, 1H), 3.16 (dd, J=9.6,3.0 Hz, 1H), 3.06 (dd, J=9.8, 8.0 Hz, 1H), 2.96 (dd, J=9.6, 7.6 Hz, 1H),2.85 (q, J=6.1 Hz, 1H), 2.47-2.56 (m, 1H), 2.30-2.35 (m, 1H), 1.93-2.07(m, 1H), 1.87-1.94 (m, 1H), 1.79-1.87 (m, 1H), 1.29-1.38 (m, 1H),1.20-1.29 (m, 1H); MS (ESI+) m/z 443 (M+H)⁺.

Example 287(3aR,4S,6aS)-N-(4-fluorobenzyl)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine (0.83 g, 3.84mmol) from Step A of Example 33 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand 4-fluorobenzaldehyde for pivalaldehyde in the procedure described inExample 281: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.79-7.80 (bs, 1H),7.58-7.61 (m, 1H), 7.60 (s, 1H), 7.44-7.49 (m, 1H), 7.39-7.44 (m, 2H),7.12 (t, J=8.6 Hz, 2H), 3.71-3.79 (m, 2H), 3.55-3.56 (bs, 2H), 2.96 (q,J=5.1 Hz, 1H), 2.57-2.63 (m, 1H), 2.51 (dd, J=8.8, 3.2 Hz, 1H),2.39-2.43 (m, 1H), 2.31-2.39 (m, 3H), 1.91-1.98 (m, 2H), 1.72-1.93 (m,1H), 1.34-1.48 (m, 2H); MS (ESI+) m/z 393 (M+H)⁺.

Example 288(3aR,4S,6aS)-N-ethyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

(3aR,4S,6aS)-2-(4-(Trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amine(120 mg, 0.359 mmol) from Step A of Example 256, iodoethane (0.287 mL,3.59 mmol), and triethylamine (0.750 mL, 5.38 mmol) were intetrahydrofuran (1 mL). The reaction was stirred at 65° C. for 3 days,and then the solvent was removed in vacuo. The residue was diluted withdichloromethane (5 mL), and addition of saturated aqueous sodiumbicarbonate gave the products as a solid. This material was purifiedusing a 12 g silica gel cartridge with a gradient of 0-5% methanol (2 Nammonia)/dichloromethane over 20 minutes to give two products. Thesecond product was further purified on 4×0.25 mm preparative thin-layerchromatography plate eluting with 6% methanol (2 Nammonia)/dichloromethane to give the title compound: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.17-8.19 (m, 2H), 7.93-7.95 (m, 2H), 3.38 (dd,J=9.8, 3.1 Hz, 1H), 3.15 (dd, J=9.6, 3.2 Hz, 1H), 3.06 (dd, J=9.8, 8.0Hz, 1H), 2.96 (dd, J=9.6, 7.7 Hz, 1H), 2.78 (q, J=6.1 Hz, 1H), 2.44-2.58(m, 4H), 2.25-2.33 (m, 1H), 1.85-1.92 (m, 1H), 1.75-1.85 (m, 1H),1.16-1.34 (m, 2H), 1.05 (t, J=7.1 Hz, 3H); MS (ESI+) m/z 363 (M+H)⁺.

Example 289(3aR,4S,6aS)-N,N-diethyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

The first product from Example 288 was purified on a 2×0.25 mmpreparative thin-layer chromatography plate eluting with acetone to givethe title compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.18-8.20 (m,2H), 7.94-7.97 (m, 2H), 3.43 (dd, J=9.6, 2.6 Hz, 1H), 3.22 (dd, J=9.5,2.6 Hz, 1H), 2.98 (dd, J=9.6, 7.8 Hz, 1H), 2.88 (dd, J=9.5, 7.4 Hz, 1H),2.70-2.75 (m, 1H), 2.30-2.50 (m, 5H), 2.22-2.29 (m, 1H), 1.75-1.81 (m,1H), 1.62-1.68 (m, 1H), 1.25-1.34 (m, 1H), 1.16-1.25 (m, 1H), 0.92 (t,J=7.0 Hz, 6H); MS (ESI+) m/z 391 (M+H)⁺.

Example 290(3aR,4S,6aS)-N-propyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared by substituting 1-iodopropane foriodoethane in the procedure described in Example 288: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.17-8.19 (m, 2H), 7.93-7.95 (m, 2H), 3.39 (dd,J=9.8, 3.1 Hz, 1H), 3.16 (dd, J=9.6, 3.2 Hz, 1H), 3.07 (dd, J=9.8, 8.0Hz, 1H), 2.98 (dd, J=9.6, 7.7 Hz, 1H), 2.77 (q, J=5.9 Hz, 1H), 2.50-2.58(m, 1H), 2.39-2.51 (m, 2H), 2.24-2.30 (m, 1H), 1.77-1.92 (m, 2H),1.36-1.50 (m, 2H), 1.16-1.57 (m, 1H), 1.19-1.34 (m, 2H), 0.88 (t, J=7.4Hz, 3H); MS (ESI+) m/z 377 (M+H)⁺.

Example 291(3aR,4S,6aS)-N,N-dipropyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared as described in Example 290 followingthe procedures described in Examples 288 and 289: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.18-8.20 (m, 2H), 7.93-7.95 (m, 2H), 3.48 (dd,J=9.5, 2.3 Hz, 1H), 3.23 (dd, J=9.5, 2.8 Hz, 1H), 2.99 (dd, J=9.4, 7.7Hz, 1H), 2.92 (dd, J=9.3, 7.8 Hz, 1H), 2.74-2.80 (m, 1H), 2.37-2.48 (m,1H), 2.19-2.35 (m, 5H), 1.78-1.84 (m, 1H), 1.61-1.66 (m, 1H), 1.16-1.39(m, 6H), 0.84 (t, J=7.3 Hz, 6H); MS (ESI+) m/z 419 (M+H)⁺.

Example 292(3aR,4S,6aS)-N-(cyclopropylmethyl)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared by substituting(bromomethyl)cyclopropane for iodoethane in the procedure described inExample 288: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.17-8.19 (m, 2H),7.93-7.95 (m, 2H), 3.38 (dd, J=9.8, 3.2 Hz, 1H), 3.16 (dd, J=9.6, 3.2Hz, 1H), 3.07 (dd, J=9.8, 8.0 Hz, 1H), 2.98 (dd, J=9.6, 7.6 Hz, 1H),2.79-2.84 (m, 1H), 2.51-2.58 (m, 1H), 2.36-2.50 (m, 2H), 2.26-2.32 (m,1H), 1.85-1.93 (m, 1H), 1.78-1.85 (m, 1H), 1.35-1.78 (m, 1H), 1.22-1.33(m, 2H), 0.89-0.98 (m, 1H), 0.36-0.44 (m, 2H), 0.11-0.13 (m, 2H); MS(ESI+) m/z 389 (M+H)⁺.

Example 293(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N-ethyloctahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared by substituting(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-aminefrom Step B of Example 284 for(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 288: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.37 (d, J=8.2 Hz, 1H), 8.03 (s, 1H), 7.78 (dd, J=8.3, 1.7 Hz,1H), 3.54 (dd, J=10.0, 3.5 Hz, 1H), 3.43 (dd, J=10.0, 8.0 Hz, 1H),3.27-3.36 (m, 2H), 2.86 (q, J=5.9 Hz, 1H), 2.59-2.65 (m, 1H), 2.47-2.58(m, 2H), 2.35-2.41 (m, 1H), 1.82-1.95 (m, 2H), 1.04-1.73 (m, 1H),1.25-1.40 (m, 2H), 1.05 (t, J=7.1 Hz, 3H); MS (ESI+) m/z 397 (M+H)⁺.

Example 294(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N,N-diethyloctahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared as described in Example 293 followingthe procedures described in Examples 288 and 289: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.38 (d, J=8.2 Hz, 1H), 8.04 (d, J=1.7 Hz, 1H),7.77-7.79 (m, 1H), 3.57 (dd, J=9.9, 2.7 Hz, 1H), 3.34-3.41 (m, 2H), 3.29(dd, J=9.9, 7.3 Hz, 1H), 2.81-2.87 (m, 1H), 2.33-2.57 (m, 6H), 1.80-1.86(m, 1H), 1.68-1.74 (m, 1H), 1.22-1.43 (m, 2H), 0.94 (t, J=7.1 Hz, 6H);MS (ESI+) m/z 442 (M+NH₄)⁺.

Example 295(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-amine

(3aR,4S,6aS)-2-{[2-Chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine(70 mg, 0.190 mmol) from Step B of Example 284,2-bromo-5-(trifluoromethyl)pyridine (42.9 mg, 0.190 mmol), andtriethylamine (0.079 mL, 0.569 mmol) were combined in ethanol (0.6 mL).The reaction was heated at 86° C. for 5 days and the solvent wasevaporated in vacuo. The resultant material was purified using a 12 gsilica gel cartridge with a gradient of 0-0.8% methanol (2 Nammonia)/dichloromethane over 20 minutes to give crude product. It wasfurther purified by loading it onto 2×0.25 mm preparative thin-layerchromatography plate and eluted with 30% acetone/hexanes to give thetitle compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.50-8.52 (bs, 1H),8.40 (d, J=8.2 Hz, 1H), 8.03 (s, 1H), 7.96-7.98 (m, 1H), 7.75-7.78 (m,1H), 7.54-7.59 (m, 1H), 6.59 (d, J=8.8 Hz, 1H), 4.30-4.42 (m, 1H), 3.89(dd, J=10.2, 2.7 Hz, 1H), 3.57 (dd, J=10.2, 7.0 Hz, 1H), 3.43 (dd,J=9.9, 6.7 Hz, 1H), 3.39 (dd, J=10.0, 2.9 Hz, 1H), 2.68 (d, J=3.5 Hz,2H), 2.13-2.20 (m, 1H), 1.90-1.97 (m, 1H), 1.59-1.66 (m, 1H), 1.40-1.48(m, 1H); MS (ESI+) m/z 514 (M+H)⁺.

Example 296tert-butyl(S)-1-(ethyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid fromStep A of Example 247 for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-N-ethyl-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 288 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.11 (d, J=8.3, 2H), 7.83 (d, J=8.4, 2H), 5.44-4.96 (m, 2H),4.20-3.97 (m, 1H), 3.57-3.39 (m, 2H), 3.38-3.23 (m, 2H), 3.19 (d, J=4.1,2H), 2.89 (s, 3H), 2.85-2.73 (m, 1H), 2.72-2.59 (m, 1H), 2.25-2.08 (m,1H), 1.97-1.73 (m, 3H), 1.52 (s, 9H), 1.35-1.21 (m, 1H), 1.17 (t, J=7.0,3H), 0.97 (s, 9H); MS (ESI+) m/z 604(M+H)⁺.

Example 297tert-butyl(S)-4,4-dimethyl-1-oxo-1-(propyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)pentan-2-yl(methyl)carbamate

The title compound was prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid fromStep A of Example 247 for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-N-propyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-aminefrom Example 290 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.11 (d, J=8.2, 2H), 7.83 (d, J=8.4, 2H), 5.37-5.09 (m, 1H),4.15-3.99 (m, 1H), 3.54 (dd, J=10.1, 3.2, 1H), 3.48-3.35 (m, 1H), 3.29(dt, J=9.1, 8.7, 1H), 3.18 (dd, J=9.1, 4.5, 3H), 2.90 (s, 3H), 2.86-2.77(m, 1H), 2.74-2.64 (m, 1H), 2.24-2.09 (m, 1H), 1.96-1.86 (m, 2H),1.85-1.75 (m, 1H), 1.59 (dt, J=15.2, 7.5, 3H), 1.52 (s, 9H), 1.34-1.22(m, 1H), 0.98 (s, 9H), 0.90 (t, J=7.3, 3H); MS (ESI+) m/z 618(M+H)⁺.

Example 298tert-butyl(S)-1-((cyclopropylmethyl)((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid fromStep A of Example 247 for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-N-(cyclopropylmethyl)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-aminefrom Example 292 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.11 (d, J=8.2, 2H), 7.83 (d, J=8.3, 2H), 5.39-5.07 (m, 1H),4.12-3.95 (m, 1H), 3.58 (dd, J=9.9, 3.4, 1H), 3.44-3.24 (m, 3H), 3.20(d, J=4.7, 2H), 3.11-2.96 (m, 1H), 2.88 (s, 3H), 2.80-2.65 (m, 1H),2.32-2.16 (m, 1H), 2.13-2.00 (m, 1H), 1.99-1.90 (m, 1H), 1.90-1.80 (m,1H), 1.51 (m, 10H), 1.31 (ddd, J=20.7, 12.5, 7.9, 1H), 1.03-0.92 (m,10H), 0.55 (tt, J=14.1, 7.5, 2H), 0.47-0.36 (m, 1H), 0.32-0.22 (m, 1H);MS (ESI+) m/z 630(M+H)⁺.

Example 2992-nitro-N-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)benzenesulfonamide

(3aR,4S,6aS)-2-(4-(Trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amine(300 mg, 0.897 mmol) from Step A of Example 256 and triethylamine (0.313mL, 2.243 mmol) were combined in dichloromethane (20 mL).2-Nitrobenzene-1-sulfonyl chloride (258 mg, 1.166 mmol) indichloromethane (5 mL) was added dropwise. The reaction mixture wasstirred at room temperature for 16 hours. The reaction was quenched withwater, and the organic layer was separated and concentrated. Theresulted crude material was triturated with 50% diethyl ether/hexane,collected by filtration, washed with water then hexane to yield a solid.The crude solid was purified using a 12 g silica gel cartridge with agradient of 10-100% ethyl acetate/hexane over 20 minutes to give thetitle compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.69 (s, 1H), 8.31(dd, J=6.0, 3.3, 1H), 8.12 (d, J=8.2, 2H), 7.92 (dd, J=8.6, 2.1, 3H),7.67 (dd, J=5.9, 3.3, 2H), 4.94 (s, 2H), 3.84 (dd, J=15.0, 6.2, 1H),3.58 (dd, J=10.0, 2.4, 1H), 3.17 (dd, J=9.7, 2.7, 1H), 2.94 (dd, J=10.0,7.7, 1H), 2.87 (dd, J=9.6, 7.7, 1H), 2.71 (td, J=9.3, 2.4, 1H),2.60-2.50 (m, 1H), 1.94-1.80 (m, 2H), 1.71-1.58 (m, 1H), 1.23 (tt,J=10.5, 6.5, 1H); MS (ESI+) m/z 518(M+H)⁺.

Example 300N-methyl-2-nitro-N-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)benzenesulfonamide

2-Nitro-N-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)benzenesulfonamide(250 mg, 0.481 mmol) from Example 299 and dimethyl sulfate (0.138 mL,1.444 mmol) were combined in N,N-dimethylformamide (3 mL) at 0° C. and1,8-diazabicyclo[5.4.0]undec-7-ene (0.145 mL, 0.962 mmol) was addeddropwise. The reaction mixture was stirred for 0.5 hours, water wasadded, and the precipitate was collected by filtration. The resultantcrude material was purified using a 12 g silica gel cartridge elutingwith a gradient of 0-60% ethyl acetate/hexane over 20 minutes to givethe title compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.15 (dd,J=12.1, 4.7, 3H), 7.94 (d, J=8.3, 2H), 7.88 (dd, J=7.7, 1.3, 1H), 7.68(dtd, J=19.1, 7.5, 1.3, 2H), 4.29 (dt, J=10.8, 7.0, 1H), 3.63 (dd,J=9.9, 1.5, 1H), 3.21 (dd, J=9.7, 2.3, 1H), 2.90 (s, 3H), 2.89-2.81 (m,2H), 2.58-2.39 (m, 2H), 1.83-1.72 (m, 1H), 1.68-1.58 (m, 1H), 1.50 (qd,J=11.8, 7.3, 1H), 1.21 (ddd, J=19.4, 12.4, 7.1, 1H); MS (ESI+) m/z551(M+NH₄)^(+‘.)

Example 301 (3aR,4S,6aS)-N-methyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

2-Mercaptoethanol (0.056 mL, 0.793 mmol) was added dropwise to a mixtureofN-methyl-2-nitro-N-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)benzenesulfonamide(235 mg, 0.440 mmol) from Example 300 and1,8-diazabicyclo[5.4.0]undec-7-ene (0.166 mL, 1.101 mmol) inN,N-dimethylformamide (1 mL) at room temperature. The reaction mixturewas stirred for 30 minutes, and 1 N NaHCO3 solution was added, Themixture was extracted with dichloromethane, and the separated theorganic layer was concentrated. The resultant crude material waspurified using a SF15-12g cartridge (Analogix®, Burlington, Wis.) with agradient of 0-5.5% methanol (2 N NH₃)/dichloromethane over 20 minutes togive the title compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.17 (d,J=8.1, 2H), 7.94 (d, J=8.2, 2H), 4.93-4.86 (m, 1H), 3.34 (dd, J=9.8,3.3, 1H), 3.14 (dd, J=9.7, 3.2, 1H), 3.06 (dd, J=9.7, 8.2, 1H), 2.65 (q,J=5.7, 1H), 2.57-2.46 (m, 1H), 2.29 (s, 3H), 2.25 (ddd, J=8.6, 5.0, 2.5,1H), 1.86 (ddd, J=12.0, 8.6, 6.1, 1H), 1.80-1.72 (m, 1H), 1.61-1.32 (m,1H), 1.32-1.19 (m, 2H); MS (ESI+) m/z 349(M+H)⁺.

Example 302tert-butyl(S)-4,4-dimethyl-1-(methyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid fromStep A of Example 247 for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-N-methyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-aminefrom Example 301 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.11 (d, J=8.2, 2H), 7.83 (d, J=8.3, 2H), 5.37-5.10 (m, 1H),4.73-4.53 (m, 1H), 3.57 (d, J=9.1, 1H), 3.24 (dd, J=16.5, 7.2, 2H), 3.16(dd, J=9.9, 3.4, 1H), 2.94 (s, 3H), 2.88 (s, 3H), 2.64-2.51 (m, 2H),2.25-2.09 (m, 1H), 1.89-1.78 (m, 1H), 1.77-1.54 (m, 3H), 1.52 (s, 9H),1.26 (dt, J=17.5, 7.1, 1H), 0.96 (s, 9H); MS (ESI+) m/z 590(M+H)⁺.

Example 303(2S)-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methyl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide

Step A:(25)-N-[(3aS,4R,6aR)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide(265 mg, 0.611 mmol) from Example 220 Step D and ethanol (20 mL) wereadded to 20% Pd(OH)₂ on carbon, wet (53.0 mg, 0.377 mmol) in a 50 mLpressure bottle and stirred for 48 hours under 30 psi hydrogen at 50° C.The mixture was filtered through a nylon membrane and the solventremoved in vacuo to give(2S)-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]pentanamide:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.89 (dd, J=6.6, 18.9, 1H),4.55-4.50 (m, 1H), 4.42-4.31 (m, 1H), 3.99-3.91 (m, 1H), 3.44-3.39 (m,1H), 3.34 (dd, J=2.8, 11.4, 0.5H), 3.29-3.25 (m, 2H), 3.21 (dd, J=5.4,13.2, 1H), 3.13 (dd, J=7.7, 11.2, 0.5H), 2.99 (td, J=7.5, 10.8, 1H),2.79 (dd, J=3.3, 10.9, 0.5H), 2.73 (dd, J=3.3, 10.9, 0.5H), 2.69-2.55(m, 2H), 2.31-2.16 (m, 2H), 2.12-2.00 (m, 1H), 1.94-1.78 (m, 4H), 1.69(dddd, J=5.2, 11.0, 16.7, 19.8, 2H), 1.49-1.29 (m, 1H), 0.88 (t, J=6.5,3H), 0.83 (t, J=6.4, 3H); MS (ESI+) m/z 344(M+H)⁺

Step B:(2S)-2-(1,1-Dioxidoisothiazolidin-2-yl)-4-methyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]pentanamide(204 mg, 0.594 mmol) and 3-(trifluoromethyl)benzaldehyde (0.158 mL,1.188 mmol) were dissolved in dichloromethane (3 mL). Acetic acid (1 mL)was added. The reaction was stirred at ambient temperature for 20 min,then PS-cyanoborohydride (487 mg, 1.188 mmol) was added. The reactionwas stirred at room temperature overnight, then filtered, and thesolvent was removed in vacuo. The crude material was purified by silicagel chromatography using 1-10% methanol (2 N ammonia)/dichloromethane tothe title compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.79 (d, J=7.0,1H), 7.75 (d, J=10.3, 1H), 7.61-7.54 (m, 2H), 7.44 (t, J=7.7, 1H), 4.52(dd, J=6.6, 8.9, 1H), 4.38 (dq, J=6.4, 12.6, 1H), 3.94 (dd, J=7.3, 16.2,1H), 3.57 (dd, J=9.1, 13.5, 1H), 3.50-3.37 (m, 2H), 3.31-3.19 (m, 2H),2.79 (ddd, J=3.0, 9.1, 19.0, 1H), 2.62-2.54 (m, 1H), 2.54-2.45 (m, 1H),2.43-2.36 (m, 1H), 2.31-2.16 (m, 4H), 2.13-2.03 (m, 1H), 1.94-1.78 (m,3H), 1.77-1.59 (m, 2H), 1.39 (dt, J=6.5, 19.8, 1H), 0.88 (d, J=6.6, 3H),0.82 (dd, J=2.3, 6.5, 3H); MS (ESI+) m/z 502(M+H)⁺.

Example 3042-isopropyl-3-methyl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide

The title compound was prepared by substitutingN-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-isopropyl-3-methylbutanamidefrom Example 235 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamidein the procedures described in Example 303: ^(l)H NMR (500 MHz,pyridine-d₅) δ ppm 8.12-8.14 (m, 1H), 7.75-7.76 (bs, 1H), 7.55-7.63 (m,2H), 7.44 (t, J=7.8 Hz, 1H), 4.42-4.48 (m, 1H), 3.62 (d, J=13.5 Hz, 1H),3.46 (d, J=13.5 Hz, 1H), 2.86 (dd, J=9.0, 2.4 Hz, 1H), 2.50-2.57 (m,2H), 2.44-2.49 (m, 1H), 2.25-2.31 (m, 2H), 2.06-2.15 (m, 3H), 1.83-1.90(m, 2H), 1.58-1.65 (m, 1H), 1.35-1.42 (m, 1H), 1.14 (d, J=6.7 Hz, 3H),1.13 (d, J=6.6 Hz, 3H), 0.98 (d, J=6.8 Hz, 6H); MS (ESI+) m/z 411(M+H)⁺.

Example 3052-isopropyl-3-methyl-N-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide

The title compound was prepared by substitutingN-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-isopropyl-3-methylbutanamidefrom Example 229 for(25)-N-R[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamidein the procedures described in Example 303: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.12-8.14 (m, 1H), 7.75-7.77 (bs, 1H), 7.58-7.63 (m,1H), 7.42-7.47 (m, 1H), 4.42-4.48 (m, 1H), 3.62 (d, J=13.5 Hz, 1H), 3.46(d, J=13.5 Hz, 1H), 2.85 (dd, J=8.9, 2.5 Hz, 1H), 2.50-2.58 (m, 2H),2.45-2.49 (m, 1H), 2.28 (d, J=6.6 Hz, 2H), 2.06-2.16 (m, 4H), 1.84-1.90(m, 2H), 1.58-1.66 (m, 1H), 1.35-1.42 (m, 1H), 1.14 (d, J=6.6 Hz, 3H),1.13 (d, J=6.6 Hz, 3H), 0.98 (d, J=6.8 Hz, 6H); MS (ESI−) m/z 409(M−H)−.

Example 306tert-butyl(S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-ylcarbamatefrom Example 221 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamidein the procedures described in Example 303: ¹H NMR (400 MHz,pyridine-d₅) δ ppm 8.64 (d, J=7.2 Hz, 1H), 7.96-7.99 (m, 1H), 7.72-7.77(m, 1H), 7.55-7.63 (m, 2H), 7.44 (t, J=7.7 Hz, 1H), 4.66-4.75 (m, 1H),4.35-4.44 (m, 1H), 3.59 (d, J=13.5 Hz, 1H), 3.46 (d, J=13.6 Hz, 1H),2.81-2.84 (m, 1H), 2.44-2.59 (m, 3H), 2.22-2.31 (m, 2H), 2.14 (s, 3H,OAc), 1.96-2.07 (m, 1H), 1.79-1.91 (m, 4H), 1.55-1.70 (m, 1H), 1.50 (s,9H), 1.27-1.41 (m, 1H), 0.82-0.89 (m, 6H); MS (ESI+) m/z 498 (M+H)⁺.

Example 307 tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 222 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamidein the procedures described in Example 303: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.27-8.34 (m, 1H), 7.75-7.76 (bs, 1H), 7.52-7.63 (m,2H), 7.42-7.47 (m, 1H), 5.1 (m, 0.7H), 4.7 (0.3H), 4.35-4.41 (m, 1H),3.59 (d, J=13.5 Hz, 1H), 3.45-3.49 (m, 1H), 3.04-3.13 (m, 3H), 2.82-2.85(m, 1H), 2.42-2.54 (m, 3H), 2.22-2.31 (m, 2H), 1.98-2.11 (m, 1H),1.80-2.11 (m, 1H), 1.79-1.87 (m, 2H), 1.53-1.62 (m, 2H), 1.46-1.48 (m,9H), 1.33-1.38 (m, 1H), 0.88 (d, J=6.4 Hz, 3H), 0.85 (d, J=6.6 Hz, 3H);MS (ESI+) m/z 512 (M+H)⁺.

Example 308 tert-butylmethyl(S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 222 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehydein the procedures described in Example 303: ^(l)H NMR (500 MHz,pyridine-d₅) δ ppm 8.31-8.36 (bs, 1H), 7.64-7.66 (m, 2H), 7.50-7.53 (m,2H), 5.1 (m, 0.7H) 4.7 (0.3H), 4.38-4.43 (m, 1H), 3.57 (d, J=13.7 Hz,1H), 3.45-3.49 (m, 1H), 3.04-3.12 (m, 3H), 2.84-2.87 (m, 1H), 2.51-2.56(m, 2H), 2.35-2.42 (m, 1H), 2.30-2.35 (m, 1H), 2.20-2.24 (m, 1H),2.05-2.10 (m, 1H), 1.81-1.93 (m, 3H), 1.55-1.61 (m, 2H), 1.46-1.48 (m,9H), 1.35-1.40 (m, 1H), 0.88 (d, J=6.3 Hz, 3H), 0.85 (d, J=6.6 Hz, 3H);MS (ESI+) m/z 512 (M+H)⁺.

Example 309tert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 222 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde in theprocedures described in Example 303: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.30-8.32 (m, 1H), 7.35-7.38 (m, 2H), 7.12 (t, J=8.6 Hz, 2H), 5.1 (m,0.7H) 4.7 (0.3H), 4.37-4.41 (m, 1H), 3.50 (d, J=13.1 Hz, 1H), 3.40 (d,J=13.1 Hz, 1H), 3.04-3.11 (m, 3H), 2.81-2.84 (m, 1H), 2.47-2.53 (m, 2H),2.29-2.39 (m, 2H), 2.19-2.23 (m, 1H), 2.02-2.11 (m, 1H), 1.79-1.94 (m,3H), 1.53-1.62 (m, 2H), 1.46-1.48 (m, 9H), 1.34-1.39 (m, 1H), 0.89 (d,J=6.4 Hz, 3H), 0.85 (d, J=6.6 Hz, 3H); MS (ESI+) m/z 462 (M+H)⁺.

Example 310 tert-butylethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(ethyl)carbamatefrom Example 223 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamidein the procedures described in Example 303: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.14-8.17 (m, 1H), 7.74-7.77 (m, 1H), 7.55-7.61 (m,2H), 7.41-7.46 (m, 1H), 5.1 (m, 0.7H) 4.7 (0.3H), 4.32-4.42 (m, 1H),3.59 (d, J=13.4 Hz, 1H), 3.38-3.53 (m, 3H), 2.78-2.87 (m, 1H), 2.44-2.54(m, 2H), 2.36-2.44 (m, 1H), 2.28-2.35 (m, 1H), 2.20-2.27 (m, 1H),2.01-2.13 (m, 1H), 1.91-2.01 (m, 1H), 1.79-1.88 (m, 1H), 1.71-1.79 (m,1H), 1.62-1.71 (m, 1H), 1.53-1.62 (m, 1H), 1.48 (s, 9H), 1.33-1.42 (m,1H), 1.17-1.33 (m, 3H), 0.83-0.97 (m, 6H); MS (ESI+) m/z 526 (M+H)⁺.

Example 311tert-butyl(S)-1-((3aS,4R,6aR)-2-(3-fluoro-4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Example 151 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 3-fluoro-4-(trifluoromethyl)benzaldehyde for3-(trifluoromethyl)benzaldehyde in the procedures described in Example303: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.33-8.42 (m, 1H), 7.31-7.35(m, 1H), 7.24-7.29 (m, 1H), 5.1 (m, 0.7H) 4.7 (0.3H), 4.35-4.42 (m, 1H),3.51-3.56 (m, 1H), 3.41-3.45 (m, 1H), 3.04-3.12 (m, 3H), 2.77-2.97 (m,1H), 2.47-2.52 (m, 2H), 2.29-2.35 (m, 2H), 2.19-2.22 (m, 1H), 2.06-2.15(m, 1H), 1.83-1.89 (m, 3H), 1.53-1.66 (m, 2H), 1.47 (s, 9H), 1.32-1.41(m, 2H), 0.88-0.90 (m, 3H), 0.85 (d, J=6.6 Hz, 3H); MS (ESI+) m/z 530(M+H)⁺.

Example 312tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluoro-3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Example 151 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-fluoro-3-(trifluoromethyl)benzaldehyde for3-(trifluoromethyl)benzaldehyde in the procedures described in Example303: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.32-8.39 (m, 1H), 7.62-7.75(m, 1H), 7.20-7.27 (m, 2H), 5.1 (m, 0.7H) 4.7 (0.3H), 4.29-4.47 (m, 1H),3.49-3.54 (m, 1H), 3.38-3.43 (m, 1H), 3.04-3.12 (m, 3H), 2.74-2.89 (m,1H), 2.47-2.51 (m, 2H), 2.19-2.38 (m, 3H), 2.05-2.15 (m, 1H), 1.84 (dd,J=9.0, 5.2 Hz, 3H), 1.54-1.65 (m, 2H), 1.46 (s, 9H), 1.26-1.42 (m, 1H),0.89 (d, J=6.4 Hz, 3H), 0.85 (d, J=6.6 Hz, 3H); MS (ESI+) m/z 530(M+H)⁺.

Example 313 tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

Step A: tert-Butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-norvaline forN-(tert-butoxycarbonyl)-L-leucine in the procedure described in Example221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.26-8.15 (m, 1H), 7.43 (d,J=7.4, 2H), 7.36 (t, J=7.5, 2H), 7.27 (t, J=7.3, 1H), 5.07-5.00 (m, 1H),4.72-4.58 (m, 1H), 4.46-4.31 (m, 1H), 3.59 (d, J=13.1, 1H), 3.44 (d,J=13.1, 1H), 3.12-2.99 (m, 3H), 2.83 (d, J=8.9, 1H), 2.53-2.44 (m, 2H),2.44-2.37 (m, 1H), 2.33 (d, J=7.9, 1H), 2.26-2.19 (m, 1H), 2.14-1.95 (m,2H), 1.79 (ddt, J=7.1, 5.2, 4.2, 2H), 1.62-1.51 (m, 1H), 1.46 (s, 9H),1.40-1.24 (m, 2H), 0.83 (t, J=6.7, 3H); MS (ESI+) m/z 430(M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A for(25)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamidein the procedures described in Example 303: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.24-8.26 (m, 1H), 7.75-7.76 (bs, 1H), 7.54-7.62 (m,2H), 7.44 (t, J=7.7 Hz, 1H), 5.1 (m, 0.7H), 4.7 (0.3H), 4.33-4.44 (m,1H), 3.59 (d, J=13.5 Hz, 1H), 3.45-3.48 (m, 1H), 3.02-3.10 (m, 3H),2.82-2.85 (m, 1H), 2.46-2.54 (m, 2H), 2.40-2.43 (m, 1H), 2.28-2.32 (m,1H), 2.21-2.25 (m, 1H), 1.99-2.04 (m, 2H), 1.76-1.86 (m, 2H), 1.48-1.63(m, 1H), 1.46 (s, 9H), 1.20-1.41 (m, 3H), 0.80-0.86 (m, 3H); MS (ESI+)m/z 498 (M+H)⁺.

Example 314 tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A of Example 313 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehydein the procedures described in Example 303: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.25-8.29 (bs, 1H), 7.64-7.66 (m, 2H), 7.50-7.52 (m,2H), 5.1 (m, 0.7H), 4.7 (0.3H), 4.37-4.43 (m, 1H), 3.55-3.59 (m, 1H),3.45-3.48 (m, 1H), 3.02-3.11 (m, 3H), 2.84-2.87 (m, 1H), 2.45-2.54 (m,2H), 2.30-2.39 (m, 2H), 2.20-2.23 (m, 1H), 2.02-2.15 (m, 2H), 1.77-1.87(m, 2H), 1.52-1.59 (m, 1H), 1.46-1.47 (m, 9H), 1.28-1.39 (m, 3H),0.81-0.85 (m, 3H); MS (ESI+) m/z 498 (M+H)⁺.

Example 315tert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A of Example 313 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde in theprocedures described in Example 303: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.23-8.27 (m, 1H), 7.34-7.38 (m, 2H), 7.12 (t, J=8.5 Hz, 2H), 5.1 (m,0.7H), 4.7 (0.3H), 4.33-4.45 (m, 1H), 3.50 (d, J=13.1 Hz, 1H), 3.38-3.41(m, 1H), 3.02-3.11 (m, 3H), 2.81-2.84 (m, 1H), 2.44-2.53 (m, 2H),2.29-2.39 (m, 2H), 2.19-2.23 (m, 1H), 2.02-2.04 (m, 2H), 1.81-1.84 (m,2H), 1.55-1.59 (m, 1H), 1.46-1.47 (m, 9H), 1.28-1.38 (m, 3H), 0.81-0.85(m, 3H); MS (ESI+) m/z 448 (M+H)⁺.

Example 316 tert-butylmethyl(S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamatefrom Example 232 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamidein the procedures described in Example 303: ¹H NMR (400 MHz,pyridine-d₅, temperature 90° C.) δ ppm 7.69-7.70 (bs, 1H), 7.49-7.57 (m,2H), 7.32-7.41 (m, 2H), 4.31-4.35 (m, 1H), 4.19-4.29 (m, 1H), 3.57 (d,J=13.5 Hz, 1H), 3.50 (d, J=13.6 Hz, 1H), 3.00 (s, 3H), 2.76 (d, J=6.4Hz, 1H), 2.50-2.56 (m, 1H), 2.38-2.46 (m, 3H), 2.28-2.37 (m, 2H), 2.06(dq, J=12.2, 6.1 Hz, 1H), 1.82-1.90 (m, 1H), 1.52-1.62 (m, 1H), 1.46 (s,9H), 1.35-1.44 (m, 1H), 1.00 (d, J=6.5 Hz, 3H), 0.87 (d, J=6.7 Hz, 3H);MS (ESI+) m/z 498 (M+H)⁺.

Example 317 tert-butylmethyl((S)-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom Example 233 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehydein the procedures described in Example 303: ¹H NMR (400 MHz,pyridine-d₅, temperature 90° C.) δ ppm 7.58-7.61 (m, 2H), 7.45-7.48 (m,2H), 7.18-7.28 (m, 1H), 4.70-4.75 (m, 1H), 4.22-4.30 (m, 1H), 3.48-3.59(m, 2H), 2.94 (s, 3H), 2.78-2.81 (m, 1H), 2.52-2.57 (m, 1H), 2.34-2.47(m, 3H), 2.27-2.32 (m, 1H), 2.04-2.12 (m, 1H), 1.93-2.03 (m, 1H),1.82-1.91 (m, 1H), 1.71-1.81 (m, 1H), 1.49-1.67 (m, 1H), 1.46-1.47 (m,9H), 1.37-1.46 (m, 1H), 1.26-1.36 (m, 2H), 0.87 (t, J=7.4 Hz, 3H); MS(ESI+) m/z 498 (M+H)⁺.

Example 318tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom Example 233 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde in theprocedures described in Example 303: ¹H NMR (400 MHz, pyridine-d₅,temperature 90° C.) δ ppm 7.28-7.32 (m, 2H), 7.16-7.21 (m, 1H), 7.02 (t,J=8.6 Hz, 2H), 4.69-4.77 (m, 1H), 4.21-4.28 (m, 1H), 3.49 (d, J=13.2 Hz,1H), 3.43 (d, J=13.2 Hz, 1H), 2.94 (s, 3H), 2.76-2.78 (m, 1H), 2.48-2.55(m, 1H), 2.33-2.46 (m, 3H), 2.25-2.32 (m, 1H), 2.04-2.14 (m, 1H),1.94-2.03 (m, 1H), 1.82-1.91 (m, 1H), 1.70-1.81 (m, 1H), 1.49-1.58 (m,1H), 1.46-1.48 (m, 9H), 1.37-1.44 (m, 1H), 1.28-1.36 (m, 2H), 0.87 (t,J=7.4 Hz, 3H); MS (ESI+) m/z 448 (M+H)⁺.

Example 319(2S)-4-methyl-2-morpholin-4-yl-N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide

Step A:(S)-N-((3aS,4R,6aR)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamide(0.400 g, 1.001 mmol) from Step B of Example 249 and ethanol (40 mL)were added to 20% Pd(OH)₂ on carbon, wet (0.080 g, 0.570 mmol) in a 250mL stainless steel pressure bottle and stirred for 16 hours under 30 psihydrogen at 55° C. The mixture was filtered through a nylon membrane andthe solvent removed in vacuo to give(S)-4-methyl-2-morpholino-N-((3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl)pentanamide:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.46 (d, J=6.9, 1H), 4.46-4.38 (m,1H), 3.74 (s, 4H), 3.45 (dd, J=2.0, 11.3, 1H), 3.31-3.21 (m, 2H), 3.10(dd, J=7.0, 11.0, 1H), 2.89 (dd, J=2.3, 11.0, 1H), 2.83-2.77 (m, 2H),2.76-2.67 (m, 4H), 2.09 (td, J=6.0, 11.8, 1H), 1.95-1.87 (m, 1H), 1.84(dq, J=6.0, 9.7, 2H), 1.71-1.57 (m, 2H), 1.49 (ddt, J=6.3, 9.1, 12.5,1H), 0.94 (dd, J=6.3, 11.2, 6H); MS (ESI+) m/z 310(M+H)⁺

Step B:(S)-4-methyl-2-morpholino-N-((3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl)pentanamide(191 mg, 0.617 mmol), triethylamine (0.129 mL, 0.926 mmol), and3-(trifluoromethyl)benzene-1-sulfonyl chloride (0.109 mL, 0.679 mmol)were combined in dichloromethane (0.5 mL). The reaction was stirred atroom temperature for 3 hours. The crude material was purified by silicagel chromatography using 1-10% methanol (2 N ammonia)/dichloromethane togive the title compound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.44 (d,J=6.2, 1H), 8.38 (s, 1H), 8.19 (d, J=7.9, 1H), 7.92 (d, J=7.8, 1H), 7.72(t, J=7.9, 1H), 4.27-4.20 (m, 1H), 3.90 (dd, J=2.3, 10.0, 1H), 3.76-3.67(m, 4H), 3.20 (ddd, J=3.9, 9.4, 10.9, 3H), 2.97 (dd, J=7.1, 9.6, 1H),2.78-2.72 (m, 2H), 2.72-2.67 (m, 2H), 2.62-2.53 (m, 2H), 1.94 (dt,J=6.2, 12.1, 1H), 1.89-1.77 (m, 3H), 1.64-1.54 (m, 2H), 1.30 (ddt,J=6.5, 9.3, 12.8, 1H), 0.92 (d, J=4.4, 3H), 0.91 (d, J=4.4, 3H); MS(ESI+) m/z 518(M+H)⁺.

Example 320(2S)-4-methyl-2-pyrrolidin-1-yl-N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide

The title compound was prepared by substituting(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamidefrom Example 250 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedures described in Example 319: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.37-8.39 (m, 1H), 8.17-8.20 (m, 1H), 8.12-8.15 (m,1H), 7.89-7.92 (m, 1H), 7.71 (t, J=7.8 Hz, 1H), 4.23-4.29 (m, 1H), 3.86(dd, J=9.9, 2.4 Hz, 1H), 3.16-3.20 (m, 2H), 3.13-3.15 (m, 1H), 2.97 (dd,J=9.6, 6.8 Hz, 1H), 2.65-2.69 (m, 2H), 2.55-2.61 (m, 4H), 1.90-2.00 (m,1H), 1.76-1.90 (m, 3H), 1.54-1.62 (m, 6H), 1.25-1.34 (m, 1H), 0.98 (d,J=6.3 Hz, 3H), 0.91 (d, J=6.3 Hz, 3H); MS (ESI+) m/z 502 (M+H)⁺.

Example 321(2S)-4-methyl-2-piperidin-1-yl-N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide

The title compound was prepared by substituting(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-piperidin-1-ylpentanamidefrom Example 251 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedures described in Example 319: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.38-8.39 (bs, 1H), 8.18-8.20 (m, 2H), 7.90-7.92 (m,1H), 7.71 (t, J=7.8 Hz, 1H), 4.20-4.26 (m, 1H), 3.87 (dd, J=9.9, 2.1 Hz,1H), 3.16-3.20 (m, 3H), 2.97 (dd, J=9.5, 6.3 Hz, 1H), 2.56-2.64 (m, 6H),1.80-1.97 (m, 4H), 1.46-1.59 (m, 6H), 1.23-1.37 (m, 3H), 0.93 (d, J=6.6Hz, 3H), 0.92 (d, J=6.7 Hz, 3H); MS (ESI+) m/z 516 (M+H)⁺.

Example 322 tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 222 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedures described in Example 319: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.48-8.50 (m, 1H), 8.36-8.37 (bs, 1H), 8.19 (d, J=7.9Hz, 1H), 7.91 (d, J=7.9 Hz, 1H), 7.72 (t, J=7.8 Hz, 1H), 5.13 (m, 0.7H),4.78 (m, 0.3H), 4.15-4.29 (m, 1H), 3.84 (dd, J=9.9, 2.1 Hz, 1H),3.13-3.16 (m, 1H), 3.02-3.12 (m, 4H), 2.91 (dd, J=9.6, 6.9 Hz, 1H),2.48-2.52 (m, 2H), 1.74-1.90 (m, 4H), 1.49-1.67 (m, 2H), 1.44-1.46 (m,9H), 1.16-1.29 (m, 1H), 0.89 (d, J=6.4 Hz, 3H), 0.84 (d, J=6.4 Hz, 3H);MS (ESI+) m/z 562 (M+H)⁺.

Example 323 tert-butylethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(ethyl)carbamatefrom Example 223 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedures described in Example 319: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.37-8.40 (m, 2H), 8.19 (d, J=7.9 Hz, 1H), 7.91 (d,J=7.9 Hz, 1H), 7.72 (t, J=7.9 Hz, 1H), 5.0 (m, 0.7H), 4.7 (m, 0.3H),4.16-4.27 (m, 1H), 3.83-3.86 (m, 1H), 3.43-3.49 (m, 2H), 3.09-3.18 (m,2H), 2.90-2.94 (m, 1H), 2.43-2.58 (m, 2H), 1.90-2.02 (m, 2H), 1.71-1.84(m, 2H), 1.62-1.67 (m, 1H), 1.34-1.59 (m, 10H), 1.21-1.31 (m, 4H),0.88-0.91 (m, 6H); MS (ESI+) m/z 576 (M+H)⁺.

Example 324 tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-1-leucinamidefrom Example 151 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (501 MHz, pyridine-d₅, temperature 60°C.) δ ppm 8.08-8.11 (m, 2H), 7.99-8.03 (bs, 1H), 7.84-7.87 (m, 2H), 4.95(m, 0.7H), 4.4 (m, 0.3H), 4.11-4.17 (m, 1H), 3.70-3.74 (m, 1H),3.15-3.21 (m, 1H), 3.13 (dd, J=9.8, 2.8 Hz, 1H), 3.03 (dd, J=9.7, 7.3Hz, 1H), 3.00 (s, 3H), 2.50-2.54 (m, 2H), 1.89-1.97 (m, 1H), 1.72-1.89(m, 3H), 1.50-1.61 (m, 2H), 1.45 (s, 9H), 1.28 (ddt, J=9.5, 12.9, 6.5Hz, 1H), 0.89 (d, J=6.8 Hz, 3H), 0.85 (d, J=6.5 Hz, 3H); MS (DCI+) m/z562 (M+H)⁺,579(M+NH₄)⁺.

Example 325 tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Example 151 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedures described in Example 319: ¹H NMR (501 MHz,pyridine-d₅, temperature 60° C.) δ ppm 8.32-8.33 (bs, 1H), 8.15 (d,J=8.1 Hz, 1H), 7.97-8.01 (m, 1H), 7.87 (d, J=7.7 Hz, 1H), 7.68 (t, J=7.9Hz, 1H), 4.95 (m, 0.7H), 4.4 (m, 0.3H), 4.11-4.15 (m, 1H), 3.71-3.75 (m,1H), 3.12-3.18 (m, 2H), 3.00-3.04 (m, 1H), 2.99 (s, 3H), 2.48-2.52 (m,2H), 1.90-1.96 (m, 1H), 1.73-1.86 (m, 3H), 1.50-1.60 (m, 2H), 1.46 (s,9H), 1.24-1.30 (m, 1H), 0.88 (d, J=6.6 Hz, 3H), 0.85 (d, J=6.5 Hz, 3H);MS (ESI+) m/z 579 (M+NH₄)⁺.

Example 326tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Example 151 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-fluorobenzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.51-8.58(m, 1H), 7.97-7.99 (m, 2H), 7.29-7.35 (m, 2H), 5.13 (m, 0.7H), 4.8 (m,0.3H), 4.20-4.23 (m, 1H), 3.70-3.81 (m, 1H), 3.00-3.11 (m, 5H),2.86-2.91 (m, 1H), 2.42-2.53 (m, 2H), 1.75-1.96 (m, 4H), 1.49-1.62 (m,2H), 1.41-1.50 (bs, 9H), 1.23-1.39 (m, 1H), 0.81-0.88 (m, 6H); MS (ESI+)m/z 512 (M+H)⁺.

Example 327tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluoro-3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Example 151 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-fluoro-3-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (501 MHz, pyridine-d₅, temperature 90°C.) δ ppm 8.28 (dd, J=6.6, 2.3 Hz, 1H), 8.16-8.20 (m, 1H), 7.54-7.59 (m,1H), 7.44 (t, J=9.4 Hz, 1H), 4.79-4.84 (m, 1H), 4.08 (p, J=6.9 Hz, 1H),3.67 (dd, J=10.1, 3.3 Hz, 1H), 3.25 (dd, J=10.1, 7.7 Hz, 1H), 3.09-3.17(m, 2H), 2.94 (s, 3H), 2.53-2.61 (m, 1H), 2.46-2.53 (m, 1H), 1.91-1.98(m, 1H), 1.79-1.87 (m, 2H), 1.73 (ddd, J=14.1, 9.1, 5.1 Hz, 1H),1.56-1.64 (m, 1H), 1.48-1.56 (m, 1H), 1.46 (s, 9H), 1.26-1.33 (m, 1H),0.89 (d, J=6.6 Hz, 3H), 0.87 (d, J=6.6 Hz, 3H); MS (ESI+) m/z 580(M+H)⁺.

Example 328 tert-butylmethyl((S)-1-oxo-1-((3aR,4R,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom Example 240 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (400 MHz, pyridine-d₅, temperature 90°C.) δ ppm 8.04-8.07 (m, 2H), 7.80-7.83 (m, 2H), 7.54-7.57 (m, 1H), 4.79(dd, J=9.4, 6.0 Hz, 1H), 4.29 (dq, J=9.8, 7.0 Hz, 1H), 3.49 (dd, J=10.3,4.7 Hz, 1H), 3.21 (dd, J=9.9, 7.8 Hz, 1H), 3.07-3.13 (m, 2H), 3.01 (s,3H), 2.92-3.01 (m, 1H), 2.46-2.54 (m, 1H), 1.95-2.07 (m, 1H), 1.75-1.85(m, 1H), 1.68-1.77 (m, 1H), 1.55-1.66 (m, 2H), 1.54 (s, 9H), 1.25-1.39(m, 3H), 0.87 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 548 (M+H)⁺.

Example 329 tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4R,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 241 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (400 MHz, pyridine-d₅, temperature 90°C.) δ ppm 8.04-8.07 (m, 2H), 7.80-7.83 (m, 2H), 7.54-7.61 (m, 1H), 4.90(dd, J=9.2, 6.0 Hz, 1H), 4.26-4.34 (m, 1H), 3.49 (dd, J=10.3, 4.7 Hz,1H), 3.21 (dd, J=9.9, 7.8 Hz, 1H), 3.06-3.14 (m, 2H), 3.02 (s, 3H),2.94-3.01 (m, 1H), 2.47-2.55 (m, 1H), 1.87 (ddd, J=14.2, 8.5, 5.6 Hz,1H), 1.69-1.83 (m, 2H), 1.57-1.67 (m, 3H), 1.54 (s, 9H), 1.27-1.39 (m,1H), 0.90 (d, J=6.9 Hz, 3H), 0.89 (d, J=6.9 Hz, 3H); MS (ESI+) m/z 562(M+H)⁺.

Example 330tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom

Example 233 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-fluorobenzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (400 MHz, pyridine-d₅, temperature 90°C.) δ ppm 7.90-7.97 (m, 2H), 7.38-7.48 (bs, 1H), 7.18-7.24 (m, 2H),7.18-7.23 (m, 1H), 4.65-4.75 (m, 1H), 4.03-4.13 (m, 1H), 3.58 (dd,J=10.1, 3.4 Hz, 1H), 3.22 (dd, J=10.1, 7.8 Hz, 1H), 3.03-3.13 (m, 2H),2.94 (s, 3H), 2.51-2.60 (m, 1H), 2.43-2.51 (m, 1H), 1.89-2.01 (m, 2H),1.80-1.86 (m, 1H), 1.69-1.81 (m, 1H), 1.47-1.62 (m, 1H), 1.45 (s, 9H),1.23-1.38 (m, 3H), 0.86 (t, J=7.3 Hz, 2H); MS (ESI+) m/z 498 (M+H)⁺.

Example 331 tert-butylmethyl((S)-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom Example 233 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (400 MHz, pyridine-d₅, temperature 90°C.) δ ppm 8.05-8.08 (m, 2H), 7.79-7.83 (m, 2H), 7.43-7.48 (bs, 1H),4.68-4.72 (m, 1H), 4.01-4.11 (m, 1H), 3.65 (dd, J=10.2, 3.3 Hz, 1H),3.26 (dd, J=10.1, 7.7 Hz, 1H), 3.07-3.18 (m, 2H), 2.94 (s, 3H),2.45-2.58 (m, 2H), 1.89-2.00 (m, 2H), 1.70-1.86 (m, 2H), 1.46-1.57 (m,1H), 1.45 (s, 9H), 1.31 (dt, J=15.2, 7.6 Hz, 2H), 1.23-1.37 (m, 1H),0.85 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 565 (M+NH₄)⁺.

Example 332 tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(2S,3S)-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 224 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedures described in Example 319: ^(l)H NMR (500 MHz,pyridine-d₅) δ ppm 8.66 (d, J=6.0 Hz, 1H), 8.39-8.40 (m, 1H), 8.21 (d,J=7.9 Hz, 1H), 7.92 (d, J=7.6 Hz, 1H), 7.72 (t, J=7.9 Hz, 1H), 4.67 (d,J=11.1 Hz, 1H), 4.15-4.25 (m, 1H), 4.15-4.23 (m, 1H), 3.89 (d,J=9.9 Hz,1H), 3.09-3.26 (m, 5H), 2.88-3.08 (m, 1H), 2.46-2.55 (m, 2H), 2.17-2.31(m, 1H), 1.74-1.94 (m, 2H), 1.42-1.55 (m, 1H), 1.48 (s, 9H), 1.18-1.30(m, 1H), 1.00-1.12 (m, 1H), 0.94 (d, J=6.3 Hz, 3H), 0.80 (t, J=7.0 Hz,3H); MS (ESI+) m/z 562 (M+H)⁺.

Example 333 tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(2S,3S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 224 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.68 (d,J=6.3 Hz, 1H), 8.12-8.17 (m, 2H), 7.87-7.95 (m, 2H), 4.68 (d, J=11.0 Hz,1H), 4.16-4.24 (m, 1H), 3.87 (d, J=9.8 Hz, 1H), 3.09-3.24 (m, 5H),2.89-3.08 (m, 1H), 2.50-2.58 (m, 2H), 2.22-2.27 (m, 1H), 1.77-1.85 (m,2H), 1.51-1.66 (m, 1H), 1.48 (s, 9H), 1.34-1.49 (m, 1H), 1.19-1.31 (m,1H), 0.98-1.13 (m, 1H), 0.95 (d, J=6.1 Hz, 3H), 0.80 (t, J=6.9 Hz, 3H);MS (ESI+) m/z 562 (M+H)⁺.

Example 334 tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

Step A:tert-butyl(2S,3S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamatewas prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-isoleucine forN-(tert-butoxycarbonyl)-L-leucine and(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Example16 Step E for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.43 (d, J=6.4, 1H), 7.41 (d, J=7.2, 2H), 7.36 (t, J=7.5, 2H),7.27 (t, J=7.2, 1H), 4.70 (d, J=11.1, 1H), 4.36 (d, J=4.4, 2H), 3.56 (d,J=13.0, 1H), 3.40 (d, J=13.1, 1H), 3.24 (s, 1H), 3.13 (s, 3H), 2.72 (d,J=8.6, 1H), 2.47 (s, 2H), 2.37-2.18 (m, 4H), 2.13 (dd, J=11.7, 5.6, 1H),1.91-1.76 (m, 1H), 1.65 (dd, J=11.4, 6.8, 1H), 1.48 (s, 9H), 1.11-0.95(m, 4H), 0.80 (t, J=7.1, 3H); MS (ESI+) m/z 444 (M+H)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(2S,3S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Step A for (S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedures described in Example 319: ¹H NMR (400 MHz,pyridine-d₅) δ ppm 8.68 (d, J=7.2 Hz, 1H), 8.35-8.40 (m, 1H), 8.15 (d,J=7.8 Hz, 1H), 7.91 (d, J=7.6 Hz, 1H), 7.72 (t, J=7.8 Hz, 1H), 4.68 (d,J=11.3 Hz, 1H), 4.13-4.25 (m, 1H), 3.74-3.88 (m, 1H), 3.15-3.25 (m, 1H),3.11-3.16 (bs, 3H), 2.95-3.05 (m, 1H), 2.83-2.94 (m, 1H), 2.38-2.61 (m,2H), 2.17-2.32 (m, 1H), 1.88-2.03 (m, 1H), 1.76-1.88 (m, 1H), 1.52-1.66(m, 1H), 1.44-1.53 (bs, 9H), 1.33-1.46 (m, 1H), 1.21-1.33 (m, 1H),0.96-1.12 (m, 1H), 0.94 (d, J=6.4 Hz, 3H), 0.79 (t, J=7.2 Hz, 3H); MS(ESI+) m/z 562 (M+H)⁺.

Example 335 tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(2S,3S)-1-(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Step A of Example 334 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.66-8.72(m, 1H), 8.05-8.13 (m, 2H), 7.88-7.91 (m, 2H), 4.69 (d, J=11.3 Hz, 1H),4.15-4.22 (m, 1H), 3.73-3.87 (m, 1H), 3.16-3.23 (m, 1H), 3.11-3.18 (bs,3H), 3.00 (t, J=8.3 Hz, 1H), 2.90 (t, J=8.4 Hz, 1H), 2.42-2.56 (m, 2H),2.21-2.28 (m, 1H), 1.88-2.03 (m, 1H), 1.73-1.88 (m, 1H), 1.52-1.66 (m,1H), 1.48 (s, 9H), 1.34-1.46 (m, 1H), 1.21-1.34 (m, 1H), 0.98-1.13 (m,1H), 0.94 (d, J=6.3 Hz, 3H), 0.76-0.81 (m, 3H); MS (ESI+) m/z 562(M+H)⁺.

Example 336tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 247 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedures described in Example 319: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.36-8.38 (bs, 1H), 8.30-8.37 (m, 1H), 8.19 (d, J=7.8Hz, 1H), 7.91 (d, J=7.8 Hz, 1H), 7.72 (t, J=7.8 Hz, 1H), 5.4 (m, 0.7H),4.7 (m, 0.3H), 4.16-4.20 (m, 1H), 3.86 (d, J=9.8 Hz, 1H), 3.13-3.18 (m,1H), 3.08-3.13 (m, 1H), 2.96-3.08 (bs, 3H), 2.90-2.93 (m, 1H), 2.41-2.56(m, 2H), 2.13-2.37 (m, 1H), 1.81-1.92 (m, 1H), 1.72-1.81 (m, 1H),1.60-1.72 (m, 1H), 1.47-1.60 (m, 1H), 1.41-1.50 (bs, 9H), 1.19-1.33 (m,1H), 0.87-0.99 (bs, 9H); MS (ESI+) m/z 576 (M+H)⁺,593 (M+NH₄)⁺.

Example 337tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 247 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.35-8.38(m, 1H), 8.12-8.15 (m, 2H), 7.89-7.91 (m, 2H), 5.11-5.19 (m, 1H),4.15-4.19 (m, 1H), 3.83-3.86 (m, 1H), 3.13-3.17 (m, 1H), 3.09-3.14 (m,1H), 2.97-3.09 (bs, 3H), 2.92-2.96 (m, 1H), 2.43-2.57 (m, 2H), 2.15-2.38(m, 1H), 1.81-1.91 (m, 1H), 1.72-1.81 (m, 1H), 1.61-1.72 (m, 1H),1.48-1.60 (m, 1H), 1.40-1.51 (bs, 9H), 1.20-1.36 (m, 1H), 0.89-0.99 (bs,9H); MS (ESI+) m/z 576 (M+H)⁺.

Example 338tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 248 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedures described in Example 319: ¹H NMR (400 MHz,pyridine-d₅, temperature 90° C.) δ ppm 8.29-8.30 (bs, 1H), 8.13 (d,J=7.9 Hz, 1H), 7.83 (d, J=8.6 Hz, 1H), 7.64 (t, J=7.8 Hz, 1H), 7.29 (d,J=3.9 Hz, 1H), 4.82-4.87 (bs, 1H), 4.05 (p, J=6.7 Hz, 1H), 3.63 (dd,J=10.2, 3.3 Hz, 1H), 3.25 (dd, J=10.1, 7.8 Hz, 1H), 3.07-3.17 (m, 2H),2.91 (s, 3H), 2.51-2.59 (m, 1H), 2.43-2.50 (m, 1H), 2.15 (dd, J=14.3,5.6 Hz, 1H), 1.92 (dq, J=12.2, 6.1 Hz, 1H), 1.77-1.85 (m, 1H), 1.61 (dd,J=14.3, 7.2 Hz, 1H), 1.47-1.55 (m, 1H), 1.46 (s, 9H), 1.23-1.36 (m, 1H),0.93 (s, 9H); MS (ESI+) m/z 576 (M+H)⁺.

Example 339tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 248 for (S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (400 MHz, pyridine-d₅, temperature 90°C.) δ ppm 8.05-8.08 (m, 2H), 7.79-7.82 (m, 2H), 7.28-7.32 (m, 1H),4.79-4.91 (m, 1H), 4.05 (p, J=6.7 Hz, 1H), 3.62 (dd, J=10.2, 3.4 Hz,1H), 3.26 (dd, J=10.2, 7.8 Hz, 1H), 3.09-3.17 (m, 2H), 2.92 (s, 3H),2.51-2.62 (m, 1H), 2.43-2.51 (m, 1H), 2.15 (dd, J=14.3, 5.6 Hz, 1H),1.88-1.98 (m, 1H), 1.76-1.86 (m, 1H), 1.62 (dd, J=14.3, 7.0 Hz, 1H),1.47-1.56 (m, 1H), 1.46 (s, 9H), 1.29 (ddt, J=9.0, 13.0, 6.5 Hz, 1H),0.94 (s, 9H); MS (ESI+) m/z 576 (M+H)⁺.

Example 340 tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamatefrom Example 232 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedures described in Example 319: ¹H NMR (501 MHz,pyridine-d₅, temperature 90° C.) δ ppm 8.29-8.30 (bs, 1H), 8.13 (d,J=7.8 Hz, 1H), 7.83 (d, J=7.7 Hz, 1H), 7.64 (t, J=7.8 Hz, 1H), 7.59-7.68(m, 1H), 4.32 (d, J=10.4 Hz, 1H), 4.07 (p, J=6.6 Hz, 1H), 3.64 (dd,J=10.2, 3.3 Hz, 1H), 3.23 (t, J=9.0 Hz, 1H), 3.07-3.15 (m, 2H), 3.00 (s,3H), 2.49-2.59 (m, 1H), 2.42-2.49 (m, 1H), 2.31-2.42 (m, 1H), 1.90-1.97(m, 1H), 1.79-1.86 (m, 1H), 1.47-1.59 (m, 1H), 1.45 (s, 9H), 1.24-1.33(m, 1H), 0.97 (d, J=6.5 Hz, 3H), 0.86 (d, J=6.7 Hz, 3H); MS (ESI+) m/z548 (M+H)⁺.

Example 341tert-butyl(S)-3,3-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-ylcarbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamatefrom Example 225 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.86 (d,J=6.7 Hz, 1H), 8.11-8.18 (m, 2H), 7.89-7.92 (m, 2H), 7.71 (d, J=9.5 Hz,1H), 4.56 (d, J=9.8 Hz, 1H), 4.20 (p, J=6.4 Hz, 1H), 3.79 (dd, J=10.0,3.0 Hz, 1H), 3.24 (dd, J=9.9, 7.7 Hz, 1H), 3.14 (d, J=3.2 Hz, 1H), 3.02(dd, J=9.7, 7.3 Hz, 1H), 2.55-2.65 (m, 2H), 1.76-1.84 (m, 2H), 1.44-1.56(m, 1H), 1.48 (s, 9H), 1.19-1.27 (m, 1H), 1.16 (s, 9H); MS (ESI+) m/z548 (M+H)⁺,565 (M+NH₄)⁺.

Example 342tert-butyl(S)-3,3-dimethyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-ylcarbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamatefrom Example 234 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.89 (d,J=7.4, 1H), 8.10 (d, J=8.1, 2H), 7.90 (d, J=8.3, 2H), 7.73 (s, 1H), 4.55(d, J=9.8, 1H), 4.27-4.16 (m, 1H), 3.70 (dd, J=9.8, 2.2, 1H), 3.14 (dd,J=9.8, 2.5, 1H), 2.98-2.92 (m, 1H), 2.91-2.85 (m, 1H), 2.53-2.39 (m,2H), 1.99 (td, J=11.5, 5.7, 1H), 1.83 (td, J=12.4, 7.2, 1H), 1.60 (dt,J=12.3, 8.2, 1H), 1.48 (s, 9H), 1.34-1.25 (m, 1H), 1.15 (s, 9H); MS(ESI+) m/z 548 (M+H)⁺, 565 (M+NH₄)⁺.

Example 343 tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)hexan-2-yl)carbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxohexan-2-yl(methyl)carbamatefrom Example 227 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (400 MHz, pyridine-d₅, temperature 90°C.) δ ppm 8.06-8.09 (m, 2H), 7.79-7.82 (m, 2H), 7.40 (d, J=5.6 Hz, 1H),4.68-4.72 (m, 1H), 4.07 (p, J=6.8 Hz, 1H), 3.65 (dd, J=10.2, 3.4 Hz,1H), 3.28 (dd, J=10.2, 7.7 Hz, 1H), 3.09-3.17 (m, 2H), 2.94 (s, 3H),2.54-2.59 (m, 1H), 2.47-2.53 (m, 1H), 1.97-2.07 (m, 1H), 1.87-1.96 (m,1H), 1.72-1.86 (m, 2H), 1.47-1.56 (m, 1H), 1.46 (s, 9H), 1.23-1.35 (m,1H), 1.27-1.30 (m, 4H), 0.80-0.84 (m, 3H); MS (ESI+) m/z 562 (M+H)⁺,579(M+NH₄)⁺,620 (M+CH₃CN+NH₄)⁺.

Example 344tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamatefrom Example 226 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (400 MHz, pyridine-d₅, temperature 90°C.) δ ppm 8.06-8.08 (m, 1H), 8.06 (d, J=−0.9 Hz, 1H), 7.79-7.82 (m, 2H),7.73-7.77 (m, 1H), 7.00-7.05 (m, 1H), 4.47 (td, J=8.2, 4.7 Hz, 1H),4.04-4.11 (m, 1H), 3.65 (dd, J=10.2, 3.0 Hz, 1H), 3.29 (dd, J=10.2, 7.3Hz, 1H), 3.15 (dd, J=10.0, 6.9 Hz, 1H), 3.11 (dd, J=9.9, 3.4 Hz, 1H),2.51-2.59 (m, 2H), 2.08 (dd, J=14.2, 4.6 Hz, 1H), 1.84-1.93 (m, 1H),1.75-1.83 (m, 1H), 1.69 (dd, J=14.2, 8.0 Hz, 1H), 1.48-1.56 (m, 1H),1.47 (s, 9H), 1.22-1.33 (m, 1H), 0.96 (s, 9H); MS (ESI+) m/z 562 (M+H)⁺.

Example 345(2S)-4-methyl-2-pyrrolidin-1-yl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzoyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide

The title compound was prepared by substituting(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamidefrom Example 250 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 3-(trifluoromethyl)benzoyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.41-8.17(m, 1H), 8.14-8.05 (m, 1H), 8.01-7.78 (m, 1H), 7.76-7.66 (m, 1H), 7.53(t, J=7.6, 1H), 4.51-4.29 (m, 1H), 4.20-4.00 (m, 1H), 3.89 (ddd, J=12.0,6.6, 1.5, 1H), 3.74 (tdd, J=8.3, 5.2, 2.8, 1H), 3.67-3.45 (m, 1H),3.32-3.13 (m, 2H), 2.87-2.57 (m, 6H), 2.23-2.02 (m, 1H), 1.96-1.78 (m,2H), 1.73-1.55 (m, 6H), 1.47-1.24 (m, 1H), 1.04-0.79 (m, 6H); MS (ESI+)m/z 466 (M+H)⁺.

Example 346(2S)-4-methyl-N-[(3aS,4R,6aR)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-2-pyrrolidin-1-ylpentanamide

The title compound was prepared by substituting(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamidefrom Example 250 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand methanesulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonylchloride in the procedures described in Example 319: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.24-8.26 (m, 1H), 4.35 (p, J=6.8 Hz, 1H), 3.79 (dd,J=9.9, 2.6 Hz, 1H), 3.50 (dd, J=9.9, 7.0 Hz, 1H), 3.35 (dd, J=9.6, 7.0Hz, 1H), 3.17-3.21 (m, 2H), 3.04 (s, 3H), 2.67-2.75 (m, 4H), 2.60-2.63(m, 2H), 1.99-2.07 (m, 1H), 1.78-1.95 (m, 3H), 1.58-1.68 (m, 6H),1.32-1.39 (m, 1H), 0.99 (d, J=6.2 Hz, 3H), 0.92 (d, J=6.3 Hz, 3H); MS(ESI+) m/z 372 (M+H)⁺.

Example 347(2S)-N-[(3aS,4R,6aR)-2-(cyclopropylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide

The title compound was prepared by substituting(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamidefrom Example 250 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand cyclopropanesulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduresdescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.14 (d,J=7.3 Hz, 1H), 4.33-4.40 (m, 1H), 3.82 (dd, J=9.9, 2.6 Hz, 1H), 3.57(dd, J=9.9, 7.0 Hz, 1H), 3.41 (dd, J=9.6, 7.0 Hz, 1H), 3.22 (dd, J=9.6,3.2 Hz, 1H), 3.16 (dd, J=9.2, 5.1 Hz, 1H), 2.60-2.70 (m, 7H), 2.04 (dq,J=11.9, 5.9 Hz, 1H), 1.79-1.97 (m, 3H), 1.56-1.67 (m, 6H), 1.33-1.40 (m,1H), 1.16-1.23 (m, 2H), 0.99 (d, J=6.3 Hz, 3H), 0.92 (d, J=6.4 Hz, 3H),0.86-0.92 (m, 2H); MS (ESI+) m/z 398 (M+H)⁺.

Example 348N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-1-leucinamide

tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate(60 mg, 0.135 mmol) from Example 222 was combined with 4 N hydrogenchloride in 1,4-dioxane (0.698 mL, 2.79 mmol). The reaction was stirredat room temperature for 16 hours and then concentrated. The material waspurified using a 12 g silica gel cartridge with a gradient of 1-10%methanol (2 N ammonia)/dichloromethane over 20 minutes to give the titlecompound: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.16-8.19 (m, 1H),7.44-7.46 (m, 2H), 7.37 (t, J=7.5 Hz, 2H), 7.28 (t, J=7.3 Hz, 1H),4.42-4.48 (m, 1H), 3.61 (d, J=13.1 Hz, 1H), 3.46 (d, J=13.1 Hz, 1H),3.22 (dd, J=8.2, 5.8 Hz, 1H), 2.87 (d, J=10.3 Hz, 1H), 2.51-2.61 (m,2H), 2.44 (dd, J=8.8, 7.1 Hz, 1H), 2.43 (s, 3H), 2.37 (dd, J=9.0, 2.0Hz, 1H), 2.25-2.29 (m, 1H), 2.09-2.17 (m, 1H), 1.95-2.07 (m, 1H),1.82-1.95 (m, 2H), 1.72 (ddd, J=13.5, 7.8, 5.8 Hz, 1H), 1.55-1.64 (m,2H), 1.38-1.45 (m, 1H), 0.92 (d, J=6.6 Hz, 3H), 0.86 (d, J=6.6 Hz, 3H);MS (ESI+) m/z 344 (M+H)⁺.

Example 349 tert-butylmethyl((S)-4-methyl-1-((3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl)carbamate

The title compound was prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Example 151 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedure described in Example 319 Step A: ¹H NMR (500 MHz,pyridine-d₅) δ 8.47-8.30 (m, 1H), 5.15 (dd, J=6.4, 5.1, 1H), 4.82-4.77(m, 1H), 4.40-4.21 (m, 1H), 3.25-3.04 (m, 4H), 3.03-2.92 (m, 1H), 2.88(dd, J=10.8, 7.1, 1H), 2.69 (d, J=10.2, 1H), 2.56-2.44 (m, 2H), 2.04(td, J=11.6, 5.8, 1H), 1.93-1.78 (m, 3H), 1.64-1.53 (m, 2H), 1.47 (s,9H), 1.34 (ddt, J=11.0, 7.1, 5.5, 1H), 0.89 (d, J=6.3, 3H), 0.85 (d,J=6.5, 3H); MS (ESI+) m/z 354 (M+H)⁺.

Example 350(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]piperidine-2-carboxamide

The title compound was prepared by substitutingtert-butyl(2S)-2-({[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylatefrom Example 231 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 7.67-7.70 (m, 1H), 7.42-7.44 (m, 2H), 7.36 (t, J=7.5 Hz, 2H), 7.27(t, J=7.3 Hz, 1H), 4.34-4.40 (m, 1H), 3.59 (d, J=13.1 Hz, 1H), 3.41 (d,J=13.1 Hz, 1H), 3.32 (dd, J=10.3, 3.2 Hz, 1H), 2.99-3.02 (m, 1H), 2.83(dd, J=8.9, 2.5 Hz, 1H), 2.54-2.61 (m, 1H), 2.46-2.54 (m, 1H), 2.40-2.58(m, 1H), 2.39-2.47 (m, 1H), 2.33-2.39 (m, 2H), 2.21 (dd, J=8.9, 7.2 Hz,1H), 2.02-2.10 (m, 2H), 1.77-1.84 (m, 1H), 1.64-1.74 (m, 1H), 1.47-1.64(m, 2H), 1.34-1.45 (m, 2H), 1.25-1.34 (m, 2H); MS (ESI+) m/z 328 (M+H)⁺.

Example 351N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-1-valinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamatefrom Example 232 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.10-8.12 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, J=7.5 Hz, 2H), 7.28(t, J=7.3 Hz, 1H), 4.44-4.50 (m, 1H), 3.62 (d, J=13.1 Hz, 1H), 3.44 (d,J=13.1 Hz, 1H), 2.85-2.90 (m, 2H), 2.47-2.57 (m, 2H), 2.43 (dd, J=8.8,7.0 Hz, 1H), 2.40 (s, 3H), 2.36 (dd, J=8.9, 2.7 Hz, 1H), 2.26 (dd,J=8.9, 6.8 Hz, 1H), 2.07-2.16 (m, 2H), 1.91-2.06 (m, 1H), 1.81-1.89 (m,1H), 1.59 (dq, J=12.1, 7.6 Hz, 1H), 1.38-1.45 (m, 1H), 1.06 (d, J=6.9Hz, 3H), 1.05 (d, J=6.9 Hz, 3H); MS (ESI+) m/z 330 (M+H)⁺.

Example 352N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom Example 233 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.11-8.14 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, J=7.5 Hz, 2H), 7.28(t, J=7.3 Hz, 1H), 4.42-4.48 (m, 1H), 3.61 (d, J=13.1 Hz, 1H), 3.44 (d,J=13.1 Hz, 1H), 3.16 (t, J=6.5 Hz, 1H), 2.86 (dd, J=8.9, 2.6 Hz, 1H),2.47-2.57 (m, 2H), 2.42 (dd, J=8.9, 7.2 Hz, 1H), 2.40 (s, 3H), 2.36 (dd,J=8.9, 2.7 Hz, 1H), 2.26 (dd, J=8.9, 7.0 Hz, 1H), 2.12 (dq, J=11.9, 6.0Hz, 2H), 1.77-1.89 (m, 2H), 1.65-1.73 (m, 1H), 1.54-1.64 (m, 1H),1.37-1.54 (m, 3H), 0.84 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 330 (M+H)⁺.

Example 353N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-isoleucinamide

The title compound was prepared by substitutingtert-butyl(2S,3S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 224 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.10-8.14 (m, 1H), 7.44-7.46 (m, 2H), 7.37 (t, J=7.5 Hz, 2H),7.26-7.30 (m, 1H), 4.42-4.50 (m, 1H), 3.61 (d, J=13.1 Hz, 1H), 3.46 (d,J=13.1 Hz, 1H), 2.97 (d, J=6.0 Hz, 1H), 2.87 (d, J=10.2 Hz, 1H),2.50-2.57 (m, 2H), 2.41-2.45 (m, 1H), 2.41 (s, 3H), 2.35-2.39 (m, 1H),2.24-2.29 (m, 1H), 2.07-2.16 (m, 1H), 1.89-2.09 (m, 1H), 1.73-1.92 (m,3H), 1.55-1.68 (m, 1H), 1.26-1.46 (m, 2H), 1.03 (d, J=6.7 Hz, 3H), 0.86(t, J=7.4 Hz, 3H); MS (ESI+) m/z 344 (M+H)⁺.

Example 354N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-isoleucinamide

The title compound was prepared by substitutingtert-butyl(2S,3S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Step A of Example 334 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.11-8.14 (m, 1H), 7.43-7.46 (m, 2H), 7.37 (t, J=7.5 Hz, 2H),7.25-7.30 (m, 1H), 4.44-4.51 (m, 1H), 3.62 (d, J=13.1 Hz, 1H), 3.44 (d,J=13.1 Hz, 1H), 2.96 (d, J=6.0 Hz, 1H), 2.87 (dd, J=8.9, 2.1 Hz, 1H),2.47-2.61 (m, 2H), 2.43 (dd, J=8.8, 7.0 Hz, 1H), 2.40 (s, 3H), 2.36 (dd,J=8.9, 2.4 Hz, 1H), 2.26 (dd, J=8.9, 6.6 Hz, 1H), 2.07-2.16 (m, 1H),1.88-2.02 (m, 1H), 1.73-1.91 (m, 3H), 1.60 (dq, J=12.1, 7.5 Hz, 1H),1.25-1.46 (m, 2H), 1.03 (d, J=6.8 Hz, 3H), 0.86 (t, J=7.4 Hz, 3H); MS(ESI+) m/z 344 (M+H)⁺.

Example 355N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²,4-dimethyl-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 247 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.21-8.24 (m, 1H), 7.43-7.46 (m, 2H), 7.37 (t, J=7.4 Hz, 2H),7.24-7.30 (m, 1H), 4.42-4.47 (m, 1H), 3.61 (d, J=13.0 Hz, 1H), 3.46 (d,J=13.1 Hz, 1H), 3.19-3.22 (m, 1H), 2.88 (d, J=10.0 Hz, 1H), 2.52 (d,J=4.7 Hz, 2H), 2.40-2.46 (m, 1H), 2.41 (s, 3H), 2.37 (dd, J=9.0, 2.4 Hz,1H), 2.26 (dd, J=8.7, 6.2 Hz, 1H), 2.07-2.18 (m, 1H), 1.93 (dd, J=14.1,5.1 Hz, 1H), 1.80-1.89 (m, 1H), 1.58-1.82 (m, 1H), 1.55-1.65 (m, 1H),1.51 (dd, J=14.0, 6.6 Hz, 1H), 1.34-1.46 (m, 1H), 0.98 (s, 9H); MS(ESI+) m/z 358 (M+H)⁺.

Example 356N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-L-valinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamatefrom Example 234 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.09-8.12 (m, 1H), 7.42-7.44 (m, 2H), 7.37 (t, J=7.3 Hz, 2H),7.25-7.32 (m, 1H), 4.38-4.44 (m, 1H), 3.58 (d, J=13.0 Hz, 1H), 3.44 (d,J=13.1 Hz, 1H), 3.26 (s, 1H), 2.78 (dd, J=8.9, 2.5 Hz, 1H), 2.44-2.52(m, 2H), 2.38-2.42 (m, 1H), 2.33 (dd, J=9.0, 2.7 Hz, 1H), 2.23-2.27 (m,1H), 2.07-2.16 (m, 2H), 1.91-2.26 (m, 1H), 1.80-1.88 (m, 1H), 1.55-1.62(m, 1H), 1.36-1.43 (m, 1H), 1.14 (s, 9H); MS (ESI+) m/z 330 (M+H)⁺.

Example 357N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-L-valinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamatefrom Example 225 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.07-8.10 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, J=7.4 Hz, 2H),7.25-7.31 (m, 1H), 4.42 (t, J=5.0 Hz, 1H), 3.61 (d, J=13.1 Hz, 1H), 3.44(d, J=13.1 Hz, 1H), 3.26 (s, 1H), 2.84-2.87 (m, 1H), 2.44-2.55 (m, 2H),2.41-2.44 (m, 1H), 2.33-2.36 (m, 1H), 2.24-2.27 (m, 1H), 1.96-2.20 (m,1H), 2.03-2.12 (m, 2H), 1.79-1.86 (m, 1H), 1.51-1.59 (m, 1H), 1.35-1.41(m, 1H), 1.14 (s, 9H); MS (ESI+) m/z 330 (M+H)⁺.

Example 358N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²,4-dimethyl-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 248 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.21-8.24 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, J=7.4 Hz, 2H), 7.27(t, J=7.3 Hz, 1H), 4.42-4.48 (m, 1H), 3.61 (d, J=13.1 Hz, 1H), 3.45 (d,J=13.1 Hz, 1H), 3.19 (t, J=5.8 Hz, 1H), 2.88 (d, J=10.3 Hz, 1H),2.50-2.55 (m, 2H), 2.42 (dd, J=9.0, 7.1 Hz, 1H), 2.40 (s, 3H), 2.36 (dd,J=8.6, 2.6 Hz, 1H), 2.23-2.27 (m, 1H), 2.12 (dq, J=11.9, 5.9 Hz, 1H),1.93 (dd, J=14.0, 5.2 Hz, 1H), 1.80-1.90 (m, 2H), 1.68-1.93 (m, 1H),1.55-1.64 (m, 1H), 1.51 (dd, J=14.0, 6.6 Hz, 1H), 1.36-1.45 (m, 1H),0.98 (s, 9H); MS (ESI+) m/z 358 (M+H)⁺.

Example 359N¹-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom Example 238 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.37-8.42 (m, 1H), 7.51-7.53 (m, 2H), 7.36-7.41 (m, 2H), 7.31 (t,J=7.4 Hz, 1H), 4.52-4.57 (m, 1H), 3.73 (d, J=12.7 Hz, 1H), 3.30 (d,J=12.8 Hz, 1H), 3.19 (t, J=6.2 Hz, 1H), 2.77-2.82 (m, 1H), 2.67-2.73 (m,1H), 2.39-2.47 (m, 3H), 2.40 (s, 3H), 2.18 (dd, J=9.5, 7.1 Hz, 1H),2.07-2.15 (m, 1H), 1.85-1.91 (m, 1H), 1.79-1.83 (m, 1H), 1.63-1.78 (m,2H), 1.54-1.62 (m, 1H), 1.42-1.52 (m, 2H), 1.23-1.31 (m, 1H), 0.86 (t,J=7.3 Hz, 3H); MS (ESI+) m/z 330 (M+H)⁺.

Example 360N¹-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 239 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.47 (d, J=7.3 Hz, 1H), 7.51-7.53 (m, 2H), 7.39 (t, J=7.5 Hz, 2H),7.31 (t, J=7.3 Hz, 1H), 4.52-4.58 (m, 1H), 3.77 (d, J=12.8 Hz, 1H), 3.29(d, J=12.8 Hz, 1H), 3.27 (dd, J=8.2, 5.7 Hz, 1H), 2.82 (dd, J=9.5, 2.3Hz, 1H), 2.71-2.76 (m, 1H), 2.42-2.49 (m, 1H), 2.41 (s, 3H), 2.37-2.42(m, 1H), 2.22 (dd, J=9.4, 7.2 Hz, 1H), 2.15 (t, J=8.3 Hz, 1H), 1.83-1.96(m, 2H), 1.72-1.80 (m, 1H), 1.54-1.72 (m, 3H), 1.28 (dq, J=12.9, 6.4 Hz,1H), 0.92 (d, J=6.6 Hz, 3H), 0.90 (d, J=6.6 Hz, 3H); MS (ESI+) m/z 344(M+H)⁺.

Example 361N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamatefrom Example 226 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.27-8.30 (m, 1H), 7.43-7.45 (m, 2H), 7.37 (t, J=7.4 Hz, 2H),7.25-7.29 (m, 1H), 4.36-4.42 (m, 1H), 3.58-3.61 (m, 2H), 3.45 (d, J=13.1Hz, 1H), 2.86 (dd, J=9.0, 2.4 Hz, 1H), 2.45-2.54 (m, 2H), 2.39 (dd,J=9.0, 7.2 Hz, 1H), 2.36 (dd, J=9.1, 2.5 Hz, 1H), 2.24 (dd, J=8.8, 6.9Hz, 1H), 2.18 (dd, J=14.0, 4.3 Hz, 1H), 2.01-2.23 (m, 2H), 2.07-2.14 (m,1H), 1.79-1.87 (m, 1H), 1.56 (dq, J=12.0, 7.7 Hz, 1H), 1.44 (dd, J=14.0,7.5 Hz, 1H), 1.35-1.44 (m, 1H), 0.98 (s, 9H); MS (ESI+) m/z 344 (M+H)⁺.

Example 362N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norleucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxohexan-2-yl(methyl)carbamatefrom Example 227 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.07-8.10 (m, 1H), 7.43-7.46 (m, 2H), 7.37 (t, J=7.5 Hz, 2H), 7.28(t, J=7.4 Hz, 1H), 4.42-4.47 (m, 1H), 3.61 (d, J=13.1 Hz, 1H), 3.46 (d,J=13.1 Hz, 1H), 3.15 (t, J=6.5 Hz, 1H), 2.87 (dd, J=9.0, 2.5 Hz, 1H),2.47-2.58 (m, 2H), 2.40-2.44 (m, 1H), 2.41 (s, 3H), 2.37 (dd, J=8.9, 2.6Hz, 1H), 2.26 (dd, J=8.9, 6.8 Hz, 1H), 2.08-2.17 (m, 1H), 1.93-2.16 (m,1H), 1.80-1.89 (m, 2H), 1.67-1.75 (m, 1H), 1.59 (dq, J=12.0, 7.6 Hz,1H), 1.38-1.50 (m, 3H), 1.20-1.28 (m, 2H), 0.81 (t, J=7.3 Hz, 3H); MS(ESI+) m/z 344 (M+H)⁺.

Example 363N¹-[(3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom Example 240 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.26 (d, J=7.8 Hz, 1H), 7.50-7.52 (m, 2H), 7.39 (t, J=7.5 Hz, 2H),7.32 (t, J=7.3 Hz, 1H), 4.51-4.57 (m, 1H), 3.57 (d, J=12.7 Hz, 1H), 3.42(d, J=12.7 Hz, 1H), 3.13-3.16 (m, 1H), 2.75-2.78 (m, 1H), 2.63-2.70 (m,1H), 2.45-2.49 (m, 1H), 2.39-2.47 (m, 1H), 2.39 (s, 3H), 2.14 (dd,J=8.9, 7.6 Hz, 1H), 2.09 (dd, J=9.5, 7.2 Hz, 1H), 1.82-2.27 (m, 1H),1.83-1.91 (m, 1H), 1.63-1.81 (m, 3H), 1.54-1.63 (m, 1H), 1.39-1.54 (m,2H), 1.25-1.33 (m, 1H), 0.86 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 330(M+H)⁺.

Example 364N¹-[(3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 241 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.24-8.27 (m, 1H), 7.50-7.52 (m, 2H), 7.40 (t, J=7.5 Hz, 2H), 7.32(t, J=7.4 Hz, 1H), 4.50-4.56 (m, 1H), 3.54 (d, J=12.7 Hz, 1H), 3.45 (d,J=12.7 Hz, 1H), 3.20 (dd, J=8.2, 5.7 Hz, 1H), 2.76-2.78 (m, 1H),2.64-2.71 (m, 1H), 2.46-2.49 (m, 1H), 2.41-2.47 (m, 1H), 2.39 (s, 3H),2.16 (t, J=8.2 Hz, 1H), 2.06-2.12 (m, 1H), 1.78-2.09 (m, 1H), 1.82-1.93(m, 2H), 1.63-1.76 (m, 2H), 1.55-1.63 (m, 1H), 1.48-1.56 (m, 1H),1.25-1.35 (m, 1H), 0.93 (d, J=6.5 Hz, 3H), 0.88 (d, J=6.6 Hz, 3H); MS(ESI+) m/z 344 (M+H)⁺.

Example 365N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A of Example 313 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.08-8.10 (m, 1H), 7.43-7.46 (m, 2H), 7.37 (t, J=7.4 Hz, 2H), 7.28(t, J=7.3 Hz, 1H), 4.41-4.46 (m, 1H), 3.61 (d, J=13.1 Hz, 1H), 3.45 (d,J=13.1 Hz, 1H), 3.15 (t, J=6.5 Hz, 1H), 2.86 (dd, J=9.0, 2.5 Hz, 1H),2.47-2.57 (m, 2H), 2.40-2.44 (m, 1H), 2.40 (s, 3H), 2.37 (dd, J=9.0, 2.3Hz, 1H), 2.24-2.27 (m, 1H), 2.07-2.16 (m, 1H), 1.90-2.10 (m, 1H),1.77-1.88 (m, 2H), 1.63-1.73 (m, 1H), 1.54-1.63 (m, 1H), 1.36-1.53 (m,3H), 0.84 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 330 (M+H)⁺.

Example 366N²-ethyl-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substituting tert-butylethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 310 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.23-8.26 (m, 1H), 7.76-7.77 (bs, 1H), 7.55-7.63 (m, 2H), 7.45 (t,J=7.7 Hz, 1H), 4.41-4.45 (m, 1H), 3.61 (d, J=13.5 Hz, 1H), 3.48 (d,J=13.5 Hz, 1H), 3.33 (dd, J=8.2, 5.8 Hz, 1H), 2.86 (dd, J=9.0, 2.3 Hz,1H), 2.70-2.78 (m, 1H), 2.60-2.64 (m, 1H), 2.53-2.55 (m, 2H), 2.43-2.47(m, 1H), 2.33 (dd, J=9.0, 2.4 Hz, 1H), 2.28 (dd, J=8.8, 6.3 Hz, 1H),2.08-2.12 (m, 1H), 1.80-2.05 (m, 1H), 1.82-1.95 (m, 2H), 1.72 (ddd,J=13.5, 7.8, 5.8 Hz, 1H), 1.56-1.63 (m, 2H), 1.39-1.45 (m, 1H), 1.08 (t,J=7.1 Hz, 3H), 0.92 (d, J=6.6 Hz, 3H), 0.86 (d, J=6.5 Hz, 3H); MS (ESI+)m/z 462 (M+H)⁻.

Example 367N²-methyl-N¹-{(3aS,4R,6aR)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-valinamide

Step A: tert-Butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamatewas prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamatefrom Example 232 for(2S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehydein the procedures described in Example 303: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.59 (d, J=8.0, 2H), 7.46 (d, J=7.9, 2H), 4.35 (d,J=9.6, 1H), 4.30-4.23 (m, 1H), 3.55 (d, J=13.7, 1H), 3.48 (d, J=13.7,1H), 3.01 (s, 3H), 2.77 (dd, J=8.9, 2.1, 1H), 2.57-2.48 (m, 1H), 2.42(ddd, J=10.7, 9.3, 6.0, 2H), 2.36 (dd, J=14.0, 5.7, 2H), 2.30-2.25 (m,1H), 2.12-2.03 (m, 2H), 1.87 (td, J=12.9, 6.3, 1H), 1.57 (dt, J=14.8,7.9, 1H), 1.45 (s, 9H), 1.43-1.35 (m, 1H), 1.01 (d, J=6.5, 3H), 0.87 (d,J=6.7, 3H); MS (ESI+) m/z 498 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.13-8.16 (m, 1H), 7.65-7.67 (m, 2H), 7.51-7.54 (m, 2H), 4.45-4.51(m, 1H), 3.60 (d, J=13.7 Hz, 1H), 3.47 (d, J=13.7 Hz, 1H), 2.90 (d,J=13.1 Hz, 1H), 2.88-2.90 (m, 1H), 2.48-2.59 (m, 2H), 2.40 (s, 3H),2.33-2.40 (m, 2H), 2.24 (dd, J=8.9, 7.0 Hz, 1H), 2.08-2.16 (m, 2H),1.94-2.10 (m, 1H), 1.85-1.93 (m, 1H), 1.60 (dq, J=12.0, 7.7 Hz, 1H),1.43 (ddt, J=8.9, 12.4, 6.2 Hz, 1H), 1.06 (t, J=6.9 Hz, 6H); MS (ESI+)m/z 398 (M+H)⁺.

Example 368(2S)-N-[(3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]piperidine-2-carboxamide

Step A:tert-butyl(2S)-2-({[(3aS,4R,6aR)-2-(4-flurobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylatewas prepared by substitutingtert-butyl(2S)-2-({[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylatefrom Example 231 for(2S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde in theprocedures described in Example 303: ¹H NMR (500 MHz, pyridine-d₅) δ ppm7.37 (d, J=7.2, 2H), 7.30 (t, J=7.5, 2H), 7.21 (t, J=7.3, 2H), 4.87 (d,J=3.9, 1H), 4.32-4.23 (m, 1H), 4.10 (d, J=12.8, 1H), 3.58 (d, J=13.2,1H), 3.47 (d, J=13.2, 1H), 3.29 (td, J=12.8, 2.9, 1H), 2.83-2.76 (m,1H), 2.52 (td, J=8.1, 3.4, 1H), 2.48-2.41 (m, 2H), 2.36 (dd, J=9.0, 3.1,1H), 2.33-2.28 (m, 1H), 2.24 (dd, J=11.7, 1.6, 1H), 2.07 (dq, J=12.2,6.1, 1H), 1.87-1.78 (m, 1H), 1.69-1.59 (m, 1H), 1.59-1.49 (m, 3H), 1.48(s, 9H), 1.45-1.29 (m, 3H); MS (ESI+) m/z 428 (M+H)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(2S)-2-({[(3aS,4R,6aR)-2-(4-flurobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 7.68-7.70 (m, 1H), 7.35 (dd, J=8.3, 5.6 Hz, 2H), 7.10-7.14 (m,2H), 4.34-4.40 (m, 1H), 3.51 (d, J=13.1 Hz, 1H), 3.36 (d, J=13.1 Hz,1H), 3.32 (dd, J=10.4, 3.2 Hz, 1H), 2.98-3.02 (m, 1H), 2.82 (dd, J=9.0,2.6 Hz, 1H), 2.54-2.61 (m, 1H), 2.48-2.54 (m, 1H), 2.39-2.46 (m, 1H),2.33-2.45 (m, 1H), 2.29-2.35 (m, 2H), 2.16-2.22 (m, 1H), 2.01-2.10 (m,2H), 1.78-1.87 (m, 1H), 1.65-1.74 (m, 1H), 1.56-1.64 (m, 1H), 1.47-1.56(m, 1H), 1.34-1.44 (m, 2H), 1.26-1.34 (m, 2H); MS (ESI+) m/z 346 (M+H)⁺.

Example 369N¹-[(3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-y]-N²-methyl-L-valinamide

Step A: tert-Butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamatewas prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamatefrom Example 232 for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde in theprocedures described in Example 303: ¹H NMR (500 MHz, pyridine-d₅) δ ppm7.43 (s, 1H), 7.30 (dd, J=8.3, 5.7, 2H), 7.03 (t, J=8.8, 2H), 4.35 (d,J=9.5, 1H), 4.25 (s, 1H), 3.49 (d, J=13.2, 1H), 3.41 (d, J=13.2, 1H),3.01 (s, 3H), 2.75 (dd, J=8.9, 2.3, 1H), 2.57-2.48 (m, 1H), 2.45-2.31(m, 4H), 2.27 (dd, J=8.8, 7.4, 1H), 2.11-2.03 (m, 1H), 1.85 (dt, J=20.7,6.5, 1H), 1.56 (dt, J=15.2, 7.3, 1H), 1.46 (s, 9H), 1.43-1.35 (m, 1H),1.01 (d, J=6.5, 3H), 0.87 (d, J=6.7, 3H); MS (ESI+) m/z 448 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.11-8.14 (m, 1H), 7.37 (dd, J=8.3, 5.6 Hz, 2H), 7.11-7.15 (m,2H), 4.43-4.49 (m, 1H), 3.54 (d, J=13.1 Hz, 1H), 3.39 (d, J=13.1 Hz,1H), 2.90 (d, J=5.8 Hz, 1H), 2.86 (dd, J=9.0, 2.6 Hz, 1H), 2.47-2.56 (m,2H), 2.40 (s, 3H), 2.38 (dd, J=9.0, 7.0 Hz, 1H), 2.34 (dd, J=9.0, 2.6Hz, 1H), 2.23 (dd, J=8.9, 7.0 Hz, 1H), 2.07-2.16 (m, 2H), 1.93-2.04 (m,1H), 1.83-1.92 (m, 1H), 1.59 (dq, J=12.1, 7.7 Hz, 1H), 1.41 (ddt, J=8.9,12.4, 6.2 Hz, 1H), 1.06 (t, J=6.8 Hz, 6H); MS (ESI+) m/z 348 (M+H)⁺.

Example 370(2S)-N-{(3aS,4R,6aR)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}piperidine-2-carboxamide

Step A:tert-butyl(2S)-2-({[(3aS,4R,6aR)-2-(4-(trifluromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylatewas prepared by substitutingtert-butyl(2S)-2-({[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylatefrom Example 231 for(2S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehydein the procedures described in Example 303: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 7.59 (d, J=8.1, 2H), 7.47 (d, J=8.0, 2H), 7.27-7.20(m, 1H), 4.87 (d, J=3.7, 1H), 4.32-4.23 (m, 1H), 3.57 (d, J=13.7, 1H),3.49 (d, J=13.8, 1H), 3.29 (td, J=12.8, 3.0, 1H), 2.81 (dd, J=8.7, 2.0,1H), 2.59-2.50 (m, 1H), 2.46 (ddd, J=12.1, 7.0, 2.8, 1H), 2.43-2.38 (m,1H), 2.36 (dd, J=9.0, 2.9, 1H), 2.32-2.27 (m, 1H), 2.27-2.20 (m, 1H),2.11-2.03 (m, 2H), 1.86 (ddd, J=12.7, 8.1, 6.3, 1H), 1.70-1.60 (m, 1H),1.59-1.49 (m, 4H), 1.47 (s, 9H), 1.45-1.29 (m, 2H); MS (ESI+) m/z 496(M+H)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(2S)-2-({[(3aS,4R,6aR)-2-(4-(trifluromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 7.71 (d, J=7.5 Hz, 1H), 7.64-7.66 (m, 2H), 7.49-7.52 (m, 2H),4.36-4.41 (m, 1H), 3.57 (d, J=13.7 Hz, 1H), 3.43 (d, J=13.7 Hz, 1H),3.33 (dd, J=10.3, 3.2 Hz, 1H), 2.98-3.03 (m, 1H), 2.85 (dd, J=9.0, 2.5Hz, 1H), 2.50-2.60 (m, 2H), 2.36-2.58 (m, 1H), 2.41-2.46 (m, 1H), 2.34(d, J=7.6 Hz, 1H), 2.31-2.33 (m, 1H), 2.20 (dd, J=8.9, 7.2 Hz, 1H),2.02-2.10 (m, 2H), 1.81-1.88 (m, 1H), 1.66-1.71 (m, 1H), 1.50-1.63 (m,2H), 1.35-1.42 (m, 2H), 1.24-1.34 (m, 2H); MS (ESI+) m/z 396 (M+H)⁺.

Example 371N²-methyl-N¹-{(3aS,4R,6aR)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-1-norvalinamide

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 317 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.14-8.17 (m, 1H), 7.64-7.67 (m, 2H), 7.51-7.54 (m, 2H), 4.43-4.49(m, 1H), 3.59 (d, J=13.7 Hz, 1H), 3.47 (d, J=13.7 Hz, 1H), 3.16 (t,J=6.5 Hz, 1H), 2.88 (dd, J=9.0, 2.6 Hz, 1H), 2.44-2.58 (m, 2H), 2.40 (s,3H), 2.34-2.39 (m, 2H), 2.24 (t, J=8.0 Hz, 1H), 2.12 (dq, J=11.8, 5.9Hz, 1H), 1.95-2.18 (m, 1H), 1.85-1.93 (m, 1H), 1.76-1.85 (m, 1H),1.66-1.73 (m, 1H), 1.56-1.64 (m, 1H), 1.39-1.53 (m, 3H), 0.84 (t, J=7.3Hz, 3H); MS (ESI+) m/z 398 (M+H)⁺.

Example 372N¹-[(3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom Example 318 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.12-8.15 (m, 1H), 7.35-7.39 (m, 2H), 7.11-7.15 (m, 2H), 4.41-4.47(m, 1H), 3.53 (d, J=13.1 Hz, 1H), 3.39 (d, J=13.1 Hz, 1H), 3.16 (t,J=6.5 Hz, 1H), 2.85 (dd, J=9.0, 2.6 Hz, 1H), 2.46-2.59 (m, 2H), 2.40 (s,3H), 2.38 (dd, J=8.9, 6.8 Hz, 1H), 2.34 (dd, J=8.9, 2.8 Hz, 1H), 2.23(dd, J=8.9, 7.1 Hz, 1H), 2.07-2.16 (m, 1H), 1.91-2.12 (m, 1H), 1.84-1.91(m, 1H), 1.76-1.83 (m, 1H), 1.66-1.73 (m, 1H), 1.54-1.63 (m, 1H),1.36-1.54 (m, 3H), 0.84 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 348 (M+H)⁺.

Example 373N²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-valinamide

The title compound was prepared by substituting tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamatefrom Example 316 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.13 (d, J=7.6, 1H), 7.76 (s, 1H), 7.61 (d, J=7.6, 1H), 7.56 (s,1H), 7.45 (t, J=7.7, 1H), 4.52-4.36 (m, 1H), 3.62 (d, J=13.6, 1H), 3.46(d, J=13.6, 1H), 2.92-2.79 (m, 2H), 2.59-2.46 (m, 2H), 2.43 (d, J=8.8,1H), 2.40 (s, 3H), 2.33 (dd, J=9.0, 2.5, 1H), 2.28-2.22 (m, 1H),2.15-2.05 (m, 2H), 2.04-1.93 (m, 1H), 1.86 (td, J=12.9, 6.4, 1H), 1.59(dt, J=14.9, 7.7, 1H), 1.44-1.36 (m, 1H), 1.05 (t, J=7.0, 6H); MS (ESI+)m/z 398 (M+H)⁺.

Example 374N¹-{(3aS,4R,6aR)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-(3-fluoro-4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 311 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.20-8.22 (m, 1H), 7.58-7.61 (m, 1H), 7.32-7.36 (m, 1H), 7.27-7.29(m, 1H), 4.43-4.48 (m, 1H), 3.55-3.62 (m, 1H), 3.45 (d, J=14.1 Hz, 1H),3.22 (dd, J=8.2, 5.8 Hz, 1H), 2.91 (dd, J=9.0, 2.5 Hz, 1H), 2.48-2.60(m, 2H), 2.42 (s, 3H), 2.35-2.39 (m, 2H), 2.23 (dd, J=8.9, 7.1 Hz, 1H),2.07-2.16 (m, 1H), 1.91-2.11 (m, 1H), 1.84-1.95 (m, 2H), 1.71 (ddd,J=13.5, 7.8, 5.8 Hz, 1H), 1.56-1.65 (m, 2H), 1.39-1.46 (m, 1H), 0.91 (d,J=6.6 Hz, 3H), 0.85 (d, J=6.5 Hz, 3H); MS (ESI+) m/z 430 (M+H)⁺.

Example 375N¹-{(3aS,4R,6aR)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluoro-3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 312 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.18-8.21 (m, 1H), 7.68-7.71 (m, 1H), 7.57-7.60 (m, 1H), 7.22-7.28(m, 1H), 4.42-4.46 (m, 1H), 3.55 (d, J=13.5 Hz, 1H), 3.43 (d, J=13.4 Hz,1H), 3.21 (dd, J=8.2, 5.8 Hz, 1H), 2.88 (dd, J=9.0, 2.6 Hz, 1H),2.48-2.60 (m, 2H), 2.42 (s, 3H), 2.37-2.42 (m, 1H), 2.34 (dd, J=8.8, 2.4Hz, 1H), 2.21-2.28 (m, 1H), 2.06-2.14 (m, 1H), 1.90-2.08 (m, 1H),1.83-1.94 (m, 2H), 1.71 (ddd, J=13.5, 7.8, 5.8 Hz, 1H), 1.55-1.64 (m,2H), 1.38-1.45 (m, 1H), 0.91 (d, J=6.5 Hz, 3H), 0.85 (d, J=6.5 Hz, 3H);MS (ESI+) m/z 430 (M+H)⁺.

Example 376N²-methyl-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl]-L-norvalinamide

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 313 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.09-8.12 (m, 1H), 7.76-7.77 (bs, 1H), 7.60-7.63 (m, 1H),7.55-7.58 (m, 1H), 7.45 (t, J=7.7 Hz, 1H), 4.40-4.44 (m, 1H), 3.61 (d,J=13.5 Hz, 1H), 3.47 (d, J=13.5 Hz, 1H), 3.15 (t, J=6.5 Hz, 1H), 2.87(dd, J=9.0, 2.6 Hz, 1H), 2.47-2.57 (m, 2H), 2.40-2.44 (m, 1H), 2.40 (s,3H), 2.33 (dd, J=9.0, 2.7 Hz, 1H), 2.23-2.27 (m, 1H), 2.05-2.12 (m, 1H),1.93-2.10 (m, 1H), 1.83-1.90 (m, 1H), 1.76-1.83 (m, 1H), 1.64-1.73 (m,1H), 1.54-1.63 (m, 1H), 1.36-1.53 (m, 3H), 0.84 (t, J=7.3 Hz, 3H); MS(ESI+) m/z 398 (M+H)⁺.

Example 377N²-methyl-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 314 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.12-8.15 (m, 1H), 7.64-7.67 (m, 2H), 7.51-7.54 (m, 2H), 4.42-4.47(m, 1H), 3.57-3.61 (m, 1H), 3.48 (d, J=13.7 Hz, 1H), 3.16 (t, J=6.5 Hz,1H), 2.89 (dd, J=9.0, 2.5 Hz, 1H), 2.48-2.58 (m, 2H), 2.41 (s, 3H),2.34-2.41 (m, 2H), 2.24 (dd, J=8.9, 7.0 Hz, 1H), 2.03-2.18 (m, 1H),1.94-2.26 (m, 1H), 1.77-1.95 (m, 2H), 1.66-1.73 (m, 1H), 1.55-1.64 (m,1H), 1.38-1.55 (m, 3H), 0.84 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 398(M+H)⁺.

Example 378N¹-[(3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom Example 315 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.12-8.15 (m, 1H), 7.64-7.67 (m, 2H), 7.51-7.54 (m, 2H), 4.42-4.47(m, 1H), 3.57-3.61 (m, 1H), 3.48 (d, J=13.7 Hz, 1H), 3.16 (t, J=6.5 Hz,1H), 2.89 (dd, J=9.0, 2.5 Hz, 1H), 2.48-2.58 (m, 2H), 2.41 (s, 3H),2.34-2.41 (m, 2H), 2.24 (dd, J=8.9, 7.0 Hz, 1H), 2.03-2.18 (m, 1H),1.94-2.26 (m, 1H), 1.77-1.95 (m, 2H), 1.66-1.73 (m, 1H), 1.55-1.64 (m,1H), 1.38-1.55 (m, 3H), 0.84 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 398(M+H)⁺.

Example 379N²-methyl-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl]-L-leucinamide

The title compound was prepared by substituting tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 307 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.18-8.20 (m, 1H), 7.76-7.77 (bs, 1H), 7.60-7.64 (m, 1H),7.54-7.59 (m, 1H), 7.45 (t, J=7.7 Hz, 1H), 4.40-4.47 (m, 1H), 3.61 (d,J=13.5 Hz, 1H), 3.47 (d, J=13.5 Hz, 1H), 3.22 (dd, J=8.2, 5.8 Hz, 1H),2.87 (d, J=10.4 Hz, 1H), 2.49-2.57 (m, 2H), 2.40-2.46 (m, 1H), 2.42 (s,3H), 2.33 (dd, J=8.9, 2.5 Hz, 1H), 2.26 (dd, J=8.9, 6.5 Hz, 1H),2.01-2.16 (m, 1H), 1.92-2.12 (m, 1H), 1.83-1.97 (m, 2H), 1.71 (ddd,J=13.5, 7.7, 5.8 Hz, 1H), 1.55-1.64 (m, 2H), 1.37-1.44 (m, 1H), 0.91 (d,J=6.6 Hz, 3H), 0.85 (d, J=6.5 Hz, 3H); MS (ESI+) m/z 412 (M+H)⁺.

Example 380N²-methyl-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl]-L-leucinamide

The title compound was prepared by substituting tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 308 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.19-8.22 (m, 1H), 7.64-7.67 (m, 2H), 7.51-7.54 (m, 2H), 4.43-4.48(m, 1H), 3.59 (d, J=13.7 Hz, 1H), 3.48 (d, J=13.7 Hz, 1H), 3.23 (dd,J=8.2, 5.8 Hz, 1H), 2.90 (dd, J=9.0, 2.4 Hz, 1H), 2.49-2.58 (m, 2H),2.43 (s, 3H), 2.38-2.42 (m, 1H), 2.37 (dd, J=19.2, 2.5 Hz, 1H), 2.24(dd, J=8.9, 6.8 Hz, 1H), 2.09-2.17 (m, 1H), 1.95-2.13 (m, 1H), 1.83-1.97(m, 2H), 1.72 (ddd, J=13.5, 7.8, 5.8 Hz, 1H), 1.56-1.65 (m, 2H),1.39-1.46 (m, 1H), 0.91 (d, J=6.6 Hz, 3H), 0.85 (d, J=6.5 Hz, 3H); MS(ESI+) m/z 412 (M+H)⁺.

Example 381N¹-[(3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 309 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.17-8.20 (m, 1H), 7.37 (dd, J=8.2, 5.6 Hz, 2H), 7.11-7.15 (m,2H), 4.41-4.47 (m, 1H), 3.52 (d, J=13.1 Hz, 1H), 3.40 (d, J=13.1 Hz,1H), 3.22 (dd, J=8.2, 5.8 Hz, 1H), 2.86 (dd, J=9.0, 2.4 Hz, 1H),2.46-2.57 (m, 2H), 2.42 (s, 3H), 2.34-2.41 (m, 2H), 2.24 (dd, J=8.9, 6.7Hz, 1H), 2.05-2.18 (m, 1H), 1.98-2.11 (m, 1H), 1.83-1.97 (m, 2H), 1.71(ddd, J=13.5, 7.8, 5.8 Hz, 1H), 1.55-1.64 (m, 2H), 1.41 (ddt, J=8.9,12.3, 6.2 Hz, 1H), 0.91 (d, J=6.6 Hz, 3H), 0.85 (d, J=6.6 Hz, 3H); MS(ESI+) m/z 362 (M+H)⁺.

Example 382N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl]-L-norvalinamide

Step A:tert-butyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substituting N-(tert-butoxycarbonyl)-L-norvaline forN-(tert-butoxycarbonyl)-L-leucine in the procedure described in Example221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.61-8.53 (m, 1H), 7.92 (d,J=8.2, 1H), 7.43 (d, J=7.4, 2H), 7.35 (d, J=7.6, 2H), 7.27 (t, J=7.2,1H), 4.64 (dd, J=14.4, 7.8, 1H), 4.47-4.35 (m, 1H), 3.59 (d, J=13.1,1H), 3.43 (d, J=13.2, 1H), 2.83 (dd, J=4.7, 4.1, 1H), 2.60-2.48 (m, 2H),2.47-2.40 (m, 1H), 2.32 (dd, J=5.0, 3.9, 1H), 2.27-2.20 (m, 1H),2.11-1.97 (m, 2H), 1.91-1.76 (m, 2H), 1.63-1.42 (m, 12H), 1.40-1.29 (m,1H), 0.81 (t, J=7.3, 3H); MS (ESI+) m/z 416 (M+H)⁺.

Step B:tert-Butyl-((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingtert-butyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehydein the procedures described in Example 303: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.60 (d, J=7.0, 1H), 7.93 (d, J=8.3, 1H), 7.65 (d,J=8.1, 2H), 7.51 (d, J=7.9, 2H), 4.64 (dd, J=13.0, 6.5, 1H), 4.47-4.37(m, 1H), 3.57 (d, J=13.7, 1H), 3.45 (d, J=13.7, 1H), 2.86 (d, J=8.3,1H), 2.55 (dd, J=14.1, 9.2, 2H), 2.43-2.36 (m, 1H), 2.31 (d, J=7.8, 1H),2.26-2.20 (m, 1H), 2.14 (s, 1H), 2.04 (dd, J=12.1, 6.0, 2H), 1.90-1.80(m, 2H), 1.59 (s, 1H), 1.49 (d, J=11.3, 10H), 1.37 (s, 1H), 0.81 (t,J=7.3, 3H); MS (ESI+) m/z 484 (M+H)⁺.

Step C: The title compound was prepared by substitutingtert-Butyl-((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step B fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.19-8.22 (m, 1H), 7.64-7.67 (m, 2H), 7.50-7.53 (m, 2H), 4.37-4.43(m, 1H), 3.53-3.58 (m, 2H), 3.46 (d, J=13.7 Hz, 1H), 2.86 (dd, J=9.0,2.6 Hz, 1H), 2.49-2.57 (m, 1H), 2.43-2.49 (m, 1H), 2.33-2.36 (m, 2H),2.19-2.25 (m, 1H), 2.11-2.20 (m, 2H), 2.06-2.14 (m, 1H), 1.91-2.01 (m,1H), 1.82-1.90 (m, 1H), 1.62-1.69 (m, 1H), 1.38-1.58 (m, 4H), 0.84 (t,J=7.3 Hz, 3H); MS (ESI+) m/z 384 (M+H)⁺.

Example 383N²-ethyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting tert-butylethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 323 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.37-8.39 (m, 1H), 8.32-8.37 (m, 1H), 8.19-8.21 (m, 1H), 7.90-7.93(m, 1H), 7.73 (t, J=7.9 Hz, 1H), 4.23-4.29 (m, 1H), 3.86 (d, J=11.2 Hz,1H), 3.31 (t, J=6.9 Hz, 1H), 3.18 (dd, J=9.7, 2.1 Hz, 1H), 3.16 (dd,J=9.9, 7.5 Hz, 1H), 2.96 (dd, J=9.5, 6.5 Hz, 1H), 2.68-2.75 (m, 1H),2.51-2.63 (m, 3H), 1.90-2.12 (m, 1H), 1.91-1.99 (m, 1H), 1.80-1.91 (m,2H), 1.66-1.72 (m, 1H), 1.52-1.60 (m, 2H), 1.26-1.34 (m, 1H), 1.06 (t,J=7.1 Hz, 3H), 0.92 (d, J=6.6 Hz, 3H), 0.85 (d, J=6.5 Hz, 3H); MS (ESI+)m/z 476 (M+H)⁺.

Example 384N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 322 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.38-8.39 (bs, 1H), 8.29-8.31 (m, 1H), 8.19-8.21 (m, 1H),7.91-7.93 (m, 1H), 7.73 (t, J=7.8 Hz, 1H), 4.24-4.29 (m, 1H), 3.87 (dd,J=9.9, 2.2 Hz, 1H), 3.17-3.22 (m, 2H), 3.15 (dd, J=9.8, 7.4 Hz, 1H),2.95 (dd, J=9.6, 6.7 Hz, 1H), 2.49-2.60 (m, 2H), 2.39 (s, 3H), 1.93-2.10(m, 1H), 1.91-1.99 (m, 1H), 1.80-1.91 (m, 2H), 1.68 (ddd, J=13.5, 7.8,5.8 Hz, 1H), 1.53-1.59 (m, 2H), 1.25-1.33 (m, 1H), 0.91 (d, J=6.6 Hz,3H), 0.85 (d, J=6.6 Hz, 3H); MS (ESI+) m/z 462 (M+H)⁻.

Example 385N-((3aR,4S,6aS)-2-[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamidefrom Example 269 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.38-8.39 (bs, 1H), 8.19-8.22 (m, 2H), 7.91-7.94 (m, 1H), 7.74 (t,J=7.8 Hz, 1H), 7.29-7.35 (m, 4H), 7.24-7.29 (m, 1H), 4.92-4.95 (m, 1H),4.16-4.23 (m, 1H), 3.80 (dd, J=7.6, 5.7 Hz, 1H), 3.77 (dd, J=9.8, 2.7Hz, 1H), 3.32 (dd, J=13.2, 5.7 Hz, 1H), 3.15 (dd, J=9.6, 2.9 Hz, 1H),2.99-3.03 (m, 2H), 2.89 (dd, J=9.6, 7.6 Hz, 1H), 2.41-2.47 (m, 1H),2.32-2.37 (m, 1H), 1.98-2.15 (m, 1H), 1.83-1.89 (m, 1H), 1.71-1.77 (m,1H), 1.35-1.43 (m, 1H), 1.17-1.26 (m, 1H); MS (ESI+) m/z 482 (M+H)⁺.

Example 386N-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamidefrom Example 270 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.39-8.40 (bs, 1H), 8.25 (d, J=5.1 Hz, 1H), 7.94-7.96 (m, 1H),7.79 (t, J=7.8 Hz, 1H), 7.31-7.33 (m, 4H), 7.24-7.28 (m, 1H), 4.17-4.24(m, 1H), 3.73 (dd, J=9.9, 2.8 Hz, 1H), 3.45 (t, J=6.8 Hz, 1H), 3.13-3.20(m, 2H), 3.01-3.10 (m, 2H), 2.91 (dd, J=9.6, 7.6 Hz, 1H), 2.39-2.50 (m,1H), 2.36 (s, 3H), 2.28-2.37 (m, 1H), 2.0 (m, 1H), 1.89-2.26 (m, 1H),1.84-1.92 (m, 1H), 1.72-1.79 (m, 1H), 1.40-1.48 (m, 1H), 1.18-1.26 (m,1H); MS (ESI+) m/z 496 (M+H)⁺.

Example 387N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-1-prolinamide

The title compound was prepared by substituting (S)-tert-butyl2-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylatefrom Example 271 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.35-8.38 (m, 1H), 8.17-8.19 (m, 2H), 7.90-7.92 (m, 1H), 7.72 (t,J=7.9 Hz, 1H), 4.13-4.19 (m, 1H), 3.86 (dd, J=8.6, 5.8 Hz, 1H), 3.79(dd, J=9.9, 2.6 Hz, 1H), 3.16 (dd, J=9.6, 2.9 Hz, 1H), 3.02 (dd, J=9.9,7.8 Hz, 1H), 2.66-3.18 (m, 1H), 2.79-2.91 (m, 3H), 2.48-2.55 (m, 1H),2.40-2.45 (m, 1H), 1.99-2.10 (m, 2H), 1.76-1.92 (m, 2H), 1.55-1.65 (m,1H), 1.48-1.56 (m, 1H), 1.39-1.48 (m, 1H), 1.21-1.29 (m, 1H); MS (ESI+)m/z 432 (M+H)⁺.

Example 388(3R)-3-amino-4-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide

The title compound was prepared by substitutingtert-butyl(1R)-1-isopropyl-3-oxo-3-[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]propylcarbamatefrom Example 272 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.74-8.76 (bs, 2H), 8.37-8.38 (bs, 1H), 8.19 (d, J=7.9 Hz, 1H),7.91 (d, J=7.9 Hz, 1H), 7.72 (t, J=7.8 Hz, 1H), 4.23-4.28 (m, 1H), 3.85(dd, J=9.9, 2.4 Hz, 1H), 3.14-3.19 (m, 2H), 3.12 (dd, J=9.9, 7.6 Hz,1H), 2.94 (dd, J=9.6, 6.8 Hz, 1H), 2.50-2.55 (m, 2H), 2.43 (dd, J=14.4,3.2 Hz, 1H), 2.27 (dd, J=14.4, 9.9 Hz, 1H), 1.92-1.99 (m, 1H), 1.80-1.88(m, 1H), 1.65-1.90 (m, 1H), 1.50-1.61 (m, 2H), 1.25-1.32 (m, 1H), 0.85(d, J=6.9 Hz, 3H), 0.83 (d, J=6.9 Hz, 3H); MS (ESI−) m/z 446 (M−H)⁻.

Example 389N²-methyl-N¹-((3aR,4S,6aS)-2-[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-1-valinamide

The title compound was prepared by substituting tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamatefrom Example 273 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.39-8.40 (bs, 1H), 8.24 (d, J=6.9 Hz, 1H), 8.21 (d, J=7.8 Hz,1H), 7.91-7.93 (m, 1H), 7.73 (t, J=7.8 Hz, 1H), 4.24-4.28 (m, 1H), 3.86(dd, J=9.9, 2.4 Hz, 1H), 3.18 (dd, J=9.7, 2.4 Hz, 1H), 3.15 (dd, J=9.9,7.5 Hz, 1H), 2.96 (dd, J=9.6, 6.9 Hz, 1H), 2.88 (d, J=5.9 Hz, 1H),2.51-2.56 (m, 2H), 2.38 (s, 3H), 2.04-2.14 (m, 1H), 1.88-2.12 (m, 1H),1.90-1.98 (m, 1H), 1.80-1.88 (m, 1H), 1.51-1.58 (m, 1H), 1.29 (ddt,J=9.6, 12.8, 6.4 Hz, 1H), 1.04 (d, J=6.9 Hz, 3H), 1.01-1.05 (m, 6H),1.02 (d, J=6.9 Hz, 3H); MS (ESI+) m/z 448 (M+H)⁺.

Example 390(2S)-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)piperidine-2-carboxamide

The title compound was prepared by substitutingtert-butyl(2S)-2-{[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylatefrom Example 274 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.35-8.36 (bs, 1H), 8.17-8.19 (m, 1H), 7.90-7.92 (m, 1H),7.78-7.80 (m, 1H), 7.73 (t, J=7.8 Hz, 1H), 4.16-4.23 (m, 1H), 3.79 (dd,J=9.8, 2.6 Hz, 1H), 3.32 (dd, J=10.3, 3.2 Hz, 1H), 3.15 (dd, J=9.6, 2.9Hz, 1H), 3.02 (dd, J=9.8, 7.7 Hz, 1H), 2.96-3.00 (m, 1H), 2.89 (dd,J=9.6, 7.4 Hz, 1H), 2.49-2.59 (m, 2H), 2.42-2.49 (m, 1H), 2.18-2.71 (m,1H), 2.01-2.05 (m, 1H), 1.87-1.95 (m, 1H), 1.75-1.83 (m, 1H), 1.65-1.71(m, 1H), 1.54-1.61 (m, 1H), 1.44-1.52 (m, 1H), 1.35-1.43 (m, 1H),1.19-1.35 (m, 3H); MS (ESI+) m/z 446 (M+H)⁺.

Example 391(3S)-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide

The title compound was prepared by substitutingtert-butyl(3S)-3-{[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}-3,4-dihydroisoquinoline-2(1H)-carboxylatefrom Example 275 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (501 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.30-8.31 (bs, 1H), 8.13-8.16 (m, 1H),7.83-7.85 (m, 1H), 7.68-7.71 (m, 1H), 7.65 (t, J=7.9 Hz, 1H), 7.08-7.12(m, 3H), 6.97-7.00 (m, 1H), 4.05-4.15 (m, 2H), 3.94-3.98 (m, 1H), 3.66(dd, J=10.3, 3.4 Hz, 1H), 3.63 (dd, J=9.8, 5.2 Hz, 1H), 3.21-3.26 (m,1H), 3.11-3.18 (m, 3H), 2.99-3.06 (m, 1H), 2.54-2.58 (m, 1H), 2.47-2.52(m, 1H), 1.96 (m, 1H), 1.87-1.94 (m, 1H), 1.78-1.85 (m, 1H), 1.45-1.54(m, 1H), 1.23-1.31 (m, 1H); MS (ESI−) m/z 492 (M−H)⁻.

Example 3924-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-1-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamatefrom Example 276 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (501 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.30-8.31 (bs, 1H), 8.13-8.16 (m, 1H),7.82-7.85 (m, 2H), 7.65 (t, J=7.9 Hz, 1H), 4.03-4.10 (m, 1H), 3.69 (dd,J=10.1, 3.4 Hz, 1H), 3.48 (dd, J=7.5, 4.0 Hz, 1H), 3.23-3.27 (m, 1H),3.11-3.13 (m, 2H), 2.54-2.59 (m, 1H), 2.46-2.51 (m, 1H), 2.07 (dd,J=14.1, 4.0 Hz, 1H), 2.0 (m, 1H), 1.89-1.96 (m, 1H), 1.78-1.87 (m, 1H),1.65-1.92 (m, 1H), 1.46-1.55 (m, 1H), 1.34 (dd, J=14.1, 7.6 Hz, 1H),1.23-1.32 (m, 1H), 0.96 (s, 9H); MS (ESI+) m/z 462 (M+H)⁻.

Example 393N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norleucinamide

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)hexan-2-yl)carbamatefrom Example 277 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.38-8.39 (bs, 1H), 8.19-8.23 (m, 2H), 7.91-7.93 (m, 1H), 7.73 (t,J=7.8 Hz, 1H), 4.24-4.29 (m, 1H), 3.87 (dd, J=9.9, 2.3 Hz, 1H), 3.18(dd, J=9.8, 2.3 Hz, 1H), 3.11-3.16 (m, 2H), 2.94 (dd, J=9.6, 6.8 Hz,1H), 2.53-2.66 (m, 2H), 2.39 (s, 3H), 1.98-2.19 (m, 1H), 1.91-1.99 (m,1H), 1.78-1.88 (m, 2H), 1.65-1.73 (m, 1H), 1.50-1.59 (m, 1H), 1.35-1.48(m, 2H), 1.20-1.33 (m, 3H), 0.81 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 462(M+H)⁺.

Example 394N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 278 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.38-8.39 (bs, 1H), 8.19-8.21 (m, 2H), 7.90-7.93 (m, 1H), 7.72 (t,J=7.9 Hz, 1H), 4.22-4.29 (m, 1H), 3.87 (dd, J=9.9, 2.5 Hz, 1H), 3.18(dd, J=9.6, 2.4 Hz, 1H), 3.10-3.15 (m, 2H), 2.94 (dd, J=9.6, 7.0 Hz,1H), 2.49-2.57 (m, 2H), 2.37 (s, 3H), 1.92-2.22 (m, 1H), 1.89-1.99 (m,1H), 1.74-1.87 (m, 2H), 1.62-1.70 (m, 1H), 1.40-1.58 (m, 3H), 1.25-1.32(m, 1H), 0.84 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 448 (M+H)⁺.

Example 395N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

Step A: tert-Butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 222 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.08 (d,J=8.2, 2H), 7.82 (d, J=8.2, 2H), 7.51 (d, J=2.1, 1H), 4.83 (s, 1H),4.12-4.04 (m, 1H), 3.67 (dd, J=10.2, 3.4, 1H), 3.27 (dd, J=10.2, 7.8,1H), 3.14-3.09 (m, 2H), 2.94 (s, 3H), 2.63-2.46 (m, 2H), 1.95-1.68 (m,4H), 1.60 (td, J=13.4, 6.8, 1H), 1.54-1.47 (m, 1H), 1.46 (s, 9H), 1.27(ddt, J=13.3, 9.3, 6.7, 1H), 0.89 (dd, J=10.7, 6.6, 6H); MS (ESI+) m/z562 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.32-8.34 (m, 1H), 8.13-8.16 (m, 2H), 7.90-7.92 (m, 2H), 4.23-4.30(m, 1H), 3.86 (dd, J=9.9, 2.4 Hz, 1H), 3.22 (dd, J=8.2, 5.9 Hz, 1H),3.18 (dd, J=9.8, 2.4 Hz, 1H), 3.15 (dd, J=10.0, 7.6 Hz, 1H), 2.97 (dd,J=9.6, 6.8 Hz, 1H), 2.53-2.60 (m, 2H), 2.41 (s, 3H), 2.0 (m, 1H),1.91-1.99 (m, 1H), 1.80-1.91 (m, 2H), 1.69 (ddd, J=13.5, 7.7, 5.9 Hz,1H), 1.52-1.60 (m, 2H), 1.26-1.35 (m, 1H), 0.91 (d, J=6.6 Hz, 3H), 0.85(d, J=6.5 Hz, 3H); MS (ESI+) m/z 462 (M+H)⁺.

Example 396N-((3aS,4R,6aR)-2-[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-prolinamide

The title compound was prepared by substituting (S)-tert-butyl2-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylatefrom Example 266 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.36-8.37 (bs, 1H), 8.17-8.19 (m, 2H), 7.90-7.92 (m, 1H), 7.72 (t,J=7.8 Hz, 1H), 4.13-4.19 (m, 1H), 3.81-3.85 (m, 2H), 3.17 (dd, J=9.6,2.9 Hz, 1H), 3.05 (dd, J=9.9, 7.8 Hz, 1H), 2.80-2.91 (m, 3H), 2.50-2.55(m, 1H), 2.39-2.45 (m, 1H), 1.97-2.09 (m, 2H), 1.96 (m, 1H), 1.84-1.91(m, 1H), 1.76-1.82 (m, 1H), 1.56-1.65 (m, 1H), 1.48-1.56 (m, 1H),1.40-1.48 (m, 1H), 1.21-1.29 (m, 1H); MS (ESI+) m/z 432 (M+H)⁺.

Example 397(3R)-3-amino-4-methyl-N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide

The title compound was prepared by substitutingtert-butyl(1R)-1-isopropyl-3-oxo-3-[((3S,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]propylcarbamatefrom Example 267 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.37-8.38 (bs, 1H), 8.20 (d, J=7.9 Hz, 1H), 7.90-7.92 (m, 1H),7.72 (t, J=7.8 Hz, 1H), 4.22-4.27 (m, 1H), 3.86 (dd, J=9.9, 2.4 Hz, 1H),3.12-3.18 (m, 3H), 2.95 (dd, J=9.6, 6.8 Hz, 1H), 2.51-2.56 (m, 2H), 2.45(dd, J=14.4, 3.2 Hz, 1H), 2.27 (dd, J=14.4, 9.9 Hz, 1H), 1.90-1.98 (m,1H), 1.79-1.88 (m, 1H), 1.63-1.83 (m, 3H), 1.49-1.62 (m, 2H), 1.24-1.32(m, 1H), 0.80-0.95 (m, 6H); MS (ESI+) m/z 448 (M+H)⁺.

Example 398(2S)-N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)piperidine-2-carboxamide

The title compound was prepared by substitutingtert-butyl(2S)-2-{[((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylatefrom Example 268 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.35-8.36 (bs, 1H), 8.17 (d, J=7.9 Hz, 1H), 7.90-7.92 (m, 1H),7.78-7.80 (m, 1H), 7.72 (t, J=7.8 Hz, 1H), 4.16-4.23 (m, 1H), 3.83 (dd,J=9.9, 2.7 Hz, 1H), 3.30 (dd, J=10.3, 3.2 Hz, 1H), 3.16 (dd, J=9.6, 2.8Hz, 1H), 3.04 (dd, J=9.8, 7.8 Hz, 1H), 2.95-3.00 (m, 1H), 2.89 (dd,J=9.6, 7.4 Hz, 1H), 2.49-2.59 (m, 2H), 2.41-2.49 (m, 1H), 2.29-2.51 (m,1H), 1.96-2.04 (m, 1H), 1.86-1.92 (m, 1H), 1.77-1.83 (m, 1H), 1.64-1.70(m, 1H), 1.52-1.61 (m, 1H), 1.43-1.53 (m, 1H), 1.34-1.43 (m, 1H),1.20-1.34 (m, 3H); MS (ESI+) m/z 446 (M+H)⁺.

Example 399(2S)-N-{(3aS,4R,6aR)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}piperidine-2-carboxamide

Step A:tert-butyl(2S)-2-{[((3aS,4R,6aR)-2-{[4-fluorophenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylatewas prepared by substitutingtert-butyl(2S)-2-({[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylatefrom Example 231 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-fluorobenzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.98-7.91(m, 2H), 7.47-7.40 (m, 1H), 7.22 (dd, J=12.0, 5.3, 2H), 4.88-4.80 (m,1H), 4.13-4.05 (m, 2H), 3.61 (dd, J=10.1, 3.3, 1H), 3.30 (td, J=12.8,3.2, 1H), 3.23 (dd, J=10.0, 7.8, 1H), 3.07 (dd, J=8.6, 5.3, 2H),2.60-2.46 (m, 2H), 2.19 (dd, J=12.5, 1.1, 1H), 1.97-1.89 (m, 1H),1.85-1.77 (m, 1H), 1.66-1.49 (m, 5H), 1.47 (s, 9H), 1.31 (dtdd, J=13.3,6.8, 6.0, 3.1, 2H); MS (ESI+) m/z 513 (M+NH₄)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(2S)-2-{[((3aS,4R,6aR)-2-{[4-fluorophenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 7.96-7.99 (m, 2H), 7.78 (d, J=7.0 Hz, 1H), 7.30-7.34 (m, 2H), 4.20(p, J=7.0 Hz, 1H), 3.75 (dd, J=9.9, 2.9 Hz, 1H), 3.30 (dd, J=10.3, 3.2Hz, 1H), 3.11 (dd, J=9.6, 2.9 Hz, 1H), 2.96-3.03 (m, 2H), 2.87 (dd,J=9.6, 7.4 Hz, 1H), 2.48-2.60 (m, 2H), 2.42-2.49 (m, 1H), 2.28-2.46 (m,1H), 2.00-2.05 (m, 1H), 1.86-1.92 (m, 1H), 1.76-1.83 (m, 1H), 1.66-1.71(m, 1H), 1.44-1.62 (m, 2H), 1.24-1.41 (m, 4H); MS (ESI+) m/z 396 (M+H)⁺.

Example 400N¹-{(3aS,4R,6aR)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-valinamide

Step A: tert-Butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamatewas prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamatefrom Example 232 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-fluorobenzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.97-7.89(m, 2H), 7.74-7.63 (m, 1H), 7.25-7.18 (m, 2H), 4.34 (d, J=10.1, 1H),4.08 (dt, J=13.5, 6.7, 1H), 3.57 (dd, J=10.1, 3.3, 1H), 3.22-3.16 (m,1H), 3.07 (d, J=5.5, 2H), 3.01 (s, 3H), 2.57-2.50 (m, 1H), 2.50-2.43 (m,1H), 2.38 (qd, J=13.2, 6.6, 1H), 1.94 (td, J=12.2, 6.5, 1H), 1.86-1.77(m, 1H), 1.54 (ddd, J=16.4, 12.6, 7.7, 1H), 1.45 (s, 9H), 1.34-1.24 (m,1H), 0.98 (d, J=6.5, 3H), 0.86 (d, J=6.7, 3H); MS (ESI+) m/z 498 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.13-8.31 (m, 1H), 7.99-8.02 (m, 2H), 7.30-7.34 (m, 2H), 4.24-4.29(m, 1H), 3.78 (dd, J=9.9, 2.5 Hz, 1H), 3.11-3.14 (m, 2H), 2.94 (dd,J=9.6, 6.9 Hz, 1H), 2.87 (d, J=5.8 Hz, 1H), 2.47-2.58 (m, 2H), 2.37 (s,3H), 2.05-2.14 (m, 1H), 1.92-2.08 (m, 1H), 1.91-1.98 (m, 1H), 1.80-1.87(m, 1H), 1.51-1.59 (m, 1H), 1.25-1.35 (m, 1H), 0.98-1.08 (m, 6H); MS(ESI+) m/z 398 (M+H)⁺.

Example 401(2S)-N-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)piperidine-2-carboxamide

Step A:tert-butyl(2S)-2-{[((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylatewas prepared by substitutingtert-butyl(2S)-2-({[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylatefrom Example 231 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.08 (d,J=8.1, 2H), 7.82 (d, J=8.2, 2H), 7.46 (d, J=5.2, 1H), 4.84 (d, J=3.3,1H), 4.09 (dt, J=13.3, 6.6, 2H), 3.68 (dd, J=10.2, 3.3, 1H), 3.34-3.24(m, 2H), 3.12 (d, J=5.5, 2H), 2.61-2.48 (m, 2H), 2.22-2.15 (m, 1H), 1.93(dt, J=11.8, 6.6, 1H), 1.81 (dtd, J=12.7, 7.6, 4.8, 1H), 1.65-1.49 (m,5H), 1.47 (s, 9H), 1.40-1.24 (m, 2H); MS (ESI+) m/z 563 (M+NH₄)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(2S)-2-{[((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.10-8.13 (m, 2H), 7.89-7.92 (m, 2H), 7.79 (d, J=7.0 Hz, 1H),4.17-4.22 (m, 1H), 3.82 (dd, J=9.9, 2.8 Hz, 1H), 3.30 (dd, J=10.3, 3.2Hz, 1H), 3.16 (dd, J=9.6, 2.9 Hz, 1H), 3.03-3.07 (m, 1H), 2.96-2.99 (m,1H), 2.92 (dd, J=9.6, 7.4 Hz, 1H), 2.50-2.59 (m, 2H), 2.43-2.50 (m, 1H),2.27-2.53 (m, 1H), 2.00-2.04 (m, 1H), 1.86-1.92 (m, 1H), 1.76-1.83 (m,1H), 1.64-1.70 (m, 1H), 1.53-1.63 (m, 1H), 1.43-1.53 (m, 1H), 1.35-1.43(m, 1H), 1.20-1.35 (m, 3H); MS (ESI+) m/z 446 (M+H)⁺.

Example 402N²-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide

Step A: tert-Butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamatewas prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamatefrom Example 232 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.07 (d,J=8.2, 2H), 7.82 (d, J=8.2, 2H), 7.72 (s, 1H), 4.34 (d, J=10.4, 1H),4.09 (dd, J=13.6, 6.7, 1H), 3.64 (dd, J=10.2, 3.3, 1H), 3.26-3.19 (m,1H), 3.15-3.07 (m, 2H), 3.01 (s, 3H), 2.58-2.51 (m, 1H), 2.50-2.44 (m,1H), 2.38 (qd, J=13.2, 6.6, 1H), 1.93 (td, J=12.1, 6.5, 1H), 1.82 (td,J=12.7, 7.5, 1H), 1.53 (ddd, J=15.6, 12.6, 8.3, 1H), 1.45 (s, 9H), 1.29(ddd, J=15.9, 13.2, 6.7, 1H), 0.97 (d, J=6.5, 3H), 0.86 (d, J=6.7, 3H);MS (ESI+) m/z 548 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.22-8.25 (m, 1H), 8.13-8.15 (m, 2H), 7.89-7.92 (m, 2H), 4.23-4.29(m, 1H), 3.86 (dd, J=9.9, 2.6 Hz, 1H), 3.13-3.20 (m, 2H), 2.98 (dd,J=9.6, 7.0 Hz, 1H), 2.87 (d, J=5.8 Hz, 1H), 2.50-2.59 (m, 2H), 2.37 (s,3H), 2.05-2.13 (m, 1H), 1.93-2.11 (m, 1H), 1.90-1.98 (m, 1H), 1.80-1.87(m, 1H), 1.51-1.58 (m, 1H), 1.26-1.34 (m, 1H), 1.04 (d, J=6.9 Hz, 3H),1.02 (d, J=6.9 Hz, 3H); MS (ESI+) m/z 448 (M+H)⁺.

Example 403N¹-{(3aS,4R,6aR)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom Example 330 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.23 (d, J=7.2 Hz, 1H), 7.98-8.01 (m, 2H), 7.30-7.34 (m, 2H), 4.26(p, J=6.8 Hz, 1H), 3.77 (dd, J=9.9, 2.7 Hz, 1H), 3.09-3.15 (m, 3H), 2.93(dd, J=9.6, 7.1 Hz, 1H), 2.47-2.58 (m, 2H), 2.38 (s, 3H), 1.92-2.21 (m,1H), 1.91-1.99 (m, 1H), 1.75-1.87 (m, 2H), 1.64-1.71 (m, 1H), 1.51-1.60(m, 1H), 1.38-1.51 (m, 2H), 1.25-1.35 (m, 1H), 0.84 (t, J=7.3 Hz, 3H);MS (ESI+) m/z 398 (M+H)⁺.

Example 404N²-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 331 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.24-8.26 (m, 1H), 8.12-8.15 (m, 2H), 7.89-7.92 (m, 2H), 4.26 (p,J=6.9 Hz, 1H), 3.85 (dd, J=9.9, 2.7 Hz, 1H), 3.18 (dd, J=9.6, 2.7 Hz,1H), 3.15 (dd, J=7.7, 3.9 Hz, 1H), 3.13 (d, J=7.0 Hz, 1H), 2.97 (dd,J=9.6, 7.2 Hz, 1H), 2.51-2.61 (m, 2H), 2.38 (s, 3H), 1.95-2.31 (m, 1H),1.92-1.98 (m, 1H), 1.75-1.87 (m, 2H), 1.64-1.72 (m, 1H), 1.51-1.59 (m,1H), 1.39-1.52 (m, 2H), 1.30 (ddt, J=9.7, 13.0, 6.5 Hz, 1H), 0.84 (t,J=7.3 Hz, 3H); MS (ESI+) m/z 448 (M+H)⁺.

Example 405N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 259 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.20-8.23 (m, 1H), 8.13-8.15 (m, 2H), 7.89-7.92 (m, 2H), 4.22-4.29(m, 1H), 3.85 (dd, J=9.9, 2.7 Hz, 1H), 3.18 (dd, J=9.7, 2.7 Hz, 1H),3.11-3.16 (m, 2H), 2.96 (dd, J=9.6, 7.1 Hz, 1H), 2.50-2.61 (m, 2H), 2.38(s, 3H), 1.98-2.07 (m, 1H), 1.90-1.98 (m, 1H), 1.75-1.87 (m, 2H),1.63-1.70 (m, 1H), 1.41-1.58 (m, 3H), 1.26-1.33 (m, 1H), 0.84 (t, J=7.3Hz, 3H); MS (ESI+) m/z 448 (M+H)⁺.

Example 406N²-methyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide

The title compound was prepared by substituting tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamatefrom Example 340 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.39-8.40 (bs, 1H), 8.24 (d, J=7.2 Hz, 1H), 8.18-8.22 (m, 1H),7.90-7.92 (m, 1H), 7.72 (t, J=7.8 Hz, 1H), 4.24-4.30 (m, 1H), 3.86 (dd,J=9.9, 2.3 Hz, 1H), 3.14-3.20 (m, 2H), 2.96 (dd, J=9.7, 7.1 Hz, 1H),2.86 (d, J=5.8 Hz, 1H), 2.50-2.57 (m, 2H), 2.37 (s, 3H), 2.04-2.13 (m,1H), 1.88-2.08 (m, 1H), 1.89-1.98 (m, 1H), 1.80-1.89 (m, 1H), 1.50-1.59(m, 1H), 1.25-1.34 (m, 1H), 1.03 (d, J=6.9 Hz, 3H), 1.01 (d, J=7.0 Hz,3H); MS (ESI+) m/z 448 (M+H)⁺.

Example 407N¹-((3aS,4R,6aR)-2-{[4-fluoro-3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluoro-3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 327 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.35 (dd, J=6.5, 1.9 Hz, 1H), 8.31 (d, J=7.3 Hz, 1H), 8.26 (ddd,J=8.5, 4.7, 2.4 Hz, 1H), 7.53-7.58 (m, 1H), 4.24-4.30 (m, 1H), 3.88 (dd,J=9.9, 2.5 Hz, 1H), 3.16-3.20 (m, 3H), 3.00 (dd, J=9.6, 7.2 Hz, 1H),2.53-2.62 (m, 2H), 2.38 (s, 3H), 1.82-2.01 (m, 4H), 1.67 (ddd, J=13.5,7.8, 5.7 Hz, 1H), 1.53-1.59 (m, 2H), 1.32 (ddt, J=9.7, 12.9, 6.5 Hz,1H), 0.89 (d, J=6.6 Hz, 3H), 0.84 (d, J=6.5 Hz, 3H); MS (ESI+) m/z 480(M+H)⁺.

Example 4083-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide

The title compound was prepared by substitutingtert-butyl(S)-3,3-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-ylcarbamatefrom Example 341 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.25 (d, J=6.7 Hz, 1H), 8.12-8.16 (m, 2H), 7.90-7.92 (m, 2H),4.18-4.24 (m, 1H), 3.82 (dd, J=10.0, 2.3 Hz, 1H), 3.24 (s, 1H),3.13-3.18 (m, 2H), 2.98 (dd, J=9.5, 6.5 Hz, 1H), 2.49-2.60 (m, 2H),1.93-2.29 (m, 2H), 1.85-1.95 (m, 1H), 1.77-1.85 (m, 1H), 1.47-1.55 (m,1H), 1.22-1.31 (m, 1H), 1.12 (s, 9H); MS (ESI−) m/z 446 (M−H)⁻.

Example 4093-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide

The title compound was prepared by substitutingtert-butyl(S)-3,3-dimethyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-ylcarbamatefrom Example 342 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.23 (d, J=6.7 Hz, 1H), 8.12-8.14 (m, 2H), 7.89-7.91 (m, 2H),4.18-4.25 (m, 1H), 3.80 (dd, J=9.9, 2.7 Hz, 1H), 3.24 (s, 1H), 3.16 (dd,J=9.7, 2.8 Hz, 1H), 3.10 (dd, J=9.9, 7.5 Hz, 1H), 2.95 (dd, J=9.6, 7.2Hz, 1H), 2.45-2.55 (m, 2H), 1.96-2.22 (m, 2H), 1.88-1.96 (m, 1H),1.78-1.85 (m, 1H), 1.49-1.57 (m, 1H), 1.20-1.32 (m, 1H), 1.11 (s, 9H).

Example 410N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-isoleucinamide

The title compound was prepared by substituting tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 332 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.39-8.40 (bs, 1H), 8.24 (d, J=7.2 Hz, 1H), 8.19-8.22 (m, 1H),7.91-7.93 (m, 1H), 7.73 (d, J=7.9 Hz, 1H), 4.24-4.30 (m, 1H), 3.87 (dd,J=9.9, 2.3 Hz, 1H), 3.13-3.20 (m, 2H), 2.95 (d, J=6.3 Hz, 2H), 2.50-2.58(m, 2H), 2.38 (s, 3H), 1.89-2.02 (m, 1H), 1.90-1.98 (m, 1H), 1.79-1.89(m, 2H), 1.72-1.82 (m, 1H), 1.51-1.59 (m, 1H), 1.23-1.40 (m, 2H), 1.00(d, J=6.8 Hz, 3H), 0.86 (t, J=7.4 Hz, 3H); MS (ESI+) m/z 462 (M+H)⁺.

Example 411N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-isoleucinamide

The title compound was prepared by substituting tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 333 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.24-8.26 (m, 1H), 8.13-8.16 (m, 2H), 7.90-7.92 (m, 2H), 4.23-4.30(m, 1H), 3.86 (dd, J=9.9, 2.5 Hz, 1H), 3.19 (dd, J=9.6, 2.4 Hz, 1H),3.15 (dd, J=9.8, 7.6 Hz, 1H), 2.97 (dd, J=9.4, 6.9 Hz, 1H), 2.95 (d,J=6.0 Hz, 1H), 2.52-2.60 (m, 2H), 2.39 (s, 3H), 1.92-2.04 (m, 1H),1.91-1.97 (m, 1H), 1.80-1.88 (m, 2H), 1.72-1.80 (m, 1H), 1.51-1.60 (m,1H), 1.25-1.36 (m, 2H), 1.01 (d, J=6.9 Hz, 3H), 0.86 (t, J=7.4 Hz, 3H);MS (ESI+) m/z 462 (M+H)⁺.

Example 412N²-methyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-isoleucinamide

The title compound was prepared by substituting tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 334 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.23-8.26 (m, 1H), 8.12-8.16 (m, 2H), 7.89-7.91 (m, 2H), 4.24-4.29(m, 1H), 3.86 (dd, J=9.9, 2.5 Hz, 1H), 3.15-3.20 (m, 2H), 2.98 (dd,J=9.6, 6.9 Hz, 1H), 2.94 (d, J=6.1 Hz, 1H), 2.50-2.62 (m, 2H), 2.38 (s,3H), 1.91-2.04 (m, 1H), 1.91-1.98 (m, 1H), 1.80-1.88 (m, 2H), 1.72-1.80(m, 1H), 1.51-1.59 (m, 1H), 1.24-1.35 (m, 2H), 1.00 (d, J=6.8 Hz, 3H),0.85 (t, J=7.4 Hz, 3H); MS (ESI+) m/z 462 (M+H)⁺.

Example 413N²-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-isoleucinamide

The title compound was prepared by substituting tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 335 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.38-8.39 (bs, 1H), 8.24 (d, J=7.0 Hz, 1H), 8.19-8.22 (m, 1H),7.90-7.92 (m, 1H), 7.72 (t, J=7.8 Hz, 1H), 4.23-4.30 (m, 1H), 3.86 (dd,J=9.9, 2.2 Hz, 1H), 3.14-3.20 (m, 2H), 2.97 (dd, J=9.6, 6.6 Hz, 1H),2.93 (d, J=6.1 Hz, 1H), 2.55 (t, J=4.5 Hz, 2H), 2.37 (s, 3H), 1.92-2.10(m, 1H), 1.91-1.99 (m, 1H), 1.80-1.89 (m, 2H), 1.71-1.81 (m, 1H),1.51-1.59 (m, 1H), 1.24-1.40 (m, 2H), 0.99 (d, J=6.8 Hz, 3H), 0.84 (t,J=7.4 Hz, 3H); MS (ESI+) m/z 462 (M+H)⁺.

Example 414N²,4-dimethyl-N¹(3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamatefrom Example 336 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.38-8.40 (m, 1H), 8.34 (d, J=6.9 Hz, 1H), 8.20-8.22 (m, 1H),7.90-7.93 (m, 1H), 7.73 (d, J=7.9 Hz, 1H), 4.23-4.28 (m, 1H), 3.89 (dd,J=9.9, 2.1 Hz, 1H), 3.16-3.21 (m, 2H), 3.15 (dd, J=9.8, 7.4 Hz, 1H),2.93-2.97 (m, 1H), 2.50-2.58 (m, 2H), 2.38 (s, 3H), 2.00-2.06 (m, 1H),1.90-1.99 (m, 1H), 1.90 (dd, J=14.1, 5.1 Hz, 1H), 1.79-1.87 (m, 1H),1.51-1.60 (m, 1H), 1.48 (dd, J=14.0, 6.5 Hz, 1H), 1.25-1.32 (m, 1H),0.97 (s, 9H); MS (ESI+) m/z 476 (M+H)⁺.

Example 415N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamatefrom Example 337 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.37-8.40 (m, 1H), 8.14-8.16 (m, 2H), 7.90-7.92 (m, 2H), 4.23-4.27(m, 1H), 3.87 (dd, J=9.9, 2.2 Hz, 1H), 3.22 (t, J=5.9 Hz, 1H), 3.18 (dd,J=9.7, 2.1 Hz, 1H), 3.15 (dd, J=9.9, 7.5 Hz, 1H), 2.95-2.99 (m, 1H),2.55-2.58 (m, 2H), 2.40 (s, 3H), 1.91-1.98 (m, 1H), 1.92 (dd, J=14.0,5.1 Hz, 2H), 1.80-1.86 (m, 1H), 1.52-1.61 (m, 1H), 1.50 (dd, J=14.0, 6.4Hz, 1H), 1.25-1.34 (m, 1H), 0.97 (s, 9H); MS (ESI+) m/z 476 (M+H)⁺.

Example 416N²,4-dimethyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamatefrom Example 338 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.37-8.39 (bs, 1H), 8.33-8.36 (m, 1H), 8.18-8.21 (m, 1H), 7.91 (d,J=7.0 Hz, 1H), 7.72 (t, J=7.8 Hz, 1H), 4.23-4.29 (m, 1H), 3.88 (dd,J=9.9, 2.1 Hz, 1H), 3.12-3.20 (m, 3H), 2.94 (dd, J=9.6, 6.6 Hz, 1H),2.54 (t, J=4.6 Hz, 2H), 2.37 (s, 3H), 1.92-2.00 (m, 1H), 1.75-2.14 (m,1H), 1.90 (dd, J=14.0, 5.2 Hz, 1H), 1.80-1.87 (m, 1H), 1.51-1.59 (m,1H), 1.49 (dd, J=14.0, 6.6 Hz, 1H), 1.24-1.33 (m, 1H), 0.96 (s, 9H); MS(ESI+) m/z 476 (M+H)⁺.

Example 417N²,4-dimethyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamatefrom Example 339 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.36-8.38 (m, 1H), 8.13-8.15 (m, 2H), 7.89-7.91 (m, 2H), 4.22-4.29(m, 1H), 3.87 (d, J=10.4 Hz, 1H), 3.16-3.20 (m, 2H), 3.14 (dd, J=9.9,7.5 Hz, 1H), 2.96 (dd, J=9.6, 6.8 Hz, 1H), 2.54-2.59 (m, 2H), 2.38 (s,3H), 1.91-1.99 (m, 1H), 1.95 (m, 1H), 1.91 (dd, J=14.0, 5.2 Hz, 1H),1.79-1.87 (m, 1H), 1.52-1.60 (m, 1H), 1.50 (dd, J=14.0, 6.6 Hz, 1H),1.26-1.33 (m, 1H), 0.96 (s, 9H); MS (ESI+) m/z 476 (M+H)⁺.

Example 418N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norleucinamide

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)hexan-2-yl)carbamatefrom Example 343 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.21-8.24 (m, 1H), 8.13-8.15 (m, 2H), 7.90-7.92 (m, 2H), 4.23-4.30(m, 1H), 3.86 (dd, J=9.9, 2.5 Hz, 1H), 3.18 (dd, J=9.6, 2.6 Hz, 1H),3.12-3.16 (m, 2H), 2.96 (dd, J=9.6, 7.0 Hz, 1H), 2.54-2.61 (m, 2H), 2.40(s, 3H), 1.94-2.28 (m, 1H), 1.91-1.98 (m, 1H), 1.78-1.87 (m, 2H),1.65-1.73 (m, 1H), 1.51-1.59 (m, 1H), 1.36-1.50 (m, 2H), 1.27-1.34 (m,1H), 1.24 (h, J=7.4 Hz, 2H), 0.81 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 462(M+H)⁺.

Example 4194-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamatefrom Example 344 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.39-8.41 (m, 1H), 8.13-8.15 (m, 2H), 7.90-7.92 (m, 2H), 4.18-4.24(m, 1H), 3.85 (dd, J=9.9, 2.6 Hz, 1H), 3.59 (dd, J=7.4, 4.3 Hz, 1H),3.16 (dd, J=9.6, 2.8 Hz, 1H), 3.10 (dd, J=9.9, 7.4 Hz, 1H), 2.95 (dd,J=9.6, 7.1 Hz, 1H), 2.48-2.58 (m, 2H), 2.16 (dd, J=14.0, 4.3 Hz, 1H),2.06-2.22 (m, 1H), 1.88-1.95 (m, 1H), 1.78-1.83 (m, 1H), 1.47-1.55 (m,1H), 1.43 (dd, J=13.9, 7.4 Hz, 1H), 1.23-1.31 (m, 1H), 0.98 (s, 9H); MS(ESI+) m/z 462 (M+H)⁺.

Example 420N²-methyl-N¹-((3aR,4R,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4R,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 328 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.52 (d, J=7.9 Hz, 1H), 8.10-8.15 (m, 2H), 7.88-7.91 (m, 2H),4.44-4.50 (m, 1H), 3.63 (dd, J=9.5, 2.8 Hz, 1H), 3.23-3.26 (m, 1H),3.14-3.19 (m, 1H), 2.98 (dd, J=25.4, 9.3 Hz, 3H), 2.49-2.56 (m, 1H),2.48 (s, 3H), 1.86-1.92 (m, 1H), 1.90 (m, 1H), 1.75-1.83 (m, 1H),1.69-1.75 (m, 2H), 1.59-1.68 (m, 1H), 1.44-1.59 (m, 2H), 1.33-1.39 (m,1H), 0.88 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 448 (M+H)⁺.

Example 421N²-methyl-N¹-((3aR,4R,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4R,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 329 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.60-8.65 (m, 1H), 8.12-8.14 (m, 2H), 7.88-7.91 (m, 2H), 4.45-4.50(m, 1H), 3.63-3.66 (m, 1H), 3.33-3.37 (m, 1H), 3.15 (dd, J=9.6, 3.0 Hz,1H), 2.95-3.05 (m, 3H), 2.51 (s, 3H), 2.46-2.52 (m, 1H), 1.91-1.97 (m,2H), 1.78-1.83 (m, 1H), 1.72-1.75 (m, 3H), 1.63 (dq, J=13.0, 8.2 Hz,1H), 1.34-1.39 (m, 1H), 0.94 (d, J=6.5 Hz, 3H), 0.88 (d, J=6.5 Hz, 3H);MS (ESI+) m/z 462 (M+H)⁺.

Example 422N¹-((3aR,4S,6aS)-2-[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-1-norvalinamide

Step A:tert-Butyl-((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingtert-butyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 382 Step A for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.13 (d,J=8.1, 2H), 7.96 (d, J=8.0, 1H), 7.90 (d, J=8.3, 2H), 4.60 (dd, J=14.5,8.2, 1H), 4.27-4.18 (m, 1H), 3.81 (dd, J=9.8, 1.5, 1H), 3.21-3.10 (m,2H), 2.99-2.92 (m, 1H), 2.61-2.50 (m, 2H), 2.00 (dd, J=14.3, 5.4, 1H),1.84 (ddd, J=13.4, 11.2, 6.8, 3H), 1.55-1.44 (m, 13H), 1.25 (d, J=8.9,1H), 0.81 (t, J=7.3, 3H); MS (ESI+) m/z 551 (M+NH₄)⁺.

Step B: The title compound was prepared by substitutingtert-butyl-((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.28 (d, J=7.0 Hz, 1H), 8.11-8.15 (m, 2H), 7.89-7.92 (m, 2H),4.17-4.24 (m, 1H), 3.82 (dd, J=9.9, 2.8 Hz, 1H), 3.52 (dd, J=7.9, 4.9Hz, 1H), 3.16 (dd, J=9.6, 2.9 Hz, 1H), 3.09 (dd, J=9.9, 7.7 Hz, 1H),2.94 (dd, J=9.6, 7.3 Hz, 1H), 2.46-2.57 (m, 2H), 2.07-2.18 (m, 2H),1.88-1.96 (m, 2H), 1.77-1.84 (m, 1H), 1.63 (dddd, J=13.1, 8.0, 10.1, 5.1Hz, 1H), 1.40-1.53 (m, 3H), 1.23-1.32 (m, 1H), 0.85 (t, J=7.3 Hz, 3H);MS (ESI+) m/z 434 (M+H)⁺.

Example 423N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-1-norvalinamide

Step A:tert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-ylcarbamate was prepared by substitutingN-(tert-butoxycarbonyl)L-norvaline for N-(tert-butoxycarbonyl)-L-leucineand (3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine fromExample 16 Step E for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.58 (d, J=7.2, 1H), 7.91 (d, J=8.3, 1H), 7.42 (d, J=7.3, 2H), 7.36 (t,J=7.4, 2H), 7.27 (t, J=7.2, 1H), 4.64 (dd, J=14.4, 7.7, 1H), 4.45-4.35(m, 1H), 3.56 (d, J=13.1, 1H), 3.40 (d, J=13.2, 1H), 2.74 (d, J=8.9,1H), 2.52-2.43 (m, 2H), 2.39-2.27 (m, 2H), 2.26-2.19 (m, 1H), 2.14 (dq,J=12.0, 6.0, 1H), 2.02 (dt, J=13.9, 6.7, 1H), 1.85 (td, J=13.8, 8.2,2H), 1.65 (td, J=14.3, 7.3, 1H), 1.49 (d, J=8.5, 11H), 1.44-1.32 (m,1H), 0.86-0.76 (m, 3H); MS (ESI+) m/z 416 (M+H)⁺.

Step B:tert-Butyl-((S)-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-ylcarbamate from Step A for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.79 (d,J=6.8, 1H), 8.11 (d, J=8.1, 2H), 7.98 (d, J=8.1, 1H), 7.90 (d, J=8.3,2H), 4.59 (dd, J=14.4, 7.8, 1H), 4.28-4.20 (m, 1H), 3.78 (d, J=9.7, 1H),3.14 (d, J=9.6, 1H), 3.05-2.98 (m, 1H), 2.93-2.86 (m, 1H), 2.50 (d,J=2.3, 2H), 2.02-1.92 (m, 2H), 1.88-1.77 (m, 2H), 1.63-1.53 (m, 1H),1.53-1.38 (m, 11H), 1.33-1.22 (m, 1H), 0.79 (t, J=7.4, 3H); MS (ESI+)m/z 551 (M+NH₄)⁺.

Step C: The title compound was prepared by substitutingtert-butyl-((S)-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step B fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.27 (d, J=7.2 Hz, 1H), 8.10-8.14 (m, 2H), 7.89-7.91 (m, 2H),4.18-4.24 (m, 1H), 3.83 (dd, J=9.9, 2.9 Hz, 1H), 3.51 (dd, J=7.9, 4.9Hz, 1H), 3.16 (dd, J=9.6, 2.9 Hz, 1H), 3.08 (dd, J=9.9, 7.7 Hz, 1H),2.93 (dd, J=9.6, 7.4 Hz, 1H), 2.45-2.56 (m, 2H), 2.03-2.23 (m, 2H),1.88-1.95 (m, 2H), 1.77-1.84 (m, 1H), 1.64 (dddd, J=13.1, 8.1, 10.1, 5.1Hz, 1H), 1.38-1.54 (m, 3H), 1.24-1.32 (m, 1H), 0.84 (t, J=7.3 Hz, 3H);MS (ESI-) m/z 432 (M−H)⁻.

Example 424N¹-((3aR,4S,6aS)-2-[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

Step A:tert-Butyl-((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingtert-butyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 382 Step A for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedure described in Example 319: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.70 (d, J=6.9, 1H), 8.37 (s, 1H), 8.18 (d, J=7.8, 1H), 7.95 (d,J=8.0, 1H), 7.91 (d, J=7.8, 1H), 7.72 (t, J=7.9, 1H), 4.59 (dd, J=14.1,7.8, 1H), 4.23 (dt, J=13.0, 6.5, 1H), 3.82 (dd, J=9.7, 1.4, 1H),3.18-3.07 (m, 2H), 2.98-2.90 (m, 1H), 2.62-2.48 (m, 2H), 2.00 (ddd,J=15.3, 11.0, 6.5, 1H), 1.91-1.74 (m, 3H), 1.57-1.39 (m, 12H), 1.23(ddd, J=16.9, 12.6, 6.1, 1H), 0.81 (t, J=7.3, 3H); MS (ESI+) m/z 551(M+NH₄)⁺.

Step B: The title compound was prepared by substitutingtert-butyl-((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.36-8.37 (bs, 1H), 8.26 (d, J=6.9 Hz, 1H), 8.17-8.20 (m, 1H),7.90-7.92 (m, 1H), 7.70-7.74 (m, 1H), 4.18-4.24 (m, 1H), 3.83 (dd,J=9.8, 2.7 Hz, 1H), 3.52 (dd, J=7.9, 4.9 Hz, 1H), 3.16 (dd, J=9.6, 2.8Hz, 1H), 3.07 (dd, J=9.9, 7.5 Hz, 1H), 2.91 (dd, J=9.6, 7.3 Hz, 1H),2.44-2.54 (m, 2H), 1.95-2.28 (m, 2H), 1.86-1.99 (m, 2H), 1.77-1.84 (m,1H), 1.59-1.66 (m, 1H), 1.39-1.54 (m, 3H), 1.22-1.32 (m, 1H), 0.84 (t,J=7.3 Hz, 3H); MS (ESI+) m/z 434 (M+H)⁺.

Example 425N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

Step A:tert-Butyl-((S)-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-ylcarbamate from Example 423 Step A for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedure described in Example 319: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.77 (d, J=6.9, 1H), 8.35 (s, 1H), 8.16 (d, J=7.7, 1H), 7.96 (d,J=8.2, 1H), 7.90 (d, J=8.0, 1H), 7.72 (t, J=7.9, 1H), 4.58 (dd, J=14.4,8.0, 1H), 4.30-4.20 (m, 1H), 3.84-3.75 (m, 1H), 3.15 (d, J=9.4, 1H),3.04-2.95 (m, 1H), 2.91-2.79 (m, 1H), 2.47 (dd, J=2.3, 1.2, 2H),2.03-1.91 (m, 2H), 1.88-1.76 (m, 2H), 1.64-1.53 (m, 1H), 1.53-1.40 (m,11H), 1.33-1.19 (m, 1H), 0.79 (t, J=7.3, 3H); MS (ESI+) m/z 551(m+NH₄)⁺.

Step B: The title compound was prepared by substitutingtert-butyl-((S)-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingtert-butyl-((S)-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.35-8.37 (m, 1H), 8.27 (d, J=7.0 Hz, 1H), 8.17-8.19 (m, 1H),7.90-7.92 (m, 1H), 7.72 (t, J=7.8 Hz, 1H), 4.18-4.25 (m, 1H), 3.84 (dd,J=9.9, 2.7 Hz, 1H), 3.51 (dd, J=7.9, 4.9 Hz, 1H), 3.17 (dd, J=9.6, 2.8Hz, 1H), 3.07 (dd, J=9.9, 7.6 Hz, 1H), 2.91 (dd, J=9.6, 7.3 Hz, 1H),2.43-2.54 (m, 2H), 1.96-2.32 (m, 2H), 1.87-1.95 (m, 2H), 1.78-1.84 (m,1H), 1.59-1.67 (m, 1H), 1.37-1.53 (m, 3H), 1.23-1.32 (m, 1H), 0.83 (t,J=7.3 Hz, 3H); MS (ESI−) m/z 432 (M−H)⁻.

Example 4263-cyclohexyl-N¹-(3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-alaninamide

Step A:tert-butyl(S)-3-cyclohexyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)propan-2-ylcarbamatewas prepared by substituting(S)-2-(tert-butoxycarbonylamino)-3-cyclohexylpropanoic acid for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 256 Step A for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.76 (s, 1H), 8.13 (d, J=8.1, 2H), 8.01 (d, J=8.3, 1H), 7.90 (d,J=8.3, 2H), 4.74-4.65 (m, 1H), 4.31-4.19 (m, 1H), 3.85-3.78 (m, 1H),3.21-3.10 (m, 2H), 3.01-2.93 (m, 1H), 2.64-2.51 (m, 2H), 1.96-1.74 (m,6H), 1.69-1.60 (m, 1H), 1.60-1.45 (m, 13H), 1.32-1.18 (m, 1H), 1.16-0.96(m, 3H), 0.94-0.81 (m, 1H), 0.79-0.67 (m, 1H); MS (ESI+) m/z 605(M+NH₄)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(S)-3-cyclohexyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)propan-2-ylcarbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.35 (d, J=7.0 Hz, 1H), 8.12-8.15 (m, 2H), 7.90-7.92 (m, 2H),4.20-4.26 (m, 1H), 3.83 (dd, J=9.9, 2.7 Hz, 1H), 3.63 (dd, J=9.2, 4.7Hz, 1H), 3.17 (dd, J=9.7, 2.8 Hz, 1H), 3.10 (dd, J=9.8, 7.6 Hz, 1H),2.96 (dd, J=9.6, 7.2 Hz, 1H), 2.46-2.61 (m, 2H), 1.97-2.47 (m, 2H),1.86-1.96 (m, 2H), 1.78-1.86 (m, 1H), 1.72-1.78 (m, 1H), 1.65-1.71 (m,1H), 1.47-1.62 (m, 6H), 1.22-1.33 (m, 1H), 0.99-1.23 (m, 3H), 0.91 (qd,J=12.5, 3.4 Hz, 1H), 0.79 (qd, J=12.0, 3.4 Hz, 1H); MS (ESI+) m/z 488(M+H)⁺.

Example 4273-cyclohexyl-N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-alaninamide

Step A:tert-butyl(S)-3-cyclohexyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)propan-2-yl(methyl)carbamatewas prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)-3-cyclohexylpropanoic acid for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 256 Step A for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.51 (d, J=6.9, 1H), 8.13 (d, J=8.2, 2H), 7.90 (d, J=8.3, 2H),5.23-5.14 (m, 0.4H), 4.89-4.79 (m, 0.6H), 4.28-4.15 (m, 1H), 3.83 (d,J=10.6, 1H), 3.17-3.01 (m, 5H), 2.94 (dd, J=9.4, 7.2, 1H), 2.57-2.48 (m,2H), 1.99-1.74 (m, 5H), 1.67 (d, J=13.1, 1H), 1.62-1.48 (m, 4H), 1.45(s, 9H), 1.34-1.20 (m, 2H), 1.18-1.00 (m, 3H), 0.98-0.85 (m, 1H),0.81-0.66 (m, 1H); MS (ESI+) m/z 602 (M+H)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(S)-3-cyclohexyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)propan-2-yl(methyl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.30 (d, J=7.2 Hz, 1H), 8.13-8.16 (m, 2H), 7.89-7.93 (m, 2H),4.24-4.32 (m, 1H), 3.86 (dd, J=9.9, 2.3 Hz, 1H), 3.25 (dd, J=7.8, 5.6Hz, 1H), 3.13-3.21 (m, 2H), 2.98 (dd, J=9.5, 6.8 Hz, 1H), 2.47-2.63 (m,2H), 2.41 (s, 3H), 1.95-2.23 (m, 1H), 1.91-1.99 (m, 1H), 1.79-1.90 (m,1H), 1.66-1.78 (m, 3H), 1.51-1.62 (m, 6H), 1.26-1.35 (m, 1H), 1.00-1.23(m, 3H), 0.76-0.93 (m, 2H); MS (ESI+) m/z 502 (M+H)⁺.

Example 428N¹-((3aR,4S,6aS)-2-[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-L-leucinamide

Step A:tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(2-chloror-5-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamatewas prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamatefrom Example 226 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 2-chlroro-5-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.56 (d,J=1.9, 1H), 8.14 (d, J=8.7, 1H), 7.80 (dd, J=8.3, 1.9, 1H), 7.73 (d,J=8.3, 1H), 4.92 (s, 1H), 4.70 (td, J=8.3, 5.1, 1H), 4.34-4.25 (m, 1H),3.91 (dd, J=10.1, 2.9, 1H), 3.54 (dd, J=10.2, 7.7, 1H), 3.36 (dd, J=9.9,7.5, 1H), 3.27 (dd, J=10.0, 3.3, 1H), 2.72-2.57 (m, 2H), 2.13 (dd,J=14.1, 4.8, 1H), 1.94 (qd, J=6.4, 1.2, 1H), 1.86-1.77 (m, 2H),1.60-1.52 (m, 1H), 1.49 (s, 9H), 1.35-1.25 (m, 1H), 0.96 (s, 9H); MS(ESI+) m/z 596 (M+H)⁻.

Step B: The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(2-chloror-5-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.56 (d, J=2.2 Hz, 1H), 8.41 (d, J=7.0 Hz, 1H), 7.80 (dd, J=8.3,2.2 Hz, 1H), 7.74 (d, J=8.3 Hz, 1H), 4.25-4.32 (m, 1H), 3.94 (dd,J=10.2, 2.6 Hz, 1H), 3.58 (dd, J=7.4, 4.3 Hz, 1H), 3.49 (dd, J=10.1, 7.2Hz, 1H), 3.34 (dd, J=9.9, 7.0 Hz, 1H), 3.30 (dd, J=9.9, 3.1 Hz, 1H),2.58-2.66 (m, 2H), 1.87-2.45 (m, 2H), 2.14 (dd, J=14.0, 4.4 Hz, 1H),1.96-2.04 (m, 1H), 1.82-1.88 (m, 1H), 1.52-1.60 (m, 1H), 1.41 (dd,J=13.9, 7.5 Hz, 1H), 1.30-1.38 (m, 1H), 0.97 (s, 9H); MS (ESI−) m/z 494(M−H)⁻.

Example 429N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-L-leucinamide

Step A:tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(2-chloror-4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamatewas prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamatefrom Example 226 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 2-chloro-4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.33 (d,J=8.2, 1H), 8.14 (d, J=8.7, 1H), 7.99 (s, 1H), 7.75-7.71 (m, 1H), 4.95(s, 1H), 4.71 (td, J=8.3, 4.9, 1H), 4.33-4.25 (m, 1H), 3.92 (dd, J=10.2,2.9, 1H), 3.53 (dd, J=10.2, 7.7, 1H), 3.38 (dd, J=9.9, 7.4, 1H), 3.30(dd, J=10.0, 3.3, 1H), 2.72-2.58 (m, 2H), 2.14 (dd, J=14.1, 4.7, 1H),1.93 (dt, J=18.2, 6.2, 1H), 1.86-1.77 (m, 2H), 1.57 (ddd, J=16.4, 12.5,8.6, 1H), 1.50 (s, 9H), 1.31 (ddd, J=16.0, 13.2, 6.7, 1H), 0.97 (s, 9H);MS (ESI+) m/z 596 (M+H)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.44 (d, J=7.0 Hz, 1H), 8.35 (d, J=8.2 Hz, 1H), 7.99 (d, J=1.7 Hz,1H), 7.74 (dd, J=8.2, 1.7 Hz, 1H), 4.25-4.32 (m, 1H), 3.94 (dd, J=10.1,2.8 Hz, 1H), 3.59 (dd, J=7.4, 4.4 Hz, 1H), 3.49 (dd, J=10.2, 7.3 Hz,1H), 3.31-3.39 (m, 2H), 2.58-2.67 (m, 2H), 1.86-2.48 (m, 2H), 2.15 (dd,J=14.0, 4.4 Hz, 1H), 1.97-2.05 (m, 1H), 1.82-1.88 (m, 1H), 1.53-1.61 (m,1H), 1.42 (dd, J=14.0, 7.4 Hz, 1H), 1.31-1.39 (m, 1H), 0.98 (s, 9H); MS(ESI−) m/z 494 (M−H)⁻.

Example 430N-methyl-N-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide

The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-N-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamidefrom Example 258 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.15-8.20 (m, 3H), 7.92-7.96 (m, 2H), 7.29-7.34 (m, 4H), 7.24-7.28(m, 1H), 3.75 (dd, J=9.9, 2.9 Hz, 1H), 3.43 (t, J=6.8 Hz, 1H), 3.13-3.20(m, 3H), 3.04-3.10 (m, 3H), 2.95 (dd, J=9.6, 7.6 Hz, 1H), 2.43-2.52 (m,1H), 2.34 (s, 3H), 1.75-2.16 (m, 1H), 1.84-1.91 (m, 1H), 1.70-1.79 (m,1H), 1.37-1.47 (m, 1H), 1.19-1.28 (m, 1H); MS (ESI+) m/z 496 (M+H)⁺,554(M+CH₃CN+NH₄)⁺.

Example 431N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²,4-dimethyl-L-leucinamide

Step A:tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamatewas prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 247 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 2-chloro-4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.40 (d,J=6.9, 1H), 8.34 (d, J=8.1, 1H), 7.99 (d, J=1.1, 1H), 7.76-7.67 (m, 1H),5.19-5.10 (m, 1H), 4.31-4.20 (m, 1H), 3.93 (dd, J=10.2, 2.0, 1H),3.53-3.44 (m, 1H), 3.39-3.28 (m, 2H), 3.01 (s, 3H), 2.67-2.53 (m, 2H),2.22-2.11 (m, 1H), 2.00-1.88 (m, 1H), 1.85-1.74 (m, 1H), 1.70-1.60 (m,1H), 1.60-1.49 (m, 1H), 1.44 (d, J=11.0, 9H), 1.37-1.25 (m, 1H), 0.91(d, J=8.9, 9H); MS (ESI+) m/z 610 (M+H)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.34-8.37 (m, 2H), 7.99 (d, J=1.7 Hz, 1H), 7.72-7.75 (m, 1H),4.30-4.35 (m, 1H), 3.96 (dd, J=10.2, 2.3 Hz, 1H), 3.53 (dd, J=10.1, 7.2Hz, 1H), 3.39 (dd, J=10.0, 7.1 Hz, 1H), 3.35 (dd, J=9.9, 2.9 Hz, 1H),3.17 (dd, J=6.5, 5.1 Hz, 1H), 2.64-2.70 (m, 2H), 2.38 (s, 3H), 2.03(dtd, J=12.5, 6.3, 4.2 Hz, 1H), 1.89 (dd, J=14.0, 5.2 Hz, 1H), 1.83-1.92(m, 1H), 1.67-2.06 (m, 1H), 1.56-1.66 (m, 1H), 1.47 (dd, J=14.0, 6.6 Hz,1H), 1.32-1.43 (m, 1H), 0.96 (s, 9H); MS (ESI+) m/z 510 (M+H)⁺.

Example 432N-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N-methyl-L-phenylalaninamide

Step A:N-(tert-Butoxycarbonyl)-N-methyl-N-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamidewas prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-L-phenylalanine forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-aminefrom Example 284 Step B for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.69-8.55 (m, 1H), 8.37 (d, J=8.2, 1H), 8.01 (d, J=1.1, 1H), 7.76 (dd,J=8.3, 1.0, 1H), 7.28 (d, J=15.4, 4H), 7.23 (d, J=1.3, 1H), 5.38-5.26(m, 1H), 4.38-4.20 (m, 1H), 3.95-3.80 (m, 1H), 3.65-3.48 (m, 1H),3.48-3.40 (m, 1H), 3.37-3.25 (m, 2H), 3.15-3.07 (m, 1H), 3.05 (s, 3H),2.59-2.48 (m, 1H), 2.48-2.39 (m, 1H), 2.06-1.86 (m, 1H), 1.83-1.70 (m,1H), 1.61-1.43 (m, 1H), 1.39-1.20 (m, 10H); MS (ESI+) m/z 630 (M+H)⁺.

Step B: The title compound was prepared by substitutingN-(tert-butoxycarbonyl)-N-methyl-N-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamidefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.37 (d, J=8.2, 1H), 8.20 (d, J=7.3, 1H), 8.01 (d, J=1.2, 1H),7.76 (dd, J=8.3, 1.1, 1H), 7.35-7.23 (m, 5H), 4.34-4.24 (m, 1H), 3.85(dd, J=10.2, 3.0, 1H), 3.49-3.27 (m, 4H), 3.17 (dd, J=13.3, 6.8, 1H),3.05 (dd, J=13.3, 6.8, 1H), 2.61-2.50 (m, 1H), 2.49-2.39 (m, 1H), 2.34(s, 3H), 2.10-2.01 (m, 1H), 1.96 (dtd, J=10.8, 6.5, 4.4, 1H), 1.83-1.72(m, 1H), 1.53-1.41 (m, 1H), 1.31 (ddt, J=13.2, 9.6, 6.7, 1H); MS (ESI+)m/z 530 (M+H)⁺.

Example 433N¹-cyclopropyl-N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

Step A:(3aR,4S,6aS)-N-Cylopropyl-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminewas prepared by substituting(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 256 Step A for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand (1-ethoxycyclopropoxy)trimethylsilane for pivalaldehyde in theprocedure described in Example 281: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.19 (d, J=8.1, 2H), 7.94 (d, J=8.3, 2H), 3.44 (dd, J=9.8, 2.9, 1H),3.17 (dd, J=9.6, 3.2, 1H), 3.06 (dd, J=9.8, 7.9, 1H), 2.96 (dd, J=9.6,7.7, 1H), 2.88 (dd, J=13.2, 5.8, 1H), 2.56-2.46 (m, 1H), 2.28 (ddd,J=12.1, 9.0, 2.9, 1H), 2.20-2.07 (m, 1H), 1.99 (dq, J=6.3, 4.0, 1H),1.89-1.79 (m, 2H), 1.37-1.18 (m, 2H), 0.42-0.25 (m, 4H); MS (ESI+) m/z375 (M+H)⁺.

Step B:tert-butyl(S)-1-(cyclopropyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamatewas prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-N-cylopropyl-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Step A for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.12-8.07 (m, 2H), 7.86-7.80 (m, 2H), 5.85-5.57 (m, 1H), 3.93 (s,1H), 3.56 (dd, J=10.0, 3.2, 1H), 3.19 (dd, J=10.0, 3.4, 2H), 3.13 (dd,J=16.7, 9.1, 1H), 2.98-2.88 (m, 4H), 2.76 (ddd, J=11.0, 7.1, 4.2, 1H),2.72-2.64 (m, 1H), 2.15 (ddd, J=18.3, 11.1, 7.7, 1H), 2.05-1.97 (m, 1H),1.97-1.88 (m, 1H), 1.80-1.71 (m, 1H), 1.68-1.56 (m, 1H), 1.49 (s, 9H),1.35-1.20 (m, 1H), 1.05 (dtd, J=10.0, 6.8, 5.0, 1H), 0.99 (s, 9H), 0.88(dddd, J=9.6, 8.1, 6.7, 3.3, 2H), 0.79-0.70 (m, 1H); MS (ESI+) m/z 616(M+H)⁺.

Step C: The title compound was prepared by substitutingtert-butyl(S)-1-(cyclopropyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamatefrom Step B fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.08-8.11 (m, 2H), 7.81-7.85 (m, 2H), 4.00(dd, J=8.3, 4.1 Hz, 1H), 3.91-3.97 (m, 2H), 3.51 (dd, J=9.6, 2.8 Hz,1H), 3.08-3.24 (m, 4H), 2.66-2.77 (m, 1H), 2.60-2.66 (m, 1H), 2.30 (s,3H), 2.11 (qd, J=11.1, 7.6 Hz, 1H), 1.89-2.02 (m, 1H), 1.79-1.86 (m,1H), 1.59 (dd, J=14.1, 4.0 Hz, 1H), 1.45 (dd, J=14.2, 8.1 Hz, 1H), 1.27(tt, J=11.9, 7.5 Hz, 1H), 1.02 (s, 9H), 0.73-0.97 (m, 4H); MS (ESI+) m/z516 (M+H)⁺.

Example 434N¹-ethyl-N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-(ethyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 296 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.08-8.11 (m, 2H), 7.82-7.85 (m, 2H),4.18-4.25 (m, 1H), 3.66 (d, J=9.9 Hz, 1H), 3.17-3.54 (m, 4H), 2.84-3.15(m, 2H), 2.52-2.82 (m, 2H), 2.22-2.50 (m, 3H), 1.87-2.19 (m, 2H),1.67-1.85 (m, 2H), 1.61 (dd, J=14.2, 3.8 Hz, 1H), 1.48 (dd, J=14.2, 8.2Hz, 1H), 1.27-1.40 (m, 1H), 1.17 (t, J=7.0 Hz, 3H), 1.04 (s, 9H); MS(ESI+) m/z 505 (M+H)⁺.

Example 435N²,4-dimethyl-N¹-propyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-oxo-1-(propyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)pentan-2-yl(methyl)carbamatefrom Example 297 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.08-8.11 (m, 2H), 7.82-7.85 (m, 2H),4.18-4.30 (m, 1H), 3.64-3.75 (m, 2H), 2.97-3.36 (m, 5H), 2.18-2.88 (m,5H), 1.72-2.14 (m, 4H), 1.55-1.71 (m, 3H), 1.48 (dd, J=14.3, 8.3 Hz,1H), 1.28-1.34 (m, 1H), 1.04-1.06 (m, 9H), 0.87 (t, J=7.4 Hz, 3H); MS(ESI+) m/z 518 (M+H)⁺.

Example 436N¹-(cyclopropylmethyl)-N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((cyclopropylmethyl)((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 298 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.08-8.11 (m, 2H), 7.82-7.85 (m, 2H),4.13-4.26 (m, 1H), 3.51-3.78 (m, 2H), 3.20-3.35 (m, 3H), 2.82-3.18 (m,2H), 2.52-2.81 (m, 2H), 2.29-2.50 (m, 3H), 1.77-2.10 (m, 3H), 1.70-2.15(m, 1H), 1.65 (dd, J=14.2, 3.8 Hz, 1H), 1.48 (dd, J=14.3, 8.2 Hz, 1H),1.27-1.40 (m, 1H), 1.05 (s, 10H), 0.43-0.72 (m, 2H), 0.31-0.35 (m, 2H);MS (ESI+) m/z 530 (M+H)⁺.

Example 437N¹,N²,4-trimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-(methyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-1-oxopentan-2-yl(methyl)carbamatefrom Example 302 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.08-8.11 (m, 2H), 7.82-7.85 (m, 2H),4.14-4.96 (m, 1H), 3.62 (dd, J=9.9, 1.8 Hz, 2H), 3.00-3.30 (m, 3H), 2.89(s, 3H), 2.49-2.65 (m, 2H), 2.25-2.47 (m, 3H), 1.59-2.10 (m, 5H), 1.46(dd, J=14.2, 7.6 Hz, 1H), 1.22-1.41 (m, 1H), 1.01-1.03 (m, 9H); MS(ESI+) m/z 5490 (M+H)⁺.

Example 438N¹,N²-dimethyl-N¹-(3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

Step A: tert-Butylmethyl((S)-1-(methyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-1-oxopentan-2-yl)carbamatewas prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)pentanoic acid for(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid and(3aR,4S,6aS)-N-methyl-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 301 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 266: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.11 (d, J=8.3, 2H), 7.83 (d, J=8.3, 2H), 4.69-4.57 (m, 1H), 3.59(dd, J=9.9, 1.2, 1H), 3.29-3.18 (m, 2H), 3.16 (dd, J=9.8, 3.3, 1H), 2.88(s, 3H), 2.86 (s, 3H), 2.61-2.50 (m, 2H), 1.91-1.56 (m, 6H), 1.51 (s,10H), 1.40-1.21 (m, 3H), 0.91 (t, J=7.4, 3H); MS (ESI+) m/z 562 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-1-(methyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-1-oxopentan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅,temperature 90° C.) δ ppm 8.08-8.11 (m, 2H), 7.82-7.85 (m, 2H),4.48-4.67 (bs, 1H), 3.61 (dd, J=10.0, 2.0 Hz, 1H), 3.41-3.56 (m, 1H),2.93-3.34 (m, 4H), 2.86 (s, 3H), 2.50-2.62 (m, 2H), 2.22-2.49 (m, 3H),1.80-1.95 (m, 1H), 1.39-1.79 (m, 6H), 1.23-1.38 (m, 1H), 0.89 (t, J=7.2Hz, 3H); MS (ESI+) m/z 462 (M+H)⁺.

Example 439N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N¹,N²,4-trimethyl-L-leucinamide

Step A:tert-butyl(3aR,4S,6aS)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate(62 mg, 0.132 mmol) from Example 284 Step A was dissolved in1,2-dimethoxyethane (1.0 mL) and lithium aluminum hydride (10.04 mg,0.264 mmol) was added portionwise. The reaction was stirred at 70° C.overnight, then it was quenched with wet sodium sulfate. The crudematerial was applied to a 4 g silica gel cartridge and purified with agradient of 1-10% methanol (2 N ammonia)/dichloromethane over 20 minutesto give(3aR,4S,6aS)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)-N-methyloctahydrocyclopenta[c]pyrrol-4-amine:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.46 (s, 1H), 8.34 (d, J=8.2, 1H),7.99 (s, 1H), 4.92 (s, 3H), 4.32 (dt, J=13.7, 7.0, 1H), 3.89 (dd,J=10.2, 3.0, 1H), 3.49 (dd, J=10.2, 7.5, 1H), 3.41-3.30 (m, 2H),2.70-2.59 (m, 2H), 2.48 (dt, J=4.4, 2.2, 1H), 2.01 (td, J=11.8, 6.6,1H), 1.95-1.83 (m, 1H), 1.59 (ddd, J=16.1, 10.8, 7.7, 1H), 1.37 (dt,J=22.2, 6.5, 1H); MS (APCI+) m/z 383 (M+H)⁺.

Step B:tert-butyl(S)-1-(((3aR,4S,6aS)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)(methyl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamatewas prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)-N-methyloctahydrocyclopenta[c]pyrrol-4-aminefrom Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: MS (ESI+) m/z 625 (M+H)⁺.

Step C: The title compound was prepared by substitutingtert-butyl(S)-1-(((3aR,4S,6aS)-2-(2-chloro-4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)(methyl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamatefrom Step B fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.30 (d, J=8.2, 1H), 7.90 (s, 1H), 7.69 (d, J=8.1, 1H), 3.80-3.72(m, J=7.3, 1H), 3.68 (d, J=9.8, 1H), 3.50-3.27 (m, 3H), 2.94 (s, 3H),2.74-2.58 (m, J=5.3, 11.8, 2H), 2.38 (s, 3H), 1.99-1.87 (m, J=8.2, 18.8,1H), 1.85-1.64 (m, 4H), 1.53 (dd, J=7.0, 14.1, 1H), 1.47-1.33 (m, 1H),0.99 (s, 9H); MS (ESI+) m/z 525 (M+H)⁺.

Example 4404-methyl-N¹-{(3aR,4S,6aS)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamatefrom Example 262 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.62 (d, J=2.4 Hz, 1H), 8.48-8.50 (m, 1H), 7.67 (dd, J=8.9, 2.5Hz, 1H), 6.38 (d, J=8.9 Hz, 1H), 4.35-4.41 (m, 1H), 3.80-3.83 (m, 1H),3.65 (dd, J=7.5, 4.4 Hz, 1H), 3.60-3.66 (m, 1H), 3.54-3.60 (m, 1H),3.30-3.34 (m, 1H), 2.68-2.79 (m, 2H), 2.20 (dd, J=14.0, 4.4 Hz, 1H),1.73-2.56 (m, 2H), 2.10-2.17 (m, 1H), 1.89-1.97 (m, 1H), 1.68 (dq,J=12.7, 8.1 Hz, 1H), 1.47 (dd, J=14.0, 7.5 Hz, 1H), 1.35-1.42 (m, 1H),1.01 (s, 9H); MS (ESI+) m/z 399 (M+H)⁺.

Example 4414-methyl-N¹-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(6-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamatefrom Example 264 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.43-8.46 (m, 1H), 7.51 (t, J=7.9 Hz, 1H), 6.98 (d, J=7.2 Hz, 1H),6.50 (d, J=8.5 Hz, 1H), 4.32-4.38 (m, 1H), 3.71 (dd, J=10.9, 2.9 Hz,1H), 3.64 (dd, J=7.5, 4.3 Hz, 1H), 3.46-3.60 (m, 2H), 3.27 (dd, J=10.9,3.5 Hz, 1H), 2.65-2.74 (m, 2H), 2.19 (dd, J=13.9, 4.3 Hz, 1H), 1.71-2.58(m, 2H), 2.06-2.15 (m, 1H), 1.87-1.97 (m, 1H), 1.65 (dq, J=12.7, 8.0 Hz,1H), 1.46 (dd, J=14.0, 7.5 Hz, 1H), 1.32-1.39 (m, 1H), 1.01 (s, 9H); MS(ESI+) m/z 399 (M+H)⁺.

Example 4424-methyl-N¹-{(3aR,4S,6aS)-2-[2-(methylsulfonyl)pyrimidin-5-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-4,4-dimethyl-1-((3aR,4S,6aS)-2-(2-(methylsulfonyl)pyrimidin-5-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-ylcarbamatefrom Example 265 fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.45 (s, 2H), 8.43 (d, J=7.3 Hz, 1H), 4.95 (s, 3H), 4.39 (p, J=7.0Hz, 1H), 3.97 (dd, J=11.9, 3.3 Hz, 1H), 3.76 (dd, J=12.0, 7.7 Hz, 1H),3.70 (dd, J=11.6, 8.1 Hz, 1H), 3.62 (dd, J=7.5, 4.2 Hz, 1H), 3.44 (dd,J=11.7, 4.5 Hz, 1H), 2.65-2.75 (m, 2H), 2.18 (dd, J=14.0, 4.3 Hz, 1H),2.09-2.16 (m, 1H), 2.02-2.19 (m, 2H), 1.86-1.94 (m, 1H), 1.65 (dq,J=12.7, 8.2 Hz, 1H), 1.45 (dd, J=14.0, 7.5 Hz, 1H), 1.33-1.42 (m, 1H),1.00 (s, 9H); MS (ESI+) m/z 411 (M+H)⁺.

Example 443N¹-{(3aS,4R,6aR)-2-[(3-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide

Step A: tert-Butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-1-leucinamidefrom Example 151 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 3-fluorobenzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: MS (APCI+) m/z 512 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.38 (d, J=6.6 Hz, 1H), 7.84 (dt, J=8.2, 2.0 Hz, 1H), 7.77 (d,J=7.8 Hz, 1H), 7.53 (td, J=8.0, 5.5 Hz, 1H), 7.38 (td, J=8.4, 2.4 Hz,1H), 4.23-4.29 (m, 1H), 3.81 (dd, J=9.9, 2.3 Hz, 1H), 3.25 (dd, J=8.1,5.9 Hz, 1H), 3.11-3.16 (m, 2H), 2.94 (dd, J=9.6, 6.7 Hz, 1H), 2.53-2.56(m, 2H), 2.42 (s, 3H), 1.92-2.00 (m, 1H), 1.79-1.92 (m, 2H), 1.9 (m,1H), 1.68-1.74 (m, 1H), 1.52-1.62 (m, 2H), 1.24-1.36 (m, 1H), 0.90 (d,J=6.6 Hz, 3H), 0.85 (d, J=6.5 Hz, 3H); MS (ESI−) m/z 410 (M−H)⁻.

Example 444N¹-{(3aS,4R,6aR)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide

Step A: tert-Butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzylectahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Example 151 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-fluorobenzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: MS (APCI+) m/z 512 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.30 (d, J=7.2 Hz, 1H), 7.98-8.01 (m, 2H), 7.30-7.35 (m, 2H),4.25-4.29 (m, 1H), 3.79 (dd, J=9.9, 2.6 Hz, 1H), 3.19 (dd, J=8.2, 5.8Hz, 1H), 3.14 (d, J=2.9 Hz, 1H), 3.10-3.12 (m, 1H), 2.93 (dd, J=9.6, 6.9Hz, 1H), 2.52-2.58 (m, 2H), 2.39 (s, 3H), 1.92-2.00 (m, 1H), 1.78-2.08(m, 1H), 1.80-1.92 (m, 2H), 1.68 (ddd, J=13.5, 7.7, 5.8 Hz, 1H), 1.58(dd, J=8.1, 6.4 Hz, 1H), 1.52-1.58 (m, 1H), 1.26-1.35 (m, 1H), 0.90 (d,J=6.6 Hz, 3H), 0.84 (d, J=6.6 Hz, 3H); MS (ESI+) m/z 412 (M+H)⁺.

Example 445N¹-{(3aS,4R,6aR)-2-[(3,4-difluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide

Step A: tert-Butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3,4-difluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzylectahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-1-leucinamidefrom Example 151 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 3,4-difluorobenzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: MS (APCI+) m/z 530 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3,4-difluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.30 (d, J=7.3 Hz, 1H), 8.00 (ddd, J=9.6, 7.3, 2.2 Hz, 1H),7.76-7.79 (m, 1H), 7.35-7.49 (m, 1H), 4.24-4.30 (m, 1H), 3.82 (dd,J=9.9, 2.6 Hz, 1H), 3.19 (dd, J=7.5, 5.0 Hz, 1H), 3.13-3.17 (m, 2H),2.98 (dd, J=9.6, 7.1 Hz, 1H), 2.52-2.62 (m, 2H), 2.39 (s, 3H), 1.86-2.18(m, 1H), 1.94-2.02 (m, 1H), 1.79-1.92 (m, 2H), 1.63-1.74 (m, 1H),1.53-1.62 (m, 2H), 1.28-1.40 (m, 1H), 0.90 (d, J=6.7 Hz, 3H), 0.84 (d,J=6.6 Hz, 3H); MS (ESI+) m/z 430 (M+H)⁺.

Example 446N¹-{(3aS,4R,6aR)-2-[(3,5-difluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide

Step A: tert-Butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3,5-difluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Example 151 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 3,5-difluorobenzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: MS (APCI+) m/z 530 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3,5-difluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.32 (d, J=7.2 Hz, 1H), 7.66-7.69 (m, 2H), 7.33-7.42 (m, 1H),4.24-4.30 (m, 1H), 3.84 (dd, J=9.9, 2.5 Hz, 1H), 3.16-3.21 (m, 3H), 3.00(dd, J=9.7, 7.0 Hz, 1H), 2.48-2.60 (m, 2H), 2.39 (s, 3H), 1.89-2.25 (m,1H), 1.93-2.01 (m, 1H), 1.81-1.92 (m, 2H), 1.68 (ddd, J=13.6, 7.8, 5.8Hz, 1H), 1.52-1.63 (m, 2H), 1.31 (ddt, J=9.7, 12.9, 6.4 Hz, 1H), 0.90(d, J=6.6 Hz, 3H), 0.84 (d, J=6.6 Hz, 3H); MS (ESI+) m/z 430 (M+H)⁺.

Example 447N¹-{(3aS,4R,6aR)-2-[(4-chlorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide

Step A: tert-Butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-chlorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-1-leucinamidefrom Example 151 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-chlorobenzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: MS (APCI+) m/z 530 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-chlorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.29-8.31 (m, 1H), 7.91-7.93 (m, 2H), 7.57-7.59 (m, 2H), 4.24-4.31(m, 1H), 3.80 (dd, J=9.9, 2.5 Hz, 1H), 3.19 (dd, J=8.2, 5.8 Hz, 1H),3.13 (dd, J=9.4, 2.7 Hz, 1H), 3.11 (dd, J=9.5, 7.2 Hz, 1H), 2.92 (dd,J=9.6, 7.0 Hz, 1H), 2.52-2.59 (m, 2H), 2.39 (s, 3H), 1.90-2.16 (m, 1H),1.92-2.00 (m, 1H), 1.80-1.91 (m, 2H), 1.68 (ddd, J=13.5, 7.8, 5.8 Hz,1H), 1.52-1.62 (m, 2H), 1.27-1.34 (m, 1H), 0.90 (d, J=6.6 Hz, 3H), 0.85(d, J=6.5 Hz, 3H); MS (ESI−) m/z 426 (M−H)⁻.

Example 448N²-methyl-N¹-[(3aS,4R,6aR)-2-(phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-leucinamide

Step A: tert-Butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Example 151 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand benzenesulfonyl chloride for 3-(trifluoromethyl)benzene-1-sulfonylchloride in the procedure described in Example 319: MS (APCI+) m/z 494(M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-chlorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.28 (d, J=7.0 Hz, 1H), 7.97-8.00 (m, 2H), 7.52-7.58 (m, 3H),4.24-4.31 (m, 1H), 3.79 (dd, J=9.9, 2.4 Hz, 1H), 3.19 (dd, J=8.2, 5.8Hz, 1H), 3.08-3.15 (m, 2H), 2.91 (dd, J=9.6, 6.7 Hz, 1H), 2.48-2.52 (m,2H), 2.39 (s, 3H), 1.77-2.03 (m, 4H), 1.68 (ddd, J=13.5, 7.8, 5.8 Hz,1H), 1.49-1.60 (m, 2H), 1.24-1.33 (m, 1H), 0.90 (d, J=6.6 Hz, 3H), 0.84(d, J=6.5 Hz, 3H); MS (ESI−) m/z 392 (M−H)⁻.

Example 449N²-methyl-N¹-{(3aS,4R,6aR)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl]-L-leucinamide

Step A:tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatewas prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Example 151 for(2S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-(trifluoromethyl)benzaldehyde for 3-(trifluoromethyl)benzaldehydein the procedure described in Example 303: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.36-8.27 (m, 1H), 7.65 (d, J=8.1, 2H), 7.50 (d, J=7.6, 2H), 5.14(m, 0.4H), 4.78 (m, 0.6H), 4.45-4.31 (m, 1H), 3.62-3.51 (m, 1H), 3.45(ddd, J=7.5, 5.3, 3.5, 1H), 3.05 (s, 3H), 2.90-2.73 (m, 1H), 2.55-2.41(m, 2H), 2.31 (d, J=5.7, 2H), 2.23-2.17 (m, 1H), 2.10 (dt, J=11.5, 5.8,1H), 1.94-1.75 (m, 3H), 1.65-1.51 (m, 2H), 1.46 (s, 9H), 1.42-1.34 (m,1H), 0.88 (d, J=6.3, 3H), 0.84 (d, J=6.6, 3H); MS (ESI+) m/z 512 (M+H)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.19-8.21 (m, 1H), 7.64-7.67 (m, 2H), 7.51-7.53 (m, 2H), 4.44-4.50(m, 1H), 3.57-3.61 (m, 1H), 3.47 (d, J=13.6 Hz, 1H), 3.22 (dd, J=8.2,5.8 Hz, 1H), 2.89 (dd, J=9.0, 2.6 Hz, 1H), 2.48-2.58 (m, 2H), 2.42 (s,3H), 2.34-2.40 (m, 2H), 2.24 (dd, J=8.9, 7.0 Hz, 1H), 2.09-2.17 (m, 1H),1.92-2.08 (m, 1H), 1.84-1.94 (m, 2H), 1.71 (ddd, J=13.5, 7.8, 5.8 Hz,1H), 1.56-1.65 (m, 2H), 1.39-1.47 (m, 1H), 0.91 (d, J=6.5 Hz, 3H), 0.85(d, J=6.5 Hz, 3H); MS (ESI+) m/z 412 (M+H)⁺.

Example 450N¹-[(3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide

Step A:tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatewas prepared by substitutingN¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamidefrom Example 151 for(2S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 4-fluorobenzaldehyde for 3-(trifluoromethyl)benzaldehyde in theprocedure described in Example 303: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.30 (d, J=6.2, 1H), 7.39-7.32 (m, 2H), 7.12 (t, J=8.8, 2H), 5.18-5.11(m, 1H), 4.44-4.33 (m, 1H), 3.54-3.46 (m, 1H), 3.38 (t, J=13.8, 1H),3.05 (s, 3H), 2.87-2.71 (m, 1H), 2.53-2.41 (m, 2H), 2.31 (d, J=6.3, 2H),2.23-2.17 (m, 1H), 2.13-2.06 (m, 1H), 1.83 (dd, J=9.0, 5.2, 3H),1.64-1.52 (m, 2H), 1.46 (s, 9H), 1.42-1.33 (m, 1H), 0.88 (d, J=6.4, 3H),0.84 (d, J=6.5, 3H); MS (ESI+) m/z 462 (M+H)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.23-8.25 (m, 1H), 7.37 (dd, J=8.3, 5.4 Hz, 2H), 7.13 (t, J=8.6Hz, 2H), 4.43-4.48 (m, 1H), 3.53 (d, J=13.1 Hz, 1H), 3.40 (d, J=13.1 Hz,1H), 3.24 (dd, J=8.1, 5.9 Hz, 1H), 2.85 (dd, J=9.1, 2.6 Hz, 1H),2.48-2.56 (m, 2H), 2.42 (s, 3H), 2.39 (dd, J=8.8, 7.1 Hz, 1H), 2.34 (dd,J=9.0, 2.3 Hz, 1H), 2.24 (dd, J=8.9, 6.9 Hz, 1H), 2.13 (dq, J=11.9, 6.0Hz, 1H), 1.62-2.52 (m, 1H), 1.85-1.94 (m, 2H), 1.72 (ddd, J=13.5, 7.7,5.8 Hz, 1H), 1.56-1.65 (m, 2H), 1.38-1.45 (m, 1H), 0.91 (d, J=6.6 Hz,3H), 0.86 (d, J=6.5 Hz, 3H); MS (ESI+) m/z 362 (M+H)⁺.

Example 451N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide

Step A: tert-Butylmethyl((S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamatewas prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 256 Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.08 (d, J=8.1, 2H), 7.81 (d, J=8.3, 2H), 7.58-7.53 (m, 1H), 4.31 (d,J=10.6, 1H), 4.11-4.02 (m, 1H), 3.66 (dd, J=10.2, 3.3, 1H), 3.31 (dd,J=10.2, 7.8, 1H), 3.19-3.09 (m, 2H), 3.00 (s, 3H), 2.63-2.47 (m, 2H),2.43-2.33 (m, 1H), 1.94-1.75 (m, 2H), 1.55-1.47 (m, 1H), 1.45 (s, 9H),1.28 (ddd, J=13.0, 8.9, 6.2, 1H), 0.98 (d, J=6.5, 3H), 0.86 (d, J=6.7,3H).

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.25-8.27 (m, 1H), 8.13-8.16 (m, 2H), 7.90-7.92 (m, 2H), 4.23-4.30(m, 1H), 3.85 (dd, J=9.9, 2.6 Hz, 1H), 3.13-3.20 (m, 2H), 2.97 (dd,J=9.6, 7.0 Hz, 1H), 2.88 (d, J=5.9 Hz, 1H), 2.48-2.62 (m, 2H), 2.39 (s,3H), 2.05-2.13 (m, 1H), 1.94-2.09 (m, 1H), 1.90-1.97 (m, 1H), 1.80-1.87(m, 1H), 1.51-1.59 (m, 1H), 1.30 (ddt, J=9.7, 12.9, 6.4 Hz, 1H),1.02-1.05 (m, 6H); MS (ESI+) m/z 448 (M+H)¹.

Example 452N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-valinamide

Step A:tert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamatewas prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)-3-methylbutanoic acid forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 261 Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm7.94 (dd, J=8.6, 5.3, 2H), 7.20 (t, J=8.7, 2H), 4.31 (d, J=11.2, 1H),4.07 (dt, J=13.3, 6.8, 1H), 3.59 (dd, J=9.9, 3.7, 1H), 3.27 (dd, J=10.1,7.8, 1H), 3.15-3.03 (m, 2H), 2.99 (s, 3H), 2.61-2.46 (m, 2H), 2.38 (dq,J=17.5, 6.8, 1H), 1.94-1.75 (m, 2H), 1.51 (dd, J=14.6, 6.6, 1H), 1.45(s, 9H), 1.33-1.21 (m, 1H), 0.98 (d, J=6.5, 3H), 0.86 (d, J=6.7, 3H); MS(ESI+) m/z 498 (M+H)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.26 (d, J=6.7 Hz, 1H), 7.99-8.02 (m, 2H), 7.31-7.35 (m, 2H),4.24-4.31 (m, 1H), 3.78 (dd, J=9.9, 2.5 Hz, 1H), 3.09-3.14 (m, 2H), 2.93(dd, J=9.6, 6.8 Hz, 1H), 2.89 (d, J=5.9 Hz, 1H), 2.48-2.58 (m, 2H), 2.39(s, 3H), 2.05-2.13 (m, 1H), 1.92-2.12 (m, 1H), 1.90-1.98 (m, 1H),1.80-1.87 (m, 1H), 1.52-1.59 (m, 1H), 1.24-1.34 (m, 1H), 1.04 (d, J=7.2Hz, 3H), 1.03 (d, J=7.2 Hz, 3H); MS (ESI−) m/z 396 (M−H)⁻.

Example 453N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-4-methyl-L-leucinamide

Step A:tert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamatewas prepared by substituting(S)-2-(tert-butoxycarbonylamino)-4,4-dimethylpentanoic acid forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 261 Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.70 (d, J=7.0, 1H), 8.14 (d, J=8.7, 1H), 7.99 (dd, J=8.6, 5.2, 2H),7.32 (t, J=8.6, 2H), 4.75-4.65 (m, 1H), 4.27-4.18 (m, 1H), 3.74 (dd,J=9.9, 2.7, 1H), 3.10 (ddd, J=13.9, 9.6, 5.4, 2H), 2.92 (dd, J=9.4, 7.7,1H), 2.61-2.47 (m, 2H), 2.15 (dd, J=14.2, 4.7, 1H), 1.89-1.73 (m, 3H),1.56-1.45 (m, 10H), 1.28-1.18 (m, 1H), 0.98 (s, 9H); MS (ESI+) m/z 512(M+H)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.38-8.40 (m, 1H), 7.98-8.01 (m, 2H), 7.31-7.38 (m, 2H), 4.20-4.23(m, 1H), 3.77 (dd, J=9.8, 2.6 Hz, 1H), 3.59 (dd, J=7.4, 4.3 Hz, 1H),3.11 (dd, J=9.6, 2.7 Hz, 1H), 3.06 (dd, J=9.9, 7.3 Hz, 1H), 2.91 (dd,J=9.6, 7.0 Hz, 1H), 2.46-2.58 (m, 2H), 2.16 (dd, J=14.0, 4.3 Hz, 1H),1.98-2.31 (m, 2H), 1.88-1.96 (m, 1H), 1.77-1.85 (m, 1H), 1.47-1.57 (m,1H), 1.43 (dd, J=14.0, 7.6 Hz, 1H), 1.23-1.32 (m, 1H), 0.99 (s, 9H); MS(ESI−) m/z 410 (M−H)⁻.

Example 454N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norleucinamide

Step A:tert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxohexan-2-yl(methyl)carbamatewas prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)hexanoic acid forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 261 Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.45 (d, J=6.8, 1H), 7.99 (dd, J=8.7, 5.2, 2H), 7.32 (t, J=8.7, 2H),4.94 (s, 3H), 4.28-4.15 (m, 1H), 3.75 (d, J=10.4, 1H), 3.07 (dd, J=20.0,10.4, 4H), 2.89 (dd, J=9.5, 7.2, 1H), 2.57-2.46 (m, 2H), 2.13-1.98 (m,1H), 1.93-1.68 (m, 3H), 1.45 (s, 9H), 1.26 (d, J=6.0, 5H), 0.78 (s, 3H);MS (ESI+) m/z 512 (M+H)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxohexan-2-yl(methyl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.20-8.22 (m, 1H), 7.99-8.02 (m, 2H), 7.31-7.38 (m, 2H), 4.24-4.30(m, 1H), 3.78 (dd, J=9.9, 2.5 Hz, 1H), 3.08-3.16 (m, 3H), 2.88-2.94 (m,1H), 2.52-2.59 (m, 2H), 2.40 (s, 3H), 1.92-1.98 (m, 1H), 1.60-2.28 (m,1H), 1.78-1.87 (m, 2H), 1.65-1.73 (m, 1H), 1.52-1.59 (m, 1H), 1.36-1.50(m, 2H), 1.27-1.35 (m, 1H), 1.24 (h, J=7.4 Hz, 2H), 0.81 (t, J=7.3 Hz,3H); MS (ESI−) m/z 410 (M−H)⁻.

Example 455N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide

Step A:tert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatewas prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)-4-methylpentanoic acid forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 261 Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm7.94 (dd, J=8.1, 5.2, 2H), 7.44-7.37 (m, 1H), 7.20 (t, J=8.5, 2H),4.85-4.77 (m, 1H), 4.12-4.03 (m, 1H), 3.61-3.55 (m, 1H), 3.27-3.21 (m,1H), 3.13-3.02 (m, 2H), 2.93 (s, 3H), 2.59-2.44 (m, 2H), 1.83 (ddd,J=37.1, 15.2, 5.0, 4H), 1.50 (d, J=0.6, 2H), 1.46 (d, J=0.8, 9H),1.33-1.22 (m, 1H), 0.89 (t, J=7.2, 6H); MS (ESI+) m/z 512 (M+H)⁺.

Step B: The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.29-8.31 (m, 1H), 7.99-8.02 (m, 2H), 7.31-7.35 (m, 2H), 4.24-4.30(m, 1H), 3.79 (dd, J=9.9, 2.4 Hz, 1H), 3.21 (dd, J=8.2, 5.9 Hz, 1H),3.09-3.14 (m, 2H), 2.93 (dd, J=9.6, 6.7 Hz, 1H), 2.53-2.59 (m, 2H), 2.40(s, 3H), 1.89-2.27 (m, 1H), 1.91-1.99 (m, 1H), 1.79-1.91 (m, 2H), 1.69(ddd, J=13.5, 7.7, 5.8 Hz, 1H), 1.53-1.59 (m, 2H), 1.25-1.35 (m, 1H),0.91 (d, J=6.6 Hz, 3H), 0.85 (d, J=6.6 Hz, 3H); MS (ESI−) m/z 410(M−H)⁻.

Example 456N²-methyl-N¹-((3aS,4S,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

Step A: tert-Butylmethyl((S)-1-oxo-1-((3aS,4S,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingtert-butyl(S)-1-((3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom Example 238 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: MS (ESI+) m/z 548 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aS,4S,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.52 (d, J=6.8 Hz, 1H), 8.12-8.14 (m, 2H), 7.90-7.92 (m, 2H), 4.47(p, J=7.6 Hz, 1H), 3.64 (dd, J=9.5, 2.9 Hz, 1H), 3.24 (dd, J=7.3, 5.4Hz, 1H), 3.16 (dd, J=9.7, 3.1 Hz, 1H), 2.96-3.05 (m, 3H), 2.51 (s, 3H),2.45-2.54 (m, 1H), 1.79-2.31 (m, 1H), 1.86-1.94 (m, 1H), 1.69-1.75 (m,3H), 1.47-1.65 (m, 3H), 1.34-1.40 (m, 1H), 0.90 (t, J=7.3 Hz, 3H); MS(ESI+) m/z 448 (M+H)⁺.

Example 457N²-methyl-N¹-((3aS,4S,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

Step A: tert-Butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4S,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substitutingtert-butyl(S)-1-((3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Example 239 for(S)-N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethyl)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.99-8.92(m, 1H), 8.12 (d, J=8.0, 2H), 7.91 (d, J=8.2, 2H), 5.33-5.24 (m, 1H),4.44-4.28 (m, 1H), 3.65 (dd, J=10.0, 2.8, 1H), 3.19-3.09 (m, 4H),3.03-2.81 (m, 3H), 2.50-2.42 (m, 1H), 2.05-1.92 (m, 2H), 1.73-1.55 (m,4H), 1.50 (s, 9H), 1.35-1.25 (m, 1H), 0.97 (d, J=6.6, 3H), 0.89-0.79 (m,3H); MS (ESI+) m/z 562 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4S,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.61 (d, J=6.9 Hz, 1H), 8.12-8.14 (m, 2H), 7.90-7.92 (m, 2H), 4.48(s, 1H), 3.65 (dd, J=9.6, 3.1 Hz, 1H), 3.29-3.33 (m, 1H), 3.16 (dd,J=9.6, 3.1 Hz, 1H), 3.01-3.06 (m, 1H), 2.98-3.03 (m, 1H), 2.94-2.98 (m,1H), 2.52 (s, 3H), 2.46-2.52 (m, 1H), 1.90-1.99 (m, 1H), 1.77-1.84 (m,1H), 1.28-2.16 (m, 1H), 1.67-1.76 (m, 2H), 1.57-1.66 (m, 2H), 1.34-1.40(m, 1H), 0.97 (d, J=6.6 Hz, 3H), 0.90 (d, J=6.6 Hz, 3H); MS (ESI+) m/z462 (M+H)⁺.

Example 458N¹-{(3aR,4S,6aS)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide

Step A:tert-butyl(S)-1-((3aR,4S,6aS)-2-(3,3-bis(4-fluorophenyl)propyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatewas prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 313 Step A for(2S)-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamideand 3,3-bis(4-fluorophenyl)propanal for 3-(trifluoromethyl)benzaldehydein the procedure described in Example 303: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.35-8.19 (m, 1H), 7.42-7.31 (m, 4H), 7.18-7.06 (m, 4H), 4.92-4.88(m, 1H), 4.52-4.42 (m, 1H), 4.28 (dd, J=10.0, 5.3, 1H), 3.15-3.02 (m,3H), 2.92 (dd, J=4.9, 4.1, 1H), 2.48 (dd, J=7.1, 5.7, 2H), 2.41-2.35 (m,1H), 2.33-2.27 (m, 2H), 2.26-2.17 (m, 3H), 2.15-2.08 (m, 2H), 2.08-1.99(m, 2H), 1.93-1.75 (m, 2H), 1.62-1.50 (m, 1H), 1.48 (d, J=7.3, 9H),1.37-1.28 (m, 2H), 0.88-0.80 (m, 3H); MS (ESI+) m/z 570 (M+H)¹.

Step B: The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-(3,3-bis(4-fluorophenyl)propyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom Step A fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.12-8.15 (m, 1H), 7.34-7.42 (m, 4H), 7.11-7.17 (m, 4H), 4.48-4.54(m, 1H), 4.28 (t, J=7.6 Hz, 1H), 3.18 (t, J=6.5 Hz, 1H), 2.93 (dd,J=9.0, 2.2 Hz, 1H), 2.49-2.57 (m, 1H), 2.43-2.49 (m, 1H), 2.42 (s, 3H),2.28-2.33 (m, 2H), 2.18-2.28 (m, 3H), 2.08-2.28 (m, 3H), 1.95-2.15 (m,1H), 1.89-2.00 (m, 1H), 1.79-1.87 (m, 1H), 1.67-1.75 (m, 1H), 1.43-1.61(m, 4H), 0.85 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 470 (M+H)⁺.

Example 4592,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-2-(N-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide

Step A:N-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-2,2-bis(4-fluorophenyl)acetamide(150 mg, 0.336 mmol) from Example 228 and ethanol (20 ml) were added to20% Pd(OH)₂ on carbon, wet (30.0 mg, 0.214 mmol) in a 50 mL pressurebottle and stirred for 2 hours at under 30 psi hydrogen at 50° C. Themixture was filtered and the solvent removed in vacuo to give2,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide:¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.09 (d, J=7.1, 1H), 7.60-7.55 (m,4H), 7.13 (q, J=8.2, 4H), 5.26 (s, 1H), 4.36-4.27 (m, 1H), 3.06 (dd,J=10.9, 2.7, 1H), 2.92 (dd, J=10.9, 7.0, 1H), 2.81 (dd, J=10.7, 7.0,1H), 2.59 (dd, J=10.8, 2.8, 1H), 2.52-2.41 (m, 2H), 2.33-2.25 (m, 1H),2.06-1.96 (m, 1H), 1.83 (td, J=12.7, 6.9, 1H), 1.65-1.52 (m, 1H), 1.26(ddt, J=12.3, 8.7, 6.1, 1H); MS (ESI+) m/z 357(M+H)⁺.

Step B:2,2-Bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide(30 mg, 0.084 mmol) and(S)-2-(tert-butoxycarbonyl(methyl)amino)-4-methylpentanoic acid (22.71mg, 0.093 mmol) were dissolved in dichloromethane (0.5 mL) and thentreated with 1-hydroxybenzotriazole hydrate (14.18 mg, 0.093 mmol).After 10 minutes,N¹-((ethylimino)methylene)-N³,N³-dimethylpropane-1,3-diamine (0.016 mL,0.093 mmol) was added, and the reaction mixture was stirred at ambienttemperature overnight followed by quenching with water. The material inthe organic layer was purified with a 4 g silica gel cartridge elutingwith 1-10% methanol (2 N ammonia)/dichloromethane to givetert-butyl(S)-1-((3aR,4S,6aS)-4-(2,2-bis(4-fluorophenyl)acetamido)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4-methyl-1-oxopentan-2-yl(methyl)carbamate:¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.25 (s, 1H), 7.46 (td, J=8.5, 5.5,4H), 7.08-6.96 (m, 4H), 5.08 (s, 2H), 4.29-4.18 (m, 1H), 3.80 (s, 2H),3.69 (s, 1H), 3.43 (dd, J=11.7, 3.5, 1H), 2.93 (s, 3H), 2.63 (s, 2H),2.10 (td, J=12.9, 6.9, 1H), 1.91-1.69 (m, 3H), 1.63 (dt, J=13.2, 6.5,2H), 1.51 (s, 9H), 1.40-1.26 (m, 1H), 0.97 (d, J=6.5, 3H), 0.92 (d,J=6.6, 3H); MS (ESI+) m/z 584(M+H)⁺.

Step C: The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-4-(2,2-bis(4-fluorophenyl)acetamido)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4-methyl-1-oxopentan-2-yl(methyl)carbamatefrom Step B fortert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.36-8.22 (m, 1H), 7.46 (td, J=8.4, 5.5, 4H), 7.03 (td, J=8.7,3.4, 4H), 5.10 (s, 1H), 4.34-4.23 (m, 1H), 3.77-3.66 (m, 2H), 3.63-3.52(m, 2H), 3.47-3.37 (m, 2H), 2.67-2.56 (m, 2H), 2.38 (s, 3H), 2.14-2.02(m, 1H), 1.99-1.82 (m, 2H), 1.70-1.57 (m, 1H), 1.49 (t, J=6.7, 2H), 1.36(dt, J=15.6, 6.5, 1H), 0.91 (dd, J=8.7, 6.8, 6H); MS (ESI+) m/z484(M+H)⁺.

Example 4602,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-2-(N-methyl-L-norvalyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide

The title compound was prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)pentanoic acid for(S)-2-(tert-butoxycarbonyl(methyl)amino)-4-methylpentanoic acid in theprocedure described in Example 459: ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.35-8.24 (m, 1H), 7.50-7.40 (m, 4H), 7.07-6.98 (m, 4H), 5.10 (s, 1H),4.31-4.21 (m, 1H), 3.75-3.64 (m, 2H), 3.61-3.51 (m, 2H), 3.41-3.31 (m,1H), 2.66-2.54 (m, 2H), 2.37 (s, 3H), 2.14-2.02 (m, 1H), 1.92-1.83 (m,1H), 1.71-1.40 (m, 6H), 1.33 (dd, J=12.9, 8.1, 1H), 0.87 (t, J=7.2, 3H);MS (ESI+) m/z 470(M+H)⁺.

Example 461N-[(3aR,4S,6aS)-2-(N,4-dimethyl-L-leucyl)octahydrocyclopenta[e]pyrrol-4-yl]-2,2-bis(4-fluorophenyl)acetamide

The title compound was prepared by substituting(S)-2-(tert-butoxycarbonyl(methyl)amino)-4,4-dimethylpentanoic acid for(S)-2-(tert-butoxycarbonyl(methyl)amino)-4-methylpentanoic acid in theprocedure described in Example 459: ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.36-8.25 (m, 1H), 7.49-7.40 (m, 4H), 7.03 (ddd, J=8.8, 6.3, 3.9, 4H),5.10 (s, 1H), 4.35-4.20 (m, 1H), 3.77-3.66 (m, 2H), 3.63-3.51 (m, 2H),3.49-3.38 (m, 1H), 2.68-2.54 (m, 2H), 2.36 (s, 3H), 2.16-2.00 (m, 1H),1.95-1.78 (m, 2H), 1.71 (dd, J=14.1, 4.9, 1H), 1.66-1.56 (m, 1H),1.53-1.43 (m, 1H), 1.41-1.27 (m, 1H), 0.99 (s, 9H); MS (ESI+) m/z498(M+H)⁺.

Example 4622,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-2-(4-methyl-L-leucyl)octahydrocyclopenta[e]pyrrol-4-yl]acetamide

The title compound was prepared by substituting(S)-2-(tert-butoxycarbonylamino)-4,4-dimethylpentanoic acid for(S)-2-(tert-butoxycarbonyl(methyl)amino)-4-methylpentanoic acid in theprocedure described in Example 459: ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.37-8.15 (m, 1H), 7.46 (td, J=8.6, 5.6, 4H), 7.09-6.96 (m, 4H), 5.09(s, 1H), 4.32-4.18 (m, 1H), 3.76-3.63 (m, 4H), 3.62-3.51 (m, 2H),3.51-3.32 (m, 1H), 2.68-2.52 (m, 2H), 2.12-1.99 (m, 1H), 1.93-1.77 (m,2H), 1.62 (td, J=15.7, 7.8, 1H), 1.44 (dd, J=14.1, 7.5, 1H), 1.39-1.23(m, 1H), 0.99 (s, 9H); MS (ESI+) m/z 498(M+H)⁺.

Example 463tert-butyl(S)-1-((3aR,4S,6aS)-4-((S)-2-(tert-butoxycarbonylamino)-4,4-dimethylpentanamido)hexahydrocyclopenta[e]pyrrol-2(1H)-yl)-4,4-dimethyl-1-oxopentan-2-ylcarbamate

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamatefrom Example 226 forN-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-2,2-bis(4-fluorophenyl)acetamide(150 mg, 0.336 mmol) and(S)-2-(tert-butoxycarbonylamino)-4,4-dimethylpentanoic acid for(S)-2-(tert-butoxycarbonyl(methyl)amino)-4-methylpentanoic acid in theprocedure described in Example 459 Steps A and B: ¹H NMR (400 MHz,pyridine-d₅) δ ppm 7.76 (d, J=5.2, 1H), 7.02 (d, J=4.7, 1H), 6.97-6.86(m, 1H), 4.78 (td, J=8.7, 4.5, 1H), 4.49 (td, J=8.2, 4.6, 1H), 4.25-4.14(m, 1H), 3.84-3.76 (m, 2H), 3.54-3.35 (m, 1H), 2.73-2.59 (m, 2H), 2.07(ddd, J=20.0, 13.7, 5.6, 2H), 1.94-1.81 (m, 2H), 1.69 (ddd, J=11.1, 7.4,3.2, 2H), 1.64-1.55 (m, 1H), 1.48 (s, 9H), 1.48 (s, 9H), 1.38-1.27 (m,1H), 1.02 (s, 9H), 0.97 (s, 9H); MS (ESI+) m/z 581(M+H)⁺.

Example 4644-methyl-N¹-[(3aR,4S,6aS)-2-(4-methyl-1-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-4-((S)-2-(tert-butoxycarbonylamino)-4,4-dimethylpentanamido)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4,4-dimethyl-1-oxopentan-2-ylcarbamatefrom Example 463 fortert-butyl(S)-1-((3aR,4S,6aS)-4-(2,2-bis(4-fluorophenyl)acetamido)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 459 Step C: ¹H NMR (400 MHz,pyridine-d₅) δ ppm 7.88-7.76 (m, 1H), 4.22-4.14 (m, 1H), 3.78-3.66 (m,6H), 3.61 (dddd, J=9.1, 4.5, 2.1, 0.7, 2H), 3.50 (dd, J=7.5, 4.1, 2H),2.70-2.60 (m, 1H), 2.60-2.51 (m, 1H), 2.11-2.00 (m, 2H), 1.96-1.83 (m,2H), 1.66-1.53 (m, 1H), 1.45 (dd, J=14.1, 7.4, 1H), 1.36 (dd, J=14.1,7.5, 2H), 1.00 (s, 9H), 0.97 (s, 9H); MS (ESI+) m/z 381(M+H)⁻.

Example 4654-methyl-N¹-[(3aR,4S,6aS)-2-L-phenylalanyloctahydrocyclopenta[c]pyrrol-4-yl]-L-leucinamide

The title compound was prepared by substitutingtert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamatefrom Example 226 forN-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-2,2-bis(4-fluorophenyl)acetamideand (S)-2-(tert-butoxycarbonylamino)-3-phenylpropanoic acid for(S)-2-(tert-butoxycarbonyl(methyl)amino)-4-methylpentanoic acid in theprocedure described in Example 459: ¹H NMR (400 MHz, pyridine-d₅) δ ppm7.84-7.68 (m, 1H), 7.34-7.24 (m, 3H), 7.18 (t, J=6.8, 2H), 4.08 (dt,J=14.3, 7.0, 1H), 3.81-3.67 (m, 6H), 3.53-3.46 (m, 4H), 3.10 (dd,J=13.2, 7.0, 1H), 2.88 (dd, J=13.2, 6.8, 1H), 2.53 (td, J=14.0, 7.9,1H), 2.41 (dt, J=14.4, 7.0, 1H), 2.10-2.04 (m, 1H), 1.98 (ddd, J=19.6,7.2, 5.1, 1H), 1.80 (dt, J=13.0, 7.8, 1H), 1.53 (dq, J=12.8, 8.1, 1H),1.35 (dd, J=14.1, 7.6, 1H), 1.25-1.05 (m, 1H), 0.97 (s, 9H); MS (ESI+)m/z 401(M+H)⁺.

Example 466(3a,R,4S,6aS)—N-benzhydryl-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-amine

(3aR,4S,6aS)-2-(3-(Trifluoromethyl)benzypoctahydrocyclopenta[c]pyrrol-4-amine(60 mg, 0.211 mmol), from Example 156 Step A was combined with(bromomethylene)dibenzene (62.6 mg, 0.253 mmol) and potassium carbonate(87 mg, 0.633 mmol) in N,N-dimethylformamide (1 mL). The reaction wasstirred at room temperature for 72 hours. The reaction was quenched withwater and extracted with diethyl ether. The ether extracts were washedwith water (3×1 mL) and the solvent removed. The crude material waspurified using a 12 g silica gel cartridge eluting with a gradient of0-3% methanol (2 N ammonia)/dichloromethane to give(3aR,4S,6aS)—N-benzhydry1-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-amine:¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.71 (s, 1H), 7.64-7.59 (m, 4H),7.52 (d, J=7.7, 1H), 7.44 (t, J=7.7, 1H), 7.33 (td, J=7.6, 4.7, 4H),7.25-7.21 (m, 4H), 5.09 (s, 1H), 3.51 (q, J=13.5, 2H), 3.02 (dd, J=12.9,5.5, 1H), 2.63-2.54 (m, 1H), 2.51 (dd, J=8.8, 2.8, 1H), 2.47-2.41 (m,1H), 2.37 (t, J=8.0, 1H), 2.32-2.25 (m, 2H), 1.98 (td, J=11.4, 5.6, 1H),1.89 (ddd, J=12.7, 10.4, 5.8, 1H), 1.45 (ddd, J=14.7, 11.9, 8.1, 1H),1.32-1.23 (m, 1H); MS (ESI+) m/z 451(M+H)⁺.

Example 467(3aS,4R,6aR)—N-benzhydryl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared by substituting(3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-aminefrom Example 254 Step A for(3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 466: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.35-8.36 (bs, 1H), 8.17-8.19 (m, 1H), 7.92-7.95 (m, 1H), 7.75 (t,J=7.8 Hz, 1H), 7.61-7.64 (m, 2H), 7.57-7.60 (m, 2H), 7.32-7.38 (m, 4H),7.22-7.26 (m, 2H), 5.02 (s, 1H), 3.33 (dd, J=9.7, 3.1 Hz, 1H), 3.07 (dd,J=9.6, 3.0 Hz, 1H), 3.03 (dd, J=9.8, 7.9 Hz, 1H), 2.90-2.95 (m, 2H),2.48-2.57 (m, 1H), 2.39-2.45 (m, 1H), 2.17-2.48 (m, 1H), 1.80-1.88 (m,2H), 1.31-1.39 (m, 1H), 1.04-1.12 (m, 1H); MS (ESI+) m/z 501 (M+H)⁺.

Example 468(3aR,4S,6aS)—N-benzhydryl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine

The title compound was prepared by substituting(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 252 Step D for(3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 466: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.35-8.36 (bs, 1H), 8.17-8.19 (m, 1H), 7.92-7.95 (m, 1H), 7.74 (t,J=7.8 Hz, 1H), 7.61-7.64 (m, 2H), 7.57-7.60 (m, 2H), 7.31-7.39 (m, 4H),7.22-7.27 (m, 2H), 5.01-5.06 (m, 1H), 3.33 (dd, J=9.8, 3.1 Hz, 1H), 3.07(dd, J=9.6, 2.9 Hz, 1H), 3.03 (dd, J=9.5, 8.2 Hz, 1H), 2.90-2.94 (m,2H), 2.49-2.55 (m, 1H), 2.38-2.45 (m, 1H), 2.28-2.38 (m, 1H), 1.80-1.88(m, 2H), 1.31-1.39 (m, 1H), 1.04-1.12 (m, 1H); MS (ESI+) m/z 501 (M+H)⁺.

Example 469N¹-[(3aS,4R,6aR)-2-benzhydryloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide

Step A: tent-Butyl(S)-1-((3aS,4R,6aR)-2-benzhydryloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatewas prepared by substituting tert-butylmethyl((S)-4-methyl-1-((3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl)carbamatefrom Example 349 for(3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 466: MS (APCI+) m/z 520 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butyl(S)-1-((3aS,4R,6aR)-2-benzhydryloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methy1-1-oxopentan-2-yl(methyl)carbamatefrom Step A for tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.16-8.18 (m, 1H), 7.63-7.65 (m, 2H), 7.56-7.62 (m, 2H), 7.27-7.37(m, 4H), 7.13-7.20 (m, 2H), 4.47-4.54 (m, 1H), 4.21 (s, 1H), 3.20 (dd,J=8.2, 5.9 Hz, 1H), 2.78-2.85 (m, 1H), 2.48-2.59 (m, 2H), 2.39 (s, 3H),2.34-2.38 (m, 2H), 2.20-2.28 (m, 2H), 1.87-2.07 (m, 1H), 1.81-1.94 (m,2H), 1.60-1.71 (m, 2H), 1.52-1.59 (m, 1H), 1.44-1.52 (m, 1H), 0.89 (d,J=6.6 Hz, 3H), 0.83 (d, J=6.5 Hz, 3H); MS (ESI+) m/z 420 (M+H)⁺.

Example 4704-methyl-N²-propyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand 1-iodopropane for iodoethane in the procedure described in Example288: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.31-8.34 (m, 1H), 8.14-8.16(m, 2H), 7.90-7.92 (m, 2H), 4.22-4.27 (m, 1H), 3.86 (d, J=11.3 Hz, 1H),3.28 (t, J=5.7 Hz, 1H), 3.15-3.20 (m, 2H), 2.98 (dd, J=9.5, 6.5 Hz, 1H),2.52-2.62 (m, 4H), 1.92-2.00 (m, 1H), 1.89 (dd, J=14.1, 4.8 Hz, 1H),1.81-1.88 (m, 1H), 1.65-1.86 (m, 1H), 1.53-1.62 (m, 1H), 1.40-1.54 (m,3H), 1.27-1.38 (m, 1H), 0.99 (s, 9H), 0.89 (t, J=7.4 Hz, 3H); MS (ESI+)m/z 504 (M+H)⁺.

Example 471N²-(cyclopropylmethyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand (bromomethyl)cyclopropane for iodoethane in the procedure describedin Example 288: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.29-8.31 (m, 1H),8.13-8.15 (m, 2H), 7.89-7.91 (m, 2H), 4.21-4.26 (m, 1H), 3.87 (dd,J=9.9, 2.3 Hz, 1H), 3.31 (dd, J=7.0, 4.5 Hz, 1H), 3.18 (dd, J=9.8, 2.1Hz, 1H), 3.16 (dd, J=9.8, 7.5 Hz, 1H), 2.97 (dd, J=9.6, 6.7 Hz, 1H),2.49-2.59 (m, 4H), 1.90-2.04 (m, 1H), 1.92-1.98 (m, 1H), 1.90 (dd,J=14.1, 4.5 Hz, 1H), 1.80-1.87 (m, 1H), 1.53-1.61 (m, 1H), 1.50 (dd,J=14.1, 7.1 Hz, 1H), 1.26-1.34 (m, 1H), 0.99 (s, 9H), 0.92-1.03 (m, 1H),0.39-0.47 (m, 2H), 0.13-0.19 (m, 2H); MS (ESI+) m/z 516 (M+H)⁻.

Example 472N²-(cyclobutylmethyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand (bromomethyl)cyclobutane for iodoethane in the procedure describedin Example 288: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.28-8.30 (m, 1H),8.14-8.16 (m, 2H), 7.89-7.92 (m, 2H), 4.23-4.27 (m, 1H), 3.88 (dd,J=9.9, 2.2 Hz, 1H), 3.27 (dd, J=7.0, 4.6 Hz, 1H), 3.16-3.20 (m, 2H),2.98 (dd, J=9.5, 6.5 Hz, 1H), 2.58-2.69 (m, 4H), 2.36-2.47 (m, 1H),1.94-2.03 (m, 3H), 1.88 (dd, J=14.0, 4.6 Hz, 1H), 1.74-1.88 (m, 3H),1.62-1.73 (m, 2H), 1.53-1.62 (m, 1H), 1.48 (dd, J=14.1, 7.1 Hz, 1H),1.32 (ddt, J=9.6, 12.8, 6.4 Hz, 1H), 0.99 (s, 9H); MS (ESI+) m/z 530(M+H)⁺.

Example 473N²-isobuty1-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand 1-iodo-2-methylpropane for iodoethane in the procedure described inExample 288: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.26-8.28 (m, 1H),8.14-8.16 (m, 2H), 7.89-7.92 (m, 2H), 4.22-4.28 (m, 1H), 3.86 (dd,J=10.0, 2.4 Hz, 1H), 3.25 (dd, J=7.1, 4.6 Hz, 1H), 3.16-3.21 (m, 2H),2.99 (dd, J=9.6, 6.8 Hz, 1H), 2.54-2.60 (m, 2H), 2.38-2.46 (m, 2H), 1.96(dq, J=11.8, 5.9 Hz, 1H), 1.87 (dd, J=14.1, 4.7 Hz, 1H), 1.80-1.88 (m,1H), 1.63-1.77 (m, 1H), 1.62-1.70 (m, 1H), 1.53-1.61 (m, 1H), 1.50 (dd,J=14.0, 7.2 Hz, 1H), 1.28-1.35 (m, 1H), 0.99 (s, 9H), 0.92 (d, J=6.7 Hz,3H), 0.90 (d, J=6.7 Hz, 3H); MS (ESI+) m/z 518 (M+H)⁺.

Example 474N²-(cyclopentylmethyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand (iodomethyl)cyclopentane for iodoethane in the procedure describedin Example 288: ¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.30-8.32 (m, 1H),8.13-8.16 (m, 2H), 7.89-7.92 (m, 2H), 4.22-4.27 (m, 1H), 3.87 (dd,J=9.9, 2.2 Hz, 1H), 3.28 (dd, J=7.1, 4.5 Hz, 1H), 3.15-3.22 (m, 2H),2.96-3.01 (m, 1H), 2.46-2.60 (m, 4H), 1.82-2.01 (m, 4H), 1.20-2.29 (m,1H), 1.67-1.79 (m, 2H), 1.42-1.63 (m, 6H), 1.13-1.36 (m, 3H), 1.00 (s,9H); MS (ESI+) m/z 544 (M+H)⁺.

Example 475N²-(cyclohexylmethyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand (bromomethyl)cyclohexane for iodoethane in the procedure describedin Example 288: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.27-8.29 (m, 1H),8.14-8.16 (m, 2H), 7.89-7.92 (m, 2H), 4.23-4.28 (m, 1H), 3.88 (dd,J=9.9, 2.2 Hz, 1H), 3.25 (dd, J=7.1, 4.5 Hz, 1H), 3.16-3.21 (m, 2H),2.99 (dd, J=9.6, 6.5 Hz, 1H), 2.59-2.61 (m, 2H), 2.47 (dd, J=11.1, 6.7Hz, 1H), 2.43 (dd, J=11.2, 6.2 Hz, 1H), 1.98 (dq, J=11.8, 5.9 Hz, 1H),1.89 (dd, J=14.2, 4.4 Hz, 1H), 1.82-1.89 (m, 1H), 1.71-1.82 (m, 2H),1.58-1.79 (m, 1H), 1.56-1.67 (m, 4H), 1.52 (dd, J=14.0, 7.2 Hz, 1H),1.28-1.41 (m, 2H), 1.05-1.22 (m, 3H), 1.00 (s, 9H), 0.86-0.98 (m, 2H);MS (ESI+) m/z 558 (M+H)⁻.

Example 476N²-butyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand 1-iodobutane for iodoethane in the procedure described in Example288: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.32-8.34 (m, 1H), 8.14-8.16(m, 2H), 7.90-7.92 (m, 2H), 4.24-4.29 (m, 1H), 3.87 (dd, J=9.9, 2.1 Hz,1H), 3.29 (dd, J=6.8, 4.8 Hz, 1H), 3.15-3.21 (m, 2H), 2.99 (dd, J=9.5,6.4 Hz, 1H), 2.55-2.66 (m, 4H), 1.94-2.01 (m, 1H), 1.90 (dd, J=14.0, 4.9Hz, 1H), 1.82-1.89 (m, 1H), 1.64-1.88 (m, 1H), 1.54-1.63 (m, 1H), 1.51(dd, J=14.0, 6.9 Hz, 1H), 1.39-1.47 (m, 2H), 1.26-1.38 (m, 3H), 0.99 (s,9H), 0.84 (t, J=7.3 Hz, 3H); MS (ESI−) m/z 516 (M−H)⁻.

Example 477N²-ethyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 288: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.35-8.38 (m, 1H), 8.14-8.16 (m, 2H), 7.90-7.92 (m, 2H), 4.22-4.27(m, 1H), 3.86 (dd, J=10.0, 2.2 Hz, 1H), 3.30 (t, J=5.8 Hz, 1H),3.14-3.20 (m, 2H), 2.98 (dd, J=9.5, 6.4 Hz, 1H), 2.65-2.72 (m, 1H),2.57-2.63 (m, 1H), 2.56-2.60 (m, 2H), 1.92-1.99 (m, 1H), 1.90 (dd,J=14.0, 5.0 Hz, 1H), 1.79-1.88 (m, 1H), 1.62-1.94 (m, 1H), 1.52-1.63 (m,1H), 1.50 (dd, J=14.0, 6.6 Hz, 1H), 1.26-1.40 (m, 1H), 1.06 (t, J=7.1Hz, 3H), 0.98 (s, 9H); MS (ESI+) m/z 490 (M+H)⁺.

Example 478N²-(cyclopropylmethyl)-4-methyl-N¹-{(3aR,4S,6aS)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-{(3aR,4S,6aS)-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 440 for(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand (bromomethyl)cyclopropane for iodoethane in the procedure describedin Example 288: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.62-8.63 (bs, 1H),8.38-8.41 (m, 1H), 7.68 (dd, J=8.9, 2.5 Hz, 1H), 6.40 (d, J=8.9 Hz, 1H),4.38-4.44 (m, 1H), 3.82-3.86 (m, 1H), 3.66-3.70 (m, 1H), 3.56-3.61 (m,1H), 3.29-3.41 (m, 2H), 2.75-2.78 (m, 2H), 2.57 (dd, J=6.7, 2.1 Hz, 2H),2.12-2.21 (m, 1H), 1.92-2.00 (m, 1H), 1.95 (dd, J=14.0, 4.5 Hz, 1H),1.71 (dq, J=12.7, 8.1 Hz, 1H), 1.54 (dd, J=14.1, 7.0 Hz, 1H), 1.38-1.48(m, 1H), 1.02 (s, 9H), 0.96-1.05 (m, 1H), 0.45-0.48 (m, 2H), 0.16-0.24(m, 2H); MS (ESI+) m/z 453 (M+H)⁺.

Example 479N²-(cyclopropylmethyl)-4-methyl-N¹-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 441 for(3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand (bromomethyl)cyclopropane for iodoethane in the procedure describedin Example 288: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.34-8.36 (m, 1H),7.51 (t, J=7.9 Hz, 1H), 6.98 (d, J=7.2 Hz, 1H), 6.52 (d, J=8.5 Hz, 1H),4.35-4.41 (m, 1H), 3.73 (dd, J=10.9, 2.9 Hz, 1H), 3.60-3.65 (m, 1H),3.52 (dd, J=10.7, 7.3 Hz, 1H), 3.36 (dd, J=7.1, 4.5 Hz, 1H), 3.29 (dd,J=10.9, 3.6 Hz, 1H), 2.69-2.77 (m, 2H), 2.55 (dd, J=6.7, 2.8 Hz, 2H),2.10-2.16 (m, 1H), 1.94 (dd, J=14.1, 4.5 Hz, 1H), 1.89-1.96 (m, 1H),1.74-2.09 (m, 1H), 1.69 (dq, J=12.7, 7.9 Hz, 1H), 1.53 (dd, J=14.1, 7.0Hz, 1H), 1.31-1.42 (m, 1H), 1.02 (s, 9H), 0.95-1.05 (m, 1H), 0.42-0.51(m, 2H), 0.15-0.25 (m, 2H); MS (ESI+) m/z 453 (M+H)⁺.

Example 480N²-isopropyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-(3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.26-8.29 (m, 1H), 8.13-8.16 (m,2H), 7.89-7.91 (m, 2H), 4.21-4.26 (m, 1H), 3.85 (dd, J=9.9, 2.3 Hz, 1H),3.36 (dd, J=7.5, 4.1 Hz, 1H), 3.15-3.20 (m, 2H), 2.98 (dd, J=9.6, 6.7Hz, 1H), 2.83 (hept, J=6.2 Hz, 1H), 2.51-2.62 (m, 2H), 1.91-1.97 (m,1H), 1.79-1.88 (m, 2H), 1.63-1.81 (m, 1H), 1.51-1.59 (m, 1H), 1.47 (dd,J=14.1, 7.5 Hz, 1H), 1.31 (ddt, J=9.6, 12.8, 6.4 Hz, 1H), 1.03 (dd,J=6.2, 2.7 Hz, 6H), 0.98 (s, 9H); MS (ESI+) m/z 504 (M+H)⁺.

Example 481N²-isopropyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substitutingN¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamidefrom Example 422 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.31-8.34 (m, 1H), 8.13-8.15 (m,2H), 7.89-7.91 (m, 2H), 4.21-4.27 (m, 1H), 3.84 (dd, J=9.9, 2.7 Hz, 1H),3.31-3.34 (m, 1H), 3.18 (dd, J=9.8, 2.8 Hz, 1H), 3.16 (dd, J=10.2, 7.9Hz, 1H), 2.98 (dd, J=9.6, 7.0 Hz, 1H), 2.83 (hept, J=6.1 Hz, 1H),2.46-2.60 (m, 2H), 1.94 (dq, J=11.8, 5.9 Hz, 1H), 1.77-1.87 (m, 2H),1.59-1.69 (m, 1H), 1.37-1.59 (m, 4H), 1.27-1.35 (m, 1H), 1.05 (d, J=6.3Hz, 3H), 1.03 (d, J=6.3 Hz, 3H), 0.85 (t, J=7.4 Hz, 3H); MS (ESI+) m/z476 (M+H)⁺.

Example 482N²-isopropyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substitutingN¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamidefrom Example 423 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.26-8.28 (m, 1H), 8.11-8.14 (m,2H), 7.88-7.91 (m, 2H), 4.23 (p, J=6.9 Hz, 1H), 3.85 (dd, J=9.9, 2.9 Hz,1H), 3.30 (dd, J=7.5, 5.5 Hz, 1H), 3.18 (dd, J=9.7, 3.0 Hz, 1H), 3.14(dd, J=9.9, 7.7 Hz, 1H), 2.97 (dd, J=9.6, 7.3 Hz, 1H), 2.81 (p, J=6.2Hz, 1H), 2.49-2.61 (m, 2H), 1.90-1.99 (m, 1H), 1.81-1.92 (m, 1H),1.81-1.88 (m, 1H), 1.74-1.81 (m, 1H), 1.59-1.68 (m, 1H), 1.37-1.58 (m,3H), 1.27-1.36 (m, 1H), 1.02 (dd, J=6.2, 1.5 Hz, 6H), 0.85 (t, J=7.3 Hz,3H); MS (ESI+) m/z 476 (M+H)⁺.

Example 483N²-isopropyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substitutingN¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamidefrom Example 424 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.38-8.39 (bs, 1H), 8.26-8.28 (m,1H), 8.20 (d, J=7.9 Hz, 1H), 7.90-7.92 (m, 1H), 7.72 (t, J=7.8 Hz, 1H),4.20-4.27 (m, 1H), 3.85 (dd, J=9.9, 2.5 Hz, 1H), 3.29 (dd, J=7.6, 5.5Hz, 1H), 3.18 (dd, J=20.2, 2.5 Hz, 1H), 3.14-3.18 (m, 1H), 2.96 (dd,J=9.6, 7.0 Hz, 1H), 2.77-2.83 (m, 1H), 2.51-2.57 (m, 2H), 1.89-1.99 (m,1H), 1.82-1.93 (m, 1H), 1.80-1.88 (m, 1H), 1.73-1.81 (m, 1H), 1.56-1.67(m, 1H), 1.36-1.56 (m, 3H), 1.25-1.35 (m, 1H), 1.02 (dd, J=9.4, 6.2 Hz,6H), 0.85 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 476 (M+H)⁺.

Example 484N²-isopropyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substitutingN¹-((3aS,4R,6aR)-2-}[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamidefrom Example 425 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.37-8.38 (bs, 1H), 8.26-8.28 (m,1H), 8.17-8.20 (m, 1H), 7.90-7.92 (m, 1H), 7.71 (t, J=7.8 Hz, 1H),4.21-4.27 (m, 1H), 3.86 (dd, J=9.9, 2.7 Hz, 1H), 3.29 (dd, J=7.5, 5.5Hz, 1H), 3.18 (dd, J=9.6, 2.8 Hz, 1H), 3.14 (dd, J=9.9, 7.5 Hz, 1H),2.95 (dd, J=9.6, 7.2 Hz, 1H), 2.76-2.84 (m, 1H), 2.47-2.58 (m, 2H),1.91-1.98 (m, 1H), 1.82-1.93 (m, 1H), 1.81-1.89 (m, 1H), 1.73-1.81 (m,1H), 1.57-1.66 (m, 1H), 1.36-1.57 (m, 3H), 1.25-1.35 (m, 1H), 1.02 (dd,J=6.2, 2.0 Hz, 6H), 0.84 (t, J=7.3 Hz, 3H).

Example 4853-cyclohexyl-N²-isopropyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-alaninamide

The title compound was prepared by substituting3-cyclohexyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-alaninamidefrom Example 426 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.32 (d, J=7.2 Hz, 1H), 8.13-8.16(m, 2H), 7.89-7.95 (m, 2H), 4.22-4.30 (m, 1H), 3.85 (dd, J=10.0, 2.3 Hz,1H), 3.41 (dd, J=8.5, 5.2 Hz, 1H), 3.15-3.21 (m, 2H), 2.99 (dd, J=9.6,6.7 Hz, 1H), 2.85 (p, J=6.2 Hz, 1H), 2.56-2.61 (m, 2H), 1.83-2.11 (m,1H), 1.90-2.00 (m, 1H), 1.79-1.89 (m, 1H), 1.66-1.78 (m, 3H), 1.46-1.65(m, 6H), 1.25-1.37 (m, 1H), 1.08-1.25 (m, 3H), 1.06 (d, J=6.3 Hz, 3H),1.04 (d, J=6.3 Hz, 3H), 0.75-1.00 (m, 2H); MS (ESI+) m/z 530 (M+H)⁺.

Example 486N¹-((3aR,4S,6aS)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-isopropyl-4-methyl-L-leucinamide

The title compound was prepared by substitutingN¹-((3aR,4S,6aS)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-L-leucinamidefrom Example 428 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.57 (d, J=2.2 Hz, 1H), 8.32-8.35(m, 1H), 7.81 (dd, J=8.3, 2.2 Hz, 1H), 7.75 (d, J=8.3 Hz, 1H), 4.29-4.35(m, 1H), 3.93 (dd, J=10.2, 2.2 Hz, 1H), 3.56 (dd, J=10.1, 6.6 Hz, 1H),3.35-3.41 (m, 2H), 3.32 (dd, J=10.0, 2.6 Hz, 1H), 2.83 (hept, J=6.2 Hz,1H), 2.66-2.68 (m, 2H), 2.01-2.08 (m, 1H), 1.86-1.93 (m, 1H), 1.84 (dd,J=14.2, 4.3 Hz, 1H), 1.66-1.81 (m, 1H), 1.56-1.66 (m, 1H), 1.46 (dd,J=14.1, 7.4 Hz, 1H), 1.35-1.42 (m, 1H), 1.03 (d, J=6.1 Hz, 3H), 1.02 (d,J=6.1 Hz, 3H), 0.98 (s, 9H); MS (ESI+) m/z 538 (M+H)⁻.

Example 487N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-isopropyl-4-methyl-L-leucinamide

The title compound was prepared by substitutingN¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-L-leucinamidefrom Example 429 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (501 MHz, pyridine-d₅) δ ppm 8.35 (d, J=8.2 Hz, 1H), 8.29-8.32(m, 1H), 7.99 (s, 1H), 7.73 (d, J=9.1 Hz, 1H), 4.29-4.35 (m, 1H), 3.95(dd, J=10.2, 2.4 Hz, 1H), 3.54 (dd, J=10.1, 6.9 Hz, 1H), 3.40 (dd,J=10.0, 6.5 Hz, 1H), 3.33-3.36 (m, 2H), 2.82 (dq, J=12.4, 6.2 Hz, 1H),2.65-2.68 (m, 2H), 2.00-2.07 (m, 1H), 1.85-1.92 (m, 1H), 1.84 (dd,J=14.1, 4.2 Hz, 1H), 1.65-1.82 (m, 1H), 1.55-1.65 (m, 1H), 1.46 (dd,J=14.1, 7.6 Hz, 1H), 1.34-1.43 (m, 1H), 1.03 (d, J=6.1 Hz, 3H), 1.02 (d,J=6.3 Hz, 3H), 0.98 (s, 9H); MS (ESI+) m/z 538 (M+H)⁺.

Example 488N²-isopropyl-N¹-[(3aR,4S,6aS)-2-(N-isopropyl-4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-[(3aR,4S,6aS)-2-(4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-leucinamidefrom Example 464 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (400 MHz, pyridine-d₅) δ ppm 7.77-7.66 (m, 1H), 4.30-4.18 (m,1H), 3.80-3.72 (m, 3H), 3.72-3.61 (m, 3H), 3.60-3.45 (m, 1H), 3.32 (dd,J=7.3, 4.2, 1H), 2.87-2.77 (m, 2H), 2.76-2.68 (m, 1H), 2.68-2.60 (m,1H), 2.17-2.05 (m, 1H), 2.02-1.90 (m, 1H), 1.82 (dd, J=14.2, 4.2, 1H),1.64 (dd, J=14.2, 4.2, 2H), 1.46 (ddd, J=27.5, 14.2, 7.7, 3H), 1.12-0.92(m, 30H); MS (ESI+) m/z 465 (M+H)⁺.

Example 489N²-isopropyl-N¹-[(3aR,4S,6aS)-2-(N-isopropyl-L-phenylalanyl)octahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-[(3aR,4S,6aS)-2-L-phenylalanyloctahydrocyclopenta[c]pyrrol-4-yl]-leucinamidefrom Example 465 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (400 MHz, pyridine-d₅) δ ppm 7.74-7.61 (m, 1H), 7.36-7.23 (m,4H), 7.22-7.15 (m, 2H), 4.19-4.02 (m, 2H), 3.77 (dd, J=11.9, 3.7, 5H),3.56-3.48 (m, 1H), 3.32 (dd, J=7.3, 4.3, 1H), 3.05-2.94 (m, 2H),2.92-2.76 (m, 2H), 2.66-2.50 (m, 1H), 2.48-2.35 (m, 1H), 2.06-1.92 (m,1H), 1.83 (dd, J=14.2, 4.3, 2H), 1.55 (dq, J=12.8, 8.0, 1H), 1.42 (dd,J=14.2, 7.3, 1H), 1.08-1.00 (m, 12H), 0.99 (s, 9H); MS (ESI+) m/z 485(M+H)⁺.

Example 490N²-isopropyl-4-methyl-N¹-{(3aR,4S,6aS)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-{(3aR,4S,6aS)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 440 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.62-8.63 (bs, 1H), 8.34-8.36 (m,1H), 7.68 (dd, J=8.9, 2.5 Hz, 1H), 6.40 (d, J=8.9 Hz, 1H), 4.39-4.44 (m,1H), 3.82-3.85 (m, 1H), 3.67-3.71 (m, 1H), 3.57-3.61 (m, 1H), 3.29-3.44(m, 2H), 2.88 (hept, J=6.2 Hz, 1H), 2.74-2.76 (m, 2H), 2.13-2.20 (m,1H), 1.64-2.00 (m, 4H), 1.51 (dd, J=14.1, 7.6 Hz, 1H), 1.39-1.46 (m,1H), 1.08 (d, J=6.3 Hz, 3H), 1.07 (d, J=6.3 Hz, 3H), 1.01 (s, 9H); MS(ESI+) m/z 441 (M+H)⁺.

Example 491N²-isopropyl-4-methyl-N¹-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 441 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.31-8.34 (m, 1H), 7.51 (t, J=7.9Hz, 1H), 6.98 (d, J=7.2 Hz, 1H), 6.52 (d, J=8.6 Hz, 1H), 4.36-4.41 (m,1H), 3.73 (dd, J=10.9, 3.0 Hz, 1H), 3.63 (dd, J=10.9, 7.0 Hz, 1H), 3.53(dd, J=10.8, 7.4 Hz, 1H), 3.40 (dd, J=7.5, 4.0 Hz, 1H), 3.29 (dd,J=10.9, 3.6 Hz, 1H), 2.88 (p, J=6.2 Hz, 1H), 2.74 (dd, J=5.6, 2.8 Hz,2H), 2.09-2.16 (m, 1H), 1.89-1.98 (m, 1H), 1.90 (dd, J=14.1, 4.0 Hz,1H), 1.69-1.85 (m, 1H), 1.63-1.73 (m, 1H), 1.50 (dd, J=14.1, 7.6 Hz,1H), 1.36-1.43 (m, 1H), 1.07 (d, J=6.3 Hz, 3H), 1.07 (d, J=6.1 Hz, 3H),1.01 (s, 9H); MS (ESI+) m/z 441 (M+H)⁻.

Example 4922,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-2-(N-isopropyl-4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide

The title compound was prepared by substituting2,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-2-(4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamidefrom Example 462 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.35-8.23 (m, 1H), 7.49-7.41 (m,4H), 7.07-6.99 (m, 4H), 5.10 (s, 1H), 4.37-4.19 (m, 1H), 3.78-3.70 (m,2H), 3.66-3.41 (m 4H), 2.84-2.71 (m, 1H), 2.69-2.54 (m, 2H), 2.14-2.00(m, 1H), 1.95-1.80 (m, 1H), 1.63 (ddd, J=12.4, 9.1, 6.0, 2H), 1.48 (dd,J=14.2, 8.0, 1H), 1.42-1.29 (m, 1H), 1.08-0.95 (m, 15H); MS (ESI+) m/z526 (M+H)⁺.

Example 493N²-isopropyl-4-methyl-N¹-{(3aR,4S,6aS)-2-[2-(methylsulfonyl)pyrimidin-5-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-{(3aR,4S,6aS)-2-[2-(methylsulfonyl)pyrimidin-5-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 442 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.45 (s, 2H), 8.31-8.33 (m, 1H),4.95 (s, 3H), 4.40-4.46 (m, 1H), 3.97 (dd, J=11.8, 2.8 Hz, 1H), 3.80(dd, J=11.9, 7.6 Hz, 1H), 3.73 (dd, J=11.6, 8.1 Hz, 1H), 3.45 (dd,J=11.7, 4.1 Hz, 1H), 3.40 (dd, J=7.5, 4.0 Hz, 1H), 2.86 (hept, J=6.2 Hz,1H), 2.70-2.78 (m, 2H), 2.13-2.19 (m, 1H), 1.89-1.98 (m, 1H), 1.89 (dd,J=14.2, 4.1 Hz, 1H), 1.65-1.81 (m, 1H), 1.63-1.72 (m, 1H), 1.49 (dd,J=14.1, 7.6 Hz, 1H), 1.38-1.45 (m, 1H), 1.06 (d, J=6.1 Hz, 3H), 1.05 (d,J=6.1 Hz, 3H), 1.00 (s, 9H); MS (ESI+) m/z 450 (M+H)⁺.

Example 494N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-isopropyl-L-norvalinamide

Step A:N¹-{(3aR,4S,6aS)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamidewas prepared by substituting tert-butyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 382 Step A for tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-y1(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.17 (d, J=7.3, 1H), 7.43 (d, J=7.4, 2H), 7.36 (t, J=7.6, 2H),7.27 (t, J=7.3, 1H), 4.42-4.35 (m, 1H), 3.59 (d, J=13.2, 1H), 3.53 (dd,J=7.9, 4.9, 1H), 3.44 (d, J=13.1, 1H), 2.84 (dd, J=8.9, 2.4, 1H),2.54-2.42 (m, 2H), 2.41-2.33 (m, 2H), 2.23 (dd, J=8.7, 7.3, 1H), 2.10(dt, J=17.7, 5.8, 3H), 1.98-1.90 (m, 1H), 1.82 (dt, J=20.2, 6.2, 1H),1.69-1.61 (m, 1H), 1.58-1.34 (m, 4H), 0.84 (t, J=7.3, 3H); MS (ESI+) m/z316 (M+H)⁺.

Step B: The title compound was prepared by substitutingN¹-{(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamidefrom Step A for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.17-8.19 (m, 1H), 7.43-7.46 (m,2H), 7.37 (t, J=7.5 Hz, 2H), 7.28 (t, J=7.3 Hz, 1H), 4.39-4.44 (m, 1H),3.61 (d, J=13.1 Hz, 1H), 3.46 (d, J=13.1 Hz, 1H), 3.32 (dd, J=7.6, 5.5Hz, 1H), 2.81-2.86 (m, 2H), 2.48-2.59 (m, 2H), 2.45 (dd, J=8.7, 7.2 Hz,1H), 2.36 (dd, J=9.0, 2.7 Hz, 1H), 2.28 (dd, J=8.9, 6.8 Hz, 1H), 2.12(dq, J=12.0, 6.0 Hz, 1H), 1.84-1.99 (m, 1H), 1.77-1.89 (m, 2H),1.40-1.67 (m, 5H), 1.05 (d, J=6.1 Hz, 3H), 1.04 (d, J=6.0 Hz, 3H), 0.85(t, J=7.3 Hz, 3H); MS (ESI+) m/z 358 (M+H)⁺.

Example 495N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-isopropyl-L-norvalinamide

Step A: tent-Butyl((S)-1-oxo-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substituting N-(tent-butoxycarbonyl)-L-norvaline forN-(tent-butoxycarbonyl)-L-leucine and(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Example16 Step D for (3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.58 (d, J=7.2, 1H), 7.91 (d, J=8.3, 1H), 7.42 (d, J=7.3, 2H),7.36 (t, J=7.4, 2H), 7.27 (t, J=7.2, 1H), 4.64 (dd, J=14.4, 7.7, 1H),4.45-4.34 (m, 1H), 3.56 (d, J=13.1, 1H), 3.40 (d, J=13.2, 1H), 2.74 (d,J=8.9, 1H), 2.48 (d, J=0.7, 2H), 2.39-2.27 (m, 2H), 2.26-2.19 (m, 1H),2.14 (dq, J=12.0, 6.0, 1H), 2.07-1.96 (m, 1H), 1.85 (td, J=13.8, 8.2,2H), 1.65 (td, J=14.3, 7.3, 1H), 1.49 (d, J=8.5, 11H), 1.45-1.33 (m,1H), 0.81 (t, J=7.3, 3H); MS (ESI+) m/z 416 (M+H)⁺.

Step B:N¹-{(3aS,4R,6aR)-2-Benzyloctahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamidewas prepared by substitutingtert-butyl-((S)-1-oxo-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A for tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.19 (d, J=7.4, 1H), 7.43 (d, J=7.3, 2H), 7.36 (t, J=7.6, 2H),7.27 (t, J=7.3, 1H), 4.43-4.35 (m, 1H), 3.59 (d, J=13.1, 1H), 3.53 (dd,J=7.9, 5.0, 1H), 3.43 (d, J=13.2, 1H), 2.83 (dd, J=8.9, 2.4, 1H),2.55-2.48 (m, 1H), 2.44 (ddd, J=9.2, 6.0, 3.6, 1H), 2.41-2.33 (m, 2H),2.23 (dd, J=8.8, 7.3, 1H), 2.10 (td, J=11.8, 5.9, 3H), 1.98-1.89 (m,1H), 1.83 (dt, J=20.4, 6.2, 1H), 1.70-1.60 (m, 1H), 1.58-1.33 (m, 4H),0.84 (t, J=7.3, 3H); MS (ESI+) m/z 316 (M+H)⁺.

Step C: The title compound was prepared by substitutingN¹-{(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamidefrom Step B for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.18-8.20 (m, 1H), 7.43-7.45 (m,2H), 7.37 (t, J=7.5 Hz, 2H), 7.28 (t, J=7.3 Hz, 1H), 4.40-4.46 (m, 1H),3.60 (d, J=13.1 Hz, 1H), 3.44 (d, J=13.1 Hz, 1H), 3.32 (dd, J=7.5, 5.5Hz, 1H), 2.80-2.86 (m, 2H), 2.46-2.59 (m, 2H), 2.43 (dd, J=8.8, 7.2 Hz,1H), 2.35 (dd, J=8.9, 2.9 Hz, 1H), 2.27 (dd, J=8.9, 7.1 Hz, 1H), 2.12(dq, J=12.0, 6.0 Hz, 1H), 1.86-2.04 (m, 1H), 1.77-1.90 (m, 2H),1.55-1.70 (m, 2H), 1.38-1.55 (m, 3H), 1.05 (d, J=6.9 Hz, 3H), 1.04 (d,J=6.6 Hz, 3H), 0.85 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 358 (M+H)⁺.

Example 496N²-isopropyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

Step A:tert-Butyl-((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substituting(3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminefrom 252 Step D for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (400 MHz, pyridine-d₅) δ ppm8.75 (d, J=13.1, 1H), 8.37 (s, 1H), 8.18 (d, J=7.7, 1H), 8.00 (d, J=8.4,1H), 7.91 (d, J=7.9, 1H), 7.71 (t, J=7.9, 1H), 4.70-4.59 (m, 1H),4.29-4.18 (m, 1H), 3.82 (dd, J=10.1, 2.4, 1H), 3.15 (dd, J=9.9, 7.6,2H), 2.99-2.89 (m, 1H), 2.62-2.44 (m, 2H), 1.93-1.70 (m, 5H), 1.55-1.44(m, 10H), 1.30-1.16 (m, 1H), 0.86 (d, J=5.9, 3H), 0.83 (d, J=5.9, 3H). ;MS (ESI−) m/z 545 (M−H)⁻.

Step B:N¹-((3aR,4S,6aS)-2-{[3-(Trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidewas prepared by substitutingtert-butyl-((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A for tent-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.44-8.32 (m, 2H), 8.19 (d, J=7.9, 1H), 7.91 (d, J=7.9, 1H),7.79-7.66 (m, 1H), 4.72-4.38 (m, 3H), 4.29-4.15 (m, 1H), 3.84 (dd,J=9.9, 2.4, 1H), 3.60 (dd, J=9.3, 4.5, 1H), 3.06 (dt, J=21.7, 10.8, 1H),2.92 (dd, J=9.6, 7.2, 1H), 2.57-2.45 (m, 2H), 1.98-1.76 (m, 4H),1.61-1.43 (m, 2H), 1.26 (ddt, J=13.2, 9.9, 6.5, 1H), 0.90 (d, J=6.4,3H), 0.84 (d, J=6.3, 3H); MS (ESI−) m/z 448 (M−H)⁻.

Step C: The title compound was prepared by substitutingN¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Step B for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.38 (s, 1H), 8.30-8.33 (m, 1H),8.20 (d, J=7.9 Hz, 1H), 7.90-7.93 (m, 1H), 7.72 (t, J=7.8 Hz, 1H),4.20-4.26 (m, 1H), 3.86 (dd, J=9.9, 2.3 Hz, 1H), 3.35 (dd, J=8.9, 5.1Hz, 1H), 3.14-3.20 (m, 2H), 2.97 (dd, J=9.6, 6.8 Hz, 1H), 2.83 (hept,J=6.2 Hz, 1H), 2.52-2.56 (m, 2H), 2.07-2.81 (m, 1H), 1.78-2.01 (m, 3H),1.64 (ddd, J=13.6, 8.4, 5.2 Hz, 1H), 1.47-1.59 (m, 2H), 1.25-1.36 (m,1H), 1.04 (d, J=6.3 Hz, 3H), 1.02 (d, J=6.1 Hz, 3H), 0.91 (d, J=6.7 Hz,3H), 0.85 (d, J=6.6 Hz, 3H); MS (ESI−) m/z 488 (M−H)⁻.

Example 497N²,N²-dimethyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substitutingN²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 384 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand formaldehyde for pivalaldehyde in the procedure described in Example281: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.37 (s, 1H), 8.26 (d, J=7.0,1H), 8.19 (d, J=7.9, 1H), 7.91 (d, J=7.9, 1H), 7.72 (t, J=7.9, 1H), 4.24(dt, J=13.3, 6.5, 1H), 3.85 (dd, J=10.0, 2.0, 1H), 3.20-3.11 (m, 3H),2.94 (dd, J=9.6, 7.1, 1H), 2.59-2.48 (m, 2H), 2.33 (s, 6H), 1.96 (dt,J=12.3, 6.3, 1H), 1.81 (tdd, J=14.4, 11.4, 6.9, 3H), 1.56 (ddt, J=18.7,13.2, 8.6, 2H), 1.28 (ddt, J=13.0, 9.8, 6.4, 1H), 0.93 (d, J=6.5, 3H),0.90 (d, J=6.4, 3H); MS (ESI+) m/z 476 (M+H)⁺.

Example 498(3R)-3-(dimethylamino)-4-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide

The title compound was prepared by substituting(3R)-3-amino-4-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamidefrom Example 388 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand formaldehyde for pivalaldehyde in the procedure described in Example281: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.47-8.49 (m, 1H), 8.37-8.38(bs, 1H), 8.20 (d, J=7.9 Hz, 1H), 7.91 (d, J=7.9 Hz, 1H), 7.71 (t, J=7.8Hz, 1H), 4.24 (p, J=6.4 Hz, 1H), 3.85 (dd, J=9.9, 2.4 Hz, 1H), 3.13-3.18(m, 2H), 2.95-3.01 (m, 2H), 2.48-2.55 (m, 3H), 2.23 (s, 6H), 2.20 (dd,J=15.1, 5.8 Hz, 1H), 1.95 (dq, J=11.8, 5.9 Hz, 1H), 1.80-1.88 (m, 1H),1.63-1.73 (m, 1H), 1.51-1.59 (m, 1H), 1.29 (ddt, J=9.4, 12.7, 6.4 Hz,1H), 0.98 (d, J=6.6 Hz, 3H), 0.92 (d, J=6.6 Hz, 3H); MS (ESI+) m/z 476(M+H)⁺.

Example 499N²-cyclopropyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand (1-ethoxycyclopropoxy)trimethylsilane for pivalaldehyde in theprocedure described in Example 281: ¹FINMR (500 MHz, pyridine-d₅) δ ppm8.54-8.56 (m, 1H), 8.14-8.16 (m, 2H), 7.89-7.92 (m, 2H), 4.27-4.31 (m,1H), 3.89 (dd, J=9.9, 2.6 Hz, 1H), 3.44 (t, J=6.0 Hz, 1H), 3.15-3.21 (m,2H), 2.99 (dd, J=9.6, 6.9 Hz, 1H), 2.53-2.66 (m, 2H), 2.24-2.28 (m, 1H),1.94-2.00 (m, 1H), 1.81-1.90 (m, 3H), 1.56-1.64 (m, 1H), 1.51 (dd,J=13.9, 6.6 Hz, 1H), 1.31 (ddt, J=9.7, 12.8, 6.4 Hz, 1H), 0.96 (s, 9H),0.46-0.51 (m, 1H), 0.30-0.45 (m, 3H); MS (ESI+) m/z 502 (M+H)⁺.

Example 500N²,N²-dicyclopropyl-4-methyl-N¹-(3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-}[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand (1-ethoxycyclopropoxy)trimethylsilane for pivalaldehyde in theprocedure described in Example 281: ¹FINMR (500 MHz, pyridine-d₅) δ ppm8.13-8.15 (m, 2H), 7.88-7.90 (m, 2H), 7.83-7.85 (m, 1H), 4.21 (dq,J=9.1, 6.2 Hz, 1H), 3.89 (dd, J=9.9, 2.2 Hz, 1H), 3.53 (dd, J=9.1, 1.8Hz, 1H), 3.16 (dd, J=9.9, 7.4 Hz, 2H), 2.96 (dd, J=9.6, 6.7 Hz, 1H),2.62 (dd, J=13.6, 9.3 Hz, 1H), 2.46-2.57 (m, 2H), 2.23-2.28 (m, 2H),1.88-1.94 (m, 1H), 1.76-1.82 (m, 1H), 1.65 (dd, J=13.6, 1.9 Hz, 1H),1.48-1.58 (m, 1H), 1.23-1.32 (m, 1H), 1.00 (s, 9H), 0.44-0.56 (m, 8H);MS (ESI+) m/z 542 (M+H)⁺.

Example 501N²-cyclopentyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand cyclopentanone for pivalaldehyde in the procedure described inExample 281: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.34-8.36 (m, 1H),8.13-8.16 (m, 2H), 7.89-7.91 (m, 2H), 4.23-4.29 (m, 1H), 3.88 (dd,J=10.0, 2.1 Hz, 1H), 3.34 (dd, J=7.4, 4.3 Hz, 1H), 3.10-3.22 (m, 3H),2.96-3.00 (m, 1H), 2.56-2.58 (m, 2H), 1.90-2.02 (m, 1H), 1.81-1.89 (m,2H), 1.70-1.84 (m, 1H), 1.55-1.75 (m, 5H), 1.36-1.54 (m, 5H), 1.24-1.35(m, 1H), 0.99 (s, 9H); MS (ESI+) m/z 530 (M+H)⁺.

Example 502N²-cyclohexyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand cyclohexanone for pivalaldehyde in the procedure described inExample 281: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.25-8.27 (m, 1H),8.13-8.16 (m, 2H), 7.89-7.91 (m, 2H), 4.22-4.28 (m, 1H), 3.86 (dd,J=9.9, 2.1 Hz, 1H), 3.42 (dd, J=7.6, 3.8 Hz, 1H), 3.12-3.22 (m, 2H),2.99 (dd, J=9.6, 6.4 Hz, 1H), 2.55-2.65 (m, 2H), 2.47-2.53 (m, 1H),1.91-2.01 (m, 1H), 1.78-1.91 (m, 4H), 1.65-1.76 (m, 1H), 1.60-1.67 (m,2H), 1.54-1.60 (m, 1H), 1.45-1.52 (m, 2H), 1.28-1.37 (m, 1H), 1.03-1.25(m, 5H), 1.00 (s, 9H); MS (ESI+) m/z 544 (M+H)⁺.

Example 503N²-(1-ethylpropyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand pentan-3-one for pivalaldehyde in the procedure described in Example281: ¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.25-8.27 (m, 1H), 8.13-8.16(m, 2H), 7.89-7.92 (m, 2H), 4.21-4.27 (m, 1H), 3.85 (d, J=11.2 Hz, 1H),3.40 (dd, J=7.0, 4.7 Hz, 1H), 3.18 (dd, J=10.2, 2.7 Hz, 2H), 2.97-3.02(m, 1H), 2.55-2.59 (m, 2H), 2.45 (p, J=5.7 Hz, 1H), 1.96 (dt, J=11.8,5.9 Hz, 1H), 1.86 (dd, J=14.1, 4.5 Hz, 1H), 1.78-1.89 (m, 1H), 1.53-1.81(m, 1H), 1.26-1.63 (m, 7H), 1.00 (s, 9H), 0.92 (t, J=7.4 Hz, 3H), 0.84(t, J=7.4 Hz, 3H); MS (ESI+) m/z 532 (M+H)⁺.

Example 504N²-cyclobutyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand cyclobutanone for pivalaldehyde in the procedure described inExample 281: ¹H NMR (501 MHz, pyridine-d₅) δ ppm 8.30-8.33 (m, 1H),8.13-8.16 (m, 2H), 7.89-7.91 (m, 2H), 4.21-4.27 (m, 1H), 3.88 (dd,J=10.0, 2.0 Hz, 1H), 3.31 (t, J=6.5 Hz, 2H), 3.15-3.20 (m, 2H),2.96-2.99 (m, 1H), 2.56-2.59 (m, 2H), 2.08-2.21 (m, 2H), 2.01-2.16 (m,1H), 1.92-1.99 (m, 1H), 1.88 (dd, J=14.1, 5.3 Hz, 1H), 1.82-1.86 (m,2H), 1.70-1.78 (m, 1H), 1.48-1.64 (m, 4H), 1.27-1.34 (m, 1H), 0.98 (s,9H); MS (ESI+) m/z 516 (M+H)⁻.

Example 5054-methyl-N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 419 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 281: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.20-8.22 (m, 1H), 8.14-8.16 (m, 2H), 7.89-7.92 (m, 2H), 4.21-4.28(m, 1H), 3.86 (dd, J=10.0, 2.8 Hz, 1H), 3.23 (dd, J=7.9, 4.0 Hz, 1H),3.17-3.21 (m, 2H), 3.00 (dd, J=9.7, 7.2 Hz, 1H), 2.52-2.58 (m, 2H), 2.39(d, J=11.1 Hz, 1H), 2.31 (d, J=11.1 Hz, 1H), 1.94-2.01 (m, 1H), 1.87(dd, J=14.1, 4.2 Hz, 1H), 1.83-1.89 (m, 2H), 1.52-1.61 (m, 1H), 1.50(dd, J=14.0, 7.8 Hz, 1H), 1.29-1.36 (m, 1H), 0.99 (s, 9H), 0.92 (s, 9H);MS (ESI+) m/z 532 (M+H)⁺.

Example 506N²-cyclopentyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substitutingN¹-((3aR,4S,6aS)-2-}[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamidefrom Example 422 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand cyclopentanone for pivalaldehyde in the procedure described inExample 281: ¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.30-8.33 (m, 1H),8.12-8.15 (m, 2H), 7.88-7.91 (m, 2H), 4.21-4.29 (m, 1H), 3.86 (d, J=11.3Hz, 1H), 3.27 (t, J=6.5 Hz, 1H), 3.12-3.21 (m, 3H), 2.96-3.01 (m, 1H),2.50-2.64 (m, 2H), 1.89-2.18 (m, 2H), 1.24-1.90 (m, 15H), 0.86 (t, J=7.3Hz, 3H); MS (ESI+) m/z 502 (M+H)⁺.

Example 507N²-cyclohexyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substitutingN¹-((3aR,4S,6aS)-2-}[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamidefrom Example 422 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand cyclohexanone for pivalaldehyde in the procedure described inExample 281: ¹H NMR (400 MHz, pyridine-d₅) δ ppm 8.25-8.27 (m, 1H),8.12-8.15 (m, 2H), 7.89-7.92 (m, 2H), 4.20-4.28 (m, 1H), 3.84 (dd,J=10.0, 2.4 Hz, 1H), 3.35 (dd, J=7.6, 5.4 Hz, 1H), 3.14-3.21 (m, 2H),2.96-3.01 (m, 1H), 2.51-2.65 (m, 2H), 2.40-2.51 (m, 1H), 1.75-2.01 (m,6H), 1.44-1.67 (m, 7H), 1.26-1.38 (m, 1H), 1.04-1.24 (m, 5H), 0.87 (t,J=7.3 Hz, 3H); MS (ESI+) m/z 516 (M+H)⁻.

Example 508N²-cyclopentyl-N¹-[(3aR,4S,6aS)-2-(N-cyclopentyl-4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-L-leucinamide

The title compound was prepared by substituting4-methyl-N¹-[(3aR,4S,6aS)-2-(4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-leucinamidefrom Example 464 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand cyclopentanone for pivalaldehyde in the procedure described inExample 281: ¹H NMR (400 MHz, pyridine-d₅) δ ppm 7.73 (d, J=5.6, 1H),4.31-4.20 (m, 1H), 3.83-3.71 (m, 2H), 3.72-3.49 (m, 3H), 3.31 (dd,J=7.2, 4.4, 1H), 3.19-3.07 (m, 2H), 2.78-2.63 (m, 2H), 2.12 (dt, J=12.6,6.4, 1H), 1.96 (tt, J=5.7, 5.0, 1H), 1.86-1.59 (m, 12H), 1.57-1.33 (m,12H), 1.04 (s, 9H), 0.99 (s, 9H); MS (ESI+) m/z 517 (M+H)⁺.

Example 509N²,N²-dimethyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingN²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 164 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand formaldehyde for pivalaldehyde in the procedure described in Example281: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.17-8.20 (m, 1H), 7.76-7.77(bs, 1H), 7.63-7.65 (m, 2H), 7.50 (t, J=7.7 Hz, 1H), 4.48-4.54 (m, 1H),3.74 (d, J=13.1 Hz, 1H), 3.30 (d, J=13.1 Hz, 1H), 3.05 (dd, J=9.0, 5.0Hz, 1H), 2.74-2.78 (m, 1H), 2.68-2.74 (m, 1H), 2.42-2.47 (m, 1H), 2.33(s, 7H), 2.21 (dd, J=9.4, 7.2 Hz, 1H), 2.14 (dd, J=9.0, 7.5 Hz, 1H),1.76-1.89 (m, 3H), 1.67-1.74 (m, 1H), 1.53-1.61 (m, 2H), 1.21-1.28 (m,1H), 0.96 (d, J=6.6 Hz, 3H), 0.94 (d, J=6.7 Hz, 3H); MS (ESI−) m/z 424(M−H)⁻.

Example 510N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-N²-neopentyl-L-leucinamide

The title compound was prepared by substitutingN¹-{(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamidefrom Example 165 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-aminein the procedure described in Example 281: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.15-8.17 (m, 1H), 7.43-7.46 (m, 2H), 7.37 (t, J=7.5 Hz, 2H), 7.28(t, J=7.3 Hz, 1H), 4.39-4.45 (m, 1H), 3.61 (d, J=13.1 Hz, 1H), 3.46 (d,J=13.1 Hz, 1H), 3.27 (dd, J=7.9, 6.0 Hz, 1H), 2.85 (dd, J=8.9, 2.0 Hz,1H), 2.52-2.58 (m, 2H), 2.46-2.52 (m, 2H), 2.45 (s, 3H), 2.43 (d, J=13.8Hz, 1H), 2.29-2.36 (m, 2H), 2.12 (dq, J=12.2, 6.1 Hz, 1H), 1.82-2.02 (m,3H), 1.53-1.63 (m, 2H), 1.37-1.47 (m, 1H), 0.95 (d, J=6.6 Hz, 3H), 0.94(d, J=6.6 Hz, 3H), 0.90 (s, 9H); MS (ESI+) m/z 414 (M+H)⁻.

Example 511N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(3,3-dimethylbutyl)-N²-methyl-L-leucinamide

The title compound was prepared by substitutingN¹-{(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamidefrom Example 165 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand 3,3-dimethylbutanal for pivalaldehyde in the procedure described inExample 281: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.04-8.06 (m, 1H),7.43-7.46 (m, 2H), 7.37 (t, J=7.5 Hz, 2H), 7.28 (t, J=7.4 Hz, 1H),4.42-4.48 (m, 1H), 3.63 (d, J=13.1 Hz, 1H), 3.46 (d, J=13.1 Hz, 1H),3.33 (dd, J=8.2, 5.3 Hz, 1H), 2.89-2.92 (m, 1H), 2.55-2.66 (m, 4H),2.44-2.48 (m, 1H), 2.39 (s, 3H), 2.36-2.39 (m, 1H), 2.27 (dd, J=8.8, 6.1Hz, 1H), 2.12 (dq, J=11.9, 6.0 Hz, 1H), 1.83-1.99 (m, 3H), 1.56-1.63 (m,2H), 1.40-1.48 (m, 3H), 0.95 (d, J=6.3 Hz, 6H), 0.89 (s, 9H); MS (ESI+)m/z 428 (M+H)⁻.

Example 512N²,N²-dimethyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide

The title compound was prepared by substitutingN¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamidefrom Example 184 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand formaldehyde for pivalaldehyde in the procedure described in Example281: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.38-8.39 (bs, 1H), 8.18-8.25(m, 2H), 7.90-7.92 (m, 1H), 7.72 (t, J=7.8 Hz, 1H), 4.20-4.25 (m, 1H),3.88 (d, J=10.8 Hz, 1H), 3.18 (dd, J=9.8, 2.5 Hz, 1H), 3.11-3.18 (m,2H), 2.95-2.98 (m, 1H), 2.51-2.60 (m, 2H), 2.32 (s, 6H), 1.90-1.97 (m,1H), 1.75-1.86 (m, 3H), 1.49-1.60 (m, 2H), 1.24-1.32 (m, 1H), 0.90 (d,J=6.4 Hz, 3H), 0.90 (d, J=6.4 Hz, 3H); MS (ESI+) m/z 476 (M+H)⁺.

Example 513N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(4-fluorobenzyl)-N²-methyl-L-leucinamide

The title compound was prepared by substitutingN¹-{(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamidefrom Example 165 for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand 4-fluorobenzaldehyde for pivalaldehyde in the procedure described inExample 281: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.25-8.27 (m, 1H),7.36-7.46 (m, 6H), 7.28 (t, J=7.3 Hz, 1H), 7.13-7.17 (m, 2H), 4.45-4.50(m, 1H), 3.86 (d, J=13.7 Hz, 1H), 3.76 (d, J=13.7 Hz, 1H), 3.63 (d,J=13.1 Hz, 1H), 3.47 (d, J=13.1 Hz, 1H), 3.41 (dd, J=7.7, 6.2 Hz, 1H),2.91 (dd, J=9.0, 2.7 Hz, 1H), 2.53-2.64 (m, 2H), 2.49 (dd, J=8.8, 7.0Hz, 1H), 2.34-2.39 (m, 1H), 2.36 (s, 3H), 2.30 (dd, J=8.9, 6.9 Hz, 1H),2.10-2.22 (m, 1H), 1.84-1.94 (m, 3H), 1.67-1.76 (m, 1H), 1.59-1.67 (m,1H), 1.39-1.46 (m, 1H), 0.93 (d, J=6.8 Hz, 3H), 0.91 (d, J=6.6 Hz, 3H);MS (ESI+) m/z 452 (M+H)⁺.

Example 514(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-(methylsulfonyl)piperidine-2-carboxamide

The title compound was prepared by substituting(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]piperidine-2-carboxamidefrom Example 350 for (S)-tert-butyl 2-amino-4-methylpentanoate in theprocedure described in Example 242 Step A: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.54 (d, J=7.2, 1H), 7.43 (d, J=7.2, 2H), 7.37 (dd, J=10.2, 4.7,2H), 7.28 (t, J=7.2, 1H), 4.89 (d, J=3.1, 1H), 4.40-4.31 (m, 1H),3.90-3.77 (m, 2H), 3.57 (d, J=13.1, 1H), 3.45 (d, J=13.1, 1H), 3.15 (s,3H), 2.79 (dd, J=9.0, 2.1, 1H), 2.54-2.41 (m, 2H), 2.40-2.31 (m, 2H),2.24 (dd, J=8.8, 6.9, 1H), 2.20-2.14 (m, 1H), 2.09 (dq, J=12.0, 6.0,1H), 1.88-1.78 (m, 1H), 1.67-1.53 (m, 4H), 1.51-1.34 (m, 3H); MS (ESI+)m/z 406 (M+H)³⁰ .

Example 515(3R)-4-methyl-3-[(methylsulfonyl)amino]-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide

The title compound was prepared by substituting(3R)-3-amino-4-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamidefrom Example 388 for (S)-tent-butyl 2-amino-4-methylpentanoate in theprocedure described in Example 242 Step A: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.77 (d, J=6.6, 1H), 8.42-8.34 (m, 2H), 8.20 (d, J=7.8, 1H), 7.91(d, J=7.8, 1H), 7.72 (t, J=7.9, 1H), 4.21 (dq, J=13.4, 6.1, 2H), 3.85(dd, J=9.9, 1.7, 1H), 3.23 (s, 3H), 3.17 (dd, J=9.6, 1.9, 1H), 3.11 (dd,J=9.8, 7.3, 1H), 2.93 (dd, J=9.5, 7.1, 1H), 2.76-2.65 (m, 2H), 2.56-2.45(m, 2H), 2.11 (dq, J=13.5, 6.8, 1H), 1.95 (td, J=12.2, 6.3, 1H), 1.83(dt, J=12.5, 6.4, 1H), 1.55 (ddd, J=15.9, 12.3, 9.1, 1H), 1.28 (ddd,J=12.8, 9.4, 6.3, 1H), 1.02 (d, J=6.8, 3H), 0.97 (d, J=6.8, 3H); MS(ESI+) m/z 524 (M+H)⁺.

Example 516N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

Step A: tert-Butyl(S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamatewas prepared by substituting(3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 156 Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.67 (d, J=7.2, 1H), 7.96 (d, J=8.4, 1H), 7.75 (s, 1H), 7.61 (s, 1H),7.56 (s, 1H), 7.45 (dd, J=14.3, 6.7, 1H), 4.75-4.66 (m, 1H), 4.45-4.36(m, 1H), 3.59 (d, J=13.5, 1H), 3.46 (d, J=13.6, 1H), 2.81 (dd, J=9.1,2.3, 1H), 2.62-2.56 (m, 1H), 2.56-2.49 (m, 1H), 2.49-2.43 (m, 1H), 2.27(d, J=5.3, 2H), 2.03 (td, J=11.6, 5.7, 1H), 1.94-1.78 (m, 4H), 1.65-1.56(m, 1H), 1.50 (s, 9H), 1.35 (dt, J=13.6, 5.7, 1H), 0.86 (dd, J=11.2,5.7, 6H); MS (ESI+) m/z 498 (M+H)⁻.

Step B:N¹-{(3aR,4S,6aS)-2-[3-(Trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidewas prepared by substituting tert-butyl(S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamatefrom Step A for tert-butyl(5)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348:

¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.31 (d, J=7.5, 1H), 7.76 (s, 1H),7.62 (d, J=7.9, 1H), 7.56 (s, 1H), 7.46 (t, J=7.7, 1H), 4.44-4.33 (m,1H), 3.63-3.56 (m, 2H), 3.47 (d, J=13.5, 1H), 2.83 (dd, J=9.0, 2.3, 1H),2.58-2.46 (m, 2H), 2.44-2.39 (m, 1H), 2.32 (dd, J=9.0, 2.6, 1H),2.28-2.23 (m, 1H), 2.08 (td, J=11.9, 5.9, 2H), 1.95-1.81 (m, 4H),1.62-1.51 (m, 2H), 1.43-1.34 (m, 1H), 0.90 (d, J=6.3, 3H), 0.85 (d,J=6.2, 3H); MS (ESI+) m/z 398 (M+H)⁺.

Step C: The title compound was prepared by substitutingN¹-{(3aR,4S,6aS)-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Step B for (S)-tert-butyl 2-amino-4-methylpentanoate in theprocedure described in Example 242 Step A: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.36 (d, J=8.9, 1H), 9.24 (d, J=7.3, 1H), 7.3, 1H), 7.78 (s, 1H),7.62 (d, J=8.2, 2H), 7.46 (t, J=7.7, 1H), 4.48 (qd, J=13.1, 7.5, 2H),3.62 (d, J=13.5, 1H), 3.50 (d, J=13.5, 1H), 3.20 (s, 3H), 2.86 (dd,J=9.1, 2.9, 1H), 2.64 (dt, J=8.4, 6.1, 1H), 2.60-2.53 (m, 1H), 2.49 (dd,J=8.8, 7.5, 1H), 2.34-2.27 (m, 2H), 2.15-2.09 (m, 1H), 2.04-1.95 (m,1H), 1.90 (ddd, J=14.5, 9.2, 4.2, 2H), 1.78 (ddd, J=13.9, 8.5, 5.7, 1H),1.65 (dt, J=19.1, 7.2, 1H), 1.41 (dq, J=13.9, 6.1, 1H), 0.83 (d, J=6.7,3H), 0.81 (d, J=6.7, 3H), 0.81 (d, J=6.6, 3H); MS (ESI+) m/z 476 (M+H)⁺.

Example 517N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide

Step A: tert-Butyl(R)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamatewas prepared by substituting(3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 156 Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine andN-(tert-butoxycarbonyl)-D-leucine for N-(tent-butoxycarbonyl)-L-leucinein the procedure described in Example 221:

¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.70 (d, J=7.4, 1H), 7.95 (d, J=8.4,1H), 7.73 (s, 1H), 7.59 (s, 1H), 7.56 (s, 1H), 7.45 (t, J=7.7, 1H), 4.72(br s, 1H), 4.40 (br s, 1H), 3.57 (d, J=13.4, 1H), 3.42 (d, J=13.6, 1H),2.73 (d, J=9.0, 1H), 2.50 (s, 2H), 2.39-2.39-2.32 (m, 1H), 2.25 (dd,J=12.9, 7.0, 2H), 2.11 (dq, J=12.3, 6.2, 1H), 1.94-1.78 (m, 4H), 1.66(dq, J=21.9, 7.3, 1H), 1.50 (s, 9H), 1.39 (d, J=7.0, 1H), 0.86 (dd,J=10.2, 5.6, 6H); MS (ESI+) m/z 498 (M+H)⁺.

Step B:N¹-{(3aR,4S,6aS)-2-[3-(Trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamidewas prepared by substituting tert-butyl(R)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamatefrom Step A for tert-butyl(S)-1-[3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate in the procedure described in Example 348:

¹H NMR (500 MHz, pyridine-d₅) δ ppm 8.33 (d, J=7.6, 1H), 7.75 (s, 1H),7.62 (s, 1H), 7.56 (s, 1H), 7.46 (t, J=7.7, 1H), 4.43-4.34 (m, 1H),3.64-3.56 (m, 2H), 3.46 (d, J=13.5, 1H), 2.82 (dd, J=9.0, 2.5, 1H),2.59-2.45 (m, 2H), 2.44-2.39 (m, 1H), 2.31 (dd, J=9.0, 2.8 1H), 2.25(dd, J=8.8, 7.1, 1H), 2.09 (td, J=11.9, 5.9, 2H), 1.88 (tdd, J=13.5,8.9, 6.0, 4H), 1.57 (tt, J=18.0, 6.6, 2H), 1.44-1.34 (m, 1H), 0.90 (d,J=6.4, 3H), 0.85 (d, J=6.3, 3H); MS (ESI+) m/z 398 (M+H)⁺.

Step C: The title compound was prepared by substitutingN¹-{(3aR,4S,6aS)-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Step B for (S)-tert-butyl 2-amino-4-methylpentanoate in theprocedure described in Example 242 Step A: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.35 (d, J=8.5, 1H), 9.24 (d, J=7.2, 1H), 7.76 (s, 1H), 7.63-7.56(m, 2H), 7.45 (dd, J=14.6, 7.0, 1H), 4.47 (dt, J=13.0, 8.2, 2H), 3.59(d, J=13.6, 1H), 3.48 (d, J=13.5, 1H), 3.18 (s, 3H), 2.85 (dd, J=9.1,2.5, 1H), 2.63-2.49 (m, 2H), 2.39 (dd, J=9.0, 7.1, 1H), 2.33 (dd, J=9.0,2.6, 1H), 2.29-2.22 (m, 1H), 2.29-2.22 (m, 1H), 2.15 (dt, J=12.2, 6.1,1H), 2.04-1.95 (m, 1H), 1.94-1.84 (m, 2H), 1.81-1.66 (m, 2H), 1.43 (dt,J=21.0, 6.4, 1H), 0.85-0.79 (m, 6H); MS (ESI+) m/z 476 (M+H)⁺.

Example 518N²-ethyl-N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingN²-ethyl-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 366 for (S)-tert-butyl 2-amino-4-methylpentanoate in theprocedure described in Example 242 Step A: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.83 (d, J=7.3, 1H), 7.77 (s, 1H), 7.63-7.55 (m, 2H), 7.45 (t,J=7.7, 1H), 4.71 (t, J=6.9, 1H), 4.43-4.34 (m, 1H), 3,93 (td, J=13.9,6.8, 1H), 3.63-3.45 (m, 3H), 3.15 (d, J=5.3, 3H), 2.89-2.81 (m, 1H),2.54 (ddd, J=29.4, 12.7, 9.2, 2H), 2.46-2.42 (m, 1H), 2.39-2.30 (m, 1H),2.24 (dd, J=17.4, 8.7, 1H), 2.08 (ddt, J=17.6, 11.7, 5.8, 1H), 1.90-1.75(m, 4H), 1.68-1.53 (m, 1H), 1.40 (dd, J=12.7, 6.4, 1H), 1.36-1.30 (m,3H), 0.85 (d, J=5.4, 3H), 0.82 (t, J=5.3, 3H); MS (ESI+) m/z 502 (M+H)⁺.

Example 5194-methyl-N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

Step A: tert-Butyl(S)-1-((3aR,4S,6aS)-2-[4-trifluromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamatewas prepared by substituting tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamatefrom Example 226 for(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-((1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamidein the procedure described in Example 303: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.60 (d, J=7.5, 1H), 8.12 (d, J=8.9, 1H), 7.65 (d, J=8.0, 2H),7.51 (d, J=8.0, 2H), 4.75 (td, J=8.4, 5.1, 1H), 4.45-4.37 (m, 1H), 3.56(d, J=13.8, 1H), 3.46 (d, J=13.7, 1H), 2.86 (dd, J=9.0, 2.2, 1H),2.62-2.46 (m, 2H), 2.42-2.36 (m, 1H), 2.30 (dd, J=8.7, 2.2, 1H),2.26-2.20 (m, 1H), 2.19-2.12 (m, 1H), 2.04 (td, J=11.7, 5.7, 1H),1.89-1.80 (m, 2H), 1.64-1.53 (m, 1H), 1.51 (s, 9H), 1.36 (dt, J=21.2,7.3, 1H), 0.98 (s, 9H); MS (ESI+) m/z 512 (M+H)⁺.

Step B:4-Methyl-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidewas prepared by substituting tert-butyl(S)-1-((3aR,4S,6aS)-2-[4-trifluromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamatefrom Step A for tert-butyl(S)-1-(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.31 (d, J=7.7, 1H), 7.65 (d, J=8.0, 2H), 7.52 (d, J=7.9, 2H),4.45-4.31 (m, 1H), 3.62-3.53 (m, 2H), 3.47 (d, J=13.9, 1H), 2.89 (d,J=8.4, 1H), 2.58-2.43 (m, 2H), 2.35 (t, J=7.6, 2H), 2.25-2.15 (m, 3H),2.10 (dt, J=11.7, 6.7, 2H), 1.87 (td, J=13.1, 6.6, 1H), 1.57 (dt,J=14.8, 7.7, 1H), 1.48-1.36 (m, 2H), 0.98 (s, 9H); MS (ESI+) m/z 412(M+H)⁺.

Step C: The title compound was prepared by substituting4-methyl-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Step B for (S)-tert-butyl 2-amino-4-methylpentanoate in theprocedure described in Example 242 Step A: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.55 (d, J=9.7, 1H), 9.30 (d, J=7.3, 1H), 7.66 (d, J=8.1, 2H),7.54 (d, J=8.0, 2H), 4.57-4.51 (m, 1H), 4.51-4.44 (m, 1H), 3.60 (d,J=13.8, 1H), 3.50 (d, J=13.8, 1H), 3.18 (s, 3H), 2.92 (dd, J=9.0, 2.5,1H), 2.67-2.61 (m, 1H), 2.58-2.50 (m, 1H), 2.43 (dd, J=8.9, 7.3, 1H),2.36 (dd, J=9.0, 2.6, 1H), 2.25 (dd, J=8.7, 7.5, 1H), 2.17-2.10 (m, 1H),2.03 (dd, J=14.1, 5.4, 1H), 1.95-1.85 (m, 2H), 1.64 (dtd, J=12.2, 8.1,5.8, 1H), 1.46-1.37 (m, 1H), 0.96 (s, 9H); MS (ESI+) m/z 490 (M+H)⁺.

Example 5203-methyl-N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-valinamide

Step A: tert-Butyl(S)-1-((3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamatewas prepared by substituting tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamatefrom Example 225 for(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamidein the procedure described in Example 303: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 7.72 (d, J=9.7, 1H), 7.66 (d, J=8.1, 2H), 7.52 (d, J=8.0, 2H),7.37 (d, J=3.1, 1H), 4.61 (d, J=9.8, 1H), 4.46-4.39 (m, 1H), 3.60 (d,J=13.7, 1H), 3.46 (d, J=13.7, 1H), 2.89 (dd, J=9.1, 2.5, 1H), 2.63-2.57(m, 1H), 2.57-2.50 (m, 1H), 2.46-2.41 (m, 1H), 2.35-2.29 (m, 1H),2.28-2.22 (m, 1H), 1.99 (dq, J=11.8, 5.7, 1H), 1.84 (td, J=12.7, 6.2,1H), 1.57-1.49 (m, 1H), 1.48 (s, 9H), 1.40-1.31 (m, 1H), 1.18 (s, 9H);MS (ESI+) m/z 498 (M+H)⁻.

Step B:3-Methyl-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-valinamidewas prepared by substituting tert-butyl(S)-1-((3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamatefrom Step A for tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.15-8.06 (m, 1H), 7.66 (d, J=8.1, 2H), 7.52 (d, J=8.0, 2H),4.47-4.40 (m, 1H), 3.59 (d, J=13.6, 1H), 3.46 (d, J=13.8, 1H), 3.27 (s,1H), 2.89-2.85 (m, 1H), 2.56-2.50 (m, 2H), 2.41-2.36 (m, 1H), 2.35-2.32(m, 1H), 2.26-2.21 (m, 1H), 2.19-2.12 (m, 2H), 2.11-2.02 (m, 1H),1.90-1.82 (m, 1H), 1.60-1.52 (m, 1H), 1.43-1.35 (m, 1H), 1.14 (s, 9H);MS (ESI+) m/z 398 (M+H)⁻.

Step C: The title compound was prepared by substituting3-methyl-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-valinamidefrom Step B for (S)-tert-butyl 2-amino-4-methylpentanoate in theprocedure described in Example 242 Step A: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.28 (d, J=10.4, 1H), 9.13 (d, J=7.4, 1H), 7.67 (d, J=8.1, 2H),7.55 (d, J=8.1, 2H), 4.54-4.46 (m, 1H), 4.19 (d, J=10.4, 1H), 3.64 (d,J=13.7, 1H), 3.50 (d, J=13.7, 1H), 3.13 (s, 3H), 2.92 (dd, J=9.0, 2.4,1H), 2.67-2.52 (m, 2H), 2.46 (dd, J=8.8, 7.1, 1H), 2.37 (dd, J=9.0, 2.5,1H), 2.30-2.23 (m, 1H), 2.09 (dq, J=11.7, 5.8, 1H), 1.94-1.83 (m, 1H),1.62-1.53 (m, 1H), 1.45-1.37 (m, 1H), 1.18 (s, 9H); MS (ESI+) m/z 476(M+H)⁺.

Example 521N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide

The title compound was prepared by substitutingN¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamidefrom Example 382 for (S)-tert-butyl 2-amino-4-methylpentanoate in theprocedure described in Example 242 Step A: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.42 (d, J=9.2, 1H), 9.10 (d, J=7.4, 1H), 7.66 (d, J=8.0, 2H),7.53 (d, J=8.0, 2H), 4.50-4.39 (m, 2H), 3.60 (d, J=13.7, 1H), 3.49 (d,J=13.7, 1H), 3.19 (s, 3H), 2.89 (dd, J=9.1, 2.4, 1H), 2.65-2.58 (m, 1H),2.58-2.51 (m, 1H), 2.46-2.40 (m, 1H), 2.35 (dd, J=9.0, 2.5, 1H),2.28-2.23 (m, 1H), 2.13 (dt, J=11.9, 6.0, 1H), 1.98 (tt, J=13.2, 6.5,1H), 1.94-1.83 (m, 2H), 1.63 (dt, J=19.4, 7.6, 1H), 1.58-1.47 (m, 2H),1.42 (dt, J=14.6, 6.3, 1H), 0.77 (t, J=7.4, 3H); MS (ESI+) m/z 462(M+H)⁺.

Example 522N²-(isopropylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingN¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 170 Step B for (S)-tert-butyl 2-amino-4-methylpentanoateand propane-2-sulfonylchloride for methanesulfonyl chloride in theprocedure described in Example 242 Step A: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.34 (d, J=9.2, 1H), 9.12 (d, J=7.4, 1H), 7.75 (d, J=12.2, 2H),7.61 (d, J=7.5, 1H), 7.45 (t, J=7.8, 1H), 4.50-4.41 (m, 2H), 3.58 (d,J=13.5, 1H), 3.51 (d, J=13.4, 1H), 3.38-3.31 (m, 1H), 2.89 (d, J=9.6,1H), 2.56 (qd, J=5.6, 1.6, 2H), 2.41-2.34 (m, 2H), 2.25 (dd, J=8.7, 6.7,1H), 2.19-2.12 (m, 1H), 2.06-1.97 (m, 1H), 1.95-1.86 (m, 3H), 1.79-1.66(m, 2H), 1.46 (d, J=6.8, 6H), 0.82 (d, J=6.5, 1H); MS (ESI+) m/z 504(M+H)⁺.

Example 523N²-(phenylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingN¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 170 Step B for (S)-tert-butyl 2-amino-4-methylpentanoateand benzenesulfonyl chloride for methanesulfonyl chloride in theprocedure described in Example 242 Step A: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 10.09-9.90 (m, 1H), 8.77 (d, J=7.3, 1H), 8.18 (dd, J=8.0, 1.5,2H), 7.78 (s, 1H), 7.62 (d, J=7.9, 1H), 7.51-7.34 (m, 5H), 4.36 (dd,J=9.4, 5.5, 1H), 4.16-4.08 (m, 1H), 3.59 (d, J=13.5, 1H), 3.49 (d,J=13.6, 1H), 2.60 (dd, J=9.1, 3.0, 1H), 2.51-2.42 (m, 1H), 2.33 (dd,J=8.9, 7.6, 1H), 2.27 (dd, J=11.1, 6.5, 2H), 2.24-2.17 (m, 1H), 2.05(td, J=12.1, 5.9, 1H), 1.98 (dd, J=13.8, 6.7, 1H), 1.88-1.79 (m, 2H),1.72 (ddd, J=13.7, 8.6, 5.4, 1H), 1.58 (dt, J=19.1, 7.0, 1H), 1.36 (dt,J=20.4, 6.2, 1H), 0.81 (d, J=6.7, 3H), 0.77 (d, J=6.5, 3H); MS (ESI+)m/z 538 (M+H)⁺.

Example 524N²-(cyclopentylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide

The title compound was prepared by substitutingN¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 170 Step B for (S)-tert-butyl 2-amino-4-methylpentanoateand cyclopentanesulfonyl chloride for methanesulfonyl chloride in theprocedure described in Example 242 Step A: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.30 (d, J=9.6, 1H), 9.12 (d, J=7.5, 1H), 7.76 (d, J=15.6, 2H),7.45 (dd, J=17.4, 9.7, 2H), 4.53-4.44 (m, 2H), 3.59 (d, J=13.4, 1H),3.53 (d, J=13.7, 1H), 2.91 (d, J=8.0, 1H), 2.60-2.54 (m, 2H), 2.39 (t,J=9.0, 2H), 2.34-2.10 (m, 6H), 2.08-1.99 (m, 2H), 1.96-1.85 (m, 3H),1.79-1.63 (m, 3H), 1.49-1.35 (m, 3H), 0.82 (d, J=6.6, 6H); MS (ESI+) m/z530 (M+H)⁺.

Example 525 Isopropyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate

The title compound was prepared by substituting4-methyl-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamidefrom Example 519 Step B for (S)-tert-butyl 2-amino-4-methylpentanoateand isopropyl carbonochloridate for methanesulfonyl chloride in theprocedure described in Example 242 Step A: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.38 (d, J=9.0, 1H), 7.65 (d, J=8.1, 2H), 7.51 (d, J=8.0, 2H),5.08 (dt, J=12.8, 6.5, 1H), 4.81 (td, J=8.5, 5.3, 1H), 4.46-4.38 (m,1H), 3.57 (d, J=13.7, 1H), 3.46 (d, J=13.8, 1H), 2.88 (dd, J=8.8, 1.7,1H), 2.63-2.54 (m, 1H), 2.49 (tt, J=4.3, 3.3, 1H), 2.43-2.36 (m, 1H),2.31 (dd, J=8.9, 2.5, 1H), 2.25-2.21 (m, 1H), 2.21-2.17 (m, 1H), 2.16(d, J=4.8, 1H), 2.10-1.99 (m, 1H), 1.90-1.77 (m, 2H), 1.59 (ddd, J=14.7,12.6, 7.8, 1H), 1.41-1.32 (m, 1H), 1.23 (d, J=6.2, 3H), 1.14 (d, J=6.2,3H), 0.98 (s, 9H); MS (ESI+) m/z 498 (M+H)⁻.

Example 526 Isopropyl(S)-3,3-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-ylcarbamate

The title compound was prepared by substituting3-methyl-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-valinamidefrom Example 520 Step B for (S)-tert-butyl 2-amino-4-methylpentanoateand isopropyl carbonochloridate for methanesulfonyl chloride in theprocedure described in Example 242 Step A: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.84 (d, J=7.3, 1H), 8.05 (d, J=9.6, 1H), 7.66 (d, J=8.1, 2H),7.52 (d, J=8.0, 2H), 5.06 (dt, J=12.6, 6.3, 1H), 4.67 (d, J=9.8, 1H),4.44 (p, J=7.3, 1H), 3.61 (d, J=13.8, 1H), 3.47 (d, J=13.7, 1H), 2.89(dd, J=9.0, 2.5, 1H), 2.66-2.58 (m, 1H), 2.57-2.50 (m, 1H), 2.49-2.41(m, 1H), 2.29 (dt, J=15.8, 7.5, 2H), 2.00 (td, J=11.5, 5.3, 1H), 1.85(dt, J=20.3, 6.6, 1H), 1.54 (dt, J=15.1, 7.3, 1H), 1.41-1.30 (m, 1H),1.24 (d, J=6.2, 3H), 1.19 (s, 9H), 1.12 (d, J=6.0, 3H); MS (ESI+) m/z484 (M+H)⁺.

Example 527 Cyclopentyl(S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate

The title compound was prepared by substitutingN¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamidefrom Example 382 for (S)-tert-butyl 2-amino-4-methylpentanoate andcyclopentyl carbonochloridate for methanesulfonyl chloride in theprocedure described in Example 242 Step A: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.76 (d, J=1.7, 1H), 8.22 (d, J=8.4, 1H), 7.65 (d, J=8.1, 2H),7.51 (d, J=7.9, 2H), 5.32-5.24 (m, 1H), 4.71 (dd, J=14.3, 7.9, 1H),4.49-4.39 (m, 1H), 3.57 (d, J=13.7, 1H), 3.46 (d, J=14.0, 1H), 2.87 (dd,J=8.8, 1.7, 1H), 2.63-2.50 (m, 2H), 2.41 (dd, J=8.6, 7.5, 1H), 2.31 (dd,J=8.0, 1.8, 1H), 2.27-2.20 (m, 1H), 2.12-198 (m, 2H), 1.93-1.82 (m, 2H),1.81-1.73 (m, 2H), 1.73-1.65 (m, 2H), 1.65-1.55 (m, 3H), 1.54-1.45 (m,2H), 1.45-1.31 (m, 3H), 0.81 (t, J=7.4, 3H); MS (ESI+) m/z 496 (M+H)⁺.

Example 528N²-(2,2-dimethylpropanoyl)-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide

The title compound was prepared by substitutingN¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamidefrom Example 382 for (S)-tert-butyl 2-amino-4-methylpentanoate andpivaloyl chloride for methanesulfonyl chloride in the proceduredescribed in Example 242 Step A: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.70 (d, J=7.6, 1H), 7.72 (d, J=7.9, 1H), 7.65 (d, J=8.0, 2H), 7.51 (d,J=8.0, 2H), 4.45-4.36 (m, 1H), 3.57 (d, J=13.9, 1H), 3.47 (d, J=13.8,1H), 2.85 (dd, J=9.1, 2.0, 1H), 2.60-2.51 (m, 2H), 2.42 (dd, J=8.8, 6.9,1H), 2.32 (dd, J=8.9, 2.0, 1H), 2.28-2.23 (m, 1H), 2.06 (dq, J=12.1,6.0, 1H), 1.97 (dq, J=9.4, 6.4, 1H), 1.90-1.75 (m, 2H), 1.59 (dt,J=14.2, 7.3, 1H), 1.51-1.37 (m, 3H), 1.36 (s, 1H), 1.31 (s, 9H), 0.79(t, J=7.4, 3H); MS (ESI+) m/z 468 (M+H)⁺.

Example 529 Tert-butyl(S)-1-((3aR,4S,6aS)-2-(3-chloro-4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 313 Step A for(S)—N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 3-chloro-4-fluorobenzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (300 MHz, CDCl₃) ppm 7.88 (dd, J=6.7,2.2 Hz, 1H), 7.70 (ddd, J=8.6, 4.4, 2.2 Hz, 1H), 7.26-7.33 (m, 1H),5.73-6.40 (m, 1H), 4.43 (d, J=4.3 Hz, 1H), 3.85-3.95 (m, 1H), 3.40-3.52(m, 1H), 3.09 (dd, J=9.6, 3.2 Hz, 1H), 3.05 (dd, J=10.1, 8.3 Hz, 1H),2.97 (dd, J=9.6, 7.4 Hz, 1H), 2.73 (s, 3H), 2.63-2.76 (m, 2H), 2.32-2.42(m, 1H), 1.76-2.09 (m, 3H), 1.58-1.72 (m, 1H), 1.46 (s, 9H), 1.19-1.34(m, 3H), 0.94 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 532 (M+H)⁺.

Example 530 Tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(pyridin-3-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 313 Step A for(S)—N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand pyridine-3-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (300 MHz, CDCl₃) δ ppm 9.01-9.04 (bs,1H), 8.80-8.85 (bs, 1H), 8.09 (ddd, J=8.0, 2.2, 1.7 Hz, 1H), 7.49 (dd,J=8.0, 4.8 Hz, 1H), 5.78-6.33 (m, 1H), 4.32-4.52 (m, 1H), 3.84-3.95 (m,1H), 3.40-3.52 (m, 1H), 3.05-3.15 (m, 2H), 3.02 (dd, J=9.7, 7.4 Hz, 1H),2.73 (s, 3H), 2.61-2.75 (m, 1H), 2.33-2.50 (m, 1H), 1.77-2.07 (m, 3H),1.53-1.71 (m, 2H), 1.46 (s, 9H), 1.18-1.32 (m, 3H), 0.94 (t, J=7.3 Hz,3H); MS (ESI+) m/z 481 (M+H)⁻.

Example 531 Tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(thiophen-2-ylsulfonyl)octahydrocyclopenta[e]pyrrol-4-ylamino)pentan-2-yl)carbamate

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 313 Step A for(S)—N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand thiophene-2-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: ¹H NMR (300 MHz, CDCl₃) δ ppm 7.62 (dd, J=5.0,1.3 Hz, 1H), 7.56 (dd, J=3.7, 1.3 Hz, 1H), 7.16 (dd, J=5.0, 3.7 Hz, 1H),5.75-6.30 (m, 1H), 4.33-4.53 (m, 1H), 3.88-3.97 (m, 1H), 3.37 (dd,J=10.2, 3.6 Hz, 1H), 3.04-3.20 (m, 3H), 2.73 (s, 3H), 2.63-2.75 (m, 1H),2.36-2.50 (m, 1H), 1.77-2.10 (m, 3H), 1.55-1.71 (m, 1H), 1.46 (s, 9H),1.35-1.55 (m, 2H), 1.19-1.32 (m, 2H), 0.94 (t, J=7.3 Hz, 3H); MS (ESI+)m/z 486 (M+H)⁺.

Example 532N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethoxy)phenyl]sulfonyl}octahydrocyclopenta[e]pyrrol-4-yl)-L-norvalinamide

Step A: tert-Butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-{[4-(trifluoromethoxy)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 313 Step A for(S)—N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-(trifluoromethoxy)benzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: MS (APCI+) m/z 564 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-{[4-(trifluoromethoxy)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A for tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 9.99-10.02 (m, 1H), 8.05-8.07 (m, 2H), 7.50-7.52 (m, 2H),4.55-4.59 (m, 1H), 4.26-4.36 (m, 1H), 3.73 (dd, J=9.9, 2.8 Hz, 1H), 3.18(dd, J=9.6, 2.9 Hz, 1H), 3.11 (dd, J=9.9, 7.9 Hz, 1H), 2.92 (s, 3H),2.88-2.94 (m, 1H), 2.73-2.86 (m, 1H), 2.62-2.68 (m, 1H), 2.19-2.40 (m,2H), 1.97-2.07 (m, 2H), 1.77-1.87 (m, 1H), 1.51-1.75 (m, 2H), 1.31-1.38(m, 1H), 0.85 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 464 (M+H)⁺.

Example 533N²-methyl-N¹-[(3aR,4S,6aS)-2-(thien-2-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-norvalinamide

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(thiophen-2-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 531 for tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 10.02-10.04 (m, 1H), 7.86 (d, J=5.4 Hz, 1H), 7.76 (d, J=4.2 Hz,1H), 7.18-7.22 (m, 1H), 6.93-6.93 (m, 1H), 4.65 (dd, J=9.1, 4.8 Hz, 1H),4.28-4.36 (m, 1H), 3.72 (dd, J=10.0, 3.0 Hz, 1H), 3.24 (dd, J=10.0, 8.0Hz, 1H), 3.19 (dd, J=9.7, 3.1 Hz, 1H), 3.04 (dd, J=9.7, 7.7 Hz, 1H),2.94 (s, 3H), 2.78-2.84 (m, 1H), 2.66-2.72 (m, 1H), 2.35-2.42 (m, 1H),2.22-2.30 (m, 1H), 1.98-2.11 (m, 2H), 1.81-1.89 (m, 1H), 1.66-1.77 (m,1H), 1.54-1.66 (m, 1H), 1.31-1.38 (m, 1H), 0.86 (t, J=7.3 Hz, 3H); MS(ESI+) m/z 386 (M+H)⁺.

Example 534N¹-{(3aR,4S,6aS)-2-[(3-chloro-4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide

The title compound was prepared by substituting tert-butyl(S)-1-((3aR,4S,6aS)-2-(3-chloro-4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamatefrom Example 529 for tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 10.05-10.07 (m, 1H), 8.19 (dd, J=6.8, 2.2 Hz, 1H), 7.89 (ddd,J=8.6, 4.4, 2.2 Hz, 1H), 7.44 (t, J=8.7 Hz, 1H), 4.66 (dd, J=9.1, 4.8Hz, 1H), 4.27-4.36 (m, 1H), 3.72 (dd, J=9.9, 2.9 Hz, 1H), 3.06-3.18 (m,2H), 2.94 (s, 3H), 2.90-2.93 (m, 1H), 2.80-2.85 (m, 1H), 2.67-2.73 (m,1H), 2.35-2.42 (m, 1H), 2.22-2.30 (m, 1H), 1.99-2.10 (m, 2H), 1.82-1.90(m, 1H), 1.66-1.76 (m, 1H), 1.53-1.65 (m, 1H), 1.33-1.40 (m, 1H), 0.85(t, J=7.3 Hz, 3H); MS (ESI+) m/z 432 (M+H)⁻.

Example 535N²-methyl-N¹-[(3aR,4S,6aS)-2-(pyridin-3-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-norvalinamide

The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(pyridin-3-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 530 for tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 10.18-10.21 (m, 1H), 9.34 (d, J=2.3 Hz, 1H), 8.92 (dd, J=4.8, 1.6Hz, 1H), 8.25 (ddd, J=8.0, 2.4, 1.6 Hz, 1H), 7.50 (dd, J=8.0, 4.8 Hz,1H), 4.73 (dd, J=9.3, 4.6 Hz, 1H), 4.30 (p, J=6.3 Hz, 1H), 3.71 (dd,J=10.0, 2.9 Hz, 1H), 3.08-3.21 (m, 2H), 2.87-3.07 (m, 4H), 2.78-2.83 (m,1H), 2.64-2.70 (m, 1H), 2.40-2.47 (m, 1H), 2.26-2.34 (m, 1H), 1.98-2.17(m, 2H), 1.78-1.92 (m, 1H), 1.55-1.77 (m, 2H), 1.29-1.36 (m, 1H), 0.84(t, J=7.3 Hz, 3H); MS (ESI+) m/z 381 (M+H)⁺.

Example 536N¹-{(3aR,4S,6aS)-2-[(4-cyanophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide

Step A: tert-Butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-[(4-cyanophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatewas prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 313 Step A for(S)—N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamideand 4-cyanobenzene-1-sulfonyl chloride for3-(trifluoromethyl)benzene-1-sulfonyl chloride in the proceduredescribed in Example 319: MS (APCI+) m/z 505 (M+H)⁺.

Step B: The title compound was prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-[(4-cyanophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Step A for tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamatein the procedure described in Example 348: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 10.09-10.11 (m, 1H), 8.05-8.07 (m, 2H), 7.94-7.96 (m, 2H), 4.68(dd, J=9.2, 4.6 Hz, 1H), 4.26-4.35 (m, 1H), 3.71 (dd, J=10.0, 3.0 Hz,1H), 3.14-3.18 (m, 2H), 2.93-2.99 (m, 1H), 2.95 (s, 3H), 2.80-2.86 (m,1H), 2.67-2.73 (m, 1H), 2.36-2.43 (m, 1H), 2.23-2.31 (m, 1H), 1.99-2.14(m, 2H), 1.83-1.90 (m, 1H), 1.65-1.75 (m, 1H), 1.55-1.65 (m, 1H),1.31-1.40 (m, 1H), 0.85 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 405 (M+H)⁺.

Example 537N¹-{(3aR,4S,6aS)-2-[(4-methoxyphenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide

Step A: tert-Butylmethyl((S)-1-((3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl)carbamatewas prepared by substituting tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamatefrom Example 313 Step A for(S)—N-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-2-morpholinopentanamidein the procedure described in Example 319 Step A: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.44-8.32 (m, 1H), 4.76-4.57 (m, 1H), 4.41-4.26 (m,1H), 3.30 (dd, J=11.1, 1.6, 1H), 3.17-2.95 (m, 5H), 2.78 (d, J=9.8, 1H),2.60 (s, 2H), 2.11-1.93 (m, 2H), 1.91-1.71 (m, 2H), 1.62-1.53 (m, 1H),1.46 (s, 9H), 1.40-1.24 (m, 4H), 0.84 (t, J=6.0, 3H); MS (ESI+) m/z 340(M+H)⁺.

Step B: The title compound was prepared by combining tert-butylmethyl((S)-1-((3aR,4S,6aS)-octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl)carbamate(0.075 g, 0.221 mmol) from Step A with 4-methoxybenzene-1-sulfonylchloride (0.050 g, 0.243 mmol) and diisopropylethylamine (0.042 mL,0.243 mmol) in dichloromethane (5 mL). The reaction was stirred atambient temperature overnight and volatiles were removed in vacuo. Tothe resulting mixture was added 4 N HCl/dioxane (5 mL), and theresultant reaction mixture was stirred at ambient temperature for 30minutes. The volatiles were removed in vacuo, and the crude material waspurified by preparative reverse-phase HPLC (Phenomenex® Luna® C8(2) 5 μm100 ÅAXIA column, 30×75 mm, 10-95% gradient of acetonitrile in 0.1%aqueous trifluoroacetic acid, flow rate 50 mL/minute) to afford thetitle compound as the trifluoroacetic acid salt: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 9.83 (d, J=6.7 Hz, 1H), 7.94-7.97 (m, 2H), 7.09-7.13(m, 2H), 4.39 (t, J=6.8 Hz, 1H), 4.32 (p, J=6.5 Hz, 1H), 3.73 (s, 3H),3.69-3.76 (m, 1H), 3.04-3.19 (m, 2H), 2.87-2.95 (m, 2.90 (s, 3H),2.64-2.71 (m, 1H), 2.56-2.64 (m, 1H), 2.07-2.19 (m, 2H), 1.96-2.04 (m,1H), 1.86-1.96 (m, 1H), 1.62-1.71 (m, 1H), 1.47-1.61 (m, 2H), 1.29-1.39(m, 1H), 0.80 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 410 (M+H)⁺.

Example 538N¹-((3aR,4S,6aS)-2-{[3,5-bis(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-norvalinamide

The title compound was prepared by substituting3,5-bis(trifluoromethyl)phenyl-1-sulfonyl chloride for4-methoxybenzene-1-sulfonyl chloride in the procedure described inExample 537: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.73 (d, J=6.7 Hz, 1H),8.84 (s, 1H), 8.63 (s, 2H), 8.46-8.47 (bs, 1H), 4.47 (t, J=6.7 Hz, 1H),4.26-4.34 (m, 1H), 3.87 (dd, J=10.0, 2.6 Hz, 1H), 3.20-3.29 (m, 2H),3.03 (dd, J=9.5, 7.7 Hz, 1H), 2.96 (s, 3H), 2.69-2.77 (m, 1H), 2.60-2.69(m, 1H), 2.04-2.17 (m, 2H), 1.90-2.05 (m, 2H), 1.66-1.74 (m, 1H),1.43-1.61 (m, 2H), 1.27-1.37 (m, 1H), 0.78 (t, J=7.3 Hz, 3H).

Example 539N¹-{(3aR,4S,6aS)-2-[(2-chloro-4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide

The title compound was prepared by substituting2-chloro-4-fluorophenyl-1-sulfonyl chloride for4-methoxybenzene-1-sulfonyl chloride in the procedure described inExample 537:

¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.84-9.86 (m, 1H), 8.22 (dd, J=8.9,6.0 Hz, 1H), 7.45 (dd, J=8.5, 2.4 Hz, 1H), 7.19-7.23 (m, 1H), 4.46 (t,J=6.8 Hz, 1H), 4.30-4.39 (m, 1H), 3.81 (dd, J=10.1, 3.0 Hz, 1H), 3.48(dd, J=10.1, 7.7 Hz, 1H), 3.23-3.35 (m, 2H), 2.94 (s, 3H), 2.75-2.82 (m,1H), 2.67-2.75 (m, 1H), 2.02-2.19 (m, 3H), 1.92-1.99 (m, 1H), 1.73 (dq,J=12.5, 8.1 Hz, 1H), 1.47-1.62 (m, 2H), 1.39 (ddt, J=9.1, 13.0, 6.5 Hz,1H), 0.80 (t, J=7.3 Hz, 3H); MS (ESI−) m/z 430 (M−H)⁻.

Example 540N²-methyl-N¹-[(3aR,4S,6aS)-2-(1-naphthylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-norvalinamide

The title compound was prepared by substituting 1-naphthyl-1-sulfonylchloride for 4-methoxybenzene-1-sulfonyl chloride in the proceduredescribed in Example 537: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.74-9.78(m, 1H), 9.25 (d, J=8.7 Hz, 1H), 8.43 (d, J=7.3 Hz, 1H), 8.12 (d, J=8.2Hz, 1H), 7.98 (d, J=8.2 Hz, 1H), 7.69 (t, J=7.8 Hz, 1H), 7.54-7.57 (m,1H), 4.38 (t, J=6.8 Hz, 1H), 4.26-4.32 (m, 1H), 3.83 (dd, J=9.9, 2.7 Hz,1H), 3.29 (dd, J=9.9, 7.8 Hz, 1H), 3.22 (dd, J=9.7, 2.7 Hz, 1H), 3.08(dd, J=9.6, 7.5 Hz, 1H), 2.89 (s, 3H), 2.59-2.66 (m, 1H), 2.50-2.59 (m,1H), 2.02-2.15 (m, 2H), 1.80-2.00 (m, 2H), 1.57-1.67 (m, 1H), 1.45-1.55(m, 2H), 1.23-1.30 (m, 1H), 0.78 (t, J=7.3 Hz, 3H); MS (ESI−) m/z 428M−H)⁻.

Example 541N¹-((3aR,4S,6aS)-2-{[4-bromo-3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-norvalinamide

The title compound was prepared by substituting4-bromo-3-(trifluoromethyl)phenyl-1-sulfonyl chloride for4-methoxybenzene-1-sulfonyl chloride in the procedure described inExample 537: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.81-9.83 (m, 1H), 8.32(d, J=2.0 Hz, 1H), 8.04 (dd, J=8.3, 2.0 Hz, 1H), 8.01 (d, J=8.3 Hz, 1H),6.60-8.44 (bs, 1H), 4.33-4.38 (m, 1H), 4.26-4.33 (m, 1H), 3.82 (dd,J=9.9, 2.6 Hz, 1H), 3.21 (dd, J=9.8, 2.7 Hz, 1H), 3.18 (dd, J=9.8, 7.9Hz, 1H), 2.96 (dd, J=9.6, 7.5 Hz, 1H), 2.89 (s, 3H), 2.69-2.76 (m, 1H),2.61-2.69 (m, 1H), 2.05-2.17 (m, 2H), 1.97-2.05 (m, 1H), 1.89-1.97 (m,1H), 1.64-1.72 (m, 1H), 1.45-1.59 (m, 2H), 1.34 (ddt, J=9.3, 13.0, 6.5Hz, 1H), 0.79 (t, J=7.3 Hz, 3H); MS (ESI−) m/z 524 (M−H)⁻.

Example 542N¹-{(3aR,4S,6aS)-2-[(3,4-dichlorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide

The title compound was prepared by substituting3,4-dichlorophenyl-1-sulfonyl chloride for 4-methoxybenzene-1-sulfonylchloride in the procedure described in Example 537:

¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.84-9.86 (m, 1H), 7.41-8.78 (bs,1H), 7.82 (dd, J=8.3, 2.1 Hz, 1H), 7.69 (d, J=8.3 Hz, 1H), 7.58-7.59(bs, 1H), 4.45 (t, J=6.8 Hz, 1H), 4.30 (p, J=6.7 Hz, 1H), 3.76 (dd,J=9.9, 2.7 Hz, 1H), 3.16 (dd, J=9.9, 2.9 Hz, 1H), 3.14 (dd, J=10.0, 8.0Hz, 1H), 2.94 (s, 3H), 2.89-2.95 (m, 1H), 2.70-2.75 (m, 1H), 2.62-2.69(m, 1H), 2.06-2.18 (m, 2H), 1.97-2.04 (m, 1H), 1.90-1.96 (m, 1H),1.65-1.73 (m, 1H), 1.46-1.62 (m, 2H), 1.30-1.37 (m, 1H), 0.80 (t, J=7.3Hz, 3H); MS (ESI−) m/z 446 (M−H)⁻.

Example 543N¹-{(3aR,4S,6aS)-2-[(4-tert-butylphenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide

The title compound was prepared by substituting 4-tert-butylphenyl-sulfonyl chloride for 4-methoxybenzene-1-sulfonyl chloride in theprocedure described in Example 537: ¹H NMR (500 MHz, pyridine-d₅) δ ppm9.85 (d, J=6.8 Hz, 1H), 7.96-7.99 (m, 2H), 7.58-7.66 (m, 2H), 4.43 (t,J=6.8 Hz, 1H), 4.27-4.33 (m, 1H), 3.78 (dd, J=9.8, 2.5 Hz, 1H), 3.20(dd, J=9.6, 2.6 Hz, 1H), 3.11 (dd, J=9.8, 7.7 Hz, 1H), 2.93 (s, 3H),2.90 (dd, J=9.5, 7.6 Hz, 1H), 2.47-2.62 (m, 2H), 2.08-2.18 (m, 2H),1.93-2.01 (m, 1H), 1.85-1.92 (m, 1H), 1.60-1.68 (m, 1H), 1.48-1.59 (m,2H), 1.28-1.39 (m, 1H), 1.26 (s, 9H), 0.81 (t, J=7.3 H); MS (ESI+) m/z436 (M+H)⁺.

Example 544N¹-[(3aR,4S,6aS)-2-(1,1′-biphenyl-4-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide

The title compound was prepared by substituting 1,1′-biphenyl-4-sulfonylchloride for 4-methoxybenzene-1-sulfonyl chloride in the proceduredescribed in Example 537: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.86-9.88(m, 1H), 8.07-8.09 (m, 2H), 7.86-7.88 (m, 2H), 7.71-7.75 (m, 2H),7.48-7.53 (m, 2H), 7.41-7.47 (m, 1H), 4.44 (t, J=6.8 H), 4.29-4.36 (m,1H), 3.78 (dd, J=9.9, 2.7 Hz, 1H), 3.21 (dd, J=9.7, 2.7 Hz, 1H), 3.15(dd, J=9.8, 7.9 Hz, 1H), 2.95 (dd, J=9.5, 7.7 Hz, 1H), 2.93 (s, 3H),2.64-2.71 (m, 1H), 2.56-2.64 (m, 1H), 2.06-2.19 (m, 2H), 1.97-2.04 (m,1H), 1.88-1.97 (m, 1H), 1.62-1.73 (m, 1H), 1.48-1.62 (m, 2H), 1.30-1.40(m, 1H), 0.80 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 456 (M+H)⁻.

Example 545N¹-{(3aR,4S,6aS)-2-[(3,4-dimethoxyphenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide

The title compound was prepared by substituting3,4-dimethoxyphenyl-sulfonyl chloride for 4-methoxybenzene-1-sulfonylchloride in the procedure described in Example 537:

¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.86 (d, J=6.9 Hz, 1H), 7.66 (dd,J=8.4, 2.0 Hz, 1H), 7.55 (d, J=2.0 Hz, 1H), 7.08 (d, J=8.4 Hz, 1H),4.38-4.43 (m, 1H), 4.31-4.38 (m, 1H), 3.81 (s, 3H), 3.78 (dd, J=10.2,2.8 Hz, 1H), 3.76 (s, 3H), 3.17-3.23 (m, 2H), 3.00 (dd, J=9.6, 7.5 Hz,1H), 2.91 (s, 3H), 2.68-2.75 (m, 1H), 2.60-2.68 (m, 1H), 2.06-2.18 (m,2H), 1.98-2.06 (m, 1H), 1.88-1.98 (m, 1H), 1.64-1.73 (m, 1H), 1.49-1.59(m, 2H), 1.33-1.40 (m, 1H), 0.79 (t, J=7.3 Hz, 3H); MS (ESI−) m/z 438(M−H)⁻.

Example 546N¹-{(3aR,4S,6aS)-2-[(3-cyanophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide

The title compound was prepared by substituting 3-cyanophenyl -sulfonylchloride for 4-methoxybenzene-1-sulfonyl chloride in the proceduredescribed in Example 537: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.86-9.88(m, 1H), 8.56 (s, 1H), 8.18 (d, J=8.0 H), 7.96 (d, J=7.8 Hz, 1H), 7.66(t, J=7.8 Hz, 1H), 4.39-4.44 (m, 1H), 4.23-4.32 (m, 1H), 3.77 (dd,J=10.0, 2.7 Hz, 1H), 3.18 (dd, J=9.8, 2.9 Hz, 1H), 3.14 (dd, J=9.9, 7.8Hz, 1H), 2.03-2.96 (m, 1H), 2.91 (s, 3H), 2.65-2.72 (m, 1H), 2.58-2.65(m, 1H), 2.04-2.18 (m, 2H), 1.95-2.03 (m, 1H), 1.87-1.95 (m, 1H), 1.68(dq, J=12.3, 8.1 Hz, 1H), 1.45-1.59 (m, 2H), 1.27-1.38 (m, 1H), 0.79 (t,J=7.3 Hz, 3H); MS (ESI+) m/z 405 (M+H)⁺.

Example 547N¹-[(3aR,4S,6aS)-2-(2-furylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide

The title compound was prepared by substituting 2-furylsulfonyl chloridefor 4-methoxybenzene-1-sulfonyl chloride in the procedure described inExample 537: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.88-9.90 (m, 1H),7.86-7.87 (m, 1H), 7.26-7.28 (m, 1H), 6.58 (dd, J=3.4, 1.8 Hz, 1H), 4.42(t, J=6.8 Hz, 1H), 4.24-4.33 (m, 1H), 3.79 (dd, J=10.3, 3.2 Hz, 1H),3.46 (dd, J=10.3, 7.8 Hz, 1H), 3.20-3.32 (m, 2H), 2.92 (s, 3H),2.67-2.75 (m, 1H), 2.60-2.68 (m, 1H), 2.06-2.20 (m, 2H), 1.97-2.05 (m,1H), 1.88-1.95 (m, 1H), 1.71 (dq, J=12.5, 8.0 Hz, 1H), 1.46-1.62 (m,2H), 1.30 (ddt, J=8.9, 13.0, 6.5 Hz, 1H), 0.81 (t, J=7.3 Hz, 3H); MS(ESI+) m/z 370 (M+H)⁻.

Example 548N¹-{(3aR,4S,6aS)-2-[(2,3-dichlorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide

The title compound was prepared by substituting2,3-dichlorophenylsulfonyl chloride for 4-methoxybenzene-1-sulfonylchloride in the procedure described in Example 537: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 9.84-9.86 (m, 1H), 8.14 (dd, J=7.9, 1.5 Hz, 1H), 7.68(dd, J=8.0, 1.5 Hz, 1H), 7.34 (t, J=8.0 Hz, 1H), 4.49 (t, J=6.8 Hz, 1H),4.32-4.38 (m, 1H), 3.84-3.90 (m, 1H), 3.51 (dd, J=10.2, 7.7 Hz, 1H),3.26-3.41 (m, 2H), 2.95 (s, 3H), 2.76-2.82 (m, 1H), 2.68-2.75 (m, 1H),2.09-2.19 (m, 2H), 2.01-2.09 (m, 1H), 1.90-2.00 (m, 1H), 1.73 (dq,J=12.5, 8.1 Hz, 1H), 1.46-1.64 (m, 2H), 1.35-1.42 (m, 1H), 0.80 (t,J=7.3 Hz, 3H); MS (ESI+) m/z 448 (M+H)⁺.

Example 549N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)benzyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substituting4-(trifluoromethyl)benzyl-sulfonyl chloride for4-methoxybenzene-1-sulfonyl chloride in the procedure described inExample 537:

¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.72-9.74 (m, 1H), 7.79-7.81 (m,2H), 7.68-7.70 (m, 2H), 4.75-4.75 (bs, 2H), 4.51 (dd, J=8.3, 6.3 Hz,1H), 4.33 (p, J=6.7 Hz, 1H), 3.78 (dd, J=10.1, 3.1 Hz, 1H), 3.62 (dd,J=10.2, 7.5 Hz, 1H), 3.45 (dd, J=9.9, 7.5 Hz, 1H), 3.23 (dd, J=9.9, 3.7Hz, 1H), 2.90 (s, 3H), 2.68-2.85 (m, 2H), 2.02-2.15 (m, 3H), 1.91-1.98(m, 1H), 1.75 (dq, J=12.4, 8.1 Hz, 1H), 1.43-1.64 (m, 2H), 1.30-1.39 (m,1H), 0.81 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 462 (M+H)⁻.

Example 550N²-methyl-N¹-((3aR,4S,6aS)-2-{[2-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide

The title compound was prepared by substituting2-(trifluoromethyl)phenyl-sulfonyl chloride for4-methoxybenzene-1-sulfonyl chloride in the procedure described inExample 537:

¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.81-9.83 (m, 1H), 8.26 (d, J=7.9Hz, 1H), 7.93 (d, J=7.8 Hz, 1H), 7.73 (t, J=7.7 Hz, 1H), 7.67 (t, J=7.7Hz, 1H), 4.50 (t, J=6.8 Hz, 1H), 4.31 (p, J=6.7 Hz, 1H), 3.83 (dd,J=10.1, 2.9 Hz, 1H), 3.36 (dd, J=10.1, 7.7 Hz, 1H), 3.29 (dd, J=9.9, 3.1Hz, 1H), 3.18 (dd, J=9.9, 7.5 Hz, 1H), 2.95 (s, 3H), 2.75-2.80 (m, 1H),2.65-2.73 (m, 1H), 2.14 (q, J=7.5 Hz, 2H), 1.99-2.06 (m, 1H), 1.91-1.98(m, 1H), 1.68-1.76 (m, 1H), 1.47-1.65 (m, 2H), 1.36 (ddt, J=9.2, 12.9,6.5 Hz, 1H), 0.80 (t, J=7.3 Hz, 3H); MS (ESI+) m/z 448 (M+H)⁺.

Example 551N¹-{(3aR,4S,6aS)-2-[(3-bromophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide

The title compound was prepared by substituting2-(trifluoromethyl)phenyl-sulfonyl chloride for4-methoxybenzene-1-sulfonyl chloride in the procedure described inExample 537:

¹H NMR (500 MHz, pyridine-d₅) δ ppm 9.78-9.80 (m, 1H), 8.26 (t, J=1.8Hz, 1H), 7.90 (dt, J=7.8, 1.2 Hz, 1H), 7.78 (ddd, J=8.0, 1.9, 1.0 Hz,1H), 7.43 (t, J=7.9 Hz, 1H), 4.42 (dd, J=7.9, 5.8 Hz, 1H), 4.29 (p,J=6.7 Hz, 1H), 3.75 (dd, J=9.9, 2.7 Hz, 1H), 3.15 (dd, J=9.7, 2.8 Hz,1H), 3.10 (dd, J=9.9, 7.7 Hz, 1H), 2.92 (s, 3H), 2.88 (dd, J=9.6, 7.5Hz, 1H), 2.62-2.68 (m, 1H), 2.55-2.61 (m, 1H), 2.04-2.20 (m, 2H),1.86-2.03 (m, 2H), 1.63-1.70 (m, 1H), 1.48-1.60 (m, 2H), 1.31 (ddt,J=9.2, 12.9, 6.5 Hz, 1H), 0.80 (t, J=7.3 Hz, 3H); MS (ESI−) m/z 456(M−H)⁻.

Example 552N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-norvalinamide

The title compound was prepared by substituting2-chloro-4-(trifluoromethyl)phenylsulfonyl chloride for4-methoxybenzene-1-sulfonyl chloride in the procedure described inExample 537: ¹H NMR (500 MHz, pyridine-d₅) δ ppm 10.09-10.11 (m, 1H),8.33 (d, J=8.2 Hz, 1H), 7.99-8.00 (bs, 1H), 7.73-7.75 (m, 1H), 4.66-4.70(m, 1H), 4.35-4.44 (m, 1H), 3.85 (dd, J=10.3, 3.2 Hz, 1H), 3.55 (d,J=8.7 Hz, 1H), 3.30-3.42 (m, 2H), 2.95 (s, 3H), 2.88-2.95 (m, 1H),2.75-2.86 (m, 1H), 2.35-2.41 (m, 1H), 2.22-2.30 (m, 1H), 1.99-2.19 (m,2H), 1.89-1.95 (m, 1H), 1.54-1.77 (m, 2H), 1.39-1.47 (m, 1H), 0.85 (t,J=7.3 Hz, 3H); MS (ESI−) m/z 480 (M−H)⁻.

Example 553N¹-((3aR,4S,6aS)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-norvalinamide

The title compound was prepared by substituting2-chloro-5-(trifluoromethyl)phenylsulfonyl chloride for4-methoxybenzene-1-sulfonyl chloride in the procedure described inExample 537: ¹H NMR (400 MHz, pyridine-d₅) δ ppm 10.09-10.12 (m, 1H),8.54 (d, J=2.2 Hz, 1H), 7.82 (dd, J=8.3, 2.2 Hz, 1H), 7.76 (d, J=8.3 Hz,1H), 4.73 (dd, J=9.1, 4.6 Hz, 1H), 4.35-4.43 (m, 1H), 3.84 (dd, J=10.2,3.2 Hz, 1H), 3.56 (dd, J=10.2, 7.8 Hz, 1H), 3.29-3.40 (m, 2H), 2.96 (s,3H), 2.89-3.00 (m, 1H), 2.76-2.88 (m, 1H), 2.35-2.44 (m, 1H), 2.21-2.33(m, 1H), 2.05-2.19 (m, 2H), 1.88-1.98 (m, 1H), 1.66-1.79 (m, 1H),1.53-1.66 (m, 1H), 1.38-1.48 (m, 1H), 0.85 (t, J=7.3 Hz, 3H); MS (ESI−)m/z 480 (M−H)⁻.

Example 554N²-methyl-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzoyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide

The title compound was prepared by substituting3-(trifluoromethyl)benzoyl chloride for 4-methoxybenzene-1-sulfonylchloride in the procedure described in Example 537: ¹H NMR (400 MHz,pyridine-d₅) δ ppm 7.98 (s, 1H), 7.80 (d, J=7.7, 1H), 7.65 (d, J=7.9,1H), 7.52-7.40 (m, 3H), 4.34-4.19 (m, 1H), 3.88-3.74 (m, 3H), 3.66 (d,J=8.2, 1H), 3.44 (s, 1H), 2.85-2.52 (m, 5H), 2.51-2.38 (m, 0H), 2.11(dt, J=12.6, 6.2, 1H), 1.91 (dddd, J=22.0, 15.6, 10.7, 4.6, 3H), 1.72(dq, J=12.8, 8.0, 1H), 1.57-1.17 (m, 4H), 0.83 (t, J=7.3, 3H); MS (ESI+)m/z 412 (M+H)⁺.

Example 555N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-isopropyl-3-(trifluoromethyl)benzenesulfonamide

Step A:(3aR,4S,6aS)-2-Benzyl-N-isopropyloctahydrocyclopenta[c]pyrrol-4-aminewas prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Example33 Step A for(3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-amineand acetone for pivalaldehyde in the procedure described in Example 281:¹H NMR (500 MHz, pyridine-d₅) δ ppm 7.48 (d, J=7.5, 2H), 7.39 (t, J=7.5,2H), 7.29 (t, J=7.3, 1H), 3.61-3.51 (m, 2H), 3.05 (dd, J=12.1, 5.4, 1H),2.87-2.78 (m, 1H), 2.61-2.51 (m, 2H), 2.43-2.36 (m, 2H), 2.35-2.30 (m,1H), 2.28-2.21 (m, 1H), 2.00-1.93 (m, 1H), 1.93-1.87 (m, 1H), 1.42-1.28(m, 3H), 1.05-0.98 (m, 6H); MS (ESI+) m/z 259 (M+H)⁺.

Step B: The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyl-N-isopropyloctahydrocyclopenta[c]pyrrol-4-aminefrom Step A for (S)-tert-butyl 2-amino-4-methylpentanoate and3-(trifluoromethyl)benzene-1-sulfonylchloride for methanesulfonylchloride in the procedure described in Example 242: ¹H NMR (500 MHz,pyridine-d₅) δ ppm 8.43 (s, 1H), 8.30-8.21 (m, 1H), 7.84 (d, J=7.6, 1H),7.66-7.59 (m, 1H), 7.40 (ddd, J=12.7, 8.4, 2.6, 4H), 7.32-7.27 (m, 1H),3.82-3.70 (m, 2H), 3.51 (d, J=2.0, 2H), 2.82-2.74 (m, 1H), 2.67-2.62 (m,1H), 2.52-2.43 (m, 3H), 2.09-2.04 (m, 1H), 1.99-1.95 (m, 1H), 1.91-1.79(m, 2H), 1.75-1.65 (m, 1H), 1.26 (dd, J=6.8, 2.6, 6H); MS (ESI+) m/z 467(M+H)⁺.

Example 556N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide

The title compound was prepared by substituting(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine from Example33 Step A for (S)-tert-butyl 2-amino-4-methylpentanoate and3-(trifluoromethyl)benzene-1-sulfonylchloride for methanesulfonylchloride in the procedure described in Example 242 Step A: ¹H NMR (500MHz, pyridine-d₅) δ ppm 9.49 (d, J=7.2, 1H), 8.43 (s, 1H), 8.30 (d,J=7.9, 1H), 7.81 (d, J=7.9, 1H), 7.60 (d, J=7.9, 1H), 7.37 (dd, J=9.6,3.8, 4H), 7.33-7.26 (m, 1H), 3.83-3.75 (m, 1H), 3.50 (d, J=13.1, 1H),3.44 (d, J=13.1, 1H), 2.61 (dd, J=9.2, 2.0, 1H), 2.56-2.43 (m, 2H), 2.35(dd, J=9.1, 2.1, 1H), 2.21-2.13 (m, 2H), 1.99 (td, J=11.7, 5.8, 1H),1.82 (ddd, J=12.5, 10.2, 5.6, 1H), 1.63-1.53 (m, 1H), 1.29 (ddt, J=12.7,10.0, 6.4, 1H); MS (ESI+) m/z 442 (M+NH₄)⁺.

Example 557N-isopropyl-N-[(3aR,4S,6aS)-2-(N-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide

The title compound was prepared by substitutingN-](3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-isopropyl-3-(trifluoromethyl)benzenesulfonamidefrom Example 555 forN-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-2,2-bis(4-fluorophenyl)acetamidein the procedure described in Example 459: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.30 (s, 1H), 8.17 (d, J=7.8, 1H), 7.79 (d, J=8.1, 1H), 7.61 (t,J=7.8, 1H), 3.90-3.80 (m, 2H), 3.77-3.67 (m, 4H), 3.39 (dd, J=9.0, 4.2,1H), 3.10-3.01 (m, 1H), 2.82-2.70 (m, 1H), 2.39 (s, 3H), 2.13-2.01 (m,1H), 2.02-1.83 (m, 3H), 1.51 (t, J=6.7, 2H), 1.29 (d, J=6.8, 5H), 1.23(d, J=6.8, 3H), 0.97-0.89 (m, 6H); MS (ESI+) m/z 504 (M+H)⁺.

Example 558N-[(3aR,4S,6aS)-2-(N-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide

The title compound was prepared by substitutingN-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamidefrom Example 556 forN-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-2,2-bis(4-fluorophenyl)acetamidein the procedure described in Example 459: ¹H NMR (400 MHz, pyridine-d₅)δ ppm 8.88 (qt, J=7.3, 2.9, 1H), 8.35 (s, 1H), 8.24 (d, J=7.9, 1H), 7.79(d, J=7.9, 1H), 7.59 (t, J=8.0, 1H), 3.79-3.70 (m, 3H), 3.68-3.53 (m,2H), 3.37 (ddd, J=8.4, 7.7, 2.4, 1H), 2.77-2.62 (m, 2H), 2.37 (s, 3H),2.06-1.87 (m, 3H), 1.75-1.63 (m, 1H), 1.53-1.44 (m, 2H), 1.38-1.24 (m,1H), 0.92 (dd, J=8.8, 6.7, 7H); MS (ESI+) m/z 462 (M+H)⁺.

Example 559N-cyclopropyl-N-[(3aS*,4S*,6aR*)-[2-(N-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide

The title compound was prepared by substitutingN-[3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-cyclopropyl-3-(trifluoromethyl)benzenesulfonamidefrom Example 199 forN-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl)-2,2-bis(4-fluorophenyl)acetamidein the procedure described in Example 459: ¹H NMR (500 MHz, pyridine-d₅)δ ppm 8.50 (s, 1H), 8.39-8.31 (m, 1H), 7.96 (dd, J=20.3, 7.8, 1H),7.82-7.71 (m, 1H), 4.20 (dd, J=13.1, 5.0, 0.5H), 4.12 (dt, J=13.2, 6.7,0.5H), 4.04-3.98 (m, 0.5H), 3.97-3.80 (m, 1.5H), 3.72 (ddd, J=22.3,16.1, 9.9, 1H), 3.60 (dt, J=8.6, 7.6, 0.5H), 3.53-3.38 (m, 2H),3.29-3.21 (m, 0.5H), 2.72-2.65 (m, 0.5H), 2.63-2.52 (m, 0.5H), 2.48 (s,0.5H), 2.42 (d, J=4.6, 2H), 2.39 (s, 0.5H), 2.15-1.97 (m, 3H), 1.92-1.82(m, 1H), 1.75-1.68 (m, 1H), 1.67-1.34 (m, 5H), 1.04 (d, J=6.6, 1H),0.99-0.94 (m, 3H), 0.91 (dt, J=14.0, 5.1, 3H), 0.85-0.71 (m, 1.5H),0.69-0.59 (m, 0.5H); MS (ESI+) m/z 502 (M+H)⁺.

Example 5604-fluoro-N-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}benzamide

The title compound was prepared by substituting 4-fluorobenzoic acid forN-(tert-butoxycarbonyl)-L-leucine and(3aR,4S,6aS)-2-(6-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-aminefrom Example 264 Step A for(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-amine in theprocedure described in Example 221: ¹H NMR (500 MHz, pyridine-d₅) δ ppm8.90 (d, J=6.9, 1H), 8.27-8.21 (m, 2H), 7.55-7.50 (m, 1H), 7.20-7.14 (m,2H), 6.99 (d, J=7.2, 1H), 6.53 (d, J=8.6, 1H), 4.61-4.54 (m, 1H), 3.80(dd, J=11.0, 3.7, 1H), 3.63 (dd, J=10.9, 8.2, 1H), 3.51 (dd, J=10.8,8.4, 1H), 3.30 (dd, J=10.9, 4.6, 1H), 2.88-2.81 (m, 1H), 2.76-2.67 (m,1H), 2.23 (ddd, J=19.5, 7.1, 4.7, 1H), 1.93 (dtd, J=12.7, 8.0, 4.6, 1H),1.81 (ddd, J=16.4, 12.7, 8.1, 1H), 1.40 (dt, J=13.2, 7.6, 1H); MS (ESI+)m/z 394 (M+H)⁺.

Many variations in the invention will suggest themselves to thoseskilled in the art in light of the foregoing detailed description. Allsuch obvious variations are within the full intended scope of theappended claims.

1. A compound of formula (I),

or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or acombination thereof, wherein L¹ is C(O), S(O)₂, SO₂N(R⁴), C(O)O or—(CR^(a)R^(b))_(m)—; R¹ is alkyl, G¹, —CH(G¹)₂, —(CR^(a)R^(b))_(m)-G¹,—(CR^(a)R^(b))_(m)—CH(G¹)₂, —(CR^(e)R^(f))_(n) 13 N(R⁵)₂,—(CR^(e)R^(f))_(n)—N(R⁵)—C(O)O(alkyl),—(CR^(e)R^(f))_(n)—N(R⁵)—C(O)(alkyl), or —(CR^(e)R^(f))_(n)—N(R⁵)—SO₂R⁶;or L¹-R¹ taken together are hydrogen, alkyl, hydroxyalkyl, G¹, or—CH(G¹)₂; L² is —(CR^(c)R^(d))_(p)—, C(O), C(O)N(R⁴), S(O)₂, SO₂N(R⁵),or C(O)O; R² is alkyl, G², —C(R^(c))(G²)(G³), —(CR^(c)R^(d))_(p)-G²,—(CR^(c)R^(d))_(p)—CH(G²)(G³), —(CR^(g)R^(h))_(q)—N(R⁵)—C(O)O(alkyl),—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)O-G², —(CR^(g)R^(h))_(q)—N(R⁵)—C(O)(alkyl),—(CR^(g)R^(h))_(q)—N(R⁵)—SO₂R⁶, —(CR^(g)R^(h))_(q)—N(R⁴)(R⁵),—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)N(R⁵)-(alkyl), or—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)N(R⁵)-G²; or L²-R² taken together arealkyl, G², or —C(R^(c))(G²)(G³); m and p, at each occurrence, are eachindependently 1, 2, 3, 4, 5, or 6; n and q, at each occurrence, are eachindependently 1, 2, 3, 4, or 5; R^(a), R^(b), R^(c), and R^(d), at eachoccurrence, are each independently hydrogen, alkyl, arylalkyl, halogen,haloalkyl or OR⁷; or R^(a) and R^(b), or R^(c) and R^(d), together withthe carbon atom to which they are attached, optionally form a C₃₋₆cycloalkyl ring; R^(e), R^(f), R^(g), and R^(h), at each occurrence, areeach independently hydrogen, alkyl, halogen, haloalkyl, OR⁷,cycloalkylalkyl, heteroaryl, arylalkyl, or heteroarylalkyl; wherein thearyl, cycloalkyl and heteroaryl groups of aryl, cycloalkyl andheteroaryl are each independently unsubstituted or substituted with 1,2, 3, 4, or 5 substituents independently selected from the groupconsisting of alkyl and haloalkyl; G¹, G², and G³ at each occurrence,are each independently aryl, cycloalkyl, cycloalkenyl, heteroaryl, orheterocycle; wherein G¹, G², and G³ at each occurrence are eachindependently unsubstituted or substituted with 1, 2, 3, 4, or 5substituents selected form the group consisting of alkyl, alkenyl,alkynyl, cyano, haloalkyl, halogen, nitro, oxo, phenyl, N(R⁷)₂,N(R⁷)C(O)R⁷, OR⁷, C(O)R⁷, C(O)OR⁷, C(O)N(R⁷)₂, SO₂R⁸, and SO₂N(R⁷)₂; andwherein G^(l) is other than quinoline, quinazolinedione, orpyridopyrimidinedione; R³ is hydrogen, alkyl, haloalkyl, cycloalkyl, orcycloalkylalkyl; R⁴, R⁵, and R⁷, at each occurrence, are eachindependently hydrogen, alkyl, aryl, arylalkyl, cycloalkyl,cycloalkylalkyl, or haloalkyl; wherein said aryl, the aryl of arylalkyland cycloalkyl are independently unsubstituted or substituted with 1, 23, 4, or 5 substituents independently selected from the group consistingof alkyl, haloalkyl, and halogen; R⁶ is alkyl, aryl, cycloalkyl,cycloalkenyl, heteroaryl, or heterocycle; wherein said aryl, heteroaryl,and heterocycle are independently unsubstituted or substituted with 1, 23, 4, or 5 substituents independently selected from the group consistingof alkyl, haloalkyl, and halogen; R⁸ is alkyl or haloalkyl; with theproviso that L¹-R¹ and L²-R² are not both alkyl at the same time; andwith the proviso that when L¹-R¹ is alkyl, L²-R² is other thanC(O)N(R⁴), wherein R⁴ is alkyl; and with the further proviso that thecompound is other than:N-(2-trityloctahydrocyclopenta[c]pyrrol-4-yl)acetamide;N-(octahydrocyclopenta[c]pyrrol-4-yl)acetamideN-methyl-N-(2-trityloctahydrocyclopenta[c]pyrrol-4-yl)acetamide;N-methyl-N-(octahydrocyclopenta[c]pyrrol-4-yl)acetamide;6-(2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)octahydrocyclopenta[c]pyrrol-4-ylamino)methyl-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one;tert-butyl2-(2-(3-fluoro-6-methoxy-1,5-naphthyridin-4-yl)ethyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamate;tert-butyl 2-benzyl octahydrocyclopenta[c]pyrrol-4-ylcarbamate; ortert-butyl octahydrocyclopenta[c]pyrrol-4-ylcarbamate.
 2. The compoundaccording to claim 1, wherein L^(l) is —(CR^(a)R^(b))_(m)—; R^(a) andR^(b) are each hydrogen; m is 1; R¹ is G¹; wherein G¹ is aryl; L² isC(O); R² is —(CR^(c)R^(d))_(p)-G²; wherein G² is aryl; p is 1; R^(c) andR^(d), together with the carbon atom to which they are attached form aC₃₋₆ cycloalkyl ring; and R³ is hydrogen.
 3. The compound according toclaim 1, wherein L¹-R¹ together are alkyl; or L^(l) is—(CR^(a)R^(b))_(m)— or C(O); R¹ is G¹; wherein G¹ is aryl, cycloalkyl,or heteroaryl; L² is C(O); R² is —(CR^(c)R^(d))_(p)-G²; wherein G² isaryl and p is 1 or 2; R^(a), R^(b), R^(c), and R^(d), at each occurrenceare independently hydrogen, alkyl, or arylalkyl; and R³ is hydrogen oralkyl.
 4. The compound according to claim 1, wherein L¹ is—(CR^(a)R^(b))_(m)—; R^(a) and R^(b) at each occurrence are eachhydrogen; m is 1 or 2; R^(l) is G¹; wherein G¹ is aryl; L² is C(O)N(R⁴),wherein R⁴ is alkyl; R² is G², wherein G² is aryl; and R³ is hydrogen.5. The compound according to claim 1, wherein L¹ is —(CR^(a)R^(b))_(m)—,C(O) or S(O)₂; R^(a) and R^(b) at each occurrence are each hydrogen; mis 1; R¹ is alkyl or G¹; wherein G¹ is aryl or cycloalkyl; L² is C(O);R² is —(CR^(c)R^(d))_(p)-G²; wherein R^(c) and R^(d) at each occurrenceare independently hydrogen, alkyl or OR⁷; p is 1; G² is cycloalkyl orheterocycle; wherein said cycloalkyl or heterocycle is unsubstituted orsubstituted with 1, 2, 3, 4, or 5 substituents independently selectedfrom the group consisting of alkyl, haloalkyl, halogen, oxo and C(O)OR⁷;R⁷ is hydrogen; and R³ is hydrogen.
 6. The compound according to claim1, wherein L¹ is —(CR^(a)R^(b))_(m)—; R^(a) and R^(b) at each occurrenceare each hydrogen; m is 1; R¹ is G¹; wherein G¹ is aryl; L²-R² togetherare cycloalkyl; and R³ is hydrogen or cycloalkyl.
 7. The compoundaccording to claim 1, wherein L¹ is —(CR^(a)R^(b))_(m)—; R^(a) and R^(b)at each occurrence are each hydrogen; m is 1; R¹ is G¹; wherein G¹ isaryl; L² is C(O); R² is —C(R^(c))(G²)(G³), or—(CR^(c)R^(d))_(p)—CH(G²)(G³); wherein G² is aryl and G³ is aryl orcycloalkyl; R^(c) and R^(d) are each hydrogen; and R³ is hydrogen. 8.The compound according to claim 1, wherein L¹-R¹ together is hydrogen or—CH(G¹)₂, wherein each G¹ is aryl or heteroaryl; or L¹ is—(CR^(a)R^(b))_(m)—, C(O), or S(O)₂; R¹ is G¹, —CH(G¹)₂,—(CR^(a)R^(b))_(m)-G¹, —(CR^(a)R^(b))_(m)—CH(G¹)₂,—(CR^(e)R^(f))_(n)—N(R⁵)₂; wherein each G¹ is aryl or heteroaryl; R^(a)and R^(b) are each hydrogen; R^(e) and R^(f) at each occurrence, areeach independently hydrogen or alkyl; R⁵ at each occurrence, isindependently hydrogen or alkyl; L² is C(O); R² is —C(R^(c))(G²)(G³);wherein G² and G³ are each cycloalkyl; R^(e) hydrogen or OR⁷, wherein R⁷is hydrogen; and R³ is hydrogen.
 9. The compound according to claim 1,wherein L¹ is —(CR^(a)R^(b))_(m)— or S(O)₂; R^(a) and R^(b) at eachoccurrence are each hydrogen; m is 1; R¹ is G¹; wherein G¹ is aryl; L²is C(O); and R² is alkyl or G², wherein G² is cycloalkyl or heterocycle;and R³ is hydrogen.
 10. The compound according to claim 1, wherein L¹ is—(CR^(a)R^(b))_(m)—, C(O) or S(O)₂; R^(a) and R^(b) at each occurrenceare each hydrogen; m, at each occurrence, is 1 or 2; R¹ is G¹,—(CR^(a)R^(b))_(m)-G¹, or —CH(G¹)₂, wherein G¹, at each occurrence, isindependently aryl or heteroaryl; L² is C(O); R² is—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)O(alkyl),—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)O-G²—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)(alkyl),—(CR^(g)R^(h))_(q)—N(R⁵)—SO₂—R⁶, —(CR^(g)R^(h))_(q)—N(R⁵)-G²;—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)N(R⁵)-(alkyl), or—(CR^(g)R^(h))_(q)—N(R⁵)—C(O)N(R⁵)-G²; q is 1 or 2; R^(g) and R^(h), ateach occurrence, are each independently hydrogen, alkyl, arylalkyl, orcycloalkylalkyl; R⁴ and R⁵ at each occurrence, are each independentlyhydrogen, alkyl, arylalkyl, cycloalkyl or cycloalkylalkyl; R⁶ is alkyl,aryl, or cycloalkyl; G² is aryl or cycloalkyl; and R³ is hydrogen,alkyl, cycloalkyl or cycloalkylalkyl.
 11. The compound according toclaim 1, wherein L¹-R¹ together are hydrogen or hydroxyalkyl; or L¹ is—(CR^(a)R^(b))_(m)—, C(O) or S(O)₂; R¹ is G¹, —(CR^(a)R^(b))_(m)-G¹ or—CH(G¹)₂, wherein each G¹ is aryl or heteroaryl; R^(a) and R^(b), ateach occurrence, are each independently hydrogen or alkyl; L² is S(O)₂;R² is G², wherein G² is aryl or heteroaryl; or R³ is hydrogen, alkyl orcycloalkyl.
 12. The compound according to claim 1, wherein L¹ is—(CR^(a)R^(b))_(m)—; R^(a) and R^(b) are each hydrogen; R¹ is —CH(G¹)₂,wherein each G¹ is aryl; L² is C(O); R² is —(CR^(c)R^(d))_(p)-G²;wherein G² is aryl; p is 1; R^(c) and R^(d), at each occurrence, areeach independently hydrogen or alkyl; and R³ is hydrogen.
 13. Thecompound according to claim 1, wherein L¹ is C(O), S(O)₂ or—(CR^(a)R^(b))_(m)—; R^(a) and R^(b), at each occurrence, areindependently hydrogen or alkyl; m is 1; R¹ is G¹ or—(CR^(a)R^(b))_(m)-G¹, wherein G¹ is aryl or heteroaryl; L² is—(CR^(c)R^(d))_(p)—; R^(c) and R^(d) are each hydrogen; p is 1; R² isG², wherein G² is aryl, cycloalkyl or heteroaryl; or L²-R² takentogether are alkyl, G², or —C(R^(c))(G²)(G³), wherein G² and G³ are eacharyl or heteroaryl and R^(c) is hydrogen; and R³ is hydrogen or alkyl.14. The compound according to claim 1, wherein L¹ is C(O); R¹ is—(CR^(e)R^(f))_(n)—N(R⁵)₂; n is 1 or 2; R^(e) and R^(f) at eachoccurrence are each independently hydrogen or alkyl; R⁵ at eachoccurrence is independently hydrogen or alkyl; L² is C(O) or S(O)₂; R²is G² or —C(R^(c))(G²)(G³), wherein G² and G³ are each aryl orheteroaryl and R^(c) is hydrogen; and R³ is hydrogen, alkyl, orcycloalkyl.
 15. The compound according to claim 1, wherein L¹ is C(O);R¹ is —(CR^(e)R^(f))_(n)—N(R⁵)₂ or —(CR^(e)R^(f))_(n)—N(R⁵)C(O)O(alkyl);n is 1 or 2; R^(e) and R^(f) at each occurrence are each independentlyhydrogen, alkyl, or arylalkyl; R⁵ at each occurrence is independentlyhydrogen, alkyl or cycloalkyl; L² is C(O); R² is—(CR^(g)R^(h))_(q)N(R⁴)(R⁵) or —(CR^(g)R^(h))_(q)—N(R⁵)C(O)O(alky); q is1 or 2; R⁴ is hydrogen or alkyl; R^(g) and R^(h) at each occurrence areeach independently hydrogen or alkyl; and R³ is hydrogen.
 16. Thecompound of claim 1, wherein L¹-R¹ taken together are hydrogen, G¹ orCH(G¹)₂, wherein G¹ is aryl or heteroaryl; L² is C(O); R² is—(CR^(g)R^(h))_(q)N(R⁴)(R⁵) or —(CR^(g)R^(h))_(q)—N(R⁵)C(O)O(alkyl); qis 1 or 2; R⁴ is hydrogen, alkyl, or cycloalkylalkyl; R⁵ is hydrogen oralkyl; R^(g) and R^(h) at each occurrence are each independentlyhydrogen or alkyl; and R³ is hydrogen.
 17. The compound of claim 1,wherein L¹-R¹ taken together are G¹, wherein G¹ is aryl or heteroaryl;L² is C(O); R² is G², wherein G² is aryl or heteroaryl; and R³ ishydrogen or alkyl.
 18. The compound according to claim 1 or apharmaceutically acceptable salt thereof, selected from the groupconsisting of:N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclopentanecarboxamide;N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclopentanecarboxamide;N-[(3aR*,4R*,6aS*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclohexyl-2-phenylacetamide;N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclohexyl-2-phenylacetamide;N-[(3aR*,4R*,6aS*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;N-[(3aR*,4S*,6aS*)-2-benzyloctahydrocyclopenta[c]pyrrol-4yl]-3-methyl-2-phenylbutanamide;N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide;N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide;N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide;(2S)-2-(3-benzoylphenyl)-N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]propanamide;(2S)-2-(3-benzoylphenyl)-N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]propanamide;N-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;N-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide;(2S)—N-[3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;(2S)—N-[3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylpropanamide;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-propylpentanamide;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]cycloheptanecarboxamide;(2S)—N-[3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(4-isobutylphenyl)propanamide;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,3-diphenylpropanamide;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-methyl-3-phenylpropanamide;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-methyl-2-phenylpropanamide;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclopropanecarboxamide;2-benzyl-N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethylbutanamide;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;(2R)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;(2S)—N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopentyl-2-phenylacetamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;(2R)—N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide;(2R)—N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylpropanamide;(2S)—N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylpropanamide;(2S)—N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(4-isobutylphenyl)propanamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclopropyl-2-phenylacetamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-cyclobutyl-2-phenylacetamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(4-chlorophenyl)-3-methylbutanamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-ethyl-2-phenylpentanamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(4-hydroxyphenyl)-3-methylbutanamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclohexanecarboxamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-methyl-2-phenylpropanamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-phenylcyclopropanecarboxamide;2-benzyl-N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethylbutanamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,3-diphenylpropanamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-methyl-3-phenylpropanamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3,3-dimethyl-2-phenylbutanamide;2,2-dicyclohexyl-N-[(3aS,4S,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide;2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(2-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-[4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;N-{(3aS,4S,6aR)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[2-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(3-methylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(4-methylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-(trifluoromethoxy)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(3-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;N-{(3aS,4S,6aR)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;N-{(3aS,4S,6aR)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;N-{(3aS,4S,6aR)-2-[3-(3-chlorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-(3-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(3-phenylpropyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;2,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{3-[4-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide;2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[3-(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(pyridin-4-ylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;2,2-dicyclohexyl-N-[(3aS,4S,6aR)-2-(pyridin-3-ylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;2,2-dicyclohexyl-N-[(3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-yl]acetamide;2,2-dicyclohexyl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;2,2-dicyclohexyl-N-{(3aS,4R,6aR)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;N-{(3aS,4R,6aR)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;N-{(3aS,4R,6aR)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;2,2-dicyclohexyl-N-[(3aS,4R,6aR)-2-(3,3-diphenylpropyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;N-{(3aS,4R,6aR)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;N-{(3aS,4R,6aR)-2-[4,4-bis(4-fluorophenyl)butyl]octahydrocyclopenta[c]pyrrol-4-yl}-2,2-dicyclohexylacetamide;3-methyl-2-phenyl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;N-[(3aR,4S,6aS)-2-(cyclohexylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;3-methyl-N-[(3aR,4S,6aS)-2-methyloctahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide;N-[(3aR,4S,6aS)-2-(2-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;N-[(3aR,4S,6aS)-2-(3-chlorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;N-[(3aR,4S,6aS)-2-(3-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;3-methyl-2-phenyl-N-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;N-[(3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;N-[(3aR,4S,6aS)-2-(3-methoxybenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;3-methyl-N-[(3aR,4S,6aS)-2-(3-methylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide;3-methyl-N-[(3aR,4S,6aS)-2-(2-methylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-2-phenylbutanamide;N-[(3aR,4S,6aS)-2-(2,6-dimethylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;N-[(3aR,4S,6aS)-2-(2-methoxybenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;N-[(3aR,4S,6aS)-2-(4-tert-butylbenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;N-[(3aR,4S,6aS)-2-(4-methoxybenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;N-[(3aR,4S,6aS)-2-(3-cyanobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;3-methyl-2-phenyl-N-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;3-methyl-2-phenyl-N-{(3aR,4S,6aS)-2-[2-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;N-{(3aR,4S,6aS)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;N-{(3aR,4S,6aS)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;3-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(thien-2-ylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide;3-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(pyridin-4-ylmethyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide;3-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(2-phenylethyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide;3-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(3-phenylpropyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide;N-{(3aR,4S,6aS)-2-[3-(4-tert-butylphenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;N-{(3aR,4S,6aS)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;3-methyl-N-{(3aR,4S,6aS)-2-[3-(2-methylphenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2-phenylbutanamide;N-{(3aR,4S,6aS)-2-[3-(3-chlorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;3-methyl-N-{(3aR,4S,6aS)-2-[3-(3-methylphenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-2-phenylbutanamide;3-methyl-2-phenyl-N-((3aR,4S,6aS)-2-{3-[3-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[c]pyrrol-4-yl)butanamide;N-{(3aR,4S,6aS)-2-[3-(3-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;3-methyl-2-phenyl-N-[(3aR,4S,6aS)-2-(4-phenylbutyl)octahydrocyclopenta[c]pyrrol-4-yl]butanamide;N-{(3aR,4S,6aS)-2-[3-(3-chloro-5-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;3-methyl-2-phenyl-N-((3aR,4S,6aS)-2-{3-[4-(trifluoromethyl)phenyl]propyl}octahydrocyclopenta[c]pyrrol-4-yl)butanamide;N-[(3aR,4S,6aS)-2-(3,3-diphenylpropyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;N-{(3aR,4S,6aS)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4yl}-3-methyl-2-phenylbutanamide;N-{(3aR,4S,6aS)-2-[4,4-bis(4-fluorophenyl)butyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;N-{(3aR,4S,6aS)-2-[5,5-bis(4-fluorophenyl)pentyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-methyl-2-phenylbutanamide;N-[(3aS,4S,6aR)-2-benzhydryloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide;N-[(3aS,4R,6aR)-2-benzhydryloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-dicyclohexylacetamide;3-methyl-2-phenyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;3,3-dimethyl-2-phenyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;2,2-dicyclohexyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;2-ethyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;2-propyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide;N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}cyclohexanecarboxamide;N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}cycloheptanecarboxamide;N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}cyclopentanecarboxamide;6,6-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}hexanamide;3,3-diphenyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}propanamide;5,5-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide;3,3-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}propanamide;4,4-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;2,2-diphenyl-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;2,2-bis(4-fluorophenyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;N²-(tert-butyloxycarbonyl)-N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-(tert-butyloxycarbonyl)-N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;N²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;6,6-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}hexanamide;3,3-diphenyl-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}propanamide;5,5-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide;3,3-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}propanamide;4,4-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;2,2-diphenyl-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;2,2-bis(4-fluorophenyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;3,3-dimethyl-2-phenyl-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;N²-(tert-butyloxycarbonyl)-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-(tert-butyloxycarbonyl)-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;N²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(tert-butyloxycarbonyl)-N²-methyl-L-leucinamide;2,2-dicyclohexyl-2-hydroxy-N-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;N²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;2,2-dicyclohexyl-2-hydroxy-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;N²-(tert-butyloxycarbonyl)-N²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;2,2-dicyclohexyl-N-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;2,2-dicyclohexyl-N-{(3aR,4R,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N¹-{(3aR*,4R*,6aS*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;N²-methyl-N¹-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;N²-methyl-N¹-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;N²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;N²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-methyl-N²-(methylsulfonyl)-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-N²-(methylsulfonyl)-L-leucinamide;N²-methyl-N²-(methylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-(methylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-(methylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;N²-(cyclopropylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-(isobutylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-(cyclopropylsulfonyl)-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-acetyl-N²-methyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-(2,2-dimethylpropanoyl)-N²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-(2,2-dimethylpropanoyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;isobutyl(S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;cyclopentyl(S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;N²-[(tert-butylamino)carbonyl]-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-[(cyclopentylamino)carbonyl]-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-methyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N¹(3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;3-(trifluoromethyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide;3-(trifluoromethyl)-N-{(3aS*,4R*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide;3-(trifluoromethyl)-N-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide;3-(trifluoromethyl)-N-{(3aR,4R,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide;3-(trifluoromethyl)-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;N-{(3aS,4R,6aR)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;N-{(3aS,4R,6aR)-2-[3,5-bis(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;N-{(3aS,4R,6aR)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;N-{(3aS,4R,6aR)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-3-(trifluoromethyl)benzenesulfonamide;N-[(3aS,4S,6aR)-2-(4-hydroxybutyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;(3aS*,4S*,6aR*)-N,N-dicyclopropyl-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-amine;(3aS*,4R*,6aR*)-2-benzyl-N-cyclopropyloctahydrocyclopenta[c]pyrrol-4-amine;(3aS*,4S*,6aR*)-2-benzyl-N-cyclopropyloctahydrocyclopenta[c]pyrrol-4-amine;N-[(3aS*,4S*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;N-cyclopropyl-N-[(3aS*,4S*,6aR*)-octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;N-{(3aS*,4S*,6aR*)-2-[6,6-bis(4-fluorophenyl)hexyl]octahydrocyclopenta[c]pyrrol-4-yl}-N-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;N-{(3aS*,4S*,6aR*)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-N-cyclopropyl-3-(trifluoromethyl)benzenesulfonamide;N-cyclopropyl-3-(trifluoromethyl)-N-{(3aS*,4S*,6aR*)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}benzenesulfonamide;2,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide;2,2-dicyclohexyl-N-{(3aS,4S,6aR)-2-[(2-phenylethyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;2,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{[2-(1-naphthyl)ethyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide;2,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{[3-(trifluoromethyl)benzyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide;2,2-dicyclohexyl-N-((3aS,4S,6aR)-2-{[2-(4-fluorophenyl)ethyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)acetamide;(2S)-2-phenyl-N-{(3aR,4R,6aS)-2-[(1S)-1-phenylethyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;(2S)-2-phenyl-N-{(3aR,4S,6aS)-2-[(1S)-1-phenylethyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;(2S)-2-phenyl-N-{(3aS,4S,6aR)-2-[(1S)-1-phenylethyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;(2S)-2-phenyl-N-{(3aS,4R,6aR)-2-[(1S)-1-phenylethyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N,3-dimethyl-2-phenylbutanamide;N-[(3aS*,4R*,6aR*)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N,3-dimethyl-2-phenylbutanamide;(3aR*,4S*,6aS*)-N-benzyl-2-(3-methyl-2-phenylbutanoyl)octahydrocyclopenta[c]pyrrol-4-amine;2,2-dicyclohexyl-N-[(3aS,4R,6aR)-2-(N,N-dimethyl-D-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;N-[(3aR,4S,6aS)-2-benzoyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-2-phenylbutanamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-isopropyl-N-phenylurea;(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methylpentanamide; tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-ylcarbamate;tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(ethyl)carbamate;tert-butyl(2S,3S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxopentan-2-yl(methyl)carbamate;tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate;tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-ylcarbamate;tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxohexan-2-yl(methyl)carbamate;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2,2-bis(4-fluorophenyl)acetamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methylbutanamide;tert-butyl(2S)-2-({[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]amino}carbonyl)piperidine-1-carboxylate;tert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3-methyl-1-oxobutan-2-yl(methyl)carbamate;tert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;tert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-3,3-dimethyl-1-oxobutan-2-ylcarbamate;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-2-isopropyl-3-methylbutanamide;N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methylbutanamide;2-cyclohexyl-2-hydroxy-N-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}acetamide;tert-butyl(S)-1-((3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;tert-butyl(S)-1-((3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;tert-butyl(S)-1-((3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;tert-butyl(S)-1-((3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;S-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(methylsulfonyl)-L-leucinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(methylsulfonyl)-L-leucinamide;N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-neopentyl-L-leucinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-neopentyl-L-leucinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-neopentyl-L-norvalinamide;tert-butyl(S)-1-((3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;tert-butyl(S)-1-((3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-ylamino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-morpholin-4-ylpentanamide;(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide;(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-piperidin-1-ylpentanamide;N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-neopentyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-neopentyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N-(tent-butoxycarbonyl)-N-methyl-N-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide;tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;N²-neopentyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-neopentyl-L-leucinamide;tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;isopropyl(S)-1-oxo-1-((3aR,4S,6aS)-2-(5-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(6-(trifluoromethyl)pyridin-2-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;tert-butyl(S)-4,4-dimethyl-1-((3aR,4S,6aS)-2-(2-(methylsulfonyl)pyrimidin-5-yl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-ylcarbamate;(S)-tert-butyl2-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate;tert-butyl(1R)-1-isopropyl-3-oxo-3-[((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]propylcarbamate;tert-butyl(2S)-2-{[((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate;N-(tent-butoxycarbonyl)-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide;N-(tent-butoxycarbonyl)-N-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide;(S)-tert-butyl2-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylcarbamoyl)pyrrolidine-1-carboxylate;tert-butyl(1R)-1-isopropyl-3-oxo-3-[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]propylcarbamate;tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamate;tert-butyl(2S)-2-{[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}piperidine-1-carboxylate;tert-butyl(3S)-3-{[((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)amino]carbonyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate;tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)hexan-2-yl)carbamate;tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;isopropyl(S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;isopropyl(S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;(3aS,4R,6aR)—N-neopentyl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)—N-neopentyl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)—N-isopropyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N-isopropyloctahydrocyclopenta[c]pyrrol-4-amine;(3aS,4R,6aR)—N-(4-fluorobenzyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)—N-(4-fluorobenzyl)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)—N-(4-fluorobenzyl)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)—N-ethyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)—N,N-diethyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)—N-propyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)—N,N-dipropyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)—N-(cyclopropylmethyl)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N-ethyloctahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N,N-diethyloctahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}-N-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-amine;tert-butyl(S)-1-(ethyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;tert-butyl(S)-4,4-dimethyl-1-oxo-1-(propyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)pentan-2-yl(methyl)carbamate;tert-butyl(S)-1-((cyclopropylmethyl)((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-4,4-dimethyl-1-oxopentan-2-yl(methyl)carbamate;2-nitro-N-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)benzenesulfonamide;N-methyl-2-nitro-N-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)benzenesulfonamide;(3aR,4S,6aS)—N-methyl-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;tert-butyl(S)-4,4-dimethyl-1-(methyl((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl)amino)-1-oxopentan-2-yl(methyl)carbamate;(2S)-2-(1,1-dioxidoisothiazolidin-2-yl)-4-methyl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide;2-isopropyl-3-methyl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;2-isopropyl-3-methyl-N-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}butanamide;tert-butyl(S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;tert-butylethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butyl(S)-1-((3aS,4R,6aR)-2-(3-fluoro-4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluoro-3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butyl(S)-1-((3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamate;tert-butylmethyl((S)-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;(2S)-4-methyl-2-morpholin-4-yl-N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;(2S)-4-methyl-2-pyrrolidin-1-yl-N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;(2S)-4-methyl-2-piperidin-1-yl-N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butylethyl((S)-4-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluoro-3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-4-methyl-1-oxopentan-2-yl(methyl)carbamate;tert-butylmethyl((S)-1-oxo-1-((3aR,4R,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butylmethyl((S)-4-methyl-1-oxo-1-((3aR,4R,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butyl(S)-1-((3aS,4R,6aR)-2-(4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;tert-butylmethyl((S)-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butylmethyl((2S,3S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl(methyl)carbamate;tert-butylmethyl((S)-3-methyl-1-oxo-1-((3aS,4R,6aR)-2-(3-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-yl)carbamate;tert-butyl(S)-3,3-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-ylcarbamate;tert-butyl(S)-3,3-dimethyl-1-oxo-1-((3aS,4R,6aR)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-ylcarbamate;tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)hexan-2-yl)carbamate;tert-butyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;(2S)-4-methyl-2-pyrrolidin-1-yl-N-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzoyl]octahydrocyclopenta[c]pyrrol-4-yl}pentanamide;(2S)-4-methyl-N-[(3aS,4R,6aR)-2-(methylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-2-pyrrolidin-1-ylpentanamide;(2S)—N-[(3aS,4R,6aR)-2-(cyclopropylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-2-pyrrolidin-1-ylpentanamide;N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;tert-butylmethyl((S)-4-methyl-1-((3aS,4R,6aR)-octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl)carbamate;(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]piperidine-2-carboxamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-valinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-isoleucinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-isoleucinamide;N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²,4-dimethyl-L-leucinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-L-valinamide;N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-methyl-L-valinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²,4-dimethyl-L-leucinamide;N¹-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;N¹-[(3aS,4S,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-L-leucinamide;N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norleucinamide;N¹-[(3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;N¹-[(3aR,4R,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;N²-ethyl-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-methyl-N¹-{(3aS,4R,6aR)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-valinamide;(2S)—N-[(3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]piperidine-2-carboxamide;N¹-[(3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-valinamide;(2S)—N-{(3aS,4R,6aR)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4yl}piperidine-2-carboxamide;N²-methyl-N¹-{(3aS,4R,6aR)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;N¹-[(3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;N²-methyl-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-valinamide;N¹-{(3aS,4R,6aR)-2-[3-fluoro-4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;N¹-{(3aS,4R,6aR)-2-[4-fluoro-3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;N²-methyl-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;N²-methyl-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;N¹-[(3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;N²-methyl-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-methyl-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N¹-[(3aR,4S,6aS)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;N²-ethyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide;N-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide;N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-prolinamide;(3R)-3-amino-4-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide;(2S)—N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)piperidine-2-carboxamide;(3S)-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide;4-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norleucinamide;N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-prolinamide;(3R)-3-amino-4-methyl-N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;(2S)—N-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)piperidine-2-carboxamide;(2S)—N-{(3aS,4R,6aR)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}piperidine-2-carboxamide;N¹-{(3aS,4R,6aR)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-valinamide;(2S)—N-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)piperidine-2-carboxamide;N²-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide;N¹-{(3aS,4R,6aR)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;N²-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-methyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide;N¹-((3aS,4R,6aR)-2-{[4-fluoro-3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-leucinamide;3-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide;3-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide;N²-methyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-isoleucinamide;N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-isoleucinamide;N²-methyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-isoleucinamide;N²-methyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-isoleucinamide;N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²,4-dimethyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²,4-dimethyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norleucinamide;4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-methyl-N¹-((3aR,4R,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-methyl-N¹-((3aR,4R,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;3-cyclohexyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-alaninamide;3-cyclohexyl-N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-alaninamide;N¹-((3aR,4S,6aS)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-L-leucinamide;N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-4-methyl-L-leucinamide;N-methyl-N-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-phenylalaninamide;N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²,4-dimethyl-L-leucinamide;N-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N-methyl-L-phenylalaninamide;N¹-cyclopropyl-N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N¹-ethyl-N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²,4-dimethyl-N¹-propyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N¹-(cyclopropylmethyl)-N²,4-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N¹,N²,4-trimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N¹,N²-dimethyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N¹,N²,4-trimethyl-L-leucinamide;4-methyl-N¹-{(3aR,4S,6aS)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;4-methyl-N¹-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;4-methyl-N¹-{(3aR,4S,6aS)-2-[2-(methylsulfonyl)pyrimidin-5-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N¹-{(3aS,4R,6aR)-2-[(3-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl-}-N²-methyl-L-leucinamide;N¹-{(3aS,4R,6aR)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;N¹-{(3aS,4R,6aR)-2-[(3,4-difluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-yl-N²-methyl-L-leucinamide;N¹-{(3aS,4R,6aR)-2-[(3,5-difluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;N¹-{(3aS,4R,6aR)-2-[(4-chlorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;N²-methyl-N¹-[(3aS,4R,6aR)-2-(phenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-leucinamide;N²-methyl-N¹-{(3aS,4R,6aR)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N¹-[(3aS,4R,6aR)-2-(4-fluorobenzyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-valinamide;N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-valinamide;N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4yl}-4-methyl-L-leucinamide;N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norleucinamide;N¹-{(3aR,4S,6aS)-2-[(4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-leucinamide;N²-methyl-N¹-((3aS,4S,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-methyl-N¹-((3aS,4S,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N¹-{(3aR,4S,6aS)-2-[3,3-bis(4-fluorophenyl)propyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;2,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-2-(N-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;2,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-2-(N-methyl-L-norvalyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;N-[(3aR,4S,6aS)-2-(N,4-dimethyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-2,2-bis(4-fluorophenyl)acetamide;2,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-2-(4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;tert-butyl(S)-1-((3aR,4S,6aS)-4-(S)-2-(tert-butoxycarbonylamino)-4,4-dimethylpentanamido)hexahydrocyclopenta[c]pyrrol-2(1H)-yl)-4,4-dimethyl-1-oxopentan-2-ylcarbamate;4-methyl-N¹-[(3aR,4S,6aS)-2-(4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-leucinamide;4-methyl-N¹-[(3aR,4S,6aS)-2-L-phenylalanyloctahydrocyclopenta[c]pyrrol-4-yl]-leucinamide;(3aR,4S,6aS)—N-benzhydryl-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-amine;(3aS,4R,6aR)—N-benzhydryl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;(3aR,4S,6aS)—N-benzhydryl-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-amine;N¹-[(3aS,4R,6aR)-2-benzhydryloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-leucinamide;4-methyl-N²-propyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-(cyclopropylmethyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-(cyclobutylmethyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-isobutyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-(cyclopentylmethyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-(cyclohexylmethyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-butyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-ethyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-(cyclopropylmethyl)-4-methyl-N¹-{(3aR,4S,6aS)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-(cyclopropylmethyl)-4-methyl-N¹-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-isopropyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-isopropyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-isopropyl-N¹-((3aS,4R,6aR)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-isopropyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-isopropyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;3-cyclohexyl-N²-isopropyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-alaninamide;N¹-((3aR,4S,6aS)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-isopropyl-4-methyl-L-leucinamide;N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-isopropyl-4-methyl-L-leucinamide;N²-isopropyl-N¹-[(3aR,4S,6aS)-2-(N-isopropyl-4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-L-leucinamide;N²-isopropyl-N¹-[(3aR,4S,6aS)-2-(N-isopropyl-L-phenylalanyl)octahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-L-leucinamide;N²-isopropyl-4-methyl-N¹-{(3aR,4S,6aS)-2-[5-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-isopropyl-4-methyl-N¹-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;2,2-bis(4-fluorophenyl)-N-[(3aR,4S,6aS)-2-(N-isopropyl-4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]acetamide;N²-isopropyl-4-methyl-N¹-{(3aR,4S,6aS)-2-[2-(methylsulfonyl)pyrimidin-5-yl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N¹-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-isopropyl-L-norvalinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-isopropyl-L-norvalinamide;N²-isopropyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²,N²-dimethyl-N¹-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;(3R)-3-(dimethylamino)-4-methyl-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;N²-cyclopropyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²,N²-dicyclopropyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-cyclopentyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-cyclohexyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-(1-ethylpropyl)-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-cyclobutyl-4-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;4-methyl-N²-neopentyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N²-cyclopentyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-cyclohexyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-cyclopentyl-N¹-[(3aR,4S,6aS)-2-(N-cyclopentyl-4-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-4-methyl-L-leucinamide;N²,N²-dimethyl-N¹-{(3aS,4S,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-N²-neopentyl-L-leucinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(3,3-dimethylbutyl)-N²-methyl-L-leucinamide;N²,N²-dimethyl-N¹-((3aS,4R,6aR)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-leucinamide;N¹-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N²-(4-fluorobenzyl)-N²-methyl-L-leucinamide;(2S)—N-[(3aS,4R,6aR)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-1-(methylsulfonyl)piperidine-2-carboxamide;(3R)-4-methyl-3-[(methylsulfonyl)amino]-N-((3aR,4S,6aS)-2-{[3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)pentanamide;N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-D-leucinamide;N²-ethyl-N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;4-methyl-N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;3-methyl-N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-valinamide;N²-(methylsulfonyl)-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;N²-(isopropylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;N²-(phenylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-y4-L-leucinamide;N²-(cyclopentylsulfonyl)-N¹-{(3aS,4R,6aR)-2-[3-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-leucinamide;isopropyl(S)-4,4-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;isopropyl(S)-3,3-dimethyl-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)butan-2-ylcarbamate;cyclopentyl(S)-1-oxo-1-((3aR,4S,6aS)-2-(4-(trifluoromethyl)benzyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-ylcarbamate;N²-(2,2-dimethylpropanoyl)-N¹-{(3aR,4S,6aS)-2-[4-(trifluoromethyl)benzyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;tert-butyl(S)-1-((3aR,4S,6aS)-2-(3-chloro-4-fluorophenylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)-1-oxopentan-2-yl(methyl)carbamate;tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(pyridin-3-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;tert-butylmethyl((S)-1-oxo-1-((3aR,4S,6aS)-2-(thiophen-2-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-ylamino)pentan-2-yl)carbamate;N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethoxy)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-methyl-N¹-[(3aR,4S,6aS)-2-(thien-2-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-norvalinamide;N¹-{(3aR,4S,6aS)-2-[(3-chloro-4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;N²-methyl-N¹-[(3aR,4S,6aS)-2-(pyridin-3-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-norvalinamide;N¹-{(3aR,4S,6aS)-2-[(4-cyanophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;N¹-{(3aR,4S,6aS)-2-[(4-methoxyphenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;N¹-((3aR,4S,6aS)-2-{[3,5-bis(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-norvalinamide;N¹-{(3aR,4S,6aS)-2-[(2-chloro-4-fluorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;N²-methyl-N¹-[(3aR,4S,6aS)-2-(1-naphthylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-L-norvalinamide;N¹-((3aR,4S,6aS)-2-{[4-bromo-3-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-norvalinamide;N¹-{(3aR,4S,6aS)-2-[(3,4-dichlorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;N¹-{(3aR,4S,6aS)-2-[(4-tert-butylphenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;N¹-[(3aR,4S,6aS)-2-(1,1′-biphenyl-4-ylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;N¹-{(3aR,4S,6aS)-2-[(3,4-dimethoxyphenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;N¹-{(3aR,4S,6aS)-2-[(3-cyanophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;N¹-[(3aR,4S,6aS)-2-(2-furylsulfonyl)octahydrocyclopenta[c]pyrrol-4-yl]-N²-methyl-L-norvalinamide;N¹-{(3aR,4S,6aS)-2-[(2,3-dichlorophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;N²-methyl-N¹-((3aR,4S,6aS)-2-{[4-(trifluoromethyl)benzyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N²-methyl-N¹-((3aR,4S,6aS)-2-{[2-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-L-norvalinamide;N¹-{(3aR,4S,6aS)-2-[(3-bromophenyl)sulfonyl]octahydrocyclopenta[c]pyrrol-4-yl}-N²-methyl-L-norvalinamide;N¹-((3aR,4S,6aS)-2-{[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-norvalinamide;N¹-((3aR,4S,6aS)-2-{[2-chloro-5-(trifluoromethyl)phenyl]sulfonyl}octahydrocyclopenta[c]pyrrol-4-yl)-N²-methyl-L-norvalinamide;N²-methyl-N¹-{(3aR,4S,6aS)-2-[3-(trifluoromethyl)benzoyl]octahydrocyclopenta[c]pyrrol-4-yl}-L-norvalinamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-N-isopropyl-3-(trifluoromethyl)benzenesulfonamide;N-[(3aR,4S,6aS)-2-benzyloctahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;N-isopropyl-N-[(3aR,4S,6aS)-2-(N-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;N-[(3aR,4S,6aS)-2-(N-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;N-cyclopropyl-N-[(3aS*,4S*,6aR*)-[2-(N-methyl-L-leucyl)octahydrocyclopenta[c]pyrrol-4-yl]-3-(trifluoromethyl)benzenesulfonamide;and4-fluoro-N-{(3aR,4S,6aS)-2-[6-(trifluoromethyl)pyridin-2-yl]octahydrocyclopenta[c]pyrrol-4-yl}benzamide.19. A pharmaceutical composition comprising a therapeutically effectiveamount of a compound of formula (I) according to claim 1 or apharmaceutically acceptable salt thereof, in combination with apharmaceutically acceptable carrier.
 20. A method of treating pain in asubject in need thereof, comprising: administering to the subject atherapeutically suitable amount of a compound of formula (I), or apharmaceutically acceptable salt thereof, wherein the pain is acutepain, chronic pain, neuropathic pain, inflammatory pain, visceral pain,cancer pain, allodynia, fibromyalgia, sciatica, back pain, and headachepain including migraine, or combinations thereof.
 21. A method oftreating disorders of the central nervous system in a subject in needthereof, comprising the step of: administering a therapeuticallysuitable amount of a compound of formula (I), or a pharmaceuticallyacceptable salt thereof, wherein the disorders of the central nervoussystem include stroke, epilepsy, manic depression, bipolar disorders,depression, anxiety, schizophrenia, migraine, and psychoses; neuraldegenerative disorders including Alzheimer's disease, AIDS relateddementia, Parkinson's disease, neuropathy caused by head injury, anddementia caused by cerebrovascular disorders; disorders of the lowerurinary tract including overactive bladder, prostatis, prostadynia,interstitial cystitis, and benign prostatic hyperplasia; disorderscaused by psychogenic stress including bronchial asthma, unstableangina, and hypersensitive colon inflammation; cardiovascular disordersincluding hypertension, atherosclerosis, heart failure, and cardiacarrhythmias; drug addiction withdrawal symptoms, including ethanoladdiction withdrawal symptoms; skin disorders including pruritis andallergic dermatitis, inflammatory bowel disease; cancer; diabetes; andinfertility and sexual dysfunction, or combinations thereof